<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005652.pub2" GROUP_ID="BEHAV" ID="778303070709583647" MERGED_FROM="" MODIFIED="2017-06-30 16:57:06 +0100" MODIFIED_BY="Joanne Wilson" REVIEW_NO="F0024" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2017-04-06 17:57:32 +0100" MODIFIED_BY="Jane Dennis">
<TITLE MODIFIED="2011-06-21 15:34:13 +0100" MODIFIED_BY="[Empty name]">Psychological therapies for people with borderline personality disorder</TITLE>
<CONTACT>
<PERSON ID="2FCEA65C82E26AA2000C5DBB20C47907" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Klaus</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Lieb</LAST_NAME>
<SUFFIX/>
<POSITION>Chair of the Department of Psychiatry and Psychotherapy</POSITION>
<EMAIL_1>klaus.lieb@unimedizin-mainz.de</EMAIL_1>
<EMAIL_2>klaus.lieb@ukmainz.de</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Psychiatry and Psychotherapy</DEPARTMENT>
<ORGANISATION>University Medical Center of the Johannes Gutenberg University Mainz</ORGANISATION>
<ADDRESS_1>Untere Zahlbacherstr 8</ADDRESS_1>
<ADDRESS_2/>
<CITY>Mainz</CITY>
<ZIP>55131</ZIP>
<REGION>Rhineland-Palatinate</REGION>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 6131 177 335</PHONE_1>
<PHONE_2>+49 6131 177 336</PHONE_2>
<FAX_1>+49 6131 229 974</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2017-04-06 17:57:32 +0100" MODIFIED_BY="Jane Dennis">
<PERSON ID="2FE6F4A782E26AA2000C5DBB80392281" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Jutta</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Stoffers-Winterling</LAST_NAME>
<SUFFIX/>
<POSITION>Research Assistant</POSITION>
<EMAIL_1>jutta.winterling@gmail.com</EMAIL_1>
<EMAIL_2>jutta.stoffers@uniklinik-freiburg.de</EMAIL_2>
<URL/>
<MOBILE_PHONE>+49 151 12 705 894</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Department of Psychiatry and Psychotherapy</DEPARTMENT>
<ORGANISATION>University Medical Center Mainz</ORGANISATION>
<ADDRESS_1>Untere Zahlbacher Straße 8</ADDRESS_1>
<ADDRESS_2/>
<CITY>Mainz</CITY>
<ZIP>D-55131</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 151 12 705 894</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="2FDDC59482E26AA2000C5DBBC4F767BD" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Birgit</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Völlm</LAST_NAME>
<SUFFIX>DiplForPsych MRCPsych MD PhD</SUFFIX>
<POSITION>Clinical Associate Professor and Reader in Forensic Psychiatry</POSITION>
<EMAIL_1>birgit.vollm@nottingham.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Psychiatry &amp; Applied Psychology</DEPARTMENT>
<ORGANISATION>University of Nottingham Innovation Park</ORGANISATION>
<ADDRESS_1>Institute of Mental Health</ADDRESS_1>
<ADDRESS_2>Triumph Road</ADDRESS_2>
<CITY>Nottingham</CITY>
<ZIP>NG7 2TU</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 115 823 1266</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="0CFB145382E26AA2005EE6A627852244" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Gerta</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Rücker</LAST_NAME>
<SUFFIX/>
<POSITION>Statistician</POSITION>
<EMAIL_1>ruecker@imbi.uni-freiburg.de</EMAIL_1>
<EMAIL_2/>
<URL>http://www.imbi.uni-freiburg.de</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute for Medical Biometry and Statistics</DEPARTMENT>
<ORGANISATION>Faculty of Medicine and Medical Center &#8211; University of Freiburg</ORGANISATION>
<ADDRESS_1>Stefan-Meier-Str. 26</ADDRESS_1>
<ADDRESS_2/>
<CITY>Freiburg</CITY>
<ZIP>79104</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 761 203 6673</PHONE_1>
<PHONE_2/>
<FAX_1>+49 761 203 6680</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="C3DB143C82E26AA2014A559479172D27" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Antje</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Timmer</LAST_NAME>
<SUFFIX>MD, MSc.</SUFFIX>
<POSITION>Professor of Epidemiology and Biostatistics</POSITION>
<EMAIL_1>antje.timmer@uni-oldenburg.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Health Services Research</DEPARTMENT>
<ORGANISATION>Carl von Ossietzky University of Oldenburg</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Oldenburg</CITY>
<ZIP>26111</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="9E912AD582E26AA201B8424E499187D4" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Nick</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Huband</LAST_NAME>
<SUFFIX/>
<POSITION>Clinical Research Fellow</POSITION>
<EMAIL_1>nick.huband@nottingham.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute of Mental Health</DEPARTMENT>
<ORGANISATION>University of Nottingham</ORGANISATION>
<ADDRESS_1>Triumph Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Nottingham</CITY>
<ZIP>NG7 2TU</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 115 823 1264</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="2FCEA65C82E26AA2000C5DBB20C47907" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Klaus</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Lieb</LAST_NAME>
<SUFFIX/>
<POSITION>Chair of the Department of Psychiatry and Psychotherapy</POSITION>
<EMAIL_1>klaus.lieb@unimedizin-mainz.de</EMAIL_1>
<EMAIL_2>klaus.lieb@ukmainz.de</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Psychiatry and Psychotherapy</DEPARTMENT>
<ORGANISATION>University Medical Center of the Johannes Gutenberg University Mainz</ORGANISATION>
<ADDRESS_1>Untere Zahlbacherstr 8</ADDRESS_1>
<ADDRESS_2/>
<CITY>Mainz</CITY>
<ZIP>55131</ZIP>
<REGION>Rhineland-Palatinate</REGION>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 6131 177 335</PHONE_1>
<PHONE_2>+49 6131 177 336</PHONE_2>
<FAX_1>+49 6131 229 974</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE>Shared last authorship</FOOTNOTE>
</PERSON>
</CREATORS>
<DATES MODIFIED="2012-10-31 13:42:11 +0000" MODIFIED_BY="Jutta Stoffers">
<UP_TO_DATE>
<DATE DAY="10" MONTH="4" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="10" MONTH="10" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="10" MONTH="4" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="8" YEAR="2012"/>
</DATES>
<WHATS_NEW MODIFIED="2017-04-06 17:44:15 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2017-04-06 17:44:15 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="14" MONTH="3" YEAR="2017"/>
<DESCRIPTION>
<P>
<LINK TAG="FEEDBACK" TYPE="SECTION">Feedback</LINK> by Dr Gregory (via Cochrane Feedback mechanism, supplied to CDPLPG by Wiley 14 February 2017) incorporated. Changes included:<BR/>- correction of wording within <LINK TAG="SUMMARY_OF_RESULTS" TYPE="SECTION">Summary of main results</LINK>;<BR/>- new paragraph inserted within <LINK TAG="QUALITY_OF_EVIDENCE" TYPE="SECTION">Quality of the evidence</LINK>;<BR/>- 'Risk of bias' rating changed for <LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK> ('<B>Risk of Bias table &gt; Attention bias'</B>); and<BR/>- wording changed accordingly in <LINK TAG="OTHER_BIAS_SOURCES" TYPE="SECTION">Other potential sources of bias</LINK>.<BR/>
</P>
<P>Conclusions of review unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2017-04-06 16:50:13 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2017-04-06 16:50:13 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="31" MONTH="1" YEAR="2013"/>
<DESCRIPTION>
<P>Correction of data extraction error in relation to Davidson 2006 (analyses 1.7.4 and 1.9.5). Conclusions unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-01-31 12:22:26 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="1" MONTH="11" YEAR="2012"/>
<DESCRIPTION>
<P>Minor edit in the description of the exclusion criteria in two studies.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2012-11-01 11:37:21 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="6" MONTH="6" YEAR="2012"/>
<DESCRIPTION>
<P>Change in conclusions<BR/>New authorship<BR/>Accumulation of changes: change in methods section; rewriting of background section; changing of conclusions due to new identified evidence</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-11-01 11:37:19 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="10" MONTH="10" YEAR="2010"/>
<DESCRIPTION>
<P>New search</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2012-07-04 10:52:52 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2012-07-04 10:48:54 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2011-08-22 10:32:57 +0100" MODIFIED_BY="[Empty name]">
<NAME>Research Committee of the University Hospital Freiburg, Germany</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2012-07-04 10:48:54 +0100" MODIFIED_BY="[Empty name]">
<NAME>Nottinghamshire Healthcare NHS Trust</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2012-07-04 10:52:52 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2011-08-22 10:31:51 +0100" MODIFIED_BY="[Empty name]">
<NAME>German Federal Ministry of Education and Research, grant no. 01KG0609</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2012-06-26 14:51:21 +0100" MODIFIED_BY="[Empty name]">
<NAME>NHS Cochrane Collaboration Programme Grant Scheme (NIHR)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2012-07-04 10:52:52 +0100" MODIFIED_BY="[Empty name]">
<NAME>Ministry of Science, Research and Arts, federal state of Baden-Württemberg</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION>
<P>Stipend to JS</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2017-06-30 15:54:54 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-01-17 12:47:36 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2012-02-22 21:50:20 +0000" MODIFIED_BY="[Empty name]">Psychological therapies for borderline personality disorder</TITLE>
<SUMMARY_BODY MODIFIED="2013-01-17 12:47:36 +0000" MODIFIED_BY="[Empty name]">
<P>People with borderline personality disorder often have difficulties controlling their emotions and impulses, and find it hard to keep relationships. They can experience feelings of emptiness, suffer quick changes in mood and they may harm themselves. Problems coping with abandonment and a rapidly changing view of other people can form part of their difficulties. All of these things make it hard for them to engage with any treatment they may be offered. Those who are able to engage often find it hard to stick with the treatment and leave before the end. Certain types of psychological treatment ('talking therapies') have been developed in recent years to help people with this disorder. This review summarises what is currently known about the effects of these treatments. It updates a review published in the Cochrane Database of Systematic Reviews in 2006.</P>
<P>We found 28 studies that had involved a total of 1804 people with borderline personality disorder. These studies examined various psychological treatments. Some of these are called 'comprehensive' treatments because the person talks one-to-one with a professional for at least part of the time. Other treatments are called 'non-comprehensive' because they do not involve this one-to-one work.</P>
<P>A number of studies have been carried out on one particular type of comprehensive treatment, called Dialectical Behaviour Therapy. For this treatment, there were sufficient studies for us to pool the results and draw conclusions. The results indicate Dialectical Behaviour Therapy is helpful for people with borderline personality disorder. Effects included a decrease in inappropriate anger, a reduction in self-harm and an improvement in general functioning.</P>
<P>There were generally too few studies to allow firm conclusions to be drawn about the value of all the other kinds of psychotherapeutic interventions evaluated. However, single studies show encouraging findings for each treatment that was investigated, both 'comprehensive' and 'non-comprehensive' types. More research is needed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-07-06 10:26:15 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2012-06-13 11:01:20 +0100" MODIFIED_BY="[Empty name]">
<P>Psychotherapy is regarded as the first-line treatment for people with borderline personality disorder. In recent years, several disorder-specific interventions have been developed. This is an update of a review published in the Cochrane Database of Systematic Reviews in 2006.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-06-13 11:18:56 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effects of psychological interventions for borderline personality disorder (BPD).</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-06-13 11:01:45 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the following databases: CENTRAL 2010(3), MEDLINE (1950 to October 2010), EMBASE (1980 to 2010, week 39), ASSIA (1987 to November 2010), BIOSIS (1985 to October 2010), CINAHL (1982 to October 2010), Dissertation Abstracts International (31 January 2011), National Criminal Justice Reference Service Abstracts (15 October 2010), PsycINFO (1872 to October Week 1 2010), Science Citation Index (1970 to 10 October 2010), Social Science Citation Index (1970 to 10 October 2010), Sociological Abstracts (1963 to October 2010), ZETOC (15 October 2010) and the metaRegister of Controlled Trials (15 October 2010). In addition, we searched Dissertation Abstracts International in January 2011 and ICTRP in August 2011.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-06-06 10:41:49 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised studies with samples of patients with BPD comparing a specific psychotherapeutic intervention against a control intervention without any specific mode of action or against a comparative specific psychotherapeutic intervention. Outcomes included overall BPD severity, BPD symptoms (DSM-IV criteria), psychopathology associated with but not specific to BPD, attrition and adverse effects.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-06-05 13:46:56 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors independently selected studies, assessed the risk of bias in the studies and extracted data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-07-06 10:26:15 +0100" MODIFIED_BY="[Empty name]">
<P>Twenty-eight studies involving a total of 1804 participants with BPD were included. Interventions were classified as comprehensive psychotherapies if they included individual psychotherapy as a substantial part of the treatment programme, or as non-comprehensive if they did not.</P>
<P>Among comprehensive psychotherapies, dialectical behaviour therapy (DBT), mentalisation-based treatment in a partial hospitalisation setting (MBT-PH), outpatient MBT (MBT-out), transference-focused therapy (TFP), cognitive behavioural therapy (CBT), dynamic deconstructive psychotherapy (DDP), interpersonal psychotherapy (IPT) and interpersonal therapy for BPD (IPT-BPD) were tested against a control condition. Direct comparisons of comprehensive psychotherapies included DBT versus client-centered therapy (CCT); schema-focused therapy (SFT) versus TFP; SFT versus SFT plus telephone availability of therapist in case of crisis (SFT+TA); cognitive therapy (CT) versus CCT, and CT versus IPT.</P>
<P>Non-comprehensive psychotherapeutic interventions comprised DBT-group skills training only (DBT-ST), emotion regulation group therapy (ERG), schema-focused group therapy (SFT-G), systems training for emotional predictability and problem solving for borderline personality disorder (STEPPS), STEPPS plus individual therapy (STEPPS+IT), manual-assisted cognitive treatment (MACT) and psychoeducation (PE). The only direct comparison of an non-comprehensive psychotherapeutic intervention against another was MACT versus MACT plus therapeutic assessment (MACT+). Inpatient treatment was examined in one study where DBT for PTSD (DBT-PTSD) was compared with a waiting list control. No trials were identified for cognitive analytical therapy (CAT).</P>
<P>Data were sparse for individual interventions, and allowed for meta-analytic pooling only for DBT compared with treatment as usual (TAU) for four outcomes. There were moderate to large statistically significant effects indicating a beneficial effect of DBT over TAU for anger (n = 46, two RCTs; standardised mean difference (SMD) -0.83, 95% confidence interval (CI) -1.43 to -0.22; I<SUP>2 </SUP>= 0%), parasuicidality (n = 110, three RCTs; SMD -0.54, 95% CI -0.92 to -0.16; I<SUP>2 </SUP>= 0%) and mental health (n = 74, two RCTs; SMD 0.65, 95% CI 0.07 to 1.24 I<SUP>2 </SUP>= 30%). There was no indication of statistical superiority of DBT over TAU in terms of keeping participants in treatment (n = 252, five RCTs; risk ratio 1.25, 95% CI 0.54 to 2.92).</P>
<P>All remaining findings were based on single study estimates of effect. Statistically significant between-group differences for comparisons of psychotherapies against controls were observed for BPD core pathology and associated psychopathology for the following interventions: DBT, DBT-PTSD, MBT-PH, MBT-out, TFP and IPT-BPD. IPT was only indicated as being effective in the treatment of associated depression. No statistically significant effects were found for CBT and DDP interventions on either outcome, with the effect sizes moderate for DDP and small for CBT. For comparisons between different comprehensive psychotherapies, statistically significant superiority was demonstrated for DBT over CCT (core and associated pathology) and SFT over TFP (BPD severity and treatment retention). There were also encouraging results for each of the non-comprehensive psychotherapeutic interventions investigated in terms of both core and associated pathology.</P>
<P>No data were available for adverse effects of any psychotherapy.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-07-04 14:07:27 +0100" MODIFIED_BY="[Empty name]">
<P>There are indications of beneficial effects for both comprehensive psychotherapies as well as non-comprehensive psychotherapeutic interventions for BPD core pathology and associated general psychopathology. DBT has been studied most intensely, followed by MBT, TFP, SFT and STEPPS. However, none of the treatments has a very robust evidence base, and there are some concerns regarding the quality of individual studies. Overall, the findings support a substantial role for psychotherapy in the treatment of people with BPD but clearly indicate a need for replicatory studies.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2017-06-30 15:54:54 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-01-16 15:28:38 +0000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2013-01-16 15:28:38 +0000" MODIFIED_BY="[Empty name]">
<P>According to current diagnostic criteria, borderline personality disorder (BPD) is characterised by a pervasive pattern of instability in affect regulation, impulse control, interpersonal relationships and self-image. Clinical hallmarks include emotional dysregulation, impulsive aggression, repeated self-injury and chronic suicidal tendencies (<A HREF="Lieb 2004">Lieb 2004</A>). Whereas some authors have suggested that BPD is a variant of affective disorders (<A HREF="Akiskal 2004">Akiskal 2004</A>), others claim only partially overlapping aetiologies (<A HREF="Paris 2007">Paris 2007</A>). Despite its controversial nature, borderline personality disorder is the focus of great interest. Its importance stems from the huge suffering of the persons concerned, the functional impairment (<A HREF="Skodol 2002">Skodol 2002</A>) caused and from the significant impact it has on mental health services (<LINK REF="REF-Zanarini-2004" TYPE="REFERENCE">Zanarini 2004</LINK>
<A HREF="Zanarini 2004a">a</A>).</P>
<P>The <I>Diagnostic and Statistical Manual of Mental Disorders</I> (DSM-IV-TR) (<LINK REF="REF-APA-2000" TYPE="REFERENCE">APA 2000</LINK>a) definition of BPD comprises nine criteria that cover the above features; for a definite diagnosis five of these must be met, and a probable diagnosis requires four. The competing <I>International Classification of Diseases </I>in its 10th edition (ICD-10) refers to the condition 'Emotionally Unstable Personality Disorder' (F60.3), of which there is an impulsive type (F60.30) and a borderline type (F60.31) (<A HREF="WHO 2003">WHO 2003</A>). The latter essentially overlaps with the DSM-IV definition of BPD. A significant problem with this type of definition is that it is possible for two people to satisfy the criteria and yet have very different personalities. This heterogeneity is a major problem in assessing the impact of an intervention. Additional to the specific BPD criteria, DSM-IV-TR and ICD-10 provide general diagnostic criteria for any personality disorder that must also be met.</P>
<P>The prevalence of BPD is estimated at about 1.5% in the general population (<A HREF="Torgersen 2005">Torgersen 2005</A>), but higher (up to 20%) among psychiatric inpatients and prison populations, and it is predominantly diagnosed in women (75%; <LINK REF="REF-APA-2000" TYPE="REFERENCE">APA 2000</LINK>
<A HREF="APA 2000a">a</A>). There are particular problems with its diagnosis in adolescents and young adults where existential dilemmas may mistakenly be classified as BPD (DSM-IV). BPD commonly co-occurs with mood disorders, substance misuse, eating disorders and post-traumatic stress disorder (PTSD), and is also associated with other personality disorders (<A HREF="McGlashan 2000">McGlashan 2000</A>). Recent findings also suggest a close association between BPD and adult attention-deficit/hyperactivity disorder (ADHD). Prevalence estimates of comorbid adult ADHD in people with BPD range from 16% (<LINK REF="REF-Philipsen-2008" TYPE="REFERENCE">Philipsen 2008</LINK>) up to 38% (<LINK REF="REF-Ferrer-2010" TYPE="REFERENCE">Ferrer 2010</LINK>), and genetic analyses underline a genetic correlation of traits of both disorders (<LINK REF="REF-Distel-2011" TYPE="REFERENCE">Distel 2011</LINK>). Suicidal behaviour is reported to occur in up to 84% of patients with BPD (<A HREF="Soloff 2002">Soloff 2002</A>), with comorbid mood disorders or substance use being the most relevant risk factors for completion (<A HREF="Black 2004">Black 2004</A>).</P>
<P>Although the short- to medium-term outcome of BPD is poor, similar to that of schizophrenia, there is some evidence that the long-term follow-up course is more favourable with remission rates of about 88% within 10 years (<LINK REF="REF-Zanarini-2007" TYPE="REFERENCE">Zanarini 2007</LINK>). However, remission here only means that diagnostic criteria are not fulfilled and not the absence of any symptoms. Indeed, whereas acute symptoms, such as self-mutilation, help-seeking suicide threats or attempts and impulsivity decrease with time in most cases, affective symptoms reflecting areas of chronic dysphoria, such as chronic feelings of emptiness, intense anger or profound abandonment, largely remain (<LINK REF="REF-Zanarini-2007" TYPE="REFERENCE">Zanarini 2007</LINK>). The majority of people with BPD thus continue to experience significant levels of symptoms. Risk factors for a poorer long-term outcome are a comorbid substance use disorder; PTSD; an anxious cluster disorder (<A HREF="Zanarini 2005">Zanarini 2005</A>, <LINK REF="REF-Zanarini-2007" TYPE="REFERENCE">Zanarini 2007</LINK>); family history of psychiatric disorder (especially mood disorder and substance use disorder), and demographic factors, such as older age, longer treatment history, pathological childhood experiences, temperament problems and poor adult psychosocial functioning (<LINK REF="REF-Zanarini-2007" TYPE="REFERENCE">Zanarini 2007</LINK>). It is estimated that about 60% to 70% of patients with BPD make suicide attempts, although the rate of completed suicides is far less. Zanarini and colleagues found suicide rates of 4% during a 10-year follow-up (<LINK REF="REF-Zanarini-2007" TYPE="REFERENCE">Zanarini 2007</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2012-07-04 14:14:35 +0100" MODIFIED_BY="[Empty name]">
<P>Psychotherapeutic interventions for BPD encompass a broad range of treatments. As for any other mental disorder, established psychotherapies from the major psychotherapeutic schools are used, such as psychodynamic psychotherapy, cognitive behaviour therapy (CBT) or client-centered therapy. In addition, several specific psychotherapeutic approaches have been developed in the last decades to meet the challenges of BPD treatment. These disorder-specific approaches are based on principles of the established psychotherapeutic schools, but they are usually precisely structured and manualised. Strategies are provided for addressing interpersonal difficulties, which are a core problem for people with BPD and lead to difficulties in forming a therapeutic alliance. Most BPD-specific psychotherapies include treatment contracts, actively take measures to minimise premature non-completion of treatment and provide a crisis intervention protocol (<LINK REF="REF-De-Groot-2008" TYPE="REFERENCE">De Groot 2008</LINK>).</P>
<P>Among the psychological interventions used with people with BPD, the most commonly used are transference-focused therapy (TFP), dialectical behaviour therapy (DBT), mentalisation-based treatment (MBT), schema-focused therapy (SFT) and the systems training for emotional predictability and problem solving (STEPPS). Most of these treatments are designed as outpatient psychotherapies of six to 12 months duration with one or two weekly individual sessions. Some also include additional group therapy sessions. </P>
<P>In this review, we categorise therapies involving substantial one-to-one work as 'comprehensive' and those without this element as 'non-comprehensive'.</P>
</INTERVENTION>
<THEORY MODIFIED="2012-07-04 14:13:59 +0100" MODIFIED_BY="[Empty name]">
<P>According to the treatment guidelines of the American Psychiatric Association (APA), "clinical experience suggests that most patients with borderline personality disorder will need some form of extended psychotherapy in order to resolve interpersonal problems and attain and maintain lasting improvements in their personality and overall functioning" (<LINK REF="REF-APA-2001" TYPE="REFERENCE">APA 2001</LINK>, p.18), whereas drug treatment is accredited an adjunctive role.</P>
<P>Psychotherapeutic treatments are based on their specific assumptions about the aetiology and maintenance of the disorder. Broadly speaking, psychoanalytic therapies aim to help their patients understand and reflect on their inner mental processes and make links between their past and current difficulties. Treatments based on CBT place emphasis on self-directed learning processes; patients are encouraged to identify their core beliefs, evaluate and modify their behaviour accordingly and gain new experiences.</P>
<P>As mentioned previously, numerous disorder-specific approaches have been derived from the major psychotherapeutic schools. Some of the most prominent are dialectical behavioural therapy, mentalisation-based therapy, schema-focused therapy and transference-focused psychotherapy.</P>
<P>Dialectical behavioural therapy (DBT) (<A HREF="http://archie.cochrane.org/sections/documents/view?document=F8D9073182E26AA20019EB899B64C741&amp;format=REVMAN#REF-Linehan-1993">Linehan 1993</A>) is a complex psychological intervention that was developed using some of the principles of CBT in combination with mindfulness-based and systemic strategies. It aims to change behaviour and the ability to contain difficult feelings by focusing on improving skills, stress tolerance, emotion regulation, interpersonal behaviour and mindfulness.</P>
<P>Mentalisation-based therapy (MBT) (<LINK REF="REF-Bateman-2004" TYPE="REFERENCE">Bateman 2004</LINK>) is a complex psychoanalytically-based psychological intervention that aims to increase the reflective or mentalising capacity of the individual, helping the person to understand and recognise the feelings they evoke in others and the feelings they experience themselves.</P>
<P>Schema-focused therapy (SFT) (<LINK REF="REF-Young-2003" TYPE="REFERENCE">Young 2003</LINK>) draws from both behavioural and psychoanalytic theories and helps people with BPD to identify their self-defeating core themes arising from unmet emotional needs in childhood and presenting as maladaptive coping styles in adulthood. The goal of SFT is to aid patients in getting their needs met.</P>
<P>Transference-focused psychotherapy (TFP) (<LINK REF="REF-Clarkin-1999" TYPE="REFERENCE">Clarkin 1999</LINK>) strives to achieve integrated representations of self and others, modification of primitive defence operations and resolution of identity diffusion by analysis of the transference within the therapeutic relationship. Primitive object relations (for example, split, polarised) may be transformed to advanced ones (for example, differentiated, integrated).</P>
<P>In summary, psychotherapeutic approaches claim slightly different mechanisms of action, according to their underlying specific aetiology models. A common element is that they aim to ameliorate BPD pathology by use of verbal communication. Psychoanalytically-based therapies usually emphasise and use the therapeutic relationship as a model for other relationships, whereas cognitive behaviour therapy-based therapies primarily aim at acquiring new learning experiences and general self-management skills.</P>
</THEORY>
<IMPORTANCE MODIFIED="2012-07-04 14:16:50 +0100" MODIFIED_BY="[Empty name]">
<P>In addition to the suffering experienced by people with BPD and their relatives, considerable direct costs arise from the significant demands they make on health professionals. In medical settings, people with BPD often present after having self-harmed or in suicidal crisis and are treated in emergency settings. In many cases, repeated psychiatric hospitalisations occur. Additionally, according to a US study more than 80% of patients with BPD are in individual psychotherapy for at least half of a six-year period (<LINK REF="REF-Zanarini-2004" TYPE="REFERENCE">Zanarini 2004</LINK>), though treatment settings and provisions for patients with BPD vary across different countries. However, it remains unclear which treatments are helpful. This review aims to provide a systematic summary of the evidence from randomised controlled trials to help people with BPD and their health care workers make informed decisions about their treatment.</P>
<P>This is an update of a Cochrane review previously published in 2006 (<LINK REF="REF-Binks-2006" TYPE="REFERENCE">Binks 2006</LINK>). At that time, the authors concluded that "some of the problems frequently encountered by people with borderline personality disorder may be amenable to talking/behavioural treatments but all therapies remain experimental and the studies are too few and small to inspire full confidence in their results." A number of new studies on this topic has become available in the meantime, so that an update of the evidence seems timely.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-06-06 11:03:55 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate the effects of psychological interventions for people with borderline personality disorder (BPD).</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-07-11 11:28:38 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2012-07-11 11:28:38 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2012-06-05 13:47:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised studies involving parallel-arm comparisons examining psychotherapeutic interventions for people with BPD were included. Data from randomised cross-over studies up to the point of first cross-over were eligible for inclusion (first phase only). We excluded data from subsequent phases of cross-over trials because of the characteristically unstable course of BPD. In studies where participants served as their own controls (within-subject comparisons), we used first period data only (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). For further details, see <LINK TAG="UNIT_OF_ANALYSIS" TYPE="SECTION">Unit of analysis issues</LINK>.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2012-02-14 13:37:57 +0000" MODIFIED_BY="[Empty name]">
<P>Adults (aged 18 years or over) with a diagnosis of BPD according to DSM criteria (see table below), however diagnosed. Since the introduction of the diagnosis in 1980, the operational criteria have only changed marginally. Studies in which at least 70% participants had a formal diagnosis of BPD were included.</P>
<TABLE COLS="2" ROWS="12">
<TR>
<TD>
<P>
<B>DSM-III (</B>
<LINK REF="REF-APA-1980" TYPE="REFERENCE">APA 1980</LINK>
<B>)</B>
</P>
<P>
<B>301.83 Borderline Personality Disorder</B>
</P>
</TD>
<TD>
<P>
<B>DSM-IV-TR (</B>
<LINK REF="REF-APA-2000" TYPE="REFERENCE">APA 2000</LINK>
<B>)</B>
</P>
<P>
<B>301.83 Borderline Personality Disorder</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>
<I>Diagnostic criterion A (5 of the following are required)</I>
</B>
</P>
</TD>
<TD>
<P>
<B>
<I>Diagnostic criterion A: A pervasive pattern of instability of interpersonal relationships, self-image, and affects, and marked impulsivity beginning by early adulthood and present in a variety of contexts, as indicated by five (or more) of the following:</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>(6) intolerance of being alone, e.g., frantic efforts to avoid being alone, depressed when alone</P>
</TD>
<TD>
<P>(1) frantic efforts to avoid real or imagined abandonment - note: do not include suicidal or self-mutilating behavior covered in criterion 5</P>
</TD>
</TR>
<TR>
<TD>
<P>(2) a pattern of unstable and intense interpersonal relationships, e.g., marked shifts of attitude, idealization, devaluation, manipulation (consistently using others for one's own ends)</P>
</TD>
<TD>
<P>(2) a pattern of unstable and intense interpersonal relationships characterized by alternating between extremes of idealization and devaluation</P>
</TD>
</TR>
<TR>
<TD>
<P>(4) identity disturbance manifested by uncertainty about several issues relating to identity, such as self-image, gender identity, long-term goals or career choice, friendship patters, values, and loyalties, e.g., 'Who am I', 'I feel like I am my sister when I am good'</P>
</TD>
<TD>
<P>(3) identity disturbance: markedly and persistently unstable self-image or sense of self </P>
</TD>
</TR>
<TR>
<TD>
<P>(1) impulsivity or unpredictability in at least two areas that are potentially self-damaging, e.g., spending, sex, substance use, shoplifting, overeating, physically self-damaging acts</P>
</TD>
<TD>
<P>(4) impulsivity in at least two areas that are potentially self-damaging (e.g., spending, sex, substance abuse, reckless driving, binge eating) - note: do not include suicidal or self-mutilating behavior covered in criterion 5</P>
</TD>
</TR>
<TR>
<TD>
<P>(7) physically self-damaging acts, e.g., suicidal gestures, self-mutilation, recurrent accidents or physical fights</P>
</TD>
<TD>
<P>(5) recurrent suicidal behavior, gestures, or threats, or self-mutilating behavior </P>
</TD>
</TR>
<TR>
<TD>
<P>(5) affective instability: marked shifts from normal mood to depression, irritability, or anxiety, usually lasting a few hours and only rarely more than a few days, with a return to normal mood</P>
</TD>
<TD>
<P>(6) affective instability due to a marked reactivity of mood (e.g., intense episodic dysphoria, instability, or anxiety usually lasting a few hours and only rarely more than a few days)</P>
</TD>
</TR>
<TR>
<TD>
<P>(8) chronic feelings of emptiness or boredom</P>
</TD>
<TD>
<P>(7) chronic feelings of emptiness</P>
</TD>
</TR>
<TR>
<TD>
<P>(3) inappropriate, intense anger or lack of control of anger, e.g., frequent displays of temper, constant anger</P>
</TD>
<TD>
<P>(8) inappropriate, intense anger or difficulty controlling anger (e.g., frequent displays of temper, constant anger, recurrent physical fights)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>(9) transient, stress-related paranoid ideation or severe dissociate symptoms</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>
<I>Diagnostic criterion B: If under 18, does not meet the criteria for Identity Disorder</I>
</B>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<P/>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-07-04 14:17:39 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Experimental interventions</HEADING>
<P>Experimental interventions comprised any well-defined, theory-driven psychotherapeutic treatment. According to the index of Medical Subject Headings (MeSH), the thesaurus of the US National Library of Medicine's controlled vocabulary, psychotherapy was defined as "treatment of mental illness or emotional disturbances primarily by verbal or nonverbal communication" (<LINK REF="REF-NLM-2009" TYPE="REFERENCE">NLM 2009</LINK>). We considered all types of psychotherapy, regardless of theoretical orientation or treatment setting, including, for example, psychodynamic therapy, CBT, systemic therapy or eclectic therapies designed for BPD treatment. We also included any kind of treatment setting, that is, inpatient, outpatient or partially hospitalised. Trials on relaxation techniques and patient education programs were also eligible.</P>
<P>After all relevant trials had been identified and the variety of types of interventions became clear, we decided to arrange the results according to classes of interventions, and defined these classes as follows:</P>
<P>a) comprehensive psychotherapies: includes individual psychotherapy as substantial part of the intervention; additional group therapy may or may not be included; duration of at least three months;</P>
<P>b) non-comprehensive psychotherapeutic interventions: does not include individual psychotherapy as a substantial part of the intervention.</P>
<P>If the same interventions were tested in different settings (that is, outpatient, inpatient, partially hospitalised), we did not pool them together but treated them as different kinds of interventions.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparator interventions</HEADING>
<P>Eligible comparator interventions were grouped as follows:</P>
<UL>
<LI>unspecific control interventions; includes clinical management (CM), standard care (SC), treatment as usual (TAU) or waiting list (WL) (these are conditions without any specific mode of action);</LI>
<LI>comparative specific psychotherapeutic interventions; well-defined and theory-driven (head-to-head comparison).</LI>
</UL>
<P>Concomitant drug treatment was allowed if applied to both treatment conditions.</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-07-11 11:28:38 +0100" MODIFIED_BY="[Empty name]">
<P>Outcomes were either self-rated or interviewer-assessed. Only adequately validated measures were included. Studies were only included if they provided data that could be used for effect size calculation for at least one of the primary or secondary outcomes defined below.</P>
<P>If a study provided more than one measure for the same construct (for example, depression), the measure most often used in the whole pool of included studies was used for effect size calculation in order to minimise heterogeneity of outcomes in form and content. If a study reported the data of two assessment instruments that were equally frequently used, two review authors (JS, BV) discussed the issue and chose the one that they judged was most adequate for assessment of patients with BPD. Self-rated measures were preferred. We combined self- and observer-rated measures in the same analysis if no self-reported measure was available and it seemed appropriate to do so in terms of content validity. The possibility of heterogeneity was examined by considering I<SUP>2</SUP> values and a visual inspection of forest plots (see <LINK TAG="HETEROGENEITY_ASSESSMENT" TYPE="SECTION">Assessment of heterogeneity</LINK>).</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2012-07-11 11:28:38 +0100" MODIFIED_BY="[Empty name]">
<P>The following outcomes were defined as primary outcomes.</P>
<UL>
<LI>Overall BPD severity</LI>
<LI>Severity of single BPD criteria according to DSM, subsumed into the following symptom clusters:</LI>
<UL>
<LI>affective dysregulative cluster symptoms</LI>
<UL>
<LI>anger</LI>
<LI>affective instability</LI>
<LI>chronic feelings of emptiness</LI>
</UL>
<LI>impulsive cluster symptoms</LI>
<UL>
<LI>impulsivity</LI>
<LI>suicidality: severity of intent of killing oneself. Includes continuous measures of intent severity or numbers of suicidal acts and dichotomous measures of proportions of participants with suicidal acts. </LI>
<LI>parasuicidality: tendency or severity of intent of doing self-inflicted harm. Includes continuous measures of severity and dichotomous measures of proportion of participants with parasuicidal episodes.</LI>
</UL>
<LI>interpersonal cluster symptoms</LI>
<UL>
<LI>interpersonal problems general</LI>
<LI>avoidance of abandonment</LI>
</UL>
<LI>cognitive cluster symptoms</LI>
<UL>
<LI>identity disturbance</LI>
<LI>dissociation/stress-related paranoid ideation</LI>
</UL>
</UL>
</UL>
<P>'Summary of findings' tables are provided for the primary outcomes.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2012-07-10 12:08:18 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Depression</LI>
<LI>Anxiety</LI>
<LI>General psychopathology: composite measures of current general psychpathology)</LI>
<LI>Mental health status/functioning: measures of general psychosocial functioning on a hypothetical continuum of mental health to mental illness or full function to disability.</LI>
<LI>Leaving the study early</LI>
<LI>Adverse effects</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-07-04 14:19:04 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2012-06-13 10:56:43 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the following databases.</P>
<UL>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL), 2010, Issue 3, part of <I>The Cochrane Library</I>
</LI>
<LI>MEDLINE, 1950 to current, searched 15 October 2010</LI>
<LI>EMBASE, 1980 to 2010, Week 39, searched 15 October 2010</LI>
<LI>ASSIA, 1987 to current, searched 17 November 2010</LI>
<LI>BIOSIS, 1985 to current, searched 12 October 2010</LI>
<LI>CINAHL, 1982 to current, searched 8 October 2010</LI>
<LI>Dissertation Abstracts International, searched 31 January 2011</LI>
<LI>ICTRP, searched August 2011</LI>
<LI>metaRegister of Controlled Trials, searched 15 October 2010</LI>
<LI>National Criminal Justice Reference Service Abstracts, searched 15 October 2010</LI>
<LI>PsycINFO, 1872 to October Week 1 2010</LI>
<LI>Science Citation Index, 1970 to 10 October 2010</LI>
<LI>Social Science Citation Index, 1970 to 10 October 2010</LI>
<LI>Sociological Abstracts, 1963 to current, searched 11 October 2010</LI>
<LI>Zetoc (conference search), searched 15 October 2010</LI>
</UL>
<P>We included search terms for all types of personality disorder in the search strategy as this is one of a series of personality disorder reviews. Search terms and syntax were modified as necessary for each database (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>). There were no restrictions on language, date or document format.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2012-07-04 14:19:04 +0100" MODIFIED_BY="[Empty name]">
<P>Relevant journals such as the <I>Journal of Personality Disorders</I>, the<I> American Journal of Psychiatry</I>, <I>Archives of General Psychiatry</I>, the<I> British Journal of Psychiatry</I> and the <I>Journal of Clinical Psychiatry</I> were surveyed on a regular basis. Additionally, we contacted the lead authors of published RCTs via e-mail and kept track of any developments presented at relevant international meetings including the conferences of the International Society for the Study of Personality Disorders (ISSPD; <LINK REF="REF-ISSPD-2007" TYPE="REFERENCE">ISSPD 2007</LINK>; <LINK REF="REF-ISSPD-2009" TYPE="REFERENCE">ISSPD 2009</LINK>; <LINK REF="REF-ISSPD-2011" TYPE="REFERENCE">ISSPD 2011</LINK>) and the 1st International Congress of the European Society for the Study of Personality Disorders (<LINK REF="REF-ESSPD-2010" TYPE="REFERENCE">ESSPD 2010</LINK>). We also searched trial registers in order to identify any ongoing research (see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>). Cross-references from relevant literature were also traced.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-07-11 11:27:24 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2012-07-04 14:30:45 +0100" MODIFIED_BY="[Empty name]">
<P>Database and clinical trial register searches yielded 38,701 records, which were imported into ProCite reference management software. After electronic and manual deduplication, there were 28,535 records. We used the global search in ProCite to identify obviously irrelevant records (for example, about "borderline hypertension" or "borderline fractures"). The remaining 2458 records were divided up amongst various review authors (NH, MF, NS, MP) to assess study eligibility using titles and abstracts. All were double-checked by a second review author (JD). After exclusion of 1955 records, the remaining 503 references were made available in full text and assessed by two review authors independently (JD, JS). At this stage, multiple reports of the same study were linked together. If the two review authors disagreed, a third person (BV) adjudicated upon inclusion or exclusion. At the end of this process, 91 records for 28 RCTs were included in quantitative synthesis (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>)</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-06-05 13:48:45 +0100" MODIFIED_BY="[Empty name]">
<P>Data were independently extracted by two review authors (JS, BV) using standardised data extraction forms and double-entry into the Review Manager software. Any discrepancies were resolved through discussion or, if required, by an adjudicator (KL). We contacted study authors where publications reported incomplete data or where relevant subsample data were lacking.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2012-06-26 14:20:36 +0100" MODIFIED_BY="[Empty name]">
<P>Risk of bias was assessed using The Cochrane Collaboration's tool for assessing risk of bias (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Assessments included ratings of the likelihood for selection bias (random sequence generation, concealment of allocation), detection bias (blinding of outcome assessors), reporting bias (selective reporting), performance bias (treatment adherence), bias due to allegiance effects and attention bias.</P>
<P>Selection bias and reporting bias were assessed using the criteria for judging respective risks of bias as delineated in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>Though the importance of blinding and the possibility of bias due to lack of blinding are beyond question, it is still unclear how this issue should best be dealt with in research practice (<LINK REF="REF-Boutron-2008" TYPE="REFERENCE">Boutron 2008</LINK>). We did not judge the likelihood of detection bias due to inadequate blinding of patients and personnel, since in psychotherapy outcome research it is quite impossible to blind therapists and patients, and both also need to be informed about theoretical frameworks of the therapy provided to gain an in-depth understanding of the conditions and postulated mechanisms of change. However, if interviewer-rated measures were used, we assessed the likelihood of detection bias due to inadequate blinding of outcome assessors.</P>
<P>In addition, we assessed the likelihood of performance bias due to inadequate treatment adherence. The risk of bias was judged low if any means had been undertaken to assure adequate treatment adherence, for example, by regular supervision or use of adherence ratings of videotaped or audiotaped therapy sessions.</P>
<P>Psychotherapy trials are especially prone to bias due to "allegiance bias". That means, that "despite care in design, the therapeutic allegiance of the experimenter might in some way influence the results" (<LINK REF="REF-Luborsky-1975" TYPE="REFERENCE">Luborsky 1975</LINK>, p. 1003). However, the existence of the allegiance bias hypothesis, that advantageous findings result from the investigators' allegiances rather than from their inherent superiority, has yet to be proved (<LINK REF="REF-Leykin-2009" TYPE="REFERENCE">Leykin 2009</LINK>).</P>
<P>Last, the likelihood of bias due to different amounts of attention given to the treatment groups was rated (attention bias). Findings of beneficial effects by one treatment may primarily result from simply being paid attention to or being provided with any kind of intervention rather than from a specific mechanism of action. If there was a substantial difference of attention, this was regarded as possibly introducing bias, irrespective of other treatment options the participants may have used from other providers.</P>
<P>The 'Risk of bias' tool was applied by two review authors independently (JS, BV), and discrepancies were discussed in order to arrive at a consensus. A third person (KL) could have been called upon, but that was not necessary. All 'Risk of bias' domains mentioned above were included in a graph (see <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>) and summary (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). Trials were included irrespective of risk of bias, but possible impacts on effect estimates are discussed (see <LINK TAG="QUALITY_OF_EVIDENCE" TYPE="SECTION">Quality of the evidence</LINK>).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2012-06-05 13:49:03 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Continuous data</HEADING>
<P>Standardised mean differences (SMDs) were calculated on the basis of post-treatment group results. If the direction of a scale was opposite to most of the other scales, the corresponding mean values were multiplied by -1. Following (<LINK REF="REF-Cohen-1988" TYPE="REFERENCE">Cohen 1988</LINK>), SMD scores around 0.20 were regarded small, scores of 0.50 as moderate and scores of 0.80 or more as large.</P>
<P>In single studies, for example <LINK REF="STD-Giesen_x002d_Bloo-2006" TYPE="STUDY">Giesen-Bloo 2006</LINK>, effect sizes could not be calculated for some outcomes since data were not reported in a format usable for SMD calculation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous data</HEADING>
<P>Regarding dichotomous outcomes, the risk ratio (RR) was computed on an intention-to-treat (ITT) basis. We made the conservative assumption that all participants who were lost to post-treatment assessment had an unfavourable outcome, for example, they had left because the treatment had not been acceptable for them. All calculations were done using the latest release of the Review Manager software (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>).</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2012-06-13 13:54:20 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Repeated observations</HEADING>
<P>Study estimates were calculated on basis of post-treatment group results. Interim observations were not used.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cross-over trials</HEADING>
<P>
<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>
</P>
<P>Though cross-over studies were eligible, no such study was available for inclusion. See <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> for information about future updates of this review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cluster-randomised trials</HEADING>
<P>We intended to follow the guidance on statistical methods for cluster-randomised trials described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>). We would have sought direct estimates of the effect (for example, an odds ratio with its confidence interval) from an analysis that properly accounted for the cluster design. Alternatively, we would have extracted or calculated effect estimates and their standard errors as for a parallel group trial and adjusted the standard errors to account for the clustering (<LINK REF="REF-Donner-1980" TYPE="REFERENCE">Donner 1980</LINK>). This would have required information on an intra-class correlation coefficient (ICC), which describes the relative variability in outcome within and between clusters (<LINK REF="REF-Donner-1980" TYPE="REFERENCE">Donner 1980</LINK>). We would have extracted this information from the articles if available; otherwise, we would have contacted the authors or used external estimates obtained from similar studies. We would have searched for closest matching scenarios (with regard to both outcome measures and types of clusters) from existing databases of ICCs (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>) and if we had been unable to identify any, we would have performed sensitivity analyses using a high ICC of 0.1, a moderate ICC of 0.01 and a small ICC of 0.001. We recognise that these values are relatively arbitrary but would have preferred to use them to adjust the effect estimates and their standard errors due to the implausibility that the ICC is actually zero. Subsequently, we would have combined the estimates and their corrected standard errors from the cluster-randomised trials with those from parallel designs using the generic inverse variance method in Review Manager 5 (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>).</P>
<P>None of the included studies applied a cluster-randomisation procedure.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Multi-arm trials</HEADING>
<P>We would have included all eligible outcome measures for all trial arms in this review. If there had been more than two arms of a trial meeting the inclusion criteria, each referring to a different treatment, we would have included them as different comparisons (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>). If two or more arms referred to the same type of treatment, we would have combined these groups to create a single pair-wise comparison (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>).</P>
<P>There were no multi-arm trials.</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2012-06-26 14:23:19 +0100" MODIFIED_BY="[Empty name]">
<P>In cases of incomplete reporting of outcomes stated as having been assessed, we contacted the study authors.</P>
<P>Effect sizes were preferably calculated on the basis of ITT data. If only available case analysis (ACA) data were reported, we calculated effect sizes on this basis. In case of dichotomous data that were not presented on the basis of ITT data, the number of participants lost in each group were added to the participants with unfavourable results, acting on the assumption that most patients with BPD do not get lost at random.</P>
<P>For continuous outcomes we used per protocol analysis as available from the reports (that is, results are based on the number of patients at follow-up). If data were not reported in an immediately usable way but required processing before being analysed, a statistician (GR) was consulted. This was the case for the study of <LINK REF="STD-Blum-2008" TYPE="STUDY">Blum 2008</LINK> where standard deviations of mean values had to be calculated from standard errors.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2012-06-13 13:54:30 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed studies for clinical homogeneity with respect to type of therapy, therapy setting and control group. For any studies judged as clinically homogeneous and adequate for pooling, statistical heterogeneity was investigated by both visual inspection of the graphs and the I<SUP>2</SUP> statistics (<A HREF="Higgins 2003">Higgins 2003</A>). An I<SUP>2</SUP> score of &gt; 75% was regarded as representing considerable heterogeneity (<LINK REF="REF-Higgins-2011c" TYPE="REFERENCE">Higgins 2011c</LINK>).</P>
<P>We intended to carry out meta-analyses even if there was substantial concern about heterogeneity, but to interpret the results with caution, discuss possible reasons and investigate them by conducting subgroup analyses.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2012-07-11 11:27:24 +0100" MODIFIED_BY="[Empty name]">
<P>We planned to use funnel plots for comparisons with sufficient primary studies. No single comparison included sufficient effect estimates to allow for drawing of a conclusive funnel plot.</P>
<P>However, we drew a funnel plot for the one outcome (parasuicidality) for which data were available from 18 out of the 22 included controlled comparisons. Some studies reported continuous and some dichotomous measures, but the majority used continuous measures; we therefore decided to re-express dichotomous outcomes as SMDs using the approach of <LINK REF="REF-Chinn-2000" TYPE="REFERENCE">Chinn 2000</LINK>.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2012-06-12 12:29:58 +0100" MODIFIED_BY="[Empty name]">
<P>If several effect estimates were available, these were pooled and their 95% confidence interval (CI) calculated. The random-effects model was used, as some degree of clinical heterogeneity was present in most cases.</P>
<P>Separate comparisons were performed by type of intervention, that is, all approaches were analysed separately (for example, DBT versus control, MBT versus control), as were comparisons of the same type of psychotherapy to different kinds of controls (for example, DBT versus treatment as usual; DBT versus general management). In addition, separate comparisons were done if the same psychotherapy was delivered in different treatment settings (that is, MBT-partially hospitalised setting versus control, MBT-outpatient versus control).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2012-07-04 14:33:48 +0100" MODIFIED_BY="[Empty name]">
<P>Pre-planned subgroup analyses according to participant characteristics (sex, presence of distinct psychiatric comorbidities such as depression, addictive behaviour or post-traumatic stress disorder, having undergone psychotherapy previously) or treatment characteristics (duration less or more than one year) could not be performed due to lack of studies.</P>
<P>There were only single studies available per comparison except for DBT versus TAU (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>; <LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>; <LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>). The DBT versus TAU studies studies did not vary clinically with regard to predefined subgroup criteria, so we did not perform subgroup analyses.</P>
<P>Statistical heterogeneity in terms of an I<SUP>2</SUP>score exceeding 75% was only found for one analysis (<LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>). We discussed reasons (<LINK TAG="INTERVENTION_EFFECTS" TYPE="SECTION">Effects of interventions</LINK>, 1.1.9) and undertook a post-hoc sensitivity analysis (<LINK REF="CMP-001.19" TYPE="ANALYSIS">Analysis 1.19</LINK>).</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2012-07-04 14:35:46 +0100" MODIFIED_BY="[Empty name]">
<P>Sensitivity analyses for the primary outcomes were planned to be performed as follows.</P>
<UL>
<LI>Trials requiring participants to have a certain psychiatric comorbidity in addition to BPD were to be excluded.</LI>
<LI>Only ITT-data based outcomes were to be included.</LI>
</UL>
<P>Given the small numbers of effect estimates per comparison and outcome, we did not conduct sensitivity analyses, as this would only have led to omitting results. Instead, we strived to make trial characteristics as well as all potential shortcomings of methodological quality explicit (compare <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> tables and <LINK TAG="STUDY_QUALITY" TYPE="SECTION">Risk of bias in included studies</LINK> section of the <LINK TAG="STUDY_DESCRIPTION" TYPE="SECTION">Description of studies</LINK> section) and to critically discuss all findings.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2017-04-06 17:46:12 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-01-31 16:52:58 +0000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2012-07-04 14:42:12 +0100" MODIFIED_BY="[Empty name]">
<P>All electronic databases and search periods are listed in the <LINK TAG="METHODS" TYPE="SECTION">Methods</LINK> section (see <LINK TAG="ELECTRONIC_SEARCHES" TYPE="SECTION">Electronic searches</LINK>) and in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> and <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>. There were no language, date or document format restrictions. This review is part of a series of reviews on interventions for personality disorders and so a very comprehensive search strategy was used covering all psychotherapeutic and/or pharmacological treatment of any personality disorder.</P>
<P>The searches generated 38,701 records altogether, of which 10,166 were identified as duplicates. After screening of titles and abstracts, 503 citations merited closer inspection. Assessment of full texts lead to the exclusion of 362 records: 164 were not trials; 143 did not have psychotherapy as the intervention; 30 were not RCTs, and 25 were excluded on the grounds of sample characteristics. This left 141 records. 32 of those records related to 28 different ongoing studies (see <LINK TAG="ONGOING_STUDIES" TYPE="SECTION">Ongoing studies</LINK>). Eighteen records related to eight different RCTs that either had not assessed any of the pre-defined outcomes of interest of this review or did not provide usable data were excluded. This left 91 eligible papers altogether (see <LINK TAG="INCLUDED_STUDIES" TYPE="SECTION">Included studies</LINK>), that is, primary or secondary publications of primary studies, conference proceedings and trial register entries, covering 28 different RCTs that were included in quantitative syntheses (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-01-31 16:52:58 +0000" MODIFIED_BY="[Empty name]">
<P>For essential characteristics of the 28 included studies, please see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. The studies were published between 1991 and 2010: three during the 1990s, another three between 2000 and 2005 and a much larger number (22) between 2006 and 2010.</P>
<SUBSECTION>
<HEADING LEVEL="4">Design</HEADING>
<P>All primary studies were randomised, parallel-arm trials. Most studies (n = 19) were conducted at a single site. The remaining nine had several participating study centres, that is, n = 2 ( <LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK>; <LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK>; <LINK REF="STD-Cottraux-2009" TYPE="STUDY">Cottraux 2009</LINK>; <LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK>; <LINK REF="STD-Bos-2010" TYPE="STUDY">Bos 2010</LINK>; <LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK>), n = 3 (<LINK REF="STD-Davidson-2006" TYPE="STUDY">Davidson 2006</LINK>), n = 4 (<LINK REF="STD-Giesen_x002d_Bloo-2006" TYPE="STUDY">Giesen-Bloo 2006</LINK>) or n = 8 (<LINK REF="STD-Nadort-2009" TYPE="STUDY">Nadort 2009</LINK>) study sites.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sample sizes</HEADING>
<P>The sample sizes ranged from n = 16 to n = 180. Altogether, n = 1804 participants were included (mean = 64.4, SD = 42.7). Six trials had sample sizes of more than 100 participants (<LINK REF="STD-Davidson-2006" TYPE="STUDY">Davidson 2006</LINK>; <LINK REF="STD-Linehan-2006" TYPE="STUDY">Linehan 2006</LINK>; <LINK REF="STD-Blum-2008" TYPE="STUDY">Blum 2008</LINK>; <LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK>; <LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK>; <LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Setting</HEADING>
<P>All but two trials were conducted in an outpatient setting. In contrast, participants of the <LINK REF="STD-Bateman-1999" TYPE="STUDY">Bateman 1999</LINK> study were partially hospitalised if allocated to the experimental group, but remained outpatients if allocated to the control group. The study of <LINK REF="STD-Steil-2010" TYPE="STUDY">Steil 2010</LINK> tested DBT-PTSD, an adaption of DBT for the treatment of patients with BPD with comorbid posttraumatic stress disorder. It includes several stages from a diagnostic outpatient phase to an inpatient stay and an additional outpatient booster session after the end of inpatient treatment. However, the main interventions were conducted in an inpatient setting.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Sex</HEADING>
<P>Twelve studies consisted of female participants only (<LINK REF="STD-Linehan-1991" TYPE="STUDY">Linehan 1991</LINK>; <LINK REF="STD-Linehan-1994" TYPE="STUDY">Linehan 1994</LINK>; <LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK>; <LINK REF="STD-Van-den-Bosch-2005" TYPE="STUDY">Van den Bosch 2005</LINK>; <LINK REF="STD-Gratz-2006" TYPE="STUDY">Gratz 2006</LINK>; <LINK REF="STD-Linehan-2006" TYPE="STUDY">Linehan 2006</LINK>; <LINK REF="STD-Weinberg-2006" TYPE="STUDY">Weinberg 2006</LINK>; <LINK REF="STD-Zanarini-2008" TYPE="STUDY">Zanarini 2008</LINK>; <LINK REF="STD-Farrell-2009" TYPE="STUDY">Farrell 2009</LINK>; <LINK REF="STD-Carter-2010" TYPE="STUDY">Carter 2010</LINK>; <LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK>; <LINK REF="STD-Steil-2010" TYPE="STUDY">Steil 2010</LINK>). All remaining studies were mixed but predominantly female. More than 75% of participants were female in <LINK REF="STD-Turner-2000" TYPE="STUDY">Turner 2000</LINK>; <LINK REF="STD-Davidson-2006" TYPE="STUDY">Davidson 2006</LINK>; <LINK REF="STD-Giesen_x002d_Bloo-2006" TYPE="STUDY">Giesen-Bloo 2006</LINK>; <LINK REF="STD-Bellino-2007" TYPE="STUDY">Bellino 2007</LINK>; <LINK REF="STD-Blum-2008" TYPE="STUDY">Blum 2008</LINK>; <LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>; <LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK>; <LINK REF="STD-Cottraux-2009" TYPE="STUDY">Cottraux 2009</LINK>; <LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK>; <LINK REF="STD-Nadort-2009" TYPE="STUDY">Nadort 2009</LINK>;<LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>; <LINK REF="STD-Bos-2010" TYPE="STUDY">Bos 2010</LINK>; <LINK REF="STD-Morey-2010" TYPE="STUDY">Morey 2010</LINK>. Only three studies had less than 75% female participants (<LINK REF="STD-Bateman-1999" TYPE="STUDY">Bateman 1999</LINK>: 57.9%; <LINK REF="STD-Bellino-2006" TYPE="STUDY">Bellino 2006</LINK>: 60.0%; <LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK>: 67.3%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Diagnostic criteria and means of assessment</HEADING>
<P>Participants were diagnosed as having BPD according to DSM-III (<LINK REF="STD-Linehan-1991" TYPE="STUDY">Linehan 1991</LINK>), DSM-III-R (<LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK>; <LINK REF="STD-Linehan-1994" TYPE="STUDY">Linehan 1994</LINK>; <LINK REF="STD-Bateman-1999" TYPE="STUDY">Bateman 1999</LINK>; <LINK REF="STD-Turner-2000" TYPE="STUDY">Turner 2000</LINK>; <LINK REF="STD-Farrell-2009" TYPE="STUDY">Farrell 2009</LINK>) or DSM-IV (<LINK REF="STD-Van-den-Bosch-2005" TYPE="STUDY">Van den Bosch 2005</LINK>; <LINK REF="STD-Bellino-2006" TYPE="STUDY">Bellino 2006</LINK>; <LINK REF="STD-Davidson-2006" TYPE="STUDY">Davidson 2006</LINK>; <LINK REF="STD-Giesen_x002d_Bloo-2006" TYPE="STUDY">Giesen-Bloo 2006</LINK>; <LINK REF="STD-Gratz-2006" TYPE="STUDY">Gratz 2006</LINK>; <LINK REF="STD-Linehan-2006" TYPE="STUDY">Linehan 2006</LINK>; <LINK REF="STD-Weinberg-2006" TYPE="STUDY">Weinberg 2006</LINK>; <LINK REF="STD-Bellino-2007" TYPE="STUDY">Bellino 2007</LINK>; <LINK REF="STD-Blum-2008" TYPE="STUDY">Blum 2008</LINK>; <LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>; <LINK REF="STD-Zanarini-2008" TYPE="STUDY">Zanarini 2008</LINK>; <LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK>; <LINK REF="STD-Cottraux-2009" TYPE="STUDY">Cottraux 2009</LINK>; <LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK>; <LINK REF="STD-Nadort-2009" TYPE="STUDY">Nadort 2009</LINK>;<LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>; <LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK>; <LINK REF="STD-Bos-2010" TYPE="STUDY">Bos 2010</LINK>; <LINK REF="STD-Carter-2010" TYPE="STUDY">Carter 2010</LINK>; <LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK>; <LINK REF="STD-Morey-2010" TYPE="STUDY">Morey 2010</LINK>; <LINK REF="STD-Steil-2010" TYPE="STUDY">Steil 2010</LINK>).</P>
<P>The presence of BPD was confirmed by some standardised means of assessment in all studies. The most frequently used assessment instrument was the Structured Clinical Interview for DSM-III-R (<LINK REF="REF-Spitzer-1985" TYPE="REFERENCE">Spitzer 1985</LINK>) or DSM-IV (<LINK REF="REF-First-1997" TYPE="REFERENCE">First 1997</LINK>) personality disorders (<U>SCID-II</U>). It was used by <LINK REF="STD-Linehan-1994" TYPE="STUDY">Linehan 1994</LINK>; <LINK REF="STD-Bateman-1999" TYPE="STUDY">Bateman 1999</LINK>; <LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK>; <LINK REF="STD-Van-den-Bosch-2005" TYPE="STUDY">Van den Bosch 2005</LINK>; <LINK REF="STD-Bellino-2006" TYPE="STUDY">Bellino 2006</LINK>; <LINK REF="STD-Davidson-2006" TYPE="STUDY">Davidson 2006</LINK>; <LINK REF="STD-Giesen_x002d_Bloo-2006" TYPE="STUDY">Giesen-Bloo 2006</LINK>; <LINK REF="STD-Linehan-2006" TYPE="STUDY">Linehan 2006</LINK>; <LINK REF="STD-Weinberg-2006" TYPE="STUDY">Weinberg 2006</LINK>; <LINK REF="STD-Bellino-2007" TYPE="STUDY">Bellino 2007</LINK>; <LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>; <LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK>; <LINK REF="STD-Nadort-2009" TYPE="STUDY">Nadort 2009</LINK>; <LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>; <LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK>; <LINK REF="STD-Bos-2010" TYPE="STUDY">Bos 2010</LINK>; <LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK>. Other DSM-oriented means of assessment were the Structured Interview for DSM-IV Personality (<U>SIDP-IV</U>; <LINK REF="REF-Pfohl-1997" TYPE="REFERENCE">Pfohl 1997</LINK>), which was used by <LINK REF="STD-Blum-2008" TYPE="STUDY">Blum 2008</LINK>, and the International Personality Disorder Examination (<U>IPDE</U>; <LINK REF="REF-Loranger-1995" TYPE="REFERENCE">Loranger 1995</LINK>), which was used by <LINK REF="STD-Carter-2010" TYPE="STUDY">Carter 2010</LINK>, <LINK REF="STD-Steil-2010" TYPE="STUDY">Steil 2010</LINK> and <LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK>. <LINK REF="STD-Carter-2010" TYPE="STUDY">Carter 2010</LINK> specifically used the IPDE-self rating screening questionnaire the preliminary findings of which were confirmed in clinical interviews by a psychiatrist. <LINK REF="STD-Turner-2000" TYPE="STUDY">Turner 2000</LINK> used a preceding version of IPDE, the Personality Disorders Examination (<U>PDE</U>; <LINK REF="REF-Loranger-1988" TYPE="REFERENCE">Loranger 1988</LINK>). The Diagnostic Interview for DSM-IV Personality Disorders (<U>DIPD-IV</U>; <LINK REF="REF-Zanarini-1987" TYPE="REFERENCE">Zanarini 1987</LINK>) was used in the studies of <LINK REF="STD-Gratz-2006" TYPE="STUDY">Gratz 2006</LINK>; <LINK REF="STD-Zanarini-2008" TYPE="STUDY">Zanarini 2008</LINK> and <LINK REF="STD-Morey-2010" TYPE="STUDY">Morey 2010</LINK>). Another frequently used standardised interview was the <U>DIB</U> (<LINK REF="REF-Gunderson-1981" TYPE="REFERENCE">Gunderson 1981</LINK>) or <U>DIB-R</U> (<LINK REF="REF-Zanarini-1989" TYPE="REFERENCE">Zanarini 1989</LINK>), which was originally developed to categorically assess BPD not as defined by DSM but as conceptualised by J.G. Gunderson and his group before publication of DSM-III. It is indicative of a diagnosis of BPD but can not be relied upon to make a DSM diagnosis due to its somewhat different conceptualisation (<LINK REF="REF-Rush--2005" TYPE="REFERENCE">Rush 2005</LINK>). It was used additionally to another DSM-oriented interview by <LINK REF="STD-Linehan-1994" TYPE="STUDY">Linehan 1994</LINK>; <LINK REF="STD-Bateman-1999" TYPE="STUDY">Bateman 1999</LINK>; <LINK REF="STD-Turner-2000" TYPE="STUDY">Turner 2000</LINK>; <LINK REF="STD-Weinberg-2006" TYPE="STUDY">Weinberg 2006</LINK>; <LINK REF="STD-Zanarini-2008" TYPE="STUDY">Zanarini 2008</LINK>; <LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>. It was used as only standardised means of diagnostic assessment by <LINK REF="STD-Cottraux-2009" TYPE="STUDY">Cottraux 2009</LINK> and <LINK REF="STD-Linehan-1991" TYPE="STUDY">Linehan 1991</LINK>, but the DSM diagnosis was additionally confirmed by clinical interviews. <LINK REF="STD-Farrell-2009" TYPE="STUDY">Farrell 2009</LINK> also used DIB-R but also the Borderline Syndrome Index (<U>BSI</U>; <LINK REF="REF-Conte-1980" TYPE="REFERENCE">Conte 1980</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Exclusion criteria</HEADING>
<P>People with evidence of mental impairment, organic brain disorder, insufficient commend of the language spoken, severe disabling organic conditions, dementia or neurologic diseases, place of residence too far from the study centre or being in coercive treatment were not eligible for most studies. Comorbid personality disorders were no reason for exclusion from most trials, but <LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK>; <LINK REF="STD-Giesen_x002d_Bloo-2006" TYPE="STUDY">Giesen-Bloo 2006</LINK>; <LINK REF="STD-Cottraux-2009" TYPE="STUDY">Cottraux 2009</LINK>; <LINK REF="STD-Carter-2010" TYPE="STUDY">Carter 2010</LINK>; <LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK>; and <LINK REF="STD-Nadort-2009" TYPE="STUDY">Nadort 2009</LINK> excluded those with antisocial features or full antisocial personality disorder and <LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK> did not include people with any comorbid personality disorder. Of the axis-I disorders, schizophrenia, schizoaffective and other psychotic disorders were reasons for exclusion from all studies except <LINK REF="STD-Bos-2010" TYPE="STUDY">Bos 2010</LINK>. Bipolar disorder, mostly not further specified, was also a very common reason for exclusion, except for the studies of <LINK REF="STD-Blum-2008" TYPE="STUDY">Blum 2008</LINK>; <LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>; <LINK REF="STD-Cottraux-2009" TYPE="STUDY">Cottraux 2009</LINK>; <LINK REF="STD-Farrell-2009" TYPE="STUDY">Farrell 2009</LINK>; <LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK>; <LINK REF="STD-Bos-2010" TYPE="STUDY">Bos 2010</LINK>; <LINK REF="STD-Morey-2010" TYPE="STUDY">Morey 2010</LINK>. <LINK REF="STD-Gratz-2006" TYPE="STUDY">Gratz 2006</LINK>; <LINK REF="STD-Zanarini-2008" TYPE="STUDY">Zanarini 2008</LINK>; <LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK>; <LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK> specified that only people with bipolar I disorder were excluded. Other common reasons for exclusion were substance-related disorders. People with current substance abuse were not eligible for the studies of <LINK REF="STD-Bateman-1999" TYPE="STUDY">Bateman 1999</LINK>; <LINK REF="STD-Bellino-2006" TYPE="STUDY">Bellino 2006</LINK>; <LINK REF="STD-Bellino-2007" TYPE="STUDY">Bellino 2007</LINK>; <LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK>; <LINK REF="STD-Morey-2010" TYPE="STUDY">Morey 2010</LINK>. Dependence was a reason for exclusion from the trials of <LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK> (opiates); <LINK REF="STD-Linehan-1991" TYPE="STUDY">Linehan 1991</LINK>; <LINK REF="STD-Linehan-1994" TYPE="STUDY">Linehan 1994</LINK>; <LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK>; <LINK REF="STD-Davidson-2006" TYPE="STUDY">Davidson 2006</LINK>; <LINK REF="STD-Gratz-2006" TYPE="STUDY">Gratz 2006</LINK>; <LINK REF="STD-Weinberg-2006" TYPE="STUDY">Weinberg 2006</LINK>; <LINK REF="STD-Zanarini-2008" TYPE="STUDY">Zanarini 2008</LINK>; <LINK REF="STD-Cottraux-2009" TYPE="STUDY">Cottraux 2009</LINK>; <LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK>; <LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>; <LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK> (any substance). People with acute substance dependence were excluded from the studies of <LINK REF="STD-Giesen_x002d_Bloo-2006" TYPE="STUDY">Giesen-Bloo 2006</LINK> and <LINK REF="STD-Nadort-2009" TYPE="STUDY">Nadort 2009</LINK> if clinical detoxification was required but could enter the trial afterwards. In contrast, all participants of <LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK> had a current diagnosis of alcohol abuse or dependence. Both <LINK REF="STD-Giesen_x002d_Bloo-2006" TYPE="STUDY">Giesen-Bloo 2006</LINK> and <LINK REF="STD-Nadort-2009" TYPE="STUDY">Nadort 2009</LINK> excluded possible participants with a dissociative identity disorder and those with attention-deficit/hyperactivity disorder. <LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK> was the only study explicitly excluding people with a current major depressive episode. Severity-related reasons for exclusion were rare. For the <LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK> study, people with a CGI-S score of &#8807; 4, that is, moderately ill or worse, were not eligible. Acute danger to self and/or others as reason for ineligibility was explicitly specified only by <LINK REF="STD-Gratz-2006" TYPE="STUDY">Gratz 2006</LINK>; <LINK REF="STD-Weinberg-2006" TYPE="STUDY">Weinberg 2006</LINK>; <LINK REF="STD-Bos-2010" TYPE="STUDY">Bos 2010</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Severity of illness/level of functioning</HEADING>
<P>There was no standard way of reporting or describing the overall severity of illness or the level of functioning of study participants.</P>
<P>The Global Assessment of Functioning Scale (<U>GAF</U>; <LINK REF="REF-APA-1987" TYPE="REFERENCE">APA 1987</LINK>) was used by five trials. On a scale from one (persistent danger of severely hurting self or others ) to 100 (superior functioning), participants of <LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK> and <LINK REF="STD-Farrell-2009" TYPE="STUDY">Farrell 2009</LINK> scored between 41 and 50 and thus had "serious symptoms (for example, suicidal ideation, severe obsessional rituals, frequent shoplifting) OR any serious impairment in social, occupational, or school functioning (for example, no friends, unable to keep a job)". Participants of <LINK REF="STD-Zanarini-2008" TYPE="STUDY">Zanarini 2008</LINK>; <LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK>; <LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK> scored between 51 and 60 and therefore had "moderate symptoms (for example, flat affect and circumstantial speech, occasional panic attacks) OR moderate difficulty in social, occupational, or school functioning (for example, few friends, conflicts with peers or co-workers)".</P>
<P>Another trial used the Global Assessment Scale (<U>GAS</U>; <LINK REF="REF-Endicott-1976" TYPE="REFERENCE">Endicott 1976</LINK>), the scale that the GAF originally was derived from. It also uses a 1 to 100 continuum, with 1 indicating the lowest level of functioning in a hypothetical continuum of mental illness to health. Participants of <LINK REF="STD-Linehan-1994" TYPE="STUDY">Linehan 1994</LINK> scored between 31 and 40 on average at baseline, which indicates "major impairment in several areas, such as work, family relations, judgment, thinking or mood OR some impairment in reality testing or communication OR single serious suicide attempt".</P>
<P>Another widely used measure was the Clinical Global Impression Scale (CGI, <LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>). Scores on its Severity of Illness Subscale (<U>CGI-S</U>) range from 1 = "not ill at all" to 7 = "among the most extremely ill". In primary studies included here, the average CGI-S baseline scores described samples as "mildly to moderately ill" (<LINK REF="STD-Bellino-2007" TYPE="STUDY">Bellino 2007</LINK>), "moderately to markedly ill" (<LINK REF="STD-Bellino-2006" TYPE="STUDY">Bellino 2006</LINK>) or "markedly to severely ill" (<LINK REF="STD-Blum-2008" TYPE="STUDY">Blum 2008</LINK>; <LINK REF="STD-Cottraux-2009" TYPE="STUDY">Cottraux 2009</LINK>; <LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK>).</P>
<P>An adaptation of CGI for BPD (Clinical Global Impression-Scale for Borderline Personality Disorder Patients; <U>CGI-BPD</U>; <LINK REF="REF-P_x00e9_rez-2007" TYPE="REFERENCE">Pérez 2007</LINK>) was used in one trial (<LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>), indicating a "moderately to markedly ill" sample of patients on average.</P>
<P>Another indicator of severity of illness was the reported mean <U>number of fulfilled BPD criteria</U> (five out of nine are required for a diagnosis). These were 6.8 for the samples of <LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK> and <LINK REF="STD-Nadort-2009" TYPE="STUDY">Nadort 2009</LINK>, 6.9 for <LINK REF="STD-Giesen_x002d_Bloo-2006" TYPE="STUDY">Giesen-Bloo 2006</LINK>, 7.4 for <LINK REF="STD-Van-den-Bosch-2005" TYPE="STUDY">Van den Bosch 2005</LINK> and 7.5 for <LINK REF="STD-Gratz-2006" TYPE="STUDY">Gratz 2006</LINK>.</P>
<P>
<LINK REF="STD-Davidson-2006" TYPE="STUDY">Davidson 2006</LINK> used the <U>SFQ</U> (Social Functioning Questionnaire; <LINK REF="REF-Tyrer-2005" TYPE="REFERENCE">Tyrer 2005</LINK>). The score range is 0 to 24, and a score of 10 or more indicates poor social functioning. The mean SFQ score of the sample was 14.6, comparable to psychiatric emergencies.</P>
<P>The remaining studies reported no standardised measures of severity.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>The duration of trial interventions ranged from 1.5 to 36 months. The mean duration was 10.19 months (SD = 7.02). Seven trials with interventions of predominantly psychoeducational character had a duration of less than six months (<LINK REF="STD-Gratz-2006" TYPE="STUDY">Gratz 2006</LINK>; <LINK REF="STD-Weinberg-2006" TYPE="STUDY">Weinberg 2006</LINK>; <LINK REF="STD-Blum-2008" TYPE="STUDY">Blum 2008</LINK>; <LINK REF="STD-Zanarini-2008" TYPE="STUDY">Zanarini 2008</LINK>; <LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>; <LINK REF="STD-Bos-2010" TYPE="STUDY">Bos 2010</LINK>; <LINK REF="STD-Morey-2010" TYPE="STUDY">Morey 2010</LINK>). In addition, the inpatient treatment in the study of <LINK REF="STD-Steil-2010" TYPE="STUDY">Steil 2010</LINK> was also of less than six months duration, that is, three months. The studies of <LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK>; <LINK REF="STD-Bellino-2006" TYPE="STUDY">Bellino 2006</LINK>; <LINK REF="STD-Bellino-2007" TYPE="STUDY">Bellino 2007</LINK>; <LINK REF="STD-Carter-2010" TYPE="STUDY">Carter 2010</LINK> lasted six months, those of <LINK REF="STD-Farrell-2009" TYPE="STUDY">Farrell 2009</LINK> and <LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK> eight months. The major part of 10 studies (<LINK REF="STD-Linehan-1991" TYPE="STUDY">Linehan 1991</LINK>; <LINK REF="STD-Linehan-1994" TYPE="STUDY">Linehan 1994</LINK>; <LINK REF="STD-Turner-2000" TYPE="STUDY">Turner 2000</LINK>; <LINK REF="STD-Van-den-Bosch-2005" TYPE="STUDY">Van den Bosch 2005</LINK>; <LINK REF="STD-Davidson-2006" TYPE="STUDY">Davidson 2006</LINK>; <LINK REF="STD-Linehan-2006" TYPE="STUDY">Linehan 2006</LINK>; <LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>; <LINK REF="STD-Cottraux-2009" TYPE="STUDY">Cottraux 2009</LINK>; <LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK>; <LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK>) were of one year's duration. The three studies of <LINK REF="STD-Bateman-1999" TYPE="STUDY">Bateman 1999</LINK>; <LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK>; <LINK REF="STD-Nadort-2009" TYPE="STUDY">Nadort 2009</LINK> lasted 18 months, and the trial of <LINK REF="STD-Giesen_x002d_Bloo-2006" TYPE="STUDY">Giesen-Bloo 2006</LINK> was the longest with a duration of 36 months.</P>
<P>In the following, the interventions tested in the included RCTs will be described briefly. However, it is not possible to provide a comprehensive account of each psychological intervention. Only very short descriptions will be given and relevant references indicated.</P>
<SUBSECTION>
<HEADING LEVEL="5">Comprehensive psychotherapies</HEADING>
<P>As depicted above, comprehensive psychotherapies were defined as including individual psychotherapy as substantial part of the intervention. Duration must have been three months or more. Group therapy may or may not be delivered.</P>
<SUBSECTION>
<HEADING LEVEL="6">Dialectical behaviour therapy (DBT) and modified DBT-related treatments (eight studies: Carter 2010; Koons 2001; Linehan 1991; Linehan 1994; Linehan 2006; McMain 2009; Turner 2000; van den Bosch 2005)</HEADING>
<P>Dialectical behavioural therapy (DBT; <LINK REF="REF-Linehan-1993a" TYPE="REFERENCE">Linehan 1993a</LINK>; <LINK REF="REF-Linehan-1993b" TYPE="REFERENCE">Linehan 1993b</LINK>) is a multi-module psychological intervention that was developed using some of the principles of CBT in combination with mindfulness-based techniques. It aims to change behaviour by improving skills and the ability to contain difficult feelings, but also applies supportive elements, for example, in the principles of validation of emotions and acceptance. Problem-oriented behaviour "skills" are targeted at enhanced stress tolerance, interpersonal situations, emotion regulation and mindfulness. DBT was originally designed as an outpatient treatment. It includes weekly individual sessions along with weekly "skills group training", and telephone access for patients to individual therapists in times of crisis. Therapists meet in teams for regular supervision and exchange. Usually DBT is delivered for a period of 12 months.</P>
<P>Dialectical behaviour therapy (DBT) according to Linehan (<LINK REF="REF-Linehan-1993a" TYPE="REFERENCE">Linehan 1993a</LINK>; <LINK REF="REF-Linehan-1993b" TYPE="REFERENCE">Linehan 1993b</LINK>) was used in eight studies (<LINK REF="STD-Linehan-1991" TYPE="STUDY">Linehan 1991</LINK>; <LINK REF="STD-Linehan-1994" TYPE="STUDY">Linehan 1994</LINK>; <LINK REF="STD-Turner-2000" TYPE="STUDY">Turner 2000</LINK>; <LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK>; <LINK REF="STD-Van-den-Bosch-2005" TYPE="STUDY">Van den Bosch 2005</LINK>; <LINK REF="STD-Linehan-2006" TYPE="STUDY">Linehan 2006</LINK>; <LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK>; <LINK REF="STD-Carter-2010" TYPE="STUDY">Carter 2010</LINK>). A summary of major modifications and/or adaptations is given in the table below.</P>
<TABLE COLS="2" ROWS="9">
<TR>
<TH>
<P>
<B>Study</B>
</P>
</TH>
<TH>
<P>
<B>Modifications</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Carter-2010" TYPE="STUDY">Carter 2010</LINK>
</P>
</TD>
<TD>
<UL>
<LI>duration: six months (treatment of 12 months length, but outcome assessment after six)</LI>
</UL>
<UL>
<LI>telephone access was available but not from participants' individual therapists but other DBT therapists or the local psychiatric hospital</LI>
</UL>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK>
</P>
</TD>
<TD>
<UL>
<LI>duration: six months</LI>
</UL>
<UL>
<LI>length of skills training group and therapist consultation meeting shortened to 90 minutes per week</LI>
</UL>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Linehan-1991" TYPE="STUDY">Linehan 1991</LINK>
</P>
</TD>
<TD>
<P>no major modifications</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Linehan-1994" TYPE="STUDY">Linehan 1994</LINK>
</P>
</TD>
<TD>
<P>no major modifications</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Linehan-2006" TYPE="STUDY">Linehan 2006</LINK>
</P>
</TD>
<TD>
<P>no major modifications</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK>
</P>
</TD>
<TD>
<P>no major modifications</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Turner-2000" TYPE="STUDY">Turner 2000</LINK>
</P>
</TD>
<TD>
<UL>
<LI>psychodynamic techniques incorporated to conceptualise patients' behavioural, emotional and cognitive relationship schemata</LI>
<LI>no skills group, skills training provided during individual therapy sessions</LI>
</UL>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Van-den-Bosch-2005" TYPE="STUDY">Van den Bosch 2005</LINK>
</P>
</TD>
<TD>
<P>no major modifications</P>
</TD>
</TR>
</TABLE>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">DBT for Borderline Personality Disorder with Severe Posttraumatic Stress Disorder after Childhood Sexual Abuse (DBT-PTSD; one study: Steil 2010)</HEADING>
<P>DBT-PTSD aims at meeting the special demands of people with both BPD and chronic post-traumatic stress disorder (PTSD) after sexual abuse in childhood (<LINK REF="REF-Steil-2010a" TYPE="REFERENCE">Steil 2010a</LINK>). It draws from and employs principles and modules of standard DBT but enhances them by PTSD specific cognitive restructuring and exposure techniques. DBT-PTSD was delivered in an inpatient setting of three months duration in the study of <LINK REF="STD-Steil-2010" TYPE="STUDY">Steil 2010</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Mentalisation-based treatment (MBT; two studies: Bateman 1999; Bateman 2009)</HEADING>
<P>Mentalisation-based therapy (MBT; <LINK REF="REF-Bateman-2004" TYPE="REFERENCE">Bateman 2004</LINK>; <LINK REF="REF-Bateman-2006" TYPE="REFERENCE">Bateman 2006</LINK>) is a complex psychoanalytically and attachment theory-based treatment. It aims to increase the reflective or mentalising capacity of the participant, helping them to understand and recognise the feelings they evoke in others and the feelings they experience themselves as a result of others. Thus, "mentalising" means the implicit and explicit interpretation of the actions of oneself and others as meaningful in view of intentional mental states such as desires, feelings, and needs.</P>
<P>MBT was used in two trials, one in a partial hospitalised setting (MBT-PH; <LINK REF="STD-Bateman-1999" TYPE="STUDY">Bateman 1999</LINK>) and the other outpatient (MBT-OUT; <LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Cognitive-behavioural approaches (CBT; three studies: Bellino 2007; Cottraux 2009; Davidson 2006)</HEADING>
<P>Cognitive-behavioural therapy (CBT) as a generic term refers to treatments that combine cognitive and behavioural techniques. Today, neither of them is practiced without the other, so the combined term has prevailed. Originially, cognitive techniques were compiled by AT Beck who developed his approach initially for the treatment of depression (<LINK REF="REF-Beck-1979" TYPE="REFERENCE">Beck 1979</LINK>). Current CBT is problem-focused, with therapeutical processes strongly oriented towards pre-defined and both patient- and therapist-agreed-upon treatment targets. Overall, the major goal is to help patients to develop adaptive (instead of maladaptive and dysfunctional) beliefs about self and others by self-directed learning processes. Participants are encouraged to identify their core beliefs, evaluate and modify their behaviour accordingly and gain new experiences (<LINK REF="REF-Beck-1990" TYPE="REFERENCE">Beck 1990</LINK>; <LINK REF="REF-Beck-1995" TYPE="REFERENCE">Beck 1995</LINK>). Cognitive-behavioural approaches (CBT) were used in three RCTs.</P>
<P>In the trial of <LINK REF="STD-Bellino-2007" TYPE="STUDY">Bellino 2007</LINK>, the participants of which all had an additional major depressive episode, CBT was delivered according to the basic works of Beck (<LINK REF="REF-Beck-1990" TYPE="REFERENCE">Beck 1990</LINK>; <LINK REF="REF-Beck-1995" TYPE="REFERENCE">Beck 1995</LINK>). <LINK REF="STD-Cottraux-2009" TYPE="STUDY">Cottraux 2009</LINK> delivered CBT based on further developments of A T Beck's working group for the treatment of people with personality disorders (esp.: <LINK REF="REF-Layden-1993" TYPE="REFERENCE">Layden 1993</LINK>; <LINK REF="REF-Young-1994" TYPE="REFERENCE">Young 1994</LINK>). <LINK REF="STD-Davidson-2006" TYPE="STUDY">Davidson 2006</LINK> used a CBT approach based on AT Beck work that she has specially formulated for the practical treatment of those with Cluster B personality disorders (<LINK REF="REF-Davidson-2000" TYPE="REFERENCE">Davidson 2000</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Interpersonal Psychotherapy (IPT) and related treatments (IPT-BPD; three studies: Bellino 2006; Bellino 2007; Bellino 2010)</HEADING>
<P>Interpersonal Psychotherapy (IPT) is a brief and highly structured manual-based psychotherapy that addresses interpersonal issues. It was originally developed for the treatment of depression, to the exclusion of all other foci of clinical attention (<LINK REF="REF-Klerman-1984" TYPE="REFERENCE">Klerman 1984</LINK>). It acts on the assumption that interpersonal factors play an important role in the development and maintenance of psychological problems, and emphasises interpersonal processes rather than intrapsychic ones. Participants are encouraged to acquire interpersonal skills and thus adapt their behaviour to current roles and situations.</P>
<P>IPT was used in the studies of <LINK REF="STD-Bellino-2006" TYPE="STUDY">Bellino 2006</LINK> and <LINK REF="STD-Bellino-2007" TYPE="STUDY">Bellino 2007</LINK>. In a more recent trial (<LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK>), a BPD-specific adaptation of IPT, called IPT-BPD, was used (<LINK REF="REF-Markowitz-2005" TYPE="REFERENCE">Markowitz 2005</LINK>; <LINK REF="REF-Markowitz-2006" TYPE="REFERENCE">Markowitz 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Transference-Focused Psychotherapy (TFP; two studies: Doering 2010; Giesen-Bloo 2006)</HEADING>
<P>Another popular psychodynamically-based approach is the one of transference-focused psychotherapy (TFP; <LINK REF="REF-Clarkin-1999" TYPE="REFERENCE">Clarkin 1999</LINK>). By analysis of the transference within the therapeutic relationship, integrated representations of self and others, modification of primitive defensive operations and resolution of identity diffusion are to be achieved. Primitive object relations (for example, split, polarised into 'good' and 'bad') are to be transformed to advanced ones (for example, differentiated, integrated).</P>
<P>TFP was used in two trials. <LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK> compared TFP with a control condition, and it served as comparison treatment for SFT in the study of <LINK REF="STD-Giesen_x002d_Bloo-2006" TYPE="STUDY">Giesen-Bloo 2006</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Schema-focused therapy (SFT; two studies: Giesen-Bloo 2006; Nadort 2009)</HEADING>
<P>Schema-focused therapy (SFT; <LINK REF="REF-Young-2003" TYPE="REFERENCE">Young 2003</LINK>) draws from both behavioural as well as psychoanalytic theories and helps patients to identify their self-defeating core themes that evolved from unmet emotional needs in childhood and implicate maladaptive coping styles in adulthood. The goal of SFT is to aid patients to get their needs met.</P>
<P>SFT was tested in two trials, those of <LINK REF="STD-Giesen_x002d_Bloo-2006" TYPE="STUDY">Giesen-Bloo 2006</LINK> and <LINK REF="STD-Nadort-2009" TYPE="STUDY">Nadort 2009</LINK>. The first one strongly stuck to the original SFT treatment regimen. <LINK REF="STD-Nadort-2009" TYPE="STUDY">Nadort 2009</LINK> investigated the effects of standard SFT in a regular mental health care setting and SFT plus additional crisis telephone support by individual therapists outside the office hours (SFT+).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Client-centered therapy (CCT) and related treatments (two studies: Cottraux 2009; Turner 2000)</HEADING>
<P>Client-centered (or patient-centered) therapy (CCT; <LINK REF="REF-Rogers-1951" TYPE="REFERENCE">Rogers 1951</LINK>) is a non-directive approach that aims at encouraging participants to find their own solutions to their problems. This is achieved by creating a safe, non-judgmental therapy setting in which therapists meet their clients with un-conditional respect, demonstrating warmth, empathy, and genuineness while "active listening". Participants are encouraged to explore their own experiences in-depth and express their feelings, so they can decide for themselves in what ways they need to change.</P>
<P>CCT based on C Rogers' work was one of the conditions of the RCT of <LINK REF="STD-Cottraux-2009" TYPE="STUDY">Cottraux 2009</LINK>. <LINK REF="STD-Turner-2000" TYPE="STUDY">Turner 2000</LINK> used R Carkhuff's approach, a further development of Rogers' CCT (<LINK REF="REF-Carkhuff-1969" TYPE="REFERENCE">Carkhuff 1969</LINK>; <LINK REF="REF-Carkhuff-1976" TYPE="REFERENCE">Carkhuff 1976</LINK>), emphasising therapeutic core conditions as crucial for the client's growth and development.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Dynamic deconstructive psychotherapy (DDP; one study: Gregory 2008)</HEADING>
<P>Dynamic deconstructive psychotherapy (DDP) has been developed to treat those people with BPD having co-occurring disorders, such as substance use disorders or additional personality disorders (<LINK REF="REF-Gregory-2008a" TYPE="REFERENCE">Gregory 2008a</LINK>; <LINK REF="REF-Gregory-2010" TYPE="REFERENCE">Gregory 2010</LINK>). BPD is regarded a disorder of aberrant processing of emotional experiences. Therefore, DDP aims to enhance neurocognitive self-capacities by elaborating affect-laden interpersonal experiences and integrate attributions by narrative construction through association techniques. Thus, a differentiated view of self versus others is to be developed, supported by novel experiences within the patient-therapist relationship.</P>
<P>DDP was used in a RCT conducted by its developer (<LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Non-comprehensive psychotherapeutic interventions</HEADING>
<P>As depicted above, non-comprehensive psychotherapies were defined as not including individual psychotherapy as substantial part of the intervention. They mainly focus on psychoeducation as delivered in a group-therapy settings, are of limited duration (that is, beyond six months) and focus on impartation of knowledge rather than individual therapy. These interventions may or may not be administered as an adjunctive module to ongoing individual treatments, but individual psychotherapy is not part of these interventions themselves.</P>
<SUBSECTION>
<HEADING LEVEL="6">DBT-skills training only (DBT-ST; one study: Soler 2009)</HEADING>
<P>One trial investigated the effects of DBT-skills training only (<LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>): three months of standard-DBT based skills training sessions were delivered to people who did not receive any of the remaining usual DBT components.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Emotion regulation group training (ERG; one study: Gratz 2006)</HEADING>
<P>ERG is an eclectic treatment approach that draws from Acceptance and Commitment Therapy (ACT; <LINK REF="REF-Hayes-1999" TYPE="REFERENCE">Hayes 1999</LINK>), DBT and includes aspects of emotion-focused psychotherapy (<LINK REF="REF-Greenberg-2002" TYPE="REFERENCE">Greenberg 2002</LINK>) as well as behavioural therapy. ERG was delivered for a duration of 3.5 months in the trial of <LINK REF="STD-Gratz-2006" TYPE="STUDY">Gratz 2006</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Schema-focused therapy-group (SFT-G; one study: Farrell 2009)</HEADING>
<P>
<LINK REF="STD-Farrell-2009" TYPE="STUDY">Farrell 2009</LINK> used a shortened group-only format of SFT (SFT-G), based on schema change work according to J. Young (<LINK REF="REF-Young-1994" TYPE="REFERENCE">Young 1994</LINK>; <LINK REF="REF-Young-2003" TYPE="REFERENCE">Young 2003</LINK>) in combination with BPD psychoeducation, emotional awareness training and distress management training (<LINK REF="REF-Farrell-1994" TYPE="REFERENCE">Farrell 1994</LINK>). This intervention was delivered for eight months.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Manual-assisted cognitive treatment (MACT; two studies: Morey 2010; Weinberg 2006)</HEADING>
<P>
<LINK REF="STD-Weinberg-2006" TYPE="STUDY">Weinberg 2006</LINK> and <LINK REF="STD-Morey-2010" TYPE="STUDY">Morey 2010</LINK> tested MACT, a bibliotherapeutic approach for acutely self-harming patients. The intervention comprises six individual sessions that are each structured around a chapter of a self-help book (<LINK REF="REF-Schmidt-2004" TYPE="REFERENCE">Schmidt 2004</LINK>). <LINK REF="STD-Weinberg-2006" TYPE="STUDY">Weinberg 2006</LINK> compared MACT with a control group, whereas <LINK REF="STD-Morey-2010" TYPE="STUDY">Morey 2010</LINK> tested the effects of both standard MACT as well as MACT enhanced by a therapeutic assessment (MACT+TA). The therapeutic assessment comprised an individualised collaborative assessment including development of questions the client would like to be answered by the test results and development of individualised treatment goals.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Systems training for emotional predictability and problem solving for borderline personality disorder (STEPPS; two studies: Blum 2008; Bos 2010)</HEADING>
<P>Two studies (<LINK REF="STD-Blum-2008" TYPE="STUDY">Blum 2008</LINK>; <LINK REF="STD-Bos-2010" TYPE="STUDY">Bos 2010</LINK>) applied the "Systems training for emotional predictability and problem solving for borderline personality disorder" (STEPPS) training. STEPPS is a 20-week seminar-like group treatment program. It combines cognitive-behavioural elements and skills training with a systematic approach by involving participants' relatives and other treatment providers. <LINK REF="STD-Blum-2008" TYPE="STUDY">Blum 2008</LINK> employed the generic STEPPS training as an add-on to any ongoing individual treatments, whereas <LINK REF="STD-Bos-2010" TYPE="STUDY">Bos 2010</LINK> combined STEPPS with a complementary individual therapy (STEPPS-IT) aiming to help consolidate the skills that had been acquired during STEPPS group into the individual lives of patients. However, the authors explicitly refer to the individual sessions as "limited individual [...] developed as an adjunct to STEPPS to help consolidate the newly acquired skills and to stimulate their use" (<LINK REF="STD-Bos-2010" TYPE="STUDY">Bos 2010</LINK>, p. 300). Thus, the STEPPS group remains the core element, and we decided to classify STEPPS+IT as non-comprehensive psychotherapeutic intervention.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Psychoeducation only (PE; one study: Zanarini 2008)</HEADING>
<P>
<LINK REF="STD-Zanarini-2008" TYPE="STUDY">Zanarini 2008</LINK> used a very generic form of psychoeducation. People newly diagnosed with BPD participated in a single, half-day workshop. Topics of the workshop curriculum were phenomenology, aetiology, treatment and course of BPD.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparisons</HEADING>
<P>Comparisons included both active as well as classic control conditions.</P>
<SUBSECTION>
<HEADING LEVEL="5">Controls</HEADING>
<UL>
<LI>Treatment as usual (TAU): TAU was the most commonly used control condition. TAU means that participants are allowed to use any kind of treatment they would or would not have used in case they had not been involved in the actual trial. However, TAU conditions differ slightly, especially in the extent to which the use of any alternative treatment was obligatory or not, the extent to which alternative treatments reflect the supposed usual treatment and the extent to which alternative treatments were homogenous among all participants assigned to that condition.</LI>
<UL>
<LI>obligatory/all control participants in some kind of treatment:</LI>
<UL>
<LI>
<LINK REF="STD-Bateman-1999" TYPE="STUDY">Bateman 1999</LINK>: homogeneous; standard treatment in the general psychiatric services, excluding formal psychotherapy</LI>
<LI>
<LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK>: homogeneous; structured clinical management according to best generic practice for BPD offered by non-specialist practitioners within UK psychiatric services</LI>
<LI>
<LINK REF="STD-Bos-2010" TYPE="STUDY">Bos 2010</LINK>: homogeneous; standard treatment for BPD as offered at the participating sites</LI>
<LI>
<LINK REF="STD-Davidson-2006" TYPE="STUDY">Davidson 2006</LINK>: homogeneous; standard treatment a patient would have received if the trial had not been in place as offered at the study sites</LI>
<LI>
<LINK REF="STD-Farrell-2009" TYPE="STUDY">Farrell 2009</LINK>: homogeneous; participants had to be in any individual psychotherapy to be eligible for study participation, and they had to continue this treatment for the duration of the study</LI>
<LI>
<LINK REF="STD-Gratz-2006" TYPE="STUDY">Gratz 2006</LINK>: homogeneous; participants had to be in any individual therapy and continue during the study</LI>
<LI>
<LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK>: homogeneous; participants received 60 minutes of weekly individual therapy with a clinician of the participating clinics of different orientations (none DBT) and were offered attendance of several supportive and psychoeducational group</LI>
<LI>
<LINK REF="STD-Van-den-Bosch-2005" TYPE="STUDY">Van den Bosch 2005</LINK>: homogeneous; clinical management from the original referral source, that is, addiction treatment centres or psychiatric services; generally no more than two sessions per month</LI>
<LI>
<LINK REF="STD-Weinberg-2006" TYPE="STUDY">Weinberg 2006</LINK>: heterogeneous; all participants took part in additional, ongoing treatments</LI>
</UL>
<LI>optional/treatment usage:</LI>
<UL>
<LI>
<LINK REF="STD-Blum-2008" TYPE="STUDY">Blum 2008</LINK>: heterogeneous; participants "encouraged to continue their usual care" of any kind</LI>
<LI>
<LINK REF="STD-Carter-2010" TYPE="STUDY">Carter 2010</LINK>: heterogeneous; treatment as usual plus waiting list (six months)</LI>
<LI>
<LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>: heterogeneous; participants (all with either alcohol abuse or dependence) were referred to an alcohol rehabilitation centre and given names of psychiatric clinics and therapists in the community but were also allowed to keep their current psychotherapist, if any</LI>
<LI>
<LINK REF="STD-Linehan-1991" TYPE="STUDY">Linehan 1991</LINK>: heterogeneous; participants were given alternative therapy referrals</LI>
<LI>
<LINK REF="STD-Linehan-1994" TYPE="STUDY">Linehan 1994</LINK>: heterogeneous; participants received alternative therapy referrals and were allowed to participate in any type of treatment available in the community</LI>
<LI>
<LINK REF="STD-Steil-2010" TYPE="STUDY">Steil 2010</LINK>: heterogeneous; treatment as usual plus waiting list (six months)</LI>
</UL>
</UL>
<LI>Community treatment by experts (CTBE): all participants allocated to the control condition received treatment by experienced psychotherapists in the community. Thus, treatment was obligatory, and it was standardised in that all psychotherapists were known experts through long-term experience in that field.</LI>
<UL>
<LI>
<LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK>: treatment by community psychotherapists who were known as experienced and particularly interested in people with BPD</LI>
<LI>
<LINK REF="STD-Linehan-2006" TYPE="STUDY">Linehan 2006</LINK>: community treatment by experts who had been nominated by community mental health leaders; the treatment provided was uncontrolled by the study but therapists' characteristics (sex, experience, mean number of clients etc.) were balanced among both groups</LI>
</UL>
<LI>Non-specific comparison programmes: treatments mainly designed to control for attention biases or the like by providing an alternative programme. Specific techniques or putative efficacious interventions are explicitly avoided. Those treatments are subsumed in an extra category since they will usually not be found in usual health care settings.</LI>
<UL>
<LI>
<LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>: "Standard group therapy" (SGT); "oriented to provide a relational experience allowing people with BPD to share their characteristic difficulties"; therapists present to conduct group interaction</LI>
</UL>
<LI>Clinical management (CM):</LI>
<UL>
<LI>
<LINK REF="STD-Bellino-2006" TYPE="STUDY">Bellino 2006</LINK>: appointments with a psychiatrist, fluoxetine medication (both groups received fluoxetine)</LI>
<LI>
<LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK>: appointments with the local Service for Personality Disorders, fluoxetine medication (both groups received fluoxetine)</LI>
</UL>
<LI>Waiting list without treatment (WL):</LI>
<UL>
<LI>
<LINK REF="STD-Zanarini-2008" TYPE="STUDY">Zanarini 2008</LINK>: waiting list, weekly screening appointments but no psychiatric treatment for the duration of the waiting period (12 weeks)</LI>
</UL>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Active comparators</HEADING>
<P>The following studies compared two active treatments (description of interventions see above).</P>
<UL>
<LI>
<LINK REF="STD-Bellino-2007" TYPE="STUDY">Bellino 2007</LINK>: cognitive therapy versus interpersonal therapy</LI>
<LI>
<LINK REF="STD-Cottraux-2009" TYPE="STUDY">Cottraux 2009</LINK>: cognitive therapy versus client-centered therapy</LI>
<LI>
<LINK REF="STD-Giesen_x002d_Bloo-2006" TYPE="STUDY">Giesen-Bloo 2006</LINK>: schema-focused therapy versus transference-focused therapy</LI>
<LI>
<LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK>: dialectical behaviour therapy versus APA guidelines-based treatment algorithm (general psychiatric management derived from the American Psychiatric Association (APA) guideline recommendations; combination of psychodynamically informed therapy and symptom-targeted medication management)</LI>
<LI>
<LINK REF="STD-Morey-2010" TYPE="STUDY">Morey 2010</LINK>: manual assisted cognitive therapy versus manual-assisted cognitive therapy plus therapeutic assessment</LI>
<LI>
<LINK REF="STD-Nadort-2009" TYPE="STUDY">Nadort 2009</LINK>: schema-focused therapy versus schema-focused therapy plus therapist telephone crisis support outside office hours</LI>
<LI>
<LINK REF="STD-Turner-2000" TYPE="STUDY">Turner 2000</LINK>: dialectical behaviour therapy versus client-centered therapy</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>In the case of availability of several measures relating to the same outcome construct (for example, data from several questionnaires for the assessment of depression), the one most often used in the whole pool of included studies was used for effect size calculation, in order to minimise heterogeneity of outcomes in form and content. If a study reported data of two assessment instruments that were equally frequently used, two review authors (JS, BV) discussed the issue and chose the one which was in its content most appropriate for assessing BPD-relevant pathology. Self-rated measures were preferred. If there was more than one post-treatment assessment available, we used the one which was assessed closest to the end of psychotherapeutic treatment. For the studies of <LINK REF="STD-Steil-2010" TYPE="STUDY">Steil 2010</LINK> and <LINK REF="STD-Zanarini-2008" TYPE="STUDY">Zanarini 2008</LINK>, several assessments were considered for use as post-treatment data: <LINK REF="STD-Steil-2010" TYPE="STUDY">Steil 2010</LINK> reported data that were assessed immediately at end of the three months inpatient treatment and, additionally, data that were assessed after a subsequent booster session six weeks after dismissal. As the booster session was a pre-defined part of treatment, we used the post-booster session data. <LINK REF="STD-Zanarini-2008" TYPE="STUDY">Zanarini 2008</LINK> conducted a singular psychoeducation workshop and assessed data on a weekly basis up to week 12. We decided to use the data from week 12 to ensure observation periods throughout the whole pool of studies were as homogeneous as possible.</P>
<P>All available outcomes that were included in this review are listed below as well as specific measures and the respective studies that used them.</P>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcomes  </HEADING>
<OL>
<LI>BPD severity</LI>
<OL>
<LI>Borderline evaluation of severity over time (BEST): <LINK REF="STD-Gratz-2006" TYPE="STUDY">Gratz 2006</LINK>; <LINK REF="STD-Blum-2008" TYPE="STUDY">Blum 2008</LINK>; <LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>
</LI>
<LI>Borderline personality disorder checklist-40 (BDP-40) - total score: <LINK REF="STD-Bos-2010" TYPE="STUDY">Bos 2010</LINK>
</LI>
<LI>Borderline personality disorder severity index (BPDSI-IV) - total score: <LINK REF="STD-Giesen_x002d_Bloo-2006" TYPE="STUDY">Giesen-Bloo 2006</LINK>; <LINK REF="STD-Nadort-2009" TYPE="STUDY">Nadort 2009</LINK>; <LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK>
</LI>
<LI>Borderline symptom list (BSL): <LINK REF="STD-Steil-2010" TYPE="STUDY">Steil 2010</LINK>
</LI>
<LI>Borderline syndrome index (BSI): <LINK REF="STD-Farrell-2009" TYPE="STUDY">Farrell 2009</LINK>
</LI>
<LI>Clinical global impression scale for borderline personality disorder patients (CGI-BPD) - global: <LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>
</LI>
<LI>Mean number of DSM-IV diagnostic criteria for BPD: <LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK>; <LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK>
</LI>
<LI>Personality assessment inventory - borderline features scale total (PAI-BOR-total): <LINK REF="STD-Morey-2010" TYPE="STUDY">Morey 2010</LINK>
</LI>
<LI>Zanarini rating scale for borderline personality disorder (ZAN-BPD) - total score: <LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK>
</LI>
</OL>
<LI>Affective dysregulative cluster symptoms</LI>
<OL>
<LI>anger</LI>
<OL>
<LI>Borderline personality disorder severity index (BPDSI-IV) - anger: <LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK>
</LI>
<LI>Clinical global impression scale for borderline personality disorder patients (CGI-BPD) - anger: <LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>
</LI>
<LI>Spielberger anger expression scale (STAXI) - anger out: <LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK>; <LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK>
</LI>
<LI>Spielberger anger expression scale (STAXI) - trait anger: <LINK REF="STD-Linehan-1994" TYPE="STUDY">Linehan 1994</LINK>
</LI>
<LI>Target behaviour rating (TBR) - anger: <LINK REF="STD-Turner-2000" TYPE="STUDY">Turner 2000</LINK>
</LI>
</OL>
<LI>affective instability</LI>
<OL>
<LI>Borderline personality disorder severity index (BPDSI-IV) - affective instability: <LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK>
</LI>
<LI>Clinical global impression scale for borderline personality disorder patients (CGI-BPD) - affective instability: <LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>
</LI>
<LI>Diagnostic Interview for BPD-Revised (DIB-R) - affect subscale: <LINK REF="STD-Farrell-2009" TYPE="STUDY">Farrell 2009</LINK>
</LI>
<LI>Difficulties in emotion regulation scale (DERS) - emotion dysregulation: <LINK REF="STD-Gratz-2006" TYPE="STUDY">Gratz 2006</LINK>
</LI>
<LI>Personality assessment inventory - affective instability (PAI-BOR-A): <LINK REF="STD-Morey-2010" TYPE="STUDY">Morey 2010</LINK>
</LI>
<LI>Zanarini rating scale for borderline personality disorder (ZAN-BPD) - affective instability: <LINK REF="STD-Blum-2008" TYPE="STUDY">Blum 2008</LINK>
</LI>
</OL>
<LI>chronic feelings of emptiness</LI>
<OL>
<LI>Borderline personality disorder severity index (BPDSI-IV) - emptiness: <LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK>
</LI>
<LI>Clinical global impression scale for borderline personality disorder patients (CGI-BPD) - emptiness: <LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>
</LI>
</OL>
</OL>
<LI>Impulsive cluster symptoms</LI>
<OL>
<LI>impulsivity</LI>
<OL>
<LI>Barrett impulsiveness scale (BIS): <LINK REF="STD-Blum-2008" TYPE="STUDY">Blum 2008</LINK>
</LI>
<LI>Borderline personality disorder severity index (BPDSI-IV) - impulsivity: <LINK REF="STD-Van-den-Bosch-2005" TYPE="STUDY">Van den Bosch 2005</LINK>; <LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK>
</LI>
<LI>Clinical global impression scale for borderline personality disorder patients (CGI-BPD) - impulsivity: <LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>
</LI>
<LI>Diagnostic Interview for BPD-Revised (DIB-R) - impulsive subscale: <LINK REF="STD-Farrell-2009" TYPE="STUDY">Farrell 2009</LINK>
</LI>
<LI>Difficulties in emotion regulation scale (DERS) - impulse dyscontrol: <LINK REF="STD-Gratz-2006" TYPE="STUDY">Gratz 2006</LINK>
</LI>
<LI>Eysenck impulsivity venturesomeness empathy questionnaire (IVE) - impulsivity: <LINK REF="STD-Cottraux-2009" TYPE="STUDY">Cottraux 2009</LINK>
</LI>
<LI>Number of participants scoring above BPDSI-IV-impulsivity cut-off score: <LINK REF="STD-Bos-2010" TYPE="STUDY">Bos 2010</LINK>
</LI>
<LI>Target behaviour rating (TBR) - impulsiveness: <LINK REF="STD-Turner-2000" TYPE="STUDY">Turner 2000</LINK>
</LI>
<LI>Zanarini rating scale for borderline personality disorder (ZAN-BPD) - impulsivity: <LINK REF="STD-Zanarini-2008" TYPE="STUDY">Zanarini 2008</LINK>
</LI>
</OL>
<LI>suicidality</LI>
<OL>
<LI>Beck hopelessness scale (BHS): <LINK REF="STD-Cottraux-2009" TYPE="STUDY">Cottraux 2009</LINK>
</LI>
<LI>Beck scale for suicidal ideation (BSS): <LINK REF="STD-Turner-2000" TYPE="STUDY">Turner 2000</LINK>; <LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK>
</LI>
<LI>Clinical global impression scale for borderline personality disorder patients (CGI-BPD) - suicidality: <LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>
</LI>
<LI>Number of participants with suicide attempt during previous six-month period: <LINK REF="STD-Bateman-1999" TYPE="STUDY">Bateman 1999</LINK>; <LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK>
</LI>
<LI>Number of participants with suicidal act during previous 12 months:<LINK REF="STD-Davidson-2006" TYPE="STUDY">Davidson 2006</LINK>; <LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK>
</LI>
<LI>Personality assessment inventory - suicidal ideation (PAI-SI): <LINK REF="STD-Morey-2010" TYPE="STUDY">Morey 2010</LINK>
</LI>
<LI>Suicidal behaviours questionnaire (SBQ): <LINK REF="STD-Linehan-2006" TYPE="STUDY">Linehan 2006</LINK>; <LINK REF="STD-Weinberg-2006" TYPE="STUDY">Weinberg 2006</LINK>
</LI>
</OL>
</OL>
</OL>
<UL>
<OL>
<LI>parasuicidality</LI>
<OL>
<LI>Borderline personality disorder severity index (BPDSI-IV) - parasuicidal behaviour score: <LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK>
</LI>
<LI>Deliberate self-harm inventory (DSHI) - frequency score: <LINK REF="STD-Gratz-2006" TYPE="STUDY">Gratz 2006</LINK>
</LI>
<LI>LPC-self-mutilative acts during previous three-month period: <LINK REF="STD-Van-den-Bosch-2005" TYPE="STUDY">Van den Bosch 2005</LINK>
</LI>
<LI>Mean number of suicidal and self-injurious episodes: <LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK>
</LI>
<LI>Mean number of self-harming acts during previous three-month period: <LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK>
</LI>
<LI>Number of patients scoring above BPDSI-IV-parasuicide cut-off: <LINK REF="STD-Bos-2010" TYPE="STUDY">Bos 2010</LINK>
</LI>
<LI>Number of patients with parasuicide during previous three-month period: <LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>
</LI>
<LI>Number of patients with self-harming behaviour during previous six-month period: <LINK REF="STD-Bateman-1999" TYPE="STUDY">Bateman 1999</LINK>; <LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK>; <LINK REF="STD-Carter-2010" TYPE="STUDY">Carter 2010</LINK>
</LI>
<LI>Number of patients with self-harming behaviour during previous 12-month period: <LINK REF="STD-Linehan-1991" TYPE="STUDY">Linehan 1991</LINK>; <LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK>; <LINK REF="STD-Davidson-2006" TYPE="STUDY">Davidson 2006</LINK>
</LI>
<LI>Personality assessment inventory - borderline features scale self-harm (PAI-BOR-S): <LINK REF="STD-Morey-2010" TYPE="STUDY">Morey 2010</LINK>
</LI>
<LI>Parasuicide history interview (PHI) - deliberate self-harm frequency: <LINK REF="STD-Weinberg-2006" TYPE="STUDY">Weinberg 2006</LINK>
</LI>
<LI>Self-harming behaviours checklist (SHBCL): <LINK REF="STD-Cottraux-2009" TYPE="STUDY">Cottraux 2009</LINK>
</LI>
<LI>Target behaviour rating (TBR) - frequency of parasuicide: <LINK REF="STD-Turner-2000" TYPE="STUDY">Turner 2000</LINK>
</LI>
</OL>
</OL>
</UL>
<OL>
<LI>Interpersonal cluster symptoms</LI>
<OL>
<LI>interpersonal problems general</LI>
<OL>
<LI>Borderline personality disorder severity index (BPDSI-IV) - interpersonal relationships: <LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK>
</LI>
<LI>Clinical global impression scale for borderline personality disorder patients (CGI-BPD) - unstable relations: <LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>
</LI>
<LI>Diagnostic interview for BPD-revised (DIB-R) - interpersonal subscale: <LINK REF="STD-Farrell-2009" TYPE="STUDY">Farrell 2009</LINK>
</LI>
<LI>Inventory of interpersonal problems (IIP): <LINK REF="STD-Bateman-1999" TYPE="STUDY">Bateman 1999</LINK>; <LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK>
</LI>
<LI>Inventory of interpersonal problems (IIP-C): <LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK>
</LI>
<LI>Inventory of interpersonal problems-short form (IIP-SC): <LINK REF="STD-Davidson-2006" TYPE="STUDY">Davidson 2006</LINK>
</LI>
<LI>Personality assessment inventory - borderline features scale negative relationships (PAI-BOR-N): <LINK REF="STD-Morey-2010" TYPE="STUDY">Morey 2010</LINK>
</LI>
<LI>World Health organization quality of life assessment-Bref (WHOQOL-Bref) - social relationships score: <LINK REF="STD-Bos-2010" TYPE="STUDY">Bos 2010</LINK>; <LINK REF="STD-Carter-2010" TYPE="STUDY">Carter 2010</LINK>
</LI>
<LI>Zanarini rating scale for borderline personality disorder (ZAN-BPD) - disturbed relationships score: <LINK REF="STD-Blum-2008" TYPE="STUDY">Blum 2008</LINK>; <LINK REF="STD-Zanarini-2008" TYPE="STUDY">Zanarini 2008</LINK>
</LI>
</OL>
<LI>avoidance of abandonment</LI>
<OL>
<LI>Borderline personality disorder severity index (BPDSI-IV) - abandonment: <LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK>
</LI>
</OL>
</OL>
<LI>Cognitive cluster symptoms</LI>
<OL>
<LI>identity disturbance</LI>
<OL>
<LI>Borderline personality disorder severity index (BPDSI-IV) - identity disturbance: <LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK>
</LI>
<LI>Personality assessment inventory - borderline features scale - identity disturbance: <LINK REF="STD-Morey-2010" TYPE="STUDY">Morey 2010</LINK>
</LI>
</OL>
<LI>dissociation/stress-related paranoid ideation</LI>
<OL>
<LI>Borderline personality disorder severity index (BPDSI-IV) - paranoid ideation: <LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK>
</LI>
<LI>Brief psychiatric rating scale (BPRS): <LINK REF="STD-Turner-2000" TYPE="STUDY">Turner 2000</LINK>; <LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>;</LI>
<LI>Diagnostic interview for BPD-revised (DIB-R) - cognitive subscale: <LINK REF="STD-Farrell-2009" TYPE="STUDY">Farrell 2009</LINK>
</LI>
<LI>Dissociative experiences scale (DES):<LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK>; <LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>; <LINK REF="STD-Steil-2010" TYPE="STUDY">Steil 2010</LINK>
</LI>
<LI>Zanarini rating scale for borderline personality disorder - cognitive subscale: <LINK REF="STD-Blum-2008" TYPE="STUDY">Blum 2008</LINK>
</LI>
</OL>
</OL>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcomes</HEADING>
<OL>
<LI>Depression</LI>
<OL>
<LI>Beck depression inventory (BDI): <LINK REF="STD-Bateman-1999" TYPE="STUDY">Bateman 1999</LINK>; <LINK REF="STD-Turner-2000" TYPE="STUDY">Turner 2000</LINK>; <LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK>; <LINK REF="STD-Blum-2008" TYPE="STUDY">Blum 2008</LINK>; <LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>; <LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK>; <LINK REF="STD-Cottraux-2009" TYPE="STUDY">Cottraux 2009</LINK>; <LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK>; <LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK>
</LI>
<LI>Beck depression inventory-II (BDI-II): <LINK REF="STD-Davidson-2006" TYPE="STUDY">Davidson 2006</LINK>; <LINK REF="STD-Steil-2010" TYPE="STUDY">Steil 2010</LINK>
</LI>
<LI>Depression anxiety stress scales (DASS) - depression: <LINK REF="STD-Gratz-2006" TYPE="STUDY">Gratz 2006</LINK>
</LI>
<LI>Hamilton depression inventory (Ham-D): <LINK REF="STD-Bellino-2006" TYPE="STUDY">Bellino 2006</LINK>; <LINK REF="STD-Bellino-2007" TYPE="STUDY">Bellino 2007</LINK>; <LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK>
</LI>
<LI>Hamilton depression inventory - 17-item (Ham-D-17): <LINK REF="STD-Linehan-2006" TYPE="STUDY">Linehan 2006</LINK>; <LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>
</LI>
</OL>
<LI>Anxiety</LI>
<OL>
<LI>Beck anxiety inventory (BAI):<LINK REF="STD-Turner-2000" TYPE="STUDY">Turner 2000</LINK>; <LINK REF="STD-Cottraux-2009" TYPE="STUDY">Cottraux 2009</LINK>;</LI>
<LI>Depression anxiety stress scales (DASS) - anxiety: <LINK REF="STD-Gratz-2006" TYPE="STUDY">Gratz 2006</LINK>
</LI>
<LI>Hamilton anxiety rating scale (HARS): <LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK>; <LINK REF="STD-Bellino-2006" TYPE="STUDY">Bellino 2006</LINK>; <LINK REF="STD-Bellino-2007" TYPE="STUDY">Bellino 2007</LINK>; <LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>; <LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK>
</LI>
<LI>Spielberger state-trait anxiety inventory (STAI) - state: <LINK REF="STD-Steil-2010" TYPE="STUDY">Steil 2010</LINK>
</LI>
<LI>Spielberger state-trait anxiety inventory (STAI) - trait: <LINK REF="STD-Bateman-1999" TYPE="STUDY">Bateman 1999</LINK>; <LINK REF="STD-Davidson-2006" TYPE="STUDY">Davidson 2006</LINK>; <LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK>
</LI>
</OL>
<LI>General psychopathology</LI>
<OL>
<LI>Brief symptom inventory (BSI) - global severity index (BSI-GSI): <LINK REF="STD-Davidson-2006" TYPE="STUDY">Davidson 2006</LINK>; <LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK>
</LI>
<LI>Symptom checklist-90-revised - (SCL-90-R) - global severity index (SCL-90-R-GSI): <LINK REF="STD-Bateman-1999" TYPE="STUDY">Bateman 1999</LINK>; <LINK REF="STD-Blum-2008" TYPE="STUDY">Blum 2008</LINK>; <LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK>; <LINK REF="STD-Farrell-2009" TYPE="STUDY">Farrell 2009</LINK>; <LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK>; <LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>; <LINK REF="STD-Steil-2010" TYPE="STUDY">Steil 2010</LINK>
</LI>
<LI>Symptom checklist-90-Dutch version (SCL-90-R-DV): <LINK REF="STD-Giesen_x002d_Bloo-2006" TYPE="STUDY">Giesen-Bloo 2006</LINK>; <LINK REF="STD-Nadort-2009" TYPE="STUDY">Nadort 2009</LINK>; <LINK REF="STD-Bos-2010" TYPE="STUDY">Bos 2010</LINK>
</LI>
</OL>
<LI>Mental health status/functioning</LI>
<OL>
<LI>Brief disability questionnaire (BDQ) - days out of role: <LINK REF="STD-Carter-2010" TYPE="STUDY">Carter 2010</LINK>
</LI>
<LI>Clinical global impressions scale (CGI) - severity of illness (CGI-S): <LINK REF="STD-Bellino-2006" TYPE="STUDY">Bellino 2006</LINK>; <LINK REF="STD-Bellino-2007" TYPE="STUDY">Bellino 2007</LINK>; <LINK REF="STD-Blum-2008" TYPE="STUDY">Blum 2008</LINK>; <LINK REF="STD-Cottraux-2009" TYPE="STUDY">Cottraux 2009</LINK>; <LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK>
</LI>
<LI>Clinical global impressions scale (CGI) - improvement, patient-rated (CGI-I-SR): <LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>
</LI>
<LI>Global assessment of functioning scale (GAF): <LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK>; <LINK REF="STD-Farrell-2009" TYPE="STUDY">Farrell 2009</LINK>; <LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK>
</LI>
<LI>Global assessment scale (GAS): <LINK REF="STD-Linehan-1994" TYPE="STUDY">Linehan 1994</LINK>
</LI>
<LI>Social functioning questionnaire (SFQ): <LINK REF="STD-Davidson-2006" TYPE="STUDY">Davidson 2006</LINK>
</LI>
</OL>
<LI>Leaving the study early</LI>
<OL>
<LI>Number of participants lost after randomisation for any reason; available or calculable for all primary studies</LI>
</OL>
<LI>Adverse effects: no data available from any primary study</LI>
</OL>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2012-07-04 14:27:09 +0100" MODIFIED_BY="[Empty name]">
<P>The main primary studies that readers might be expected to be included but in fact were not are listed in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table with individual reasons for exclusion. Please note that only one reason may be listed, though actually several inclusion criteria may not have been met.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2017-04-06 17:46:12 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> show the review authors' judgements about each risk of bias item for each single study and across all studies.</P>
<ALLOCATION MODIFIED="2012-06-12 11:31:33 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Sequence generation</HEADING>
<P>All trials were stated to be randomised. Those providing further information on how the randomisation sequence had been achieved, or that a minimisation or matching method had been used, were judged as having 'low' risks of bias (<LINK REF="STD-Linehan-1991" TYPE="STUDY">Linehan 1991</LINK>; <LINK REF="STD-Linehan-1994" TYPE="STUDY">Linehan 1994</LINK>; <LINK REF="STD-Van-den-Bosch-2005" TYPE="STUDY">Van den Bosch 2005</LINK>; <LINK REF="STD-Davidson-2006" TYPE="STUDY">Davidson 2006</LINK>; <LINK REF="STD-Giesen_x002d_Bloo-2006" TYPE="STUDY">Giesen-Bloo 2006</LINK>; <LINK REF="STD-Gratz-2006" TYPE="STUDY">Gratz 2006</LINK>; <LINK REF="STD-Linehan-2006" TYPE="STUDY">Linehan 2006</LINK>; <LINK REF="STD-Bellino-2007" TYPE="STUDY">Bellino 2007;</LINK> <LINK REF="STD-Blum-2008" TYPE="STUDY">Blum 2008</LINK>; <LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>; <LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK>; <LINK REF="STD-Cottraux-2009" TYPE="STUDY">Cottraux 2009</LINK>; <LINK REF="STD-Farrell-2009" TYPE="STUDY">Farrell 2009</LINK>; <LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK>; <LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>; <LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK>; <LINK REF="STD-Bos-2010" TYPE="STUDY">Bos 2010</LINK>; <LINK REF="STD-Carter-2010" TYPE="STUDY">Carter 2010</LINK>; <LINK REF="STD-Steil-2010" TYPE="STUDY">Steil 2010</LINK>). The remaining trials (<LINK REF="STD-Bateman-1999" TYPE="STUDY">Bateman 1999</LINK>; <LINK REF="STD-Turner-2000" TYPE="STUDY">Turner 2000</LINK>; <LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK>; <LINK REF="STD-Bellino-2006" TYPE="STUDY">Bellino 2006</LINK>; <LINK REF="STD-Weinberg-2006" TYPE="STUDY">Weinberg 2006</LINK>; <LINK REF="STD-Zanarini-2008" TYPE="STUDY">Zanarini 2008</LINK>; <LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK>; <LINK REF="STD-Morey-2010" TYPE="STUDY">Morey 2010</LINK>) did not describe how treatment allocation had exactly been achieved, and the risk of bias was judged 'unclear'. However, there is evidence that poor reporting of randomisation increases the odds of presenting 'significant' outcomes (<LINK REF="REF-Chalmers-1983" TYPE="REFERENCE">Chalmers 1983</LINK>; <LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<P>Those trials reporting on confident, off-site randomisation or notification of assignment by research coordinators not involved in therapy delivery were rated as having a 'low' risk of bias (<LINK REF="STD-Davidson-2006" TYPE="STUDY">Davidson 2006</LINK>; <LINK REF="STD-Giesen_x002d_Bloo-2006" TYPE="STUDY">Giesen-Bloo 2006</LINK>; <LINK REF="STD-Linehan-2006" TYPE="STUDY">Linehan 2006</LINK>; <LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>; <LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK>; <LINK REF="STD-Cottraux-2009" TYPE="STUDY">Cottraux 2009</LINK>; <LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK>; <LINK REF="STD-Nadort-2009" TYPE="STUDY">Nadort 2009</LINK>; <LINK REF="STD-Bos-2010" TYPE="STUDY">Bos 2010</LINK>; <LINK REF="STD-Carter-2010" TYPE="STUDY">Carter 2010</LINK>; <LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK>; <LINK REF="STD-Steil-2010" TYPE="STUDY">Steil 2010</LINK>). All remaining trials did not provide further information to judge about adequacy of allocation concealment, and the risk of bias was judged 'unclear' (<LINK REF="STD-Linehan-1991" TYPE="STUDY">Linehan 1991</LINK>; <LINK REF="STD-Linehan-1994" TYPE="STUDY">Linehan 1994</LINK>; <LINK REF="STD-Bateman-1999" TYPE="STUDY">Bateman 1999</LINK>; <LINK REF="STD-Turner-2000" TYPE="STUDY">Turner 2000</LINK>; <LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK>;<LINK REF="STD-Van-den-Bosch-2005" TYPE="STUDY">Van den Bosch 2005</LINK>; <LINK REF="STD-Bellino-2006" TYPE="STUDY">Bellino 2006</LINK>; <LINK REF="STD-Gratz-2006" TYPE="STUDY">Gratz 2006</LINK>; <LINK REF="STD-Weinberg-2006" TYPE="STUDY">Weinberg 2006</LINK>; <LINK REF="STD-Bellino-2007" TYPE="STUDY">Bellino 2007</LINK>; <LINK REF="STD-Blum-2008" TYPE="STUDY">Blum 2008</LINK>; <LINK REF="STD-Zanarini-2008" TYPE="STUDY">Zanarini 2008</LINK>; <LINK REF="STD-Farrell-2009" TYPE="STUDY">Farrell 2009</LINK>; <LINK REF="STD-Nadort-2009" TYPE="STUDY">Nadort 2009</LINK>; <LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>; <LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK>; <LINK REF="STD-Morey-2010" TYPE="STUDY">Morey 2010</LINK>).</P>
</SUBSECTION>
</ALLOCATION>
<BLINDING MODIFIED="2012-06-12 11:37:49 +0100" MODIFIED_BY="[Empty name]">
<P>It is almost impossible to keep psychotherapy trials participants blind to treatment allocation. Thus, the risk of bias due to non-blindness of participants is present in psychotherapy trials throughout.</P>
<P>One trial report stated clearly that there was no blinding. Since only self-rated outcomes were used, we judged there was no risk of bias due to lack of blinding (<LINK REF="STD-Gratz-2006" TYPE="STUDY">Gratz 2006</LINK>). The majority of trials report that outcome assessors were intended to be kept blind to treatment allocation (<LINK REF="STD-Linehan-1991" TYPE="STUDY">Linehan 1991</LINK>; <LINK REF="STD-Linehan-1994" TYPE="STUDY">Linehan 1994</LINK>; <LINK REF="STD-Turner-2000" TYPE="STUDY">Turner 2000</LINK>; <LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK>; <LINK REF="STD-Van-den-Bosch-2005" TYPE="STUDY">Van den Bosch 2005</LINK>; <LINK REF="STD-Bellino-2006" TYPE="STUDY">Bellino 2006</LINK>; <LINK REF="STD-Davidson-2006" TYPE="STUDY">Davidson 2006</LINK>; <LINK REF="STD-Giesen_x002d_Bloo-2006" TYPE="STUDY">Giesen-Bloo 2006</LINK>; <LINK REF="STD-Gratz-2006" TYPE="STUDY">Gratz 2006</LINK>; <LINK REF="STD-Linehan-2006" TYPE="STUDY">Linehan 2006</LINK>; <LINK REF="STD-Weinberg-2006" TYPE="STUDY">Weinberg 2006</LINK>; <LINK REF="STD-Bellino-2007" TYPE="STUDY">Bellino 2007</LINK>; <LINK REF="STD-Blum-2008" TYPE="STUDY">Blum 2008</LINK>; <LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>; <LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK>; <LINK REF="STD-Cottraux-2009" TYPE="STUDY">Cottraux 2009</LINK>; <LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK>; <LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>; <LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK>; <LINK REF="STD-Carter-2010" TYPE="STUDY">Carter 2010</LINK>; <LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK>; <LINK REF="STD-Morey-2010" TYPE="STUDY">Morey 2010</LINK>; <LINK REF="STD-Steil-2010" TYPE="STUDY">Steil 2010</LINK>). Some of them ( <LINK REF="STD-Van-den-Bosch-2005" TYPE="STUDY">Van den Bosch 2005</LINK>; <LINK REF="STD-Giesen_x002d_Bloo-2006" TYPE="STUDY">Giesen-Bloo 2006</LINK>; <LINK REF="STD-Gratz-2006" TYPE="STUDY">Gratz 2006</LINK>; <LINK REF="STD-Blum-2008" TYPE="STUDY">Blum 2008</LINK>; <LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>; <LINK REF="STD-Cottraux-2009" TYPE="STUDY">Cottraux 2009</LINK>; <LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK>; <LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>; <LINK REF="STD-Carter-2010" TYPE="STUDY">Carter 2010</LINK>) also discussed the issue of partial non-maintenance of blindness throughout the whole course of the study, since patients may have unintendedly indicated which group they were in, although they had been told not to do so. These studies were, nevertheless, rated as having a 'low' risk of bias due to partial break of blindness, since we felt it was not appropriate to downgrade these studies that discuss issues that may also have concerned those studies that did not discuss them. <LINK REF="STD-Nadort-2009" TYPE="STUDY">Nadort 2009</LINK> clearly reported that outcome assessors could not be kept blind to treatment conditions. However, since most outcomes were self-assessed by the trial participants, the risk of bias was judged 'unclear'.</P>
<P>Two trials did not mention blinding of outcome assessors (<LINK REF="STD-Bateman-1999" TYPE="STUDY">Bateman 1999</LINK>; <LINK REF="STD-Zanarini-2008" TYPE="STUDY">Zanarini 2008</LINK>), and the risk of bias was judged 'unclear'. One trial (<LINK REF="STD-Farrell-2009" TYPE="STUDY">Farrell 2009</LINK>) providing mainly interviewer-assessed outcomes reported that the interviewers were not blind to treatment allocation, and the risk of bias was judged likely.</P>
</BLINDING>
<SELECTIVE_REPORTING MODIFIED="2012-06-12 11:54:11 +0100" MODIFIED_BY="[Empty name]">
<P>For seven studies (<LINK REF="STD-Davidson-2006" TYPE="STUDY">Davidson 2006</LINK>; <LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>; <LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK>; <LINK REF="STD-Cottraux-2009" TYPE="STUDY">Cottraux 2009</LINK>; <LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK>; <LINK REF="STD-Nadort-2009" TYPE="STUDY">Nadort 2009</LINK>; <LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK>), study protocols were available from trial registers, and there was no indication of selective outcome reporting. The detailed study protocol of <LINK REF="STD-Steil-2010" TYPE="STUDY">Steil 2010</LINK> was also available, and there was also no indication of selective reporting. Those eight studies were rated as having a 'low' risk of bias in this regard.</P>
<P>For the study of <LINK REF="STD-Blum-2008" TYPE="STUDY">Blum 2008</LINK>, the study protocol was also available from a study register, but the information provided did not permit judgement of the presence of selective reporting. For the remaining studies (<LINK REF="STD-Linehan-1991" TYPE="STUDY">Linehan 1991</LINK>; <LINK REF="STD-Linehan-1994" TYPE="STUDY">Linehan 1994</LINK>; <LINK REF="STD-Bateman-1999" TYPE="STUDY">Bateman 1999</LINK>; <LINK REF="STD-Turner-2000" TYPE="STUDY">Turner 2000</LINK>; <LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK>; <LINK REF="STD-Van-den-Bosch-2005" TYPE="STUDY">Van den Bosch 2005</LINK>; <LINK REF="STD-Bellino-2006" TYPE="STUDY">Bellino 2006</LINK>; <LINK REF="STD-Giesen_x002d_Bloo-2006" TYPE="STUDY">Giesen-Bloo 2006</LINK>; <LINK REF="STD-Gratz-2006" TYPE="STUDY">Gratz 2006</LINK>; <LINK REF="STD-Linehan-2006" TYPE="STUDY">Linehan 2006</LINK>; <LINK REF="STD-Weinberg-2006" TYPE="STUDY">Weinberg 2006</LINK>; <LINK REF="STD-Bellino-2007" TYPE="STUDY">Bellino 2007</LINK>; <LINK REF="STD-Zanarini-2008" TYPE="STUDY">Zanarini 2008</LINK>; <LINK REF="STD-Farrell-2009" TYPE="STUDY">Farrell 2009</LINK>; <LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>; <LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK>; <LINK REF="STD-Bos-2010" TYPE="STUDY">Bos 2010</LINK>; <LINK REF="STD-Carter-2010" TYPE="STUDY">Carter 2010</LINK>; <LINK REF="STD-Morey-2010" TYPE="STUDY">Morey 2010</LINK>), no protocols were available. The risk of bias was judged 'unclear' for these trails.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2017-04-06 17:46:12 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Insufficient treatment adherence</HEADING>
<P>Most trials specified either routine supervision and/or objective means assessment to assure treatment adherence. All trials reporting any means of treatment adherence assurance were rated as having a 'low' risk of bias in this regard (<LINK REF="STD-Linehan-1991" TYPE="STUDY">Linehan 1991</LINK>; <LINK REF="STD-Linehan-1994" TYPE="STUDY">Linehan 1994</LINK>; <LINK REF="STD-Bateman-1999" TYPE="STUDY">Bateman 1999</LINK>; <LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK>; <LINK REF="STD-Van-den-Bosch-2005" TYPE="STUDY">Van den Bosch 2005</LINK>; <LINK REF="STD-Davidson-2006" TYPE="STUDY">Davidson 2006</LINK>; <LINK REF="STD-Giesen_x002d_Bloo-2006" TYPE="STUDY">Giesen-Bloo 2006</LINK>; <LINK REF="STD-Linehan-2006" TYPE="STUDY">Linehan 2006</LINK>; <LINK REF="STD-Bellino-2007" TYPE="STUDY">Bellino 2007</LINK>; <LINK REF="STD-Blum-2008" TYPE="STUDY">Blum 2008</LINK>; <LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>; <LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK>; <LINK REF="STD-Cottraux-2009" TYPE="STUDY">Cottraux 2009</LINK>; <LINK REF="STD-Farrell-2009" TYPE="STUDY">Farrell 2009</LINK>; <LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK>; <LINK REF="STD-Nadort-2009" TYPE="STUDY">Nadort 2009</LINK>; <LINK REF="STD-Bos-2010" TYPE="STUDY">Bos 2010</LINK>; <LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK>; <LINK REF="STD-Morey-2010" TYPE="STUDY">Morey 2010</LINK>; <LINK REF="STD-Steil-2010" TYPE="STUDY">Steil 2010</LINK>). One study reported that the only therapist was the developer of the treatment, so adherence to the original treatment regimen should be assured, and the risk of bias was also rated as 'low' (<LINK REF="STD-Gratz-2006" TYPE="STUDY">Gratz 2006</LINK>).</P>
<P>
<LINK REF="STD-Carter-2010" TYPE="STUDY">Carter 2010</LINK> reports regular therapist supervision groups, but also says that there may have been "a possible inferiority of training of DBT therapists to that of those in other studies or inferior adherence to the DBT methods despite adequate training." (<LINK REF="STD-Carter-2010" TYPE="STUDY">Carter 2010</LINK>, p. 170). However, there were no objective means of adherence assessment, so the risk of bias was judged 'unclear'. Three studies depicted therapists as experienced, but did not make mention of any kind of routine supervision or objective adherence assessment. The risk was judged 'unclear' for these trials (<LINK REF="STD-Bellino-2006" TYPE="STUDY">Bellino 2006</LINK>; <LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>; <LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK>). <LINK REF="STD-Zanarini-2008" TYPE="STUDY">Zanarini 2008</LINK> did neither specify the therapists' training nor any means of assurance of treatment integrity, so the risk of bias was also judged 'unclear'.</P>
<P>
<LINK REF="STD-Weinberg-2006" TYPE="STUDY">Weinberg 2006</LINK> reports that "this study did not monitor adherence and competence" (<LINK REF="STD-Weinberg-2006" TYPE="STUDY">Weinberg 2006</LINK>, p. 482). The risk of bias was rated 'probable' for this study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allegiance bias</HEADING>
<P>The possibility of allegiance bias was judged possible for the trials of <LINK REF="STD-Linehan-1991" TYPE="STUDY">Linehan 1991</LINK>; <LINK REF="STD-Linehan-1994" TYPE="STUDY">Linehan 1994</LINK>; <LINK REF="STD-Bateman-1999" TYPE="STUDY">Bateman 1999</LINK>, <LINK REF="STD-Davidson-2006" TYPE="STUDY">Davidson 2006</LINK>; <LINK REF="STD-Gratz-2006" TYPE="STUDY">Gratz 2006</LINK>; <LINK REF="STD-Linehan-2006" TYPE="STUDY">Linehan 2006</LINK>; <LINK REF="STD-Blum-2008" TYPE="STUDY">Blum 2008</LINK>; <LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>; <LINK REF="STD-Zanarini-2008" TYPE="STUDY">Zanarini 2008</LINK>; <LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK>; <LINK REF="STD-Farrell-2009" TYPE="STUDY">Farrell 2009</LINK>; <LINK REF="STD-Steil-2010" TYPE="STUDY">Steil 2010</LINK> since the treatment developers were directly involved as main investigators.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Attention bias</HEADING>
<P>Only 10 studies (<LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK>; <LINK REF="STD-Giesen_x002d_Bloo-2006" TYPE="STUDY">Giesen-Bloo 2006</LINK>; <LINK REF="STD-Linehan-2006" TYPE="STUDY">Linehan 2006</LINK>; <LINK REF="STD-Bellino-2007" TYPE="STUDY">Bellino 2007</LINK>; <LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK>; <LINK REF="STD-Cottraux-2009" TYPE="STUDY">Cottraux 2009</LINK>; <LINK REF="STD-Nadort-2009" TYPE="STUDY">Nadort 2009</LINK>; <LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>; <LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK>; <LINK REF="STD-Morey-2010" TYPE="STUDY">Morey 2010</LINK>) were rated as providing similar amounts of attention as obligatory components of the study protocol to all trial groups.The participants allocated to the control group of <LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>
 did not get an obligatory control treatment, but were referred to alternative treatments in the community and had not less but markedly more professional contact hours during most of the study period. The risk of attention bias was therefore also judged low for this trial. All remaining trials provided more attention (that is, in terms of frequency of appointments, involvement in additional group treatments etc.) to one group, usually the experimental group (EG).</P>
</SUBSECTION>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-01-31 15:45:30 +0000" MODIFIED_BY="[Empty name]">
<P>No adverse effects data were available for any included study.</P>
<SUBSECTION>
<HEADING LEVEL="3">1 Comprehensive psychotherapies versus control</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1.1 Dialectical behaviour therapy (DBT) versus treatment as usual (TAU)</HEADING>
<P>Five studies were included in this comparison: <LINK REF="STD-Carter-2010" TYPE="STUDY">Carter 2010</LINK> (female outpatients; six months treatment; N = 73), <LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK> (female outpatients; six months treatment; N = 28); <LINK REF="STD-Linehan-1991" TYPE="STUDY">Linehan 1991</LINK> (female outpatients; 12 months treatment; N = 61); <LINK REF="STD-Linehan-1994" TYPE="STUDY">Linehan 1994</LINK> (female outpatients; 12 months treatment; N = 26); <LINK REF="STD-Van-den-Bosch-2005" TYPE="STUDY">Van den Bosch 2005</LINK> (female outpatients; high proportion of substance abusers, that is, 53% of those who actually started treatment; 12 months treatment; N = 64).</P>
<SUBSECTION>
<HEADING LEVEL="5">1.1.1 BPD total severity</HEADING>
<P>
<LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK> provided data on BPD total severity indicating no significant difference but a tendency in favour of DBT treatment (standardised mean difference (SMD) -0.29; N = 20, one RCT, 95% confidence interval (CI) -1.17 to 0.59; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.1.2 Affective dysregulative cluster symptoms</HEADING>
<P>Anger symptoms were reported in two studies (<LINK REF="STD-Linehan-1994" TYPE="STUDY">Linehan 1994</LINK>; <LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK>). The pooled effect estimates indicate a large, significant effect of DBT in terms of anger reduction (SMD -0.83; N = 46, two RCTs, 95% CI -1.43 to -0.22; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). No specific data were available from relevant studies regarding affective instability or chronic feelings of emptiness.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.1.3 Impulsive cluster symptoms</HEADING>
<P>BPD-specific impulsivity in general was reported upon by <LINK REF="STD-Van-den-Bosch-2005" TYPE="STUDY">Van den Bosch 2005</LINK>. The data indicated a small, non-significant difference (SMD -0.17; N = 48, one RCT, 95% CI-0.74 to 0.39). One study (<LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK>) indicated a very large significant effect in favour of DBT concerning the reduction of suicidality (SMD -1.26; N = 20, one RCT, 95% CI -2.24 to -0.29; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). Three studies reported on parasuicidality in terms of the mean number of parasuicidal acts (<LINK REF="STD-Linehan-1991" TYPE="STUDY">Linehan 1991</LINK>; <LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK>; <LINK REF="STD-Van-den-Bosch-2005" TYPE="STUDY">Van den Bosch 2005</LINK>). Their pooled effect estimates indicated a moderate significant effect of parasuicidality reduction by DBT (SMD -0.54; N = 110; three RCTs, 95% CI -0.92 to -0.16; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). <LINK REF="STD-Carter-2010" TYPE="STUDY">Carter 2010</LINK>, however, found no significant difference in the proportion of participants with self-harm between both groups (risk ratio (RR) 1.11; N = 51, one RCT; 95% CI 0.78 to 1.57; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.1.4 Interpersonal cluster symptoms</HEADING>
<P>
<LINK REF="STD-Carter-2010" TYPE="STUDY">Carter 2010</LINK> report data indicating no statistically significant difference between treatment and control conditions regarding interpersonal problems, resulting in a negligible effect size (SMD -0.04, N = 48, one RCT, 95% CI -0.54 to 0.61; <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>). No data were available from any relevant studies on avoidance of abandonment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.1.5 Cognitive cluster symptoms</HEADING>
<P>
<LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK> report data indicating no statistically significant difference but favouring DBT with regard to dissociative symptoms, resulting in a large effect size (SMD -0.90; N = 20, one RCT, 95% CI -1.83 to 0.03; <LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>). No data are available for any other cognitive cluster symptoms.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.1.6 Depression</HEADING>
<P>
<LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK> report data indicating a large, statistically significant difference between treatment and control conditions in depression (SMD -1.12; N = 20, one RCT, 95% CI -2.08 to -0.16; <LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.1.7 Anxiety</HEADING>
<P>
<LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK> report data indicating a large, statistically significant difference in favour of DBT (SMD -1.22; N = 20, one RCT, 95% CI -2.20 to -0.25; <LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.1.8 Mental health status/functioning</HEADING>
<P>
<LINK REF="STD-Carter-2010" TYPE="STUDY">Carter 2010</LINK> and <LINK REF="STD-Linehan-1994" TYPE="STUDY">Linehan 1994</LINK> report on the level of functioning. The pooled effect estimates yield a moderate, significant effect in favour of DBT (SMD 0.65; N = 74, two RCTs, 95% CI 0.07 to 1.24; <LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.1.9 Leaving the study early</HEADING>
<P>Reported data indicate no statistically significant difference between treatment and control conditions for leaving the study early if considering all participants randomised (RR 1.25; N = 252; five RCTs; 95% CI 0.54 to 2.92; <LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>). However, the corresponding I<SUP>2</SUP> score of 77% suggests substantial heterogeneity. A possible reason for this may be a higher likelihood of drop-out in rural areas. A post-hoc sensitivity analysis restricting the results to non-rural areas, that is, leaving out the results of <LINK REF="STD-Carter-2010" TYPE="STUDY">Carter 2010</LINK>, resulted in a more homogenous effect (RR 0.80; N = 179; four RCTs; 95% CI 0.47 to 1.36; I<SUP>2</SUP> = 35%; <LINK REF="CMP-001.19" TYPE="ANALYSIS">Analysis 1.19</LINK>) supporting this hypothesis.</P>
<P>No data were available for the outcome of general psychopathology. See <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for an overview of primary effect outcome effect estimates.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.2 Dialectical behaviour therapy (DBT) versus general management (GM) according to APA guidelines</HEADING>
<P>One study was included in this comparison: <LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK> (outpatients, 92% female; 12 months treatment; N = 180).</P>
<SUBSECTION>
<HEADING LEVEL="5">1.2.1 BPD total severity</HEADING>
<P>
<LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK> reported data on this outcome indicating a marginal, non-statistically significant difference (SMD -0.04; N = 180, 95% CI -0.33 to 0.25; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2.2 Affective dysregulative cluster symptoms</HEADING>
<P>Data on anger symptoms indicated a very small, statistically non-significant difference between the two treatments (SMD -0.03; N = 180, 95% CI -0.32 to 0.26; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2.3 Impulsive cluster symptoms</HEADING>
<P>The findings indicate no significant difference in terms of the mean number of suicidal and/or self-injurious episodes, but favour DBT (SMD -0.23; N = 180, 95% CI -0.52 to 0.06; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>) with a small difference. No data were available for effects on impulsivity in general.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2.4 Interpersonal cluster symptoms</HEADING>
<P>
<LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK> report data indicating a marginal, statistically non-significant difference between treatment and control conditions in this regard (SMD -0.03, N = 180, 95% CI-0.32 to 0.26; <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2.5 Depression</HEADING>
<P>
<LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK> report data indicating a small, statistically, non-significant difference between both groups (SMD -0.17; N = 180, 95% CI -0.46 to 0.12; <LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2.6 General psychopathology</HEADING>
<P>
<LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK> report data indicating a marginal, non-significant difference between both groups (SMD -0.01; N = 180, 95% CI -0.30 to 0.28; <LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2.7 Leaving the study early</HEADING>
<P>Reported data indicate no statistically significant difference between treatment and control conditions for leaving the study early if considering all participants randomised (RR 1.03; N = 180; 95% CI 0.71 to 1.49; <LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>).</P>
<P>No data were available for the following outcomes: cognitive cluster-related symptoms, anxiety and mental health status/functioning. See <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for an overview of primary effect outcome effect estimates.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.3 Dialectical behaviour therapy (DBT) versus community treatment by experts (CTBE)</HEADING>
<P>One study was included in this comparison: <LINK REF="STD-Linehan-2006" TYPE="STUDY">Linehan 2006</LINK> (female outpatients; 12 months treatment; N = 101).</P>
<SUBSECTION>
<HEADING LEVEL="5">1.3.1 Impulsive cluster symptoms</HEADING>
<P>
<LINK REF="STD-Linehan-2006" TYPE="STUDY">Linehan 2006</LINK> report data indicating a small, statistically non-significant difference between treatment and control conditions in terms of suicidality (SMD -0.12; N = 89, 95% CI -0.54 to 0.30; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3.2 Depression</HEADING>
<P>
<LINK REF="STD-Linehan-2006" TYPE="STUDY">Linehan 2006</LINK> report data indicating a small to moderate, statistically non-significant difference between groups but favouring DBT (SMD -0.39; N = 89, 95% CI -0.81 to 0.04; <LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3.4 Leaving the study early</HEADING>
<P>Reported data indicate a statistically significant difference between treatment and control conditions for leaving the study early if considering all participants randomised, favouring DBT (RR 0.43; N = 101; 95% CI 0.28 to 0.67; <LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>).</P>
<P>No data were available for the following outcomes: BPD total severity; affective dysregulative, interpersonal and cognitive cluster symptoms; anxiety, general psychopathology, mental health status/functioning. See <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for an overview of primary effect outcome effect estimates.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.4 DBT adapted for BPD + post-traumatic stress disease (DBT-PTSD) versus waiting list (WL)</HEADING>
<P>One trial was included in this comparison: <LINK REF="STD-Steil-2010" TYPE="STUDY">Steil 2010</LINK> (inpatients; 100% females with comorbid PTSD from childhood sexual abuse; three months inpatient treatment plus additional booster session 6 months after discharge; N = 32).</P>
<SUBSECTION>
<HEADING LEVEL="5">1.4.1 BPD total severity</HEADING>
<P>
<LINK REF="STD-Steil-2010" TYPE="STUDY">Steil 2010</LINK> report data indicating a moderate to large, statistically significant difference between experimental and control conditions in terms of overall BPD severity after treatment,favouring DBT-PTSD (SMD -0.74; N = 31; 95% CI -1.47 to -0.01; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.4.2 Cognitive cluster symptoms</HEADING>
<P>Reported data indicate a small to moderate, statistically non-significant difference between experimental and control conditions in terms of dissociation (SMD -0.34; N = 30; 95% CI -1.06 to 0.38; <LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.4.3 Depression</HEADING>
<P>
<LINK REF="STD-Steil-2010" TYPE="STUDY">Steil 2010</LINK> provided data indicating a large, statistically significant difference between both conditions, with less pathology for the DBT-PTSD-treated group (SMD -1.06; N = 30; 95% CI -1.84 to -0.29; <LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.4.4 Anxiety</HEADING>
<P>Data also indicate a large, statistically significant difference between experimental and control conditions for the outcome of anxiety, favouring the experimental intervention (SMD -0.96; N = 30; 95% CI -1.72 to -0.20; <LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.4.5 General psychopathology</HEADING>
<P>No statistically significant difference is indicated by the reported data for the outcome of general psychopathology (SMD -0.70; N = 30; 95% CI -1.45 to 0.04; <LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>). However, the data indicate a favourable moderate to large effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.4.6 Leaving the study early</HEADING>
<P>Reported data indicate no statistically significant difference between treatment and control conditions for leaving the study early if considering all participants randomised exclusive of those that were excluded due to meeting exclusion criteria, which became clear after randomisation but before start of treatment (RR 1.94; N = 32; 95% CI 0.44 to 8.57; <LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>).</P>
<P>No data were available for the following outcomes: affective-dysregulative, impulsive and interpersonal cluster symptoms; mental health status/functioning. See <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for an overview of primary effect outcome effect estimates.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.5 Mentalisation based treatment - partial hospitalisation (MBT-PH) versus treatment as usual (TAU)</HEADING>
<P>One study was included in this comparison: <LINK REF="STD-Bateman-1999" TYPE="STUDY">Bateman 1999</LINK> (partially hospitalised versus outpatient participants, 58% females; 18 months treatment; N = 44).</P>
<SUBSECTION>
<HEADING LEVEL="5">1.5.1 Impulsive cluster symptoms</HEADING>
<P>No data available on general impulsivity. <LINK REF="STD-Bateman-1999" TYPE="STUDY">Bateman 1999</LINK> report data indicating large, significant effects on both less suicidality (RR 0.08; N = 38, 95% CI 0.01 to 0.58; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>) and parasuicidality (RR 0.44; N = 38, 95% CI 0.24 to 0.81; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>) favouring the experimental group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.5.2 Interpersonal cluster symptoms</HEADING>
<P>
<LINK REF="STD-Bateman-1999" TYPE="STUDY">Bateman 1999</LINK> report data indicating a very large, significant effect of less interpersonal pathology in partially-hospitalised MBT patients (SMD -2.22; N = 38, 95% CI -3.04 to -1.39; <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>). No further data on avoidance of abandonment available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.5.3 Depression</HEADING>
<P>
<LINK REF="STD-Bateman-1999" TYPE="STUDY">Bateman 1999</LINK> report data indicating a very large, statistically significant difference in favour of MBT-PH (SMD -1.98; N = 38, 95% CI -2.78 to -1.19; <LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.5.4 Anxiety</HEADING>
<P>
<LINK REF="STD-Bateman-1999" TYPE="STUDY">Bateman 1999</LINK> report data indicating a moderate, statistically non-significant difference in terms of anxious pathology (SMD -0.49; N = 38, 95% CI -1.14 to 0.16; <LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.5.5 General psychopathology</HEADING>
<P>
<LINK REF="STD-Bateman-1999" TYPE="STUDY">Bateman 1999</LINK> report data indicating a small to moderate, statistically non-significant difference (SMD -0.39; N = 38, 95% CI -1.03 to 0.26; <LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.5.6 Leaving the study early</HEADING>
<P>Reported data indicate no statistically significant difference between treatment and control conditions for leaving the study early if considering all participants randomised (RR 1.00; N = 44; 95% CI 0.23 to 4.42; <LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>).</P>
<P>No data were available for the following outcomes: BPD total severity; affective-dysregulative and cognitive cluster symptoms; mental health status/functioning. See<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> for an overview of primary effect outcome effect estimates.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.6 Mentalisation based treatment - outpatient (MBT-out) versus treatment as usual (TAU)</HEADING>
<P>One study was included in this comparison: <LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK> (outpatients, 80% females; 18 months treatment; N = 134).</P>
<SUBSECTION>
<HEADING LEVEL="5">1.6.1 Impulsive cluster symptoms</HEADING>
<P>No data available on general impulsivity. <LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK> report data indicating large, significant effects of smaller proportions of participants with both suicidality (RR 0.11; N = 134, 95% CI 0.03 to 0.46; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>) and parasuicidality (RR 0.56; N = 134, 95% CI 0.34 to 0.92; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>) in the experimental group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.6.2 Interpersonal cluster symptoms</HEADING>
<P>
<LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK> report data indicating a large, statistically significant difference in favour or MBT-outpatient treatment in terms of interpersonal pathology (SMD -0.95; N = 134, 95% CI -1.30 to -0.59; <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>). No further data on avoidance of abandonment available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.6.3 Depression</HEADING>
<P>
<LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK> report data indicating a moderate, statistically significant difference in favour of MBT-out (SMD -0.45; N = 134, 95% CI -0.79 to -0.10; <LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.6.4 General psychopathology</HEADING>
<P>
<LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK> report data indicating a moderate to large statistically significant difference between the two treatment conditions in favour of MBT-outpatient treatment (SMD -0.67, N = 134, 95% CI -1.02 to -0.33; <LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.6.5 Mental health status/functioning</HEADING>
<P>
<LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK> report data indicating a statistically significant difference between the two treatment conditions in favour of MBT-outpatient treatment (SMD 0.55, N = 134, 95% CI 0.20 to 0.89; <LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.6.6 Leaving the study early</HEADING>
<P>Reported data indicate no statistically significant difference between treatment and control conditions for leaving the study early if considering all participants randomised (RR 1.05; N = 134; 95% CI 0.59 to 1.87; <LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>).</P>
<P>No data were available for the following outcomes: BPD severity; affective-dysregulative and cognitive cluster symptoms; anxiety. See<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> for an overview of primary effect outcome effect estimates.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.7 Transference-focused therapy (TFP) versus community treatment by experts (CTBE)</HEADING>
<P>One study was included in this comparison: <LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK> (female outpatients; 12 months treatment; N = 104).</P>
<SUBSECTION>
<HEADING LEVEL="5">1.7.1 BPD total severity</HEADING>
<P>Data reported by <LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK> indicate a moderate, statistically significant effect in favour of TFP concerning overall BPD severity reduction (SMD -0.55; N = 104, 95% CI -0.95 to -0.16; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.7.2 Impulsive cluster symptoms</HEADING>
<P>
<LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK> report data indicating no statistically significant difference in the proportion of participants with any suicidal act (RR 0.64; N = 104, 95% CI 0.27 to 1.51; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>) or any self-harming behaviour (RR 1.09; N = 104, 95% CI 0.84 to 1.40; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>). No data available on impulsivity in general.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.7.3 Depression</HEADING>
<P>
<LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK> report data indicating a very small, statistically non-significant difference between the groups in terms of depression (SMD 0.12; N = 104, 95% CI -0.26 to 0.51; <LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.7.4 Anxiety</HEADING>
<P>
<LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK> report data indicating a marginal, statistically non-significant difference between the groups regarding anxiety (SMD 0.04; N = 104, 95% CI -0.35 to 0.42; <LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.7.5 General psychopathology</HEADING>
<P>
<LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK> report data indicating a marginal, statistically non-significant difference between the groups in terms of general psychopathology(SMD 0.08; N = 104, 95% CI -0.31 to 0.46; <LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.7.6 Mental health status/functioning</HEADING>
<P>
<LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK> report data indicating a small, statistically non-significant difference between the groups in terms of overall functioning (SMD 0.34; N = 104, 95% CI -0.05 to 0.73; <LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.7.7 Leaving the study early</HEADING>
<P>Reported data indicate a statistically significant difference between treatment and control conditions for leaving the study early if considering all participants randomised, favouring TFP (RR 0.57; N = 104; 95% CI 0.39 to 0.85; <LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>).</P>
<P>No data were available for the following outcomes: Affective-dysregulative, interpersonal and cognitive cluster symptoms. See <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK> for an overview of primary effect outcome effect estimates.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.8 Cognitive-behavioural therapy (CBT) versus TAU</HEADING>
<P>One study was included in this comparison: <LINK REF="STD-Davidson-2006" TYPE="STUDY">Davidson 2006</LINK> (outpatients, 84% females; 12 months treatment; N = 106).</P>
<SUBSECTION>
<HEADING LEVEL="5">1.8.1 Impulsive cluster symptoms</HEADING>
<P>Reported data indicate a smaller proportion of participants with any suicidal act in the CBT group (RR 0.78; N = 101; 95% CI 0.47 to 1.27; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>, but a higher proportion of participants with any self-mutilation (RR 1.17; N = 99; 95% CI 0.86 to 1.60; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>). Neither of these effects was statistically significant. </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.8.2 Interpersonal cluster symptoms</HEADING>
<P>Data indicate a small, but statistically non-significant difference in terms of interpersonal pathology between the two conditions (SMD 0.23; N = 99; 95% CI -0.16 to 0.63; <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.8.3 Depression</HEADING>
<P>We found only a very small, statistically non-significant difference between both groups in terms of depression (SMD -0.11; N = 99; 95% CI -0.50 to 0.29; <LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.8.4 Anxiety</HEADING>
<P>There was no indication of a statistically significant difference between both conditions in terms of anxious pathology, the effect size was only marginal in size (SMD -0.03; N = 99; 95% CI -0.42 to 0.37; <LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.8.5 General psychopathology</HEADING>
<P>General psychopathological burden was not found to differ statistically significant between both groups, and was also marginal in size (SMD -0.03; N = 99, 95% CI -0.43 to 0.36; <LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.8.6 Mental health status/functioning</HEADING>
<P>Data indicated no statistically significant difference between both groups in terms of the level of functioning at the end of treatment (SMD 0.00; N = 99, 95% CI -0.39 to 0.39; <LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>). The numerical effect size indicated no difference between the two treatment groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.8.7 Leaving the study early</HEADING>
<P>Reported data indicate no statistically significant difference between treatment and control conditions for leaving the study early if considering all participants randomised (RR 0.48; N = 106; 95% CI 0.09 to 2.52; <LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>).</P>
<P>No data were available for the following outcomes: BPD total severity; affective-dysregulative and cognitive cluster symptoms. See <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK> for an overview of primary effect outcome effect estimates.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.9 Deconstructive dynamic psychotherapy (DDP) versus treatment as usual (TAU)</HEADING>
<P>One study was included in this comparison: <LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK> (outpatients, 80% females, all with active alcohol abuse or dependence; 12 months treatment; N = 30)</P>
<SUBSECTION>
<HEADING LEVEL="5">1.9.1 BPD total severity</HEADING>
<P>Reported data indicate a moderate, statistically non-significant difference between both conditions (SMD -0.44; N = 30; 95% CI -1.16 to 0.29; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.9.2 Affective dysregulative cluster symptoms</HEADING>
<P>No data available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.9.3 Impulsive cluster symptoms</HEADING>
<P>
<LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK> report data that indicate no statistically significant difference between both conditions in terms of proportion of participants with self-mutilating behaviour (RR 0.89; N = 30; 95% CI 0.47 to 1.67, <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.9.4 Cognitive cluster symptoms</HEADING>
<P>As for dissociation, reported data indicate no statistically significant difference between the two conditions (SMD 0.25; N = 30; 95% CI -0.47 to 0.97; <LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.9.5 Depression</HEADING>
<P>Reported data indicate a moderate but statistically non-significant difference between the conditions in terms of depression (SMD -0.52; N = 30; 95% CI -1.24 to 0.21; <LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.9.6 Leaving the study early</HEADING>
<P>Reported data indicate no statistically significant difference between treatment and control conditions for leaving the study early if considering all participants randomised (RR 0.83; N = 30; 95% CI 0.32 to 2.15; <LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>).</P>
<P>No data were available for the following outcomes: interpersonal cluster symptoms; anxiety, general psychopathology, mental health status/functioning. See <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK> for an overview of primary effect outcome effect estimates.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.10 Interpersonal psychotherapy (IPT) + fluoxetine versus clinical management (CM) + fluoxetine</HEADING>
<P>One trial was included in this comparison: <LINK REF="STD-Bellino-2006" TYPE="STUDY">Bellino 2006</LINK> (outpatients, all with current major depressive episode, 60% females; six months treatment; additional antidepressive medication was given (fluoxetine 20-40mg/d) to participants of both conditions; N = 39).</P>
<SUBSECTION>
<HEADING LEVEL="5">1.10.1 Depression</HEADING>
<P>Reported data indicate a large, statistically significant difference between both conditions favouring combined treatment (that is, IPT plus medication; SMD -0.90; N = 32; 95% CI -1.63 to -0.16; <LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.10.2 Anxiety</HEADING>
<P>There is no indication of a statistically significant difference between both groups (SMD 0.20; N = 32; 95% CI -0.49 to 0.90; <LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>). Data indicated a small effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.10.3 Mental health status/functioning</HEADING>
<P>Again, there is no indication of a statistically significant difference, with a very small effect size (SMD 0.12; N = 32; 95% CI -0.57 to 0.81; <LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.10.4 Leaving the study early</HEADING>
<P>Reported data indicate no statistically significant difference between treatment and control conditions for leaving the study early if considering all participants randomised (RR 0.79; N = 39; 95% CI 0.20 to 3.07; <LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>).</P>
<P>No data were available for the following outcomes: BPD total severity; affective-dysregulative, impulsive, interpersonal and cognitive cluster symptoms; general psychopathology. See <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK> for an overview of primary effect outcome effect estimates.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.11 IPT adapted to BPD (IPT-BPD) + fluoxetine versus clinical management + fluoxetine</HEADING>
<P>One trial was included in this comparison: <LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK> (outpatients, 67% females; eight months treatment, additional antidepressive medication was given (fluoxetine 20-40 mg/d) to participants of both conditions; N = 55).</P>
<SUBSECTION>
<HEADING LEVEL="5">1.11.1 BPD total severity</HEADING>
<P>
<LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK> report data that indicate no clinical or statistically significant difference between both conditions (SMD -0.03; N = 44; 95% CI -0.62 to 0.56; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.11.2 Affective dysregulative cluster symptoms</HEADING>
<P>Reported data indicate no clinical or statistically significant differences between both conditions in terms of inappropriate anger (SMD 0.01; N = 44; 95% CI -0.58 to 0.60; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>) and chronic feelings of emptiness (SMD 0.09; N = 44; 95% CI -0.50 to 0.68; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). A large, statistically significant difference is indicated for affective instability, favouring IPT-BPD (SMD -0.92; N = 44; 95% CI -1.54 to -0.30; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.11.3 Impulsive cluster symptoms</HEADING>
<P>
<LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK> report data indicating only a marginal, statistically non-significant difference between both groups in terms of parasuicidality (SMD 0.02; N = 44; 95% CI -0.58 to 0.61; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>) but in terms of general impulsivity, favouring IPT-BPD with a large effect (SMD -0.91; N = 44; 95% CI-1.53 to -0.28; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.11.4 Interpersonal cluster symptoms</HEADING>
<P>There is indication for a statistically significant difference between both groups in terms of interpersonal problems, favouring IPT-BPD with a large effect (SMD -0.82; N = 44; 95% CI -1.44 to -0.20; <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>). However, both groups did not different in terms of avoidance of abandonment (SMD 0.01; N = 44; 95% CI -0.58 to 0.60; <LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.11.5 Cognitive cluster symptoms</HEADING>
<P>Reported data indicate neither a statistically significant difference between both groups for the outcome of identity disturbance (SMD -0.03; N = 44; 95% CI -0.62 to 0.56; <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>) nor for the outcome of paranoid ideation (SMD 0.10; N = 44; 95% CI -0.49 to 0.70; <LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>), with very small effect sizes for both outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.11.6 Depression</HEADING>
<P>No indication is given for a statistically significant difference between both conditions in terms of depression (SMD -0.05; N = 44; 95% CI -0.64 to 0.55; <LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.11.7 Anxiety</HEADING>
<P>There is no indication for a statistically significant difference between both groups (SMD -0.52; N = 44, 95% CI -1.12 to 0.08; <LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>). However, data indicate a moderate favourable effect of IPT-BPD.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.11.8 Mental health status/functioning</HEADING>
<P>Reported data indicate no statistically significant difference between both groups with regard to this outcome (SMD -0.04; N = 44; 95% CI -0.63 to 0.55; <LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.11.9 Leaving the study early</HEADING>
<P>Reported data indicate no statistically significant difference between treatment and control conditions for leaving the study early if considering all participants randomised (RR 0.35; N = 55; 95% CI 0.08 to 1.57; <LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>).</P>
<P>No data were available for the outcome of general psychopathologiy burden. See <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK> for an overview of primary effect outcome effect estimates.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2 Non-comprehensive psychotherapeutic interventions versus control</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">2.1 Dialectical behaviour therapy-skills training only (DBT-ST) versus standard group (SG)</HEADING>
<P>One study was included in this comparison: <LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK> (outpatients, 83% females; three months treatment; N = 60).</P>
<SUBSECTION>
<HEADING LEVEL="5">2.1.1 BPD total severity</HEADING>
<P>Reported data indicate a very large, statistically significant difference at end of treatment between both conditions, favouring DBT-ST (SMD -1.01; N = 59; 95% CI-1.55 to -0.47; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.1.2 Affective dysregulative cluster symptoms</HEADING>
<P>Data indicate large to very large statistically significant differences in favour of DBT-ST concerning inappropriate anger (SMD-0.84; N = 59; 95% CI -1.37 to -0.30; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>) and affective instability (SMD -1.07; N = 59; 95% CI -1.61 to -0.52; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>). No statistically significant difference was found for the outcome of chronic feelings of emptiness, with a moderate effect size (SMD -0.43; N = 59; 95% CI -0.95 to 0.09; <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.1.3 Impulsive cluster symptoms</HEADING>
<P>Available data indicate a moderate, statistically significant difference favouring DBT-ST in terms of impulsivity (SMD -0.61; N = 59; 95% CI -1.14 to -0.09; <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>) but not suicidality (SMD -0.10; N = 59; 95% CI -0.61 to 0.41; <LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>). For suicidality, the effect size indicates only a very small to marginal difference.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.1.4 Interpersonal cluster symptoms</HEADING>
<P>There was no indication of a statistically significant difference concerning interpersonal pathology, with a small effect size (SMD -0.29; N = 59; 95% CI -0.80 to 0.23; <LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.1.5 Cognitive cluster symptoms</HEADING>
<P>Data indicate a moderate to large statistically significant difference favouring DBT-ST in terms of psychotic symptoms (SMD -0.66; N = 59; 95% CI -1.18 to -0.13; <LINK REF="CMP-002.11" TYPE="ANALYSIS">Analysis 2.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.1.6 Depression</HEADING>
<P>A large, statistically significant difference is indicated by the reported data favouring DBT-ST with regard to depressive pathology (SMD -0.97; N = 59; 95% CI -1.51 to -0.43; <LINK REF="CMP-002.12" TYPE="ANALYSIS">Analysis 2.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.1.7 Anxiety</HEADING>
<P>There is also an indication of statistically superiority with regard to anxious pathology with a moderate effect size (SMD -0.67; N = 59; 95% CI -1.20 to -0.15; <LINK REF="CMP-002.13" TYPE="ANALYSIS">Analysis 2.13</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.1.8 General psychopathology</HEADING>
<P>A small to moderate, but statistically non-significant difference was found for general psychopathology (SMD -0.42; N = 59; 95% CI -0.93 to 0.10; <LINK REF="CMP-002.14" TYPE="ANALYSIS">Analysis 2.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.1.9 Mental health status/functioning</HEADING>
<P>Data indicated a small but statistically non-significant difference regarding the overall level of functioning (SMD -0.29; N = 59; 95% CI -0.80 to 0.22; <LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.1.10 Leaving the study early</HEADING>
<P>Reported data indicate no statistically significant difference between treatment and control conditions for leaving the study early if considering all participants randomised (RR 0.58; N = 60; 95% CI 0.34 to 1.00; <LINK REF="CMP-002.16" TYPE="ANALYSIS">Analysis 2.16</LINK>).</P>
<P>See <LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK> for an overview of primary effect outcome effect estimates.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.2 Emotion regulation group (ERG) versus treatment as usual (TAU)</HEADING>
<P>One trial was included in this comparison: <LINK REF="STD-Gratz-2006" TYPE="STUDY">Gratz 2006</LINK> (female outpatients; 3.5 months treatment; N = 24)</P>
<SUBSECTION>
<HEADING LEVEL="5">2.2.1 BPD total severity</HEADING>
<P>Reported data indicate a very large, statistically significant difference favouring ERG treatment (SMD -1.02; N = 22; 95% CI -1.92 to -0.11; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2.2 Affective dysregulative cluster symptoms</HEADING>
<P>Available data indicate a very large, statistically significant difference favouring ERG over TAU alone regarding affective instability (SMD -1.65; N = 22; 95% CI -2.65 to -0.55; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2.3 Impulsive cluster symptoms</HEADING>
<P>Data indicate very large, statistically significant differences between both conditions favouring ERG regarding the outcomes of impulsivity (SMD -1.30; N = 22; 95% CI -2.24 to -0.36; <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>) and parasuicidality (SMD -0.98; N = 22; 95% CI -1.88 to -0.09; <LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2.4 Depression</HEADING>
<P>Reported data indicate very large, statistically significant difference (SMD -1.20; N = 22; 95% CI -2.13 to -0.28; <LINK REF="CMP-002.12" TYPE="ANALYSIS">Analysis 2.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2.5 Anxiety</HEADING>
<P>There was also indication of a large, statistically significant difference regarding anxious pathology (SMD -0.89; N = 22; 95% CI -1.78 to -0.01; <LINK REF="CMP-002.13" TYPE="ANALYSIS">Analysis 2.13</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2.6 Leaving the study early</HEADING>
<P>Reported data indicate no statistically significant difference between treatment and control conditions for leaving the study early if considering all participants randomised (RR 0.58; N = 60; 95% CI 0.34 to 1.00; <LINK REF="CMP-002.16" TYPE="ANALYSIS">Analysis 2.16</LINK>).</P>
<P>No data were available for the following outcomes: interpersonal and cognitive cluster symptoms; general psychopathology, mental health status/functioning. See <LINK REF="TBL-08" TYPE="TABLE">Table 8</LINK> for an overview of primary effect outcome effect estimates.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.3 Schema-focused therapy - group intervention (SFT-G) versus treatment as usual (TAU)</HEADING>
<P>One study was included in this comparison: <LINK REF="STD-Farrell-2009" TYPE="STUDY">Farrell 2009</LINK> (female outpatients; 8 months treatment; N = 32).</P>
<SUBSECTION>
<HEADING LEVEL="5">2.3.1 BPD total severity</HEADING>
<P>
<LINK REF="STD-Farrell-2009" TYPE="STUDY">Farrell 2009</LINK> report data indicating a very large, statistically significant effect in favour of SFT-G (SMD -1.66; N = 28, 95% CI -2.54 to -0.78; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3.2 Affective dysregulative cluster symptoms</HEADING>
<P>Reported data indicate a very large, statistically significant difference with regard to general affective instability (SMD -1.41; N = 28, 95% CI -2.26 to -0.57; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3.3 Impulsive cluster symptoms</HEADING>
<P>
<LINK REF="STD-Farrell-2009" TYPE="STUDY">Farrell 2009</LINK> found a very large, statistically significant difference favouring SFT-G with regard to BPD-specific impulsivity (SMD -1.92; N = 28, 95% CI -2.85 to -1.00; <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3.4 Interpersonal cluster symptoms</HEADING>
<P>There was a very large, statistically significant difference between both groups with regard to interpersonal pathology in favour of SFT-G (SMD -1.94, N = 28, 95% CI -2.87 to-1.02; <LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3.5 Cognitive cluster symptoms</HEADING>
<P>Reported data indicate a very large, statistically significant difference in favour of SFT-G with regard to cognitive-cluster symptoms (SMD -1.37, N = 28, 95% CI -2.21 to -0.53; <LINK REF="CMP-002.11" TYPE="ANALYSIS">Analysis 2.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3.6 General psychopathology</HEADING>
<P>
<LINK REF="STD-Farrell-2009" TYPE="STUDY">Farrell 2009</LINK> report data indicating a very large, statistically significant difference between the two conditions with better outcomes for the SFT-G group (SMD -1.06, N = 28, 95% CI -1.87 to -0.25; <LINK REF="CMP-002.14" TYPE="ANALYSIS">Analysis 2.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3.7 Mental health status/functioning</HEADING>
<P>Again, <LINK REF="STD-Farrell-2009" TYPE="STUDY">Farrell 2009</LINK> report data indicating a very large, statistically significant difference in favour of SFT-G (SMD 1.20; N = 28, 95% CI 0.38 to 2.03; <LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3.8 Leaving the study early</HEADING>
<P>Reported data indicate no statistically significant difference between treatment and control conditions for leaving the study early if considering all participants randomised (RR 0.11; N = 32; 95% CI 0.01 to 1.91; <LINK REF="CMP-002.16" TYPE="ANALYSIS">Analysis 2.16</LINK>).</P>
<P>No data were available for the following outcomes: depression, anxiety. See <LINK REF="TBL-09" TYPE="TABLE">Table 9</LINK> for an overview of primary effect outcome effect estimates.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.4 Manual-assisted cognitive treatment (MACT) versus treatment as usual (TAU)</HEADING>
<P>One trial was included in this comparison: <LINK REF="STD-Weinberg-2006" TYPE="STUDY">Weinberg 2006</LINK> (female outpatients; 1.5 months treatment; N = 30)</P>
<SUBSECTION>
<HEADING LEVEL="5">2.4.1 Impulsive cluster symptoms</HEADING>
<P>Reported data indicate statistically significant differences favouring MACT for the outcomes of suicidality (SMD -0.86; N = 28; 95% CI -1.64 to -0.07; <LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>) and parasuicidality (SMD -0.88; N = 28; 95% CI -1.67 to -0.10; <LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>) with large effects.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4.2 Leaving the study early</HEADING>
<P>Reported data indicate no statistically significant difference between treatment and control conditions for leaving the study early if considering all participants randomised (RR 0.20; N = 30; 95% CI 0.01 to 3.85; <LINK REF="CMP-002.16" TYPE="ANALYSIS">Analysis 2.16</LINK>).</P>
<P>No data were available for the following outcomes: BPD total severity; affective-dysregulative, interpersonal and cognitive cluster symptoms; depression, anxiety, general psychopathology, mental health status/functioning. See <LINK REF="TBL-10" TYPE="TABLE">Table 10</LINK> for an overview of primary effect outcome effect estimates.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.5 Systems training for emotional predictability and problem solving for BPD (STEPPS) versus treatment as usual (TAU)</HEADING>
<P>One trial was included in this comparison: <LINK REF="STD-Blum-2008" TYPE="STUDY">Blum 2008</LINK> (outpatients, 83% females; five months treatment; N = 124).</P>
<SUBSECTION>
<HEADING LEVEL="5">2.5.1 BPD total severity</HEADING>
<P>Reported data indicate a small, statistically non-significant difference between the treatment groups (SMD -0.17; N = 124; 95% CI -0.52 to 0.19; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.5.2 Affective dysregulative cluster symptoms</HEADING>
<P>There was a small, statistically non-significant difference between conditions in terms of affective instability (SMD -0.32; N = 124; 95% CI -0.67 to 0.04; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.5.3 Impulsive cluster symptoms</HEADING>
<P>Available data indicate a small, statistically non-significant difference between both groups for BPD-speciifc impulsivity (SMD -0.29; N = 124; 95% CI -0.64 to 0.07; <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.5.4 Interpersonal cluster symptoms</HEADING>
<P>We found a small to moderate statistically significant difference favouring STEPPS treatment for the outcome of interpersonal pathology (SMD -0.42; N = 124; 95% CI -0.78 to -0.06; <LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.5.5 Cognitive cluster symptoms</HEADING>
<P>There was also a small to moderate statistically significant difference with better outcomes of cognitive cluster symptoms in the STEPPS group (SMD -0.42; N = 124; 95% CI -0.78 to -0.06; <LINK REF="CMP-002.11" TYPE="ANALYSIS">Analysis 2.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.5.6 Depression</HEADING>
<P>Data indicate a small, but statistically non-significant difference between conditions for the outcome of depression (SMD -0.24; N = 124; 95% CI -0.59 to 0.11; <LINK REF="CMP-002.12" TYPE="ANALYSIS">Analysis 2.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.5.7 General psychopathology</HEADING>
<P>There was a small, statistically non-significant difference for the outcome of general psychopathology (SMD -0.29; N = 124; 95% CI -0.64 to 0.07; <LINK REF="CMP-002.14" TYPE="ANALYSIS">Analysis 2.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.5.8 Mental health status/functioning</HEADING>
<P>The treatment groups differed statistically significantly at the end of treatment with a small to moderate effect indicating better results for STEPPS, that is, better mental health status (SMD 0.38; N = 124; 95% CI 0.02 to 0.73; <LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.5.9 Leaving the study early</HEADING>
<P>Reported data indicate a statistically significant difference between both condition in terms of different proportion of those leaving the study early (RR 2.27; N = 124; 95% CI 1.08 to 4.76; <LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>), with a higher drop-out rate for STEPPS.</P>
<P>No data were available for the outcome of anxiety. See <LINK REF="TBL-11" TYPE="TABLE">Table 11</LINK> for an overview of primary effect outcome effect estimates.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.6 Systems training for emotional predictability and problem solving for BPD + individual therapy (STEPPS) versus treatment as usual (TAU)</HEADING>
<P>One study was included in this comparison: <LINK REF="STD-Bos-2010" TYPE="STUDY">Bos 2010</LINK> (outpatients, 86% females; 6 months treatment; N = 79)</P>
<SUBSECTION>
<HEADING LEVEL="5">2.6.1 BPD total severity</HEADING>
<P>
<LINK REF="STD-Bos-2010" TYPE="STUDY">Bos 2010</LINK> report data indicating a moderate, statistically non-significant difference between both conditions, but the boundaries of the 95% CI are very close to significance, favouring STEPPS + IT (SMD -0.55; N = 52; 95% CI -1.11 to 0.00; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.6.2 Impulsive cluster symptoms</HEADING>
<P>There are no statistically significant differences between both conditions in terms of proportion of those participants beyond the cut-off scores of clinically relevant impulsivity (RR 0.93; N = 58; 95% CI 0.66 to 1.29; <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>) and clinically relevant parasuicidality (RR 1.32; N = 58; 95% CI 0.78 to 2.22; <LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.6.3 Interpersonal cluster symptoms</HEADING>
<P>Data indicate a small, statistically non-significant difference between both treatment groups in terms of interpersonal pathology (SMD -0.27; N = 53; 95% CI -0.81 to 0.27; <LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.6.4 General psychopathology</HEADING>
<P>There was a moderate, statistically significant difference between both conditions in favour of STEPPS + IT (SMD -0.60; N = 51; 95% CI -1.16 to -0.04; <LINK REF="CMP-002.14" TYPE="ANALYSIS">Analysis 2.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.6.5 Leaving the study early</HEADING>
<P>Reported data indicate no statistically significant difference between treatment and control conditions for leaving the study early if considering all participants randomised (RR 1.47; N = 79; 95% CI 0.59 to 3.65; <LINK REF="CMP-002.16" TYPE="ANALYSIS">Analysis 2.16</LINK>).</P>
<P>No data were available for the following outcomes: affective-dysregulative and cognitive cluster symptoms; depression, anxiety, mental health status/functioning. See <LINK REF="TBL-11" TYPE="TABLE">Table 11</LINK> for an overview of primary effect outcome effect estimates.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.7 Psychoeducation (PE) versus waiting list (WL)</HEADING>
<P>The only study included in this comparison was <LINK REF="STD-Zanarini-2008" TYPE="STUDY">Zanarini 2008</LINK> (newly-diagnosed female outpatients; three months treatment; N = 50)</P>
<SUBSECTION>
<HEADING LEVEL="5">2.7.1 Impulsive cluster symptoms</HEADING>
<P>Data indicate a small to moderate but statistically non-significant difference between both groups in terms of impulsivity baseline to endpoint change scores (SMD -0.47; N = 50; 95% CI -1.04 to 0.10; <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.7.2 Interpersonal cluster symptoms</HEADING>
<P>We found a moderate to large, statistically significant difference between both groups in terms of interpersonal pathology baseline to endpoint change scores (SMD -0.75; N = 50; 95% CI -1.33 to -0.16; <LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.7.3 Leaving the study early</HEADING>
<P>All participants attended every visit, there were no non-attendances in either group.</P>
<P>No data were available for the following outcomes: BPD total severity; affective-dysregulative and cognitive cluster symptoms; depression, anxiety, general psychopathology, mental health status/functioning. See <LINK REF="TBL-12" TYPE="TABLE">Table 12</LINK> for an overview of primary effect outcome effect estimates.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3 Comprehensive psychotherapies: active versus active conditions</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">3.1 Dialectical behaviour therapy (DBT) versus Client-centered therapy (CCT)</HEADING>
<P>This comparison included one trial: <LINK REF="STD-Turner-2000" TYPE="STUDY">Turner 2000</LINK> (outpatients, 79% females; 12 months therapy; N = 24)</P>
<SUBSECTION>
<HEADING LEVEL="5">3.1.1 Affective dysregulative cluster symptoms</HEADING>
<P>Data indicate a tendency towards better results of DBT with a large effect for the outcome of anger, but no statistically significant difference (SMD -0.79; N = 24; 95% CI -1.62 to 0.05; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.2 Impulsive cluster symptoms</HEADING>
<P>Reported data indicate large to very large statistically significant differences between both groups for impulsive symptom cluster outcomes, all favouring DBT over CCT (impulsivity: SMD -1.05, N = 24, 95% CI -1.92 to -0.19, <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>; suicidality: SMD -0.87, N = 24, 95% CI -1.71 to -0.02, <LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>; parasuicidality: SMD -1.28, N = 24, 95% CI -2.17 to -0.38, <LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.3 Cognitive cluster symptoms</HEADING>
<P>There was also a very large, statistically significant difference for the outcome of psychotic symptoms, favouring DBT over CCT treatment (SMD -1.11; N = 24; 95% CI -1.98 to -0.24; <LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.4 Depression</HEADING>
<P>Available data also indicate a very large, significant difference for the outcome of depression, with lower burden in DBT-treated participants (SMD -1.26; N = 24; 95% CI -2.15 to -0.37; <LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.5 Anxiety</HEADING>
<P>Data indicate no significant difference between both conditions for the outcome of anxiety, but a moderate to large difference (SMD -0.70; N = 24; 95% CI -1.53 to 0.13; <LINK REF="CMP-003.08" TYPE="ANALYSIS">Analysis 3.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.6 Leaving the study early</HEADING>
<P>Reported data indicate no statistically significant difference between treatment and control conditions for leaving the study early if considering all participants randomised (RR 0.50; N = 24; 95% CI 0.16 to 1.55; <LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>).</P>
<P>No data were available for the following outcomes: BPD total severity; interpersonal cluster symptoms; general psychopathology, mental health status/functioning.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.2 Schema-focused therapy (SFT) versus Transference-focused therapy (TFP)</HEADING>
<P>One trial was included in this comparison: <LINK REF="STD-Giesen_x002d_Bloo-2006" TYPE="STUDY">Giesen-Bloo 2006</LINK> (outpatients, 93% females; 36 months treatment; N = 88).</P>
<SUBSECTION>
<HEADING LEVEL="5">3.2.1 BPD total severity</HEADING>
<P>
<LINK REF="STD-Giesen_x002d_Bloo-2006" TYPE="STUDY">Giesen-Bloo 2006</LINK> report data indicating a moderate, statistically significant difference between both treatment groups. SFT-treated participants showed significantly lower levels of BPD total severity (SMD -0.45; N = 86; 95% CI -0.88 to -0.02; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2.2 General psychopathology</HEADING>
<P>Data indicate no statistically significant difference between both conditions for the outcome of general psychopathology (SMD -0.09; N = 86; 95% CI -0.52 to 0.33; <LINK REF="CMP-003.09" TYPE="ANALYSIS">Analysis 3.9</LINK>), with a marginal effect size.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2.3 Leaving the study early</HEADING>
<P>Reported data indicate a statistically significant difference between both condition in terms of a different proportion of those leaving the study early (RR 0.52; N = 88; 95% CI 0.30 to 0.92; <LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>), with a smaller drop-out rate for SFT.</P>
<P>No data were available for the following outcomes: affective-dysregulative, impulsive, interpersonal and cognitive cluster symptoms; depression, anxiety, mental health status/functioning.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.3 Schema-focused therapy (SFT) versus Schema-focused therapy + Therapist Telephone Availability (SFT+TTA)</HEADING>
<P>One trial was included in this comparison: <LINK REF="STD-Nadort-2009" TYPE="STUDY">Nadort 2009</LINK> (outpatients, 9´7% females; 18 months treatment; N = 62).</P>
<SUBSECTION>
<HEADING LEVEL="5">3.3.1 BPD total severity</HEADING>
<P>Data indicate no clinically or statistically significant difference between both conditions for the outcome of BPD total severity (SMD -0.03; N = 61; 95% CI -0.53 to 0.47; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.3.2 General psychopathologiy</HEADING>
<P>Data indicate a very small, statistically non-significant difference between both conditions for the outcome of general psychopathology (SMD 0.14; N = 61; 95% CI -0.37 to 0.64; <LINK REF="CMP-003.09" TYPE="ANALYSIS">Analysis 3.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.3.3 Leaving the study early</HEADING>
<P>Reported data indicate no statistically significant difference between both conditions in terms of a different proportion of those leaving the study early (RR 0.91; N = 62; 95% CI 0.35 to 2.41; <LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>).</P>
<P>No data were available for the following outcomes: affective-dysregulative, impulsive, interpersonal and cognitive cluster symptoms; depression, anxiety, mental health status/functioning.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.4 Cognitive therapy (CT) versus Client-centered therapy (CCT)</HEADING>
<P>One trial was included in this comparison: <LINK REF="STD-Cottraux-2009" TYPE="STUDY">Cottraux 2009</LINK> (outpatients, 77% females; 12 months treatment; N = 65)</P>
<SUBSECTION>
<HEADING LEVEL="5">3.4.1 Impulsive cluster symptoms</HEADING>
<P>Data were available for the outcomes of impulsivity, suicidality and parasuicidality. Neither indicated a statistically significant difference between the experimental conditions (impulsivity: SMD -0.22, N = 38, 95% CI -0.86 to 0.41, <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>; suicidality: SMD 0.13, N = 38, 95% CI -0.51 to 0.77, <LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>; parasuicidality: SMD 0.59, N = 38, 95% CI -0.06 to 1.24, <LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>). The data favoured CT for impulsivity with a small effect, and CCT for the outcomes of suicidality (very small effect) and parasuicidality (moderate effect).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.4.2 Depression</HEADING>
<P>Data indicate a very small, statistically non-significant difference between the two conditions (SMD 0.10; N = 38; 95% CI -0.54 to 0.73; <LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.4.3 Anxiety</HEADING>
<P>There was also no indication of a statistically significant difference between the two conditions in terms of anxious pathology, with a moderate effect favouring CT (SMD -0.51; N = 38; 95% CI -1.16 to 0.13; <LINK REF="CMP-003.08" TYPE="ANALYSIS">Analysis 3.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.4.4 Mental health status/functioning</HEADING>
<P>The two treatments did also not differ in a statistically significant way regarding the outcome of general psychopathological burden, with a small effect favouring CT (SMD 0.30; N = 38; 95% CI -0.34 to 0.94; <LINK REF="CMP-003.10" TYPE="ANALYSIS">Analysis 3.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.4.5 Leaving the study early</HEADING>
<P>Reported data indicate no statistically significant difference between treatment and control conditions for leaving the study early if considering all participants randomised (RR 0.90; N = 65; 95% CI 0.51 to 1.60; <LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>).</P>
<P>No data were available for the following outcomes: BPD total severity; affective-dysregulative, interpersonal and cognitive cluster symptoms; general psychopathology.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.5 Cognitive therapy (CT) versus Interpersonal psychotherapy (IPT)</HEADING>
<P>One study was included in this comparison: <LINK REF="STD-Bellino-2007" TYPE="STUDY">Bellino 2007</LINK> (outpatients with concurrent major depressive disorder, 79% females; six months treatment; N = 32).</P>
<SUBSECTION>
<HEADING LEVEL="5">3.5.1 Depression</HEADING>
<P>Data indicated no statistically significant difference between both conditions with regard to the outcome of depression, with a marginal effect size (SMD -0.07; N = 26; 95% CI -0.84 to 0.70; <LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.5.2 Anxiety</HEADING>
<P>There was also no indication of a statistically significant difference between the two conditions in terms of anxious pathology (SMD -0.53; N = 26; 95% CI -1.32 to 0.26; <LINK REF="CMP-003.08" TYPE="ANALYSIS">Analysis 3.8</LINK>). However, the effect was moderate in size, favouring CT.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.5.3 Mental health status/functioning</HEADING>
<P>Data indicated no statistically significant difference between both conditions with regard to the outcome of the level of functioning, favouring CT with a small effect (SMD 0.19; N = 26; 95% CI -0.58 to 0.97; <LINK REF="CMP-003.10" TYPE="ANALYSIS">Analysis 3.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.5.4 Leaving the study early</HEADING>
<P>Reported data indicate no statistically significant difference between treatment and control conditions for leaving the study early if considering all participants randomised (RR 2.00; N = 32; 95% CI 0.42 to 9.42; <LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>).</P>
<P>No data were available for the following outcomes: BPD total severity; affective-dysregulative, impulsive, interpersonal and cognitive cluster symptoms; general psychopathology.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. Non-comprehensive psychotherapeutic interventions: active versus active conditions</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">4.1 Manual-assisted cognitive therapy (MACT) versus manual-assisted cognitive therapy plus therapeutic assessment (MACT+TA)</HEADING>
<P>One study was included in this comparison: <LINK REF="STD-Morey-2010" TYPE="STUDY">Morey 2010</LINK> (outpatients, 81% females; six weekly sessions; N = 16)</P>
<SUBSECTION>
<HEADING LEVEL="5">4.1.1 BPD total severity</HEADING>
<P>Data indicated a small, statistically non-significant difference between both conditions with regard to the outcome of BPD total severity (SMD -0.33; N = 16; 95% CI -1.32 to 0.66; <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.1.2 Affective dysregulative cluster symptoms</HEADING>
<P>Available data indicated a moderate to large, statistically non-significant difference in terms of affective instability scores after treatment, favouring MACT (SMD -0.71; N = 16; 95% CI -1.73 to 0.31; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.1.3 Impulsive cluster symptoms</HEADING>
<P>
<LINK REF="STD-Morey-2010" TYPE="STUDY">Morey 2010</LINK> reported both on suicidality as well as parasuicidality. Both rendered marginal, statistically not different between-group effects (suicidality: SMD -0.03; N = 16; 95% CI -1.01 to 0.95; <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>; parasuicidality: SMD 0.08; N = 16; 95% CI -0.90 to 1.06; <LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.1.4 Interpersonal cluster symptoms</HEADING>
<P>Data indicated a marginal, statistically non-significant difference between both conditions with regard to the outcome of interpersonal problems (SMD -0.04; N = 16; 95% CI -1.02 to 0.94; <LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.1.5 Cognitive cluster symptoms</HEADING>
<P>There was also no indication of a statistically significant difference between the two conditions in terms of identity disturbance, with a small to moderate effect favouring MACT (SMD -0.45; N = 16; 95% CI -1.44 to 0.55; <LINK REF="CMP-004.06" TYPE="ANALYSIS">Analysis 4.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.1.6 Leaving the study early</HEADING>
<P>Reported data indicate no statistically significant difference between treatment and control conditions for the risk of non-completing all six therapy sessions (RR 0.80; N = 16; 95% CI 0.33 to 1.92; <LINK REF="CMP-004.07" TYPE="ANALYSIS">Analysis 4.7</LINK>).</P>
<P>No data were available for the following outcomes: depression, anxiety, general psychopathology, mental health status/functioning.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2017-06-30 15:54:54 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2017-06-30 15:54:54 +0100" MODIFIED_BY="[Empty name]">
<P>The following summary is ordered according to the overall number of trials available for a certain treatment or adaptations of the "original" treatment. For a summary of primary outcome effect estimates of controlled comparisons, see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> to <LINK REF="TBL-12" TYPE="TABLE">Table 12</LINK>.</P>
<P>Dialectical Behaviour Therapy (DBT) and DBT-derived treatments have been studied most intensively among the included trials. Findings from five studies comparing DBT to treatment as usual (TAU) (<LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK>; <LINK REF="STD-Linehan-1991" TYPE="STUDY">Linehan 1991</LINK>; <LINK REF="STD-Linehan-1994" TYPE="STUDY">Linehan 1994</LINK>; <LINK REF="STD-Van-den-Bosch-2005" TYPE="STUDY">Van den Bosch 2005</LINK>; <LINK REF="STD-Carter-2010" TYPE="STUDY">Carter 2010</LINK>) indicate statistically significantly beneficial effects for the broadest range of outcomes relative to remaining treatments. The comparison of DBT to TAU was the only comparison that allowed for meta-analytic pooling of effect estimates from several studies, but only for the outcomes of anger, parasuicidality and mental health status. Standard DBT was found to have beneficial effects in terms of anger (large effect), suicidal behaviour (very large effect) and parasuicidality (moderate effect), associated psychopathology such as depression (very large effect) and anxiety (very large effect) and overall mental health status (moderate to large effect). The remaining statistically non-significant findings were based on single study results each, yielding a large effect for the outcome of dissociation and small effects for the outcomes of overall BPD severity, impulsivity and interpersonal problems.</P>
<P>However, if compared to more rigorous control conditions, that is, general management according to the APA guidelines (<LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK>) or community treatment by experts (CTBE) (<LINK REF="STD-Linehan-2006" TYPE="STUDY">Linehan 2006</LINK>), there were no statistically significant group differences for pathology-related outcomes, but DBT was statistically superior to CTBE in terms of treatment retention. DBT was only marginally superior to APA guidelines general management (BPD severity, anger, interpersonal problems, general psychopathology), and small differences were found for the outcomes of parasuicidality and depression, favouring DBT. Compared with CTBE, there was a very small effect favouring DBT in terms of suicidality, and a small to moderate effect in terms of less depression in DBT-treated patients.</P>
<P>DBT-PTSD, a modified DBT approach developed to meet the specific needs of those with comorbid PTSD, was also found to be effective in the reduction of overall BPD severity, depression and anxiety (<LINK REF="STD-Steil-2010" TYPE="STUDY">Steil 2010</LINK>), with moderate (BPD severity) and very large (depression, anxiety), statistically significant effects. Statistically non-significant effects were found for the outcomes of general psychopathology (moderate to large effect) and dissociation (small effect).</P>
<P>As compared to Client-Centered Therapy CCT (the effects of which have not been tested against a control condition in BPD treatment up to now, and the efficacy of which thus is unclear), DBT showed better results in the reduction of impulsivity, suicidality, parasuicidality, dissociative pathology and depression, with large to very large, statistically significant effects throughout (<LINK REF="STD-Turner-2000" TYPE="STUDY">Turner 2000</LINK>). DBT had also favourable results for the outcomes of anger, depression and anxiety, with moderate to very large, but statistically non-significant effects.</P>
<P>These findings are consolidated by trials of short-term interventions derived from or including elements of DBT. A trial of DBT skills training only (DBT-ST) as compared to a non-specific standard group (<LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>) resulted in statistically significant results favouring DBT-ST for BPD severity, anger, affective instability, impulsivity, dissociation, depression and anxiety with moderate to very large effects. Small to moderate, statistically non significant effects were found for the outcomes of chronic feelings of emptiness, suicidality, interpersonal problems, general psychopathology and overall mental health status, each favouring DBT-ST.</P>
<P>Emotion Regulation Group Training (ERG), which was developed as a short-time, group-based approach and combines elements of DBT and Acceptance and Commitment Therapy (ACT), also showed encouraging, statistically significant results in terms of amelioration of BPD severity, affective instability, impulsivity, parasuicidality, depression and anxiety, with large to very large effects (<LINK REF="STD-Gratz-2006" TYPE="STUDY">Gratz 2006</LINK>).</P>
<P>In sum, DBT and related treatments provide the most solid (but not sufficiently robust) evidence of efficacy relative to all treatments that have been investigated in RCTs so far.</P>
<P>Mentalisation-Based treatment (MBT) is, second to DBT, the one treatment that provides most robust evidence of its efficacy. It has been compared with control groups in two trials, one testing MBT in a partial hospitalisation (MBT-PH; <LINK REF="STD-Bateman-1999" TYPE="STUDY">Bateman 1999</LINK>) and one testing MBT in an outpatient setting (MBT-out; <LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK>). Both show consistently beneficial effects concerning the reduction of suicidality, parasuicidality, interpersonal problems and depression, with very large, statistically significant effects. In addition, data indicate beneficial effects also in terms of amelioration of general psychopathology and overall functioning for the outpatient setting. Small to moderate, statistically non-significant effects were found for the reduction of anxiety and general psychopathology by MBT-PH.</P>
<P>Transference-Focused Psychotherapy (TFP) was tested in an outpatient study against an unspecific control therapy (CTBE; treatment period 12 months; <LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK>) and directly against SFT (treatment period three years; <LINK REF="STD-Giesen_x002d_Bloo-2006" TYPE="STUDY">Giesen-Bloo 2006</LINK>). Though tested against a rigorous comparison treatment (CTBE), TFP was found to have encouraging effects for the reduction of BPD severity (statistically significant, moderate effect) and treatment retention. There were small, unfavourable but statistically non-significant effects for the outcomes of parasuicidality, depression, anxiety and general psychopathology, and a small, statistically non-significant effect in favour of TFP for the outcome of overall functioning. As compared to Schema-Focused Therapy (SFT), results indicated statistical superiority of SFT over TFP in the reduction of overall BPD severity (moderate effect) and treatment retention. As concerns general psychopathology, both treatments differed only marginally, resulting in a non-significant finding.</P>
<P>SFT and derived treatments were subject to three trials: First, SFT was compared with TFP (<LINK REF="STD-Giesen_x002d_Bloo-2006" TYPE="STUDY">Giesen-Bloo 2006</LINK>), with the above reported results of SFT being more effective in reducing overall BPD severity and keeping patients in treatment, but not in terms of reducing general psychopathology. Second, modified SFT in a group only format (SFT-G) was subject to another trial (<LINK REF="STD-Farrell-2009" TYPE="STUDY">Farrell 2009</LINK>). The authors report findings resulting in very large, statistically significant effects for all reported pathology-related outcomes, that is, BPD severity, affective instability, impulsivity, interpersonal problems, dissociative/psychotic symptoms, general psychopathology, and overall mental health status. Third, SFT was compared with a modified form of SFT with additional therapist telephone availability in times of crisis (SFT+TTA; <LINK REF="STD-Nadort-2009" TYPE="STUDY">Nadort 2009</LINK>). Both treatments did not differ in a statistically significant way, with marginal effects in terms of BPD severity and general psychopathology.</P>
<P>Interpersonal Psychotherapy (IPT) (<LINK REF="STD-Bellino-2006" TYPE="STUDY">Bellino 2006</LINK>) and IPT adapted for BPD (IPT-BPD; <LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK>) were supported by statistically significant findings of single trials each. IPT had statistically significant beneficial effects in terms of an amelioration of depression, with a large effect, though effects on BPD core pathology were not assessed and remain unclear. IPT-BPD, however, showed large, statistically significant effects in the reduction of affective instability impulsivity and interpersonal problems. The remaining statistically non-significant effects were marginal in size (anger, chronic feelings of emptiness, parasuicidality, avoidance of abandonment, identity disturbance, dissociative/psychotic symptoms, depression and mental health status). However, there was a moderate, statistically non significant effect favouring IPT-BPD for the outcome of anxiety.</P>
<P>Cognitive-Behaviour Therapy (CBT) was compared with TAU in a single trial (<LINK REF="STD-Davidson-2006" TYPE="STUDY">Davidson 2006</LINK>). There were no statistically significant between-group differences at post-treatment for any out outcome. There was a trend of better results for CBT for the outcomes of suicidality, depression, anxiety, general psychopathology and mental health status. For two outcomes, the effects were opposite, favouring the control group with very small (parasuicidality) and small (interpersonal problems), statistically non-significant effects.</P>
<P>Cognitive Therapy (CT) was compared with two alternate active treatments, that is, CCT (<LINK REF="STD-Cottraux-2009" TYPE="STUDY">Cottraux 2009</LINK>) and IPT (<LINK REF="STD-Bellino-2007" TYPE="STUDY">Bellino 2007</LINK>). Both comparisons yielded no statistically significant differences for any outcome. As compared to CCT, results indicated a superiority of CT over CCT for the outcomes of impulsivity, suicidality, anxiety and mental health status with very small to moderate effects, and superiority of CCT for parasuicidality (moderate effect) and depression (very small effect). As compared to IPT, better results were found for CT for the outcomes anxiety (moderate effect) and mental health status (small effect). For the outcome of depression, the difference was marginal in size.</P>
<P>Dynamic Deconstructive Psychotherapy (DDP) was also investigated in a single trial only (<LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>). There were no statistically significant results, but DDP was indicated to be superior to the control group in terms of BPD severity and parasuicidality and depression with small to moderate effects.</P>
<P>Systems training for emotional predictability and problem solving for borderline personality disorder (STEPPS) was subject to two trials. First, STEPPS was compared with TAU (<LINK REF="STD-Blum-2008" TYPE="STUDY">Blum 2008</LINK>). All results favoured STEPPS with statistically significant, small to moderate effects for interpersonal problems, dissociation and mental health status, and small, statistically non-significant effects for the outcomes of overall BPD severity, affective instability, impulsivity, depression and general psychopathology. Notably, there was a statistically significant higher drop-out rate in the STEPPS group. Another trial compared STEPPS plus limited individual therapy (STEPPS + IT; <LINK REF="STD-Bos-2010" TYPE="STUDY">Bos 2010</LINK>) to TAU. There was a statistically significant, moderate effect indicating beneficial effects of STEPPS in terms of general psychopathology. Statistically non-significant, favourable effects were found for the reduction of BPD severity (moderate in size), impulsivity (small effect), and interpersonal problems (small effect). For the outcome of parasuicidality, there was statistically non-significant effect indicating more such pathology in the STEPPS + IT group.</P>
<P>Manual-Assisted Cognitive Treatment (MACT) was also tested in two trials: First, it was compared with TAU (<LINK REF="STD-Weinberg-2006" TYPE="STUDY">Weinberg 2006</LINK>). There were two large, significant effects favouring MACT over TAU in terms of suicidality and parasuicidality. Second, MACT was compared with MACT enhanced by pre-treatment individual therapeutic assessment (<LINK REF="STD-Morey-2010" TYPE="STUDY">Morey 2010</LINK>). There were no statistically significant differences, with a moderate to large effect for affective instability, a moderate for identity disturbance and a small one for BPD severity, all favouring MACT. Differences in terms of suicidality and parasuicidality were marginal.</P>
<P>At last, a very generic psychoeducative intervention (PE) was compared with a waiting list (WL) control group (<LINK REF="STD-Zanarini-2008" TYPE="STUDY">Zanarini 2008</LINK>). There was a nearly large, statistically significant effect for the reduction of interpersonal problems, and an almost moderate but non-significant effect for the reduction of impulsivity by this intervention.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2012-07-11 09:51:08 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Participants</HEADING>
<P>Most trial participants were women. Overall, 89% of included participants were female, and there was not a single study with more men than women, or even balanced proportions. This pattern may reflect reality in clinical settings, where about 75% of all BPD diagnoses are given to women (<LINK REF="REF-APA-2000" TYPE="REFERENCE">APA 2000</LINK>). However, some doubt that the 'real' prevalence of BPD is actually higher in women than men, and there are contradictory findings of balanced proportions or even higher prevalence rates in men (<LINK REF="REF-Torgersen-2009" TYPE="REFERENCE">Torgersen 2009</LINK>). Men with BPD may exhibit another clinical picture than women, and especially antisocial features may be more prevalent in men than women with BPD (<LINK REF="REF-Skodol-2009" TYPE="REFERENCE">Skodol 2009</LINK>). From a clinical point of view, this may yield different treatment approaches or special requirements that may not be reflected in the actual findings from the RCT evidence. In contrast, antisocial features or full antisocial personality disorder were reasons for exclusion in several trials (see <LINK TAG="CRIT_PARTICIPANTS" TYPE="SECTION">Types of participants</LINK>). Thus, the applicability of findings of this review, and most BPD research findings, to men may be confined.</P>
<P>Objective measures of levels of functioning at baseline were not available from all studies, and if so, different measures were used, rendering comparability of single study samples difficult. Overall, drawing from those studies that reported objective measures such as GAF, GAS, CGI or SFQ, the severity of illness ranged between major impairment, comparable to psychiatric emergencies, and mild illness, with the majority of samples exhibiting serious to moderate levels of illness. Regarding comorbidity, those with comorbid "severe mental disorders" such as psychotic and/or bipolar disorders were not eligible for study participation in most trials, as were those with mental impairments, organic brain disorder and severe organic conditions. Substance-related disorders were also common reasons for exclusion (17 studies; some differentiated between substance abuse and addiction or specific substances, some did not (see. <LINK TAG="CRIT_PARTICIPANTS" TYPE="SECTION">Types of participants</LINK>). Some studies, however, concentrated on participants with distinct comorbid conditions, such as alcohol abuse or dependence (<LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>), post-traumatic stress disorder (<LINK REF="STD-Steil-2010" TYPE="STUDY">Steil 2010</LINK>) or major depressive disorder episodes (<LINK REF="STD-Bellino-2006" TYPE="STUDY">Bellino 2006</LINK>; <LINK REF="STD-Bellino-2007" TYPE="STUDY">Bellino 2007</LINK>).</P>
<P>Notably, acute endangerment of self and/or others was explicitly specified a reason for exclusion only in three trials. However, it seems not improbable that others may also have excluded patients in acute crisis. However, anxiety-related disorders or eating disorders were not explicit reasons of exclusion in any study. There was only one trial that explicitly did not include patients with concurrent major depressive episode (<LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>).</P>
<P>Most studies were conducted either in Western Europe (14 trials: <LINK REF="STD-Bateman-1999" TYPE="STUDY">Bateman 1999</LINK>; <LINK REF="STD-Van-den-Bosch-2005" TYPE="STUDY">Van den Bosch 2005</LINK>; <LINK REF="STD-Bellino-2006" TYPE="STUDY">Bellino 2006</LINK>; <LINK REF="STD-Davidson-2006" TYPE="STUDY">Davidson 2006</LINK>; <LINK REF="STD-Giesen_x002d_Bloo-2006" TYPE="STUDY">Giesen-Bloo 2006</LINK>; <LINK REF="STD-Bellino-2007" TYPE="STUDY">Bellino 2007</LINK>; <LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK>; <LINK REF="STD-Cottraux-2009" TYPE="STUDY">Cottraux 2009</LINK>; <LINK REF="STD-Nadort-2009" TYPE="STUDY">Nadort 2009</LINK>; <LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>; <LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK>; <LINK REF="STD-Bos-2010" TYPE="STUDY">Bos 2010</LINK>; <LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK>; <LINK REF="STD-Steil-2010" TYPE="STUDY">Steil 2010</LINK>) or North America (13 trials: <LINK REF="STD-Linehan-1991" TYPE="STUDY">Linehan 1991</LINK>; <LINK REF="STD-Linehan-1994" TYPE="STUDY">Linehan 1994</LINK>; <LINK REF="STD-Turner-2000" TYPE="STUDY">Turner 2000</LINK>; <LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK>; <LINK REF="STD-Gratz-2006" TYPE="STUDY">Gratz 2006</LINK>; <LINK REF="STD-Linehan-2006" TYPE="STUDY">Linehan 2006</LINK>; <LINK REF="STD-Weinberg-2006" TYPE="STUDY">Weinberg 2006</LINK>; <LINK REF="STD-Blum-2008" TYPE="STUDY">Blum 2008</LINK>; <LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>; <LINK REF="STD-Zanarini-2008" TYPE="STUDY">Zanarini 2008</LINK>; <LINK REF="STD-Farrell-2009" TYPE="STUDY">Farrell 2009</LINK>; <LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK>; <LINK REF="STD-Morey-2010" TYPE="STUDY">Morey 2010</LINK>). One study was conducted in New Zealand (<LINK REF="STD-Carter-2010" TYPE="STUDY">Carter 2010</LINK>). Thus, the applicability of findings to other locations and ethnicities, that is, as found in South America, Asia, Africa and also other parts of Europe and Oceania remains unclear.</P>
<P>In summary, the findings may be mostly applicable to a female, moderately to severely ill BPD patient without any comorbid severe mental condition such as psychotic disorder or substance-related disorder, mental retardation or severe organic condition. However, we tried to exactly specify and describe all studies with regard to their crucial characteristics (see <LINK TAG="STUDY_DESCRIPTION" TYPE="SECTION">Description of studies</LINK>, <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>) in order to let the reader decide about applicability of relevant study characteristics to his or her decisive situation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">
<I>Interventions</I>    </HEADING>
<P>All major psychotherapeutic treatments for BPD (DBT, MBT, SFT, TFP) have been tested in RCTs so far, though the number of RCTs varies with most trials investigating DBT. Treatment periods range broadly. Even if looking at long-term treatments only (defined here as covering a period of more than six months), there is a broad range from six up to 36 months. It may surely depend of the specific national mental health care setting which treatment periods fit into the context of current practice, that is, which "amounts" of psychotherapeutic treatment a patient may be enabled to use.</P>
<P>A new trend of group-based short-time interventions can be observed in recent trials, with all referring studies dating from 2006 or later. Those short-time interventions draw from already-established interventions, especially DBT, and combine them with new elements and/or modify them according to group settings. Thus, a certain eclecticism can be observed, and in some cases it remains unclear which sources have been used. Short-term interventions show encouraging results, however, the long-term stability of effects has to be established. From a clinical point of view, it should also be made clear which "experience of treatment" a patient must already have to profit from those interventions, or if they should only be recommended to those patients who can use them as "booster treatment" on basis of their already-gained treatment experience or as add-on to concurrent individual psychotherapies only.</P>
<P>Most trials allowed concurrent psychotropic treatments. With the exception of the trials of <LINK REF="STD-Bellino-2006" TYPE="STUDY">Bellino 2006</LINK>, <LINK REF="STD-Bellino-2007" TYPE="STUDY">Bellino 2007</LINK> and <LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK>, the participants of which were all given the SSRI antidepressant fluoxetine, most trialists did not prevent participants from taking concomitant medication. Some cited the APA guidelines as a rough orientation for medication regimens (<LINK REF="STD-Giesen_x002d_Bloo-2006" TYPE="STUDY">Giesen-Bloo 2006</LINK>; <LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>; <LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK>, <LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK> for control group patients). Most DBT trials explicitly encouraged tapering-off of medications as an explicit treatment goal (<LINK REF="STD-Linehan-1991" TYPE="STUDY">Linehan 1991</LINK>; <LINK REF="STD-Linehan-1994" TYPE="STUDY">Linehan 1994</LINK>; <LINK REF="STD-Linehan-2006" TYPE="STUDY">Linehan 2006</LINK>; <LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK>). Thus, the actual use of medications during the study period differed between DBT and control groups as a consequence of the psychotherapy treatment goal of tapering-off medications ("rely on skills over pills"), but the study groups did not differ at pretreatment. Overall, the wide-spread use of pharmacotherapy in patients with BPD (<LINK REF="REF-Ansell-2007" TYPE="REFERENCE">Ansell 2007</LINK>; <LINK REF="REF-H_x00f6_rz-2010" TYPE="REFERENCE">Hörz 2010</LINK>) is adequately reflected by the included primary studies.</P>
<P>During the time-span that the included trials cover (that is, publication years range from 1991 to 2011), the understanding of the relative efficacy of medications in BPD has changed. For example, SSRIs that were once regarded the first-line treatment for BPD (compare APA guidelines: <LINK REF="REF-APA-2001" TYPE="REFERENCE">APA 2001</LINK>; <LINK REF="REF-Rush--2005" TYPE="REFERENCE">Rush 2005</LINK>) for the treatment of various symptom clusters lack corresponding evidence, whereas mood stabilisers and second-generation antipsychotics are supported by some evidence (<LINK REF="REF-Stoffers-2010" TYPE="REFERENCE">Stoffers 2010</LINK>). It is therefore possible that  the efficacy of concurrent medications may have changed throughout  this long time-span and may have confounded the corresponding findings. Within this review, this could possibly concern the comparison of DBT to TAU as this was the only comparison for which several study findings were pooled, covering a time-span of publication years 1991 to 2010. However, in examining more closely the actual concomitant drug treatment in these studies, it becomes clear that antidepressants were most frequently used in all studies, rendering them studies comparable and limiting the risk of any confounding medication effects.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparisons</HEADING>
<P>There was a large heterogeneity of control group treatments. Even "treatment as usual", a very common control condition, varied between studies. Some TAU participants were completely free to use or not to use any kind of care they would have used if not included into the study. Some TAU participants, however, received some minimum standard of care, for example, referrals to other providers (that participants could follow up or not) or a rough, guideline-oriented but non-specific treatment regimen. What is more, TAU will certainly vary internationally, the "usual" standards of mental health care are known to be different depending on national health care systems.</P>
<P>There is a clear trend towards new kinds of control conditions such as CTBE (<LINK REF="STD-Linehan-2006" TYPE="STUDY">Linehan 2006</LINK>; <LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK>) or guideline-oriented treatments (<LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK>; <LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK>). Reasons may be ethical considerations taking into account that severely ill patient should not be left untreated if established treatments such as DBT are available. In addition, it is interesting for the assessment of a certain therapy if this therapy not only works compared with TAU but also if compared with experienced therapists or therapists using guidelines. However, such comparisons will yield smaller between-group effects if using more rigorous comparison conditions, and this should be taken into account if comparing data from such studies with those studies that use less rigorous control groups. From a reviewer's point of view, it is sometimes difficult to classify these newer comparison treatments. One may argue to group them as controls or as active comparisons, as well. Here, we decided to classify them as controls, since they do not use specific treatment manuals but only rough guidelines, so that there could have been variation in the type of treatment received by participants within the same control group. .</P>
<P>Another problem is the head-to-head testing of treatments before investigating the mere effects of the two treatments against control treatments (for example, CCT, SFT). Thus, it remains unclear what a between-group difference really means. What is more, not only controlled studies but also pilot studies are mostly missing. This is in some ways astonishing taking into account the burden conducting a psychotherapy RCT to both investigators and participants.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcomes</HEADING>
<P>Starting from the phenomenological diversity of BPD, there is also a high variety of possible outcomes, and by now there is only a small consensus about really important outcomes. Identifying theory-inherent outcomes related to putative mechanisms of change is a major problem especially in psychotherapy research. The real core symptoms that people with BPD and caregivers may be interested in when looking for a helpful treatment option are sometimes neglected. Trialists should keep in mind that anyone concerned will certainly not be interested in how a change will putatively be achieved but if a change will be achieved at all, to what extent, and in terms of which pathology. The development of new outcome scales such as BPDSI-IV, CGI-BPD or ZAN-BPD allows for distinct assessment of BPD symptoms. These scales, encouragingly, have potential to measure outcomes such as change in chronic feelings of emptiness or in avoidance of abandonment, which are significant traits in many people with BPD.</P>
<P>Attrition data must be interpreted with caution. There is a high risk of bias especially in small sample studies with, for example, also small numbers of therapists. What is more, there is a substantial likelihood of attrition rates depending on the kind of control groups used. For example, waiting list participants seem to be more prone to leaving the study early than TAU participants. In addition, geographical conditions and accessibility of study centres can play an important role (for example, if it is a rural region with high costs and burden for participants to go study assessments, higher drop-out rates can be expected than in urban settings, cf. <LINK REF="STD-Blum-2008" TYPE="STUDY">Blum 2008</LINK>; <LINK REF="STD-Carter-2010" TYPE="STUDY">Carter 2010</LINK>).</P>
<P>None of the studies considered adverse or undesired effects. Some argue that psychotherapy, constituing a potent intervention, may both have the potential to cure and harm. A broad range of possible adverse outcomes has been discussed so far, including, e.g., the lack of significant improvement, acceleration of ongoing deterioration or increase of substance use if a certain intervention inducing high emotional arousal (<LINK REF="REF-Berk-2009" TYPE="REFERENCE">Berk 2009</LINK>). </P>
</SUBSECTION>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2017-04-06 17:49:35 +0100" MODIFIED_BY="[Empty name]">
<P>Overall, a total of 28 studies involving 1804 participants have been included in this review. Study sample sizes ranged between 16 and 180. However, except for DBT, the review findings are based on single study effects only. There were either single trials available for a certain intervention (for example, CBT, DDP, ERG, MACT), or the intervention had actually been tested in several trials, but in modified forms (for example, MBT and MBT-PH; SFT and SFT-G, STEPPS and STEPPS + IT), and/or it had been compared with different conditions (for example, CT, IPT), so the study effects could not be pooled either. 'Summary of findings' tables (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK> to <LINK REF="SOF-18" TYPE="SOF">Summary of results table 18</LINK>) are provided for all active to control group comparisons, focusing on primary outcomes. The comparison of DBT with TAU was the only comparison that allowed for pooling of several effect estimates. The overall quality of evidence ranges between moderate and low, depending on overall sample sizes. According to the GRADE system, a rating of 'high quality' requires as a rule of thumb large sample sizes of at least 400 due to statistical precision issues. To date, there are no such sample sizes available for any psychotherapy.</P>
<P>Key methodological limitations were, as usual in psychotherapy research, the lack of caregiver and patient blinding. Another limitation was potential bias due to allegiance effects, which were present in the majority of trials. However, it seems inevitable that psychotherapists who must undergo a thorough, often time- and cost-intensive training to be able to deliver a certain psychotherapy properly, are allied to a certain psychotherapy they have "invested" in. On the other hand, a certain allegiance may also motivate them to deliver the treatment as properly as possible. However, treatment developers who also act as main investigators of their treatments should be prevented from suspicions that positive results stem from biased study designs or bias study conducting, so there is an urgent need for independent research endeavours to undermine available findings.</P>
<P>Another major limitation of most studies was attention bias. In the majority of trials, control group participants did not receive comparable amounts of professional attention as obligatory elements of their treatment regimen. Findings of beneficial effects by one treatment may then primarily result from simply being paid attention to or being provided with some kind of intervention rather than from a specific mechanism of action.</P>
<P>Most studies had comparatively small samples (12 out of 28 trials included 39 participants or less). As a consequence, the experimental groups may seem to be imbalanced at baseline, which was, for example, the case in the RCT of <LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>. Dr Gregory, the main investigator of this trial, has raised concerns about the appropriateness of using endpoint data alone for effect size calculation, and referred to "substantially greater baseline psychopathology" in the active group, which may have led to an underestimation of positive treatment effects and a Type II error (<LINK REF="REF-Gregory-2017" TYPE="REFERENCE">Gregory 2017</LINK>). However, group allocation was randomised (as in any here-included study), so any imbalances at baseline are regarded to be due to chance alone, and the the statistical methods used in this review allow for such chance differences.</P>
<P>Nevertheless, we are aware that the power of studies including smaller samples (such as <LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>) may be too small to detect a real effect as statistically significant if it exists. Therefore, we have not only reported statistically significance throughout the text but also referred to their magnitude ("small, moderate, large").</P>
<P>A funnel plot was drawn for all controlled comparisons and the outcome of parasuicidality (cf. <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). The funnel plot is rather symmetric in shape and indicates no selection bias (for example, publication, delayed-publication or location bias) or spurious inflation of effects in smaller studies due to poor methodological quality.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2012-06-26 15:46:54 +0100" MODIFIED_BY="[Empty name]">
<P>With regard to our inclusion criteria, we tried to retain a homogeneous pool of primary studies. However, there were some inconsistencies between studies, particularly pertaining to psychiatric comorbidity of study participants. For example, presence of a substance-related disorder was a common exclusion criterion (see <LINK TAG="CRIT_PARTICIPANTS" TYPE="SECTION">Types of participants</LINK>), whereas one study (<LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>) required participants to have such a disorder, and another study included a mixed sample of participants with and without substance abuse problems (<LINK REF="STD-Van-den-Bosch-2005" TYPE="STUDY">Van den Bosch 2005</LINK>). In addition, the severity of illness varied between studies, covering a range of severe to mild.</P>
<P>Many studies provide outcome measures that appear to reflect theory-inherent, putative mechanisms of change than consumer-relevant data. We tried to deal with this by first defining all patient-relevant outcome variables that are directly (primary outcomes) or indirectly (secondary outcomes) associated with BPD, that is, all outcome variables that a consumer and his or her therapist are likely to be interested in, and took BPD pathology as defined in the DSM-IV criteria (<LINK REF="REF-APA-2000" TYPE="REFERENCE">APA 2000</LINK>) as a guideline for primary outcomes. We feel that these are most likely to be shared by the majority of patients with BPD, and did not regard cost-related issues.</P>
<P>We decided to focus on RCTs only as they provide the only way to prevent systematic differences and confounders. One major concern against uncontrolled trials of BPD treatment outcome pertains to the characteristically unstable course of BPD, findings of amelioration over time and high affective responsiveness, which render simple pre-post comparisons (within-subject) difficult and prone to bias. Another practical consideration was the availability of reliable methods for identifying studies of another type. The identification of 28 relevant RCTs seems to vindicate this strategy.</P>
<P>A potential bias in the review process may have resulted from the decision not to include RCTs that do not provide any outcome of interest. Thus, the trials of <LINK REF="STD-Linehan-1999" TYPE="STUDY">Linehan 1999</LINK> and <LINK REF="STD-Linehan-2002" TYPE="STUDY">Linehan 2002</LINK> that both concentrate on outcome measures related to substance-related disorders were excluded. In addition, the lack of usable data led to exclusion of <LINK REF="STD-Clarkin-2007" TYPE="STUDY">Clarkin 2007</LINK> (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
<P>We strived to identify all relevant published and unpublished RCT evidence (see <LINK TAG="SEARCH_METHODS" TYPE="SECTION">Search methods for identification of studies</LINK>). The search was not restricted to any language. In spite of great efforts to minimise publication bias, we were able to include only one unpublished study, the publication of which is impending (<LINK REF="STD-Steil-2010" TYPE="STUDY">Steil 2010</LINK>).</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2012-07-04 16:07:47 +0100" MODIFIED_BY="[Empty name]">
<P>This review differs from its preceding version (<LINK REF="REF-Binks-2006" TYPE="REFERENCE">Binks 2006</LINK>) insofar as more RCTs are available for inclusion. The previous version included seven studies compared to the 28 in the current version. However, the statement that "the studies are too few and small to inspire full confidence in their results" (<LINK REF="REF-Binks-2006" TYPE="REFERENCE">Binks 2006</LINK>) remains relevant. The variety of available treatments has increased, whereas robustness has not, with the exception of DBT and MBT. On the other hand, the earlier conclusion that "some of the problems frequently encountered by people with borderline personality disorder may be amenable to talking/behavioural treatments" (<LINK REF="REF-Binks-2006" TYPE="REFERENCE">Binks 2006</LINK>) has been strengthened.</P>
<P>Though this Cochrane Collaboration review is not a guideline, its findings are likely to be checked against guideline recommendations and the following may be relevant.</P>
<P>The current APA guidelines (<LINK REF="REF-APA-2001" TYPE="REFERENCE">APA 2001</LINK>; <LINK REF="REF-Oldham-2005" TYPE="REFERENCE">Oldham 2005</LINK>) are substantially outdated, with the most recent psychotherapy RCT evidence included dating from 2003. In their 2005 update, the guideline authors conclude: "All in all, the database is growing, and further evidence is accumulating that BPD is a condition that can be effectively treated by a combination of psychotherapy and symptom-targeted pharmacotherapy." (<LINK REF="REF-Oldham-2005" TYPE="REFERENCE">Oldham 2005</LINK>, p. 4). We can not draw any distinct conclusions about the combination of psychotherapy and pharmacotherapy from this review. However, there were two RCTs in which all participants were given fluoxetine, and a psychotherapeutic approach (<LINK REF="STD-Bellino-2006" TYPE="STUDY">Bellino 2006</LINK>: IPT; <LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK>: IPT-BPD) was compared with CM in each case. Both trials consistently indicate that the group receiving combined treatment of psychotherapy and pharmacotherapy had superior results as compared to medication plus CM only. This finding advocates in particular for the conclusion of the APA guidelines that "...psychotherapy represents the primary, or core, treatment for this disorder and that adjunctive, symptom-targeted pharmacotherapy can be helpful." (<LINK REF="REF-Oldham-2005" TYPE="REFERENCE">Oldham 2005</LINK>, p. 3).</P>
<P>The comparison of pharmacotherapeutic and psychotherapeutic interventions was neither the scope of this review nor can it be answered from the here-included evidence. The effects of pharmacotherapy of BPD is the subject of two other Cochrane Collaboration reviews (<LINK REF="REF-Lieb-2010" TYPE="REFERENCE">Lieb 2010</LINK>; <LINK REF="REF-Stoffers-2010" TYPE="REFERENCE">Stoffers 2010</LINK>). One may argue that in the light of comparable effect sizes and a by and large comparable robustness of underlying evidence, it is not clear if either drug treatment or psychotherapy should be regarded the first-line treatment and which one the adjunctive one. Again, this question can neither be answered from this review nor can the results of the two reviews be directly compared with each other. However, some observations from the two reviews: the pharmacotherapy review (<LINK REF="REF-Stoffers-2010" TYPE="REFERENCE">Stoffers 2010</LINK>) included three trials testing psychotherapy plus drug against psychotherapy plus placebo (<LINK REF="REF-Simpson-2004" TYPE="REFERENCE">Simpson 2004</LINK>; <LINK REF="REF-Soler-2005" TYPE="REFERENCE">Soler 2005</LINK>; <LINK REF="REF-Linehan-2008" TYPE="REFERENCE">Linehan 2008</LINK>). The findings were not conclusive in terms of a clear superiority of combined treatments. In contrast, there were indeed favourable results for psychotherapy plus placebo over psychotherapy plus drug, especially with regard to self-harming and dissociative behaviour. As discussed previously, the two trials included here testing drug treatment plus psychotherapy against drug treatment plus clinical management only (<LINK REF="STD-Bellino-2006" TYPE="STUDY">Bellino 2006</LINK>; <LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK>), indicated superior results for those participants who received additional psychotherapy. As a consequence, drug treatment plus psychotherapy seems not clearly superior to psychotherapy alone, whereas psychotherapy plus drug treatment had favourable results as compared to drug treatment alone. These findings support the role of psychotherapy as the core treatment, as also suggested by the APA guidelines (<LINK REF="REF-APA-2001" TYPE="REFERENCE">APA 2001</LINK>; <LINK REF="REF-Oldham-2005" TYPE="REFERENCE">Oldham 2005</LINK>).</P>
<P>However, the effectiveness of therapies in combination still remains unclear on basis of this review and the available RCT evidence.</P>
<P>The UK National Institute for Health and Clinical Excellence (NICE) published their guidelines in 2009 (<LINK REF="REF-NICE-2009" TYPE="REFERENCE">NICE 2009</LINK>), covering relevant evidence available up to April 2008. This review now includes 21 more studies. However, the conclusions that "There are few studies; low numbers of patients and therefore low power; multiple outcomes with few in common between studies; and a heterogeneous diagnostic system which makes it hard to target specific treatment on patients with specific sets of symptoms." (<LINK REF="REF-NICE-2009" TYPE="REFERENCE">NICE 2009</LINK>, p. 204) remain relevant. This review is also in line with NICE concerning the valuation that especially DBT and MBT are supported by the current evidence. However, TFP and SFT must be added to the class of treatments that showed beneficial effects in at least one methodologically sound, medium-size trial. NICE concluded that "very brief interventions (less than 3 months) do not appear to be effective in the treatment of borderline personality disorder" (<LINK REF="REF-NICE-2009" TYPE="REFERENCE">NICE 2009</LINK>, p. 204). From our findings, based also on more recent RCTs, short-time interventions of up to six months duration show at least encouraging results in small studies, though the necessary contexts that patients can profit from these interventions remains unclear as previously discussed (see <LINK TAG="APPLICABILITY_OF_FINDINGS" TYPE="SECTION">Overall completeness and applicability of evidence</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-07-06 17:05:25 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2012-07-06 17:05:25 +0100" MODIFIED_BY="[Empty name]">
<P>In sum, the up-to-date available randomised controlled trial (RCT) evidence for psychotherapeutic treatments is scarce, and replicative studies would be most desirable for each type of treatment. Therefore, conclusions have to be drawn carefully.</P>
<P>Most "robust" conclusions can be drawn from evidence of dialectical behaviour therapy (DBT). It is the only psychotherapy for which, in comparison with treatment as usual (TAU), data could be accumulated from several trials. For all remaining comparisons and psychotherapies, single study effects are available only. Thus, the evidence is not as robust as would be desirable, but the findings indicate the usefulness of both comprehensive psychotherapies and non-comprehensive psychotherapeutic interventions in the treatment of both core borderline personality disorder (BPD) pathology and its associated pathology.</P>
<P>Comorbid conditions have been recognised by RCT research, but the evidence base for BPD treatment in the presence of defined comorbidities (for example, substance-related disorders, post-traumatic stress disorder (PTSD), depressive episodes) is still small and only single studies are available. Studies of DBT-PTSD for patients with BPD with comorbid PTSD and dynamic deconstructive psychotherapy (DDP) for patients with concurrent addictive disorders found encouraging effects on core BPD pathology as well as associated pathology, indicating that psychotherapy may have beneficial effects in severely ill groups of patients. Interpersonal psychotherapy (IPT) which was developed for people with depressive disorders was successful in reducing depressive pathology, but the effects on BPD core pathology remain unclear as no such data were assessed.</P>
<P>Trials of non-comprehensive psychotherapeutic interventions suggest large effects for several approaches and indicate that these rather short-term interventions may (at least as add-ons to long-term treatments) be helpful; further research is required. To date, it is rather unclear if these interventions are equally effective in patients with BPD who have already experienced several individual therapies as in patients who are "psychotherapy naive".</P>
<P>In sum, it can be concluded that disorder-specific treatments should be used. Although nonspecific treatments were scarcely investigated, those that were (cognitive behavioural therapy (CBT), client-centered therapy (CCT), IPT) showed no encouraging effects for the treatment of BPD core pathology. Beneficial findings from group-only interventions are mostly based on studies of participants with another ongoing individual treatment, and it is therefore unclear which treatment exerts the major effect. The optimal length of treatment is unclear from the up-to-date RCT evidence. On the basis of the available findings, a treatment of 12 to 18 months seems to be appropriate.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-06-12 12:31:00 +0100" MODIFIED_BY="[Empty name]">
<P>First, replication studies would be most desirable, especially from independent researchers not involved in treatment development and/or delivery. Future studies should focus on male patients with BPD who have been neglected in BPD treatment studies so far, and treatment efficacy in patients with BPD with defined comorbid conditions should be investigated in more detail. In addition, it remains unclear how psychotherapy and pharmacotherapy interact. There is some evidence that psychotherapy may enhance pharmacotherapy effects (<LINK REF="REF-Lieb-2010" TYPE="REFERENCE">Lieb 2010</LINK>; <LINK REF="REF-Stoffers-2010" TYPE="REFERENCE">Stoffers 2010</LINK>). There is a need for agreement on a minimum core battery of BPD outcomes. There is currently a huge heterogeneity of outcome variables and assessment instruments. A consensus on a minimum set of therapy outcome variables that are most likely to be of interest for any patient with BPD would be desirable. Outcome assessment should be more specific and sensitive to BPD pathology. Assessment instruments have been developed lately to reflect BPD core pathology as described precisely by the DSM-IV criteria (for example, the BPDSI scale by <LINK REF="REF-Arntz-2003" TYPE="REFERENCE">Arntz 2003</LINK>, the CGI-BPD scale by <LINK REF="REF-Perez-2007" TYPE="REFERENCE">Perez 2007</LINK>, or the ZAN-BPD scale by <LINK REF="REF-Zanarini-2003" TYPE="REFERENCE">Zanarini 2003</LINK>a). Further investigation of the impact of different treatment settings, that is, inpatient, outpatient, and day hospital, during acute and non-acute stages of the course of illness would also be helpful. Some researchers advocate for the development of an integrated psychotherapy on the basis of effective treatments that combines methods which work from all therapies (for example, <LINK REF="REF-Livesley-2007" TYPE="REFERENCE">Livesley 2007</LINK>; <LINK REF="REF-Livesley-2012" TYPE="REFERENCE">Livesley 2012</LINK>). However, as discussed previously, there is still an urgent need for additional evidence to answer the question of which treatments are really effective, and which work for whom.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-07-04 16:08:47 +0100" MODIFIED_BY="[Empty name]">
<P>We are grateful to Jane Dennis, Margaret Anderson, Laura MacDonald, Elaine McKay, Chris Champion and Geraldine MacDonald from the Cochrane Developmental, Psychosocial and Learning Problems Group. In particular, we thank Jane Dennis, Margaret Anderson, Nick Huband, Mike Ferriter, Nadja Smajlaigic and Melanie Powney for their help in identifying relevant studies. We would also like to thank all primary study authors who responded to our requests and provided further information, and Mr H A Glazener who helped translating a Dutch paper.</P>
<P>We would like to thank the previous authors of this review, Claire Binks, Mark Fenton, Lucy McCarthy, Tracy Lee, Clive Adams and Conor Duggan. Additionally, we thank the German Cochrane Centre for supporting this work. We are grateful to Gerd Antes, director of the German Cochrane Centre, who made contact with CDPLPG and helped in gaining grants for financing this work. We are also grateful to Martin Schumacher, director of the Institute of Biostatistics and Medical Informatics at the University Medical Center Freiburg, who gave support in application submission. We are grateful to the German Ministry of Education and Research (BMBF; grant no. 01KG0609), the research committee of the University Medical Center Freiburg and the NHS Cochrane Collaboration Programme Grant Scheme (NIHR), UK for supporting this work. JS would like to thank the Ministry of Science, Research and Arts of the federal state of Baden-Württemberg for supporting this work by a stipend. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2017-04-06 18:03:14 +0100" MODIFIED_BY="[Empty name]">
<P>Jutta M Stoffers is a board-certified psychologist (cognitive behaviour therapy), who has worked on a Dialectical Behaviour Therapy (DBT) ward, and attended courses on DBT and Schema-focused therapy (SFT).<BR/>Birgit A Völlm &#8212; none known.<BR/>Gerta Rücker &#8212; none known.<BR/>Antje Timmer &#8212; none known.<BR/>Nick Huband was employed as a Clinical Research Fellow with the Institute of Mental Health, Nottingham and Nottinghamshire Healthcare NHS Trust during the production of this review.<BR/>Klaus Lieb is an Editor with Cochrane Developmental, Psychosocial and Learning Problems. He is a board-certified cognitive behaviour therapist with a special interest in schema therapy. KL has been involved in trials investigating inpatient DBT (<LINK REF="REF-Bohus-2004" TYPE="REFERENCE">Bohus 2004</LINK>) and inpatient schema-focused therapy (<LINK REF="REF-Reiss-2014" TYPE="REFERENCE">Reiss 2014</LINK>).</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-02-15 10:17:32 +0000" MODIFIED_BY="[Empty name]">
<P>Jutta Stoffers: wrote final report, selected studies, obtained papers, extracted data, appraised quality of trials, entered data.<BR/>Birgit Völlm: helped write final report, selected studies, obtained papers, extracted data, appraised quality of trials, entered data.<BR/>Gerta Rücker: helped write final report, gave statistical support and helped extract data.<BR/>Antje Timmer: helped design review, corrected final report.<BR/>Nick Huband: helped write final report, selected studies<BR/>Klaus Lieb: sought funds, wrote to authors of papers for additional information, revised final report.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2012-07-04 14:35:29 +0100" MODIFIED_BY="[Empty name]">
<P>The outcomes are different from the previous version of this review and we have used the new Cochrane Collaboration tool to update the risk of bias assessment of the studies. We changed the planned sensitivity analyses.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2012-02-25 18:28:33 +0000" MODIFIED_BY="[Empty name]">
<P>This is an update of a published review: Binks C, Fenton M, McCarthy L, Lee T, Adams CE, Duggan C. Psychological therapies for people with borderline personality disorder. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD005652. DOI: 10.1002/14651858.CD005652. </P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-06-30 16:57:06 +0100" MODIFIED_BY="Joanne Wilson">
<STUDIES MODIFIED="2012-06-26 15:07:38 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2012-06-26 15:07:38 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bateman-1999" MODIFIED="2012-06-26 15:07:38 +0100" MODIFIED_BY="[Empty name]" NAME="Bateman 1999" YEAR="2008">
<REFERENCE MODIFIED="2012-06-01 21:27:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bateman A, Fonagy P</AU>
<TI>8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2008</YR>
<VL>165</VL>
<NO>5</NO>
<PG>631-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283345"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-01 21:27:41 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;ALREADY INCLUDED IN A BPD REVIEW: WE SAID: INCLUDE ?&lt;br&gt;ProCite field [3]: Bateman, Anthony: St Ann's Hosp, Haringey Healthcare NHS Trust, London, England&lt;/p&gt;" NOTES_MODIFIED="2012-06-01 21:27:41 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bateman A, Fonagy P</AU>
<TI>Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1999</YR>
<VL>156</VL>
<NO>10</NO>
<PG>1563-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283346"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-07-28 11:00:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bateman A, Fonagy P</AU>
<TI>Health care utilization costs for borderline personality disorder patients treated with psychoanalytically oriented partial hospitalization versus general psychiatric care</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2003</YR>
<VL>160</VL>
<PG>169-71</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283347"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-11 16:21:31 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;ALREADY INCLUDED IN A BPD REVIEW: WE SAID: INCLUDE (SECONDARY FOLLOWUP?)&lt;br&gt;ProCite field [3]: Halliwick Day Unit, St. Ann's Hospital, University College London, London, UK. anthony@mullins.demon.co.uk&lt;/p&gt;" NOTES_MODIFIED="2011-08-11 16:21:31 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bateman A, Fonagy P</AU>
<TI>Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2001</YR>
<VL>158</VL>
<NO>1</NO>
<PG>36-42</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283348"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-26 15:07:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<SO>Intensive outpatient and partial hospital care for BPD. Proceedings of the 157th American Psychiatric Association Annual Meeting; 1-6 May 2004</SO>
<YR>2004</YR>
<PG>NO.100B</PG>
<ED>Bateman A</ED>
<PB>American Psychiatric Association</PB>
<CY>New York</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283349"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 12:59:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Bateman A</AU>
<TI>Important: Question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]</TI>
<SO>Email to: K Lieb, J Stoffers</SO>
<YR>14 December 2010</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283350"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 13:50:58 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;INCLUDE (SECONDARY - CORRESPONDENCE REGARDING AN ALREADY INCLUDED RCT)&lt;/p&gt;" NOTES_MODIFIED="2012-06-07 13:50:58 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bateman AW, Fonagy P</AU>
<TI>Partial hospitalization for borderline personality disorder: reply</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2001</YR>
<VL>158</VL>
<NO>11</NO>
<PG>1932-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283351"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-22 21:27:42 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;INCLUDE?&lt;/p&gt;" NOTES_MODIFIED="2011-08-22 21:27:42 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Evans C</AU>
<TI>Treatment benefits of psychoanalytically oriented partial hospitalisation were maintained over 18 months in borderline personality disorder</TI>
<SO>Evidence-Based Mental Health</SO>
<YR>2001</YR>
<VL>4</VL>
<NO>3</NO>
<PG>73</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283352"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-22 21:29:55 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;INCLUDE? ONGOING STUDY MENTIONED! - REVIEW ARTICLE SUMMARISING RCTS IN MENALIZING TREATMENT IN BPD INCLUDING AN ONGOING&lt;br&gt;ProCite field [3]: Fonagy, Peter: Sub-Department of Clinical Health Psychology, University College London, London, United Kingdom Bateman, Anthony W.: Sub-Department of Clinical Health Psychology, University College London, London, United Kingdom&lt;/p&gt;" NOTES_MODIFIED="2011-08-22 21:29:55 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fonagy P, Bateman AW</AU>
<TI>Mentalizing and borderline personality disorder</TI>
<SO>Journal of Mental Health</SO>
<YR>2007</YR>
<VL>16</VL>
<NO>1</NO>
<PG>83-101</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283353"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 13:54:57 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;INCLUDE (SECONDARY TO STUDY BY BATEMAN AND FONAGY?)&lt;/p&gt;" NOTES_MODIFIED="2012-06-07 13:54:57 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stern R</AU>
<TI>Partial hospitalization for borderline personality disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2001</YR>
<VL>158</VL>
<NO>11</NO>
<PG>1932</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283354"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283344"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bateman-2009" MODIFIED="2012-06-07 14:02:56 +0100" MODIFIED_BY="[Empty name]" NAME="Bateman 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-06-01 21:30:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bateman A, Fonagy P</AU>
<TI>Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2009</YR>
<VL>166</VL>
<NO>12</NO>
<PG>1355-64</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283356"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 13:55:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Bateman A, Fonagy P</AU>
<TI>Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Online data supplement to article of same title</TI>
<SO>http://ajp.psychiatryonline.org/cgi/content/full/appi.ajp.2009.09040539/DC1</SO>
<YR>(accessed 20 April 2010)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283357"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 14:02:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bateman AW</AU>
<TI>Mentalization, borderline personality disorder and what works for whom?</TI>
<SO>11th International Congress of the International Society for the Study of Personality Disorders; 2009 Aug 21-23; New York. Available from www.borderlinepersonalitydisorder.com/Conferences/ISSPD/isspd_09_Bateman.pdf</SO>
<YR>(accessed 21 April 2010)</YR>
<PB>National Education Alliance for Borderline Personality Disorder</PB>
<CY>New York</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283358"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-10-28 10:52:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ISRCTN27660668</AU>
<TI>Randomised controlled trial of manualised out-patient individual and group therapy for borderline personality disorder</TI>
<SO>http://www.controlled-trials.com/ISRCTN27660668</SO>
<YR>(accessed 28 October 2010)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283359"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283355"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bellino-2006" MODIFIED="2012-06-07 14:07:34 +0100" MODIFIED_BY="[Empty name]" NAME="Bellino 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-06-07 14:05:19 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;INCLUDE? THE RECORD IS IN CENTRAL, SO MUST AT LEAST BE INVESTIGATED.&lt;br&gt;Medium Designator: Terapia combinata con psicoterapia interpersonale di pazienti depressi maggiori con disturbo borderline di personalita: confronto con la farmacoterapia&lt;br&gt;ProCite field [7]: CN-00595151&lt;/p&gt;" NOTES_MODIFIED="2012-06-07 14:05:19 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bellino S, Paradiso E, Zizza M, Di Lorenzo R, Bogetto F</AU>
<TI>Combined therapy with interpersonal psychotherapy of major depressed patients with borderline personality disorder: a comparison with pharmacotherapy</TI>
<SO>Italian Journal of Psychopathology</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>1</NO>
<PG>34-42</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283361"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 14:06:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bellino S, Zizza M, Rinaldi C, Bogetto F</AU>
<TI>Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy</TI>
<SO>Canadian Journal of Psychiatry (Revue Canadienne de Psychiatrie)</SO>
<YR>2006</YR>
<VL>51</VL>
<NO>7</NO>
<PG>453-60</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283362"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 14:07:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Bellino S</AU>
<TI>Question regarding your BPD trials [electronic mail on the internet]</TI>
<SO>Email to: J Stoffers.</SO>
<YR>16 December 2010</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283363"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283360"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bellino-2007" MODIFIED="2012-06-07 14:08:39 +0100" MODIFIED_BY="[Empty name]" NAME="Bellino 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-01-04 13:08:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bellino S, Zizza M, Rinaldi C, Bogetto F</AU>
<TI>Combined therapy of major depression with concomitant borderline personality disorder: comparison of interpersonal and cognitive psychotherapy</TI>
<SO>Canadian Journal of Psychiatry - Revue Canadienne de Psychiatrie</SO>
<YR>2007</YR>
<VL>52</VL>
<NO>11</NO>
<PG>718-25</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283365"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 14:08:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Bellino S</AU>
<TI>Re: Question regarding your BPD trials [personal communication]</TI>
<SO>Email to: J Stoffers.</SO>
<YR>16 December 2010</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283366"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283364"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bellino-2010" MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]" NAME="Bellino 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-04-21 10:56:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bellino S, Rinaldi C, Bogetto F</AU>
<TI>Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy</TI>
<SO>Canadian Journal of Psychiatry</SO>
<YR>2010</YR>
<VL>55</VL>
<PG>74-81</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283368"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-07-29 12:43:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zizza M, Fenocchio M, Rinaldi C, Bellino S</AU>
<TI>Combined treatment of borderline personality disorder: a trial of modified interpersonal therapy</TI>
<SO>World Psychiatry</SO>
<YR>2009</YR>
<VL>8</VL>
<NO>Suppl 1</NO>
<PG>234</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283369"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283367"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blum-2008" MODIFIED="2012-06-07 14:20:22 +0100" MODIFIED_BY="[Empty name]" NAME="Blum 2008" YEAR="">
<REFERENCE MODIFIED="2012-06-07 14:09:42 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;INCLUDE (SECONDARY - PROTOCOL FOR BLUM'S STUDY)&lt;br&gt;ProCite field [3]: (Black) Psychiatry Research/MEB, University of Iowa, Roy J. and Lucille A. Carver College of Medicine, Iowa City, IA 52242, United States&lt;/p&gt;" NOTES_MODIFIED="2012-06-07 14:09:42 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Black D W, Blum N, Pfohl B, St. John D</AU>
<TI>The STEPPS group treatment program for outpatients with borderline personality disorder</TI>
<SO>Journal of Contemporary Psychotherapy</SO>
<YR>2004</YR>
<VL>34</VL>
<NO>3</NO>
<PG>193-210</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283371"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 14:10:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Black D</AU>
<TI>Question regarding your BPD trial [personal communication]</TI>
<SO>Email to: J Stoffers.</SO>
<YR>04 January 2011</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283372"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-04-23 09:12:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Black DW, Allen J, St. John D, Pfohl B, McCormick B, Blum N</AU>
<TI>Predictors of response to systems training for emotional predictability and problem solving (STEPPS) for borderline personality disorder: an exploratory study</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>2009</YR>
<VL>120</VL>
<PG>53-61</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283373"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 14:11:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Black DW, Blum N, Pfohl BM, St. John D</AU>
<TI>Randomised clinical trial of stepps versus treatment as usual</TI>
<SO>158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta, GA</SO>
<YR>2005</YR>
<PG>1B</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283374"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 14:18:29 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;INCLUDE (SECONDARY PAPER TO BLUM'S STUDY - CORRESPONDENCE)&lt;/p&gt;" NOTES_MODIFIED="2012-06-07 14:18:29 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blum N, Allen J, McCormick B, Black DW</AU>
<TI>Effectiveness of adjunctive STEPPS group treatment in borderline personality disorder patients: reply</TI>
<SO>American Journal of Psychiatry</SO>
<YR>Oct 2008</YR>
<VL>165</VL>
<NO>10</NO>
<PG>1354-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283375"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 14:19:02 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;INCLUDE (SECONDARY PAPER TO A CLINICAL TRIAL THAT MAY BE INCLUDED)&lt;br&gt;ProCite field [3]: Blum, Nancee: Department of Psychiatry, University of Iowa, Roy J. and Lucille A. Carver College of Medicine, Iowa City, IA, US Franklin, Joann: Department of Psychiatry, University of Iowa, Roy J. and Lucille A. Carver College of Medicine, Iowa City, IA, US Hansel, Rebecca: Department of Psychiatry, University of Iowa, Roy J. and Lucille A. Carver College of Medicine, Iowa City, IA, US McCormick, Brett: Department of Psychiatry, University of Iowa, Roy J. and Lucille A. Carver College of Medicine, Iowa City, IA, US St. John, Don: Department of Psychiatry, University of Iowa, Roy J. and Lucille A. Carver College of Medicine, Iowa City, IA, US Pfohl, Bruce: Department of Psychiatry, University of Iowa, Roy J. and Lucille A. Carver College of Medicine, Iowa City, IA, US Allen, Jeff: Department of Psychiatry, University of Iowa, Roy J. and Lucille A. Carver College of Medicine, Iowa City, IA, US Black, Donald W.: Department of Psychiatry, University of Iowa, Roy J. and Lucille A. Carver College of Medicine, Iowa City, IA, US&lt;/p&gt;" NOTES_MODIFIED="2012-06-07 14:19:02 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blum N, Franklin J, Hansel R, McCormick B, St. John D, et al</AU>
<TI>Relationship of age to symptom severity, psychiatric comorbidity and health care utilization in persons with borderline personality disorder</TI>
<SO>Personality and Mental Health</SO>
<YR>2008</YR>
<VL>2</VL>
<NO>1</NO>
<PG>25-43</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283376"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 14:19:24 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;ALREADY INCLUDED IN A BPD REVIEW: WE SAID: INCLUDE ?&lt;br&gt;ProCite field [3]: Black, Donald W.: Psychiatry Research, University of Iowa, Carver College of Medicine, Iowa City, IA, US&lt;/p&gt;" NOTES_MODIFIED="2012-06-07 14:19:24 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blum N, St John D, Pfohl B, Stuart S, McCormick B, Allen J, et al</AU>
<TI>Systems Training for Emotional Predictability and Problem Solving (STEPPS) for outpatients with borderline personality disorder: A randomized controlled trial and 1-year follow-up: correction</TI>
<SO>American Journal of Psychiatry</SO>
<YR>Jun 2008</YR>
<VL>165</VL>
<NO>6</NO>
<PG>777</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283377"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 14:20:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Blum N, St John D, Pfohl B, Stuart S, McCormick B, Allen J, et al</AU>
<TI>Systems training for emotional predictability and problem solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2008</YR>
<VL>165</VL>
<NO>4</NO>
<PG>468-78</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283378"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-11 16:46:56 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;INCLUDE (SECONDARY PAPER: THIS MUST BE A WRITE-UP OF ANOTHER RCT)&lt;/p&gt;" NOTES_MODIFIED="2011-08-11 16:46:56 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davidson KM</AU>
<TI>Borderline personality disorder: STEPPS improves symptoms</TI>
<SO>Evidence-Based Mental Health</SO>
<YR>2008</YR>
<VL>11</VL>
<NO>4</NO>
<PG>120</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283379"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-09 09:19:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00055315</AU>
<TI>Treatment for borderline personality disorder</TI>
<SO>http://clinicaltrials.gov/ct2/show/study/NCT00055315</SO>
<YR>(accessed 09 August 2011)</YR>
<IDENTIFIERS MODIFIED="2011-08-09 09:18:49 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283380"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283370"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bos-2010" MODIFIED="2012-06-07 14:23:20 +0100" MODIFIED_BY="[Empty name]" NAME="Bos 2010" YEAR="2009">
<REFERENCE MODIFIED="2012-06-01 21:38:13 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;ALREADY INCLUDED IN A BPD REVIEW: WE SAID: INCLUDE ?&lt;br&gt;ProCite field [3]: Bos, Elisabeth H.: Lentis, Groningen, Netherlands van Wel, E. Bas: Dimence Mental Health Care Overijssel, Deventer, Netherlands Appelo, Martin T.: Lentis, Groningen, Netherlands Verbraak, Marc J. P. M.: Behavioral Science Institute, Radboud University, Nijmegen, Netherlands&lt;/p&gt;" NOTES_MODIFIED="2012-06-01 21:38:13 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bos EH, Van Wel E, Bas AMT, Verbraak MJP</AU>
<TI>A randomized controlled trial of a Dutch version of systems training for emotional predictability and problem solving for borderline personality disorder</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>2010</YR>
<VL>198</VL>
<NO>4</NO>
<PG>299-304</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283382"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 14:23:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Wel EB, Bos EH, Appelo MT, Berendsen EM, Willgeroth FC, Verbraak MJPM</AU>
<TI>The efficacy of the systems training for emotional predictability and problem solving (stepps) in the treatment of borderline personality disorder: a randomized controlled trial</TI>
<TO>De effectiviteit van de vaardigheidstraining emotieregulatiestoornis (VERS) in de behandeling van de borderlinepersoonlijkheidsstoornis: een gerandomiseerd onderzoek</TO>
<SO>Tijdschrift voor Psychiatrie</SO>
<YR>2009</YR>
<VL>51</VL>
<PG>291-301</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283383"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283381"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carter-2010" MODIFIED="2012-06-07 14:24:55 +0100" MODIFIED_BY="[Empty name]" NAME="Carter 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-06-07 14:24:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Carter G</AU>
<TI>Question regarding your BPD trial [personal communication]</TI>
<SO>Email to: J Stoffers.</SO>
<YR>21 December 2010</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283385"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 14:24:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Carter GL, Willcox CH, Lewin TJ, Conrad AM, Bendit N</AU>
<TI>Hunter DBT project: randomized controlled trial of dialectical behaviour therapy in women with borderline personality disorder</TI>
<SO>Australian and New Zealand Journal of Psychiatry</SO>
<YR>2010</YR>
<VL>44</VL>
<NO>2</NO>
<PG>162-73</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283386"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283384"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cottraux-2009" MODIFIED="2012-06-07 14:25:13 +0100" MODIFIED_BY="[Empty name]" NAME="Cottraux 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-06-07 14:25:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cottraux J, Note ID, Boutitie F, Milliery M, Genouihlac V, Yao SN, et al</AU>
<TI>Cognitive therapy versus rogerian supportive therapy in borderline personality disorder</TI>
<SO>Psychotherapy and Psychosomatics</SO>
<YR>2009</YR>
<VL>78</VL>
<PG>307-16</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283388"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-09 09:26:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00131781</AU>
<TI>Cognitive therapy versus supportive therapy in borderline personality disorder</TI>
<SO>http://clinicaltrials.gov/ct2/show/record/NCT00131781</SO>
<YR>(accessed 09 August 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283389"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283387"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davidson-2006" MODIFIED="2012-06-07 14:31:28 +0100" MODIFIED_BY="[Empty name]" NAME="Davidson 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-08-22 21:11:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Davidson K, Norrie J, Tyrer P, Gumley A, Tata P, Murray H, et al</AU>
<TI>The effectiveness of cognitive behavior therapy for borderline personality disorder: results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial</TI>
<SO>Journal of Personality Disorders</SO>
<YR>2006 Oct</YR>
<VL>20</VL>
<NO>5</NO>
<PG>450-65</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283391"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-22 21:12:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davidson K, Tyrer P, Gumley A, Tata P, Norrie J, Palmer S, et al</AU>
<TI>A randomized controlled trial of cognitive behavior therapy for borderline personality disorder: rationale for trial, method, and description of sample</TI>
<SO>Journal of Personality Disorders</SO>
<YR>2006 Oct</YR>
<VL>20</VL>
<NO>5</NO>
<PG>431-49</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283392"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 14:26:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davidson KM, Tyrer P, Norrie J, Palmer SJ, Tyrer H</AU>
<TI>Cognitive therapy v usual treatment for borderline personality disorder: prospective 6-year follow-up</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2010</YR>
<VL>197</VL>
<PG>456-62</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283393"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 14:31:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ISRCTN86177428</AU>
<TI>Borderline personality disorder study of cognitive therapy trial</TI>
<SO>http://www.controlled-trials.com/ISRCTN86177428</SO>
<YR>(accessed 02 November 2010)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283394"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-09 17:53:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00538135</AU>
<TI>BOSCOT: A randomised controlled trial of cognitive behavioural therapy in borderline personality disorder</TI>
<SO>http://clinicaltrials.gov/show/NCT00538135</SO>
<YR>(accessed 09 August 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283395"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-02 12:46:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Palmer S, Davidson K, Tyrer P, Gumley A, Tata P, Norrie J, et al</AU>
<TI>The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial</TI>
<SO>Journal of Personality Disorders</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>5</NO>
<PG>466-81</PG>
<IDENTIFIERS MODIFIED="2009-05-15 10:53:42 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283396"/><IDENTIFIER TYPE="OTHER" VALUE=""/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283390"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Doering-2010" MODIFIED="2012-06-07 14:33:28 +0100" MODIFIED_BY="[Empty name]" NAME="Doering 2010" YEAR="2009">
<REFERENCE MODIFIED="2012-06-07 14:32:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Doering S, Hörz S, Rentrop M, Fischer-Kern M, Schuster P, Benecke C, et al</AU>
<TI>Transference-focused psychotherapy v. treatment by community psychotherapists for borderline personality disorder: randomised controlled trial</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2010</YR>
<VL>196</VL>
<NO>5</NO>
<PG>389-95</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283398"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 14:33:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Doering S</AU>
<TI>Question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]</TI>
<SO>Email to: K Lieb, J Stoffers.</SO>
<YR>10 December 2010</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283399"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-09 12:04:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00714311</AU>
<TI>Efficacy of transference-focused psychotherapy for borderline personality disorder</TI>
<SO>http://clinicaltrials.gov/ct2/show/record/NCT00714311</SO>
<YR>(accessed 09 August 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283400"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283397"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Farrell-2009" MODIFIED="2012-06-07 14:41:44 +0100" MODIFIED_BY="[Empty name]" NAME="Farrell 2009" YEAR="2008">
<REFERENCE MODIFIED="2012-06-07 14:41:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Farrell JM, Shaw IA, Webber MA</AU>
<TI>A schema-focused approach to group psychotherapy for outpatients with borderline personality disorder: a randomized controlled trial</TI>
<SO>Journal of Behavior Therapy and Experimental Psychiatry</SO>
<YR>2009</YR>
<VL>40</VL>
<NO>2</NO>
<PG>317-28</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283402"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 14:41:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Farrell JM</AU>
<TI>Question regarding your BPD trials [personal communication]</TI>
<SO>Email to: K Lieb, J Stoffers.</SO>
<YR>09 December 2010</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283403"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283401"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Giesen_x002d_Bloo-2006" MODIFIED="2012-06-07 14:43:28 +0100" MODIFIED_BY="[Empty name]" NAME="Giesen-Bloo 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-06-07 14:41:58 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;INCLUDE (SECONDARY)?&lt;br&gt;Author Affiliation: Arntz, Arnoud: Department of Medical, Clinical, and Experimental Psychology, University of Maastricht, Maastricht, Netherlands&lt;/p&gt;" NOTES_MODIFIED="2012-06-07 14:41:58 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giesen-Bloo J, Arntz A</AU>
<TI>Outpatient psychotherapy for borderline personality disorder: A randomized trial of schema-focused therapy vs transference-focused psychotherapy: reply</TI>
<SO>Archives of General Psychiatry</SO>
<YR>May 2007</YR>
<VL>64</VL>
<NO>5</NO>
<PG>610-1</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283405"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-02 12:47:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Giesen-Bloo J, Van Dyck R, Spinhoven P, Van Tilburg W, Dirksen C, Van Asselt T, et al</AU>
<TI>Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy.[erratum appears in Arch Gen Psychiatry. 2006 Sep;63(9):1008]</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2006</YR>
<VL>63</VL>
<NO>6</NO>
<PG>649-58</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283406"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 14:43:28 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;INCLUDE ?&lt;br&gt;Document Type: English&lt;/p&gt;" NOTES_MODIFIED="2012-06-07 14:43:28 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giesen-Bloo</AU>
<TI>Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2006</YR>
<VL>63</VL>
<NO>9</NO>
<PG>1008</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283407"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-22 21:23:23 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;INCLUDE?&lt;br&gt;ProCite field [3]: Spinhoven, Philip: Department of Psychology, Leiden University, Leiden, Netherlands Giesen-Bloo, Josephine: Department of Medical, Clinical, and Experimental Psychology, University Maastricht, Maastricht, Netherlands van Dyck, Richard: Department of Psychiatry, Institute for Research in Extramural Medicine, University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands Kooiman, Kees: Leiden University Medical Center, Leiden, Netherlands Arntz, Arnoud: Department of Medical, Clinical, and Experimental Psychology, University Maastricht, Maastricht, Netherlands&lt;/p&gt;" NOTES_MODIFIED="2011-08-22 21:23:23 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spinhoven P, Giesen-Bloo J, Van Dyck R, Kooiman K, Arntz A</AU>
<TI>The therapeutic alliance in schema-focused therapy and transference-focused psychotherapy for borderline personality disorder</TI>
<SO>Journal of Consulting and Clinical Psychology</SO>
<YR>2007</YR>
<VL>76</VL>
<NO>1</NO>
<PG>104-15</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283408"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-02 12:49:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Asselt ADI, Dirksen CD, Arntz A, Giesen-Bloo JH, Van Dyck R, Spinhoven P, et al</AU>
<TI>Out-patient psychotherapy for borderline personality disorder: cost-effectiveness of schema-focused therapy v. transference-focused psychotherapy</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2008</YR>
<VL>192</VL>
<PG>450-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283409"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-02 12:48:36 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;INCLUDE (SECONDARY ANALYSIS FROM AN EXISTING BIG MULTICENTRE RCT)&lt;br&gt;Document Type: English&lt;/p&gt;" NOTES_MODIFIED="2012-06-02 12:48:36 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Asselt ADI, Dirksen CD, Arntz A, Severens JL</AU>
<TI>Difficulties in calculating productivity costs: work disability associated with borderline personality disorder</TI>
<SO>Value in Health</SO>
<YR>2008</YR>
<VL>11</VL>
<NO>4</NO>
<PG>637-44</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283410"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283404"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gratz-2006" MODIFIED="2012-06-07 14:44:47 +0100" MODIFIED_BY="[Empty name]" NAME="Gratz 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-08-19 20:30:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gratz KL, Gunderson JG</AU>
<TI>Preliminary data on an acceptance-based emotion regulation group intervention for deliberate self-harm among women with borderline personality disorder</TI>
<SO>Behavior Therapy</SO>
<YR>2006</YR>
<VL>37</VL>
<NO>1</NO>
<PG>25-35</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283412"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 14:44:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Gratz KL</AU>
<TI>Question regarding your BPD trials [personal communication]</TI>
<SO>Email to: J Stoffers.</SO>
<YR>11 December 2010</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283413"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283411"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gregory-2008" MODIFIED="2012-06-07 14:46:42 +0100" MODIFIED_BY="[Empty name]" NAME="Gregory 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-06-07 14:45:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gregory RJ, Chlebowski S, Kang D, Remen A, Soderberg M</AU>
<TI>Psychodynamic therapy for borderline personality disorder and co-occurring alcohol use disorders: a newly designed ongoing study</TI>
<SO>Journal of the American Psychoanalytic Association</SO>
<YR>2006</YR>
<VL>54</VL>
<NO>4</NO>
<PG>1331-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283415"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-02 12:51:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gregory RJ, Chlebowski S, Kang D, Remen AL, Soderberg MG, Stepkovitch J, et al</AU>
<TI>A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder</TI>
<SO>Psychotherapy</SO>
<YR>2008</YR>
<VL>45</VL>
<NO>1</NO>
<PG>28-41</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283416"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 14:46:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gregory RJ, DeLucia-Deranja E, Mogle JA</AU>
<TI>Dynamic deconstructive psychotherapy versus optimized community care for borderline personality disorder co-occuring with alcohol use disorders</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>2010</YR>
<VL>198</VL>
<NO>4</NO>
<PG>292-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283417"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 14:46:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gregory RJ, Remen AL, Soderberg M, Ploutz-Snyder RJP</AU>
<TI>A controlled trial of psychodynamic psychotherapy for co-occurring boderline personality disorder and alcohol use disorder: six-month outcome</TI>
<SO>Journal of the American Psychoanalytic Association</SO>
<YR>2009</YR>
<VL>57</VL>
<NO>1</NO>
<PG>199-205</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283418"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-09 09:29:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00145678</AU>
<TI>Psychodynamic therapy for co-occurring borderline personality disorder and alcohol use disorder</TI>
<SO>http://clinicaltrials.gov/show/NCT00145678</SO>
<YR>(accessed 09 August 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283419"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283414"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koons-2001" MODIFIED="2012-06-07 14:47:13 +0100" MODIFIED_BY="[Empty name]" NAME="Koons 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-06-07 14:47:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koons CR, Robins CJ, Tweed JL, Lynch TR, Gonzalez AM, Morse JQ, et al</AU>
<TI>Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder</TI>
<SO>Behavior Therapy</SO>
<YR>2001</YR>
<VL>32</VL>
<NO>2</NO>
<PG>371-90</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283421"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283420"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Linehan-1991" MODIFIED="2012-06-07 14:49:28 +0100" MODIFIED_BY="[Empty name]" NAME="Linehan 1991" YEAR="1991">
<REFERENCE MODIFIED="2012-06-07 14:49:28 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;INCLUDE (SECONDARY ANALYSIS OF TWO RCTS IN THE AREA)&lt;br&gt;CODEN: DABBBA&lt;/p&gt;" NOTES_MODIFIED="2012-06-07 14:49:28 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindenboim Noam</AU>
<TI>To know me is to keep me: self-verification, validation, and therapy dropout in the treatment of borderline personality disorder [PhD thesis]</TI>
<SO>Dissertation Abstracts International</SO>
<YR>5831</YR>
<VL>70</VL>
<NO>9</NO>
<PG>2010</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283423"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-02 12:52:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Linehan MM, Armstrong HE, Suarez A, Allmon D, Heard HL</AU>
<TI>Cognitive-behavioral treatment of chronically parasuicidal borderline patients</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1991</YR>
<VL>48</VL>
<NO>12</NO>
<PG>1060-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283424"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-11 17:10:53 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;ALREADY INCLUDED IN A BPD REVIEW: WE SAID: INCLUDE? (SECONDARY, FOLLOWUP)&lt;br&gt;Author Affiliation: Department of Psychology, University of Washington, Seattle&lt;/p&gt;" NOTES_MODIFIED="2011-08-11 17:10:53 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Linehan MM, Heard HL, Armstrong HE</AU>
<TI>Naturalistic follow-up of a behavioral treatment for chronically parasuicidal borderline patients.[Erratum appears in Arch Gen Psychiatry 1994 May;51(5):422]</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1993</YR>
<VL>50</VL>
<NO>12</NO>
<PG>971-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283425"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-02 12:53:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Linehan MM, Heard HL</AU>
<TI>Impact of treatment accessibility on clinical course of parasuicidal patients-reply</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1993</YR>
<VL>50</VL>
<NO>2</NO>
<PG>157-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283426"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283422"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Linehan-1994" MODIFIED="2012-06-07 15:02:30 +0100" MODIFIED_BY="[Empty name]" NAME="Linehan 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-06-02 12:54:14 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;INCLUDE (SECONDARY PAPER TO AN EXISTING RCT)&lt;br&gt;Author Affiliation: Heard, Heidi Lynn: U Washington, US&lt;/p&gt;" NOTES_MODIFIED="2012-06-02 12:54:14 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heard HL</AU>
<TI>Cost-effectiveness of dialectical behavior therapy in the treatment of borderline personality disorder</TI>
<SO>Dissertation Abstracts International: Section B: The Sciences and Engineering</SO>
<YR>2000</YR>
<VL>61</VL>
<NO>6-B</NO>
<PG>3278</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283428"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 15:02:30 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;INCLUDE (SECONDARY ANALYSIS OF TWO RCTS IN THE AREA)&lt;br&gt;CODEN: DABBBA&lt;/p&gt;" NOTES_MODIFIED="2012-06-07 15:02:30 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindenboim Noam</AU>
<TI>To know me Is to keep me: self-verification, validation, and therapy dropout in the treatment of borderline personality disorder</TI>
<SO>Dissertation Abstracts International</SO>
<YR>5831</YR>
<VL>70</VL>
<NO>9</NO>
<PG>2010</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283429"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-11 17:11:33 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;ALREADY INCLUDED IN A BPD REVIEW: WE SAID: INCLUDE? (SECONDARY, FOLLOWUP)&lt;br&gt;Author Affiliation: Department of Psychology, University of Washington, Seattle&lt;/p&gt;" NOTES_MODIFIED="2011-08-11 17:11:33 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Linehan MM, Heard HL, Armstrong HE</AU>
<TI>Naturalistic follow-up of a behavioral treatment for chronically parasuicidal borderline patients.[Erratum appears in Arch Gen Psychiatry 1994 May;51(5):422]</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1993</YR>
<VL>50</VL>
<NO>12</NO>
<PG>971-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283430"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-02 12:55:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Linehan MM, Tutek DA, Heard HL, Armstrong HE</AU>
<TI>Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1994</YR>
<VL>151</VL>
<NO>12</NO>
<PG>1771-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283431"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283427"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Linehan-2006" MODIFIED="2012-06-07 15:05:10 +0100" MODIFIED_BY="[Empty name]" NAME="Linehan 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-08-12 13:11:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brown MZ, Linehan MM, Comtois KA, Murray A, Chapman AL</AU>
<TI>Shame as a prospective predictor of self-inflicted injury in borderline personality disorder: a multi-modal analysis</TI>
<SO>Behavior Research and Therapy</SO>
<YR>2009</YR>
<VL>47</VL>
<PG>815-22</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283433"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 15:03:15 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;ALREADY INCLUDED IN A BPD REVIEW: WE SAID: INCLUDE ?&lt;br&gt;Author Affiliation: Harned, Melanie S.: Department of Psychology, University of Washington, Seattle, WA, US Chapman, Alexander L.: Department of Psychology, Simon Fraser University, Burnaby, BC, Canada Dexter-Mazza, Elizabeth T.: Department of Psychology, University of Washington, Seattle, WA, US Murray, Angela: Department of Psychology, University of Washington, Seattle, WA, US Comtois, Katherine A.: Department of Psychiatry, University of Washington, Seattle, WA, US Linehan, Marsha M.: Department of Psychology, University of Washington, Seattle, WA, US&lt;/p&gt;" NOTES_MODIFIED="2012-06-07 15:03:15 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harned MS, Chapman AL, Dexter-Mazza ET, Murray A, Comtois KA, Linehan MM</AU>
<TI>Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts</TI>
<SO>Personality Disorders: Theory, Research, and Treatment</SO>
<YR>Aug 2009</YR>
<VL>S(1)</VL>
<PG>35-45</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283434"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 15:04:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harned MS, Chapman AL, Dexter-Mazza ET, Murray A, Comtois KA, Linehan MM</AU>
<TI>Treating co-ocurring axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts</TI>
<SO>Journal of Consulting and Clinical Psychology</SO>
<YR>2008</YR>
<VL>76</VL>
<NO>6</NO>
<PG>1068-75</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283435"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-12 13:13:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harned MS, Jackson SC, Comtois KA, Linehan MM</AU>
<TI>Dialectical behavior therapy as a precursor to PTSD treatment for suicidal and/or self-injuring women with bordreline personality disorder</TI>
<SO>Journal of Traumatic Stress</SO>
<YR>2010</YR>
<VL>23</VL>
<NO>4</NO>
<PG>421-9</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283436"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-02 12:56:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindenboim N, Comtois KA, Linehan MM</AU>
<TI>Skills practice in dialectical behavior therapy for suicidal women meeting criteria for borderline personality disorder</TI>
<SO>Cognitive and Behavioral Practice</SO>
<YR>2007</YR>
<VL>14</VL>
<NO>2</NO>
<PG>147-56</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283437"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 15:04:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Linehan MM, Comtois KA, Murray AM, Brown MZ, Gallop RJ, Heard HL, et al</AU>
<TI>Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2006</YR>
<VL>63</VL>
<NO>7</NO>
<PG>757-66</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283438"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 15:05:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Linehan MM</AU>
<TI>Erratum: Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2007</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1401</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283439"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-22 21:14:45 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;INCLUDE (BUT THIS IS A SECONDARY, IT IS JUST A WRITE-UP OF ANOTHER, PRIMARY STUDY)&lt;/p&gt;" NOTES_MODIFIED="2011-08-22 21:14:45 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McMain S</AU>
<TI>Dialectic behaviour therapy reduces suicide attempts compared with non-behavioural psychotherapy in women with borderline personality disorder</TI>
<SO>Evidence-Based Mental Health</SO>
<YR>2007 Feb</YR>
<VL>10</VL>
<NO>1</NO>
<PG>18</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283440"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-22 21:15:41 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;INCLUDE (SECONDARY PAPER TO THREE RCTS OF DBT)&lt;br&gt;ProCite field [3]: Neacsiu, Andrada D.: University of Washington, Behavioral Research and Therapy Clinics, Department of Clinical Psychology, Seattle, WA, US Rizvi, Shireen L.: Rutgers University Graduate School of Applied and Professional Psychology, Piscatawa, NJ, US Linehan, Marsha M.: University of Washington, Behavioral Research and Therapy Clinics, Department of Clinical Psychology, Seattle, WA, US&lt;/p&gt;" NOTES_MODIFIED="2011-08-22 21:15:41 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neacsiu AD, Rizvi SL, Linehan MM</AU>
<TI>Dialectical behavior therapy skills use as a mediator and outcome of treatment for borderline personality disorder</TI>
<SO>Behaviour Research and Therapy</SO>
<YR>Sep 2010</YR>
<VL>48</VL>
<NO>9</NO>
<PG>832-9</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283441"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283432"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McMain-2009" MODIFIED="2012-06-07 15:08:16 +0100" MODIFIED_BY="[Empty name]" NAME="McMain 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-06-07 15:07:26 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;INCLUDE (SECONDARY TO AN ALREADY INCLUDED RCT?)&lt;/p&gt;" NOTES_MODIFIED="2012-06-07 15:07:26 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Case BG</AU>
<TI>Dialectical behavior therapy versus general psychiatric management in the treatment of borderline personality disorder</TI>
<SO>The American Journal of Psychiatry</SO>
<YR>Apr 2010</YR>
<VL>167</VL>
<NO>4</NO>
<PG>475</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283443"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-09 10:40:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ISRCTN02634417</AU>
<TI>Evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder: a randomised controlled trial</TI>
<SO>www.controlled-trials.com/ISRCTN02634417/02634417</SO>
<YR>(accessed 02 November 2010)</YR>
<IDENTIFIERS MODIFIED="2010-12-09 10:38:32 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283444"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-02 12:57:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al</AU>
<TI>A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2009</YR>
<VL>166</VL>
<PG>1365-74</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283445"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 15:08:16 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;INCLUDE (SECONDARY TO AN ALREADY INCLUDED RCT?)&lt;/p&gt;" NOTES_MODIFIED="2012-06-07 15:08:16 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McMain Shelley F</AU>
<TI>Dialectical behavior therapy versus general psychiatric management in the treatment of borderline personality disorder: reply</TI>
<SO>The American Journal of Psychiatry</SO>
<YR>Apr 2010</YR>
<VL>167</VL>
<NO>4</NO>
<PG>475-6</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283446"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-22 21:07:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00154154</AU>
<TI>Hope for the chronically suicidal patient</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00154154?term=NCT00154154&amp;rank=1</SO>
<YR>(accessed 09 August 2011)</YR>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283447"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283442"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morey-2010" MODIFIED="2012-06-07 15:09:17 +0100" MODIFIED_BY="[Empty name]" NAME="Morey 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-06-07 15:09:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morey LC, Lowmaster SE, Hopwood CJ</AU>
<TI>A pilot study of manual-assisted cognitive therapy with a therapeutic assessment augmentation for borderline personality disorder</TI>
<SO>Psychiatry Research</SO>
<YR>2010</YR>
<VL>178</VL>
<NO>3</NO>
<PG>531-5</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283449"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283448"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nadort-2009" MODIFIED="2012-06-07 15:10:20 +0100" MODIFIED_BY="[Empty name]" NAME="Nadort 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-04-20 14:04:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NTR1781</AU>
<TI>Implementation of out-patient schema-focused therapy for borderline personality disorder in regular mental healthcare</TI>
<SO>www.trialregister.nl/trialreg/admin/rctview.asp?TC=1781</SO>
<YR>(accessed 09 December 2010)</YR>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283451"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 15:10:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nadort M, Arntz A, Smit JH, Giesen-Bloo J, Eikelenboom J, Spinhoven P, et al</AU>
<TI>Implementation of outpatient schema therapy for borderline personality disorder with versus without crisis support by the therapist outside office hours: a randomized trial</TI>
<SO>Behaviour Research and Therapy</SO>
<YR>2009</YR>
<VL>47</VL>
<NO>11</NO>
<PG>961-73</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283452"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-02 12:58:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nadort M, Arntz A, Smit JH, Giesen-Bloo J, Eikelenboom M, Spinhoven P, et al</AU>
<TI>Implementation of outpatient schema therapy for borderline personality disorder: study design</TI>
<SO>BMC Psychiatry</SO>
<YR>2009</YR>
<VL>9</VL>
<PG>64</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283453"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283450"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soler-2009" MODIFIED="2012-06-07 15:12:53 +0100" MODIFIED_BY="[Empty name]" NAME="Soler 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-06-07 15:12:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Soler J, Pascual JC, Tiana T, Cebrià A, Barrachina J, Campins MJ, et al</AU>
<TI>Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial</TI>
<SO>Behaviour Research and Therapy</SO>
<YR>2009</YR>
<VL>47</VL>
<NO>5</NO>
<PG>353-8</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283455"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 15:12:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Soler J</AU>
<TI>Question regarding your BPD trials [personal communication]</TI>
<SO>Email to: J Stoffers.</SO>
<YR>15 December 2010</YR>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283456"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283454"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Steil-2010" MODIFIED="2012-06-07 15:13:26 +0100" MODIFIED_BY="[Empty name]" NAME="Steil 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-10-19 10:13:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>DBT working group at the Central Institute for Mental Health, Mannheim, Germany</AU>
<TI>Requested supplementary data (as supplied 1 October 2010)</TI>
<SO>Data on file</SO>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283458"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 15:13:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Steil R, Dyer A, Priebe K, Kleindienst N, Bohus M</AU>
<TI>Dialectical Behavior Therapy for Posttraumatic Stress Disorder related to childhood sexual abuse: a pilot study of an intensive treament program</TI>
<SO>submitted</SO>
<YR>2010</YR>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283459"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283457"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Turner-2000" MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]" NAME="Turner 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-05-29 14:07:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Turner RM</AU>
<TI>Naturalistic evaluation of dialectical behavior therapy-oriented treatment for borderline personality disorder</TI>
<SO>Cognitive and Behavioral Practice</SO>
<YR>2000</YR>
<VL>7</VL>
<PG>413-9</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283461"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283460"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-den-Bosch-2005" MODIFIED="2012-06-07 15:16:59 +0100" MODIFIED_BY="[Empty name]" NAME="Van den Bosch 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-06-07 15:16:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van den Bosch LM, Verheul R, Schippers GM, Van den Brink W</AU>
<TI>Dialectical Behavior Therapy of borderline patients with and without substance use problems. Implementation and long-term effects</TI>
<SO>Addictive Behaviors</SO>
<YR>2002</YR>
<VL>27</VL>
<PG>911-23</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283463"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 15:16:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Van den Bosch LMC, Koeter MWJ, Stijnen T, Verheul R, Van den Brink W</AU>
<TI>Sustained efficacy of dialectical behaviour therapy for borderline personality disorder</TI>
<SO>Behaviour Research and Therapy</SO>
<YR>2005</YR>
<VL>43</VL>
<NO>9</NO>
<PG>1231-41</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283464"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-02 13:01:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van den Bosch LMC</AU>
<TI>Efficacy of dialectical behaviour therapy in the treatment of female borderline patients with and without substance abuse problems: results of a Dutch study</TI>
<TO>Dialectische gedragstherapie bij nederlandse vrouwen met een borderline persoonlijkheidsstoornis, met en zonder verslavingsproblemen</TO>
<SO>Tijdschrift voor psychiatrie</SO>
<YR>2005</YR>
<VL>47</VL>
<NO>3</NO>
<PG>127-37</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283465"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-02 12:59:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Verheul R, Van den Bosch LM, Koeter MW, De Ridder MA, Stijnen T, Van den Brink W</AU>
<TI>Dialectical behaviour therapy for women with borderline personality disorder: 12-month, randomised clinical trial in The Netherlands</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2003</YR>
<VL>182</VL>
<PG>135-40</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283466"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283462"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weinberg-2006" MODIFIED="2012-06-07 15:18:30 +0100" MODIFIED_BY="[Empty name]" NAME="Weinberg 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-06-07 15:18:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weinberg I, Gunderson JG, Hennen J, Cutter Jr CJ</AU>
<TI>Manual assisted cognitive treatment for deliberate self-harm in borderline personality disorder patients</TI>
<SO>Journal of Personality Disorders</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>5</NO>
<PG>482-92</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283468"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283467"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zanarini-2008" MODIFIED="2012-06-26 15:05:44 +0100" MODIFIED_BY="[Empty name]" NAME="Zanarini 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-06-26 15:05:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<SO>A randomized trial of psychoeducation for patients with BPD. Proceedings of the 57th annual meeting of the American Psychiatry Association; 1-6 May 2004</SO>
<YR>2004</YR>
<ED>Zanarini MC, Frankenburg FR</ED>
<PB>American Psychiatric Association</PB>
<CY>New York</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283470"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-02 13:02:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zanarini MC, Frankenburg FR</AU>
<TI>A preliminary, randomized trial of psychoeducation for women with borderline personality disorder</TI>
<SO>Journal of Personality Disorders</SO>
<YR>2008</YR>
<VL>22</VL>
<NO>3</NO>
<PG>284-90</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283471"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283469"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-06-07 15:56:46 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abbass-2008" MODIFIED="2012-06-07 15:26:47 +0100" MODIFIED_BY="[Empty name]" NAME="Abbass 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-06-07 15:26:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abbass A, Sheldon A, Gyra J, Kalpin A</AU>
<TI>Intensive short-term dynamic psychotherapy for DSM-IV personality disorders - a randomized controlled trial</TI>
<SO>The Journal of Nervous and Mental Disease</SO>
<YR>2008</YR>
<VL>196</VL>
<NO>3</NO>
<PG>211-6</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283473"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283472"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arnevik-2009" MODIFIED="2012-06-07 15:27:35 +0100" MODIFIED_BY="[Empty name]" NAME="Arnevik 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-06-07 15:27:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arnevik E, Wilberg T, Urnes Ø, Johansen M, Monsen JT, Karterud S</AU>
<TI>Psychotherapy for personality disorders: short-term day hospital psychotherapy versus outpatient individual therapy - a randomized controlled study</TI>
<SO>European Psychiatry</SO>
<YR>2009</YR>
<VL>24</VL>
<NO>2</NO>
<PG>71-8</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283475"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283474"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ball-2007" MODIFIED="2012-06-07 15:28:05 +0100" MODIFIED_BY="[Empty name]" NAME="Ball 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-06-07 15:28:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ball SA</AU>
<TI>Comparing individual therapies for personality disordered opioid dependent patients</TI>
<SO>Journal of Personality Disorders</SO>
<YR>2007</YR>
<VL>21</VL>
<NO>3</NO>
<PG>305-21</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283477"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283476"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beecham-2006" MODIFIED="2012-06-07 15:28:45 +0100" MODIFIED_BY="[Empty name]" NAME="Beecham 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-06-07 15:28:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beecham J, Sleed M, Knapp M, Chiesa M, Drahorad C</AU>
<TI>The costs and effectiveness of two psychosocial treatment programmes for personality disorder: a controlled study</TI>
<SO>European Psychiatry</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>2</NO>
<PG>102-9</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283479"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283478"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bellino-2005" MODIFIED="2012-06-02 14:38:25 +0100" MODIFIED_BY="[Empty name]" NAME="Bellino 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-06-02 14:38:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bellino S, Zizza M, Di Lorenzo R, Rinaldi C, Bogetto F</AU>
<TI>Combined therapy with interpersonal psychotherapy of major depressed patients: comparison between patients with borderline personality disorder and patients with other personality disorders</TI>
<TO>La terapie combinata con psicoterapia interpersonale della depressione maggiore: confronto tra pazienti con disturbo boderline di personalità e pazienti con altre diagnosi di asse II</TO>
<SO>Giornale Italiano di Psicopatologia</SO>
<YR>2005</YR>
<VL>11</VL>
<PG>157-64</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283481"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283480"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berget-2008" MODIFIED="2012-06-07 15:39:44 +0100" MODIFIED_BY="[Empty name]" NAME="Berget 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-06-07 15:39:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berget B, Ekeberg Ø, Braastad BO</AU>
<TI>Animal-assisted therapy with farm animals for persons with psychiatric disorders: effects on self-efficacy, coping ability yand quality of life, a randomized controlled trial</TI>
<SO>Clinical Practice and Epidemiology in Mental Health</SO>
<YR>2008</YR>
<VL>4</VL>
<PG>9</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283483"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283482"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blum-2002" MODIFIED="2012-06-02 14:38:49 +0100" MODIFIED_BY="[Empty name]" NAME="Blum 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-06-02 14:38:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blum N, Pfohl B, St John D, Monahan P, Black D</AU>
<TI>STEPPS: a cognitive-behavioral systems-based group treatment for outpatients with borderline personality disorder - a preliminary report</TI>
<SO>Comprehensive Psychiatry</SO>
<YR>2002</YR>
<VL>43</VL>
<PG>301-10</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283485"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283484"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bohus-2000" MODIFIED="2012-06-02 14:38:58 +0100" MODIFIED_BY="[Empty name]" NAME="Bohus 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-06-02 14:38:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bohus M, Haaf B, Stiglmayr C, Pohl U, Böhme R, Linehan M</AU>
<TI>Evaluation of inpatient dialectical-behavioral therapy for borderline personality disorder - a prospective study</TI>
<SO>Behaviour Research and Therapy</SO>
<YR>2000</YR>
<VL>38</VL>
<PG>875-87</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283487"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283486"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bohus-2004" MODIFIED="2012-06-02 14:39:23 +0100" MODIFIED_BY="[Empty name]" NAME="Bohus 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-06-02 14:39:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bohus M, Haaf B, Simms T, Limberger MF, Schmahl C, Unckel C, et al</AU>
<TI>Effectiveness of inpatient dialectical behavioral therapy for borderline personality disorder: a controlled trial</TI>
<SO>Behaviour Research and Therapy</SO>
<YR>2004</YR>
<VL>42</VL>
<PG>487-99</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283489"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283488"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brassington-2006" MODIFIED="2012-06-02 14:39:33 +0100" MODIFIED_BY="[Empty name]" NAME="Brassington 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-06-02 14:39:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brassington J, Krawitz R</AU>
<TI>Australasian dialectical behaviour therapy pilot outcome study: effectiveness, utility and feasibility</TI>
<SO>Australasian Psychiatry</SO>
<YR>2006</YR>
<VL>14</VL>
<PG>313-9</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283491"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283490"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brown-2004" MODIFIED="2012-06-02 14:39:45 +0100" MODIFIED_BY="[Empty name]" NAME="Brown 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-06-02 14:39:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brown GK, Newman CF, Charlesworth SE, Crits-Christoph P, Beck AT</AU>
<TI>An open clinical trial of cognitive therapy for borderline personality disorder</TI>
<SO>Journal of Personality Disorders</SO>
<YR>2004</YR>
<VL>18</VL>
<PG>257-71</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283493"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283492"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carter-2007" MODIFIED="2012-06-02 14:40:01 +0100" MODIFIED_BY="[Empty name]" NAME="Carter 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-06-02 14:40:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carter GL, Clover K, Whyte IM, Dawson AH, D'Este C</AU>
<TI>Postcards from the EDge: 24-month outcomes of a randomised controlled trial for hospital-treated self-poisoning</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2007</YR>
<VL>191</VL>
<PG>548-53</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283495"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283494"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chanen-2008" MODIFIED="2012-06-02 14:40:25 +0100" MODIFIED_BY="[Empty name]" NAME="Chanen 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-06-02 14:40:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chanen AM, Jackson HJ, McCutcheon LK, Jovev M, Dudgeon P, Yuen HP, et al</AU>
<TI>Early intervention for adolescents with borderline personality disorder using cognitive analytic therapy: randomised controlled trial</TI>
<SO>The British Journal of Psychiatry</SO>
<YR>2008</YR>
<VL>193</VL>
<PG>477-84</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283497"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283496"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chiesa-2000" MODIFIED="2012-06-02 14:40:44 +0100" MODIFIED_BY="[Empty name]" NAME="Chiesa 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-06-02 14:40:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chiesa M, Fonagy P</AU>
<TI>Cassel Personality Disorder Study</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>485-91</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283499"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283498"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clarkin-2007" MODIFIED="2012-06-07 15:43:10 +0100" MODIFIED_BY="[Empty name]" NAME="Clarkin 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-06-02 14:40:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Clarkin JF, Levy KN, Lenzenweger MF, Kernberg OF</AU>
<TI>Evaluating three treatments for borderline personality disorder: a multiwave study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2007</YR>
<VL>164</VL>
<PG>922-8</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283501"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 15:43:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clarkin JF, Levy KN, Lenzenweger MF, Kernberg OF</AU>
<TI>The Personality Disorders Institute/Borderline Personality Disorder Research Foundation randomized control trial for borderline personality disorder: rationale, methods, and patient characteristics</TI>
<SO>Journal of Personality Disorders</SO>
<YR>2004</YR>
<VL>18</VL>
<PG>52-72</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283502"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283500"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Colom-2004" MODIFIED="2012-06-02 14:42:02 +0100" MODIFIED_BY="[Empty name]" NAME="Colom 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-06-02 14:42:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Colom F, Vieta E, Sánchez-Moreno J, Martínez-Arán A, Torrent C, Reinares M, et al</AU>
<TI>Psychoeducation in bipolar patients with comorbid personality disorders</TI>
<SO>Bipolar Disorders</SO>
<YR>2004</YR>
<VL>6</VL>
<PG>294-8</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283504"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283503"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dolan-1997" MODIFIED="2012-06-02 14:42:16 +0100" MODIFIED_BY="[Empty name]" NAME="Dolan 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-06-02 14:42:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dolan B, Warren F, Norton K</AU>
<TI>Change in borderline symptoms one year after therapeutic community treatment for severe personality disorder</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>171</VL>
<PG>274-9</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283506"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283505"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evans-1999a" MODIFIED="2012-06-02 14:43:58 +0100" MODIFIED_BY="[Empty name]" NAME="Evans 1999a" YEAR="1999">
<REFERENCE MODIFIED="2012-06-02 14:42:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Evans K, Tyrer P, Catalan J, Schmidt U, Davidson K, Dent J, et al</AU>
<TI>Manual-assisted cognitive-behaviour therapy (MACT): a randomized controlled trial of a brief intervention with bibliotherapy in the treatment of recurrent deliberate self-harm</TI>
<SO>Psychological Medicine</SO>
<YR>1999</YR>
<VL>29</VL>
<PG>19-25</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283508"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283507"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evans-1999b" MODIFIED="2012-06-02 14:44:23 +0100" MODIFIED_BY="[Empty name]" NAME="Evans 1999b" YEAR="1999">
<REFERENCE MODIFIED="2012-06-02 14:44:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Evans MO, Morgan HG, Hayward A, Gunnell DJ</AU>
<TI>Crisis telephone consultation for deliberate self-harm patients: effects on repetition</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1999</YR>
<VL>175</VL>
<PG>23-7</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283510"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283509"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gabbard-2000" MODIFIED="2012-06-02 14:44:41 +0100" MODIFIED_BY="[Empty name]" NAME="Gabbard 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-06-02 14:44:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gabbard GO, Coyne L, Allen JG, Spohn H, Colson DB, Vary M</AU>
<TI>Evaluation of intensive inpatient treatment of patients with severe personality disorders</TI>
<SO>Psychiatric Services</SO>
<YR>2000</YR>
<VL>51</VL>
<PG>893-8</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283512"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283511"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guthrie-2001" MODIFIED="2012-06-02 14:45:10 +0100" MODIFIED_BY="[Empty name]" NAME="Guthrie 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-06-02 14:45:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guthrie E, Kapur N, Mackway-Jones K, Chew-Graham C, Moorey J, Mendel E, et al</AU>
<TI>Randomised controlled trial of brief psychological intervention after deliberate self poisoning</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<PG>1-5</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283514"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283513"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hagen-2005" MODIFIED="2012-06-02 14:45:29 +0100" MODIFIED_BY="[Empty name]" NAME="Hagen 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-06-02 14:45:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hagen R, Nordahl HM, Kristiansen L, Morken G</AU>
<TI>A randomized trial of cognitive group therapy vs. waiting list for patients with co-morbid psychiatric disorders: effect of cogniitve group therapy after treatment and six and twelve months follow-up</TI>
<SO>Behavioural and Cognitive Psychotherapy</SO>
<YR>2005</YR>
<VL>33</VL>
<PG>33-44</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283516"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283515"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huband-2007" MODIFIED="2012-06-02 14:45:50 +0100" MODIFIED_BY="[Empty name]" NAME="Huband 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-06-02 14:45:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huband N, McMurran M, Evans C, Duggan C</AU>
<TI>Social problem-solving plus psychoeducation for adults with personality disorders</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2007</YR>
<VL>190</VL>
<PG>307-13</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283518"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283517"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kool-2003" MODIFIED="2012-06-02 14:46:06 +0100" MODIFIED_BY="[Empty name]" NAME="Kool 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-06-02 14:46:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kool S, Dekker J, Duijsens IJ, De Jonghe F, Puite B</AU>
<TI>Changes in personality pathology after pharmacotherapy and combined therapy for depressed patients</TI>
<SO>Journal of Personality Disorders</SO>
<YR>2003</YR>
<VL>17</VL>
<PG>60-72</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283520"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283519"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Korner-2006" MODIFIED="2012-06-02 14:46:21 +0100" MODIFIED_BY="[Empty name]" NAME="Korner 2006" YEAR="2008">
<REFERENCE MODIFIED="2012-06-02 14:46:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Korner A, Gerull F, Meares R, Stevenson J</AU>
<TI>Borderline personality disorder treated with the conversational model: a replication study</TI>
<SO>Comprehensive Psychiatry</SO>
<YR>2006</YR>
<VL>47</VL>
<PG>406-11</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283522"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283521"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kr_x00f6_ger-2006" MODIFIED="2012-06-02 14:46:43 +0100" MODIFIED_BY="[Empty name]" NAME="Kröger 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-06-02 14:46:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kröger C, Schwieger U, Sipos V, Arnold R, Kahl KG, Schunert T, et al</AU>
<TI>Effectiveness of dialectical behaviour therapy for borderline personality disorder in an inpatient setting</TI>
<SO>Behaviour Research and Therapy</SO>
<YR>2006</YR>
<VL>44</VL>
<PG>1211-7</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283524"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283523"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Linehan-1999" MODIFIED="2012-06-02 14:47:00 +0100" MODIFIED_BY="[Empty name]" NAME="Linehan 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-06-02 14:47:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Linehan MM, Schmidt H III, Dimeff LA, Craft JC, Kanter J, Comtois KA</AU>
<TI>Dialectical behavior therapy for patients with personality disorder and drug-dependence</TI>
<SO>The American Journal on Addictions</SO>
<YR>1999</YR>
<VL>8</VL>
<PG>279-92</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283526"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283525"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Linehan-2002" MODIFIED="2012-06-02 14:47:19 +0100" MODIFIED_BY="[Empty name]" NAME="Linehan 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-06-02 14:47:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Linehan MM, Dimeff LA, Reynolds SK, Comtois KA, Welch SS, Heagerty P, et al</AU>
<TI>Dialectical behavior therapy versus comprehensive validation therapy plus 12-step for the treatment of opioid dependent women meeting criteria for borderline personality disorder</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2002</YR>
<VL>67</VL>
<PG>13-26</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283528"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283527"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-L_x00f3_pez-2004" MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]" NAME="López 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-08-22 21:39:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>López D, Cuevas P, Gómez A, Mendoza J</AU>
<TI>Transference-focused psychotherapy in borderline personality disorder</TI>
<TO>Psicoterapia focalizada en la transferencia para el trastorno límite de la personalidad</TO>
<SO>Salud Mental</SO>
<YR>2004</YR>
<VL>27</VL>
<PG>44-54</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283530"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283529"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lynch-2007" MODIFIED="2012-06-02 14:47:38 +0100" MODIFIED_BY="[Empty name]" NAME="Lynch 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-06-02 14:47:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lynch TR, Cheavens JS, Cukrowicz KC, Thorp SR, Bronner L, Beyer J</AU>
<TI>Treatment of older adults with co-morbid personality disorder and depression: a dialectical behavior therapy approach</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>2007</YR>
<VL>22</VL>
<PG>131-43</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283532"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283531"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McQuillan-2005" MODIFIED="2012-06-02 14:47:49 +0100" MODIFIED_BY="[Empty name]" NAME="McQuillan 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-06-02 14:47:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McQuillan A, Nicastro R, Guenot F, Girard M, Lissner C, Ferrero F</AU>
<TI>Intensive dialectical behavior therapy for outpatients with borderline personality disorder who are in crisis</TI>
<SO>Psychiatric Services</SO>
<YR>2005</YR>
<VL>56</VL>
<PG>193-7</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283534"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283533"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meares-1999" MODIFIED="2012-06-02 14:48:00 +0100" MODIFIED_BY="[Empty name]" NAME="Meares 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-06-02 14:48:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meares R, Stevenson J, Comerford A</AU>
<TI>Psychotherapy with borderline patients: a comparison between treated and untreated cohorts</TI>
<SO>Australian and New Zealand Journal of Psychiatry</SO>
<YR>1999</YR>
<VL>33</VL>
<PG>467-72</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283536"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283535"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mueser-2004" MODIFIED="2012-06-02 14:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Mueser 2004" YEAR="2006">
<REFERENCE MODIFIED="2012-06-02 14:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mueser KT, Clark RE, Haines M, Drake RE, McHugo GJ, Bond GR, et al</AU>
<TI>The Hartford Study of supported employment for persons with severe mental illness</TI>
<SO>Journal of Consulting and Clinical Psychology</SO>
<YR>2004</YR>
<VL>72</VL>
<PG>479-90</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283538"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283537"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Munroe_x002d_Blum-1995" MODIFIED="2012-06-02 14:48:35 +0100" MODIFIED_BY="[Empty name]" NAME="Munroe-Blum 1995" YEAR="1995">
<REFERENCE MODIFIED="2012-06-02 14:48:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Munroe-Blum H, Marziali E</AU>
<TI>A controlled trial of short-term group treatment for borderline personality disorder</TI>
<SO>Journal of Personality Disorders</SO>
<YR>1995</YR>
<VL>9</VL>
<PG>190-8</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283540"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283539"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muran-2009" MODIFIED="2012-06-02 14:48:47 +0100" MODIFIED_BY="[Empty name]" NAME="Muran 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-06-02 14:48:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muran JC, Safran JD, Gorman BS, Samstag LW, Eubanks-Carter C, Winston A</AU>
<TI>The relationship of early alliance ruptures and their resolution to process and outcome in three time-limited psychotherapies for personality disorders</TI>
<SO>Psychotherapy Theory, Research, Practice, Training</SO>
<YR>2009</YR>
<VL>46</VL>
<PG>233-48</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283542"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283541"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petersen-2008" MODIFIED="2012-06-02 14:49:13 +0100" MODIFIED_BY="[Empty name]" NAME="Petersen 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-06-02 14:49:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petersen B, Toft J, Christensen NB, Foldager L, Munk-Jörgensen P, Lien K, et al</AU>
<TI>Outcome of a psychotherapeutic programme for patients with severe personality disorders</TI>
<SO>Nordic Journal of Psychiatry</SO>
<YR>2008</YR>
<VL>62</VL>
<PG>450-6</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283544"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283543"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ranger-2009" MODIFIED="2012-06-02 14:49:37 +0100" MODIFIED_BY="[Empty name]" NAME="Ranger 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-06-02 14:49:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ranger M, Tyrer P, Miloseska K, Fourie H, Khaleel I, North B, et al</AU>
<TI>Cost-effectiveness of nidotherapy for comorbid personality disorder and severe mental illness: randomized controlled trial</TI>
<SO>Epidemiologia e Psichiatria Sociale</SO>
<YR>2009</YR>
<VL>18</VL>
<PG>128-36</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283546"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283545"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rathus-2002" MODIFIED="2012-06-02 14:49:49 +0100" MODIFIED_BY="[Empty name]" NAME="Rathus 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-06-02 14:49:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rathus JH, Miller AL</AU>
<TI>Dialectical behavior therapy adapted for suicidal adolescents</TI>
<SO>Suicide and Life-Threatening Behavior</SO>
<YR>2002</YR>
<VL>32</VL>
<PG>146-57</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283548"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283547"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sachsse-2006" MODIFIED="2012-06-02 14:50:06 +0100" MODIFIED_BY="[Empty name]" NAME="Sachsse 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-06-02 14:50:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sachsse U, Vogel C, Leichsenring F</AU>
<TI>Results of psychodynamically oriented trauma-focused inpatient treatment for women with complex posttraumatic stress disorder (PTSD) and borderline personality disorder (BPD)</TI>
<SO>Bulletin of the Menninger Clinic</SO>
<YR>2006</YR>
<VL>70</VL>
<PG>125-44</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283550"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283549"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schuppert-2009" MODIFIED="2012-06-02 14:50:27 +0100" MODIFIED_BY="[Empty name]" NAME="Schuppert 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-06-02 14:50:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schuppert HM, Giesen-Bloo J, Van Gemert TG, Wiersema HM, Minderaa RB, Emmelkamp PM, et al</AU>
<TI>Effectiveness of an emotion regulation group training for adolescents - a randomized controlled pilot study</TI>
<SO>Clinical Psychology &amp; Psychotherapy</SO>
<YR>2009</YR>
<VL>16</VL>
<NO>6</NO>
<PG>467-78</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283552"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283551"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Slee-2008" MODIFIED="2012-06-02 14:50:43 +0100" MODIFIED_BY="[Empty name]" NAME="Slee 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-06-02 14:50:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Slee N, Garnefski N, Van der Leeden R, Arensman E, Spinhoven P</AU>
<TI>Cognitive-behavioural intervention for self-harm: randomised controlled trial</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2008</YR>
<VL>192</VL>
<PG>202-11</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283554"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283553"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Springer-1996" MODIFIED="2012-06-07 15:50:09 +0100" MODIFIED_BY="[Empty name]" NAME="Springer 1996" YEAR="1996">
<REFERENCE MODIFIED="2012-06-07 15:50:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Springer T, Lohr NE, Buchtel HA, Silk KR</AU>
<TI>A preliminary report of short-term cognitive-behavioral group therapy for inpatients with personality disorders</TI>
<SO>Journal of Psychotherapy Practice and Research</SO>
<YR>1996</YR>
<VL>5</VL>
<NO>1</NO>
<PG>57-71</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283556"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283555"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stanley-2007" MODIFIED="2012-06-02 14:51:02 +0100" MODIFIED_BY="[Empty name]" NAME="Stanley 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-06-02 14:51:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stanley B, Brodsky B, Nelson JD, Dulit R</AU>
<TI>Brief dialectial behavior therapy (DBT-B) for suicidal behavior and non-suicidal self injury</TI>
<SO>Archives of Suicide Research</SO>
<YR>2007</YR>
<VL>11</VL>
<PG>337-41</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283558"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283557"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stevenson-1992" MODIFIED="2012-06-02 14:51:13 +0100" MODIFIED_BY="[Empty name]" NAME="Stevenson 1992" YEAR="1992">
<REFERENCE MODIFIED="2012-06-02 14:51:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stevenson J, Meares R</AU>
<TI>An outcome study of psychotehrapy for patients with borderline personality disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1992</YR>
<VL>149</VL>
<PG>358-62</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283560"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283559"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stiles-2006" MODIFIED="2012-06-02 14:51:25 +0100" MODIFIED_BY="[Empty name]" NAME="Stiles 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-06-02 14:51:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stiles WB, Barkham M, Twigg E, Mellor-Clark J, Cooper M</AU>
<TI>Effectiveness of cognitive-behavioural, person-centered and psychodynamic therapies as practised in UK National Health Service settings</TI>
<SO>Psychological Medicine</SO>
<YR>2006</YR>
<VL>36</VL>
<PG>555-66</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283562"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283561"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trupin-2002" MODIFIED="2012-06-02 14:51:38 +0100" MODIFIED_BY="[Empty name]" NAME="Trupin 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-06-02 14:51:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trupin EW, Stewart DG, Beach B, Boesky L</AU>
<TI>Effectiveness of a dialectical behaviour therapy program for incarcerated female juvenile offenders</TI>
<SO>Child and Adolescent Mental Health</SO>
<YR>2002</YR>
<VL>7</VL>
<PG>121-7</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283564"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283563"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tyrer-2003" MODIFIED="2012-06-02 14:52:12 +0100" MODIFIED_BY="[Empty name]" NAME="Tyrer 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-06-02 14:52:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tyrer P, Thompson S, Schmidt U, Jones V, Knapp M, Davidson K,</AU>
<TI>Randomized controlled trial of brief cognitive behaviour therapy versus treatment as usual in recurrent deliberate self-harm: the POPMACT study</TI>
<SO>Psychological Medicine</SO>
<YR>2003</YR>
<VL>33</VL>
<PG>969-76</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283566"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283565"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tyrer-2009" MODIFIED="2012-06-02 14:52:33 +0100" MODIFIED_BY="[Empty name]" NAME="Tyrer 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-06-02 14:52:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tyrer P, Cooper S, Rutter D, Seivewright H, Duggan C, Maden T, et al</AU>
<TI>The assessment of dangerous and severe personality disorder: lessons from a randomised controlled trial linked to qualitative analysis</TI>
<SO>The Journal of Forensic Psychiatry &amp; Psychology</SO>
<YR>2009</YR>
<VL>20</VL>
<PG>132-46</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283568"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283567"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vinnars-2009" MODIFIED="2012-06-02 14:52:48 +0100" MODIFIED_BY="[Empty name]" NAME="Vinnars 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-06-02 14:52:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vinnars B, Thormählen B, Gallop R, Norén K, Barber JP</AU>
<TI>Do personality problems improve during psychodynamic supportive-expressive psychotherapy? Secondary outcome results from a randomized controlled trial for psychiatric outpatients with personality disorders</TI>
<SO>Psychotherapy: Theory, Research, Practice, Training</SO>
<YR>2009</YR>
<VL>46</VL>
<PG>362-75</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283570"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283569"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Waltz-2009" MODIFIED="2012-06-02 14:53:01 +0100" MODIFIED_BY="[Empty name]" NAME="Waltz 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-06-02 14:53:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Waltz J, Dimeff LA, Koerner K, Linehan MM, Taylor L, Miller C</AU>
<TI>Feasibility of using video to teach a dialectical behavior therapy skill to clients with borderline personality disorder</TI>
<SO>Cognitive and Behavioral Practice</SO>
<YR>2009</YR>
<VL>16</VL>
<PG>214-22</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283572"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283571"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weertman-2007" MODIFIED="2012-06-02 14:53:14 +0100" MODIFIED_BY="[Empty name]" NAME="Weertman 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-06-02 14:53:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weertman A, Arntz A</AU>
<TI>Effectiveness of treatment of childhood memories in cognitive therapy for personality disorders: a controlled study contrasting methods focusing on the present and methods focusing on childhood memories</TI>
<SO>Behaviour Research and Therapy</SO>
<YR>2007</YR>
<VL>45</VL>
<PG>2133-43</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283574"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283573"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wildgoose-2001" MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]" NAME="Wildgoose 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-04-09 14:19:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wildgoose A, Clarke S, Waller G</AU>
<TI>Treating personality fragmentation and dissociation in borderline personality disorder: a pilot study of the impact of cognitive analytic therapy</TI>
<SO>British Journal of Medical Psychology</SO>
<YR>2001</YR>
<VL>74</VL>
<PG>47-55</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283576"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283575"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yen-2009" MODIFIED="2012-06-02 14:53:35 +0100" MODIFIED_BY="[Empty name]" NAME="Yen 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-06-02 14:53:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yen S, Johnson J, Costello E, Simpson EB</AU>
<TI>A 5-day dialectical behavior therapy partial hospital program for women with borderline personality disorder: predictors of outcome from a 3-month follow-up study</TI>
<SO>Journal of Psychiatric Practice</SO>
<YR>2009</YR>
<VL>15</VL>
<PG>173-82</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283578"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283577"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zorn-2007" MODIFIED="2012-06-07 15:56:46 +0100" MODIFIED_BY="[Empty name]" NAME="Zorn 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-06-07 15:56:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zorn P, Roder V, Müller DR, Tschacher W, Thommen M</AU>
<TI>Schema Focussed Emotive Behavioural Therapy (SET): a randomised controlled trial on patients with cluster B and C personality disorders</TI>
<TO>Schemazentrierte emotiv-behaviorale Therapie (SET): eine randomisierte evaluationsstudie an patienten mit persönlichkeitsstörungen aus den Clustern B und C</TO>
<SO>Verhaltenstherapie</SO>
<YR>2007</YR>
<VL>17</VL>
<PG>233-41</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283580"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283579"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2010-05-03 15:53:49 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2012-06-26 15:04:53 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-ACTRN12605000594628" MODIFIED="2012-06-07 15:58:24 +0100" MODIFIED_BY="[Empty name]" NAME="ACTRN12605000594628" YEAR="4628">
<REFERENCE MODIFIED="2012-06-07 15:58:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ACTRN12605000594628</AU>
<TI>A pilot study to evaluate the feasibility, safety and efficacy of psychotherapeutic intervention for comorbid BPD and first-episode psychosis</TI>
<SO>www.anzctr.org.au/ACTRN12605000594628.aspx</SO>
<YR>(accessed 8 August 2011)</YR>
<IDENTIFIERS MODIFIED="2010-12-08 16:27:58 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283582"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283581"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ACTRN12606000206527" MODIFIED="2012-06-07 15:58:21 +0100" MODIFIED_BY="[Empty name]" NAME="ACTRN12606000206527" YEAR="6527">
<REFERENCE MODIFIED="2012-06-07 15:58:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ACTRN12606000206527</AU>
<TI>Process and outcome of acceptance based outpatient skills training groups for people with four or more criteria of borderline personality disorder</TI>
<SO>http://www.anzctr.org.au/trial_view.aspx?ACTRN=12606000206527</SO>
<YR>(accessed 8 August 2011)</YR>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283584"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283583"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ACTRN12610000100099" MODIFIED="2012-06-07 15:58:17 +0100" MODIFIED_BY="[Empty name]" NAME="ACTRN12610000100099" YEAR="0099">
<REFERENCE MODIFIED="2012-06-07 15:58:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ACTRN12610000100099</AU>
<TI>A randomised controlled trial (RCT) of specialised early intervention, with and without psychotherapy, versus a standard youth mental health intervention, for youth presenting with first presentation borderline personality disorder (BPD)</TI>
<SO>www.anzctr.org.au/ACTRN12610000100099.aspx</SO>
<YR>(accessed 9 August 2011)</YR>
<IDENTIFIERS MODIFIED="2010-12-08 16:34:49 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283586"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283585"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DRKS00000068" MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]" NAME="DRKS00000068" YEAR="0068">
<REFERENCE MODIFIED="2011-08-08 14:52:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>DRKS00000068</AU>
<TI>Psychoanalytical interactional psychotherapy in cluster B personality disorders</TI>
<TO>Psychoanalytisch-Interaktionelle Therapie bei Cluster B-Persönlichkeitsstörungen</TO>
<SO>https://drks-neu.uniklinik-freiburg.de/drks_web/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00000068</SO>
<YR>(accessed 08 August 2010)</YR>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283588"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283587"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ISRCTN12440268" MODIFIED="2012-06-02 14:54:34 +0100" MODIFIED_BY="[Empty name]" NAME="ISRCTN12440268" YEAR="0268">
<REFERENCE MODIFIED="2011-08-09 17:17:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ISRCTN12440268</AU>
<TI>JOSHUA: a pilot randomised controlled trial of joint crisis plans for people who self harm</TI>
<SO>www.controlled-trials.com/ISRCTN12440268/12440268</SO>
<YR>(accessed 31 July 2011)</YR>
<IDENTIFIERS MODIFIED="2010-12-09 10:47:09 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283590"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-02 14:54:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moran P, Borschman R, Flach C, Barrett B, Byford S, Hogg J, et al</AU>
<TI>The effectiveness of joint crisis plans for people with borderline personality disorder: protocol for an exploratory randomised controlled trial</TI>
<SO>Trials</SO>
<YR>2010</YR>
<VL>11</VL>
<PG>18</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283591"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283589"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ISRCTN51304415" MODIFIED="2012-06-07 16:00:22 +0100" MODIFIED_BY="[Empty name]" NAME="ISRCTN51304415" YEAR="4415">
<REFERENCE MODIFIED="2012-06-07 16:00:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ISRCTN51304415</AU>
<TI>Nice OUtcomes for Referrals with Impulsivity, Self-Harm and Eating Disorders: the NOURISHED study</TI>
<SO>http://www.controlled-trials.com/ISRCTN51304415</SO>
<YR>(accessed 08 August 2011)</YR>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283593"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283592"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ISRCTN54233644" MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]" NAME="ISRCTN54233644" YEAR="3644">
<REFERENCE MODIFIED="2011-08-09 17:20:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ISRCTN54233644</AU>
<TI>Dialectical behaviour therapy in patients with borderline personality disorder who self-harm: a pragmatic exploratory trial</TI>
<SO>www.controlled-trials.com/ISRCTN54233644/54233644</SO>
<YR>(accessed 31 July 2011)</YR>
<IDENTIFIERS MODIFIED="2011-01-03 09:45:46 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283595"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283594"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ISRCTN72677277" MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]" NAME="ISRCTN72677277" YEAR="7277">
<REFERENCE MODIFIED="2011-08-08 15:54:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ISRCTN72677277</AU>
<TI>Psychological treatments for severe and complex mental health problems/personality disorder. A phase II randomised controlled trial (SPeDi)</TI>
<SO>http://www.controlled-trials.com/ISRCTN72677277</SO>
<YR>(accessed 08 August 2011)</YR>
<IDENTIFIERS MODIFIED="2011-08-08 15:53:24 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283597"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283596"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ISRCTN79187618" MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]" NAME="ISRCTN79187618" YEAR="7618">
<REFERENCE MODIFIED="2011-08-08 16:04:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ISRCTN79187618</AU>
<TI>Psychoanalytically oriented brief group treatment for borderline personality disorder: a randomised controlled trial</TI>
<SO>http://www.controlled-trials.com/ISRCTN79187618</SO>
<YR>(accessed 08 August 2011)</YR>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283599"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283598"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ISRCTN98982683" MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]" NAME="ISRCTN98982683" YEAR="2683">
<REFERENCE MODIFIED="2011-01-03 09:44:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ISRCTN98982683</AU>
<TI>Mentalisation-based treatment for dual diagnoses</TI>
<SO>www.controlled-trials.com/ISRCTN98982683</SO>
<YR>(accessed 02 November 2010)</YR>
<IDENTIFIERS MODIFIED="2011-01-03 09:43:17 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283601"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283600"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-J_x00f8_rgensen-2009" MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]" NAME="Jørgensen 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-08-05 10:24:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jørgensen CR, Kjølbye M, Freund C, Bøye R, Jordet H, Andersen D</AU>
<TI>Level of functioning in patients with borderline personality disorder. The Risskov-I study</TI>
<SO>Nordic Psychology</SO>
<YR>2009</YR>
<VL>61</VL>
<NO>1</NO>
<PG>42-60</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283603"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283602"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00117741" MODIFIED="2012-06-07 16:03:21 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00117741" YEAR="7741">
<REFERENCE MODIFIED="2012-06-07 16:03:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00117741</AU>
<TI>Evaluation of DBT compared to drug counseling for opiate addicts</TI>
<SO>www.clinicaltrials.gov/ct2/show/NCT00117741?term=00117741&amp;rank=1</SO>
<YR>(accessed 9 August 2011)</YR>
<IDENTIFIERS MODIFIED="2010-12-09 10:20:52 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283605"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283604"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00183651" MODIFIED="2012-06-07 16:03:18 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00183651" YEAR="3651">
<REFERENCE MODIFIED="2012-06-07 16:03:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00183651</AU>
<TI>Treatment of suicidal women with borderline personality disorders</TI>
<SO>www.clinicaltrials.gov/ct2/show/NCT00183651?term=00183651&amp;rank=1</SO>
<YR>(accessed 9 December 2010)</YR>
<IDENTIFIERS MODIFIED="2010-12-09 10:22:26 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283607"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283606"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00218595" MODIFIED="2012-06-07 16:03:39 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00218595" YEAR="8595">
<REFERENCE MODIFIED="2012-06-07 16:03:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00218595</AU>
<TI>DBT compared to I/GDC for the treatment of opiate addiction in emotionally dysregulated patients</TI>
<SO>www.clinicaltrials.gov/show/NCT00218595</SO>
<YR>(accessed 3 January 2011)</YR>
<IDENTIFIERS MODIFIED="2011-01-03 09:47:42 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283609"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283608"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00247234" MODIFIED="2012-06-07 16:03:51 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00247234" YEAR="7234">
<REFERENCE MODIFIED="2012-06-07 16:03:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00247234</AU>
<TI>Effectiveness of group based schema therapy in the treatment of personality disorders</TI>
<SO>www.clinicaltrials.gov/show/NCT00247234</SO>
<YR>(accessed 9 August 2011)</YR>
<IDENTIFIERS MODIFIED="2010-12-09 09:30:01 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283611"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283610"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00378248" MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00378248" YEAR="8248">
<REFERENCE MODIFIED="2011-08-09 10:27:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00378248</AU>
<TI>Ullevål personality project</TI>
<SO>http://clinicaltrials.gov/show/NCT00378248</SO>
<YR>(accessed 09 August 2011)</YR>
<IDENTIFIERS MODIFIED="2011-08-09 10:24:54 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283613"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283612"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00533117" MODIFIED="2012-06-07 16:04:27 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00533117" YEAR="3117">
<REFERENCE MODIFIED="2012-06-07 16:04:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00533117</AU>
<TI>Treating suicidal behavior and self-mutilation in people with borderline personality disorder</TI>
<SO>www.clinicaltrials.gov/ct2/show/NCT00533117?term=00533117&amp;rank=1</SO>
<YR>(accessed 3 January 2011)</YR>
<IDENTIFIERS MODIFIED="2011-01-03 09:50:13 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283615"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283614"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00603421" MODIFIED="2012-06-02 14:55:59 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00603421" YEAR="3421">
<REFERENCE MODIFIED="2011-08-09 10:53:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00603421</AU>
<TI>Effectiveness of a 24 hour phone line on the rate of suicide attempts in borderline patients</TI>
<SO>http://clinicaltrials.gov/show/NCT00603421</SO>
<YR>(accessed 09 August 2011)</YR>
<IDENTIFIERS MODIFIED="2011-08-09 10:52:26 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283617"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-02 14:55:59 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;INCLUDE (IF 'CRISIS HOTLINE' MEETS INCLUSION CRITERIA FOR PSYCHOLOGICAL INTERVENTION)&lt;br&gt;Document Type: French&lt;/p&gt;" NOTES_MODIFIED="2012-06-02 14:55:59 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pham-Scottez A</AU>
<TI>Impact of a 24/24 phone permanency on suicide attempts of borderline patients</TI>
<SO>Annales Medico-Psychologiques</SO>
<YR>2010</YR>
<VL>168</VL>
<NO>2</NO>
<PG>141-3</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283618"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283616"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00834834" MODIFIED="2012-06-07 16:05:28 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00834834" YEAR="4834">
<REFERENCE MODIFIED="2012-06-07 16:05:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00834834</AU>
<TI>Comparing treatments for self-injury and suicidal behavior in people with borderline personality disorder</TI>
<SO>www.clinicaltrials.gov/ct2/show/NCT00834834?term=00834834&amp;rank=1</SO>
<YR>(accessed 3 January 2011)</YR>
<IDENTIFIERS MODIFIED="2011-01-03 09:56:58 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283620"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283619"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00980824" MODIFIED="2012-06-07 16:06:27 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00980824" YEAR="0824">
<REFERENCE MODIFIED="2012-06-07 16:06:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00980824</AU>
<TI>ENGAGE - Meeting mental health needs of complex comorbid patients attending A&amp;E following a suicide attempt. A pilot study</TI>
<SO>www.clinicaltrials.gov/ct2/show/NCT00980824?term=00980824&amp;rank=1</SO>
<YR>(accessed 8 December 2010)</YR>
<IDENTIFIERS MODIFIED="2010-12-08 16:44:12 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283622"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283621"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01033708" MODIFIED="2012-06-07 16:06:38 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01033708" YEAR="3708">
<REFERENCE MODIFIED="2012-06-07 16:06:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01033708</AU>
<TI>A randomized control trial of narrative exposure therapy versus treatment as usual in the therapy of borderline personality disorder (NET)</TI>
<SO>www.clinicaltrials.gov/show/NCT01033708</SO>
<YR>(accessed 9 August 2011)</YR>
<IDENTIFIERS MODIFIED="2011-01-03 09:38:01 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283624"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283623"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01081314" MODIFIED="2012-06-07 16:07:00 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01081314" YEAR="1314">
<REFERENCE MODIFIED="2012-06-07 16:07:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01081314</AU>
<TI>Treating PTSD in patients with borderline personality disorder</TI>
<SO>www.clinicaltrials.gov/ct2/show/NCT01081314?term=01081314&amp;rank=1</SO>
<YR>(accessed 9 December 2010)</YR>
<IDENTIFIERS MODIFIED="2010-12-09 10:11:35 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283626"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283625"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01132976" MODIFIED="2012-06-07 16:07:23 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01132976" YEAR="2976">
<REFERENCE MODIFIED="2012-06-07 16:07:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01132976</AU>
<TI>The personal concerns inventory study (PCI)</TI>
<SO>http://clinicaltrials.gov/show/NCT01132976</SO>
<YR>(accessed 9 August 2011)</YR>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283628"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283627"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01193205" MODIFIED="2012-06-07 16:07:51 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01193205" YEAR="3205">
<REFERENCE MODIFIED="2012-06-07 16:07:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01193205</AU>
<TI>Evaluating the effectiveness of dialectical behaviour skills training for suicidality in borderline personality disorder</TI>
<SO>www.clinicaltrials.gov/ct2/show/NCT01193205?term=01193205&amp;rank=1</SO>
<YR>(accessed 9 December 2010)</YR>
<IDENTIFIERS MODIFIED="2010-12-09 10:42:23 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283630"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283629"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NTR1186" MODIFIED="2012-06-26 15:04:53 +0100" MODIFIED_BY="[Empty name]" NAME="NTR1186" YEAR="1186">
<REFERENCE MODIFIED="2012-06-26 15:04:53 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;INCLUDE / ONGOING?&lt;br&gt;ProCite field [3]: (Bernstein, Arntz) Clinical Psychological Science, Maastricht University, Maastricht, Netherlands (Bernstein) Forensic Psychiatric Center de Rooyse Wissel, Venray, Netherlands&lt;/p&gt;" NOTES_MODIFIED="2012-06-26 15:04:53 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bernstein D, Arntz A</AU>
<TI>Schema focused therapy for forensic patients with personality disorders: new research findings</TI>
<SO>New Diagnostic Approaches in psychiatry: Relevance for Research and Practice in Europe. Proceedings of the 17th European Congress of Psychiatry of the European Psychiatric Association; January 2009</SO>
<YR>2009</YR>
<PG>38</PG>
<PB>European Psychiatric Association</PB>
<CY>Lisbon, Portugal</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283632"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 16:11:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NTR1186</AU>
<TI>Efficacy of schema-focused therapy versus usual treatment in forensic patients with personality disorder: a three-year randomized clinical trial</TI>
<SO>www.trialregister.nl/trialreg/admin/rctview.asp?TC=1186</SO>
<YR>(accessed 3 January 2011)</YR>
<IDENTIFIERS MODIFIED="2011-01-03 09:58:31 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283633"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283631"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NTR2175" MODIFIED="2012-06-07 16:11:52 +0100" MODIFIED_BY="[Empty name]" NAME="NTR2175" YEAR="2175">
<REFERENCE MODIFIED="2012-06-07 16:11:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NTR2175</AU>
<TI>Mentalisation-based treatment versus care-as-usual in the treatment of severe borderline personality disorders</TI>
<SO>www.trialregister.nl/trialreg/admin/rctview.asp?TC=2175</SO>
<YR>(accessed 9 December 2010)</YR>
<IDENTIFIERS MODIFIED="2010-12-09 09:15:06 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283635"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283634"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NTR2292" MODIFIED="2012-06-07 16:12:56 +0100" MODIFIED_BY="[Empty name]" NAME="NTR2292" YEAR="2292">
<REFERENCE MODIFIED="2012-06-07 16:12:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NTR2292</AU>
<TI>Intensive outpatient mentalisation-based treatment versus day hospital mentalisation-based treatment: a randomised controlled trial</TI>
<SO>http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=2292</SO>
<YR>(accessed 9 August 2011)</YR>
<IDENTIFIERS MODIFIED="2011-08-09 12:33:35 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283637"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283636"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NTR2392" MODIFIED="2012-06-07 16:13:50 +0100" MODIFIED_BY="[Empty name]" NAME="NTR2392" YEAR="2392">
<REFERENCE MODIFIED="2012-06-07 16:13:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ACTRN1261100015965</AU>
<TI>Group Schema Therapy for Borderline Personality Disorder. International multi-site RCT of two versions of Group Schema Therapy compared to treatment as usual for Borderline Personality Disorder in reducing symptom severity and improving quality of life</TI>
<SO>http://www.anzctr.org.au/ACTRN12611000158965.aspx</SO>
<YR>(accessed 9 August 2011)</YR>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283639"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 16:13:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NTR2392</AU>
<TI>Group schema therapy for borderline personality disorder</TI>
<SO>www.trialregister.nl/trialreg/admin/rctview.asp?TC=2392</SO>
<YR>(accessed 9 December 2010)</YR>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3283640"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3283638"/></IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2017-06-30 15:48:26 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2017-06-30 15:48:26 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Ansell-2007" MODIFIED="2012-06-02 14:56:59 +0100" MODIFIED_BY="[Empty name]" NAME="Ansell 2007" TYPE="JOURNAL_ARTICLE">
<AU>Ansell EB, Sanislow CA, McGlashan TH, Grilo CM</AU>
<TI>Psychosocial impairment and treatment utilization by patients with borderline personality disorder, other personality disorders, mood and anxiety disorders, and a healthy comparison group</TI>
<SO>Comprehensive Psychiatry</SO>
<YR>2007</YR>
<VL>48</VL>
<PG>329-36</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-APA-1980" MODIFIED="2012-06-07 16:15:06 +0100" MODIFIED_BY="[Empty name]" NAME="APA 1980" TYPE="BOOK">
<AU>American Psychiatric Asssociation</AU>
<SO>Diagnostic and Statistical Manual of Mental Disorders (DSM-III)</SO>
<YR>1980</YR>
<EN>3rd</EN>
<PB>American Psychiatric Association</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-APA-1987" MODIFIED="2012-06-07 16:15:33 +0100" MODIFIED_BY="[Empty name]" NAME="APA 1987" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R)</SO>
<YR>1987</YR>
<EN>3rd</EN>
<PB>American Psychiatric Association</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-APA-2000" MODIFIED="2012-06-07 16:16:16 +0100" MODIFIED_BY="[Empty name]" NAME="APA 2000" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR)</SO>
<YR>2000</YR>
<EN>4th</EN>
<PB>American Psychiatric Association</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-APA-2001" MODIFIED="2010-11-24 15:41:50 +0000" MODIFIED_BY="[Empty name]" NAME="APA 2001" TYPE="JOURNAL_ARTICLE">
<AU>American Psychiatric Association</AU>
<TI>Practice guideline for the treatment of patients with borderline personality disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2001</YR>
<VL>158</VL>
<NO>suppl. 2-2</NO>
<PG>1-52</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Arntz-2003" MODIFIED="2012-06-02 14:58:53 +0100" MODIFIED_BY="[Empty name]" NAME="Arntz 2003" TYPE="JOURNAL_ARTICLE">
<AU>Arntz A, Van den Hoorn M, Cornelis J, Verheul R, Van den Bosch W, De Bie AJHT</AU>
<TI>Reliability and validity of the Borderline Personality Disorder Severity Index</TI>
<SO>Journal of Personality Disorders</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>1</NO>
<PG>45-59</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Bateman-2004" MODIFIED="2012-06-07 16:18:57 +0100" MODIFIED_BY="[Empty name]" NAME="Bateman 2004" TYPE="BOOK">
<AU>Bateman A, Fonagy P</AU>
<SO>Psychotherapy for Borderline Personality Disorder: Mentalisation Based Treatment</SO>
<YR>2004</YR>
<PB>Oxford University Press</PB>
<CY>Oxford, UK</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Bateman-2006" MODIFIED="2012-06-07 16:19:05 +0100" MODIFIED_BY="[Empty name]" NAME="Bateman 2006" TYPE="BOOK">
<AU>Bateman A, Fonagy P</AU>
<SO>Mentalization Based Treatment: a Practical Guide</SO>
<YR>2006</YR>
<PB>Oxford University Press</PB>
<CY>Oxford, UK</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Bateman-2010" MODIFIED="2012-06-07 16:19:29 +0100" MODIFIED_BY="[Empty name]" NAME="Bateman 2010" TYPE="CORRESPONDENCE">
<AU>Bateman A</AU>
<TI>Important: Question regarding your BPD trial for systematic review in Cochrane Collaboration [personal communication]</TI>
<SO>Email to: K Lieb, J Stoffers</SO>
<YR>14 December 2010</YR>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Beck-1979" MODIFIED="2012-06-07 16:19:41 +0100" MODIFIED_BY="[Empty name]" NAME="Beck 1979" TYPE="BOOK">
<AU>Beck AT, Rush AJ, Schaw BF, Emery G</AU>
<SO>Cognitive Therapy of Depression</SO>
<YR>1979</YR>
<PB>The Guilford Press</PB>
<CY>New York</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Beck-1990" MODIFIED="2012-06-07 16:19:51 +0100" MODIFIED_BY="[Empty name]" NAME="Beck 1990" TYPE="BOOK">
<AU>Beck AT, Freeman A</AU>
<SO>Cognitive Therapy of Personality Disorders</SO>
<YR>1990</YR>
<PB>Guilford Press</PB>
<CY>New York</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Beck-1995" MODIFIED="2012-06-07 16:20:00 +0100" MODIFIED_BY="[Empty name]" NAME="Beck 1995" TYPE="BOOK">
<AU>Beck JS</AU>
<SO>Cognitive Therapy: Basics and Beyond</SO>
<YR>1995</YR>
<PB>The Guilford Press</PB>
<CY>New York</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Bellino-2010a-_x005b_pers-comm_x005d_" MODIFIED="2012-06-07 16:22:34 +0100" MODIFIED_BY="[Empty name]" NAME="Bellino 2010a [pers comm]" TYPE="CORRESPONDENCE">
<AU>Bellino S</AU>
<TI>Question regarding your BPD trials [personal communication]</TI>
<SO>Email to: J Stoffers.</SO>
<YR>16 December 2010</YR>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Berk-2009" MODIFIED="2012-07-11 09:45:08 +0100" MODIFIED_BY="[Empty name]" NAME="Berk 2009" TYPE="JOURNAL_ARTICLE">
<AU>Berk M, Parker G</AU>
<TI>The elefant on the couch: side-effects of psychotherapy</TI>
<SO>Australian and New Zealand Journal of Psychiatry</SO>
<YR>2009</YR>
<VL>43</VL>
<PG>787-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bohus-2004" MODIFIED="2017-04-06 17:08:15 +0100" MODIFIED_BY="[Empty name]" NAME="Bohus 2004" TYPE="JOURNAL_ARTICLE">
<AU>Bohus M, Haaf B, Simms T, Limberger MF, Schmal C, Unckel C, et al</AU>
<TI>Effectiveness of inpatient dialectical behavioral therapy for borderline personality disorder: a controlled trial</TI>
<SO>Behaviour Research and Therapy</SO>
<YR>2004</YR>
<VL>42</VL>
<NO>5</NO>
<PG>487-99</PG>
<IDENTIFIERS MODIFIED="2017-04-06 17:08:05 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-04-06 17:07:59 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/S0005-7967(03)00174-8"/><IDENTIFIER MODIFIED="2017-04-06 17:08:05 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15033496"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Boutron-2008" MODIFIED="2012-06-07 16:20:36 +0100" MODIFIED_BY="[Empty name]" NAME="Boutron 2008" TYPE="JOURNAL_ARTICLE">
<AU>Boutron I, Moher D, Altman DG, Schulz K, Ravaud P, the CONSORT group</AU>
<TI>Extending the CONSORT Statement to randomised trials of nonpharmacologic treatment: explanation and elaboration</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2008</YR>
<VL>148</VL>
<PG>295-309</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Carkhuff-1969" MODIFIED="2012-06-07 16:20:50 +0100" MODIFIED_BY="[Empty name]" NAME="Carkhuff 1969" TYPE="BOOK">
<AU>Carkhuff RR</AU>
<SO>Helping and Human Relations</SO>
<YR>1969</YR>
<PB>Holt, Rinehart &amp; Winston</PB>
<CY>New York</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Carkhuff-1976" MODIFIED="2012-06-07 16:21:08 +0100" MODIFIED_BY="[Empty name]" NAME="Carkhuff 1976" TYPE="BOOK">
<AU>Carkhuff RR, Pierce R, Cannon J</AU>
<SO>The Art of Helping</SO>
<YR>1976</YR>
<PB>Human Resources Press</PB>
<CY>Amherst, MA</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Carter-2010a-_x005b_pers-comm_x005d_" MODIFIED="2012-06-07 16:23:04 +0100" MODIFIED_BY="[Empty name]" NAME="Carter 2010a [pers comm]" TYPE="CORRESPONDENCE">
<AU>Carter G</AU>
<TI>Question regarding your BPD trial [personal communication]</TI>
<SO>Email to: J Stoffers.</SO>
<YR>21 December 2010</YR>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Chalmers-1983" MODIFIED="2010-10-20 16:04:21 +0100" MODIFIED_BY="[Empty name]" NAME="Chalmers 1983" TYPE="JOURNAL_ARTICLE">
<AU>Chalmers TC, Celano P, Sacks HS, Smith H Jr</AU>
<TI>Bias in treatment assignment in controlled clinical trials</TI>
<SO>New England Journal of Medicine</SO>
<YR>1983</YR>
<VL>309</VL>
<PG>1358-61</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Chinn-2000" MODIFIED="2011-11-03 10:11:18 +0000" MODIFIED_BY="[Empty name]" NAME="Chinn 2000" TYPE="JOURNAL_ARTICLE">
<AU>Chinn S</AU>
<TI>A simple method for converting an odds ratio to effect size for use in meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2000</YR>
<VL>19</VL>
<PG>3127-31</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Clarkin-1999" MODIFIED="2012-06-02 15:03:47 +0100" MODIFIED_BY="[Empty name]" NAME="Clarkin 1999" TYPE="BOOK">
<AU>Clarkin JF, Yeomans FE, Kernberg OF</AU>
<SO>Psychotherapy for Borderline Personality</SO>
<YR>1999</YR>
<PB>J. Wiley &amp; Sons</PB>
<CY>New York (NY)</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Cohen-1988" MODIFIED="2012-06-13 14:00:51 +0100" MODIFIED_BY="[Empty name]" NAME="Cohen 1988" TYPE="BOOK">
<AU>Cohen J</AU>
<SO>Statistical Power Analysis in the Behavioural Sciences</SO>
<YR>1988</YR>
<EN>2nd</EN>
<PB>Lawrence Erlbaum Associates</PB>
<CY>Hillsdale (NJ)</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Conte-1980" MODIFIED="2010-06-01 15:51:09 +0100" MODIFIED_BY="[Empty name]" NAME="Conte 1980" TYPE="JOURNAL_ARTICLE">
<AU>Conte HR, Plutchik R, Karasu TB, Jerrett I</AU>
<TI>A self-report borderline scale. Discriminative validity and preliminary norms</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1980</YR>
<VL>100</VL>
<PG>428-35</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Davidson-2000" MODIFIED="2012-06-02 15:04:29 +0100" MODIFIED_BY="[Empty name]" NAME="Davidson 2000" TYPE="BOOK">
<AU>Davidson KM</AU>
<SO>Cognitive Therapy for Personality Disorders: a Guide for Clinicans</SO>
<YR>2000</YR>
<PB>Butterworth Heinemann Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Davidson-2006a" MODIFIED="2011-08-22 21:59:13 +0100" MODIFIED_BY="[Empty name]" NAME="Davidson 2006a" TYPE="JOURNAL_ARTICLE">
<AU>Davidson K, Tyrer P, Gumley A, Tata P, Norrie J, Palmer S, et al</AU>
<TI>A randomized controlled trial of cognitive behavior therapy for borderline personality disorder: rationale for trial, method, and description of sample</TI>
<SO>Journal of Personality Disorders</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>5</NO>
<PG>431-49</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-DBT-working-group-at-CIMH" MODIFIED="2010-11-02 15:17:44 +0000" MODIFIED_BY="[Empty name]" NAME="DBT working group at CIMH" TYPE="UNPUBLISHED">
<AU>DBT working group at the Central Institute for Mental Health, Mannheim, Germany</AU>
<TI>Requested supplementary data (as supplied 1 October 2010)</TI>
<SO>Data on file</SO>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-De-Groot-2008" MODIFIED="2012-06-02 15:04:59 +0100" MODIFIED_BY="[Empty name]" NAME="De Groot 2008" TYPE="JOURNAL_ARTICLE">
<AU>De Groot ER, Verheul R, Trijsburg RW</AU>
<TI>An integrative perspective on psychotherapeutic treatments for borderline personality disorders</TI>
<SO>Journal of Personality Disorders</SO>
<YR>2008</YR>
<VL>22</VL>
<NO>4</NO>
<PG>332-52</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Distel-2011" MODIFIED="2012-06-02 15:06:10 +0100" MODIFIED_BY="[Empty name]" NAME="Distel 2011" TYPE="JOURNAL_ARTICLE">
<AU>Distel MA, Carlier A, Middeldorp CM, Derom CA, Lubke GH, Boomsma DI</AU>
<TI>Borderline personality traits and adult attention-deficit hyperactivity disorder symptoms: a genetic analysis of comorbidity</TI>
<SO>American Journal of Medical Genetics Part B</SO>
<YR>2011</YR>
<VL>156</VL>
<PG>817-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donner-1980" MODIFIED="2011-11-02 11:02:45 +0000" MODIFIED_BY="[Empty name]" NAME="Donner 1980" TYPE="JOURNAL_ARTICLE">
<AU>Donner A, Koval JJ</AU>
<TI>The estimation of intraclass correlation in the analysis of family data</TI>
<SO>Biometrics</SO>
<YR>1980</YR>
<VL>36</VL>
<NO>1</NO>
<PG>19-25</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2012-06-02 15:06:35 +0100" MODIFIED_BY="[Empty name]" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vaillancourt JM</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<PG>140-9</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Endicott-1976" MODIFIED="2012-06-02 15:06:46 +0100" MODIFIED_BY="[Empty name]" NAME="Endicott 1976" TYPE="JOURNAL_ARTICLE">
<AU>Endicott J, Spitzer RL, Fleiss JL, Cohen J</AU>
<TI>The Global Assessment Scale: A procedure for measuring overall severity of psychiatric disturbance</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1976</YR>
<VL>33</VL>
<PG>766-71</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-ESSPD-2010" MODIFIED="2012-07-04 13:58:48 +0100" MODIFIED_BY="[Empty name]" NAME="ESSPD 2010" TYPE="CONFERENCE_PROC">
<AU>ESSPD 2010</AU>
<SO>Proceedings of the 1st International Congress on Borderline Personality Disorder; 1-3 July 2010, Berlin, Germany</SO>
<YR>2011</YR>
<PB>European Society for the Study of Personality Disorders</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Farrell-1994" MODIFIED="2010-08-04 13:21:05 +0100" MODIFIED_BY="[Empty name]" NAME="Farrell 1994" TYPE="JOURNAL_ARTICLE">
<AU>Farrell JM, Shaw IA</AU>
<TI>Emotional awareness training: a prerequisite to effective cognitive-behavioral treatment of borderline personality disorder</TI>
<SO>Cognitive and Behavioral Practice</SO>
<YR>1994</YR>
<VL>1</VL>
<PG>71-91</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Ferrer-2010" MODIFIED="2012-06-02 15:34:06 +0100" MODIFIED_BY="[Empty name]" NAME="Ferrer 2010" TYPE="JOURNAL_ARTICLE">
<AU>Ferrer M, Andión Ó, Matalí J, Valero S, Navarro JA, Ramos-Quiroga JA, et al</AU>
<TI>Comorbid attention-deficit/hyperactivity disorder in borderline patients defines an impulsive subtype of borderline personality disorder</TI>
<SO>Journal of Personality Disorders</SO>
<YR>2010</YR>
<VL>24</VL>
<NO>6</NO>
<PG>812-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-First-1997" MODIFIED="2010-06-01 12:44:06 +0100" MODIFIED_BY="[Empty name]" NAME="First 1997" TYPE="BOOK">
<AU>First MB, Spitzer RL, Gibbon M, Williams JB, Benjamin LS</AU>
<SO>Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II)</SO>
<YR>1997</YR>
<PB>American Psychiatric Press</PB>
<CY>Washington (DC)</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Greenberg-2002" MODIFIED="2012-06-02 15:08:38 +0100" MODIFIED_BY="[Empty name]" NAME="Greenberg 2002" TYPE="BOOK">
<AU>Greenberg LS</AU>
<SO>Emotion-focused Therapy: Coaching Clients to Work Through Their Feelings</SO>
<YR>2002</YR>
<PB>American Psychiatric Press</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Gregory-2008a" MODIFIED="2011-08-22 21:46:09 +0100" MODIFIED_BY="[Empty name]" NAME="Gregory 2008a" TYPE="JOURNAL_ARTICLE">
<AU>Gregory RJ, Remen AL</AU>
<TI>A manual-based psychodynamic therapy for treatment-resistant borderline personality disorder</TI>
<SO>Psychotherapy: theory, research, practice, training</SO>
<YR>2008</YR>
<VL>45</VL>
<PG>15-27</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Gregory-2010" MODIFIED="2010-08-11 14:22:12 +0100" MODIFIED_BY="[Empty name]" NAME="Gregory 2010" TYPE="OTHER">
<AU>Gregory RJ</AU>
<TI>Remediation for treatment-resistant borderline personality disorder: manual of dynamic deconstructive psychotherapy (c)</TI>
<SO>http://www.upstate.edu/psych/education/psychotherapy/pdf/ddp_manual.pdf</SO>
<YR>(accessed 19 February 2010)</YR>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Gregory-2017" MODIFIED="2017-04-06 17:47:10 +0100" MODIFIED_BY="[Empty name]" NAME="Gregory 2017" TYPE="CORRESPONDENCE">
<AU>Gregory RJ</AU>
<TI>Comment to 'Psychological therapies for people with borderline personality disorder'</TI>
<SO>Received via the Cochrane Feedback mechanism</SO>
<YR>14 February 2017</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gunderson-1981" MODIFIED="2012-06-02 15:09:16 +0100" MODIFIED_BY="[Empty name]" NAME="Gunderson 1981" TYPE="JOURNAL_ARTICLE">
<AU>Gunderson JG, Kolb JE, Austin V</AU>
<TI>The diagnositc interview for borderlines</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1981</YR>
<VL>138</VL>
<PG>896-903</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" MODIFIED="2011-08-22 21:47:32 +0100" MODIFIED_BY="[Empty name]" NAME="Guy 1976" TYPE="BOOK_SECTION">
<AU>Guy W</AU>
<TI>Assessment manual for psychopharmacology-revised</TI>
<SO>DHEW Publ No ADM 76-338</SO>
<YR>1976</YR>
<PG>218-222</PG>
<PB>Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs</PB>
<CY>Rockville, MD</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Hayes-1999" MODIFIED="2012-06-02 15:09:58 +0100" MODIFIED_BY="[Empty name]" NAME="Hayes 1999" TYPE="BOOK">
<AU>Hayes SC, Strosahl KD, Wilson KG</AU>
<SO>Acceptance and Commitment Therapy: an Experiential Approach to Behavior Change</SO>
<YR>1999</YR>
<PB>Guilford Press</PB>
<CY>New York</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-06-13 14:00:57 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<ED>Higgins JPT, Green S</ED>
<PB>John Wiley &amp; Sons</PB>
<CY>Chichester (UK)</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011a" MODIFIED="2012-06-13 13:57:26 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011a" TYPE="OTHER">
<AU>Higgins JPT, Deeks JJ, Altman DG (editors)</AU>
<TI>Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<ED>Higgins JPT, Green S</ED>
<PB>John Wiley &amp; Sons</PB>
<CY>Chichester (UK)</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011b" MODIFIED="2012-06-13 13:58:02 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011b" TYPE="OTHER">
<AU>Higgins JPT, Deeks JJ (editors)</AU>
<TI>Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<ED>Higgins JPT, Green S</ED>
<PB>John Wiley &amp; Sons</PB>
<CY>Chichester (UK)</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011c" MODIFIED="2012-06-13 13:58:40 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011c" TYPE="OTHER">
<AU>Deeks JJ, Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analysis. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<ED>Higgins JPT, Green S</ED>
<PB>John Wiley &amp; Sons</PB>
<CY>Chichester (UK)</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2017-_x005b_pers-comm_x005d_" MODIFIED="2017-06-30 15:48:26 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2017 [pers comm]" TYPE="CORRESPONDENCE">
<AU>Higgins JPT</AU>
<TI>Seeking advice on comments rec'd through Feedback system [personal communication]</TI>
<SO>Email to: J Dennis</SO>
<YR>27 February 2017</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-H_x00f6_rz-2010" MODIFIED="2012-06-02 15:10:24 +0100" MODIFIED_BY="[Empty name]" NAME="Hörz 2010" TYPE="JOURNAL_ARTICLE">
<AU>Hörz S, Zanarini MC, Frankenburg FR, Reich DB, Fitzmaurice G</AU>
<TI>Ten-year use of mental health services by patients with borderline personality disorder and with other axis II disorders</TI>
<SO>Psychiatric Services</SO>
<YR>2010</YR>
<VL>61</VL>
<PG>612-6</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-ISSPD-2007" MODIFIED="2012-07-04 16:12:07 +0100" MODIFIED_BY="[Empty name]" NAME="ISSPD 2007" TYPE="CONFERENCE_PROC">
<SO>Proceedings of the Xth International Congress of the International Society for the Study of Personality Disorders (ISSPD); 22-29 Sept 2007; The Hague, The Netherlands</SO>
<PB>International Society for the Study of Personality Disorders</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ISSPD-2009" MODIFIED="2012-07-04 16:11:40 +0100" MODIFIED_BY="[Empty name]" NAME="ISSPD 2009" TYPE="CONFERENCE_PROC">
<SO>Proceedings of the XIth International Congress of the International Society for the Study of Personality Disorders (ISSPD); Aug 21-23 2009; New York, NY</SO>
<PB>International Society for the Study of Personality Disorders</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ISSPD-2011" MODIFIED="2012-07-04 16:12:28 +0100" MODIFIED_BY="[Empty name]" NAME="ISSPD 2011" TYPE="CONFERENCE_PROC">
<SO>Proceedings of the XIIth International Congress of the International Society for the Study of Personality Disorders (ISSPD); 1-4 Mar 2011; Melbourne, Australia</SO>
<PB>International Society for the Study of Personality Disorders</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jakobsen-2014" MODIFIED="2016-01-28 14:49:28 +0000" MODIFIED_BY="[Empty name]" NAME="Jakobsen 2014" TYPE="JOURNAL_ARTICLE">
<AU>Jakobsen JC, Gluud C, Kongerslev M, Larsen KA, Sørensen P, Winkel P, et al</AU>
<TI>Third-wave cognitive therapy versus mentalisation-based treatment for major depressive disorder: a randomised clinical trial</TI>
<SO>BMJ Open</SO>
<YR>2014</YR>
<VL>4</VL>
<NO>8</NO>
<PG>e004903</PG>
<IDENTIFIERS MODIFIED="2016-01-28 14:49:17 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-01-28 14:49:17 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1136/bmjopen-2014-004903"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Klerman-1984" MODIFIED="2012-06-02 15:10:46 +0100" MODIFIED_BY="[Empty name]" NAME="Klerman 1984" TYPE="BOOK">
<AU>Klerman GL, Weissman MM, Rounsaville BJ, Chevron ES</AU>
<SO>Interpersonal Psychotherapy of Depression</SO>
<YR>1984</YR>
<PB>Basic Books</PB>
<CY>New York (NY)</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Layden-1993" MODIFIED="2012-06-02 15:11:11 +0100" MODIFIED_BY="[Empty name]" NAME="Layden 1993" TYPE="BOOK">
<AU>Layden MA, Newman CF, Freeman A, Morse SB</AU>
<SO>Cognitive Therapy of Borderline Personality Disorder</SO>
<YR>1993</YR>
<PB>Allyn &amp; Bacon</PB>
<CY>Boston</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Leykin-2009" MODIFIED="2010-11-15 10:55:58 +0000" MODIFIED_BY="[Empty name]" NAME="Leykin 2009" TYPE="JOURNAL_ARTICLE">
<AU>Leykin Y, DeRubeis RJ</AU>
<TI>Allegiance in psychotherapy outcome research: separating association from bias</TI>
<SO>Clinical Psychology in Science and Practice</SO>
<YR>2009</YR>
<VL>16</VL>
<PG>54-65</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Lieb-2010" MODIFIED="2010-11-24 16:07:23 +0000" MODIFIED_BY="[Empty name]" NAME="Lieb 2010" TYPE="JOURNAL_ARTICLE">
<AU>Lieb K, Völlm BA, Rücker G, Timmer A, Stoffers JM</AU>
<TI>Cochrane systematic review of randomised trials</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2010</YR>
<VL>196</VL>
<PG>4-12</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Linehan-1993a" MODIFIED="2012-06-02 15:11:56 +0100" MODIFIED_BY="[Empty name]" NAME="Linehan 1993a" TYPE="BOOK">
<AU>Linehan MM</AU>
<SO>Cognitive Behavioral Treatment of Borderline Personality Disorder</SO>
<YR>1993</YR>
<PB>Guilford</PB>
<CY>New York</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Linehan-1993b" MODIFIED="2012-06-02 15:12:31 +0100" MODIFIED_BY="[Empty name]" NAME="Linehan 1993b" TYPE="BOOK">
<AU>Linehan MM</AU>
<SO>The Skills Training Manual for Treating Borderline Personality Disorder</SO>
<YR>1993</YR>
<PB>Guilford</PB>
<CY>New York</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Linehan-2008" MODIFIED="2012-06-02 15:14:51 +0100" MODIFIED_BY="[Empty name]" NAME="Linehan 2008" TYPE="JOURNAL_ARTICLE">
<AU>Linehan MM, McDavid JD, Brown MZ, Syrs JHR, Gallop RJ</AU>
<TI>Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2008</YR>
<VL>69</VL>
<NO>9</NO>
<PG>999-1005</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Livesley-2007" MODIFIED="2012-06-02 15:16:24 +0100" MODIFIED_BY="[Empty name]" NAME="Livesley 2007" TYPE="JOURNAL_ARTICLE">
<AU>Livesley WJ</AU>
<TI>An integrated approach to the treatment of personality disorder</TI>
<SO>Journal of Mental Health</SO>
<YR>2007</YR>
<VL>16</VL>
<NO>1</NO>
<PG>131-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Livesley-2012" MODIFIED="2012-06-02 15:17:26 +0100" MODIFIED_BY="[Empty name]" NAME="Livesley 2012" TYPE="JOURNAL_ARTICLE">
<AU>Livesley WJ</AU>
<TI>Integrated treatment: a conceptual framework for an evidence-based approach to the treatment of personality disorder</TI>
<SO>Journal of Personality Disorder</SO>
<YR>2012</YR>
<VL>26</VL>
<NO>1</NO>
<PG>17-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Loranger-1988" MODIFIED="2012-06-02 15:18:13 +0100" MODIFIED_BY="[Empty name]" NAME="Loranger 1988" TYPE="BOOK">
<AU>Loranger A</AU>
<SO>Personality Disorder Examination Manual</SO>
<YR>1988</YR>
<PB>D. V. Communications</PB>
<CY>Yonkers, NY</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Loranger-1995" MODIFIED="2010-06-01 13:31:23 +0100" MODIFIED_BY="[Empty name]" NAME="Loranger 1995" TYPE="BOOK">
<AU>Loranger AW</AU>
<SO>International Personality Disorder Examination (IPDE) manual</SO>
<YR>1995</YR>
<PB>Cornell Medical Center</PB>
<CY>White Plains (NY)</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Luborsky-1975" MODIFIED="2012-06-02 15:18:38 +0100" MODIFIED_BY="[Empty name]" NAME="Luborsky 1975" TYPE="JOURNAL_ARTICLE">
<AU>Luborsky L, Singer B, Luborsky L</AU>
<TI>Comparative studies of psychotherapies. Is it true that "everyone has won and all must have prizes"?</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1975</YR>
<VL>32</VL>
<PG>995-1008</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Markowitz-2005" MODIFIED="2012-06-02 15:18:58 +0100" MODIFIED_BY="[Empty name]" NAME="Markowitz 2005" TYPE="BOOK_SECTION">
<AU>Markowitz JC</AU>
<TI>Interpersonal therapy of personality disorders</TI>
<SO>Textbook of Personality Disorders</SO>
<YR>2005</YR>
<PG>321-34</PG>
<ED>Oldham JM, Skodol AE, Bender BS</ED>
<PB>American Psychiatric Press</PB>
<CY>Washington (DC)</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Markowitz-2006" MODIFIED="2010-08-03 15:11:16 +0100" MODIFIED_BY="[Empty name]" NAME="Markowitz 2006" TYPE="JOURNAL_ARTICLE">
<AU>Markowitz JC, Skodol AE, Bleiberg K</AU>
<TI>Intersonal psychotherapy for borderline personality disorder: possible mechanisms of change</TI>
<SO>Journal of Clinical Psychology</SO>
<YR>2006</YR>
<VL>62</VL>
<NO>4</NO>
<PG>431-44</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Nadort-2009b" MODIFIED="2012-06-02 15:19:24 +0100" MODIFIED_BY="[Empty name]" NAME="Nadort 2009b" TYPE="JOURNAL_ARTICLE">
<AU>Nadort M, Arntz A, Smit JH, Giesen-Bloo J, Eikelenboom M, Spinhoven P, et al</AU>
<TI>Implementation of outpatient schema therapy for borderline personality disorder: study design</TI>
<SO>BMC Psychiatry</SO>
<YR>2009</YR>
<VL>9</VL>
<PG>64</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2009" MODIFIED="2010-11-24 16:33:29 +0000" MODIFIED_BY="[Empty name]" NAME="NICE 2009" TYPE="BOOK">
<AU>National Collaborating Centre for Mental Health commissioned by theNational Institute for Health&amp; Clinical Excellence</AU>
<SO>Borderline personality disorder. The NICE guideline on treatment and management</SO>
<YR>2009</YR>
<PB>The British Psychological Society and The Royal College of Psychiatrists</PB>
<CY>London, UK</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-NLM-2009" MODIFIED="2009-03-31 13:22:38 +0100" MODIFIED_BY="[Empty name]" NAME="NLM 2009" TYPE="OTHER">
<TI>United States National Library of Medicine (NLM)</TI>
<TO>Medical Subject Headings (MeSH Browser)</TO>
<SO>www.nlm.nih.gov/mesh/2009/mesh_browser/MBrowser.html</SO>
<YR>(accessed 31 March 2009)</YR>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Oldham-2005" MODIFIED="2010-11-24 15:45:02 +0000" MODIFIED_BY="[Empty name]" NAME="Oldham 2005" TYPE="OTHER">
<AU>Oldham JM</AU>
<TI>Guideline watch: practice guideline for the treatment of patients with borderline personality disorder</TI>
<SO>American Psychiatric Association. Available at: www.psych.org</SO>
<YR>2005</YR>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Perez-2007" MODIFIED="2012-06-02 15:19:55 +0100" MODIFIED_BY="[Empty name]" NAME="Perez 2007" TYPE="JOURNAL_ARTICLE">
<AU>Perez V, Barrachina J, Soler J, Pascual JC, Campins MJ, Puigdemont D, et al</AU>
<TI>The clinical global impression scale for borderline personality disorder patients (CGI-BPD): a scale sensible to detect changes</TI>
<TO>Impresión clinica global para pacientes con trastorno límite de la personalidad (ICG-TLP): una escala sensible al cambio</TO>
<SO>Actas Espanolas de Psiquiatria</SO>
<YR>2007</YR>
<VL>35</VL>
<NO>4</NO>
<PG>229-35</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Pfohl-1997" MODIFIED="2012-06-02 15:20:10 +0100" MODIFIED_BY="[Empty name]" NAME="Pfohl 1997" TYPE="BOOK">
<AU>Pfohl B, Blum N, Zimmerman M</AU>
<SO>Structured Interview for DSM-IV Personality (SIPD-IV)</SO>
<YR>1997</YR>
<PB>American Psychiatric Publishing</PB>
<CY>Washington (DC)</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Philipsen-2008" MODIFIED="2012-06-02 15:21:06 +0100" MODIFIED_BY="[Empty name]" NAME="Philipsen 2008" TYPE="JOURNAL_ARTICLE">
<AU>Philipsen A, Limberger MF, Lieb K, Feige B, Kleindienst M, Ebner-Primer U, et al</AU>
<TI>Attention-deficit hyperactivity disorder as a potentially aggravating factor in borderline personality disorder</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2008</YR>
<VL>192</VL>
<PG>118-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-P_x00e9_rez-2007" MODIFIED="2012-06-02 15:21:29 +0100" MODIFIED_BY="[Empty name]" NAME="Pérez 2007" TYPE="JOURNAL_ARTICLE">
<AU>Pérez V, Barrachina J, Soler J, Pascual JC, Campins MJ, Puigdemont D, et al</AU>
<TI>The clinical global impression scale for borderline personality disorder patients (CGI-BPD): a scale sensible to detect changes</TI>
<SO>Actas Espanolas de Psiquiatria</SO>
<YR>2007</YR>
<VL>35</VL>
<PG>229-35</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Reiss-2014" MODIFIED="2015-07-24 09:31:12 +0100" MODIFIED_BY="[Empty name]" NAME="Reiss 2014" TYPE="JOURNAL_ARTICLE">
<AU>Reiss N, Lieb K, Arntz A, Shaw IA, Farrell J</AU>
<TI>Responding to the treatment challenge of patients with severe BPD: results of three pilot studies of inpatient schema therapy</TI>
<SO>Behavioural and Cognitive Psychotherapy</SO>
<YR>2014</YR>
<VL>42</VL>
<NO>3</NO>
<PG>355-67</PG>
<IDENTIFIERS MODIFIED="2015-07-24 09:31:12 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2015-07-24 09:31:12 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1017/S1352465813000027"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2012-05-25 15:47:48 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan) Version 5.1. Copenhagen: The Nordic Cochrane Centre</TI>
<YR>2011</YR>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rogers-1951" MODIFIED="2012-06-02 15:21:46 +0100" MODIFIED_BY="[Empty name]" NAME="Rogers 1951" TYPE="BOOK">
<AU>Rogers C</AU>
<SO>Client-centered Therapy</SO>
<YR>1951</YR>
<PB>Houghton Miflin</PB>
<CY>Boston (MA)</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Rush--2005" MODIFIED="2012-06-07 16:18:06 +0100" MODIFIED_BY="[Empty name]" NAME="Rush  2005" TYPE="BOOK">
<AU>Rush JA</AU>
<SO>Handbook of Psychiatric Measures</SO>
<YR>2005</YR>
<PB>American Psychiatric Association</PB>
<CY>Washington (DC)</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Schmidt-2004" MODIFIED="2012-06-02 15:22:49 +0100" MODIFIED_BY="[Empty name]" NAME="Schmidt 2004" TYPE="BOOK">
<AU>Schmidt U, Davidson K</AU>
<SO>Life After Self-harm: A Guide to the Future</SO>
<YR>2004</YR>
<PB>Brunner-Routledge</PB>
<CY>Hove, East Essex</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2011-08-22 21:59:49 +0100" MODIFIED_BY="[Empty name]" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-2004" MODIFIED="2012-06-02 15:25:08 +0100" MODIFIED_BY="[Empty name]" NAME="Simpson 2004" TYPE="JOURNAL_ARTICLE">
<AU>Simpson EB, Yen S, Costello E, Rosen K, Begin A, Pistorello J</AU>
<TI>Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>3</NO>
<PG>379-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Skodol-2009" MODIFIED="2012-06-02 15:25:53 +0100" MODIFIED_BY="[Empty name]" NAME="Skodol 2009" TYPE="BOOK_SECTION">
<AU>Skodol AE</AU>
<TI>Manifestations, clinical diagnosis, and comorbidity</TI>
<SO>Essentials of Personality Disorders</SO>
<YR>2009</YR>
<EN>37-61</EN>
<ED>1</ED>
<PB>Oldham JM, Skodol AE, Bender DS</PB>
<CY>American Psychiatric Publishing</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Soler-2005" MODIFIED="2012-06-02 15:26:36 +0100" MODIFIED_BY="[Empty name]" NAME="Soler 2005" TYPE="JOURNAL_ARTICLE">
<AU>Soler J Pascual JC, Campins J, Barrachina J, Puigdemont D, Alvarez E, et al</AU>
<TI>Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>162</VL>
<PG>1221-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spitzer-1985" MODIFIED="2010-06-01 12:50:57 +0100" MODIFIED_BY="[Empty name]" NAME="Spitzer 1985" TYPE="BOOK">
<AU>Spitzer RL, Williams JBW</AU>
<SO>Structured Clinical Interview for DSM-III-R Personality Disorders (SCID-II)</SO>
<YR>1985</YR>
<PB>New York State Psychiatric Institute, Biometrics Research</PB>
<CY>New York (NY)</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Steil-2010a" MODIFIED="2012-06-02 15:27:04 +0100" MODIFIED_BY="[Empty name]" NAME="Steil 2010a" TYPE="JOURNAL_ARTICLE">
<AU>Steil R, Krüger A, Dyer A, Priebe K, Feldmann Jr RE, Bohus M</AU>
<TI>Dialectical behaviour therapy for posttraumatic stress disorder and pervasisve emotional dysregulation in survivors of childhood sexual abuse</TI>
<TO>Dialektisch Behaviorale Therapie zur Behandlung der Posttraumatischen Belastungsstörung mit schwerer Störung der Emotionsregulation nach sexualisierter Gewalt in der Kindheit und Jugend</TO>
<SO>Trauma &amp; Gewalt: Forschung und Praxisfelder</SO>
<YR>2010</YR>
<VL>4</VL>
<NO>2</NO>
<PG>106-17</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Stoffers-2010" MODIFIED="2011-08-22 22:01:32 +0100" MODIFIED_BY="[Empty name]" NAME="Stoffers 2010" TYPE="COCHRANE_REVIEW">
<AU>Stoffers J, Völlm BA, Rücker G, Timmer A, Lieb K</AU>
<TI>Pharmacological interventions for borderline personality disorder</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>6</NO>
<IDENTIFIERS MODIFIED="2011-08-22 22:01:32 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2011-08-22 22:01:32 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005653.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Torgersen-2009" MODIFIED="2012-06-02 15:27:23 +0100" MODIFIED_BY="[Empty name]" NAME="Torgersen 2009" TYPE="BOOK_SECTION">
<AU>Torgersen S</AU>
<TI>Prevalence, sociodemographics, and functional impairment</TI>
<SO>Essentials of Personality Disorders</SO>
<YR>2009</YR>
<PG>83-101</PG>
<EN>1</EN>
<ED>Oldham JM, Skodol AE, Bender DS</ED>
<PB>American Psychiatric Publishing</PB>
<CY>Arlington, VA</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Tyrer-2005" MODIFIED="2012-06-02 15:27:44 +0100" MODIFIED_BY="[Empty name]" NAME="Tyrer 2005" TYPE="JOURNAL_ARTICLE">
<AU>Tyrer P, Nur U, Crawford M, Karlsen S, McLean C, Rao B, et al</AU>
<TI>The social functioning questionnaire: a rapid and robust measure of perceived functioning</TI>
<SO>International Journal of Social Psychiatry</SO>
<YR>2005</YR>
<VL>51</VL>
<NO>3</NO>
<PG>265-75</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" MODIFIED="2011-11-02 11:03:37 +0000" MODIFIED_BY="[Empty name]" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JA, Burney PG</AU>
<TI>Methods for evaluating area-wide and organisation based interventions in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>iii-92</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Verheul-2003" MODIFIED="2012-06-02 15:28:11 +0100" MODIFIED_BY="[Empty name]" NAME="Verheul 2003" TYPE="JOURNAL_ARTICLE">
<AU>Verheul R, Van den Bosch LM, Koeter MW, De Ridder MA, Stijnen T, Van den Brink W</AU>
<TI>Dialectical behaviour therapy for women with borderline personality disorder: 12-month, randomised clinical trial in The Netherlands</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2003</YR>
<VL>182</VL>
<NO>0007-1250 (Print)</NO>
<PG>135-40</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Young-1994" MODIFIED="2012-06-02 15:29:08 +0100" MODIFIED_BY="[Empty name]" NAME="Young 1994" TYPE="BOOK">
<AU>Young J</AU>
<SO>Cognitive Therapy for Personality Disorders: A Shama-focused Approach</SO>
<YR>1994</YR>
<PB>Professional Resource Exchange</PB>
<CY>Sarasota (FL)</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Young-2003" MODIFIED="2010-08-04 12:46:36 +0100" MODIFIED_BY="[Empty name]" NAME="Young 2003" TYPE="BOOK">
<AU>Young JE, Klosko JS, Weishaar ME</AU>
<SO>Schema therapy: a practicioner's guide.</SO>
<YR>2003</YR>
<PB>Guilford</PB>
<CY>New York (NY)</CY>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Zanarini-1987" MODIFIED="2010-06-01 13:51:14 +0100" MODIFIED_BY="[Empty name]" NAME="Zanarini 1987" TYPE="JOURNAL_ARTICLE">
<AU>Zanarini MC, Frankenburg FR, Chauncey DL, Gunderson JG</AU>
<TI>The Diagnostic Interview for Personality Disorders: interrater and test-retest reliability</TI>
<SO>Comprehensive Psychiatry</SO>
<YR>1987</YR>
<VL>28</VL>
<PG>467-80</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Zanarini-1989" MODIFIED="2012-06-02 15:31:53 +0100" MODIFIED_BY="[Empty name]" NAME="Zanarini 1989" TYPE="JOURNAL_ARTICLE">
<AU>Zanarini MC, Gunderson JG, Frankenburg FR, Chauncey DL</AU>
<TI>The Revised Diagnostic Interview for Borderlines: discriminating BPD from other Axis II disorders</TI>
<SO>Journal of Personality Disorders</SO>
<YR>1989</YR>
<VL>3</VL>
<PG>10-8</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Zanarini-1996" MODIFIED="2009-05-20 10:23:15 +0100" MODIFIED_BY="[Empty name]" NAME="Zanarini 1996" TYPE="UNPUBLISHED">
<AU>Zanarini MC, Frankenburg FR, Sickel AE &amp; Young L</AU>
<TI>Diagnostic interview for DSM-IV personality disorders, Unpublished measure</TI>
<SO>Boston, McLean Hospital</SO>
<YR>1996</YR>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Zanarini-2003" MODIFIED="2012-06-02 15:32:20 +0100" MODIFIED_BY="[Empty name]" NAME="Zanarini 2003" TYPE="JOURNAL_ARTICLE">
<AU>Zanarini MC</AU>
<TI>Zanarini Rating Scale for Borderline Personality Disorder (Zan-BPD): a continuous measure of DSM-IV borderline psychopathology</TI>
<SO>Journal of Personality Disorders</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>3</NO>
<PG>233-42</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Zanarini-2004" MODIFIED="2010-04-14 15:04:14 +0100" MODIFIED_BY="[Empty name]" NAME="Zanarini 2004" TYPE="JOURNAL_ARTICLE">
<AU>Zanarini MC, Frankenburg FR, Hennen J, Silk KR</AU>
<TI>Mental health service utilization by borderline personality disorder patients and axis II comparison subjects followed prospectively for six years</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2004</YR>
<VL>65</VL>
<PG>28-36</PG>
<IDENTIFIERS MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Zanarini-2007" MODIFIED="2012-07-04 16:13:26 +0100" MODIFIED_BY="[Empty name]" NAME="Zanarini 2007" TYPE="JOURNAL_ARTICLE">
<AU>Zanarini MC, Frankenburg FR, Reich DB, Silk KR, Hudson JI, McSweeney LB</AU>
<TI>The subsyndromal phenomenology of borderline personality disorder: a 10-year follow-up study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2007</YR>
<VL>164</VL>
<PG>929-35</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2012-06-04 10:47:01 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Binks-2006" MODIFIED="2012-06-04 10:47:01 +0100" MODIFIED_BY="Heather Maxwell" NAME="Binks 2006" TYPE="COCHRANE_REVIEW">
<AU>Binks C, Fenton M, McCarthy L, Lee T, Adams CE, Duggan C</AU>
<TI>Psychological therapies for people with borderline personality disorder</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-06-04 10:47:01 +0100" MODIFIED_BY="Heather Maxwell"><IDENTIFIER MODIFIED="2012-06-04 10:47:01 +0100" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD005652"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2011-08-11 17:33:14 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2017-04-06 11:47:12 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2017-04-06 11:47:12 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2012-07-11 11:39:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bateman-1999">
<CHAR_METHODS MODIFIED="2009-05-12 13:32:48 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>design:</B> randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-11 11:39:13 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>sex:</B> 22/38 females (57.9%)</P>
<P>
<B>age:</B> eligible: 31.8 years on average</P>
<P>
<B>location: </B>UK</P>
<P>
<B>setting:</B> partially hospitalised/outpatient</P>
<P>
<B>exclusions: </B>schizophrenia, bipolar disorder, substance misuse, mental impairment, evidence of organic brain disorder</P>
<P>
<B>level of functioning/severity of illness: </B>"individuals with severe borderline personality disorder who frequently harmed themselves and attempted suicide, while exhibiting severe levels of depression, suffering from high levels of symptomatic distress, and demonstrating comorbidity for affective disorders" (<LINK REF="STD-Bateman-1999" TYPE="STUDY">Bateman 1999</LINK>, p. 1568)</P>
<P>DIB scores at baseline: group 1 mean score = 7.9, SD = 0.4; group 2 mean score = 7.6, SD = 0.5</P>
<P>
<B>BPD diagnosis according to:</B> DSM-III-R (both sets of criteria of SCID and DIB had to be met)</P>
<P>
<B>means of assessment:</B> both SCID and DIB-R</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-05 13:13:54 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>group 1 (EG):</B> mentalisation-based treatment (MBT) oriented partially hospitalisation 5 days a week: once-weekly individual psychotherapy, thrice-weekly group analytic psychotherapy, once-weekly expressive therapy (psychodrama techniques oriented), once-weekly community meeting; monthly meeting with case administrator and medication review by resident psychiatrist</P>
<P>
<B>group 2 (CG):</B> standard treatment in the general psychiatric services: regular psychiatric review with psychiatrist when necessary (twice-monthly on average); inpatient admission as appropriate (90%, average stay 11.6 days) with discharge to non-psychoanalytic partial hospitalisation focusing on problem solving (72%, average stay 6 months) and standard aftercare (100%, outpatient and community follow-up by every-2-week visits by a community psychiatric nurse); no formal psychotherapy</P>
<P>
<B>duration</B>: up to 18 months (average length of stay in EG: 17.4 months</P>
<P>
<B>concomitant psychotherapy: </B>none</P>
<P>
<B>concomitant pharmacotherapy: </B>antidepressant and antipsychotic drugs prescribed as appropriate, polypharmacy was discouraged</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-07-10 11:58:41 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>outcomes considered in this review</B>
</P>
<P>
<B>self-rated:</B> interpersonal problems (IIP), depression (BDI), anxiety (STAI), general psychopathology (SCL-90-R-GSI)</P>
<P>
<B>observer-rated:</B> number of patients with self-harming behaviour during last 6-month period, number of patients with suicide attempt during last 6-month period (both assessed via the Suicide and Self-Harm Inventory, a semi-structured interview)</P>
<P>
<B>time-points used here: </B>18 months (post-treatment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-08 13:56:24 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>analyses: </B>per protocol (22 randomised to each group, only 19 per group analysed since treated per protocol)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-11 11:39:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bateman-2009">
<CHAR_METHODS MODIFIED="2010-04-20 15:28:45 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>design: </B>randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-11 11:39:20 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>sex:</B> 107/134 females (79.9%)</P>
<P>
<B>age:</B> eligible: 18-65 years of age; mean age of participants allocated to outpatient mentalisation-based treatment (MBT-OP): 31.3 years, SD 7.6; mean age of participants allocated to structured clinical management (SCM): 30.9 years, SD 7.9</P>
<P>
<B>location: </B>UK</P>
<P>
<B>setting:</B> outpatient</P>
<P>
<B>exclusions: </B>psychotic disorder, bipolar I disorder, opiate dependence requiring specialist treatment, mental impairment, evidence of organic brain disorder, being in long-term psychotherapeutic treatment</P>
<P>
<B>level of functioning/severity of illness: </B>only subjects with "suicide attempt or episode of life-threatening self-harm within last 6 months" were eligible (<LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK>, p. 1356).</P>
<P>mean GAF score at baseline: 41.0, i.e. participants had "serious symptoms OR any serious impairment in social, occupational, or school functioning"</P>
<P>
<B>BPD diagnosis according to:</B> DSM-IV</P>
<P>
<B>means of assessment:</B> SCID-II</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-02 12:42:47 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>group 1 (EG):</B> MBT-OP; weekly individual and group psychotherapy</P>
<P>
<B>group 2 (CG):</B> SCM according to generic practice for borderline personality disorder offered by non-specialist practitioners within U.K. psychiatric services; regular individual and group sessions with appointments every 3 months for psychiatric review</P>
<P>
<B>duration:</B> 18 months</P>
<P>
<B>concomitant psychotherapy: </B>patients already being in long-term psychotherapeutic treatment were not eligible</P>
<P>
<B>concomitant pharmacotherapy: </B>patients were prescribed medication according to the APA guidelines; all patients were offered medication reviews every 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-04 14:22:53 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>outcomes considered in this review</B>
</P>
<P>
<B>self-rated: </B>interpersonal problems (IIP), depression (BDI), general psychopathology (SCL-90-R-GSI)</P>
<P>
<B>observer-rated: </B>suicidal ideation (number of patients with suicide attempt during previous 6-month period), self-harming behaviour (number of patients with self-harming behaviour during previous 6-month period), mental health status (GAF)</P>
<P>
<B>time-points used here: </B>18 months (post-treatment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-20 15:49:37 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>analyses: </B>intention-to-treat analysis based on treatment assignment</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-11 11:39:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bellino-2006">
<CHAR_METHODS MODIFIED="2009-05-12 13:32:55 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>design:</B> randomised controlled trial </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-11 11:39:26 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>sex:</B> 60% females ("The ratio of men to women was 3 to 5."; <LINK REF="STD-Bellino-2006" TYPE="STUDY">Bellino 2006</LINK>, p. 455</P>
<P>
<B>age:</B> 26.4 years on average, SD = 3.7</P>
<P>
<B>location: </B>Italy</P>
<P>
<B>setting:</B> outpatient</P>
<P>
<B>exclusions: </B>lifetime diagnosis of delirium, dementia, amnestic or other cognitive disorders, schizophrenia or other psychotic disorders, patients whose major depressive episode was an expression of bipolar disorder; current diagnosis of substance abuse disorder, treatment with psychotropic drugs or psychotherapy during the 2 months prior to the study, female patients not using an adequate method of birth control</P>
<P>
<B>level of functioning/severity of illness:</B> mean baseline CGI-S = 4.35, i.e. "moderately ill".</P>
<P>
<B>BPD diagnosis according to:</B> DSM-IV-TR, comorbid diagnosis of mild to moderate major depressive episode required for inclusion</P>
<P>
<B>means of assessment:</B> SCID</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-08 10:52:11 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>group 1 (EG):</B> Fluoxetine + interpersonal therapy (IPT; 1 weekly session)</P>
<P>
<B>group 2 (CG):</B> Fluoxetine + clinical management (CM; 6 appointments, first two fortnightly, monthly afterwards)</P>
<P>
<B>duration</B>: 24 weeks</P>
<P>
<B>concomitant psychotherapy: </B>patients having received psychotherapy during the 2 months prior to the study were not eligible</P>
<P>
<B>concomitant pharmacotherapy: </B>all study participants received 20 to 40 mg fluoxetine daily; patients with psychotropic treatment during the 2 months prior to the study were not eligible for inclusion</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-04 14:22:59 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>outcomes considered in this review</B>
</P>
<P>
<B>self-rated: </B>anxiety (HARS)</P>
<P>
<B>observer-rated: </B>depression (Ham-D), mental health status (CGI-S)</P>
<P>
<B>time-points used here: </B>week 24 (post-treatment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-03 16:04:30 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>analyses: </B>per protocol (39 randomised, only 32 analysed since treated per protocol, N = 16 per group)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-11 11:39:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bellino-2007">
<CHAR_METHODS MODIFIED="2009-05-13 14:59:49 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>design: </B>randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-11 11:39:31 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>sex:</B> 63.2% females ("The ratio of men to women was 7 to 19"; <LINK REF="STD-Bellino-2007" TYPE="STUDY">Bellino 2007</LINK>, p. 720)</P>
<P>
<B>age:</B> 30.55 years on average, SD = 5.75</P>
<P>
<B>location: </B>Italy</P>
<P>
<B>setting: </B>outpatient</P>
<P>
<B>exclusions: </B>lifetime diagnosis of delirium, dementia, amnestic or other cognitive disorders, schizophrenia, other psychotic disorders, patients whose major depressive episode was an expression of bipolar disorder; current diagnosis of substance abuse disorder; treatment with psychotropic drugs or psychotherapy during 2 months prior to study, female patients of child-bearing age not using adequate method of birth control</P>
<P>
<B>level of functioning/severity of illness:</B> Mean baseline CGI-S = 3.4, i.e. "mildly ill".</P>
<P>
<B>BPD diagnosis according to:</B> DSM-IV-TR, comorbid diagnosis of mild to moderate major depressive episode required for inclusion</P>
<P>
<B>means of assessment:</B> SCID</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-13 15:59:32 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>group 1 (EG1):</B> Fluoxetine + interpersonal therapy (IPT; 1 weekly session)</P>
<P>
<B>group 2 (EG2): </B>Fluoxetine + cognitive therapy of therapy according of depression according to Beck (CT; 1 weekly session)</P>
<P>
<B>duration:</B> 24 weeks</P>
<P>
<B>concomitant psychotherapy: </B>patients having received psychotherapy during the 2 months prior to the study were not eligible</P>
<P>
<B>concomitant pharmacotherapy: </B>all study participants received 20 to 40 mg fluoxetine daily, with 7 appointments, the first 2 fortnightly and the last 5 monthly; patients with additional current psychotropic treatment were not eligible for inclusion</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-04 14:23:05 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>outcomes considered in this review</B>
</P>
<P>
<B>self-rated:</B> anxiety (HARS)</P>
<P>
<B>observer-rated:</B> depression (Ham-D), mental health status (CGI-S)</P>
<P>
<B>time-points used here: </B>week 24 (post-treatment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-03 16:04:51 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>analyses:</B> per protocol (32 randomised, only 26 analysed since treated per protocol, N = 14 in the IPT and N = 12 in the CT group)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-11 11:39:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bellino-2010">
<CHAR_METHODS MODIFIED="2010-04-21 10:59:42 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>design: </B>parallel-arm, randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-11 11:39:36 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>sex: </B>37/55 females (67.3%)</P>
<P>
<B>age:</B> combined treatment group: mean age 26.23 years, SD 6.4; pharmacotherapy group: mean age 25.86 years, SD 7.2</P>
<P>
<B>location: </B>Italy</P>
<P>
<B>setting:</B> outpatient</P>
<P>
<B>exclusions: </B>concomitant diagnoses of Axis I or Axis II disorders; esp. schizophrenia or other psychotic disorders, bipolar disorder; lifetime diagnosis of delirium, dementia, amnestic disorder, other cognitive disorders, not using adequate methods of birth control if in childbearing age, receiving psychotropic drugs during last 2 months, psychotherapy in last 6 months</P>
<P>
<B>level of functioning/severity of illness:</B> mean CGI-S at baseline: 5.45, i.e. participants were "markedly ill"; participants had no comorbid axis-I or II comorbidities</P>
<P>
<B>BPD diagnosis according to:</B> DSM-IV-TR</P>
<P>
<B>means of assessment:</B> SCID-II</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-05 13:14:48 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>group 1 (EG):</B> combined therapy of fluoxetine (20 to 40 mg/d) plus weekly individual sessions of IPT adapted to BPD (IPT-BPD)</P>
<P>
<B>group 2 (CG): </B>single pharmacotherapy treatment with fluoxetine (20 to 40 mg/d), clinical management (medical appointments lasting 15 to 20 minutes every 2 weeks, dealing with clinical issues)</P>
<P>
<B>duration: </B>32 weeks</P>
<P>
<B>concomitant psychotherapy: </B>eligible patients were not in psychotherapeutic treatment during the last 6 months prior to study entry</P>
<P>
<B>concomitant pharmacotherapy: </B>eligible patients were not receiving psychotropic drugs during the last two months prior to study entry</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-04 14:23:11 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>outcomes considered in this review</B>
</P>
<P>
<B>self-rated:</B> anxiety (HARS)</P>
<P>
<B>observer-rated:</B> BPD severity (BPDSI-IV-total), anger (BPDSI-IV-anger), affective instability (BPDSI-IV-affective instability), chronic feelings of emptiness (BPDSI-IV-emptiness), impulsivity (BPDSI-IV-impulsivity), self-harming behaviour (BPDSI-iV-parasuicidal behaviour score), interpersonal problems (BPDSI-IV-interpersonal relationships), avoidance of abandonment (BPDSI-IV-abandonment), identity disturbance (BPDSI-IV-identity disturbance), dissociation/stress-related paranoid ideation (BPDSI-IV-paranoid ideation), depression (Ham-D), mental health status (CGI-S)</P>
<P>
<B>time-points used here: </B>week 32 (post-treatment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-21 13:02:42 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>analyses:</B> per protocol (27 randomised to fluoxetine + IPT-BPD, 28 to fluoxetine + CM; only data of the 22 completers in each group were analysed)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-11 11:39:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blum-2008">
<CHAR_METHODS MODIFIED="2009-05-13 16:11:25 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>design: </B>randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-11 11:39:41 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>sex:</B> 103/124 females, i.e. 83.1%</P>
<P>
<B>age:</B> 31.5 years on average, SD = 9.5</P>
<P>
<B>location: </B>USA</P>
<P>
<B>setting:</B> outpatient</P>
<P>
<B>exclusions: </B>not speaking English, psychotic or primary neurological disorder, cognitively impaired patients, current substance abuse or dependence , participated in STEPPS treatment previously</P>
<P>
<B>level of functioning/severity of illness:</B> baseline CGI-S = 5.1 (SD = 0.8) in EG, baseline CGI-S = 4.9 (SD = 0.9) in CG; i.e. patients were "markedly ill"</P>
<P>
<B>BPD diagnosis according to:</B> DSM-IV</P>
<P>
<B>means of assessment:</B> SIDP-IV</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-05 13:15:05 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>group 1 (EG): </B>STEPPS: 20 2-hour weekly group therapy sessions + homework assignments + 1 session for family members or significant others; no individual therapy</P>
<P>
<B>group 2 (CG): </B>Treatment as usual (TAU): subjects were encouraged to continue their usual care, including individual psychotherapy, medication, and case management</P>
<P>
<B>duration</B>: 20 weeks</P>
<P>
<B>concomitant psychotherapy: </B>participants were encouraged to continue with ongoing concomitant treatments. 59% of all participants had an additional individual therapy (EG: 63%, CG: 54%; difference not significant)</P>
<P>
<B>concomitant pharmacotherapy: </B>90% of subjects reported at least one psychotropic medication at baseline; on average, participants received 2.9 psychotropic medications, SD = 2.3 (EG: 3.0, SD = 2.5; CG: 2.7, SD = 2.1; difference not significant)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-26 15:38:10 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>outcomes considered in this review</B>
</P>
<P>
<B>self-rated:</B> BPD total severity (BEST), Barratt Impulsiveness Scale (BIS), depression (BDI), general psychopathology (SCL-90-R-GSI)</P>
<P>
<B>observer-rated:</B> affective instability (ZAN-BPD-affective subscale), interpersonal problems (ZAN-BPD-disturbed relationships subscale), cognitive disturbance (ZAN-BPD-cognitive subscale), mental health status (CGI-S)</P>
<P>
<B>time-points used here:</B> week 20 (post treatment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 15:38:11 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>analysis:</B> ITT of those actually having received allocated intervention, regardless of completion or noncompletion. However, 40 participants that had been randomly allocated did not receive the allocated intervention and were not included in analyses. "Subjects with at least one postbaseline assessment were included in the analyses." (<LINK REF="STD-Blum-2008" TYPE="STUDY">Blum 2008</LINK>, p. 470).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-11 11:39:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bos-2010">
<CHAR_METHODS MODIFIED="2012-06-05 13:15:23 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>design:</B> multi-centre, parallel-arm, randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-11 11:39:47 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>sex: </B>86.1% female</P>
<P>
<B>age:</B> mean age 32.4 years (EG: 32.9, SD = 5.6; CG: 31.8, SD = 9.2)</P>
<P>
<B>location: </B>The Netherlands</P>
<P>
<B>setting:</B> outpatient</P>
<P>
<B>exclusions: </B>insufficient commend of Dutch language, intellectual disability, in coercive treatment, acute endangering self or others</P>
<P>
<B>level of functioning/severity of illness:</B> years of illness history 13.3 years (group 1) and 11.8 years (group 2). No further details.</P>
<P>
<B>BPD diagnosis according to:</B> DSM-IV</P>
<P>
<B>means of assessment:</B> SCID-II, PDQ-4+</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-06 11:21:00 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>group 1 (EG): </B>STEPPS-group program plus limited individual therapy (STEPPS + LIT; STEPPS: 18 weekly sessions and a single follow-up session 4 to 6 months after conclusion of the program, main topics: psychoeducation about BPD, emotion management skills, behaviour management skills; inclusion of near relatives and friends as "support group"; LIT: one session every other week, developed as adjunct to STEPPS group to help consolidate newly acquired skills in each patient's everyday life)</P>
<P>
<B>group 2 (CG): </B>treatment as usual (TAU, i.e. standard treatment for BPD offered at the participating sites, consisting of individual therapy from a psychotherapist, psychologist, or psychiatric nurse, offered every 1 to 4 weeks)</P>
<P>
<B>duration: </B>4.5 months</P>
<P>
<B>concomitant psychotherapy: </B>STEPPS-related treatments like DBT or family groups for family members of the patients were not allowed; all participants were allowed to have contacts with social worker or another health care professional</P>
<P>
<B>concomitant pharmacotherapy: </B>all participants were allowed to have (medication) contacts with a psychiatrist</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-07 10:11:11 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>outcomes considered in this review</B>
</P>
<P>
<B>self-rated:</B> BPD total severity (BPD-40), interpersonal problems (WHOQOL-BREF-social relationships), general psychopathology (SCL-90-R-dutch version)</P>
<P>
<B>observer-rated: </B>impulsivity (number of patients scoring above BPDSI-IV cut-off score), self-harming behaviour (number of patients scoring above BPDSI-IV parasuicide cut-off score)</P>
<P>
<B>time-points used here: </B>post-treatment, i.e. after the final of 18 weekly sessions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-18 13:44:54 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>analyses:</B> per protocol</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-11 11:40:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carter-2010">
<CHAR_METHODS MODIFIED="2012-06-05 13:15:40 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>design: </B>parallel-arm, randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-11 11:40:05 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>sex: </B>73/73 females (100%)</P>
<P>
<B>age:</B> mean age 42.5 years, SD = 6.1; eligible: 18-65 years of age</P>
<P>
<B>location: </B>Australia</P>
<P>
<B>setting:</B> outpatient</P>
<P>
<B>exclusions: </B>schizophrenia, bipolar affective disorder, psychotic depression, florid antisocial behaviour, developmental disability, disabling organic condition; "The psychiatrist assessor had the option of determining if any potential subjects were unsuitable for inclusion in therapy or unmotivated to participate, although there were no specific criteria for this exclusion." (<LINK REF="STD-Carter-2010" TYPE="STUDY">Carter 2010</LINK>, p. 164)</P>
<P>
<B>level of functioning/severity of illness:</B> all participants had a history of at least three self-reported self-harm episodes in the preceding 12 months</P>
<P>
<B>BPD diagnosis according to:</B> DSM-IV</P>
<P>
<B>means of assessment: </B>clinical interview, IPDE-Q</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-05 13:15:40 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>group 1 (EG):</B> DBT (weekly individual therapy, weekly group-based skills training, telephone access to an individual therapist, therapist supervision) modified insofar that telephone access was delivered using a group roster of DBT individual therapists in the daytime, but not contact with each participants's individual therapist, and the local psychiatric hospital at night; skills training groups dealt with all usual modules except of mindfulness</P>
<P>
<B>group 2 (CG): </B>TAU + Waiting List: participants were offered DBT treatment after a 6 month waiting period</P>
<P>
<B>duration:</B> 6 months (all participants were offered 12 months of DBT treatment, but the comparison between groups was restricted to the first 6 months of DBT vs. TAU+WL)</P>
<P>
<B>concomitant psychotherapy: </B>participants were asked to discontinue psychological therapy of any sort for at least the 12 month duration of DBT</P>
<P>
<B>concomitant pharmacotherapy: </B>not specified;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-07 10:14:45 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>outcomes considered in this review</B>
</P>
<P>
<B>self-rated: </B>interpersonal problems (WHOQOL-BREF-social relationships), mental health status (Brief Disability Questionnaire - days out of role)</P>
<P>
<B>observer-rated:</B> number of patients with self-harming behaviour</P>
<P>
<B>time-points used here: </B>6 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 15:38:28 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>analyses: </B>per protocol (DBT group: 20 completers of treatment and self-reports out of 38 allocated to this group; TAU group: 31 completers of waitlist and self-reports out of 35 allocated)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-11 11:40:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cottraux-2009">
<CHAR_METHODS MODIFIED="2010-04-20 11:06:59 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>design: </B>randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-11 11:40:09 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>sex: </B>50/65 females, i.e. 76.9%</P>
<P>
<B>age: </B>cognitive therapy (CT) group: mean age 34.3 years, SD 10.2; Rogerian supportive therapy (RST) group: mean age 32.6 years, SD 8.3</P>
<P>
<B>location: </B>France</P>
<P>
<B>setting:</B> outpatient</P>
<P>
<B>exclusions: </B>age under 18 or over 60 years, psychotic disorders with current delusions, significant drug or alcohol addiction, antisocial behaviours, living too far from the study centres</P>
<P>
<B>level of functioning/severity of illness:</B> mean CGI-S at baseline: 5.21, i.e. "markedly ill"</P>
<P>
<B>BPD diagnosis according to: </B>DSM-IV</P>
<P>
<B>means of assessment:</B> structured interview screening form, DIB-R</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-04-20 13:32:10 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>group 1 (EG):</B> cognitive therapy: individual 1-hour sessions, weekly for 6 months (24 sessions), every fortnight for another 6 months (12 sessions)</P>
<P>
<B>group 2 (CG):</B> Rogerian supportive therapy: individual 1-hour sessions, weekly for 6 months (24 sessions), every fortnight for another 6 months (12 sessions)</P>
<P>
<B>duration</B>:1 year</P>
<P>
<B>concomitant psychotherapy: </B>eligible patients were not to be following psychotherapy at the time of the study</P>
<P>
<B>concomitant pharmacotherapy: </B>participants could keep their medication as long as they accepted to have it monitored by the principal investigator</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-04 14:23:23 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>outcomes considered in this review</B>
</P>
<P>
<B>self-rated: </B>impulsivity (Eysenck Impulsivity Venturesomeness Empathy Questionnaire IVE - impulsivity), suicidality (Beck Hopelessness Scale BHS), depression (BDI), anxiety (BAI)</P>
<P>
<B>observer-rated: </B>self-harming behaviour (SHBCL), mental health status (CGI-S)</P>
<P>
<B>time-points used here: </B>week 52 (post-treatment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-20 13:35:15 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>analyses:</B> per protocol, i.e. treatment completers (of 33 people randomised to CT and 32 to RST, 20 and 18 completed, resp.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-01-31 17:13:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Davidson-2006">
<CHAR_METHODS MODIFIED="2012-06-05 13:16:12 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>design:</B> multi-centre, parallel-arm RCT (randomisation stratified by study centre and by pre-defined high or low episodes of self-harm; randomised permuted blocks of size 4)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-11 11:40:15 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>sex:</B> 89/106 females (84.0%)</P>
<P>
<B>age:</B> 31.9 years on average, SD = 9.1</P>
<P>
<B>location: </B>UK</P>
<P>
<B>setting:</B> outpatient</P>
<P>
<B>exclusions: </B>patients currently receiving in-patient treatment for a mental state disorder, currently receiving a systematic psychological therapy of specialist service, insufficient knowledge of English; evidence of organic illness, mental impairment, alcohol or drug dependence, schizophrenia or bipolar affective disorder; drug or alcohol abusing patients were eligible for inclusion</P>
<P>
<B>level of functioning/severity of illness: </B>mean social functioning (SFQ) score at baseline 14.6 (SD = 3.9),</P>
<P>
<B>BPD diagnosis according to:</B> DSM-IV; patients had to have received either in-patient psychiatric services or an assessment at accident and emergency services or an episode of deliberate self-harm (either suicidal act or self-mutilation) in the previous 12 months</P>
<P>
<B>means of assessment:</B> SCID</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-05 13:16:12 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>group 1 (EG): </B>Cognitive Behaviour Therapy + treatment as usual (CBT + TAU), up to 30 sessions, 27 sessions (SD = 13) on average</P>
<P>
<B>group 2 (CG): </B>treatment as usual (TAU; inpatient and outpatient hospital services, A&amp;E services, community based services, primary and community care services such as general practitioner, practice of Community Psychiatric Nurse)</P>
<P>
<B>duration</B>: one year</P>
<P>
<B>concomitant psychotherapy:</B> patients currently receiving in-patient treatment for a mental state disorder or a systematic psychological therapy or specialist service were excluded. All other kinds of treatments a patient would have received if the trial had not been in place (e.g., general practitioner care, contact with community mental health teams) were allowed. 90% of participants were in contact with mental health services.</P>
<P>
<B>concomitant pharmacotherapy: </B>may have been comprised in TAU. There are no details how many of the study participants actually received psychotropic medical treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-31 17:13:21 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>outcomes considered in this review</B>
</P>
<P>
<B>self-rated:</B> interpersonal problems (IIP-SC), depression (BDI-II), anxiety (STAI-trait), general psychopathology (BSI-GSI)</P>
<P>
<B>observer-rated: </B>suicidality (mean number of patients with suicidal act during previous 12 months), parasuicidality (number of patients with self-harming behaviour during previous 12-month period)</P>
<P>
<B>time-points used here: </B>12 months (post-treatment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-15 12:56:53 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>analyses: </B>ITT</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-11 11:40:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Doering-2010">
<CHAR_METHODS MODIFIED="2012-06-05 13:16:21 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>design: </B>randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-11 11:40:22 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>sex: </B>104/104 females (100%)</P>
<P>
<B>age: </B>27.3 years on average</P>
<P>
<B>location: </B>Germany, Austria</P>
<P>
<B>setting:</B> outpatient</P>
<P>
<B>exclusions: </B>schizophrenia, bipolar I and Ii disorder with a major depressive, manic, or hypomanic episode during the previous six months, substance dependency (including alcohol) during the previous six months, subjects meeting three or more DSM-IV criteria for antisocial personality disorder, organic pathology, mental retardation, insufficient command of the German language</P>
<P>
<B>level of functioning/severity of illness:</B> mean GAF score at baseline was 52.3, i.e. patients had moderate symptoms OR any moderate difficulty in social, occupational, or school functioning.</P>
<P>
<B>BPD diagnosis according to:</B> DSM-IV</P>
<P>
<B>means of assessment:</B> SCID</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 15:38:48 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>group 1 (EG): </B>Transference-Focused Psychotherapy (TFP; i.e. twice weekly individual psychotherapy sessions)</P>
<P>
<B>group 2 (CG):</B> Treatment by Experienced Community Psychotherapist (TBE; i.e. treatment was delivered by therapists known as experienced and particularly interested in BPD patients by the local administrators; therapists were free to choose the frequency of sessions according to their method; therapists' main orientations were: psychoanalytic (19), behavioral (17), client-centered (4), systematic (4), Gestalt (1), dynamic group (1), psychodynamic (1); psychotherapies continued if deemed necessary by the therapist and the patient and if paid by the insurance company</P>
<P>
<B>duration:</B> 12 months</P>
<P>
<B>concomitant psychotherapy: </B>psychotherapy other than the study treatment was not allowed in the EG</P>
<P>
<B>concomitant pharmacotherapy: </B>medication was not restricted but registered continuously</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-26 15:38:48 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>outcomes considered in this review</B>
</P>
<P>
<B>self-rated:</B> depression (BDI), anxiety (STAI-trait), general psychopathology (BSI-GSI)</P>
<P>
<B>observer-rated:</B> BPD severity (mean number of DSM-IV diagnostic criteria for BPD), suicidality (mean number of patients with suicidal act during previous 12 months), self-harming behaviour (number of patients with self-harming behaviour during previous 12-month period)</P>
<P>
<B>time-points used here: </B>12 months (post treatment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 15:38:48 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>analyses:</B> ITT, LOCF</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-11 11:40:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Farrell-2009">
<CHAR_METHODS MODIFIED="2009-05-18 09:49:14 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>design:</B> randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-11 11:40:26 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>sex: </B>32/32 females (100%)</P>
<P>
<B>age:</B> 35.6 years on average</P>
<P>
<B>location: </B>USA</P>
<P>
<B>setting:</B> outpatient</P>
<P>
<B>exclusions: </B>axis I diagnosis of a psychotic disorder confirmed by an open clinical interview, below average IQ</P>
<P>
<B>level of functioning/severity of illness:</B> mean baseline GAF score was 49.0, i.e. patients had "serious symptoms OR any serious impairment in social, occupational, or school functioning"</P>
<P>
<B>BPD diagnosis according to:</B> diagnostic criteria unclear</P>
<P>
<B>means of assessment:</B> Diagnostic Interview for Personality Disorders Revised, Borderline Syndrome Index</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-06 11:21:31 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>group 1 (EG):</B> Group Schema Focused Therapy + individual psychotherapy treatment as usual (GSFT + PTAU); thirty sessions of schema therapy group program in addition to weekly individual psychotherapy in the community (i.e. eclectic in orientation, primarily supportive)</P>
<P>
<B>group 2 (CG):</B> individual psychotherapy treatment as usual (PTAU), eclectic in orientation and primarily supportive; GSFT to be received after 14-month waiting period</P>
<P>
<B>duration:</B> eight months</P>
<P>
<B>concomitant psychotherapy: </B>all participants were in individual psychotherapy (eclectic, mainly supportive) throughout the study</P>
<P>
<B>concomitant pharmacotherapy: </B>psychopharmacological treatment was not controlled for; all participants were stable on at least one psychotropic medication at the start of the study, mostly low doses of antipsychotics and/or SSRI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-05 13:16:35 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>outcomes considered in this review</B>
</P>
<P>
<B>self-rated:</B> BPD severity (BSI), general psychopathology (SCL-90-R-GSI)</P>
<P>
<B>observer-rated:</B> affective instability (DIB-R-affect subscale), impulsivity (DIB-R-impulsive subscale), interpersonal problems (DIB-R-interpersonal subscale), dissociation/stress-related paranoia (DIB-R-cognitive subscale), mental health status (GAF)</P>
<P>
<B>time-points used here: </B>eight months (post-treatment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-03 16:05:40 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>analyses: </B>per protocol (EG: N = 16, CG: N = 12)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-11 11:40:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Giesen_x002d_Bloo-2006">
<CHAR_METHODS MODIFIED="2009-05-19 08:52:21 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>design:</B> randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-11 11:40:31 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>sex: </B>80/86 females (93.0%)</P>
<P>
<B>age: </B>30.6 years on average</P>
<P>
<B>location: </B>The Netherlands</P>
<P>
<B>setting:</B> outpatient</P>
<P>
<B>exclusions: </B>BPD not main diagnosis, psychotic disorders (except short, reactive psychotic episodes), bipolar disorder, dissociative identity disorder, antisocial personality disorder, attention-deficit/hyperactivity disorder, addiction of such severity that clinical detoxification was indicated (after which entering treatment was possible), psychiatric disorders secondary to medical conditions, mental retardation, no Dutch literacy</P>
<P>
<B>level of functioning/severity of illness: </B>mean number of SCID II BPD criteria met at baseline: group 1: 6.70, SD = 0.16; group 2: 7.12, SD = 0.19</P>
<P>
<B>BPD diagnosis according to:</B> DSM-IV</P>
<P>
<B>means of assessment:</B> SCID, BPDSI-IV</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-19 14:47:46 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>group 1 (EG):</B> Schema-Focused Therapy (SFT), 50-minute sessions twice a week</P>
<P>
<B>group 2 (CG): </B>Transference-Focused Psychotherapy (TFP), 50-minute sessions twice a week</P>
<P>
<B>duration:</B> up to three years, depending on treatment success</P>
<P>
<B>concomitant psychotherapy: </B>no additional psychotherapeutic treatment allowed</P>
<P>
<B>concomitant pharmacotherapy: </B>Prescribing according to good clinical practice, similar to American Psychiatric Association guidelines, by psychiatrists from different orientations (2 SFT therapists, 3 TFP therapists). At baseline, 74.0% of patients used psychotropic medication</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-04 14:23:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>outcomes considered in this review</B>
</P>
<P>
<B>self-rated: </B>none</P>
<P>
<B>observer-rated:</B> Borderline severity (BPDSI-IV-total), general psychopathology (SCL-90-R-dutch version)</P>
<P>
<B>time-points used here: </B>36 months (post-treatment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-02-09 10:10:14 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>analyses:</B> ITT, LOCF</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-11 11:40:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gratz-2006">
<CHAR_METHODS MODIFIED="2010-05-03 09:20:09 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>design:</B> parallel-arm randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-11 11:40:35 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>sex:</B> 25/25 females (100%)</P>
<P>
<B>age:</B> 33.3 years on average (SD = 9.98)</P>
<P>
<B>location: </B>USA</P>
<P>
<B>setting:</B> outpatient</P>
<P>
<B>exclusions: </B>diagnosis of a psychotic disorder, bipolar I disorder, substance dependence, reporting one or more suicide attempts rated as having a "high" risk of death or greater within the past 6 months, reporting greater than "some chance" of attempting suicide within the next year, participation in a DBT skills group within the past 6 months; for inclusion, a history of repeated deliberate self-harm, with at least one episode in the past 6 months was required</P>
<P>
<B>level of functioning/severity of illness:</B> 7.50 BPD criteria were met on average</P>
<P>
<B>BPD diagnosis according to:</B> DSM-IV</P>
<P>
<B>means of assessment:</B> Diagnostic Interview for DSM-IV Personality Disorders (DIPD-IV, <LINK REF="REF-Zanarini-1996" TYPE="REFERENCE">Zanarini 1996</LINK>)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-03 16:11:03 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>group 1 (EG):</B> Emotion regulation group intervention + treatment as usual, treatment by individual therapist required (ERG+TAU; 14 weekly 1.5 hour sessions; acceptance-based, behavioural group, combining elements of Acceptance and Commitment Therapy (ACT) and Dialectical Behaviour Therapy (DBT) as well as aspects of emotion-focused psychotherapy and traditional behaviour therapy)</P>
<P>
<B>group 2 (CG):</B> Treatment as usual + Waiting List (TAU+WL; treatment by individual therapist required)</P>
<P>
<B>duration</B>: 14 weeks</P>
<P>
<B>concomitant psychotherapy: </B>Participants were required to have an individual therapist; average number of individual therapy per week was 1.38 hours. 41% of therapists were clinical psychologists, 27% were psychiatrists, 32% were licensed clinical social workers</P>
<P>
<B>concomitant pharmacotherapy: </B>Participants received 3.64 psychiatric medications on average</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-04 14:23:56 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>outcomes considered in this review</B>
</P>
<P>
<B>self-rated:</B> BPD severity (BEST), affective instability (DERS-emotion dysregulation), impulsivity (DERS-impulse control), self-harming behaviour (DSHI-frequency score), depression (DASS-depression), anxiety (DASS-anxiety)</P>
<P>
<B>observer-rated:</B> none</P>
<P>
<B>time-points used here: </B>14 weeks (post-treatment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-03 16:06:02 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>analyses:</B> per protocol (EG: N = 16, CG: N = 12)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-11 11:40:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gregory-2008">
<CHAR_METHODS MODIFIED="2009-05-20 12:21:23 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>design:</B> randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-11 11:40:39 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>sex:</B> 24/30 females (80%)</P>
<P>
<B>age:</B> 28.7 years on average (SD = 7.7)</P>
<P>
<B>location: </B>USA</P>
<P>
<B>setting:</B> outpatient</P>
<P>
<B>exclusions: </B>schizophrenia, schizoaffective disorder, mental retardation, neurological condition that may produce secondary psychiatric symptoms (e.g., stroke, multiple sclerosis, partial complex seizures, or traumatic brain injury)</P>
<P>
<B>level of functioning/severity of illness: </B>"Only 10 participants (33%) were engaged in part-time or full-time employment (Hollingshead categories 1-7)" (<LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>, p. 30)</P>
<P>
<B>BPD diagnosis according to:</B> DSM-IV; in addition, a comorbid diagnosis of active alcohol abuse or dependence (not in full sustained remission) was required for inclusion</P>
<P>
<B>means of assessment:</B> SCID</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-05 13:17:41 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>group 1 (EG):</B> Dynamic deconstructive psychotherapy (DDP; weekly individual sessions over 12 to 18 months; DDP participants were also encouraged to participate in some form of group therapy, usually with interpersonal focus or 12-step; about one quarter did attend a professionally led group therapy for the first 6 months but none by 12 months)</P>
<P>
<B>group 2 (CG):</B>Treatment as usual (TAU; if not already in treatment, participants were referred to an alcohol rehabilitation centre and were also given names of psychiatric clinics and therapists in the community; they were also allowed to keep their current psychotherapist, if any)</P>
<P>
<B>duration:</B> post assessments were done after 12 months; DDP treatment could continue up to 18 months, however</P>
<P>
<B>concomitant psychotherapy: </B>If not already in treatment, CG patients were referred to an alcohol rehabilitation centre and given names of clinics an therapists in the community. If they had one, TAU participants were allowed to keep their current psychotherapist. EG participants were required to end treatment with their present psychotherapist, unless that person served primarily as a case manager or substance use counsellor; 70.0% of participants received individual psychotherapy or alcohol counselling; 30.0% received an additional professional group therapy, 36.7% participated in self-help groups</P>
<P>
<B>concomitant pharmacotherapy: </B>63.3% of all participants received separate medication management, the mean number of psychotropic medications was 2.9; medication management was provided by the DDP therapist for the EG group patients according to the American Psychiatric Association guidelines for BPD, medications specifically targeting substance use disorders were not prescribed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-05 13:17:41 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>outcomes considered in this review</B>
</P>
<P>
<B>self-rated:</B> BPD severity (BEST), dissociation/stress-related paranoia (DES), depression (DASS-depression), anxiety (DASS-anxiety)</P>
<P>
<B>observer-rated:</B> self-harming behaviour (number of patients with parasuicide during previous 3-month period)</P>
<P>
<B>time-points used here: </B>12 months (post-treatment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-02-09 10:10:33 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>analyses: </B>per protocol (EG: 10/15 allocated; CG: 9/15 allocated)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-11 11:40:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koons-2001">
<CHAR_METHODS MODIFIED="2012-06-05 13:17:57 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>design: </B>randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-11 11:40:42 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>sex:</B> 28/28 females (100%)</P>
<P>
<B>age:</B> 35.0 years on average</P>
<P>
<B>location: </B>USA</P>
<P>
<B>setting: </B>outpatient</P>
<P>
<B>exclusions: </B>schizophrenia, bipolar disorder, substance dependence, antisocial personality disorder</P>
<P>
<B>level of functioning/severity of illness:</B> At baseline, study participants met 6.8 out of 8 DSM-III-R BPD criteria on average</P>
<P>
<B>BPD diagnosis according to:</B> DSM-III-R</P>
<P>
<B>means of assessment:</B> SCID</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-05 13:17:57 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>group 1 (EG): </B>Dialectical Behavior Therapy (DBT; weekly individual therapy, weekly group skills training)</P>
<P>
<B>group 2 (CG):</B> treatment as usual (TAU; weekly individual therapy with a clinician, possibility of attending one or more supportive and psychoeducational groups, 4 participants did)</P>
<P>
<B>duration:</B> 6 months</P>
<P>
<B>concomitant psychotherapy: </B>all participants received individual psychotherapy (TAU: 4 of the therapists described themselves as cognitive-behavioural in primary orientation, 2 as psychodynamic, and 2 as eclectic). Group psychotherapy was part of DBT treatment while TAU patients were offered several group therapies at the hospital (4 out of 10 actually attended group therapy).</P>
<P>
<B>concomitant pharmacotherapy: </B>all participants, except one in the DBT condition, received pharmacotherapy(including SSRIs in each case and/or an additional mood stabiliser or low-dose neuroleptic in "some" cases; <LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK>, p. 376) pharmacotherapy and psychotherapy were provided by separate clinicians in all but one TAU case</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-06 11:21:34 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>outcomes considered in this review</B>
</P>
<P>
<B>self-rated: </B>anger (STAXI-anger-out), suicidality (BSS), dissociation (DES), depression (BDI)</P>
<P>
<B>observer-rated: </B>BPD severity (mean number of DSM-IV diagnostic criteria for BPD), self-harming behaviour (mean number of parasuicides during 3 months period), anxiety (HARS)</P>
<P>
<B>time-points used here: </B>6 months (i.e. post-treatment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-03 16:06:27 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>analyses:</B> per protocol (EG: N = 10; CG: N = 10)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-11 11:40:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Linehan-1991">
<CHAR_METHODS MODIFIED="2009-05-22 10:15:22 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>design: </B>randomised controlled trial </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-11 11:40:46 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>sex:</B> 61/61 females (100%)</P>
<P>
<B>age: </B>women between 18 and 45 years were eligible, no further details</P>
<P>
<B>location: </B>USA</P>
<P>
<B>setting:</B> outpatient</P>
<P>
<B>exclusions: </B>schizophrenia, bipolar disorder, substance dependence, mental retardation</P>
<P>
<B>level of functioning/severity of illness:</B>
</P>
<P>
<B>BPD diagnosis according to:</B> DSM-III</P>
<P>
<B>means of assessment:</B> DIB</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-10 10:27:37 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>group 1 (EG): </B>Dialectical Behavior Therapy (DBT; weekly individual therapy, weekly group therapy, telephone contact with the individual therapist between sessions)</P>
<P>
<B>group 2 (CG):</B> Treatment as usual in the community (TAU; all subjects were given alternative therapy referrals, usually by the original referral source; 9 had stable individual therapy for the year</P>
<P>
<B>duration:</B> 12 months</P>
<P>
<B>concomitant psychotherapy:</B> 13 out of 22 TAU participants were in ongoing individual psychotherapy at pretreatment, 9 out of 22 TAU participants had stable individual therapy for the year.</P>
<P>
<B>concomitant pharmacotherapy: </B>"Subjects had to consent to taper off psychotropic medications before entering the study. However, once in the study, failure to terminate or resuming use of medication was not cause for removal from the study." (<LINK REF="STD-Linehan-1991" TYPE="STUDY">Linehan 1991</LINK>, p. 1061)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-04 14:24:12 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>outcomes considered in this review</B>
</P>
<P>
<B>self-rated:</B>
</P>
<P>
<B>observer-rated: </B>Number of patients with self-harming behaviour during previous 12-month period,</P>
<P>
<B>time-points used here: </B>12 months (post-treatment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-03 16:06:41 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>analyses:</B> per protocol (EG: N = 22; CG: N = 22)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-11 11:41:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Linehan-1994">
<CHAR_METHODS MODIFIED="2012-06-26 15:39:16 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>design:</B> randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-11 11:41:15 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>sex:</B> 26/26 (100%)</P>
<P>
<B>age:</B> 26.7 years on average (SD=7.8)</P>
<P>
<B>location: </B>USA</P>
<P>
<B>setting: </B>outpatient</P>
<P>
<B>exclusions: </B>subjects currently meeting criteria for schizophrenia, bipolar disorder, primary substance dependence, mental retardation</P>
<P>
<B>level of functioning/severity of illness:</B> mean pretreatmen GAS scores: DBT 37.73 (SD=7.53), TAU 33.77 (SD=9.50), i.e. "some impairment in reality testing or communication OR major impairment in several areas, such as work or school, family relations, judgment, thinking or mood"</P>
<P>
<B>BPD diagnosis according to:</B> DSM-III-R</P>
<P>
<B>means of assessment: </B>SCID, DIB-R</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-04 12:44:45 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>group 1 (EG):</B> Dialectical Behavior Therapy (DBT; weekly individual behavioural psychotherapy, weekly psychoeducational skills training groups)</P>
<P>
<B>group 2 (CG):</B> Treatment as usual (TAU; subjects received alternative therapy referrals and were allowed to participate any type of treatment available in the community)</P>
<P>
<B>duration:</B> 12 months</P>
<P>
<B>concomitant psychotherapy: </B>patients assigned to DBT treatment had to terminate other professional mental health care</P>
<P>
<B>concomitant pharmacotherapy: </B>No between-group differences in number of subjects using psychotropic medications at pretreatment (use of: antidepressants, anticonvulsants, lithium, anxiolytics). DBT participants should taper off psychotropic medications as one goal of therapy, and eight out of 13 discontinued medication before start of treatment.</P>
<P>The remaining five DBT subjects reported using a mean of 1.80 medications (sedatives, antidepressants, anxiolytics, lithium) over the treatment year, while nine out of 13 TAU subjects reported using a mean of 3.89 different medications (antidepressants, anxiolytics, neuroleptics, sedatives, anticonvulsants).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-26 15:39:13 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>outcomes considered in this review</B>
</P>
<P>
<B>self-rated: </B>anger (STAXI-trait)</P>
<P>
<B>observer-rated: </B>mental health status (GAS)</P>
<P>
<B>time-points used here: </B>12 months (post treatment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 15:39:14 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>analyses:</B> per protocol (EG: N=13; CG: N=13)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-11 11:41:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Linehan-2006">
<CHAR_METHODS MODIFIED="2012-06-05 13:18:46 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>design:</B> randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-11 11:41:20 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>sex:</B> 101/101 females (100%)</P>
<P>
<B>age: </B>29.3 years on average, SD = 7.5</P>
<P>
<B>location: </B>USA</P>
<P>
<B>setting:</B> outpatient</P>
<P>
<B>exclusions:</B> lifetime diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, psychotic disorder not otherwise specified, mental retardation; seizure disorder requiring medication, mandate to treatment, need for primary treatment for another debilitating condition 
</P>
<P>
<B>level of functioning/severity of illness:</B>
</P>
<P>
<B>BPD diagnosis according to: </B>DSM-IV</P>
<P>
<B>means of assessment:</B> SCID, IPDE</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-06 11:21:55 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>group 1 (EG):</B> Dialectical Behavior Therapy (DBT, i.e. weekly individual psychotherapy, group skills training, telephone consultation)</P>
<P>
<B>group 2 (CG):</B> non-behavioural Community Treatment by Experts (CTBE; eligible therapists were nominated by community mental health leaders as experts in treating difficult clients; therapists were asked to provide the same type and dose of therapy that they believed was most suited to the patient, with a minimum of 1 scheduled individual session per week; the therapists described themselves as "eclectic but nonbehavioral" or "mostly psychodynamic", cognitive behaviour therapists were not eligible; therapists were free to attend a clinical supervision group at the Seattle Psychoanalytic Society and Institute)</P>
<P>
<B>duration: </B>12 months</P>
<P>
<B>concomitant psychotherapy: </B>no information given regarding further concomitant psychotherapy</P>
<P>
<B>concomitant pharmacotherapy: </B>There were no differences in types or amounts of psychotropic medication use at pretreatment, and the use of psychotropic medications decreases significantly more in the EG than the CG. No further details.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-04 14:24:17 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>outcomes considered in this review</B>
</P>
<P>
<B>self-rated:</B> suicidality (SBQ)</P>
<P>
<B>observer-rated: </B>depression (Ham-D-17)</P>
<P>
<B>time-points used here: </B>12 months, i.e. post-treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-28 18:09:35 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>analyses: </B>ITT (except of training and pilot cases)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-11 11:41:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McMain-2009">
<CHAR_METHODS MODIFIED="2010-05-03 10:00:26 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>design:</B> parallel-arm randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-11 11:41:25 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>sex:</B> 165/190 female (86.8%)</P>
<P>
<B>age: </B>mean 30.4 years, SD = 9.9</P>
<P>
<B>location: </B>Canada</P>
<P>
<B>setting:</B> outpatient</P>
<P>
<B>exclusions: </B>psychotic disorder, bipolar I disorder, delirium, dementia, mental retardation, diagnosis of substance dependence in preceding 30 days, having a medical condition that precluded psychiatric medications, living outside a 40-mile radius of Toronto, serious medical condition likely to require hospitalisation within the next year, having plans to leave the province</P>
<P>
<B>level of functioning/severity of illness:</B> mean GAF score at baseline: 52.4 (SD = 9.7), i.e. participants had moderate symptoms OR any moderate difficulty in social, occupational, or school functioning.</P>
<P>All participants had two episodes of suicidal or non-suicidal self-injurious behaviour in the past 5 years, at least one of which was in the 3 months preceding enrolment</P>
<P>
<B>BPD diagnosis according to:</B> DSM-IV</P>
<P>
<B>means of assessment:</B> IPDE</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-02 12:33:25 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>group 1 (EG):</B> DBT (individual sessions 1 hour weekly, skills group 2 hours weekly, phone coaching 2 hours weekly, consultation team for therapists 2 hours weekly), focus on self-harm and suicidal behaviour; bias toward managing crises on an outpatient basis, phone coaching to assist; patients encouraged to rely on skills over pills where appropriate, tapering from medications was a treatment goal</P>
<P>
<B>group 2 (CG):</B> general psychiatric management according to APA guideline recommendations (individual sessions 1 hour weekly, including management based on structured drug algorithm, therapist supervision meeting 90 minutes weekly), focus expanded from self-harm and suicidal behaviour; hospitalisation if indicated; patients encouraged to use medications concurrently according to medication algorithms relating to either mood lability or impulsive-aggressiveness</P>
<P>
<B>duration:</B> 12 months</P>
<P>
<B>concomitant psychotherapy: </B>non-study treatments such as individual, group, case management, day treatment or inpatient were recorded but participants were not prevented from using</P>
<P>
<B>concomitant pharmacotherapy: </B>no restrictions on ancillary pharmacotherapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-06 11:22:01 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>outcomes considered in this review</B>
</P>
<P>
<B>self-rated:</B> anger (STAXI-anger out), interpersonal problems (IIP-C), depression (BDI), general psychopathology (SCL-90-R-GSI)</P>
<P>
<B>observer-rated:</B> BPD severity (ZAN-BPD-total), parasuicidality (mean number of suicidal and self-injurious episodes),</P>
<P>
<B>time-points used here: </B>12 months (i.e. post-treatment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-02-09 10:11:21 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>analyses: </B>ITT, LOCF</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-06 11:22:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morey-2010">
<CHAR_METHODS MODIFIED="2011-04-20 16:19:01 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>design: </B>parallel-arm, randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-05 13:19:19 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>sex: </B>13/16 females (81.3%)</P>
<P>
<B>age:</B> mean age 31.1 years</P>
<P>
<B>location:</B> USA</P>
<P>
<B>setting:</B> outpatient</P>
<P>
<B>exclusions: </B>active psychosis, history of schizophrenia, substance intoxication or withdrawal</P>
<P>
<B>level of functioning/severity of illness: </B>no further information</P>
<P>
<B>BPD diagnosis according to: </B>DSM-IV</P>
<P>
<B>means of assessment: </B>DIPD-IV, PAI-BOR</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-05 13:19:19 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>group 1:</B> MACT (6 weekly sessions centred on chapters of a patient workbook)</P>
<P>
<B>group 2: </B>MACT+TA (6 weekly sessions centred on chapters of a patient workbook; initial session also included an individualised collaborative assessment with development of questions the client would like to "ask the test data" about themselves and the articulation of specific, individualised treatment goals; during second session, therapist and client discussed assessment results and motivational feedback was given; apart from these augmentations of the first two sessions, identical treatment as other group 
</P>
<P>
<B>duration:</B> 1,5 months</P>
<P>
<B>concomitant psychotherapy: </B>no other psychosocial interventions allowed</P>
<P>
<B>concomitant pharmacotherapy: </B>psychotropic medication allowed 56% were taking at baseline</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-06 11:22:04 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>outcomes considered in this review</B>
</P>
<P>
<B>self-rated:</B>
</P>
<P>
<B>observer-rated:</B> BPD severity (PAI-BOR-total), affective instability (PAI-BOR-A), suicidality (PAI-BOR-SI), parasuicidality (PAI-BOR-S), interpersonal problems (PAI-BOR-N), identity disturbance (PAI-BOR-I)</P>
<P>
<B>time-points used here: </B>1,5 months (i.e. post-treatment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-04-20 16:44:42 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>analyses: </B>ITT (completers case analysis also available but not used here)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-11-01 11:43:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nadort-2009">
<CHAR_METHODS MODIFIED="2011-04-19 13:50:14 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>design:</B> parallel-arm, randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-01 11:43:29 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>sex: </B>60/62 females (96.8%)</P>
<P>
<B>age:</B> mean age 32.0 years</P>
<P>
<B>location:</B> The Netherlands</P>
<P>
<B>setting:</B> outpatient</P>
<P>
<B>exclusions: </B>BPD not main diagnosis, psychotic disorders (except short, reactive psychotic episodes), bipolar disorder, dissociative identity disorder, antisocial personality disorder, attention-deficit/hyperactivity disorder, addiction of such severity that clinical detoxification was indicated (after which entering treatment was possible), psychiatric disorders secondary to medical conditions, mental retardation, no Dutch literacy</P>
<P>
<B>level of functioning/severity of illness: </B>mean number of SCID-II BPD criteria met at baseline: 6.8</P>
<P>
<B>BPD diagnosis according to: </B>DSM-IV</P>
<P>
<B>means of assessment: </B>SCID-II BPD section, BPDSI-IV score &gt;20</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-06 11:22:07 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>group 1: </B>SFT; 45 minute individual sessions twice a week for 12 months, one weekly session in the second year; no extra crisis support outside office hours</P>
<P>
<B>group 2:</B> Schema-focused therapy plus therapist telephone availability outside office hours in case of crisis (SFT+TTA); 45 minute individual sessions twice a week for 12 months, one weekly session in the second year; no extra crisis support outside office hours</P>
<P>
<B>duration:</B> 18 months (i.e. final evaluation after 18 months post randomisation; mean number of therapy sessions: SFT N = 67, SD = 30.85, range 1-130; SFT+TTA: N = 71, SD 34.57, range 2-142</P>
<P>
<B>concomitant psychotherapy: </B>no information</P>
<P>
<B>concomitant pharmacotherapy: </B>medication use allowed, 58% of patients used psychotropic medication at baseline</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-13 20:32:48 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>outcomes considered in this review</B>
</P>
<P>
<B>self-rated: </B>-</P>
<P>
<B>observer-rated:</B> Borderline severity (BPDSI-IV-total), general psychopathology (SCL-90-R-dutch version)</P>
<P>
<B>time-points used here: </B>18 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-04-20 13:35:35 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>analyses:</B> ITT</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-11 11:41:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Soler-2009">
<CHAR_METHODS MODIFIED="2010-05-19 13:57:27 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>design: </B>parallel-arm, randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-11 11:41:27 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>sex: </B>48/59 females (81.3%)</P>
<P>
<B>age: </B>mean age 29.2 years</P>
<P>
<B>location: </B>Spain</P>
<P>
<B>setting: </B>outpatient</P>
<P>
<B>exclusions: </B>schizophrenia, drug-induced psychosis, organic brain syndrome, alcohol or other psychoactive substance dependence, bipolar disorder, mental retardation, major depressive episode in course, CGI-S score &#8804; 4 (i.e. not at all, borderline, or mildly ill)</P>
<P>
<B>level of functioning/severity of illness:</B> mean CGI-BPD (global) scores of both groups: group 1: 4.71; range 4-7; group 2: 4.9, range 4-7; i.e. mean severity was moderately to markedly ill</P>
<P>
<B>BPD diagnosis according to:</B> DSM-IV</P>
<P>
<B>means of assessment:</B> SCID-II, DIB-R</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-06 11:22:14 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>group 1 (EG):</B> DBT skills training (DBT-ST), including DBT original skills for interpersonal effectiveness, emotional regulation, mindfulness and distress tolerance; 13 psychotherapy sessions of 120 min each, conducted by 2 therapists (a male and a female) for each group, in groups of 9-11 participants.</P>
<P>
<B>group 2 (CG):</B> Standard Group Therapy (SGT); therapeutic techniques: interpretation, highlighting, exploration, clarification, confrontation; therapists targeted specially nihilistic or destructive interactions, characteristic BPD interactions and those that could interfere with group functioning; 13 psychotherapy sessions of 120 min each, conducted by 2 therapists (a male and a female) for each group, in groups of 9-11 participants.</P>
<P>
<B>duration</B>: 3 months (i.e. 13 weekly sessions in each condition)</P>
<P>
<B>concomitant psychotherapy: </B>participants did not receive any other individual or group psychotherapy</P>
<P>
<B>concomitant pharmacotherapy: </B>pharmacological therapy was continued if initiated prior to inclusion, but type and doses could not be modified during the study period</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-04 12:48:31 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>outcomes considered in this review</B>
</P>
<P>
<B>self-rated: </B>mental health status (CGI-I-self rating)</P>
<P>
<B>observer-rated: </B>BPD severity (CBI-BPD-global), anger (CBI-BPD-anger), affective instability (CGI-BPD-affective instability), chronic feelings of emptiness ((CGI-BPD-emptiness), impulsivity (CGI-BPD-impulsivity), suicidality (CGI-BPD-suicidality), interpersonal problems (CGI-BPD-unstable relations), dissociative/psychotic pathology (BPRS), depression (Ham-D-17), anxiety (HARS), general psychopathology (SCL-90-R-GSI)</P>
<P>
<B>time-points used here: </B>3 months, i.e. post-treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-08 10:51:30 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>analyses:</B> ITT</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-11 11:41:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Steil-2010">
<CHAR_METHODS MODIFIED="2010-10-13 10:21:09 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>design:</B> randomised controlled trial</P>
<P>Originally, female participants with a diagnosis of PTSD and at least 4 criteria of DSM-IV-BPD were eligible. We refer to the subsample data of those participants fulfilling 5 or more criteria.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-11 11:41:30 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>sex: </B>31/31 females (100%)</P>
<P>
<B>age: </B>mean age 32.9 years; range 19-52 years</P>
<P>
<B>location: </B>Germany</P>
<P>
<B>setting:</B> inpatient</P>
<P>
<B>exclusions:</B> lifetime diagnosis of schizophrenic disorder, severe other mental disorder requiring immediate treatment in a different setting (e.g., eating disorder or acute delirium after withdrawal), suicide attempt with clear suicidal intention during last 4 months, severe self-injuring behaviour during last 4 months</P>
<P>
<B>level of functioning/severity of illness:</B> mean number of BPD criteria 5.85</P>
<P>all participants suffered from concurrent PTSD according to DSM-IV after childhood sexual abuse</P>
<P>
<B>BPD diagnosis according to:</B> DSM-IV</P>
<P>
<B>means of assessment: </B>IPDE</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-06 11:22:17 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>group 1 (EG):</B> DBT for patients with PTSD after childhood sexual abuse (DBT-PTSD); including: modified DBT skills training group (1 session of 90 minutes duration per week, modules: mindfulness, interpersonal skills, emotion regulation, stress tolerance; but less attention on interpersonal and detention skills as in standard DBT skills group); individual cognitive trauma therapy, exposure and discrimination training (2 sessions of 45 minutes duration per week); psychoeducation group concerning PTSD aetiology and treatment; additional group training in mindfulness- and acceptance-based techniques (three sessions of 20 minutes duration per week); participation in music, arts and exercise therapy</P>
<P>DBT skills training (DBT-ST), including DBT original skills for interpersonal effectiveness, emotional regulation, mindfulness and distress tolerance; 13 psychotherapy sessions of 120 min each, conducted by 2 therapists (a male and a female) for each group, in groups of 9-11 participants.</P>
<P>
<B>group 2 (CG):</B> waiting list (WL): continuation of already ongoing treatments for 6 months, inpatient DBT-PTSD treatment afterwards; points of measurement: baseline, 3 months, 4.5 months and 6 months after study inclusion</P>
<P>
<B>duration:</B> 3 months of inpatient treatment (i.e. 13 weekly sessions in each condition) + one booster session 6 weeks after dismissal</P>
<P>
<B>concomitant psychotherapy: </B>participants of the experimental group did not receive any other individual or group psychotherapy, participants of the waiting list condition continued their usual treatments if any</P>
<P>
<B>concomitant pharmacotherapy: </B>depressive episodes were treated with SSRI antidepressive agents (100-150 mg/d of sertraline, e.g.); difficulties of sleeping were treated with sleep-inducing antidepressants (50-100mg/d of trimipramine, e.g.); no benzodiazepines, no neuroleptics</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-18 09:47:14 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>outcomes considered in this review</B>
</P>
<P>
<B>self-rated: </B>BPD severity (BSL), dissociation (DES), depression (BDI-II), anxiety (STAI-state), general psychopathology (SCL-90-R-GSI</P>
<P>
<B>observer-rated:</B> -</P>
<P>
<B>time-points used here: </B>4.5 months, i.e. post residential treatment and one 6-week follow-up session</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-02-09 10:11:43 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>analyses:</B> ITT</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-11 11:41:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Turner-2000">
<CHAR_METHODS MODIFIED="2009-05-29 14:37:39 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>design:</B> randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-11 11:41:33 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>sex:</B> 19/24 females (79.2%)</P>
<P>
<B>age: </B>22 years on average</P>
<P>
<B>location: </B>USA</P>
<P>
<B>setting:</B> outpatient</P>
<P>
<B>exclusions: </B>schizophrenia, schizoaffective disorder, bipolar disorder, organic mental disorders, mental retardation</P>
<P>
<B>level of functioning/severity of illness:</B>
</P>
<P>
<B>BPD diagnosis according to:</B> DSM-III-R</P>
<P>
<B>means of assessment:</B> DIB, PDE</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-05 13:20:30 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>group 1 (EG1):</B> Dialectical Behavior Therapy-oriented treatment (i.e. individual DBT-oriented psychotherapy plus six group sessions with focus on significant persons in patients' natural environments; DBT modifications were the following: First: psychodynamic techniques were incorporated to conceptualise patients' behavioural, emotional, and cognitive relationship schema; second, there was no DBT skills group, but skills were provided during individual therapy)</P>
<P>
<B>group 2 (EG2): </B>Client-centered Therapy (CCT; i.e. two weekly individual sessions when possible; six group sessions with focus on significant persons in patients' natural environments (same as EG patients received)</P>
<P>
<B>duration: </B>12 months</P>
<P>
<B>concomitant psychotherapy: </B>no details</P>
<P>
<B>concomitant pharmacotherapy: </B>pharmacotherapy was not included in the study treatment regimens; at baseline, 19 patients were out of 24 reported taking prescribed psychotropic medications</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-05 13:20:30 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>outcomes considered in this review</B>
</P>
<P>
<B>self-rated:</B> anger (TBR-anger), impulsivity (TBR-impulsiveness), suicidal ideation (BSS), parasuicidality (TBR-frequency of parasuicide), depression (BDI), anxiety (BAI)</P>
<P>
<B>observer-rated:</B> dissociative/psychotic symptoms (BPRS)</P>
<P>
<B>time-points used here: </B>12 months, i.e. post-treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-29 15:32:56 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>analyses:</B> ITT</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-11 11:41:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-den-Bosch-2005">
<CHAR_METHODS MODIFIED="2009-06-02 09:09:12 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>design:</B> randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-11 11:41:36 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>sex:</B> 64/64 females (100%)</P>
<P>
<B>age:</B> 34.9 years on average, SD = 7.7</P>
<P>
<B>location: </B>The Netherlands</P>
<P>
<B>setting:</B> outpatient</P>
<P>
<B>exclusions: </B>bipolar disorder, (chronic) psychotic disorder, severe cognitive impairments, insufficient command of the Dutch language</P>
<P>
<B>level of functioning/severity of illness:</B> mean number of BPD criteria: 7.3 (SD = 1.3); participants were also required to have co-morbid substance abuse problems</P>
<P>
<B>BPD diagnosis according to: </B>DSM-IV</P>
<P>
<B>means of assessment:</B> SCID-II, Personality Diagnostic Questionnaire for DSM-IV (positive endorsement of BPD criteria was required on both instruments)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-05 13:20:46 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>group 1 (EG): </B>Dialectical Behavior Therapy (DBT; i.e. weekly individual cognitive-behavioural psychotherapy sessions, weekly skills-training groups, phone crisis consultation as needed)</P>
<P>
<B>group 2 (CG):</B> Treatment as usual (TAU; i.e. clinical management from the original referral source; two thirds: psychiatric services, one third addiction treatment centres; TAU patients attended generally no more than two sessions per month with a psychologist, a psychiatrist or a social worker)</P>
<P>
<B>duration:</B> 12 months</P>
<P>
<B>concomitant psychotherapy: </B>
</P>
<P>
<B>concomitant pharmacotherapy: </B>About 75% of participants reported the use of medication from one or more of the following categories during the study: benzodiazepines, selective serotonin reuptake inhibitors, tricyclic antidepressants, mood stabilisers and neuroleptics. No significant differences between the two groups with regard to medication use.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-06 11:22:26 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>outcomes considered in this review</B>
</P>
<P>
<B>self-rated:</B> -</P>
<P>
<B>observer-rated:</B> impulsivity (BPDSI-IV-impulsivity), parasuicidal behaviour (LPC-self-mutilative acts during previous 3-month period),</P>
<P>
<B>time-points used here: </B>week 52 (i.e. post-treatment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-06-02 13:04:20 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>analyses:</B> per protocol (data based on the number of subjects with valid data at a given measurement time)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-11 11:41:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weinberg-2006">
<CHAR_METHODS MODIFIED="2009-06-02 13:53:59 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>design:</B> randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-11 11:41:39 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>sex:</B> 30/30 females (100%)</P>
<P>
<B>age: </B>28.2 years on average</P>
<P>
<B>location: </B>USA</P>
<P>
<B>setting:</B> outpatient</P>
<P>
<B>exclusions: </B>comorbid psychotic disorders, bipolar I disorder, substance dependence, elevated suicide risk</P>
<P>
<B>level of functioning/severity of illness:</B> baseline frequency of self-harming behaviour: group 1: 9.33, SD = 14.78; group 2: 8.20, SD = 10.46</P>
<P>
<B>BPD diagnosis according to:</B> DSM-IV</P>
<P>
<B>means of assessment:</B> SCID, DIB-R (both sets of criteria had to be met for inclusion)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-03 16:12:19 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>group 1 (EG):</B> Manual-assisted cognitive treatment (MACT; i.e. adjunctive intervention to ongoing treatments of the participants; six session therapy incorporating elements of DBT, cognitive behavioural treatment, and bibliotherapy)</P>
<P>
<B>group 2 (CG):</B> Treatment as usual (TAU); all subjects took part in additional treatments not further specified</P>
<P>
<B>duration:</B> 6 weekly sessions</P>
<P>
<B>concomitant psychotherapy: </B>both EG and CG participants received treatment as usual; all participants took part in additional treatments not further specified</P>
<P>
<B>concomitant pharmacotherapy: </B>both EG and CG participants received treatment as usual; no further details on amounts or types of medications used</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-06 11:22:30 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>outcomes considered in this review</B>
</P>
<P>
<B>self-rated:</B> -</P>
<P>
<B>observer-rated: </B>suicidality (SBQ), parasuicidality (Parasuicide History Interview (PHI) - deliberate self-harm frequency),</P>
<P>
<B>time-points used here: </B>2 months (i.e. post-treatment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-02-09 10:11:55 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>analyses: </B>ITT</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-11 11:41:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zanarini-2008">
<CHAR_METHODS MODIFIED="2009-06-03 09:47:57 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>design:</B> randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-11 11:41:42 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>sex:</B> 50/50 females (100%)</P>
<P>
<B>age:</B> 19.3 years on average (SD = 1.4)</P>
<P>
<B>location: </B>USA</P>
<P>
<B>setting:</B> outpatient</P>
<P>
<B>exclusions: </B>current of lifetime schizophrenia, schizoaffective disorder, bipolar I disorder; current substance dependence (except for nicotine dependence); any type of current psychiatric treatment</P>
<P>
<B>level of functioning/severity of illness:</B> mean GAF score at baseline: 53.3, SD = 1.9; i.e. "moderate symptoms (e.g., flat affect and circumstantial speech, occasional panic attacks) OR moderate difficulty in social, occupational, or school functioning (e.g., few friends, conflicts with peers or co-workers)."</P>
<P>mean Sheehan Disability Scale-social impairment score about 4.8; mean vocational impairment subscale score was about 4.3. Scores of 5 or higher are regarded elevated and found to be associated with an increased risk of mental disorder and significant functional impairment (<LINK REF="REF-Rush--2005" TYPE="REFERENCE">Rush 2005</LINK>).</P>
<P>
<B>BPD diagnosis according to:</B> DSM-IV; all participants were newly diagnosed with BPD</P>
<P>
<B>means of assessment:</B> DIB-R, DIPD-IV (both sets of criteria had to be met for inclusion)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-06 11:22:40 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>group 1 (EG):</B> Psychoeducation workshop (PEW; i.e. latest information on BPD aetiology, phenomenology, co-occurring disorders, treatment options, longitudinal course; the workshop took place within a week of diagnostic disclosure)</P>
<P>
<B>group 2 (CG):</B> Waiting List (WL; i.e. subjects were to attend the PEW at the end of the 12-week study)</P>
<P>
<B>duration: </B>12 weeks</P>
<P>
<B>concomitant psychotherapy: </B>subjects that were in any type of current psychiatric treatment were not eligible for study participation</P>
<P>
<B>concomitant pharmacotherapy:</B> subjects that were in any type of current psychiatric treatment were not eligible for study participation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-06 11:22:42 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>outcomes considered in this review</B>
</P>
<P>
<B>self-rated: -</B>
</P>
<P>
<B>observer-rated: </B>Zanarini rating scale for borderline personality disorder (ZAN-BPD) - impulsivity, Zanarini rating scale for borderline personality disorder (ZAN-BPD) - disturbed relationships score</P>
<P>
<B>time-points used here: </B>week 12 (i.e. post-treatment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 15:33:08 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>analyses: </B>intention-to-treat analysis based on treatment assignment</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>APA: American Psychiatric Association<BR/>BDI: Beck depression inventory<BR/>CBT: cognitive behavioural therapy<BR/>CCT: client-centered therapy<BR/>CT: cognitive therapy<BR/>CTBE: community treatment by experts<BR/>DBT: dialectical behaviour therapy<BR/>BPD: borderline personality disorder<BR/>GAF: Global Assessment of Functioning Scale<BR/>GSFT: group schema-focused Therapy<BR/>HARS: Hamilton anxiety rating scale<BR/>IIP: inventory of interpersonal problems<BR/>IPDE: International Personality Disorder ExaminationITT: intention-to-treat<BR/>LOCF: last observation carried forward<BR/>MACT: manual-assisted cognitive treatment<BR/>MBT: mentalisation-based treatment<BR/>MBT_OP: outpatient mentalisation-based treatment<BR/>PTAU: psychotherapy treatment as usual<BR/>PTSD: post-traumatic stress disorder<BR/>SD: standard deviation<BR/>SFT: schema-focused therapy<BR/>SSRIs: selective serotonin reuptake inhibitors<BR/>STEPPS: systems training for emotional predictability and problem solving for borderline personality disorder<BR/>TAU: treatment as usual<BR/>TFP: transference-focused psychotherapy<BR/>TTA: therapist telephone availability<BR/>WL: waiting list</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-06-26 15:32:21 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:51:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abbass-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:51:07 +0100" MODIFIED_BY="[Empty name]">
<P>Participants: less than 70% of participants had a diagnosis of BPD.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:51:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Arnevik-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:51:07 +0100" MODIFIED_BY="[Empty name]">
<P>Participants: less than 70% of participants had a diagnosis of BPD.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:51:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ball-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:51:08 +0100" MODIFIED_BY="[Empty name]">
<P>Participants: less than 70% of participants had a diagnosis of BPD.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:51:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beecham-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:51:10 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:51:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bellino-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:51:15 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:51:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Berget-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:51:17 +0100" MODIFIED_BY="[Empty name]">
<P>Participants: less than 70% of participants had a diagnosis of BPD.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:51:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blum-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:51:18 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:51:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bohus-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:51:19 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:51:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bohus-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:51:19 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:51:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brassington-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:51:21 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:51:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brown-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:51:23 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:51:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carter-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:51:25 +0100" MODIFIED_BY="[Empty name]">
<P>Participants: presence of BPD diagnosis not assessed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:51:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chanen-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:51:26 +0100" MODIFIED_BY="[Empty name]">
<P>Participants: adolescents aged 15 to 18 years.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:51:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chiesa-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:51:27 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:51:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Clarkin-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:51:28 +0100" MODIFIED_BY="[Empty name]">
<P>Outcomes: unable to use data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:51:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Colom-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:51:32 +0100" MODIFIED_BY="[Empty name]">
<P>Participants: less than 70% of participants had a diagnosis of BPD.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:51:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dolan-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:51:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Evans-1999a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:51:38 +0100" MODIFIED_BY="[Empty name]">
<P>Participants: ratio of participants with BPD unclear.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:51:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Evans-1999b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:51:41 +0100" MODIFIED_BY="[Empty name]">
<P>Participants: ratio of participants with BPD unclear.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:51:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gabbard-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:51:43 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:51:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guthrie-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:51:44 +0100" MODIFIED_BY="[Empty name]">
<P>Participants: ratio of participants with BPD unclear.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:51:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hagen-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:51:46 +0100" MODIFIED_BY="[Empty name]">
<P>Participants: less than 70% of participants had a diagnosis of BPD.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:51:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huband-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:51:48 +0100" MODIFIED_BY="[Empty name]">
<P>Participants: less than 70% of participants had a diagnosis of BPD.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:51:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kool-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:51:49 +0100" MODIFIED_BY="[Empty name]">
<P>Participants: less than 70% of participants had a diagnosis of BPD.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:51:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Korner-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:51:50 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:51:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kr_x00f6_ger-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:51:52 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:51:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Linehan-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:51:57 +0100" MODIFIED_BY="[Empty name]">
<P>Outcomes: no pathology related outcomes of interest.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:51:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Linehan-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:51:59 +0100" MODIFIED_BY="[Empty name]">
<P>Outcomes: no pathology related outcomes of interest.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:52:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lynch-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:52:01 +0100" MODIFIED_BY="[Empty name]">
<P>Participants: less than 70% of participants had a diagnosis of BPD.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:52:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-L_x00f3_pez-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:52:02 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:52:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McQuillan-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:52:03 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:52:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meares-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:52:04 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:52:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mueser-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:52:06 +0100" MODIFIED_BY="[Empty name]">
<P>Participants: less than 70% of participants had a diagnosis of BPD.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:52:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Munroe_x002d_Blum-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:52:08 +0100" MODIFIED_BY="[Empty name]">
<P>Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:32:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Muran-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:32:21 +0100" MODIFIED_BY="[Empty name]">
<P>Participants: mixed sample of cluster C PDs.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:52:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Petersen-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:52:31 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:52:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ranger-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:52:33 +0100" MODIFIED_BY="[Empty name]">
<P>Participants: mixed sample of patients with severe mental illness, less than 70% of participants had a diagnosis of BPD.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:31:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rathus-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:31:29 +0100" MODIFIED_BY="[Empty name]">
<P>Participants: adolescents.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:31:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sachsse-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:31:29 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:31:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schuppert-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:31:29 +0100" MODIFIED_BY="[Empty name]">
<P>Participants: adolescents 14-19 years, mean age 16.14 years (SD = 1.23).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:52:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Slee-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:52:50 +0100" MODIFIED_BY="[Empty name]">
<P>Participants: unclear how many participants had a diagnosis of BPD, presence of personality disorders was not assessed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:31:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Springer-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:31:29 +0100" MODIFIED_BY="[Empty name]">
<P>Outcomes: no usable data for the BPD subsample available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 11:52:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stanley-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 11:52:55 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:31:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stevenson-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:31:30 +0100" MODIFIED_BY="[Empty name]">
<P>Allociation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:31:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stiles-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:31:30 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:31:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Trupin-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:31:30 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:31:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tyrer-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:31:30 +0100" MODIFIED_BY="[Empty name]">
<P>Participants: less than 70% of participants had a diagnosis of BPD.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:31:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tyrer-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:31:30 +0100" MODIFIED_BY="[Empty name]">
<P>Participants: unclear how many of participants actually had a diagnosis of BPD.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:31:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vinnars-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:31:30 +0100" MODIFIED_BY="[Empty name]">
<P>Participants: mixed sample of PDs, ratio of participants with BPD unclear.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:31:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Waltz-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:31:30 +0100" MODIFIED_BY="[Empty name]">
<P>Outcomes: no outcomes of interest for inclusion in this review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:31:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weertman-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:31:46 +0100" MODIFIED_BY="[Empty name]">
<P>Participants: people with BPD were not included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:31:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wildgoose-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:31:30 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:31:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yen-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:31:30 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:31:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zorn-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:31:31 +0100" MODIFIED_BY="[Empty name]">
<P>Participants: less than 70% of participants had a diagnosis of BPD.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>BPD: borderline personality disorder<BR/>PD: personality disorder<BR/>SD: standard deviation</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2010-05-03 15:53:49 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2012-07-10 12:00:10 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2012-06-05 13:27:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ACTRN12605000594628">
<CHAR_STUDY_NAME MODIFIED="2011-01-14 13:24:14 +0000" MODIFIED_BY="[Empty name]">
<P>A pilot study to evaluate the feasibility, safety and efficacy of psychotherapeutic intervention for comorbid BPD and first-episode psychosis</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-01-14 13:24:14 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-05 13:27:13 +0100" MODIFIED_BY="[Empty name]">
<P>Males and females aged 15 to 24 years with co-occurring first episode psychosis and full or sub-threshold BPD</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-03 20:17:05 +0100" MODIFIED_BY="[Empty name]">
<P>1. 16 sessions of Cognitive Analytic Therapy (CAT)</P>
<P>2. TAU</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-05 13:27:13 +0100" MODIFIED_BY="[Empty name]">
<P>Psychopathology, psychosocial functioning, and quality of life</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-01-14 13:24:14 +0000" MODIFIED_BY="[Empty name]">
<P>26 August 2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-01-14 13:24:14 +0000" MODIFIED_BY="[Empty name]">
<P>Prof. John Gleeson, Orygen Youth Health, Locked Bag 10, Parkville VIC 3052, Australia; jgleeson@unimelb.edu.au</P>
<P>Dr. Andrew Chanen, Orygen Youth Health, Locked Bag 10, Parkville VIC 3052, Australia; achanen@unimelb.edu.au</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-08-03 20:34:07 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-06-05 13:27:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ACTRN12606000206527">
<CHAR_STUDY_NAME MODIFIED="2012-06-04 11:59:48 +0100" MODIFIED_BY="[Empty name]">
<P>Process and outcome of acceptance-based outpatient skills training groups for people with four or more criteria of borderline personality disorder</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-08-08 14:27:27 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-05 13:27:19 +0100" MODIFIED_BY="[Empty name]">
<P>Males and females with four or more criteria of BPD</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-05 13:27:19 +0100" MODIFIED_BY="[Empty name]">
<P>Phase 1 is a 12 week two hours per week acceptance-based crisis skills training group. Clients have the option of continuing to Phase 2 which consists of an additional 30 weeks of skills training groups covering interpersonal skills, emotion regulation skills and mindfulness skills. The groups are a combination of Acceptance and Commitment Therapy and Dialectical Behaviour Therapy interventions in the context of Acceptance and Commitment Therapy principles of treatment.</P>
<P>Random allocation to immediate start of treatment of 3 months delay</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-05 13:27:19 +0100" MODIFIED_BY="[Empty name]">
<P>Utilisation of crisis emergency and inpatient services</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-08-08 14:30:29 +0100" MODIFIED_BY="[Empty name]">
<P>16 March 2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-08-08 14:31:18 +0100" MODIFIED_BY="[Empty name]">
<P>Elise Guymer, Spectrum PO Box 135 Ringwood East VIC 3135, Australia; eliseguymer@netscape.net</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-06-05 13:27:19 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-07-04 16:09:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ACTRN12610000100099">
<CHAR_STUDY_NAME MODIFIED="2012-06-05 13:27:24 +0100" MODIFIED_BY="[Empty name]">
<P>Monitoring Outcomes of Borderline personality disorder in Youth (MOBY): A randomised controlled trial (RCT) of specialised early intervention, with and without psychotherapy, versus a standard youth mental health intervention, for youth presenting with first presentation borderline personality disorder</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-01-14 13:26:45 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-05 13:27:24 +0100" MODIFIED_BY="[Empty name]">
<P>Males and females aged 15 to 25 years with a diagnosis of DSM-IV BPD</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-03 20:13:59 +0100" MODIFIED_BY="[Empty name]">
<P>1. HYPE: specialised early intervention service for BPD</P>
<P>2. YMH: Youth mental health care</P>
<P>3. BEF: Befriending</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-08-03 20:12:02 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: Interpersonal problems measured by the Inventory of Interpersonal Problems Circumplex Version (IIP-C); Social Adjustment measured by the Social Adjustment Scale Self Report (SAS-SR) </P>
<P>Secondary: Client satisfaction measured by the Client Satisfaction Questionnaire (CSQ-8); Suicidal Ideation as measured by the self-report Beck Suicidal Ideation Scale (BSS) and Mobiletype, a mobile phone program that asks open and closed questions about affect, suicidal ideation and parasuicidal behaviour; Parasuicidal Acts as measured by the Suicide Attempt and Self-Injury Interview (SASII) and Mobiletype, a mobile phone program that asks open and closed questions about affect, suicide ideation and parasuicidal behaviour; Affective Instability as measured by the 10-item self-report Short PANAS (Positive and Negative Affect Schedule), administered with Mobiletype; Borderline Personality Disorder Symptoms as measured by the Borderline Personality Disorder Severity Index (BPDSI-IV); Depression as measured by the self-report Center for Epidemiologic Studies Depression Scale - Revised (CESD-R) and the semi-structured interview and rating scale of the Montgomery-Asberg Depression Rating Scale (SIGMA); Substance Use as measured by the self-report Alcohol Use Disorders Identification Test (AUDIT) and the interview measure, the Opiate Treatment Index (OTI - Section II); Therapeutic Alliance as measured by the Working Alliance Inventory (WAI); Quality of Life as measured by the Assessment of Quality of Life (AQoL-8D); Social and Occupational Functioning as measured by the Social and Occupational Assessment of Functioning Scale (SOFAS); Emotion Regulation as measured by the Difficulties in Emotion Regulation Scale (DERS).   </P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-07-04 16:09:47 +0100" MODIFIED_BY="[Empty name]">
<P>10 March 2011</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-08-03 20:14:46 +0100" MODIFIED_BY="[Empty name]">
<P>Dr Andrew Chanen, Locked Bag 10, Parkville VIC 3052, Australia; achanen@unimelb.edu.au</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-06-05 13:27:25 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-06-26 15:25:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DRKS00000068">
<CHAR_STUDY_NAME MODIFIED="2011-08-08 14:52:32 +0100" MODIFIED_BY="[Empty name]">
<P>Psychoanalytical interactional psychotherapy in cluster B personality disorders</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-08-08 14:52:33 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-05 13:27:30 +0100" MODIFIED_BY="[Empty name]">
<P>Emotionally unstable personality disorder (ICD 10: F60.31), histrionic personality disorder (ICD 10: F60.4), dissocial personality disorder (ICD 10: 60.2), other specific personality disorders (ICD 10: F60.8)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 15:18:16 +0100" MODIFIED_BY="[Empty name]">
<P>Inpatient</P>
<P>1. Psychoanalytic-interactional psychotherapy</P>
<P>2. Psychodynamic therapy as usual</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-05 13:27:30 +0100" MODIFIED_BY="[Empty name]">
<P>Borderline Personality Inventory (BPI), SCL-90-R, BAI, BDI, IIP</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-08-08 15:00:03 +0100" MODIFIED_BY="[Empty name]">
<P>01 October 2008</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-26 15:25:46 +0100" MODIFIED_BY="[Empty name]">
<P>Prof Dr Falk Leichsenring, Falk.Leichsenring@psycho.med.uni-giessen.de</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-06-26 15:25:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ISRCTN12440268">
<CHAR_STUDY_NAME MODIFIED="2011-08-03 19:48:23 +0100" MODIFIED_BY="[Empty name]">
<P>JOSHUA: a pilot randomised controlled trial of joint crisis plans for people who self harm</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-08-03 19:48:51 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-03 19:55:59 +0100" MODIFIED_BY="[Empty name]">
<P>1. Service users (both males and females) aged 18 years or older 2. Current contact with a local Community Mental Health Team (CMHT) (will include assessment and brief treatment, continuing care, home treatment and out-patient clinics attached to these teams) 3. A primary clinical diagnosis of emotionally unstable personality disorder (International Statistical Classification of Diseases and Related Health Problems, 10th Revision [ICD-10] code F60.3) 4. An episode of self-harm in the previous year</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-03 19:59:20 +0100" MODIFIED_BY="[Empty name]">
<P>6 months of</P>
<P>1. joint crisis plan</P>
<P>2. TAU</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-05 13:27:36 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: Self-harm history, assessed by a questionnaire at baseline and 6 months (trial end).</P>
<P>Secondary: 1. Client's experience of the treatment that he or she received at a particular service, assessed by the Treatment Experience Scale assessed at baseline and 6 months 2. Service Engagement Scale at baseline, 6 months (trial end) and trial drop-out 3. The Work and Social Adjustment Scale (WSAS) at baseline and 6 months (trial end) 4. Euroqol EQ-5D at baseline and 6 months (trial end) 5. Client Satisfaction Questionnaire at baseline and 6 months (trial end) 6. Working Alliance Inventory - short version (WAI-S) (client version) at baseline and 6 months (trial end). This is a measure of how well a client and a clinician work together. 7. WAI-S (staff version) at baseline, 6 months (trial end) and trial drop-out 8. Adult Service Use Schedule (ADSUS) to assess which services clients have accessed in the preceding 6 months, for health economics purposes, carried out at baseline and 6 months (trial end) 9. Alcohol Use Disorders Identification Test (AUDIT) at baseline 10. Hospital Anxiety and Depression scale (HADS) at baseline</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-08-03 19:58:41 +0100" MODIFIED_BY="[Empty name]">
<P>01 October 2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-26 15:25:39 +0100" MODIFIED_BY="[Empty name]">
<P>Dr Paul Moran, Sir David Goldberg Building, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, UK, paul.moran@iop.kcl.ac.uk</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-06-05 13:27:36 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-06-26 15:25:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ISRCTN51304415">
<CHAR_STUDY_NAME MODIFIED="2011-08-08 15:18:38 +0100" MODIFIED_BY="[Empty name]">
<P>Nice OUtcomes for Referrals with Impulsivity, Self Harm and Eating Disorders: The NOURISHED Study</P>
<P>A randomised controlled trial of mentalisation based therapy against specialist supportive clinical management in patients with both eating disorders and symptoms of borderline personality disorder</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-08-08 15:18:42 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-08 15:18:57 +0100" MODIFIED_BY="[Empty name]">
<P>1. Aged over 18 years, either sex<BR/>2. Eating disorder diagnosis<BR/>3. Borderline personality disorder (BPD) symptoms. The criteria for "BPD symptoms" are that the patient fulfils both behavioural criteria of the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV), namely:<BR/>3.1. Impulsivity in at least two areas that are potentially self-damaging (e.g., spending, sexual behaviour, substance abuse, reckless driving, binge eating)<BR/>3.2. Recurrent suicidal behaviour, or self-mutilating behaviour<BR/>4. Able and willing to provide written informed consent</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-05 13:27:56 +0100" MODIFIED_BY="[Empty name]">
<P>One year of</P>
<P>1. MCT (outpatient)</P>
<P>2. specialist supportive clinical management</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-05 13:27:51 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: Eating disorder symptoms</P>
<P>Secondary: 1. Borderline Personality Disorder symptoms will be measured 6-monthly using the total score of the ZAN-BPD (Time points 0, 6, 12, 18 months); 2. The economic evaluation will examine the costs-effectiveness of Mentalization Based Therapy and Specialist Supportive Clinical Management including an analysis of incremental cost per QALY; 3. Participant rated general psychiatric symptoms of Borderline Personality Disorder will be measured 6-monthly using the DASS-21 (Time points 0, 6, 12, 18 months); 4. Possible mediators of change in Borderline Personality Disorder symptoms include reflective function and object relations, measured by the Reflective Function Questionnaire, The Reading the Mind in the Eyes test and the Object Relations Inventory and personality factors (e.g. resilience, dysregulation, restriction) thought to be important in Eating Disorders (Time points 0, 6, 12, 18 months)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-08-08 15:20:44 +0100" MODIFIED_BY="[Empty name]">
<P>01 April 2011</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-26 15:25:30 +0100" MODIFIED_BY="[Empty name]">
<P>Dr Paul Robinson, Research Department, St. Ann's Hospital, London; drpaulrobinson@gmail.com</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-06-05 13:27:56 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-06-26 15:25:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ISRCTN54233644">
<CHAR_STUDY_NAME MODIFIED="2011-08-04 10:17:06 +0100" MODIFIED_BY="[Empty name]">
<P>Dialectical behaviour therapy in patients with borderline personality disorder who self-harm: a pragmatic exploratory trial</P>
<P>DIALECT</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-08-04 10:17:08 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-26 15:11:02 +0100" MODIFIED_BY="[Empty name]">
<P>1. Frequent self-harm (more than 5 days with self-harm over 12 months)<BR/>2. Aged 16 years and older, either sex<BR/>3. Sufficient command of English<BR/>4. At least one personality disorder</P>
<P>Exclusion: learning disabilities</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 15:10:21 +0100" MODIFIED_BY="[Empty name]">
<P>DBT and care co-ordination versus waiting list control group with standard NHS care, over 12 months. DBT consists of 3 hours of therapy a week: this comprises 1 hour of individual therapy and 2 hours of group skills classes.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-26 15:10:13 +0100" MODIFIED_BY="[Empty name]">
<P>Days with self-harm during the 12 month period.</P>
<P>1. Pre-post changes in self-harming during the 12 month period<BR/>2. Number of accident and emergency (A&amp;E) attendances during the 12 month period<BR/>3. Inpatient admissions during the 12 month period<BR/>4. Use of other services in primary and secondary care during the 12 month period<BR/>5. Service costs during the 12 month period<BR/>6. Use of medication during the 12 month period<BR/>7. Pre-post changes in self-rated and observer-rated symptom level and quality of life at the end of the 12 month period<BR/>8. Quality of the therapeutic relationship at the end of the 12 month period<BR/>9. Treatment satisfaction at the end of the 12 month period</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-06-26 15:11:26 +0100" MODIFIED_BY="[Empty name]">
<P>01 February 2008</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-26 15:25:24 +0100" MODIFIED_BY="[Empty name]">
<P>Prof S Priebe, Unit for Community and Social Psychiatry, Newham Centre for Mental Health, Plaistow, London <A HREF="mailto:s.priebe@qmul.ac.uk">s.priebe@qmul.ac.uk</A>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-07-04 16:10:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ISRCTN72677277">
<CHAR_STUDY_NAME MODIFIED="2011-08-08 15:54:52 +0100" MODIFIED_BY="[Empty name]">
<P>Psychological treatments for severe and complex mental health problems/personality disorder. A phase II randomised controlled trial</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-08-08 15:54:54 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-08 15:55:45 +0100" MODIFIED_BY="[Empty name]">
<P>Adult out-patients (18-65) of community mental health teams (CMHTs); Minimum one year history of severe, complex mental health problems, diagnosis of at least one Cluster B personality disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-05 13:28:13 +0100" MODIFIED_BY="[Empty name]">
<P>1. CMHT management alone</P>
<P>2. CMHT management plus cognitively-based psychotherapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-07-04 16:10:09 +0100" MODIFIED_BY="[Empty name]"/>
<CHAR_STARTING_DATE MODIFIED="2012-07-04 16:10:05 +0100" MODIFIED_BY="[Empty name]">
<P>01 May 2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-26 15:25:20 +0100" MODIFIED_BY="[Empty name]">
<P>Prof G Parry, University of Sheffield, G.D.Parry@sheffield.ac.uk</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-07-04 16:10:01 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-06-26 15:25:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ISRCTN79187618">
<CHAR_STUDY_NAME MODIFIED="2011-08-08 16:04:43 +0100" MODIFIED_BY="[Empty name]">
<P>Psychoanalytically oriented brief group treatment for borderline personality disorder: A randomised controlled trial</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-08-08 16:04:45 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-08 16:05:06 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical diagnosis of Borderline Personality Disorder meeting DSM-IV criteria and clinical judgment of capacity of psychological mindedness.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 15:18:31 +0100" MODIFIED_BY="[Empty name]">
<P>1. Psychoanalytic brief group treatment, 20 weeks</P>
<P>2. Waiting list</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-05 13:28:19 +0100" MODIFIED_BY="[Empty name]">
<P>Self harm, suicidal ideation, reduction in symptoms, functioning, cost implications</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-08-08 16:06:20 +0100" MODIFIED_BY="[Empty name]">
<P>09 January 2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-26 15:25:15 +0100" MODIFIED_BY="[Empty name]">
<P>Dr Ravi Lingam, Regional Department of Psychotherapy, Newcastle upon Tyne, Ravi.Lingam@nmht.nhs.uk</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-06-05 13:28:19 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-07-04 14:17:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ISRCTN98982683">
<CHAR_STUDY_NAME MODIFIED="2011-08-04 10:09:24 +0100" MODIFIED_BY="[Empty name]">
<P>MBTDD: Mentalisation-Based Treatment for Dual Diagnoses - a randomised controlled trial</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-08-04 10:09:26 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-04 10:10:12 +0100" MODIFIED_BY="[Empty name]">
<P>Meet Diagnostic and Statistical Manual of Mental Disorders, Fourth edition (DSM-IV) criteria for borderline personality disorder, meet DSM-IV criteria for opiate dependence (present or in remission), ongoing pharmacological treatment with buprenorphine or methadone for at least 3 months, aged 18 to 65 years, either sex</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-05 13:28:26 +0100" MODIFIED_BY="[Empty name]">
<P>18 months of</P>
<P>1. MBT + medication assisted treatment (MAT)</P>
<P>2. MAT alone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-07-04 14:17:01 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: BPDSI-IV</P>
<P>Secondary: 1. Timeline Follow Back and specimens of urine for use of opiates, alcohol and other drugs, 2. Beck's Suicidal Intent Scale (SIS), 3. Deliberate Self-Harm Inventory (DSHI-9), 4. Global Assessment of Functioning (GAF), 5. Symptom Check List 90 (SCL-90), 6. Inventory of Interpersonal Problems (IIP), short version, 7. Social Adjustment Scale - Self Report (SAS-SR), 8. Retention in treatment, 9. Reflective Functioning Interview (for mediator analysis)<BR/>Long-term follow up from register data: 10. Health economy (health care utilisation and work/income), 11. Criminality, 12. Survival</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-08-04 10:13:44 +0100" MODIFIED_BY="[Empty name]">
<P>01 April 2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-08-04 10:14:38 +0100" MODIFIED_BY="[Empty name]">
<P>Dr. Björn Philips, Stockholm County Council, Center for Dependency Disorders, Stockhol, Sweden; bjorn.philips@ki.se</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-06-26 15:25:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-J_x00f8_rgensen-2009">
<CHAR_STUDY_NAME MODIFIED="2011-08-05 10:24:55 +0100" MODIFIED_BY="[Empty name]">
<P>Risskov-I study</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-08-05 10:24:58 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-05 13:28:35 +0100" MODIFIED_BY="[Empty name]">
<P>Males and females with diagnosis of BPD according to SCID-II</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-05 13:28:35 +0100" MODIFIED_BY="[Empty name]">
<P>2 years of</P>
<P>1. combined MBT (outpatient; weekly individual psychotherapy, weekly group psychotherapy, group-based psychoeducation once a month, medical treatment acc. to APA guidelines)</P>
<P>2. supportive psychotherapy (outpatient; two hours of supportive group therapy every two weeks, group-based psychoeducation once a month, medical treatment acc. to APA guidelines)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-08-05 10:29:46 +0100" MODIFIED_BY="[Empty name]">
<P>SCL-90-R, BDI-II, STAI, BAI, SAS-SR, GAF, suicide attempts and self-destructive behaviour (SUSS), NEO-PI-R, DSQ-40</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-06-05 13:28:35 +0100" MODIFIED_BY="[Empty name]">
<P>No information</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-26 15:25:06 +0100" MODIFIED_BY="[Empty name]">
<P>Prof Carsten René Jørgensen PhD, Department of Psychology, University of Aarhus; carsten@psy.au.dk</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-06-05 13:28:35 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-06-26 15:24:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00117741">
<CHAR_STUDY_NAME MODIFIED="2012-06-05 13:28:40 +0100" MODIFIED_BY="[Empty name]">
<P>Evaluation of DBT compared to drug counselling for opiate addicts</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-08-04 09:33:24 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-05 13:28:40 +0100" MODIFIED_BY="[Empty name]">
<P>Fulfil SCID-I criteria for opiate dependence, meet IPDE and SCID criteria for BPD (DSM-IV), over 18 years old</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 15:18:42 +0100" MODIFIED_BY="[Empty name]">
<P>1. DBT</P>
<P>2. Individual and group drug counselling</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-05 13:28:40 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: urinalysis (drug screening)</P>
<P>Secondary: suicidal behaviour, depression, anxiety, Axis I diagnostic remission</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-08-04 09:35:22 +0100" MODIFIED_BY="[Empty name]">
<P>June 2004</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-26 15:24:35 +0100" MODIFIED_BY="[Empty name]">
<P>Marsha Linehan PhD, University of Washington</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-06-05 13:28:40 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-06-26 15:25:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00183651">
<CHAR_STUDY_NAME MODIFIED="2011-08-04 09:37:32 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment of suicidal women with borderline personality disorder</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-08-04 09:37:33 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-05 13:28:46 +0100" MODIFIED_BY="[Empty name]">
<P>Females with diagnosis of BPD, at least one suicide attempt in the year prior to the study entry and at least one intentional self-injury within the 8 weeks prior to study entry, aged 18 to 60 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 15:18:51 +0100" MODIFIED_BY="[Empty name]">
<P>1. Standard DBT</P>
<P>2. Individual DBT without DBT group sessions</P>
<P>3. Group skills DBT without DBT individual sessions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-05 13:28:46 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: suicidal thoughts or attempts</P>
<P>Secondary: coping skills</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-08-04 09:41:08 +0100" MODIFIED_BY="[Empty name]">
<P>April 2004</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-26 15:25:01 +0100" MODIFIED_BY="[Empty name]">
<P>Marsha M Linehan PhD, University of Washington</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-06-05 13:28:46 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-06-26 15:24:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00218595">
<CHAR_STUDY_NAME MODIFIED="2011-08-04 10:34:32 +0100" MODIFIED_BY="[Empty name]">
<P>DBT Compared to I/GDC for the Treatment of Opiate Addiction in Emotionally Dysregulated Patients.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-08-04 10:34:34 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-04 10:35:14 +0100" MODIFIED_BY="[Empty name]">
<P>Meet SCID-I criteria for opiate dependence, meet IPDE and SCID criteria for BPD (DSM-IV), over 18 years old</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-05 13:28:53 +0100" MODIFIED_BY="[Empty name]">
<P>1. DBT + opiate replacement medication</P>
<P>2. Individual and group drug counselling + opiate replacement medication</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-05 13:28:53 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Drug use: The primary outcome measure here is proportions of urinalysis (UA) coded positive for opiates;</LI>
<LI>Suicidal behaviours: The primary outcome measure here is number of suicides + suicide attempts. The domain of suicidal behaviours also includes (a) the number, medical risk, risk/rescue score and suicide intent of all parasuicide, (b) the number of suicide threats and suicide crises, and (c) the level of suicidal ideation and suicide intent;</LI>
<LI>Therapy-interfering behaviours: The primary outcome measure here is maintenance in therapy;</LI>
<LI>Quality of life interfering behaviours: The primary outcome measure here is combined number of days on a psychiatric inpatient unit + days in jail (THI, SHI);</LI>
<LI>Behavioral skills: The primary outcome measure here is the DBT Skills scale score from the Revised Ways of Coping Checklist (RWCCL);</LI>
<LI>Risky sexual behaviour: the primary outcome measure here is the number of risky sexual behaviours in the time period [Casual Partners questionnaire revised [CPQ-R] and diary card].</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-08-04 10:38:01 +0100" MODIFIED_BY="[Empty name]">
<P>August 2004</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-26 15:24:58 +0100" MODIFIED_BY="[Empty name]">
<P>M Zachary Rosenthal PhD, Duke University Medical Center; National Institute on Drug Abuse (NIDA)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-06-05 13:28:53 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-06-26 15:24:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00247234">
<CHAR_STUDY_NAME MODIFIED="2011-08-03 20:58:29 +0100" MODIFIED_BY="[Empty name]">
<P>Effectiveness of Group Based Schema Therapy in the Treatment of Personality Disorders</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-08-03 20:58:39 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-03 20:59:01 +0100" MODIFIED_BY="[Empty name]">
<P>BPD or avoidant personality disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 15:18:59 +0100" MODIFIED_BY="[Empty name]">
<P>1. Schema therapy</P>
<P>2. Standard psychiatric outpatient care</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-05 13:29:00 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: Self-report measures of quality of life, depression, anxiety, suicidal ideation interpersonal function</P>
<P>Secondary: Number of diagnostic criteria (reSCID), Drop-out rate ,Social adjustment</P>
<P>Use of psychotropic medication</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-08-03 21:02:57 +0100" MODIFIED_BY="[Empty name]">
<P>September 2004</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-26 15:24:18 +0100" MODIFIED_BY="[Empty name]">
<P>Gunilla K Fosse, gunilla.fosse@ntnu.no</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-06-05 13:29:00 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-07-04 14:17:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00378248">
<CHAR_STUDY_NAME MODIFIED="2011-08-09 10:28:09 +0100" MODIFIED_BY="[Empty name]">
<P>Ullevål personality project</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-08-09 10:28:10 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-09 10:28:45 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with personality disorders admitted to Department for personality psychiatry, Psychiatric division, Ullevål University Hospital</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 15:19:03 +0100" MODIFIED_BY="[Empty name]">
<P>1. 18 weeks day hospital treatment followed by long-term outpatient combined group- and individual psychotherapy</P>
<P>2. Outpatient individual psychotherapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-07-04 14:17:05 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: psychosocial functioning, symptom distress, self-esteem, interpersonal problems, self-destructive behaviour, personality pathology, quality of life, health care utilisation</P>
<P>Secondary: affect consciousness, reflective functioning</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-08-09 10:30:52 +0100" MODIFIED_BY="[Empty name]">
<P>May 2004</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-26 15:24:52 +0100" MODIFIED_BY="[Empty name]">
<P>Theresa Wilberg MD PhD, Ullevål University Hospital Oslo, Norway</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-06-05 13:29:06 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-06-26 15:24:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00533117">
<CHAR_STUDY_NAME MODIFIED="2011-08-04 10:40:55 +0100" MODIFIED_BY="[Empty name]">
<P>Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-08-04 10:40:57 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-04 11:16:31 +0100" MODIFIED_BY="[Empty name]">
<P>Meet criteria for DSM-IV diagnosis of borderline personality disorder, History of at least one suicide attempt or self-mutilation episode 12 months prior to study entry, continued urges to self-mutilate or attempt suicide</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 15:19:11 +0100" MODIFIED_BY="[Empty name]">
<P>12 months of</P>
<P>1. DBT + fluoxetine</P>
<P>2. DBT + placebo</P>
<P>3. Supportive psychotherapy + fluoxetine</P>
<P>4. Supportive psychotherapy + placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-05 13:29:11 +0100" MODIFIED_BY="[Empty name]">
<P>Suicidal ideation, suicide attempts, self-mutilation</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-08-04 10:45:28 +0100" MODIFIED_BY="[Empty name]">
<P>March 2001</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-26 15:24:11 +0100" MODIFIED_BY="[Empty name]">
<P>Barbara Stanley PhD, bhs2@columbia.edu</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-06-26 15:19:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00603421">
<CHAR_STUDY_NAME MODIFIED="2011-08-09 10:53:48 +0100" MODIFIED_BY="[Empty name]">
<P>Effectiveness of a 24 Hour Phone Line on the Rate of Suicide Attempts in Borderline Patients</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-08-09 10:53:51 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-26 15:19:17 +0100" MODIFIED_BY="[Empty name]">
<P>Borderline patients (male or female) aged 18 to 40 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 15:19:15 +0100" MODIFIED_BY="[Empty name]">
<P>One year of</P>
<P>1. TAU + access to a 24 hour crisis phone line</P>
<P>2. TAU</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-05 13:29:15 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: rate of suicide attempts</P>
<P>Secondary: rate of self-injurious behaviours</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-08-09 10:55:28 +0100" MODIFIED_BY="[Empty name]">
<P>February 2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-08-09 10:56:45 +0100" MODIFIED_BY="[Empty name]">
<P>Alexandra Pham-Scottez, a.pham@ch-sainte-anne.fr; Daniel Guelfi, jd.guelfi@ch-sainte-anne.fr; Hôpital St. Anne, Paris, France</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-06-05 13:29:16 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-06-26 15:24:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00834834">
<CHAR_STUDY_NAME MODIFIED="2011-08-04 10:47:50 +0100" MODIFIED_BY="[Empty name]">
<P>Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality Disorder</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-08-04 10:47:52 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-05 13:29:21 +0100" MODIFIED_BY="[Empty name]">
<P>Meet DSM-IV criteria for borderline personality disorder (BPD) - attempted suicide in the past 2 months - at least one additional suicide attempt, suicide-related behaviour, or self-injury episode in the past year - current suicidal ideation - Able to be managed as an outpatient</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-04 10:50:33 +0100" MODIFIED_BY="[Empty name]">
<P>6 months of</P>
<P>1. SSRI antidepressive medication (fluoxetine or citalopram) + clinical management</P>
<P>2. DBT</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-05 13:29:21 +0100" MODIFIED_BY="[Empty name]">
<P>Suicidal and self-injurious behaviour</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-08-04 10:52:12 +0100" MODIFIED_BY="[Empty name]">
<P>March 2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-26 15:24:02 +0100" MODIFIED_BY="[Empty name]">
<P>Barbara H Stanley PhD, New York State Psychiatric Institute, bhs2@columbia.edu</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-07-04 16:10:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00980824">
<CHAR_STUDY_NAME MODIFIED="2011-08-03 20:36:57 +0100" MODIFIED_BY="[Empty name]">
<P>ENGAGE - Meeting Mental Health Needs of Complex Comorbid Patients Attending A&amp;E Following a Suicide Attempt. A Pilot Study.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-08-03 20:37:00 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-05 13:29:27 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with a recent episode of suicide, personality disorder and drug or alcohol abuse</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 15:19:46 +0100" MODIFIED_BY="[Empty name]">
<P>1. Six sessions of ENGAGE CBT (based on manualised-cognitive therapy, MACT)</P>
<P>2. TAU</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-07-04 16:10:26 +0100" MODIFIED_BY="[Empty name]"/>
<CHAR_STARTING_DATE MODIFIED="2012-07-04 16:10:22 +0100" MODIFIED_BY="[Empty name]">
<P>November 2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-07-04 16:10:20 +0100" MODIFIED_BY="[Empty name]"/>
<CHAR_NOTES MODIFIED="2011-08-03 20:45:34 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-06-05 13:29:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01033708">
<CHAR_STUDY_NAME MODIFIED="2011-08-04 10:01:45 +0100" MODIFIED_BY="[Empty name]">
<P>NET: A Randomized Control Trial of Narrative Exposure Therapy Versus Treatment as Usual in the Therapy of Borderline Personality Disorder</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-08-04 10:02:15 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-04 10:02:59 +0100" MODIFIED_BY="[Empty name]">
<P>DSM-IV -TR Diagnosis axis II: borderline personality disorder; axis I: posttraumatic stress disorder - stable medication - age 18-45 years, gender female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-05 13:29:32 +0100" MODIFIED_BY="[Empty name]">
<P>1. Narrative exposure therapy (NET), trauma-focused treatment for survivors of prolonged and repeated exposure to traumatic stress and childhood adversity</P>
<P>2. TAU</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-05 13:29:33 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: Clinician-Administered PTSD Scale (CAPS)</P>
<P>Secondary: Borderline symptom checklist 23 (BSL)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-08-04 10:05:36 +0100" MODIFIED_BY="[Empty name]">
<P>October 2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-08-04 10:08:04 +0100" MODIFIED_BY="[Empty name]">
<P>A. Pabst, Zentrum Integrative Psychiatrie, Kiel, Germany; a.pabst@zip-kiel.de</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-08-04 10:08:11 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-06-26 15:23:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01081314">
<CHAR_STUDY_NAME MODIFIED="2011-08-03 21:16:34 +0100" MODIFIED_BY="[Empty name]">
<P>Treating PTSD in Patients With Borderline Personality Disorder</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-08-03 21:16:36 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-26 15:21:36 +0100" MODIFIED_BY="[Empty name]">
<P>Females aged 18 to 60 years with BPD and post-traumatic stress disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 15:21:33 +0100" MODIFIED_BY="[Empty name]">
<P>1. Standard DBT + PTSD protocol (modified version of prolonged exposure therapy for PTSD)</P>
<P>2. Standard DBT</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-05 13:29:39 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: PTSD Symptom Scale - Interview, Suicide Attempt Self-Injury Interview</P>
<P>Secondary: Dissociative Experiences Scale, Hamilton Rating Scale for Depression, Suicidal Behaviors Questionnaire, Treatment History Interview</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-08-03 21:21:06 +0100" MODIFIED_BY="[Empty name]">
<P>August 2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-26 15:23:51 +0100" MODIFIED_BY="[Empty name]">
<P>Melanie S Harned PhD; University of Washington, USA; mharned@u.washington.edu</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-08-03 21:19:20 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-06-05 13:29:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01132976">
<CHAR_STUDY_NAME MODIFIED="2011-08-09 12:15:14 +0100" MODIFIED_BY="[Empty name]">
<P>The personal concerns inventory study (PCI). The Addition of a Goal-based Motivational Interview to Standardised Treatment as Usual to Reduce Dropouts From a Service for Patients With Personality Disorder: A Feasibility Study</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-08-09 12:14:42 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-09 12:16:32 +0100" MODIFIED_BY="[Empty name]">
<P>Referred to the Nottinghamshire Personality Disorder and Development Network, aged 18 or older, male or female</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-09 12:17:00 +0100" MODIFIED_BY="[Empty name]">
<P>1. TAU + goal-based motivational interview</P>
<P>2. TAU</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-05 13:29:46 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: recruitment (indicating feasibility), acceptability to patients, acceptability of staff</P>
<P>Secondary: Treatment engagement (TER), Client Service Receipt Inventory, treatment attendance</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-08-09 12:18:33 +0100" MODIFIED_BY="[Empty name]">
<P>December 2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-08-09 12:19:44 +0100" MODIFIED_BY="[Empty name]">
<P>Lucy E Hedges, lucy.hedges@nottshc.nhs.uk, Mary McMurran, Mary.McMurran@nottingham.ac.uk; Nottinghamshire Personality Disorder &amp; Development Network, Nottingham, UK</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-06-05 13:29:46 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-06-26 15:23:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01193205">
<CHAR_STUDY_NAME MODIFIED="2011-08-04 09:42:28 +0100" MODIFIED_BY="[Empty name]">
<P>20 weeks DBT group skills training study</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-08-04 09:42:30 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-05 13:29:52 +0100" MODIFIED_BY="[Empty name]">
<P>DSM-IV BPD, 18-60 years of age, two suicidal or non-suicidal self-injurious behaviours in the past five years with one occurring the past ten weeks prior to study entry</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 15:21:45 +0100" MODIFIED_BY="[Empty name]">
<P>1. DBT skills training group</P>
<P>2. Wait list</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-05 13:29:52 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: deliberate self-harm (DSHI)</P>
<P>Secondary: emergency and psychiatric hospitalizations (THI-2), impulsive behaviour (BIS-11), anger expressions (STAXI), severity of BPD symptoms (BEST), overall psychopathology (SCL-90-R)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-08-04 09:47:26 +0100" MODIFIED_BY="[Empty name]">
<P>July 2010</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-26 15:23:36 +0100" MODIFIED_BY="[Empty name]">
<P>Shelley McMain PhD, Centre for Addiction and Mental Health, Toronto/Canada; shelley_mcmain@camh.net</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-02-03 10:21:03 +0000" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-06-26 15:23:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NTR1186">
<CHAR_STUDY_NAME MODIFIED="2011-08-04 10:54:12 +0100" MODIFIED_BY="[Empty name]">
<P>Efficacy of Schema-Focused Therapy versus Usual Treatment in Forensic Patients with Personality Disorders: A Three-Year Randomized Clinical Trial.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-08-04 10:54:14 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-05 13:29:57 +0100" MODIFIED_BY="[Empty name]">
<P>Forensic patients with Antisocial, Borderline, Narcissistic, or Paranoid Personality Disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 15:17:58 +0100" MODIFIED_BY="[Empty name]">
<P>Forensic setting, three years of</P>
<P>1. individual SFT</P>
<P>2. individual TAU</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-06 11:25:17 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: severity of personality disorder symptoms, risk of recidivism and violence secondary: therapy process variables (e.g., therapeutic engagement, quality of the therapeutic alliance), and changes in the psychological processes (i.e. Early Maladaptive Schemas, Schema Modes) that are hypothesized to mediate changes in personality disorders in the Schema Focused Therapy model.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-08-04 10:59:28 +0100" MODIFIED_BY="[Empty name]">
<P>01 October 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-26 15:23:24 +0100" MODIFIED_BY="[Empty name]">
<P>Prof David Bernstein, University of Maastricht, Departement of Clinical Psychological Science, P.O. Box 616, 6200 M, Maastricht, NL; D.Bernstein@dmkep.unimaas.nl</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-06-05 13:29:58 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-06-26 15:22:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NTR2175">
<CHAR_STUDY_NAME MODIFIED="2011-08-03 20:47:50 +0100" MODIFIED_BY="[Empty name]">
<P>Mentalisation-Based Treatment versus care-as-usual in the treatment of severe borderline personality disorders</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-08-03 20:48:02 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-03 20:48:39 +0100" MODIFIED_BY="[Empty name]">
<P>A severe BPD on the basis of standardised criteria for borderline personality disorder and assessed with the Dutch version of the Structured Clinical Interview for DSM-III-R (SCID-II) (13), and the Borderline Personality Disorder Severity Index (BPDSI) (14). Patients must meet the criteria for borderline personality disorder as determined with the SCID-II and have a total score on the BPDSI of at least 24, indicating a severe BPD. Patients with co-morbid personality disorders will not be excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-05 13:30:04 +0100" MODIFIED_BY="[Empty name]">
<P>36 months of</P>
<P>1. MBT</P>
<P>2. TAU</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-05 13:30:04 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: frequency and severity of manifestations of BPD as measured with the BPDSI</P>
<P>Secondary: 1. Number of suicide acts; 2. Self-mutilation; 3. Depression; 4. Subjective experiences of symptoms; 5. Social and interpersonal functioning; 6. Personality functioning; 7. Quality of life; 8. Treatment adherence</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-08-03 20:52:24 +0100" MODIFIED_BY="[Empty name]">
<P>01 March 2010</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-26 15:22:34 +0100" MODIFIED_BY="[Empty name]">
<P>Prof Dr J Dekker, Viersprong Institute for Studies on Personality Disorders (BISPD), Department of Rehabilitation Medicine, VUmc PO Box 7057, 1007 MB, Amsterdam, NL; j.dekker@vumc.nl</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-06-05 13:30:04 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-06-05 13:30:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NTR2292">
<CHAR_STUDY_NAME MODIFIED="2011-08-09 12:34:59 +0100" MODIFIED_BY="[Empty name]">
<P>Intensive Outpatient Mentalisation-Based Treatment versus Day Hospital Mentalisation-Based Treatment: A randomised controlled trial.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-08-09 12:35:01 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-09 12:35:17 +0100" MODIFIED_BY="[Empty name]">
<P>1. Referral to the MBT-program as implemented by De Viersprong, i.e. 18-month psychotherapy designed specifically for treatment refractory patients with complex personality disorders, often complicated by multi-morbidity, who have typically had a history of unsuccessful treatments;<BR/>2. At least one PD as diagnosed according to DSM-IV criteria.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-02 12:40:25 +0100" MODIFIED_BY="[Empty name]">
<P>1. MBT-program consists of a maximum of 18 months MBT and continued by a maximum of 18 months of maintenance mentalising (group) therapy.<BR/>2. MBT-DH: The day hospital program includes daily group psychotherapy, weekly individual psychotherapy, individual crisis planning from a mentalising perspective, art therapy twice a week, mentalising cognitive therapy and writing therapy.<BR/>3. MBT-IOP: The outpatient MBT program consists of group psychotherapy twice a week, weekly individual psychotherapy, and individual crisis planning from a mentalising perspective.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-05 13:30:10 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: 1. Frequency and severity of manifestations of (borderline) personality disorder (SCID-II, PAI-BOR); 2. Number of suicide acts (SSHI); 3. Number of self-mutilation acts (SSHI); 4. Subjective experience of symptoms (BSI); 5. Quality of life (EQ-5D); 6. Care consumption (TiC-P)secondary: 1. Axis I diagnosis (SCID-I); 2. Depression (BDI); 3. Interpersonal functioning (IIP); 4. Personality functioning (DAPP-SF); 5. Mentalisation (ECR, RFQ); 6. Treatment adherence</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-08-09 12:38:14 +0100" MODIFIED_BY="[Empty name]">
<P>08 February 2010</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-08-09 12:38:53 +0100" MODIFIED_BY="[Empty name]">
<P>PhD Helene Adrea, Viersprong Institute for Studies on Personality Disorders (VISPD), The Netherlands</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-06-05 13:30:10 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-06-26 15:22:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NTR2392">
<CHAR_STUDY_NAME MODIFIED="2011-08-04 11:01:54 +0100" MODIFIED_BY="[Empty name]">
<P>Group Schema Therapy for Borderline Personality Disorder</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-08-04 11:01:56 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-08-04 11:02:40 +0100" MODIFIED_BY="[Empty name]">
<P>Age 18-65 year; primary DSM-IV diagnosis of BPD (assessed with the SCID-II interview); BPD severity above 20 on the BPDSI interview</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 15:22:18 +0100" MODIFIED_BY="[Empty name]">
<P>1. 118 group Schema Therapy sessions over 2 years with max. 17 individual sessions.</P>
<P>2. 64 group Schema Therapy over 2 years with max. 61 individual sessions</P>
<P>3. TAU - the standard treatment given for that patient at the treatment centre.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-05 13:30:15 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: Borderline Personality Disorder Severity Index, mean score</P>
<P>Secondary: BPD-checklist, BSI, GAF, Work; Social Adjustment Scale, Social Occupational Functioning Assessment Scale, Social Adjustment Scale-Self Report; WHOQOL, EuroQol, Happiness Rating; Schema questionnaire, Schema Mode Inventory, Group Climate Questionnaire (GCQ-S).</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-08-04 11:04:51 +0100" MODIFIED_BY="[Empty name]">
<P>01 February 2010</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-08-04 11:05:39 +0100" MODIFIED_BY="[Empty name]">
<P>Prof. Arnoud Arntz, University Maastricht (UM), DMKEP, P.O. Box 616, 6200 MD Maastricht, NL; Arnoud.Arntz@MP.Unimaas.nl</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-06-05 13:30:15 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<FOOTNOTES>
<P>CAT: cognitive analytic therapy<BR/>CTBE: Community treatment by experts<BR/>DBT: dialectical behaviour therapy<BR/>BPD: borderline personality disorder<BR/>MAT: medication assisted treatment<BR/>PD: personality disorder<BR/>PTSD: post-traumatic stress disorder<BR/>RCT: randomised controlled trial<BR/>TAU: treatment as usual<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2017-04-06 11:47:12 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-06-26 15:39:20 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-04 12:23:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bateman-1999">
<DESCRIPTION>
<P>Use of a minimisation method (<LINK REF="REF-Bateman-2010" TYPE="REFERENCE">Bateman 2010</LINK>).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-20 15:55:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bateman-2009">
<DESCRIPTION>
<P>"randomization using a stochastic minimization program (MINIM) balancing for age (blocked as 18-25, 26-30, &gt;30 years), gender, and presence of antisocial personality disorder." (<LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK>, p. 1357)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-07 16:22:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bellino-2006">
<DESCRIPTION>
<P>Use of a computer random number generator (<LINK REF="REF-Bellino-2010a-_x005b_pers-comm_x005d_" TYPE="REFERENCE">Bellino 2010a [pers comm]</LINK>).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-13 15:05:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bellino-2007">
<DESCRIPTION>
<P>"Patients [...] were randomized using the web program Research Randomizer v3.0 (Urbaniak &amp; Plous, Social Psychology Network, 2007)" (<LINK REF="STD-Bellino-2007" TYPE="STUDY">Bellino 2007</LINK>, p. 720)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-21 13:09:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bellino-2010">
<DESCRIPTION>
<P>"Randomization was performed using the web program Research Randomizer version 3.0 (Urbaniak and Plous, [...])." (<LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK>, p. 75)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-26 15:38:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blum-2008">
<DESCRIPTION>
<P>"Subjects were assigned by coin toss" (<LINK REF="STD-Blum-2008" TYPE="STUDY">Blum 2008</LINK>, p. 469)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-22 21:44:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bos-2010">
<DESCRIPTION>
<P>Allocation was determined by drawing of lots (equal numbers for both groups at each study site) some weeks before start of the STEPPS group after inclusion of all participants. (see van Wel 2009, p. 292)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-26 15:38:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carter-2010">
<DESCRIPTION>
<P>We used a computerised random number generator to generate allocations - placed into sealed opaque envelopes (in blocks of 8). Envelope drawn after baseline assessments complete. (<LINK REF="REF-Carter-2010a-_x005b_pers-comm_x005d_" TYPE="REFERENCE">Carter 2010a [pers comm]</LINK>)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-26 15:38:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cottraux-2009">
<DESCRIPTION>
<P>"The randomisation process used blocks of 4 patients for each centre, and was organised by the Lyon University Hospital's Biostatistics Department." (<LINK REF="STD-Cottraux-2009" TYPE="STUDY">Cottraux 2009</LINK>, p. 309)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-22 21:58:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Davidson-2006">
<DESCRIPTION>
<P>"The randomization schedules were generated by the study center at [...] Glasgow University, and kept securely and confidentially by the trial coordinator at the Study Coordinating Centre." (<LINK REF="REF-Davidson-2006a" TYPE="REFERENCE">Davidson 2006a</LINK>, p. 437)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-04 12:38:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Doering-2010">
<DESCRIPTION>
<P>Use of random numbers, matching after inclusion of 35th patient according to severity of self-harming behaviour during the last year and personality organisation (<LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK>, personal communication.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-05 13:16:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Farrell-2009">
<DESCRIPTION>
<P>"Patients were randomly assigned using a random number table" (<LINK REF="STD-Farrell-2009" TYPE="STUDY">Farrell 2009</LINK>, p. 319)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-05 13:17:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giesen_x002d_Bloo-2006">
<DESCRIPTION>
<P>"Randomization to SFT or TFP was stratified across 4 community mental health centers and was performed [...] after the adaptive biased urn procedure" (<LINK REF="STD-Giesen_x002d_Bloo-2006" TYPE="STUDY">Giesen-Bloo 2006</LINK>, p. 650)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-20 16:08:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gratz-2006">
<DESCRIPTION>
<P>"Participants [...] were matched on level of emotion dysregulation and number of lifetime incidents of self-harm and randomly assigned to either the group treatment plus TAU condition or the TAU waitlist condition." (<LINK REF="STD-Gratz-2006" TYPE="STUDY">Gratz 2006</LINK>, p. 27)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-20 16:08:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gregory-2008">
<DESCRIPTION>
<P>"A minimization method was employed for group assignment [...] ensuring comparability of the two groups on key variables or factors [...] The specific factors that we adjusted for included: age, gender, alcohol abuse versus dependence, current alcohol use, antisocial personality disorder, inpatient utilization, and number of parasuicides." (<LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>, p. 31-32)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-26 15:39:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koons-2001">
<DESCRIPTION>
<P>"28 women were randomized to treatment." (<LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK>, p. 374). No further information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-26 12:09:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Linehan-1991">
<DESCRIPTION>
<P>"Subjects were matched on the number of lifetime parasuicides and psychiatric hospitalization, age, and good vs poor clinical prognosis (with a subthreshold diagnosis on schizophrenia or substance dependence constituting poor prognosis) and randomly assigned to a treatment condition." (<LINK REF="STD-Linehan-1991" TYPE="STUDY">Linehan 1991</LINK>, p. 1061) </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-26 15:39:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Linehan-1994">
<DESCRIPTION>
<P>"assignment of subjects to treatment conditions [...] described in detail in the original outcome study [i.e., <LINK REF="STD-Linehan-1991" TYPE="STUDY">Linehan 1991</LINK>]" (<LINK REF="STD-Linehan-1994" TYPE="STUDY">Linehan 1994</LINK>, p. 1772): "Subjects were matched on the number of lifetime parasuicides and psychiatric hospitalization, age, and good vs poor clinical prognosis (with a subthreshold diagnosis on schizophrenia or substance dependence constituting poor prognosis) and randomly assigned to a treatment condition." (<LINK REF="STD-Linehan-1991" TYPE="STUDY">Linehan 1991</LINK>, p. 1061) No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-05 13:18:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Linehan-2006">
<DESCRIPTION>
<P>"Using a computerized adaptive minimization randomization procedure, eligible subjects were matched to treatment condition on 5 primary prognostic variables: (1 and 2) the number of lifetime suicide attempts or nonsuicidal self-injuries combined and psychiatric hospitalizations; (3) a history of only suicide attempts, only nonsuicidal self-injury, or both; (4) age; and (5) a negative prognostic indicator of a Beck Depression Inventory score higher than 30 or a Global Assessment of Functioning score lower than 45 for a comorbid condition [...] Based on 0.8 power to detect significant differences between conditions (P = .05, 1-sided), this procedure was used to randomize 101 subjects to DBT (n = 52) or to CTBE (n = 49)." (<LINK REF="STD-Linehan-2006" TYPE="STUDY">Linehan 2006</LINK>, p. 758)</P>
<P>"The randomization program assigned clients to DBT and CTBE therapists, matching on sex, doctoral vs master's training, and years of clinical experience. Results indicated that therapists' sex and training did not differ in the 2 conditions. The CTBE therapists, however, had more clinical experience, which was expected because they were selected for their expertise." (<LINK REF="STD-Linehan-2006" TYPE="STUDY">Linehan 2006</LINK>, p. 760)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-05 13:19:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McMain-2009">
<DESCRIPTION>
<P>"eligible participants were randomly assigned to treatment arms using a pregenerated block randomization scheme developed and held by the statistician." (<LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK>, p. 1366)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-04 12:46:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morey-2010">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-04 12:47:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nadort-2009">
<DESCRIPTION>
<P>No information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-27 15:11:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Soler-2009">
<DESCRIPTION>
<P>"Blocks of four generated using the SPSS software program served for the randomisation to DBT-ST or SGT." (<LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>, p. 354)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-19 10:13:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Steil-2010">
<DESCRIPTION>
<P>"randomisation was carried out using the procedure proposed by Efron" (<LINK REF="STD-Steil-2010" TYPE="STUDY">Steil 2010</LINK>).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-26 12:19:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Turner-2000">
<DESCRIPTION>
<P>"Following the initial assessments, patients were randomly assigned to either DBT or CCT. " (<LINK REF="STD-Turner-2000" TYPE="STUDY">Turner 2000</LINK>, p. 415) No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-20 15:42:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-den-Bosch-2005">
<DESCRIPTION>
<P>"...patients were randomly assigned to treatment conditions. A minimisation method was used to ensure comparability of the two treatment conditions on age, alcohol problems, drug problems and social problems (as measured by the European version of the Addiction Severity Index [...]" (<LINK REF="REF-Verheul-2003" TYPE="REFERENCE">Verheul 2003</LINK>, p. 135)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-02 14:25:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weinberg-2006">
<DESCRIPTION>
<P>"randomly assigned" (<LINK REF="STD-Weinberg-2006" TYPE="STUDY">Weinberg 2006</LINK>, p. 485) No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-03 11:21:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zanarini-2008">
<DESCRIPTION>
<P>"Using a 3:2 ratio, subjects were either randomized to a workshop that took place within a week of diagnostic disclosure or a waitlist." (<LINK REF="STD-Zanarini-2008" TYPE="STUDY">Zanarini 2008</LINK>, p. 286). No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-06-26 15:38:39 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-04 12:23:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bateman-1999">
<DESCRIPTION>
<P>Central allocation at the university (<LINK REF="REF-Bateman-2010" TYPE="REFERENCE">Bateman 2010</LINK>).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-20 15:56:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bateman-2009">
<DESCRIPTION>
<P>"Treatment allocation was made offsite [...] A study psychiatrist informed patients of their assignment." (<LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK>, p. 1357)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-07 16:22:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bellino-2006">
<DESCRIPTION>
<P>Central allocation (<LINK REF="REF-Bellino-2010a-_x005b_pers-comm_x005d_" TYPE="REFERENCE">Bellino 2010a [pers comm]</LINK>).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-07 16:22:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bellino-2007">
<DESCRIPTION>
<P>Central allocation (<LINK REF="REF-Bellino-2010a-_x005b_pers-comm_x005d_" TYPE="REFERENCE">Bellino 2010a [pers comm]</LINK>).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-25 09:18:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bellino-2010">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-26 15:38:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blum-2008">
<DESCRIPTION>
<P>No indication of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-22 21:44:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bos-2010">
<DESCRIPTION>
<P>Randomisation was carried out by a research assistant. (see van Wel 2009, p. 292)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-26 15:38:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carter-2010">
<DESCRIPTION>
<P>"Randomization was carried out by the research staff. [...] participants were allocated by selecton of sealed opaque envelopes." (<LINK REF="STD-Carter-2010" TYPE="STUDY">Carter 2010</LINK>, p. 164)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-26 15:38:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cottraux-2009">
<DESCRIPTION>
<P>"The allocation was confidential and delivered via phone call [of the Biostastics Department] to the secretary of each centre." (<LINK REF="STD-Cottraux-2009" TYPE="STUDY">Cottraux 2009</LINK>, p. 309)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-22 21:58:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Davidson-2006">
<DESCRIPTION>
<P>"The randomization schedules were [...] kept securely and confidentially by the trial coordinator [...] The trial coordinator informed the referring agent of the result of randomization immediately and in writing, and then contacted the CBT therapist/s in each area with the patients details so that CBT therapy could be initiated." (<LINK REF="REF-Davidson-2006a" TYPE="REFERENCE">Davidson 2006a</LINK>, p. 437). </P>
<P>106 patients enrolled and randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-25 13:37:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Doering-2010">
<DESCRIPTION>
<P>"The results of the first assessments [screening for inclusion criteria] were sent to a researcher outside the two study centers who performed the randomization." (<LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK>, p. 5) . "After randomization patients were referred to a therapist." (<LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK>, p. 6)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-05 13:32:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Farrell-2009">
<DESCRIPTION>
<P>No further details.</P>
<P>After screening for eligibility of 40 patients, N = 8 were excluded. Reasons for exclusion are only given for 3 of them (1 declined participation, 2 did not meet inclusion criteria).Thus, N = 16 were allocated to EG, N = 16 to CG.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-05 13:17:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giesen_x002d_Bloo-2006">
<DESCRIPTION>
<P>"Randomization to SFT or TFP [...] was performed by a study independent person [...] We used this procedure (1) to keep allocation at each site unpredictable until the last patient to avoid unintentionally affecting ongoing screening procedures [...]." (<LINK REF="STD-Giesen_x002d_Bloo-2006" TYPE="STUDY">Giesen-Bloo 2006</LINK>, p. 650)</P>
<P>173 patients were screened for eligibility. 85 of them were excluded, reasons are given (40 declined participation, 24 did not meet inclusion criteria, 19 met exclusion criteria, 2 had insufficient availability).</P>
<P>88 randomised, of 45 allocated to SFT, 44 were included in analyses (1 patient excluded owing to unreliable assessments due to increased patient blindness), of 43 allocated to TFP, 42 were included in analyses (1 patient excluded because untraceable after randomisation; never met or spoke to therapist)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-03 16:06:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gratz-2006">
<DESCRIPTION>
<P>24 were included and randomised. 2 drop-outs, one from each condition, no reasons given.</P>
<P>Finally, analyses refer to N = 22 patients, N = 12 in EG, N = 10 in TAU condition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-20 14:56:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gregory-2008">
<DESCRIPTION>
<P>"participants were assigned by the research coordinator to either the investigation treatment or to treatment as usual (TAU) in the community" (<LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>, p. 31)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-05 13:18:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koons-2001">
<DESCRIPTION>
<P>No further details.</P>
<P>28 participants were randomised. 8 were not included in analyses due to not completing treatment (reasons: 2 did not attend the first appointment, 2 in TAU and 3 in DBT dropped out after more than one appointment in the first half of treatment citing distance from the medical centre as reason)</P>
<P>Analyses refer to N = 10 patients in the DBT and N = 10 patients in the TAU group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-04 12:44:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Linehan-1991">
<DESCRIPTION>
<P>No further details.</P>
<P>10 dropped out during pretreatment assessment (EG: N = 5, CG: N = 5)</P>
<P>7 were dropped following pretreatment assessment for refusal or inability to meet study conditions (EG: N = 3, CG: N = 4)</P>
<P>2 EG participants quit the study with four or fewer DBT sessions and were dropped from all analyses other than treatment maintenance analyses</P>
<P>Major analyses were conducted for 44 participants, N = 22 in EG and N = 22 in CG treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-03 16:07:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Linehan-1994">
<DESCRIPTION>
<P>No further details.</P>
<P>26 women were included, data set for 26 subjects (DBT: N = 13, TAU: N = 13) provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-05 13:18:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Linehan-2006">
<DESCRIPTION>
<P>"The participant coordinator, who was not blinded to treatment condition, executed the randomization program" (<LINK REF="STD-Linehan-2006" TYPE="STUDY">Linehan 2006</LINK>, p. 758) Improbable that computerised assignment could be foreseen and thus bias be introduced.</P>
<P>101 participants were randomised, and N = 60 allocated to the EG and N = 51 to the CG arms. 8 DBT "training cases" and 2 CBT "pilot cases" were excluded from analyses, but the remaining N = 52 EG and 49 CG subjects were analysed regardless of discontinuation or getting lost to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-05 13:19:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McMain-2009">
<DESCRIPTION>
<P>"[...] statistician, who prepared 45 sealed envelopes, each containing the group allocations in random order for four participants." (<LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK>, p. 1366)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-04 12:47:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morey-2010">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-20 13:43:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nadort-2009">
<DESCRIPTION>
<P>"we used a stratified randomization procedure. The stratification procedure was performed by a study-independent person and concealed for participating therapists, patients and researchers." (<LINK REF="STD-Nadort-2009" TYPE="STUDY">Nadort 2009</LINK>, p. 962)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-26 12:17:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Soler-2009">
<DESCRIPTION>
<P>No further details.</P>
<P>Comprehensible flow diagram of patient progress through phases of study provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-19 11:00:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Steil-2010">
<DESCRIPTION>
<P>"Care was taken that the randomization was concealed to both the patient and to all persons involved in the study until the written informed consent has been given by the patient." (<LINK REF="STD-Steil-2010" TYPE="STUDY">Steil 2010</LINK>). </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-03 16:08:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Turner-2000">
<DESCRIPTION>
<P>"Next, patients were sequentially assigned to a mental health clinician." (<LINK REF="STD-Turner-2000" TYPE="STUDY">Turner 2000</LINK>, p.415).</P>
<P>No further details.</P>
<P>24 participants were randomly assigned to either DBT (N = 12) or CCT (N = 12). In spite of drop-outs from treatment (DBT: N = 4, CCT: N = 6), assessments were available for all 24 participants at all times of assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-03 16:08:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-den-Bosch-2005">
<DESCRIPTION>
<P>No further details.</P>
<P>Of 64 eligible patients, N = 31 were assigned to EG and N = 33 to CG.</P>
<P>"Two patients assigned to the treatment-as-usual condition were dropped from the intention-to-treat analyses because they did not accept the randomisation outcome and therefore refused to cooperate further with the study protocol, and four patients assigned to dialectical behaviour therapy were dropped because they refused to start treatment." (<LINK REF="REF-Verheul-2003" TYPE="REFERENCE">Verheul 2003</LINK>, p. 136)</P>
<P>Thus, analyses refer to N = 27 EG and N = 31 CG subjects that actually started treatment as allocated to.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-03 16:08:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weinberg-2006">
<DESCRIPTION>
<P>No further details.</P>
<P>After screening of 60 referrals by phone, 37 were invited for further assessments. Reasons for exclusion of N = 7 are given. N = 30 were included in the final sample. N = 15 were assigned to the EG and N = 15 to the CG.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-03 16:08:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zanarini-2008">
<DESCRIPTION>
<P>No further details.</P>
<P>"Fifty subjects were found to meet study criteria for BPD and five who were interviewed did not. These 50 subjects were either randomized to immediate (N = 30) or delayed (N = 20) psychoeducation." (<LINK REF="STD-Zanarini-2008" TYPE="STUDY">Zanarini 2008</LINK>, p. 286) No information given about drop-outs during the study course.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-11-01 12:28:44 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>observer-rated measures</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="GROUP" NO="11">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="GROUP" MODIFIED="2012-06-26 15:39:20 +0100" MODIFIED_BY="[Empty name]" NO="12">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-12.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2012-06-04 12:23:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bateman-1999">
<DESCRIPTION>
<P>Outcome assessors were blind (<LINK REF="REF-Bateman-2010" TYPE="REFERENCE">Bateman 2010</LINK>).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2012-02-09 10:09:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bateman-2009">
<DESCRIPTION>
<P>"Assessors were blind to treatment group." (<LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK>, p. 1358)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2012-02-09 10:09:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bellino-2006">
<DESCRIPTION>
<P>"assessments were performed by an investigator who was blind to the treatment methods" (<LINK REF="STD-Bellino-2006" TYPE="STUDY">Bellino 2006</LINK>, p. 455);</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2012-02-09 10:09:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bellino-2007">
<DESCRIPTION>
<P>"A psychiatrist provided pharmacotherapy. He was blind to which type of psychotherapy the patients were receiving [...] The assessments were performed by an investigator who was blind to the treatment methods." (<LINK REF="STD-Bellino-2007" TYPE="STUDY">Bellino 2007</LINK>, p. 720)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2012-02-09 10:09:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bellino-2010">
<DESCRIPTION>
<P>"Assessments were performed by an investigator who was blind to the treatment methods." (<LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK>, p. 76)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2012-06-26 15:38:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Blum-2008">
<DESCRIPTION>
<P>"While we intended to conduct blind assessments, we found it nearly impossible to maintain blindness. The convergence of both rater- and patient-administered scales suggests that this may not have been an important deficiency." (<LINK REF="STD-Blum-2008" TYPE="STUDY">Blum 2008</LINK>, p. 477).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2012-06-05 13:15:29 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bos-2010">
<DESCRIPTION>
<P>"Interviews were conducted by research assistants who were not blind to treatment group assignment." (<LINK REF="STD-Bos-2010" TYPE="STUDY">Bos 2010</LINK>, p. 300)"</P>
<P>Non-blindness of interviewers may have affected interviewer-assessed outcomes, i.e. BPDSI-IV impulsivity and parasuicide scores. All other outcomes were self-rated by participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2012-06-26 15:38:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carter-2010">
<DESCRIPTION>
<P>"Outcomes were determined [...] by assessors blinded to allocation. [...] All reasonable attempts were made to maintain blindness to allocation status for these raters, but this could not achieve perfect blindness." (<LINK REF="STD-Carter-2010" TYPE="STUDY">Carter 2010</LINK>, pp. 164 et seq.)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2012-06-26 15:38:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cottraux-2009">
<DESCRIPTION>
<P>"Psychologists who had not taken part in the treatments performed the asessment. They had no information on either the randomisation or the treatment and did not attend the team meetings about the patients." (<LINK REF="STD-Cottraux-2009" TYPE="STUDY">Cottraux 2009</LINK>, p. 310)</P>
<P>"[...] evaluators may have received inadvertent or indirect information from the patients about the treatment underway. The evaluators' blindness was not tested." (<LINK REF="STD-Cottraux-2009" TYPE="STUDY">Cottraux 2009</LINK>, p. 313)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2012-02-09 10:10:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Davidson-2006">
<DESCRIPTION>
<P>"The research assistants on each site carry out all assessments and are blind to treatment group allocation. In addition, research assistants request that patients do not mention any details of any psychological treatment they may be receiving. [...] The research assistants responsible for the recording of outcomes were unaware of the treatment allocated or received." (<LINK REF="REF-Davidson-2006a" TYPE="REFERENCE">Davidson 2006a</LINK>, p. 439).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2012-02-09 10:10:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Doering-2010">
<DESCRIPTION>
<P>"Research assistants who conducted assessments before randomization and after one year of treatment were blinded for the therapy delivered." (<LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK>, p. 7)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2012-06-05 13:16:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Farrell-2009">
<DESCRIPTION>
<P>"The DIB-R structured interviews were conducted by two Ph.D. Clinical Psychologists not involved in treatment delivery. Efforts were made to keep them blind to treatment group membership, but for 10% of the subjects the blind was broken due to patient report." (<LINK REF="STD-Farrell-2009" TYPE="STUDY">Farrell 2009</LINK>, p. 319) "Therapists were given a GAFS [Global Assessment of Function Scale] checklist to use so that the anchors for assigning scores were in front of them when they recorded their ratings. They were chosen as raters since they were removed from the hypotheses of the study, although not blind to their patients's group membership and no inter-rater reliability was possible." (<LINK REF="STD-Farrell-2009" TYPE="STUDY">Farrell 2009</LINK>, p. 319) Overall, observer-rated outcomes were not assessed by blind raters.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2012-06-05 13:17:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giesen_x002d_Bloo-2006">
<DESCRIPTION>
<P>"assessments were made [...] by independent research assistants [...] Study researchers, screeners, research assistant, and SFT/TFP therapists were masked to treatment allocation during the screening procedure and the first assessment" (<LINK REF="STD-Giesen_x002d_Bloo-2006" TYPE="STUDY">Giesen-Bloo 2006</LINK>, p. 650) "most research assistants learned their patients' treatment allocation as the study progressed, as patients talked about their treatment and therapists. However, the results of secondary computer-assessed self-report measures [...] concurred with the observer-rated (interview) findings, making it unlikely that results can be contributed to knowledge of treatment allocation." (<LINK REF="STD-Giesen_x002d_Bloo-2006" TYPE="STUDY">Giesen-Bloo 2006</LINK>, p. 657)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2012-02-09 10:10:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gratz-2006">
<DESCRIPTION>
<P>"Research team members were not blind to condition; however, all outcome measures were self-report, and there was limited interaction between participants and assessors." (<LINK REF="STD-Gratz-2006" TYPE="STUDY">Gratz 2006</LINK>, p. 30)</P>
<P>Outcomes are not likely to be influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2012-06-02 12:27:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gregory-2008">
<DESCRIPTION>
<P>"An independent, trained research assistant administered the primary and secondary outcome measures [...] blind to treatment group at the time of interviews, but blindedness was only partial, as she was able to correctly guess group assignment 67% of the time (50% correct guesses were expected by chance alone)." (<LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>, p. 35)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2012-06-26 15:39:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Koons-2001">
<DESCRIPTION>
<P>"Assesment interviews were conducted by two psychology interns who [...] were unaware of subjects' treatment condition." (<LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK>, p. 376)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2012-02-09 10:10:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Linehan-1991">
<DESCRIPTION>
<P>"Screening and assessment interviews were administered by a team of 13 research assessors. Every effort was made to keep the assessors blind about treatment condition." (<LINK REF="STD-Linehan-1991" TYPE="STUDY">Linehan 1991</LINK>, p. 1061)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2012-06-26 15:39:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Linehan-1994">
<DESCRIPTION>
<P>"Interviews blind to treatment conditions" (<LINK REF="STD-Linehan-1994" TYPE="STUDY">Linehan 1994</LINK>, p. 1772)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2012-06-05 13:18:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Linehan-2006">
<DESCRIPTION>
<P>"Assessments were conducted by blinded independent clinical assessors" (<LINK REF="STD-Linehan-2006" TYPE="STUDY">Linehan 2006</LINK>, p. 758)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2012-06-05 13:19:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McMain-2009">
<DESCRIPTION>
<P>"[...] assessors who were well trained on study instruments and blind to treatment assignment. [...] Assessors were polled after the treatment phase to ascertain whether they could correctly guess participants' treatment assignment; they did not know treatment assignment for 86% of the cases, suggesting that blinding was largely maintained." (<LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK>, p. 1366)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2012-02-09 10:11:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morey-2010">
<DESCRIPTION>
<P>"[...] assessments [...] were conducted by an independent evaluator" (<LINK REF="STD-Morey-2010" TYPE="STUDY">Morey 2010</LINK>, p. 533)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2012-02-09 10:11:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nadort-2009">
<DESCRIPTION>
<P>"Study researchers, screeners, research assistants and therapists were masked to treatment allocation during the screening period and the first assessment." (<LINK REF="STD-Nadort-2009" TYPE="STUDY">Nadort 2009</LINK>, p. 963)</P>
<P>"A limitation of the present study is that the assessments will be performed by research assistants who cannot remain blinded to the treatment condition of the included patients, as is always the case in trials studying the effects of psychotherapy. Nor are the patients blind to treatment condition. In this study, however, added to the main interview-based outcome measures, self-report questionnaires will be administered, that will not be influenced by the research assistants. (<LINK REF="REF-Nadort-2009b" TYPE="REFERENCE">Nadort 2009b</LINK>)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2012-02-09 10:11:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Soler-2009">
<DESCRIPTION>
<P>"... participants were evaluated every two weeks by experienced psychiatrists. Subjects were instructed not to disclose any information about the group (topics, group members or therapists) to maintain blind conditions." (<LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>, p. 354)</P>
<P>"Assessment and drug control were carried out by two psychiatrists who were masked to the experimental conditions." (<LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>, p. 355)</P>
<P>"We are unable to affirm that all participants refrained from disclosing information about the therapy or the therapists with the psychiatric raters during assessment visits. [...] Indeed, the observer-rater scales obtained during the interview visits and the results from self-reported measures filled in by patients during the study showed a good concordance. " (<LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>, p.357)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2012-02-09 10:11:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Steil-2010">
<DESCRIPTION>
<P>"Interviewers were blinded. [...] the diagnostician who was assessing the patient at follow-up was masked to the assignment." (<LINK REF="STD-Steil-2010" TYPE="STUDY">Steil 2010</LINK>).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2012-02-09 10:11:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Turner-2000">
<DESCRIPTION>
<P>"The outcome evaluation consisted of independent assessor ratings and patient self-report. The independent assessor was unaware of the patients' treatment condition but was aware of the purpose of the study." (<LINK REF="STD-Turner-2000" TYPE="STUDY">Turner 2000</LINK>, p. 415)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2012-02-15 12:31:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-den-Bosch-2005">
<DESCRIPTION>
<P>"although the research assessors were not informed about the treatment condition of their interviewees, it is unlikely that they remained 'masked' throughout the project. Patients might have given them this information, or it could easily have been derived from some of the interviews." (<LINK REF="REF-Verheul-2003" TYPE="REFERENCE">Verheul 2003</LINK>, p. 139)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2012-06-06 11:22:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weinberg-2006">
<DESCRIPTION>
<P>"The baseline assessment and administration of the MACT [i.e. the treatment under test] were performed by the primary investigator." (<LINK REF="STD-Weinberg-2006" TYPE="STUDY">Weinberg 2006</LINK>, p.486) "Interviewers were randomly assigned for following assessments. The interviewers were blind to baseline ratings and to participants' group allocation" (<LINK REF="STD-Weinberg-2006" TYPE="STUDY">Weinberg 2006</LINK>, p. 487)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2012-02-09 10:12:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zanarini-2008">
<DESCRIPTION>
<P>No information given if assessors were blind to treatment allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2012-06-05 13:20:04 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-04 12:48:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bateman-1999">
<DESCRIPTION>
<P>No indication for selective reporting, but Insufficient information to permit judgement of 'Yes' or 'No'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:08:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bateman-2009">
<DESCRIPTION>
<P>Study protocol available (ISRCTN27660668). No indication for selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 10:04:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bellino-2006">
<DESCRIPTION>
<P>No indication for selective reporting, but Insufficient information to permit judgement of 'Yes' or 'No'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 10:05:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bellino-2007">
<DESCRIPTION>
<P>No indication for selective reporting, but Insufficient information to permit judgement of 'Yes' or 'No'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 10:05:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bellino-2010">
<DESCRIPTION>
<P>No indication for selective reporting, but Insufficient information to permit judgement of 'Yes' or 'No'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 10:07:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blum-2008">
<DESCRIPTION>
<P>Study protocol is available, but there is no information about primary or secondary outcomes. The authors report a broad range of outcomes, so there is no indication for selective reporting given. However, there is insufficient information to permit judgment of 'Yes' or 'No'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 10:08:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bos-2010">
<DESCRIPTION>
<P>No indication for selective reporting, but Insufficient information to permit judgement of 'Yes' or 'No'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 13:34:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carter-2010">
<DESCRIPTION>
<P>No indication for selective reporting, but Insufficient information to permit judgement of 'Yes' or 'No'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:08:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cottraux-2009">
<DESCRIPTION>
<P>Study protocol available (NCT00131781). No indication for selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:08:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Davidson-2006">
<DESCRIPTION>
<P>Study protocol available (ISRCTN86177428). No indication for selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:08:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Doering-2010">
<DESCRIPTION>
<P>Study protocol available (NCT00714311). No indications for selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:21:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Farrell-2009">
<DESCRIPTION>
<P>No indication for selective reporting, but Insufficient information to permit judgement of 'Yes' or 'No'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:45:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giesen_x002d_Bloo-2006">
<DESCRIPTION>
<P>No indication for selective reporting, but Insufficient information to permit judgement of 'Yes' or 'No'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:49:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gratz-2006">
<DESCRIPTION>
<P>No indication for selective reporting, but Insufficient information to permit judgement of 'Yes' or 'No'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:08:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gregory-2008">
<DESCRIPTION>
<P>Study protocol available (NCT00145678). No indications for selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 14:59:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koons-2001">
<DESCRIPTION>
<P>No indication for selective reporting, but Insufficient information to permit judgement of 'Yes' or 'No'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 15:00:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Linehan-1991">
<DESCRIPTION>
<P>No indication for selective reporting, but Insufficient information to permit judgement of 'Yes' or 'No'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 15:00:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Linehan-1994">
<DESCRIPTION>
<P>No indication for selective reporting, but Insufficient information to permit judgement of 'Yes' or 'No'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 15:10:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Linehan-2006">
<DESCRIPTION>
<P>No indication for selective reporting, but Insufficient information to permit judgement of 'Yes' or 'No'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 12:08:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McMain-2009">
<DESCRIPTION>
<P>Study protocol available (NCT00154154). No indication for selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-20 16:56:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morey-2010">
<DESCRIPTION>
<P>No indication for selective reporting, but Insufficient information to permit judgement of 'Yes' or 'No'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-05 13:19:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nadort-2009">
<DESCRIPTION>
<P>Study protocol available (<LINK REF="REF-Nadort-2009b" TYPE="REFERENCE">Nadort 2009b</LINK>), no indication for selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-03 14:17:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Soler-2009">
<DESCRIPTION>
<P>No indication for selective reporting, but Insufficient information to permit judgement of 'Yes' or 'No'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-05 13:20:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Steil-2010">
<DESCRIPTION>
<P>Study protocol available (<LINK REF="REF-DBT-working-group-at-CIMH" TYPE="REFERENCE">DBT working group at CIMH</LINK>), no indication for selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-03 14:17:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Turner-2000">
<DESCRIPTION>
<P>No indication for selective reporting, but Insufficient information to permit judgement of 'Yes' or 'No'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-03 14:24:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-den-Bosch-2005">
<DESCRIPTION>
<P>No indication for selective reporting, but Insufficient information to permit judgement of 'Yes' or 'No'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-02 14:25:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weinberg-2006">
<DESCRIPTION>
<P>No indications for selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-03 15:15:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zanarini-2008">
<DESCRIPTION>
<P>No indication for selective reporting, but Insufficient information to permit judgement of 'Yes' or 'No'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-11-10 10:09:21 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2012-06-26 15:39:20 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Treatment adherence?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-04 12:23:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bateman-1999">
<DESCRIPTION>
<P>Adherence to therapy was monitored through supervision, verbatim session reports, and completion of a monitoring form about activities and interventions of therapists.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-20 15:59:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bateman-2009">
<DESCRIPTION>
<P>"All sessions were audiotaped. Adherence to the MBT-OP and SCM-OP manuals was determined by randomly selected audiotapes of individual and group sessions drawn from two distinct 6-months periods of each case using a modified version of the recommended adherence rating scale." (<LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK>, online data supplement, p. 1)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-07 16:22:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bellino-2006">
<DESCRIPTION>
<P>"psychotherapist [...] had 5 years of experience practising IPT" (<LINK REF="STD-Bellino-2006" TYPE="STUDY">Bellino 2006</LINK>, p. 455) </P>
<P>no specific measures to monitor treatment adherence (<LINK REF="REF-Bellino-2010a-_x005b_pers-comm_x005d_" TYPE="REFERENCE">Bellino 2010a [pers comm]</LINK>)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-13 15:30:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bellino-2007">
<DESCRIPTION>
<P>"Both psychotherapists received supervision during the treatment to assess their adherence to the psychotherapy manuals." (<LINK REF="STD-Bellino-2007" TYPE="STUDY">Bellino 2007</LINK>, p. 720)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-21 14:58:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bellino-2010">
<DESCRIPTION>
<P>"Patients in the IPT-BPD group were treated by a psychotherapist [...] who had at least 5 years of experience practising IPT" (<LINK REF="STD-Bellino-2010" TYPE="STUDY">Bellino 2010</LINK>, p. 76). No further information, adherence seems not to have been monitored.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-05 13:15:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blum-2008">
<DESCRIPTION>
<P>"Adherence to the manual was rated on a 5-point scale [...] A score of 4 (good) or higher was considered acceptable. Two Ph.D.-level psychologists who were not involved with the randomized controlled trial but familiar with STEPPS rated 43 randomly selected video-taped session. The mean adherence score was 4.4 (SD = 0.8)."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-05 13:15:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bos-2010">
<DESCRIPTION>
<P>"STEPPS therapists met twice a year under the supervision of expert trainers to evaluate the procedure and to preserve uniformity. Individual therapists in the STEPPS condition received a 1-day training and monthly phone supervision. After each session, individual therapists in both conditions completed a self-report questionnaire by which the content and frequency of the therapy contacts could be checked." (<LINK REF="STD-Bos-2010" TYPE="STUDY">Bos 2010</LINK>, p. 300)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-26 15:38:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carter-2010">
<DESCRIPTION>
<P>"The intervention condition was based on the comprehensive DBT model, a team-based approach including [...] therapist supervision groups." (<LINK REF="STD-Carter-2010" TYPE="STUDY">Carter 2010</LINK>, p. 163 et seq.)</P>
<P>"[...] possible inferiority of training of DBT therapists to that of those in other studies or inferior adherence to the DBT methods despite adequate training" (<LINK REF="STD-Carter-2010" TYPE="STUDY">Carter 2010</LINK>, p. 170)</P>
<P>No mention of any objective means of assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-26 15:38:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cottraux-2009">
<DESCRIPTION>
<P>"At the end of each session, the therapists were to complete a checklist of the techniques they used, which was revised and discussed with the prinicipal investigator [...] weekly supervision session." (<LINK REF="STD-Cottraux-2009" TYPE="STUDY">Cottraux 2009</LINK>, p. 309).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-15 10:02:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Davidson-2006">
<DESCRIPTION>
<P>"All therapists received training in the protocol at the beginning of the trial and regular meetings of all therapists were held to ensure consistency of approach across the sites. In addition, all therapists received weekly supervision from CBT experts at each site." (<LINK REF="STD-Davidson-2006" TYPE="STUDY">Davidson 2006</LINK>, p. 452)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 11:21:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Doering-2010">
<DESCRIPTION>
<P>"Video recordings of all [EG] sessions were performed and used in the group supervision. [...] Every case was supervised at least every four to six weeks. [...] Experienced community psychotherapists [i.e., CG therapists] attended supervisions according to their usual routine." (<LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK>, p. 10f.) "For the assessment of adherence and competence of the transference-focused psychotherapists a German translation of a specific Rating of Adherence and Competence [...] was used. [...] The rating was performed by the supervisor after every video-guided supervision of a therapy session." (<LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK>, p. 11)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-05 13:32:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Farrell-2009">
<DESCRIPTION>
<P>"Two of the three groups had the two program developers as therapists and the third had one developer and one clinical psychologist [...] Weekly supervision meetings took place during the course of the study and random videotapes of sessions were reviewed for fidelity by the program developers. The manual developed for the study acted as an additional fidelity check. (<LINK REF="STD-Farrell-2009" TYPE="STUDY">Farrell 2009</LINK>, p. 322)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-05 13:17:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giesen_x002d_Bloo-2006">
<DESCRIPTION>
<P>"Weekly local supervision [...], a 1-day central supervision every 4 months, and a 2-day central supervision every 9 months. [...] Treatment integrity was monitored by means of supervision. All the raters were independent of the study and masked to treatment outcome. One psychologist, masked to allocation, listened to 1 randomly selected tape of each patient, then stated the treatment administered [...] Other trained therapists for each orientation assessed the TFP Rating of Adherence and Competence Scale or the SFT Therapy Adherence and Competence Scale for BPD." (<LINK REF="STD-Giesen_x002d_Bloo-2006" TYPE="STUDY">Giesen-Bloo 2006</LINK>, p. 650-651)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-12 09:56:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gratz-2006">
<DESCRIPTION>
<P>Treatment approach was developed by the first author who also was the therapist; no further information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-03 16:06:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gregory-2008">
<DESCRIPTION>
<P>"Six therapists provided DDP, including the principal investigator [who is one of the two developers of DDP] (PI; N = 6 study participants) and five psychiatry residents (N = 9 participants) who were in their third year of residency training [...] After achieving competency, adherence to technique and treatment integrity for resident therapists was assured through weekly group supervision [...] and individual supervision of videotaped sessions with the PI [principal investigator, developer of DDP] every other week throughout treatment." (<LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>, p. 34)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-26 15:39:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Koons-2001">
<DESCRIPTION>
<P>EG therapists: "All [DBT therapists] attended the weekly consultation group, and several received additional individual supervision from each other. Two clinicians received supervision briefly from a senior trainer from Linehan's group. [...] All individual and group sessions were videotaped for later coding for adherence using the DBT Expert Rating Scale [...] At the end of treatment, a sample of eight tapes from each therapist-patient dyad, including the first session and seven others selected randomly, was coded for adherence." (<LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK>, p. 377) CG therapists: "Five [out of eight TAU] clinicians [...] received weekly supervision on their cases from attending psychiatrists or staff psychologists." (<LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK>, p. 378)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-22 10:42:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Linehan-1991">
<DESCRIPTION>
<P>"Dialectical behavior therapy was supervised by the senior author (M.M.L.) who trained all therapists, listened to audiotapes at regular intervals, and conducted weekly individual and group supervision." (<LINK REF="STD-Linehan-1991" TYPE="STUDY">Linehan 1991</LINK>, p. 1061)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-26 15:39:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Linehan-1994">
<DESCRIPTION>
<P>No details provided if supervision and/or adherence ratings had been conducted. However, the same study design was used as for <LINK REF="STD-Linehan-1991" TYPE="STUDY">Linehan 1991</LINK> ("two cohorts", cf. <LINK REF="STD-Linehan-1994" TYPE="STUDY">Linehan 1994</LINK>, p. 1772), where regular supervision was explicitely defined (cf. <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>, Risk of bias table for <LINK REF="STD-Linehan-1991" TYPE="STUDY">Linehan 1991</LINK>).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-05 13:18:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Linehan-2006">
<DESCRIPTION>
<P>"Psychotherapists recommended by colleagues as potentially good DBT therapists were recruited for the study; 8 had no previous DBT exposure and 8 had experience that ranged from workshop attendance to applied practice. [...] Training consisted of a 45-hour DBT seminar followed by supervised practice. [...] Individual therapists were hired once 6 of 8 consecutive training case sessions were rated as adherent to DBT. During the study, adherence was assessed by coding a random selection of sessions on the DBT Global Rating Scale [...] which codes DBT adherence." (<LINK REF="STD-Linehan-2006" TYPE="STUDY">Linehan 2006</LINK>, p. 759)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-05 13:19:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McMain-2009">
<DESCRIPTION>
<P>"Modality-specific adherence scales were used to evaluate treatment fidelity [...]" (<LINK REF="STD-McMain-2009" TYPE="STUDY">McMain 2009</LINK>, pp. 1368, 1370)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-22 11:21:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morey-2010">
<DESCRIPTION>
<P>"Consenting clients in both conditions were assigned to a project therapist, who worked under the supervision of the primary investigator." (<LINK REF="STD-Morey-2010" TYPE="STUDY">Morey 2010</LINK>, p. 532)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-20 13:53:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nadort-2009">
<DESCRIPTION>
<P>"Treatment adherence was monitored by means of supervision. [...] All the raters were independent of the study and masked to treatment condition and outcome. The raters were psychologists trained in ST. We used the ST Therapy Adherence and Competence Scale for BPD (Young, Arntz, &amp; Giesen-Bloo, 2006)." (<LINK REF="STD-Nadort-2009" TYPE="STUDY">Nadort 2009</LINK>, p. 965)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-12 10:28:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Soler-2009">
<DESCRIPTION>
<P>"DBT-ST intervention was led by two cognitive behavioural psychotherapists with prior experience in BPD group therapy (Soler et al., 2001, 2005) and trained in DBT in courses organised by the 'Behavioural Technology Transfer Group'." (<LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>, p. 355). </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-27 13:24:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Steil-2010">
<DESCRIPTION>
<P>Therapists were supervised weekly by the treatment developer.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-29 14:50:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Turner-2000">
<DESCRIPTION>
<P>"The investigator and the senior clinic therapist monitored adherence to the treatment protocols. Both supervisors met with the therapists weekly in two separate group supervision meetings. Therapists presented audiotapes of their previous sessions with patients during supervision." (<LINK REF="STD-Turner-2000" TYPE="STUDY">Turner 2000</LINK>, p. 415)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-02 13:01:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-den-Bosch-2005">
<DESCRIPTION>
<P>"Training, regular monitoring (using videotapes) and weekly individual and group supervision were performed by the second author (L.M.C.B.), who received intensive training from Professor Linehan in Seattle and is a member of the international dialectical behaviour therapy training group." (<LINK REF="REF-Verheul-2003" TYPE="REFERENCE">Verheul 2003</LINK>, p. 136)</P>
<P>"The median adherence score on a 5-point Likert scale was 3.8 (range 2.5&#8211;4.5), indicating &#8216;almost good DBT&#8217; in terms of conformity to the treatment manual." (<LINK REF="STD-Van-den-Bosch-2005" TYPE="STUDY">Van den Bosch 2005</LINK>, p. 1233)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-02 14:28:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Weinberg-2006">
<DESCRIPTION>
<P>"This study did not monitor adherence and competence." (<LINK REF="STD-Weinberg-2006" TYPE="STUDY">Weinberg 2006</LINK>, p. 489)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-12 10:33:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zanarini-2008">
<DESCRIPTION>
<P>No information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="STUDY" MODIFIED="2012-06-26 15:39:20 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Allegiance effect improbable?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-13 11:01:51 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bateman-1999">
<DESCRIPTION>
<P>There is no indication given for an allegiance effect. However, as both authors are the founders of MBT, the treatment actually used in the experimental group, an allegiance effect seems not improbable.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-20 15:59:45 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bateman-2009">
<DESCRIPTION>
<P>There is no indication given for an allegiance effect. However, as both authors are the founders of MBT, the treatment actually used in the experimental group, an allegiance effect seems not improbable.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-13 11:03:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bellino-2006">
<DESCRIPTION>
<P>The authors seem not to be associated with IPT.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 12:38:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bellino-2007">
<DESCRIPTION>
<P>The authors seem neither to be associated with neither IPT nor CT.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-15 12:27:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bellino-2010">
<DESCRIPTION>
<P>The working group seems to be experienced in but not to be associated with IPT (cf. <LINK REF="STD-Bellino-2006" TYPE="STUDY">Bellino 2006</LINK>; <LINK REF="STD-Bellino-2007" TYPE="STUDY">Bellino 2007</LINK>).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-26 15:38:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Blum-2008">
<DESCRIPTION>
<P>There is no indication given for an allegiance effect. However, as some authors are founders of STEPPS, the treatment actually used in the experimental group, an allegiance effect seems not improbable.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-05 13:15:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bos-2010">
<DESCRIPTION>
<P>"[...] this RCT on STEPPS is the first done by others than its developers." (<LINK REF="STD-Bos-2010" TYPE="STUDY">Bos 2010</LINK>, p. 303)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-26 15:38:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carter-2010">
<DESCRIPTION>
<P>No indication of an allegiance effect.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-26 15:38:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cottraux-2009">
<DESCRIPTION>
<P>There is no indication given for an allegiance effect. None of the authors was, to our knowledge, among the developers of any of the treatments under investigation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-16 12:31:13 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Davidson-2006">
<DESCRIPTION>
<P>There is no indication given for an allegiance effect. However, as one of the authors is the founder of the two EG treatment, an allegiance effect seems not improbable.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 13:19:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Doering-2010">
<DESCRIPTION>
<P>Some of the study authors are experienced TFP therapists, but none was personally involved in treatment development.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-05 13:16:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Farrell-2009">
<DESCRIPTION>
<P>"Two of the three groups had the two program developers as therapists and the third had one developer and one clinical psychologist" (<LINK REF="STD-Farrell-2009" TYPE="STUDY">Farrell 2009</LINK>, p. 322)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-30 14:51:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giesen_x002d_Bloo-2006">
<DESCRIPTION>
<P>Experts from both therapies supervised therapists.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 12:36:43 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gratz-2006">
<DESCRIPTION>
<P>First author developed the treatment approach investigated here. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 12:42:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gregory-2008">
<DESCRIPTION>
<P>Both developers of the experimental treatment are among study authors. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-26 15:39:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Koons-2001">
<DESCRIPTION>
<P>No indication given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-22 13:04:32 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Linehan-1991">
<DESCRIPTION>
<P>The senior author (M.M.L.) is the founder of DBT. However, there are no indications for a systematic bias given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-26 15:39:20 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Linehan-1994">
<DESCRIPTION>
<P>"The study was conducted at the institution where the treatment was developed." (<LINK REF="STD-Linehan-1994" TYPE="STUDY">Linehan 1994</LINK>, p. 1775)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-05 13:18:53 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Linehan-2006">
<DESCRIPTION>
<P>The primary author (M.L.L.) is developer of DBT.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-05 13:19:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McMain-2009">
<DESCRIPTION>
<P>The principal investigator (SMM) is affiliated to DBT and head of a DBT clinic. However, there is no decided indication of an allegiance effect.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-20 16:59:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morey-2010">
<DESCRIPTION>
<P>No indication given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-20 13:54:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nadort-2009">
<DESCRIPTION>
<P>Both interventions are SFT based. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-08 10:23:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Soler-2009">
<DESCRIPTION>
<P>No indications for allegiance effect given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-27 13:16:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Steil-2010">
<DESCRIPTION>
<P>First author developed the treatment approach investigated here.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-29 14:52:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Turner-2000">
<DESCRIPTION>
<P>No indications for allegiance effect given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-15 12:31:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-den-Bosch-2005">
<DESCRIPTION>
<P>"[...] second author (L.M.C.B.), who received intensive treatment from Professor Linehan in Seattle and is a member of the international dialectical behaviour therapy training group. (<LINK REF="REF-Verheul-2003" TYPE="REFERENCE">Verheul 2003</LINK>, p. 136)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 12:40:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weinberg-2006">
<DESCRIPTION>
<P>No indication for allegiance effect. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-03 11:57:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zanarini-2008">
<DESCRIPTION>
<P>"This workshop was led jointly by two research assistants, who used a 63-slide PowerPoint presentation designed specifically for this study."(<LINK REF="STD-Zanarini-2008" TYPE="STUDY">Zanarini 2008</LINK>, p. 285f.) The intervention seems to have been developed by the study authors for purpose of this study. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2017-04-06 11:47:12 +0100" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Attention bias: equal amounts of attention to all groups (obligatory treatment components)?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 12:27:38 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bateman-1999">
<DESCRIPTION>
<P>More attention paid to EG participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-26 15:37:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bateman-2009">
<DESCRIPTION>
<P>Equal amounts of attention paid to both groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 12:28:50 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bellino-2006">
<DESCRIPTION>
<P>More attention paid to EG participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-26 15:37:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bellino-2007">
<DESCRIPTION>
<P>Equal amounts of attention paid to both groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 12:44:21 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bellino-2010">
<DESCRIPTION>
<P>More attention paid to EG participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-26 15:38:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Blum-2008">
<DESCRIPTION>
<P>More attention paid to EG participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-05 13:15:29 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bos-2010">
<DESCRIPTION>
<P>More attention paid to EG.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-26 15:38:32 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Carter-2010">
<DESCRIPTION>
<P>More attention paid to EG participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-26 15:38:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cottraux-2009">
<DESCRIPTION>
<P>Equal amounts of attention paid to both groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 12:53:21 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Davidson-2006">
<DESCRIPTION>
<P>More attention paid to EG participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 13:03:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Doering-2010">
<DESCRIPTION>
<P>Less attention may have been paid to CG patients depending on the CTBE therapist's main orientation; however, every participant was provided the specifically full amount of necessary attention.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-05 13:16:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Farrell-2009">
<DESCRIPTION>
<P>More attention paid to EG participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 13:03:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giesen_x002d_Bloo-2006">
<DESCRIPTION>
<P>Equal amounts of attention spent to both groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 13:12:19 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gratz-2006">
<DESCRIPTION>
<P>More attention paid to EG participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-04-06 11:47:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gregory-2008">
<DESCRIPTION>
<P>Though participants of the control group did not receive an alternate, obligatory control treatment, but were free to join alternative treatments, they did not receive less professional attention. Indeed, "[...] DDP participants received fewer overall treatment contact hours than did participants receiving community care." (<LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>, p. 39). Also cf. <LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>, Tab. 2, p. 33 </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-26 15:39:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Koons-2001">
<DESCRIPTION>
<P>Equal amounts of attention paid to both groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 08:55:05 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Linehan-1991">
<DESCRIPTION>
<P>More attention spent to EG.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-26 15:39:20 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Linehan-1994">
<DESCRIPTION>
<P>More attention spent to EG.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 08:56:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Linehan-2006">
<DESCRIPTION>
<P>Equal amounts of attention spent to both groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 09:04:24 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McMain-2009">
<DESCRIPTION>
<P>More attention spent to EG.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-20 17:00:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morey-2010">
<DESCRIPTION>
<P>Beyond TA (which was the point of question of the trial), both groups received comparable amounts of attention.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-20 13:55:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nadort-2009">
<DESCRIPTION>
<P>Beyond TTA (which was the point of question of the trial), both groups received comparable amounts of attention. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 09:05:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Soler-2009">
<DESCRIPTION>
<P>Equal amounts of attention spent to both groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 09:05:37 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Steil-2010">
<DESCRIPTION>
<P>More attention paid to EG.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-26 15:39:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Turner-2000">
<DESCRIPTION>
<P>More attention paid to EG2 (CCT) participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 09:14:59 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Van-den-Bosch-2005">
<DESCRIPTION>
<P>More attention spent to EG participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 09:15:40 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Weinberg-2006">
<DESCRIPTION>
<P>More attention spent to EG participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-09 10:12:01 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zanarini-2008">
<DESCRIPTION>
<P>More attention spent to EG participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2011-11-01 12:16:07 +0000" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Attention bias: effective mental health care utilisation</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-01-31 17:31:34 +0000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-01-31 17:19:00 +0000" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2012-06-14 09:41:40 +0100" MODIFIED_BY="[Empty name]">Dialectical Behaviour Therapy (DBT) versus treatment as usual (TAU) for people with borderline personality disorder</TITLE>
<TABLE COLS="7" ROWS="15">
<TR>
<TD COLSPAN="7">
<P>
<B>DBT vs. TAU for people with borderline personality disorder</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with borderline personality disorder<BR/>
<B>Settings: </B>outpatient<BR/>
<B>Intervention:</B> DBT<BR/>
<B>Comparison: </B>TAU<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>DBT</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>BPD total severity - DBT vs. TAU</B>
<BR/>mean number of BPD criteria met<BR/>Follow-up: 6 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean BPD total severity score - DBT vs. TAU in the control groups was<BR/>
<B>4.2 criteria</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean BPD total severity score - DBT vs. TAU in the intervention groups was<BR/>
<B>0.29 standard deviations lower</B>
<BR/>(1.17 lower to 0.59 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>20<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>SMD -0.29 (-1.17 to 0.59)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Inappropriate anger - DBT vs. TAU</B>
<BR/>STAXI<SUP>2</SUP> anger out, STAXI anger trait<BR/>Follow-up: 6-12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean inappropriate anger score - DBT vs. TAU ranged across control groups from<BR/>
<B>17.9 to 40.08 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean inappropriate anger score - DBT vs. TAU in the intervention groups was<BR/>
<B>0.83 standard deviations lower</B>
<BR/>(1.43 to 0.22 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>46<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>SMD -0.83 (-1.43 to -0.22)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Impulsivity - DBT vs. TAU</B>
<BR/>BPDSI-IV<SUP>3</SUP>
<BR/>Follow-up: 12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean impulsivity score - DBT vs. TAU in the control groups was<BR/>
<B>1.06 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean impulsivity score - DBT vs. TAU in the intervention groups was<BR/>
<B>0.17 standard deviations lower</B>
<BR/>(0.74 lower to 0.39 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>48<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>SMD -0.17 (-0.74 to 0.39)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Suicidality - DBT vs. TAU</B>
<BR/>BSS<SUP>4</SUP>
<BR/>Follow-up: 6 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean suicidality score - DBT vs. TAU in the control groups was<BR/>
<B>41.5 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean suicidality score - DBT vs. TAU in the intervention groups was<BR/>
<B>1.26 standard deviations lower</B>
<BR/>(2.24 to 0.29 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>20<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>SMD -1.26 (-2.24 to -0.29)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Parasuicidality - DBT vs. TAU</B>
<BR/>acts of self-mutilation<BR/>Follow-up: 6-12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean parasuicidality score - DBT vs. TAU ranged across control groups from<BR/>
<B>1.0 to 41.6 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean parasuicidality score - DBT vs. TAU in the intervention groups was<BR/>
<B>0.54 standard deviations lower</B>
<BR/>(0.92 to 0.16 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>110<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>SMD -0.54 (-0.92 to -0.16)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>parasuicidality - DBT vs. TAU</B>
</P>
<P>acts of self-mutilation</P>
<P>Follow-up: 6 months</P>
</TD>
<TD>
<P>
<B>677 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>751 per 1000</B>
</P>
<P>(528 to 1000)</P>
</TD>
<TD>
<P>
<B>RR 1.11</B>
</P>
<P>(0.78 to 1.57)</P>
</TD>
<TD>
<P>51</P>
<P>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Interpersonal problems - DBT vs. TAU</B>
<BR/>WHOQOL-Bref<SUP>6</SUP>-social relationships multiplied by (-1)<BR/>Follow-up: 12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean interpersonal problems score - DBT vs. TAU in the control groups was<BR/>
<B>49.73 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean interpersonal problems score - DBT vs. TAU in the intervention groups was<BR/>
<B>0.04 standard deviations higher</B>
<BR/>(0.54 lower to 0.61 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>48<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>SMD -0.04 (-0.61 to 0.54)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Dissociation/psychoticism - DBT vs. TAU</B>
<BR/>DES<SUP>7</SUP>
<BR/>Follow-up: 6 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean dissociation/psychoticism score - DBT vs. TAU in the control groups was<BR/>
<B>30.6 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean dissociation/psychoticism score - DBT vs. TAU in the intervention groups was<BR/>
<B>0.9 standard deviations lower</B>
<BR/>(1.83 lower to 0.03 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>20<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>SMD -0.9 (-1.83 to 0.03)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Total sample size less than 100<BR/>
<SUP>2</SUP>Spielberger Anger Expression Scale<BR/>
<SUP>3</SUP>Borderline Personality Disorder Severity Index<BR/>
<SUP>4</SUP>Beck Scale for Suicidal Ideation<BR/>
<SUP>5</SUP>Total sample size less than 400<BR/>
<SUP>6</SUP>World Health Organization quality of life assessment<BR/>
<SUP>7</SUP>Dissociative Experiences Scale</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2013-01-31 17:31:34 +0000" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2012-07-06 17:14:51 +0100" MODIFIED_BY="[Empty name]">Dialectical Behaviour Therapy (DBT) versus general management (GM) according to APA guidelines for people with borderline personality disorder</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7">
<P>
<B>DBT vs. general management according to APA guidelines for people with borderline personality disorders</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with borderline personality disorder<BR/>
<B>Settings: </B>outpatient<BR/>
<B>Intervention:</B> DBT<BR/>
<B>Comparison: </B>general management (GM)</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>GM</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>DBT</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>BPD total severity</B>
<BR/>ZAN-BPD<SUP>1</SUP> total<BR/>Follow-up: mean 12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean BPD total severity score in the control groups was<BR/>
<B>8.16 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean BPD total severity score in the intervention groups was<BR/>
<B>0.04 standard deviations lower</B>
<BR/>(0.33 lower to 0.25 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>180<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Inappropriate anger - DBT vs. GM</B>
<BR/>STAXI<SUP>3</SUP>-anger out<BR/>Follow-up: mean 12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean inappropriate anger score - DBT vs. GM in the control groups was<BR/>
<B>5.11 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean inappropriate anger score - DBT vs. GM in the intervention groups was<BR/>
<B>0.03 standard deviations lower</B>
<BR/>(0.32 lower to 0.26 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>180<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Parasuicidality - DBT vs. GM</B>
<BR/>mean no. of suicidal and self-injurious episodes<BR/>Follow-up: mean 12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean parasuicidality score - DBT vs. GM in the control groups was<BR/>
<B>12.87 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean parasuicidality score - DBT vs. GM in the intervention groups was<BR/>
<B>0.23 standard deviations lower</B>
<BR/>(0.52 lower to 0.06 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>180<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Interpersonal problems - DBT vs. GM</B>
<BR/>IIP-C<SUP>4</SUP> total<BR/>Follow-up: mean 12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean interpersonal problems score - DBT vs. GM in the control groups was<BR/>
<B>101.58 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean interpersonal problems score - DBT vs. GM in the intervention groups was<BR/>
<B>0.03 standard deviations lower</B>
<BR/>(0.32 lower to 0.26 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>180<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Zanarini rating scale for borderline personality disorder<BR/>
<SUP>2</SUP>Total sample size less than 400<BR/>
<SUP>3</SUP>Spielberger Anger Expression Scale<BR/>
<SUP>4</SUP>Inventory of interpersonal problems-Circumplex Scales</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2013-01-31 17:20:29 +0000" MODIFIED_BY="[Empty name]" NO="3" READONLY="YES">
<TITLE MODIFIED="2012-07-06 17:15:02 +0100" MODIFIED_BY="[Empty name]">Dialectical Behaviour Therapy (DBT) versus community treatment by experts (CTBE) for people with borderline personality disorder</TITLE>
<TABLE COLS="7" ROWS="3">
<TR>
<TD COLSPAN="7">
<P>
<B>DBT compared to community treatment by experts (CTBE) for people with borderline personality disorder</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with borderline personality disorder<BR/>
<B>Settings: </B>outpatient<BR/>
<B>Intervention:</B> DBT<BR/>
<B>Comparison: </B>CTBE</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Community treatment by experts</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>DBT</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Suicidality</B>
<BR/>SBQ<SUP>1</SUP>
<BR/>Follow-up: mean 12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean suicidality score in the control groups was<BR/>
<B>32.8 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean suicidality score in the intervention groups was<BR/>
<B>0.12 standard deviations lower</B>
<BR/>(0.54 lower to 0.30 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>89<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Suicidal Behaviours Questionnaire<BR/>
<SUP>2</SUP>Total sample size less than 100</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2013-01-31 17:20:17 +0000" MODIFIED_BY="[Empty name]" NO="4" READONLY="YES">
<TITLE MODIFIED="2012-07-06 17:18:11 +0100" MODIFIED_BY="[Empty name]">Dialectical Behaviour Therapy for BPD with post-traumatic stress disorder (DBT-PTSD) versus waiting list (WL) for people with borderline personality disorder</TITLE>
<TABLE COLS="7" ROWS="9">
<TR>
<TD COLSPAN="7">
<P>
<B>DBT-PTSD compared to waiting list (WL) for people with borderline personality disorder</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with borderline personality disorder<BR/>
<B>Settings:</B> inpatient<BR/>
<B>Intervention:</B> DBT-PTSD<BR/>
<B>Comparison: </B>WL</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Waiting list</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>DBT-PTSD</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>BPD total severity</B>
<BR/>BSL<SUP>1</SUP>
<BR/>Follow-up: mean 3 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean BPD total severity score in the control groups was<BR/>
<B>2.26 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean BPD total severity score in the intervention groups was<BR/>
<B>0.74 standard deviations lower</B>
<BR/>(1.47 to 0.01 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>31<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Dissociation</B>
<BR/>DES<SUP>3</SUP>
<BR/>Follow-up: mean 3 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean dissociation score in the control groups was<BR/>
<B>19.99 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean dissociation score in the intervention groups was<BR/>
<B>0.34 standard deviations lower</B>
<BR/>(1.06 lower to 0.38 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>30<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Borderline Symptom List<BR/>
<SUP>2</SUP>Total sample size less than 100<BR/>
<SUP>2</SUP>Dissociative Experiences Scale</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-05" MODIFIED="2013-01-31 17:20:12 +0000" MODIFIED_BY="[Empty name]" NO="5" READONLY="YES">
<TITLE MODIFIED="2013-01-31 17:19:36 +0000" MODIFIED_BY="[Empty name]">Mentalisation-Based Treatment-partial hospitalisation (MBT-PH) versus treatment as usual (TAU) for people with borderline personality disorder</TITLE>
<TABLE COLS="7" ROWS="5">
<TR>
<TD COLSPAN="7">
<P>
<B>MBT-PH compared to TAU for people with borderline personality disorder</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with borderline personality disorder<BR/>
<B>Settings:</B> partial hospitalisation<BR/>
<B>Intervention:</B> MBT-PH<BR/>
<B>Comparison: </B>TAU</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>TAU</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>MBT-PH</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Suicidality</B>
<BR/>no. of participants with suicide attempt (last 6 months)<BR/>Follow-up: mean 18 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>632 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>51 per 1000</B>
<BR/>(6 to 366)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.08 </B>
<BR/>(0.01 to 0.58)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>38<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Parasuicidality</B>
<BR/>no. of participants with self-mutilating behaviour (last 6 months)<BR/>Follow-up: mean 18 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>842 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>371 per 1000</B>
<BR/>(202 to 682)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.44 </B>
<BR/>(0.24 to 0.81)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>38<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Interpersonal problems</B>
<BR/>IIP<SUP>2</SUP>
<BR/>Follow-up: mean 18 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean interpersonal problems score in the control groups was<BR/>
<B>2.6 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean interpersonal problems score in the intervention groups was<BR/>
<B>2.22 standard deviations lower</B>
<BR/>(3.04 to 1.39 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>38<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Total sample size less than 100<BR/>
<SUP>2</SUP>Inventory of interpersonal problems</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-06" MODIFIED="2013-01-31 17:21:07 +0000" MODIFIED_BY="[Empty name]" NO="6" READONLY="YES">
<TITLE MODIFIED="2012-07-06 17:16:33 +0100" MODIFIED_BY="[Empty name]">Mentalisation-Based Treatment-outpatient (MBT-out) versus treatment as usual (TAU) for people with borderline personality disorder</TITLE>
<TABLE COLS="7" ROWS="5">
<TR>
<TD COLSPAN="7">
<P>
<B>MBT-out compared to TAU for people with borderline personality disorder</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with borderline personality disorder<BR/>
<B>Settings:</B> outpatient<BR/>
<B>Intervention:</B> MBT-out<BR/>
<B>Comparison: </B>TAU</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>TAU</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>MBT-out</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Suicidality</B>
<BR/>no. of participants with life-threatening suicide attempts (last 6 months)<BR/>Follow-up: mean 18 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>254 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>28 per 1000</B>
<BR/>(8 to 117)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.11 </B>
<BR/>(0.03 to 0.46)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>134<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Parasuicidality</B>
<BR/>no. of participants with self-harm incidents (last 6 months)<BR/>Follow-up: mean 18 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>429 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>240 per 1000</B>
<BR/>(146 to 394)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.56 </B>
<BR/>(0.34 to 0.92)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>134<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Interpersonal problems</B>
<BR/>IIP<SUP>2</SUP>
<BR/>Follow-up: mean 18 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean interpersonal problems score in the control groups was<BR/>
<B>1.65 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean interpersonal problems score in the intervention groups was<BR/>
<B>0.95 standard deviations lower</B>
<BR/>(1.30 to 0.59 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>134<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Total sample size less than 400<BR/>
<SUP>2</SUP>Inventory of interpersonal problems</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-07" MODIFIED="2013-01-31 17:21:40 +0000" MODIFIED_BY="[Empty name]" NO="7" READONLY="YES">
<TITLE MODIFIED="2013-01-31 17:21:27 +0000" MODIFIED_BY="[Empty name]">Transference-Focused Psychotherapy (TFP) versus community treatment by experts (CTBE) for people with borderline personality disorder</TITLE>
<TABLE COLS="7" ROWS="10">
<TR>
<TD COLSPAN="7">
<P>
<B>TFP compared to CTBE for people with borderline personality disorder</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with borderline personality disorder<BR/>
<B>Settings:</B> outpatient<BR/>
<B>Intervention:</B> TFP<BR/>
<B>Comparison: </B>CTBE</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>CTBE</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>TFP</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>BPD total severity</B>
<BR/>mean number of BPD criteria met. Scale from: 0 to 9.<BR/>Follow-up: mean 12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean BPD total severity score in the control groups was<BR/>
<B>5.63 criteria</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean BPD total severity score in the intervention groups was<BR/>
<B>0.55 standard deviations lower</B>
<BR/>(0.95 to 0.16 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>104<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Suicidality</B>
<BR/>no. of participants with suicidal act (last 12 months)<BR/>Follow-up: mean 12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>212 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>135 per 1000</B>
<BR/>(57 to 319)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.64 </B>
<BR/>(0.27 to 1.51)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>104<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Parasuicidality</B>
<BR/>no. of participants with self-harming behaviour (last 12 months)<BR/>Follow-up: mean 12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>673 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>734 per 1000</B>
<BR/>(565 to 942)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.09 </B>
<BR/>(0.84 to 1.40)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>104<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Total sample size less than 400</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-08" MODIFIED="2013-01-31 17:27:32 +0000" MODIFIED_BY="[Empty name]" NO="8" READONLY="YES">
<TITLE MODIFIED="2013-01-17 10:39:33 +0000" MODIFIED_BY="[Empty name]">Cognitive-Behavioural Therapy (CBT) versus treatment as usual (TAU) for borderline personality disorder</TITLE>
<TABLE COLS="7" ROWS="5">
<TR>
<TD COLSPAN="7">
<P>
<B>CBT compared to TAU for borderline personality disorder</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with borderline personality disorder<BR/>
<B>Settings:</B> outpatient<BR/>
<B>Intervention:</B> CBT<BR/>
<B>Comparison: </B>TAU</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>TAU</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>CBT</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Suicidality - CBT vs. TAU</B>
<BR/>no. of participants with suicidal act (last 12 months)<BR/>Follow-up: mean 12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>438 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>342 per 1000</B>
<BR/>(206 to 556)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.78 </B>
<BR/>(0.47 to 1.27)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>101<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Parasuicidality - CBT vs. TAU</B>
<BR/>no. of participants with self-harming behaviour (last 12 months)<BR/>Follow-up: mean 12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>574 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>672 per 1000</B>
<BR/>(494 to 918)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.17 </B>
<BR/>(0.86 to 1.6)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>99<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Interpersonal problems score</B>
<BR/>IIP-SC<SUP>2</SUP>
<BR/>Follow-up: mean 12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean interpersonal problems score in the control groups was<BR/>
<B>55 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean Interpersonal problems score in the intervention groups was<BR/>
<B>0.23 standard deviations higher</B>
<BR/>(0.16 lower to 0.63 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>99<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Total sample size less than 400<BR/>
<SUP>2</SUP> Inventory of Interpersonal Problems-short form</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-09" MODIFIED="2013-01-31 17:27:55 +0000" MODIFIED_BY="[Empty name]" NO="9" READONLY="YES">
<TITLE MODIFIED="2012-07-06 17:16:53 +0100" MODIFIED_BY="[Empty name]">Dynamic-Deconstructive Psychotherapy (DDP) versus treatment as ususal (TAU) for people with borderline personality disorder</TITLE>
<TABLE COLS="7" ROWS="5">
<TR>
<TD COLSPAN="7">
<P>
<B>DDP compared to TAU for people with borderline personality disorder</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with borderline personality disorder<BR/>
<B>Settings:</B> outpatient<BR/>
<B>Intervention:</B> DDP<BR/>
<B>Comparison: </B>TAU</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>TAU</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>DDP</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>BPD total severity</B>
<BR/>BEST<SUP>1</SUP>
<BR/>Follow-up: mean 12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean BPD total severity score in the control groups was<BR/>
<B>38.4 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean BPD total severity score in the intervention groups was<BR/>
<B>0.44 standard deviations lower</B>
<BR/>(1.16 lower to 0.29 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>30<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Parasuicidality</B>
<BR/>no. of participants with parasuicide (last 3 months)<BR/>Follow-up: mean 12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>600 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>534 per 1000</B>
<BR/>(282 to 1000)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.89 </B>
<BR/>(0.47 to 1.67)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>30<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Dissociation</B>
<BR/>DES<SUP>3</SUP>
<BR/>Follow-up: mean 12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean dissociation score in the control groups was<BR/>
<B>22.3 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean dissociation score in the intervention groups was<BR/>
<B>0.25 standard deviations higher</B>
<BR/>(0.47 lower to 0.97 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>30<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Borderline evaluation of severity over time<BR/>
<SUP>2</SUP>Total sample less than 100<BR/>
<SUP>3</SUP>Dissociative Experiences Scale</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-10" MODIFIED="2013-01-31 17:28:08 +0000" MODIFIED_BY="[Empty name]" NO="10" READONLY="YES">
<TITLE MODIFIED="2012-07-06 17:17:00 +0100" MODIFIED_BY="[Empty name]">Interpersonal Psychotherapy (IPT) versus clinical management (CM) for people with borderline personality disorder</TITLE>
<TABLE COLS="7" ROWS="8">
<TR>
<TD COLSPAN="7">
<P>
<B>IPT compared to CM for people with borderline personality disorder</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with borderline personality disorder<BR/>
<B>Settings: </B>outpatient<BR/>
<B>Intervention:</B> IPT<BR/>
<B>Comparison: </B>CM</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>CM</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>IPT</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>No primary outcomes available</B>
<BR/>Follow-up: mean 6 months</P>
</TD>
<TD COLSPAN="2">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>39<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No primary outcomes available</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
<SOF_TABLE ID="SOF-11" MODIFIED="2013-01-31 17:29:39 +0000" MODIFIED_BY="[Empty name]" NO="11" READONLY="YES">
<TITLE MODIFIED="2012-07-06 17:17:06 +0100" MODIFIED_BY="[Empty name]">Interpersonal Psychotherapy adapted for BPD (IPT-BPD) versus clinical management (CM) for people with borderline personality disorder</TITLE>
<TABLE COLS="7" ROWS="17">
<TR>
<TD COLSPAN="7">
<P>
<B>IPT-BPD compared to CM for people with borderline personality disorder</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with borderline personality disorder<BR/>
<B>Settings:</B> outpatient<BR/>
<B>Intervention:</B> IPT-BPD<BR/>
<B>Comparison: </B>CM</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>CM</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>IPT-BPD</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>BPD total severity</B>
<BR/>BPDSI-IV<SUP>1</SUP>-total score<BR/>Follow-up: mean 8 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean BPD total severity score in the control groups was<BR/>
<B>33.46 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean BPD total severity score in the intervention groups was<BR/>
<B>0.03 standard deviations lower</B>
<BR/>(0.62 lower to 0.56 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>44<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Anger</B>
<BR/>BPDSI-IV<SUP>1</SUP>-anger<BR/>Follow-up: mean 8 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean anger score in the control groups was<BR/>
<B>5.25 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean anger score in the intervention groups was<BR/>
<B>0.01 standard deviations higher</B>
<BR/>(0.58 lower to 0.60 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>44<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Affective instability</B>
<BR/>BPDSI-IV<SUP>1</SUP>-affective instability<BR/>Follow-up: mean 8 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean affective instability score in the control groups was<BR/>
<B>6.63 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean affective instability score in the intervention groups was<BR/>
<B>0.92 standard deviations lower</B>
<BR/>(1.54 to 0.30 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>44<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Chronic feelings of emptiness</B>
<BR/>BPDSI-IV<SUP>1</SUP>-emptiness<BR/>Follow-up: mean 8 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean chronic feelings of emptiness score in the control groups was<BR/>
<B>7.12 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean chronic feelings of emptiness score in the intervention groups was<BR/>
<B>0.09 standard deviations higher</B>
<BR/>(0.50 lower to 0.68 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>44<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Impulsivity</B>
<BR/>BPDSI-IV<SUP>1</SUP>-impulsivity<BR/>Follow-up: mean 8 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean impulsivity in the control groups was<BR/>
<B>6.26 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean impulsivity in the intervention groups was<BR/>
<B>0.91 standard deviations lower</B>
<BR/>(1.53 to 0.28 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>44<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Parasuicidality</B>
<BR/>BPDSI-IV<SUP>1</SUP>-parasuicidal behaviour<BR/>Follow-up: mean 8 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean parasuicidality score in the control groups was<BR/>
<B>1.99 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean parasuicidality score in the intervention groups was<BR/>
<B>0.02 standard deviations higher</B>
<BR/>(0.58 lower to 0.61 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>44<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Interpersonal problems</B>
<BR/>BPDSI-IV<SUP>1</SUP>-interpersonal relationships<BR/>Follow-up: mean 8 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean interpersonal problems score in the control groups was<BR/>
<B>6.97 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean interpersonal problems score in the intervention groups was<BR/>
<B>0.82 standard deviations lower</B>
<BR/>(1.44 to 0.20 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>44<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Avoidance of abandonment</B>
</P>
<P>BPDSI-IV<SUP>1</SUP>-abandonment</P>
<P>Follow-up: mean 8 months</P>
</TD>
<TD>
<P>The mean avoidance of abandonment score in the control group was</P>
<P>
<B>6.1 points</B>
</P>
</TD>
<TD>
<P>The mean avoidance of abandonment score in the intervention groups was</P>
<P>
<B>0.01 standard deviations higher</B>
</P>
<P>(-0.58 lower to 0.60 higher)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>44<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Identity disturbance</B>
</P>
<P>BPDSI-IV<SUP>1</SUP>-identity disturbance</P>
<P>Follow-up: mean 8 months</P>
</TD>
<TD>
<P>The mean identity disturbance score in the control group was</P>
<P>
<B>2.49 points</B>
</P>
</TD>
<TD>
<P>The mean identity disturbance score in the intervention group was</P>
<P>
<B>0.03 standard deviations lower</B>
</P>
<P>(-0.62 lower to 0.56 higher)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>44<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Dissociation/paranoid ideation</B>
</P>
<P>BPDSI-IV<SUP>1</SUP>-paranoid ideation</P>
<P>Follow-up: mean 8 months</P>
<P/>
</TD>
<TD>
<P>The mean dissociation/paranoid ideation score in the control group was</P>
<P>
<B>4.09 points</B>
</P>
</TD>
<TD>
<P>The mean dissociation/paranoid ideation score in the intervention group was</P>
<P>
<B>0.10 standard deviations higher</B>
</P>
<P>(-0.49 lower to 0.70 higher)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>44<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Borderline personality disorder severity index<BR/>
<SUP>2</SUP>Total sample size less than 100</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-12" MODIFIED="2013-01-31 17:29:33 +0000" MODIFIED_BY="[Empty name]" NO="12" READONLY="YES">
<TITLE MODIFIED="2012-07-06 17:17:13 +0100" MODIFIED_BY="[Empty name]">Dialectical Behaviour Therapy-skills training only (DBT-ST)versus standard group (SG) for borderline personality disorder</TITLE>
<TABLE COLS="7" ROWS="15">
<TR>
<TD COLSPAN="7">
<P>
<B>DBT skills training only compared to standard group for borderline personality disorder</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with borderline personality disorder<BR/>
<B>Settings:</B> outpatient<BR/>
<B>Intervention:</B> DBT skills training only<BR/>
<B>Comparison: </B>standard group</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Standard group</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>DBT skills training only</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>BPD total severity</B>
<BR/>CGI-BPD<SUP>1</SUP>-global<BR/>Follow-up: mean 3 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean BPD total severity score in the control groups was<BR/>
<B>4.44 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean BPD total severity score in the intervention groups was<BR/>
<B>1.01 standard deviations lower</B>
<BR/>(1.55 to 0.47 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>59<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Anger</B>
<BR/>CGI-BPD<SUP>1</SUP>-anger<BR/>Follow-up: mean 3 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean anger score in the control groups was<BR/>
<B>3.88 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean anger score in the intervention groups was<BR/>
<B>0.84 standard deviations lower</B>
<BR/>(1.37 to 0.30 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>59<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Affective instability</B>
<BR/>CGI-BPD<SUP>1</SUP>-affective instability<BR/>Follow-up: mean 3 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean affective instability score in the control groups was<BR/>
<B>4.66 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean affective instability score in the intervention groups was<BR/>
<B>1.07 standard deviations lower</B>
<BR/>(1.61 to 0.52 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>59<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Chronic feelings of emptiness</B>
<BR/>CGI-BPD<SUP>1</SUP>-emptiness<BR/>Follow-up: mean 3 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean chronic feelings of emptiness score in the control groups was<BR/>
<B>5.00 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean chronic feelings of emptiness score in the intervention groups was<BR/>
<B>0.43 standard deviations lower</B>
<BR/>(0.95 lower to 0.09 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>59<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Impulsivity</B>
<BR/>CGI-BPD<SUP>1</SUP>-impulsivity<BR/>Follow-up: mean 3 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean impulsivity score in the control groups was<BR/>
<B>4.11 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean impulsivity score in the intervention groups was<BR/>
<B>0.61 standard deviations lower</B>
<BR/>(1.14 to 0.09 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>59<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Suicidality</B>
<BR/>CGI-BPD<SUP>1</SUP>-suicidality<BR/>Follow-up: mean 3 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean suicidality score in the control groups was<BR/>
<B>2.55 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean suicidality score in the intervention groups was<BR/>
<B>0.10 standard deviations lower</B>
<BR/>(0.61 lower to 0.41 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>59<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Interpersonal problems</B>
<BR/>CGI-BPD<SUP>1</SUP>-unstable relationships<BR/>Follow-up: mean 3 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean interpersonal problems score in the control groups was<BR/>
<B>4.44 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean interpersonal problems score in the intervention groups was<BR/>
<B>0.29 standard deviations lower</B>
<BR/>(0.80 lower to 0.23 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>59<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Dissociation/psychoticism</B>
<BR/>BPRS<SUP>3</SUP>
<BR/>Follow-up: mean 3 months</P>
</TD>
<TD>
<P>The mean dissociation/psychoticism score in the control groups was<BR/>
<B>11.89 points</B>
</P>
</TD>
<TD>
<P>The mean dissociation/psychoticism score in the intervention groups was<BR/>
<B>-0.66 standard deviations lower</B>
<BR/>(-1.18 to -0.13 lower)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>59<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Clinical global impression scale for borderline personality disorder patients<BR/>
<SUP>2</SUP>Total sample size less than 400<BR/>
<SUP>3</SUP>Brief psychiatric rating scale</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-13" MODIFIED="2013-01-31 17:29:24 +0000" MODIFIED_BY="[Empty name]" NO="13" READONLY="YES">
<TITLE MODIFIED="2012-07-11 14:23:31 +0100" MODIFIED_BY="[Empty name]">Emotion regulation group training (ERG) versus treatment as usual (TAU) for borderline personality disorder</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7">
<P>
<B>ERG compared to TAU for borderline personality disorder</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with borderline personality disorder<BR/>
<B>Settings:</B> outpatient<BR/>
<B>Intervention:</B> ERG<BR/>
<B>Comparison: </B>TAU</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>TAU</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>ERG</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>BPD total severity</B>
<BR/>BEST<SUP>1</SUP>
<BR/>Follow-up: mean 4.5 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean BPD total severity score in the control groups was<BR/>
<B>34.7 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean BPD total severity score in the intervention groups was<BR/>
<B>1.02 standard deviations lower</B>
<BR/>(1.92 to 0.11 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>22<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Affective instability</B>
<BR/>DERS<SUP>3</SUP>-emotional dysregulation<BR/>Follow-up: mean 4.5 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean affective instability score in the control groups was<BR/>
<B>115.8 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean affective instability score in the intervention groups was<BR/>
<B>1.65 standard deviations lower</B>
<BR/>(2.65 to 0.65 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>22<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Impulsivity</B>
<BR/>DERS<SUP>3</SUP>-impulse dyscontrol<BR/>Follow-up: mean 4.5 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean impulsivity score in the control groups was<BR/>
<B>17.1 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean impulsivity score in the intervention groups was<BR/>
<B>1.30 standard deviations lower</B>
<BR/>(2.24 to 0.36 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>22<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Parasuicidality</B>
<BR/>DERS<SUP>3</SUP>-self-harm frequency (transformed)<BR/>Follow-up: mean 4.5 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean parasuicidality score in the control groups was<BR/>
<B>4.48 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean parasuicidality score in the intervention groups was<BR/>
<B>0.98 standard deviations lower</B>
<BR/>(1.88 to 0.09 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>22<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Borderline Evaluation of Severity over Time<BR/>
<SUP>2</SUP>Total sample size less than 100<BR/>
<SUP>3</SUP>Difficulties in Emotion Regulation Scale</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-14" MODIFIED="2013-01-31 17:30:02 +0000" MODIFIED_BY="[Empty name]" NO="14" READONLY="YES">
<TITLE MODIFIED="2012-07-06 17:17:25 +0100" MODIFIED_BY="[Empty name]">Schema-Focused Therapy-Group (SFT-G) versus treatment as usual (TAU) for borderline personality disorder</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>SFT-G compared to TAU for borderline personality disorder</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with borderline personality disorder<BR/>
<B>Settings:</B> outpatient<BR/>
<B>Intervention:</B> SFT-G<BR/>
<B>Comparison: </B>TAU</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>TAU</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>SFT-G</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>BPD total severity</B>
<BR/>BSI<SUP>1</SUP>
<BR/>Follow-up: mean 8 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean BPD total severity score in the control groups was<BR/>
<B>32.75 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean BPD total severity score in the intervention groups was<BR/>
<B>1.66 standard deviations lower</B>
<BR/>(2.54 to 0.78 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>28<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Affective instability</B>
<BR/>DIB-R<SUP>3</SUP>-affect<BR/>Follow-up: mean 8 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean affective instability score in the control groups was<BR/>
<B>9.83 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean affective instability score in the intervention groups was<BR/>
<B>1.41 standard deviations lower</B>
<BR/>(2.26 to 0.57 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>28<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Impulsivity</B>
<BR/>DIB-R<SUP>3</SUP>-impulses<BR/>Follow-up: mean 8 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean impulsivity score in the control groups was<BR/>
<B>5.58 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean impulsivity score in the intervention groups was<BR/>
<B>1.92 standard deviations lower</B>
<BR/>(2.85 to 1.00 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>28<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>interpersonal problems</B>
<BR/>DIB-R<SUP>3</SUP>-interpersonal<BR/>Follow-up: mean 8 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean interpersonal problems score in the control groups was<BR/>
<B>12 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean interpersonal problems score in the intervention groups was<BR/>
<B>1.94 standard deviations lower</B>
<BR/>(2.87 to 1.02 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>28<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Dissociation/psychoticism</B>
<BR/>DIB-R<SUP>3</SUP>-cognition<BR/>Follow-up: mean 8 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean dissociation/psychoticism score in the control groups was<BR/>
<B>4.25 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean dissociation/psychoticism score in the intervention groups was<BR/>
<B>1.37 standard deviations lower</B>
<BR/>(2.21 to 0.53 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>28<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Borderline Syndrome Index<BR/>
<SUP>2</SUP>Total sample size less than 100<BR/>
<SUP>3</SUP>Diagnostic Interview for BPD-Revised</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-15" MODIFIED="2013-01-31 17:30:21 +0000" MODIFIED_BY="[Empty name]" NO="15" READONLY="YES">
<TITLE MODIFIED="2012-07-06 17:17:31 +0100" MODIFIED_BY="[Empty name]">Systems training for emotional predictability and problem solving for borderline personality disorder (STEPPS) versus treatment as usual (TAU) for borderline personality disorder</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>STEPPS compared to TAU for borderline personality disorder</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with borderline personality disorder<BR/>
<B>Settings:</B> outpatient<BR/>
<B>Intervention:</B> STEPPS<BR/>
<B>Comparison: </B>TAU</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>TAU</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>STEPPS</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>BPD total severity</B>
<BR/>BEST<SUP>1</SUP>
<BR/>Follow-up: mean 5 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean BPD total severity score in the control groups was<BR/>
<B>34.1 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean BPD total severity score in the intervention groups was<BR/>
<B>0.17 standard deviations lower</B>
<BR/>(0.52 lower to 0.19 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>124<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Affective instability</B>
<BR/>ZAN-BPD<SUP>3</SUP>-affective subscale<BR/>Follow-up: mean 5 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean affective instability score in the control groups was<BR/>
<B>4.9 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean affective instability score in the intervention groups was<BR/>
<B>0.32 standard deviations lower</B>
<BR/>(0.67 lower to 0.04 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>124<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Impulsivity</B>
<BR/>BIS<SUP>4</SUP>
<BR/>Follow-up: mean 5 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean impulsivity score in the control groups was<BR/>
<B>76.8 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean impulsivity score in the intervention groups was<BR/>
<B>0.29 standard deviations lower</B>
<BR/>(0.64 lower to 0.07 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>124<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Interpersonal problems</B>
<BR/>ZAN-BPD<SUP>3</SUP>-disturbed relations<BR/>Follow-up: mean 5 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean interpersonal problems score in the control groups was<BR/>
<B>3.2 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean interpersonal problems score in the intervention groups was<BR/>
<B>0.42 standard deviations lower</B>
<BR/>(0.78 to 0.06 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>124<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Dissociation/psychoticism</B>
<BR/>ZAN-BPD<SUP>3</SUP>-cognitive subscale<BR/>Follow-up: mean 5 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean dissociation/psychoticism score in the control groups was<BR/>
<B>3.00 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean dissociation/psychoticism score in the intervention groups was<BR/>
<B>0.42 standard deviations lower</B>
<BR/>(0.78 lower to 0.06 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>124<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Borderline Evaluation of Severity over Time<BR/>
<SUP>2</SUP>Total sample size less than 200<BR/>
<SUP>3</SUP>Zanarini rating scale for borderline personality disorder<BR/>
<SUP>4</SUP>Barrett Impulsiveness Scale</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-16" MODIFIED="2013-01-31 17:30:37 +0000" MODIFIED_BY="[Empty name]" NO="16" READONLY="YES">
<TITLE MODIFIED="2012-07-11 14:25:49 +0100" MODIFIED_BY="[Empty name]">Systems training for emotional predictability and problem solving for borderline personality disorder + individual therapy (STEPPS+IT) versus treatment as usual (TAU) for borderline personality disorder</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7">
<P>
<B>STEPPS+IT compared to TAU for borderline personality disorder</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with borderline personality disorder<BR/>
<B>Settings:</B> outpatient<BR/>
<B>Intervention:</B> STEPPS+IT<BR/>
<B>Comparison: </B>TAU</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>TAU</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>STEPPS+IT</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>BPD total severity</B>
<BR/>BPD-40<SUP>1</SUP>
<BR/>Follow-up: mean 4.5 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean BPD total severity score in the control groups was<BR/>
<B>95.1 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean BPDtotal severity score in the intervention groups was<BR/>
<B>0.55 standard deviations lower</B>
<BR/>(1.11 lower to 0.00 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>52<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Impulsivity</B>
<BR/>no. of participants scoring above BPDSI-IV<SUP>3</SUP> impulsivity cut-off score<BR/>Follow-up: mean 4.5 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>733 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>682 per 1000</B>
<BR/>(484 to 946)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.93 </B>
<BR/>(0.66 to 1.29)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>58<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Parasuicidality</B>
<BR/>no. of participants scoring above BPDSI-IV<SUP>3</SUP> parasuicide cut-off score<BR/>Follow-up: mean 4.5 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>433 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>572 per 1000</B>
<BR/>(338 to 962)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.32 </B>
<BR/>(0.78 to 2.22)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>58<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Interpersonal problems</B>
<BR/>WHOQOL-BREF<SUP>4</SUP>-social relationships (mean scores multiplied by -1)<BR/>Follow-up: mean 4.5 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean interpersonal problems score in the control groups was<BR/>
<B>-12.00 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean interpersonal problems score in the intervention groups was<BR/>
<B>0.27 standard deviations lower</B>
<BR/>(0.81 lower to 0.27 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>53<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Borderline Personality Disorder Checklist-40<BR/>
<SUP>2</SUP>Total sample size less than 100<BR/>
<SUP>3</SUP>Borderline Personality Disorder Severity Index<BR/>
<SUP>4</SUP>World Health Organization Quality of Life Assessment-Bref</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-17" MODIFIED="2013-01-31 17:30:59 +0000" MODIFIED_BY="[Empty name]" NO="17" READONLY="YES">
<TITLE MODIFIED="2012-07-06 17:18:48 +0100" MODIFIED_BY="[Empty name]">Manual-assisted cognitive treatment (MACT) versus treatment as usual (TAU) for borderline personality disorder</TITLE>
<TABLE COLS="7" ROWS="9">
<TR>
<TD COLSPAN="7">
<P>
<B>MACT compared to TAU for borderline personality disorder</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with borderline personality disorder<BR/>
<B>Settings:</B> outpatient<BR/>
<B>Intervention:</B> MACT<BR/>
<B>Comparison: </B>TAU</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>TAU</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>MACT</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Suicidality</B>
<BR/>SBQ<SUP>1</SUP>
<BR/>Follow-up: mean 1.5 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean suicidality score in the control groups was<BR/>
<B>17.67 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean suicidality score in the intervention groups was<BR/>
<B>0.86 standard deviations lower</B>
<BR/>(1.63 to 0.07 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>28<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Parasuicidality</B>
<BR/>PHI<SUP>3</SUP>-deliberate self-harm frequency<BR/>Follow-up: mean 1.5 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean parasuicidality score in the control groups was<BR/>
<B>3.63 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean parasuicidality score in the intervention groups was<BR/>
<B>0.88 standard deviations lower</B>
<BR/>(1.67 to 0.10 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>28<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Suicidal Behaviours Questionnaire<BR/>
<SUP>2</SUP>Total sample size less than 100<BR/>
<SUP>3</SUP>Parasuicide History Interview</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-18" MODIFIED="2013-01-31 17:31:17 +0000" MODIFIED_BY="[Empty name]" NO="18" READONLY="YES">
<TITLE MODIFIED="2012-07-06 17:18:55 +0100" MODIFIED_BY="[Empty name]">Psychoeducation (PE) versus waiting list (WL) for borderline personality disorder</TITLE>
<TABLE COLS="7" ROWS="9">
<TR>
<TD COLSPAN="7">
<P>
<B>Psychoeducation compared to waiting list for borderline personality disorder</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with borderline personality disorder<BR/>
<B>Settings:</B> outpatient<BR/>
<B>Intervention:</B> psychoeducation<BR/>
<B>Comparison: </B>waiting list</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Waiting list</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Psychoeducation</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Impulsivity</B>
<BR/>ZAN-BPD<SUP>1</SUP>-impulsivity baseline to endpoint change<BR/>Follow-up: mean 3 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean impulsivity score in the control groups was<BR/>
<B>0.05 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean impulsivity score in the intervention groups was<BR/>
<B>0.47 standard deviations lower</B>
<BR/>(1.04 lower to 0.10 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>50<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Interpersonal problems</B>
<BR/>ZAN-BPD<SUP>1</SUP>-stormy relationships baseline to endpoint change<BR/>Follow-up: mean 3 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean interpersonal problems score in the control groups was<BR/>
<B>-0.05 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean interpersonal problems score in the intervention groups was<BR/>
<B>0.75 standard deviations lower</B>
<BR/>(1.33 to 0.16 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>50<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Zanarini Rating scale for Borderline Personality Disorder<BR/>
<SUP>2</SUP>Total sample size less than 100</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2013-01-17 09:09:20 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2012-06-15 14:20:46 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-06-05 13:39:12 +0100" MODIFIED_BY="[Empty name]">Spreadsheet of primary outcome effect estimates: Dialectical behaviour therapy (DBT) versus control groups (comprehensive therapies only)</TITLE>
<TABLE COLS="5" ROWS="31">
<TR>
<TH VALIGN="TOP">
<P>
<B>Outcome/Subgroup</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Studies</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Participants</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Statistical Method</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Effect Estimate/95% CI </B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>BPD total severity</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>DBT<SUP>1</SUP> vs. TAU<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>SMD</P>
</TD>
<TD VALIGN="TOP">
<P>-0.29 [-1.17, 0.59]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>DBT vs. GM<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>180</P>
</TD>
<TD VALIGN="TOP">
<P>SMD</P>
</TD>
<TD VALIGN="TOP">
<P>-0.04 [-0.33, 0.25]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>DBT-PTSD<SUP>4</SUP> vs. WL<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>SMD</I>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>-0.74 [-1.47, -0.01]</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Inappropriate anger</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>DBT vs. TAU</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>46</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>SMD</I>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>-0.83 [-1.43, -0.22]</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>DBT vs. GM</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>180</P>
</TD>
<TD VALIGN="TOP">
<P>SMD</P>
</TD>
<TD VALIGN="TOP">
<P>-0.03 [-0.32, 0.26]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Affective instability</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-<SUP>6</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Chronic feelings of emptiness</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Impulsivity</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>DBT vs. TAU</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>48</P>
</TD>
<TD VALIGN="TOP">
<P>SMD</P>
</TD>
<TD VALIGN="TOP">
<P>-0.17 [-0.74, 0.39]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidality </B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>DBT vs. TAU</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>SMD</I>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>-1.26 [-2.24, -0.29]</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>DBT vs. CTBE<SUP>7</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>89</P>
</TD>
<TD VALIGN="TOP">
<P>SMD</P>
</TD>
<TD VALIGN="TOP">
<P>-0.12 [-0.54, 0.30]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Parasuicidality </B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>DBT vs. TAU</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>110</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>SMD</I>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>-0.54 [-0.92, -0.16]</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>DBT vs. TAU</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>51</P>
</TD>
<TD VALIGN="TOP">
<P>RR</P>
</TD>
<TD VALIGN="TOP">
<P>1.11 [0.78, 1.57]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>DBT vs. GM</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>180</P>
</TD>
<TD VALIGN="TOP">
<P>SMD</P>
</TD>
<TD VALIGN="TOP">
<P>-0.23 [-0.52, 0.06]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Interpersonal problems</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>DBT vs. TAU</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>48</P>
</TD>
<TD VALIGN="TOP">
<P>SMD</P>
</TD>
<TD VALIGN="TOP">
<P>0.04 [-0.54, 0.61]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>DBT vs. GM</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>180</P>
</TD>
<TD VALIGN="TOP">
<P>SMD</P>
</TD>
<TD VALIGN="TOP">
<P>-0.03 [-0.32, 0.26]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Avoidance of abandonment</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Identity disturbance</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Dissociation/psychoticism</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>DBT vs. TAU</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>SMD</P>
</TD>
<TD VALIGN="TOP">
<P>-0.90 [-1.83, 0.03]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>DBT-PTSD vs. WL</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>SMD</P>
</TD>
<TD VALIGN="TOP">
<P>-0.34 [-1.06, 0.38]</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<BR/>
<SUP>1</SUP>Dialectical Behaviour Therapy<BR/>
<SUP>2</SUP>treatment as usual<BR/>
<SUP>3</SUP>general management<BR/>
<SUP>4</SUP>Dialectical Behaviour Therapy for BPD with post-traumatic stress disorder<BR/>
<BR/>
<SUP>5</SUP>waiting list<BR/>
<SUP>6</SUP>No data available for this outcome<BR/>
<SUP>7</SUP>community treatment by experts<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2012-06-15 14:23:25 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2012-06-05 13:39:31 +0100" MODIFIED_BY="[Empty name]">Spreadsheet of primary outcome effect estimates: Mentalisation-based treatment (MBT) versus control groups</TITLE>
<TABLE COLS="5" ROWS="26">
<TR>
<TH VALIGN="TOP">
<P>
<B>Outcome/Subgroup</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Studies</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Participants</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Statistical Method</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Effect Estimate/95% CI </B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>BPD total severity</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Inappropriate anger</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Affective instability</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Chronic feelings of emptiness</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Impulsivity</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidality </B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>MBT-PH<SUP>2</SUP> vs. TAU</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>38</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>RR</I>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>0.08 [0.01, 0.58]</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>MBT-out<SUP>3</SUP> vs. TAU</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>134</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>RR</I>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>0.11 [0.03, 0.46]</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Parasuicidality </B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>

 

</P>
</TD>
<TD VALIGN="TOP">
<P>

 

</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>MBT-PH vs. TAU</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>38</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>RR</I>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>0.44 [0.24 to 0.81]</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>MBT-out vs. TAU</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>134</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>RR</I>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>0.56 [0.34 to 0.92]</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Interpersonal problems</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>

 

</P>
</TD>
<TD VALIGN="TOP">
<P>

 

</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>MBT-PH vs. TAU</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>38</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>SMD</I>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>-2.22 [-3.04, -1.39]</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>MBT-out vs. TAU</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>134</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>SMD</I>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>-0.95 [-1.30, -0.59]</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Avoidance of abandonment</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Identity disturbance</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Dissociation/psychoticism</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>No data available for this outcome.<BR/>
<BR/>
<BR/>
<SUP>2</SUP>Mentalisation-based Treatment, partial hospitalisation</P>
<P>
<SUP>3</SUP>TAU: treatment as usual<BR/>
<SUP>4</SUP>Mentalisation-based Treatment, outpatient<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2012-06-15 14:25:38 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2012-06-05 13:39:48 +0100" MODIFIED_BY="[Empty name]">Spreadsheet of primary outcome effect estimates: Transference-focused psychotherapy (TFP) versus control groups</TITLE>
<TABLE COLS="5" ROWS="23">
<TR>
<TH VALIGN="TOP">
<P>
<B>Outcome/Subgroup</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Studies</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Participants</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Statistical Method</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Effect Estimate/95% CI </B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>BPD total severity</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>TFP<SUP>1</SUP> vs. CTBE<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>104</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>SMD</I>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>-0.55 [-0.95, -0.16]</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Inappropriate anger</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Affective instability</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Chronic feelings of emptiness</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Impulsivity</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidality </B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>TFP vs. CTBE</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>104</P>
</TD>
<TD VALIGN="TOP">
<P>RR</P>
</TD>
<TD VALIGN="TOP">
<P>0.64 [0.27, 1.51]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Parasuicidality </B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>TFP vs. CTBE</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>104</P>
</TD>
<TD VALIGN="TOP">
<P>RR</P>
</TD>
<TD VALIGN="TOP">
<P>1.09 [0.84, 1.40]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Interpersonal problems</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Avoidance of abandonment</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Identity disturbance</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Dissociation/psychoticism</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Transference-Focused Psychotherapy<BR/>
<SUP>2</SUP>community treatment by experts<BR/>
<SUP>3</SUP> No data available for this outcome.<BR/>
<BR/>
<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2013-01-17 09:09:20 +0000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2012-06-05 13:40:11 +0100" MODIFIED_BY="[Empty name]">Spreadsheet of primary outcome effect estimates: Cognitive behavioural therapy (CBT) versus control groups</TITLE>
<TABLE COLS="5" ROWS="23">
<TR>
<TH VALIGN="TOP">
<P>
<B>Outcome/Subgroup</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Studies</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Participants</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Statistical Method</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Effect Estimate/95% CI </B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>BPD total severity</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>

 

</P>
</TD>
<TD VALIGN="TOP">
<P>

 

</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Inappropriate anger</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Affective instability</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Chronic feelings of emptiness</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Impulsivity</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidality </B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CBT<SUP>2</SUP> vs. TAU<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>101</P>
</TD>
<TD VALIGN="TOP">
<P>RR</P>
</TD>
<TD VALIGN="TOP">
<P>0.78 [0.47, 1.27</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Parasuicidality </B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CBT vs. TAU</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>99</P>
</TD>
<TD VALIGN="TOP">
<P>RR</P>
</TD>
<TD VALIGN="TOP">
<P>1.17 [0.87, 1.60]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Interpersonal problems</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CBT vs. TAU</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>99</P>
</TD>
<TD VALIGN="TOP">
<P>SMD</P>
</TD>
<TD VALIGN="TOP">
<P>0.23 [-0.16, 0.63]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Avoidance of abandonment</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Identity disturbance</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Dissociation/psychoticism</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>No data available for this outcome.<SUP>2</SUP>Cognitive Behavioural Therapy<BR/>
<SUP>3</SUP>treatment as usual<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2012-06-19 10:39:08 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2012-06-19 10:39:08 +0100" MODIFIED_BY="[Empty name]">Spreadsheet of primary outcome effect estimates: Dynamic Deconstructive psychotherapy (DDP) versus control groups</TITLE>
<TABLE COLS="5" ROWS="23">
<TR>
<TH VALIGN="TOP">
<P>
<B>Outcome/Subgroup</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Studies</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Participants</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Statistical Method</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Effect Estimate/95% CI </B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>BPD total severity</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>DDP<SUP>1</SUP> vs. TAU<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>SMD</P>
</TD>
<TD VALIGN="TOP">
<P>-0.44 [-1.16, 0.29]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Inappropriate anger</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Affective instability</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Chronic feelings of emptiness</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Impulsivity</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidality </B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Parasuicidality </B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>DDP vs. TAU</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>RR</P>
</TD>
<TD VALIGN="TOP">
<P>0.89 [0.47, 1.67]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Interpersonal problems</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Avoidance of abandonment</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Identity disturbance</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Dissociation/psychoticism</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>DDP vs. TAU</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>SMD</P>
</TD>
<TD VALIGN="TOP">
<P>0.25 [-0.47, 0.97]</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Dynamic Deconstructive Psychotherapy<BR/>
<SUP>2</SUP>treatment as usual<BR/>
<SUP>3</SUP>No data available for this outcome.<BR/>
<BR/>
<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" MODIFIED="2012-06-15 14:43:34 +0100" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2012-06-15 14:40:08 +0100" MODIFIED_BY="[Empty name]">Spreadsheet of primary outcome effect estimates: interpersonal therapy (IPT) versus. control groups</TITLE>
<TABLE COLS="5" ROWS="23">
<TR>
<TH VALIGN="TOP">
<P>
<B>Outcome/Subgroup</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Studies</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Participants</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Statistical Method</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Effect Estimate/95% CI </B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>BPD total severity</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>IPT-BPD<SUP>1</SUP> vs. CM<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>44</P>
</TD>
<TD VALIGN="TOP">
<P>SMD</P>
</TD>
<TD VALIGN="TOP">
<P>-0.03 [-0.62, 0.56]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Inappropriate anger</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>IPT-BPD vs. CM</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>44</P>
</TD>
<TD VALIGN="TOP">
<P>SMD</P>
</TD>
<TD VALIGN="TOP">
<P>0.01 [-0.58, 0.60]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Affective instability</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>IPT-BPD vs. CM</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>44</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>SMD</I>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>-0.92 [-1.54, -0.30]</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Chronic feelings of emptiness</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>IPT-BPD vs. CM</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>44</P>
</TD>
<TD VALIGN="TOP">
<P>SMD</P>
</TD>
<TD VALIGN="TOP">
<P>0.09 [-0.50, 0.68]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Impulsivity</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>IPT-BPD vs. CM</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>44</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>SMD</I>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>-0.91 [-1.53, -0.28]</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidality </B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Parasuicidality </B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>IPT-BPD vs. CM</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>44</P>
</TD>
<TD VALIGN="TOP">
<P>SMD</P>
</TD>
<TD VALIGN="TOP">
<P>0.02 [-0.58, 0.61]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Interpersonal problems</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>IPT-BPD vs. CM</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>44</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>SMD</I>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>-0.82 [-1.44, -0.20]</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Avoidance of abandonment</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>IPT-BPD vs. CM</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>44</P>
</TD>
<TD VALIGN="TOP">
<P>SMD</P>
</TD>
<TD VALIGN="TOP">
<P>0.01 [-0.58, 0.60]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Identity disturbance</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>IPT-BPD vs. CM</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>44</P>
</TD>
<TD VALIGN="TOP">
<P>SMD</P>
</TD>
<TD VALIGN="TOP">
<P>-0.03 [-0.62, 0.56]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Dissociation/psychoticism</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>IPT-BPD vs. CM</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>44</P>
</TD>
<TD VALIGN="TOP">
<P>SMD</P>
</TD>
<TD VALIGN="TOP">
<P>0.10 [-0.49, 0.70]</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>There are no data available for any primary outcome for the comparison of IPT + fluoxetine to CM + fluoxetine.</P>
<P> Both groups of the IPT-BPD vs. CM comparison received additional fluoxetine medication.<BR/>
<SUP>1</SUP>Interpersonal Psychotherapy adapted for BPD<BR/>
<SUP>2</SUP>Clinical management<BR/>
<SUP>3</SUP>No data available for this outcome</P>
<P>
<BR/>
<BR/>
<BR/>
<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-07" MODIFIED="2012-06-15 14:51:59 +0100" MODIFIED_BY="[Empty name]" NO="7">
<TITLE MODIFIED="2012-06-05 13:41:13 +0100" MODIFIED_BY="[Empty name]">Spreadsheet of primary outcome effect estimates: Dialectical behaviour therapy skills training(DBT-ST) versus control</TITLE>
<TABLE COLS="5" ROWS="23">
<TR>
<TH VALIGN="TOP">
<P>
<B>Outcome/Subgroup</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Studies</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Participants</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Statistical Method</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Effect Estimate/95% CI </B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>BPD total severity</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>DBT-ST<SUP>1</SUP> vs. SG<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>59</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>SMD</I>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>-1.01 [-1.56, -0.47]</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Inappropriate anger</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>DBT-ST vs. SG</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>59</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>SMD</I>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>-0.84 [-1.37, -0.30]</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Affective instability</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>DBT-ST vs. SG</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>59</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>SMD</I>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>-1.07 [-1.61, -0.52]</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Chronic feelings of emptiness</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>DBT-ST vs. SG</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>59</P>
</TD>
<TD VALIGN="TOP">
<P>SMD</P>
</TD>
<TD VALIGN="TOP">
<P>-0.43 [-0.95, 0.09]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Impulsivity</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>DBT-ST vs. SG</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>59</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>SMD</I>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>-0.61 [-1.14, -0.09]</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidality </B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>DBT-ST vs. SG</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>59</P>
</TD>
<TD VALIGN="TOP">
<P>SMD</P>
</TD>
<TD VALIGN="TOP">
<P>-0.10 [-0.61, 0.41]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Parasuicidality </B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Interpersonal problems</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>DBT-ST vs. SG</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>59</P>
</TD>
<TD VALIGN="TOP">
<P>SMD</P>
</TD>
<TD VALIGN="TOP">
<P>-0.29 [-0.80, 0.23]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Avoidance of abandonment</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Identity disturbance</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Dissociation/psychoticism</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>DBT-ST vs. SG</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>59</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>SMD</I>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>-0.66 [-1.18, -0.13]</I>
</B>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Dialectical Behaviour Therapy-skills training<BR/>
<SUP>2</SUP>standard group<BR/>
<SUP>3</SUP>No data available.<BR/>
<BR/>
<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-08" MODIFIED="2012-06-15 14:54:00 +0100" MODIFIED_BY="[Empty name]" NO="8">
<TITLE MODIFIED="2012-06-05 13:41:32 +0100" MODIFIED_BY="[Empty name]">Spreadsheet of primary outcome effect estimates: Emotion regulation group therapy (ERG) versus control condition</TITLE>
<TABLE COLS="5" ROWS="23">
<TR>
<TH VALIGN="TOP">
<P>
<B>Outcome/Subgroup</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Studies</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Participants</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Statistical Method</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Effect Estimate/95% CI </B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>BPD total severity</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>ERG<SUP>1</SUP> vs. TAU<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>22</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>SMD</I>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>-1.02 [-1.92, -0.11]</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Inappropriate anger</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>

 

</P>
</TD>
<TD VALIGN="TOP">
<P>

 

</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Affective instability</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>ERG vs. TAU</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>22</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>SMD</I>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>-1.65 [-1.61, -0.52]</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Chronic feelings of emptiness</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Impulsivity</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>ERG vs. TAU</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>22</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>SMD</I>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>-1.30 [-2.24, -0.36]</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidality </B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Parasuicidality </B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>ERG vs. TAU</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>22</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>SMD</I>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>-0.98 [-1.88, -0.09]</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Interpersonal problems</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Avoidance of abandonment</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Identity disturbance</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Dissociation/psychoticism</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>

 

</P>
</TD>
<TD VALIGN="TOP">
<P>

 

</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<BR/>
<BR/>
</P>
<P>
<SUP>1</SUP>Emotion Regulation Group Training<BR/>
<SUP>2</SUP>treatment as usual<BR/>
<SUP>3</SUP>No data available.<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-09" MODIFIED="2012-06-15 15:16:49 +0100" MODIFIED_BY="[Empty name]" NO="9">
<TITLE MODIFIED="2012-06-05 13:41:43 +0100" MODIFIED_BY="[Empty name]">Spreadsheet of primary outcome effect estimates: Schema-focused group therapy (SFT-G) versus control condition</TITLE>
<TABLE COLS="5" ROWS="23">
<TR>
<TH VALIGN="TOP">
<P>
<B>Outcome/Subgroup</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Studies</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Participants</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Statistical Method</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Effect Estimate/95% CI </B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>BPD total severity</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>SFT-G<SUP>1</SUP> vs. TAU<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>28</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>SMD</I>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>-1.66 [-2.54, -0.78]</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Inappropriate anger</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<SUP>-3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>

 

</P>
</TD>
<TD VALIGN="TOP">
<P>

 

</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Affective instability</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>SFT-G vs. TAU</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>28</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>SMD</I>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>-1.41 [-2.26, -0.57]</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Chronic feelings of emptiness</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Impulsivity</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>SFT-G vs. TAU</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>28</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>SMD</I>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>-1.92 [-2.85, -1.00]</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidality </B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Parasuicidality </B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>

 

</P>
</TD>
<TD VALIGN="TOP">
<P>

 

</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Interpersonal problems</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>SFT-G vs. TAU</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>28</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>SMD</I>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>-1.94 [-2.87, -1.02]</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Avoidance of abandonment</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Identity disturbance</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Dissociation/psychoticism</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>SFT-G vs. TAU</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>28</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>SMD</I>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>-1.37 [-2.21, -0.53]</I>
</B>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<BR/>
<SUP>1</SUP>Schema-Focused Therapy-group treatment <BR/>
<SUP>2</SUP>treatment as usual<BR/>
<SUP>3</SUP>No data available.<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-10" MODIFIED="2012-06-15 15:18:28 +0100" MODIFIED_BY="[Empty name]" NO="10">
<TITLE MODIFIED="2012-06-05 13:42:13 +0100" MODIFIED_BY="[Empty name]">Spreadsheet of primary outcome effect estimates: manual-assisted cognitive treatment (MACT) versus controls</TITLE>
<TABLE COLS="5" ROWS="23">
<TR>
<TH VALIGN="TOP">
<P>
<B>Outcome/Subgroup</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Studies</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Participants</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Statistical Method</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Effect Estimate/95% CI </B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>BPD total severity</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>

 

</P>
</TD>
<TD VALIGN="TOP">
<P>

 

</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Inappropriate anger</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>

 

</P>
</TD>
<TD VALIGN="TOP">
<P>

 

</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Affective instability</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>

 

</P>
</TD>
<TD VALIGN="TOP">
<P>

 

</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Chronic feelings of emptiness</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Impulsivity</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>

 

</P>
</TD>
<TD VALIGN="TOP">
<P>

 

</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidality </B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>MACT<SUP>2</SUP> vs. TAU<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>28</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>SMD</I>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>-0.86 [-1.64, -0.07]</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Parasuicidality </B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>MACT vs. TAU</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>28</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>SMD</I>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>-0.88 [-1.67, -0.10]</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Interpersonal problems</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>

 

</P>
</TD>
<TD VALIGN="TOP">
<P>

 

</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Avoidance of abandonment</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Identity disturbance</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Dissociation/psychoticism</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>

 

</P>
</TD>
<TD VALIGN="TOP">
<P>

 

</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>No data available<BR/>
<SUP>2</SUP>Manual-assisted Cognitive Treatment<BR/>
<SUP>3</SUP>treatment as usual<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-11" MODIFIED="2012-06-15 15:20:30 +0100" MODIFIED_BY="[Empty name]" NO="11">
<TITLE MODIFIED="2012-06-05 13:42:33 +0100" MODIFIED_BY="[Empty name]">Spreadsheet of primary outcome effect estimates: systems training for emotional predictability and problem solving for borderline personality disorder (STEPPS) versus controls</TITLE>
<TABLE COLS="5" ROWS="26">
<TR>
<TH VALIGN="TOP">
<P>
<B>Outcome/Subgroup</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Studies</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Participants</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Statistical Method</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Effect Estimate/95% CI </B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>BPD total severity</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>STEPPS<SUP>1</SUP> vs. TAU<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>124</P>
</TD>
<TD VALIGN="TOP">
<P>SMD</P>
</TD>
<TD VALIGN="TOP">
<P>-0.17 [-0.52, 0.19]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>STEPPS+IT<SUP>3</SUP> vs. TAU</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>52</P>
</TD>
<TD VALIGN="TOP">
<P>SMD</P>
</TD>
<TD VALIGN="TOP">
<P>-0.55 [-1.11, 0.00]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Inappropriate anger</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-<SUP>4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>

 

</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Affective instability</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>STEPPS vs. TAU</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>124</P>
</TD>
<TD VALIGN="TOP">
<P>SMD</P>
</TD>
<TD VALIGN="TOP">
<P>-0.32 [-0.67, 0.04]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Chronic feelings of emptiness</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Impulsivity</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>STEPPS vs. TAU</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>124</P>
</TD>
<TD VALIGN="TOP">
<P>SMD</P>
</TD>
<TD VALIGN="TOP">
<P>-0.29 [-0.64, 0.07]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>STEPPS+IT vs. TAU</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>58</P>
</TD>
<TD VALIGN="TOP">
<P>RR</P>
</TD>
<TD VALIGN="TOP">
<P>0.93 [0.66, 1.29]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidality </B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>

 

</P>
</TD>
<TD VALIGN="TOP">
<P>

 

</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Parasuicidality </B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>STEPPS+IT vs. TAU</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>58</P>
</TD>
<TD VALIGN="TOP">
<P>RR</P>
</TD>
<TD VALIGN="TOP">
<P>1.32 [0.78, 2.22]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Interpersonal problems</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>STEPPS vs. TAU</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>124</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>SMD</I>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>-0.42 [-0.78, -0.06]</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>STEPPS+IT vs. TAU</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>53</P>
</TD>
<TD VALIGN="TOP">
<P>SMD</P>
</TD>
<TD VALIGN="TOP">
<P>-0.27 [-0.81, 0.27]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Avoidance of abandonment</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Identity disturbance</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Dissociation/psychoticism</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>STEPPS vs. TAU</P>
</TD>
<TD VALIGN="TOP">
<P>1 </P>
</TD>
<TD VALIGN="TOP">
<P>124 </P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>SMD </I>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>-0.42 [-0.78, -0.06] </I>
</B>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<BR/>
<SUP>1</SUP>Systems Training for Emotional Predictability and Problem Solving for borderline personality disorder<BR/>
<SUP>2</SUP>Systems Training for Emotional Predictability and Problem Solving for borderline personality disorder plus individual therapy<BR/>
<SUP>3</SUP>treatment as usual</P>
<P>
<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-12" MODIFIED="2012-06-15 15:21:16 +0100" MODIFIED_BY="[Empty name]" NO="12">
<TITLE MODIFIED="2012-06-05 13:42:52 +0100" MODIFIED_BY="[Empty name]">Spreadsheet of primary outcome effect estimates: Psychoeducation (PE) versus control</TITLE>
<TABLE COLS="5" ROWS="23">
<TR>
<TH VALIGN="TOP">
<P>
<B>Outcome/Subgroup</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Studies</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Participants</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Statistical Method</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Effect Estimate/95% CI </B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>BPD total severity</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>
 
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Inappropriate anger</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>

 

</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Affective instability</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Chronic feelings of emptiness</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Impulsivity</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>PE<SUP>2</SUP> vs. WL<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>50</P>
</TD>
<TD VALIGN="TOP">
<P>SMD</P>
</TD>
<TD VALIGN="TOP">
<P>-0.47 [-1.04, 0.10]</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidality </B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>

 

</P>
</TD>
<TD VALIGN="TOP">
<P>

 

</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Parasuicidality </B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Interpersonal problems</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>PE vs. WL</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>50</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>SMD</I>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>
<I>-0.75 [-1.33, -0.16]</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Avoidance of abandonment</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Identity disturbance</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Dissociation/psychoticism</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>

 

</P>
</TD>
<TD VALIGN="TOP">
<P>

 

</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>No data available.<BR/>
<BR/>
<SUP>2</SUP>psychoeducation<BR/>
<SUP>3</SUP>waiting list</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-12-18 21:10:59 +0000" MODIFIED_BY="Mathilde Holmskov">
<COMPARISON ID="CMP-001" MODIFIED="2014-12-18 21:10:59 +0000" MODIFIED_BY="Mathilde Holmskov" NO="1">
<NAME>Comprehensive psychotherapies: active vs. control conditions</NAME>
<CONT_OUTCOME CHI2="6.820765950191267" CI_END="-0.061680356328863595" CI_START="-0.45298681153528497" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.2573335839320743" ESTIMABLE="YES" I2="26.694449912039705" I2_Q="26.694449912039723" ID="CMP-001.01" MODIFIED="2014-12-18 21:10:59 +0000" MODIFIED_BY="Mathilde Holmskov" NO="1" P_CHI2="0.23431513940310444" P_Q="0.23431513940310422" P_Z="0.009941731450325364" Q="6.8207659501912685" RANDOM="YES" SCALE="1.645308084958321" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.025477713028832175" TOTALS="SUB" TOTAL_1="206" TOTAL_2="203" UNITS="" WEIGHT="600.0" Z="2.5778494057984256">
<NAME>BPD total severity</NAME>
<GROUP_LABEL_1>active</GROUP_LABEL_1>
<GROUP_LABEL_2>control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5921875137641377" CI_START="-1.1722996877670337" DF="0" EFFECT_SIZE="-0.290056087001448" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" MODIFIED="2010-09-03 13:15:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5193295300780738" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="0.6443792661416043">
<NAME>DBT vs. TAU</NAME>
<CONT_DATA CI_END="0.5921875137641376" CI_START="-1.1722996877670337" EFFECT_SIZE="-0.290056087001448" ESTIMABLE="YES" MEAN_1="3.6" MEAN_2="4.2" MODIFIED="2010-09-03 13:15:01 +0100" MODIFIED_BY="[Empty name]" ORDER="6" SD_1="1.6" SD_2="2.3" SE="0.4501325573962637" STUDY_ID="STD-Koons-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0">
<FOOTNOTE>mean number of DSM-BPD criteria met</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2537233714876289" CI_START="-0.33068027019536683" DF="0" EFFECT_SIZE="-0.03847844935386898" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" MODIFIED="2010-09-03 12:01:12 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7963321486032013" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="90" WEIGHT="100.0" Z="0.25809686844983976">
<NAME>DBT vs. general management</NAME>
<CONT_DATA CI_END="0.2537233714876289" CI_START="-0.33068027019536683" EFFECT_SIZE="-0.03847844935386898" ESTIMABLE="YES" MEAN_1="7.93" MEAN_2="8.16" MODIFIED="2010-09-03 12:01:12 +0100" MODIFIED_BY="[Empty name]" ORDER="20" SD_1="6.11" SD_2="5.79" SE="0.149085301131219" STUDY_ID="STD-McMain-2009" TOTAL_1="90" TOTAL_2="90" WEIGHT="100.0">
<FOOTNOTE>ZAN-BPD-total score</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="8.780027225029785E-32" CI_END="-0.006218909166453623" CI_START="-1.4749435638930355" DF="0" EFFECT_SIZE="-0.7405812365297445" ESTIMABLE="YES" I2="100.0" ID="CMP-001.01.03" MODIFIED="2012-01-06 12:22:56 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.048091179437529843" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="14" WEIGHT="100.0" Z="1.9765618375823513">
<NAME>DBT-PTSD vs. WL</NAME>
<CONT_DATA CI_END="-0.006218909166453512" CI_START="-1.4749435638930353" EFFECT_SIZE="-0.7405812365297444" ESTIMABLE="YES" MEAN_1="1.67" MEAN_2="2.26" MODIFIED="2010-10-19 13:35:09 +0100" MODIFIED_BY="[Empty name]" ORDER="155" SD_1="0.71" SD_2="0.85" SE="0.374681541679259" STUDY_ID="STD-Steil-2010" TOTAL_1="17" TOTAL_2="14" WEIGHT="100.0">
<FOOTNOTE>BSL</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.16190983052245922" CI_START="-0.945841624278594" DF="0" EFFECT_SIZE="-0.5538757274005266" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.04" MODIFIED="2012-01-06 12:22:56 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.005613056628107082" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="52" WEIGHT="100.0" Z="2.7695686952930445">
<NAME>TFP vs. CTBE</NAME>
<CONT_DATA CI_END="-0.16190983052245922" CI_START="-0.945841624278594" EFFECT_SIZE="-0.5538757274005266" ESTIMABLE="YES" MEAN_1="4.79" MEAN_2="5.63" MODIFIED="2010-09-03 14:04:04 +0100" MODIFIED_BY="[Empty name]" ORDER="89" SD_1="1.54" SD_2="1.47" SE="0.19998627524273116" STUDY_ID="STD-Doering-2010" TOTAL_1="52" TOTAL_2="52" WEIGHT="100.0">
<FOOTNOTE>mean number of DSM-IV criteria for BPD met</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2881108737686805" CI_START="-1.1628091248219432" DF="0" EFFECT_SIZE="-0.4373491255266313" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.05" MODIFIED="2012-01-06 12:22:54 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.23737268293855018" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.1815793228226639">
<NAME>DDP vs. TAU</NAME>
<CONT_DATA CI_END="0.2881108737686805" CI_START="-1.1628091248219432" EFFECT_SIZE="-0.4373491255266313" ESTIMABLE="YES" MEAN_1="33.6" MEAN_2="38.4" MODIFIED="2010-09-06 10:50:26 +0100" MODIFIED_BY="[Empty name]" ORDER="85" SD_1="12.4" SD_2="8.62" SE="0.370139454101018" STUDY_ID="STD-Gregory-2008" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0">
<FOOTNOTE>BEST</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5596584120627495" CI_START="-0.6223239907621267" DF="0" EFFECT_SIZE="-0.031332789349688646" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.06" MODIFIED="2012-01-06 12:22:52 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.9172391022208011" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0" Z="0.1039121031138882">
<NAME>IPT-BPD+fluoxetine vs. CM+fluoxetine</NAME>
<CONT_DATA CI_END="0.5596584120627495" CI_START="-0.6223239907621267" EFFECT_SIZE="-0.031332789349688646" ESTIMABLE="YES" MEAN_1="33.27" MEAN_2="33.46" MODIFIED="2010-10-13 09:39:27 +0100" MODIFIED_BY="[Empty name]" ORDER="141" SD_1="5.96" SD_2="5.95" SE="0.30153166388469443" STUDY_ID="STD-Bellino-2010" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0">
<FOOTNOTE>BPDSI-IV-total score</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.024213426257196" CI_END="0.09381718379205628" CI_START="-0.3872849272809511" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.1467338717444474" ESTIMABLE="YES" I2="50.20096753338501" I2_Q="64.9862126939034" ID="CMP-001.02" MODIFIED="2012-06-13 13:26:06 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.11043816865266398" P_Q="0.05749733485153419" P_Z="0.23186851875877446" Q="5.712035611902401" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.09096177748342597" TOTALS="SUB" TOTAL_1="135" TOTAL_2="135" UNITS="" WEIGHT="300.0" Z="1.1955595176658624">
<NAME>Inappropriate anger</NAME>
<GROUP_LABEL_1>Active</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.3121778143547924" CI_END="-0.21865854814548058" CI_START="-1.4346490297807262" DF="1" EFFECT_SIZE="-0.8266537889631034" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" MODIFIED="2010-09-03 11:09:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5763469675991587" P_Z="0.007702435118526165" STUDIES="2" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="100.0" Z="2.6648426587557186">
<NAME>DBT vs. TAU</NAME>
<CONT_DATA CI_END="0.267644910965939" CI_START="-1.5397587177389909" EFFECT_SIZE="-0.636056903386526" ESTIMABLE="YES" MEAN_1="14.5" MEAN_2="17.9" MODIFIED="2010-09-03 10:30:50 +0100" MODIFIED_BY="[Empty name]" ORDER="7" SD_1="3.9" SD_2="6.1" SE="0.46108082672985296" STUDY_ID="STD-Koons-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="45.26369994124463">
<FOOTNOTE>STAXI-anger out</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-0.1624731561203524" CI_START="-1.8060592444267978" EFFECT_SIZE="-0.9842662002735751" ESTIMABLE="YES" MEAN_1="32.15" MEAN_2="40.08" MODIFIED="2010-09-03 11:09:32 +0100" MODIFIED_BY="[Empty name]" ORDER="16" SD_1="7.19" SD_2="8.37" SE="0.4192898699340505" STUDY_ID="STD-Linehan-1994" TOTAL_1="13" TOTAL_2="13" WEIGHT="54.73630005875536">
<FOOTNOTE>STAXI-anger trait</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.26318744011401024" CI_START="-0.321192326887453" DF="0" EFFECT_SIZE="-0.029002443386721345" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" MODIFIED="2010-09-03 12:03:47 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8457500652900286" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="90" WEIGHT="100.00000000000001" Z="0.1945438487485943">
<NAME>DBT vs. general management</NAME>
<CONT_DATA CI_END="0.26318744011401024" CI_START="-0.321192326887453" EFFECT_SIZE="-0.029002443386721345" ESTIMABLE="YES" MEAN_1="15.81" MEAN_2="15.96" MODIFIED="2010-09-03 12:03:47 +0100" MODIFIED_BY="[Empty name]" ORDER="21" SD_1="5.19" SD_2="5.11" SE="0.14907921053932016" STUDY_ID="STD-McMain-2009" TOTAL_1="90" TOTAL_2="90" WEIGHT="100.00000000000001">
<FOOTNOTE>STAXI-anger out</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.310102666027875E-35" CI_END="0.6049870122012815" CI_START="-0.5769317054661034" DF="0" EFFECT_SIZE="0.014027653367589066" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-001.02.03" MODIFIED="2011-08-16 10:04:28 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.9628927374904284" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0" Z="0.046523834468664094">
<NAME>IPT-BPD+fluoxetine vs. CM+fluoxetine</NAME>
<CONT_DATA CI_END="0.6049870122012815" CI_START="-0.5769317054661034" EFFECT_SIZE="0.014027653367589064" ESTIMABLE="YES" MEAN_1="5.26" MEAN_2="5.25" MODIFIED="2011-08-16 10:04:28 +0100" MODIFIED_BY="[Empty name]" ORDER="142" SD_1="0.71" SD_2="0.69" SE="0.30151541737251525" STUDY_ID="STD-Bellino-2010" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0">
<FOOTNOTE>BPDSI-IV - anger</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.2953640182277092" CI_START="-1.544007390923949" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.9196857045758291" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2012-06-13 13:44:55 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.003886687001395438" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="22" TOTAL_2="22" UNITS="" WEIGHT="99.99999999999999" Z="2.8872148725262643">
<NAME>Affective instability</NAME>
<GROUP_LABEL_1>Active</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.2953640182277092" CI_START="-1.544007390923949" DF="0" EFFECT_SIZE="-0.9196857045758291" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.01" MODIFIED="2012-01-06 12:10:12 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.003886687001395438" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="99.99999999999999" Z="2.8872148725262643">
<NAME>IPT-BPD+fluoxetine vs. CM+fluoxetine</NAME>
<CONT_DATA CI_END="-0.2953640182277092" CI_START="-1.544007390923949" EFFECT_SIZE="-0.9196857045758291" ESTIMABLE="YES" MEAN_1="5.61" MEAN_2="6.63" MODIFIED="2010-10-13 09:40:43 +0100" MODIFIED_BY="[Empty name]" ORDER="143" SD_1="1.18" SD_2="0.99" SE="0.31853732582470373" STUDY_ID="STD-Bellino-2010" TOTAL_1="22" TOTAL_2="22" WEIGHT="99.99999999999999">
<FOOTNOTE>BPDSI-IV-affective instability</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.6837182956050726" CI_START="-0.4988772651610659" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.09242051522200337" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2012-01-15 14:51:22 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.7593422859621656" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="22" TOTAL_2="22" UNITS="" WEIGHT="100.0" Z="0.30634459874077535">
<NAME>chronic feelings of emptiness</NAME>
<GROUP_LABEL_1>active</GROUP_LABEL_1>
<GROUP_LABEL_2>control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6837182956050726" CI_START="-0.4988772651610659" DF="0" EFFECT_SIZE="0.09242051522200337" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.01" MODIFIED="2010-10-13 09:47:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7593422859621656" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0" Z="0.30634459874077535">
<NAME>IPT-BPD+fluoxetine vs. CM+fluoxetine</NAME>
<CONT_DATA CI_END="0.6837182956050726" CI_START="-0.4988772651610659" EFFECT_SIZE="0.09242051522200337" ESTIMABLE="YES" MEAN_1="7.16" MEAN_2="7.12" MODIFIED="2010-10-13 09:42:16 +0100" MODIFIED_BY="[Empty name]" ORDER="144" SD_1="0.42" SD_2="0.43" SE="0.30168808460112057" STUDY_ID="STD-Bellino-2010" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0">
<FOOTNOTE>BPDSI-IV-emptiness</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.9096191592955822" CI_END="-0.08625401158626955" CI_START="-0.925547024001462" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.5059005177938658" ESTIMABLE="YES" I2="65.63124088576252" I2_Q="65.63124088576252" ID="CMP-001.05" MODIFIED="2012-06-13 13:45:07 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.08805280886443934" P_Q="0.08805280886443934" P_Z="0.018136751706090973" Q="2.9096191592955822" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.17664006802006563" TOTALS="SUB" TOTAL_1="45" TOTAL_2="47" UNITS="" WEIGHT="200.0" Z="2.362814368685892">
<NAME>Impulsivity</NAME>
<GROUP_LABEL_1>Active</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="9.190809777581362E-33" CI_END="0.39395485169240174" CI_START="-0.7409290520170707" DF="0" EFFECT_SIZE="-0.17348710016233448" ESTIMABLE="YES" I2="100.0" ID="CMP-001.05.01" MODIFIED="2010-09-03 12:16:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.5490192559782883" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="25" WEIGHT="100.0" Z="0.5992304005529628">
<NAME>DBT vs. TAU</NAME>
<CONT_DATA CI_END="0.39395485169240174" CI_START="-0.7409290520170707" EFFECT_SIZE="-0.17348710016233446" ESTIMABLE="YES" MEAN_1="0.92" MEAN_2="1.06" MODIFIED="2010-09-03 12:16:25 +0100" MODIFIED_BY="[Empty name]" ORDER="26" SD_1="0.74" SD_2="0.84" SE="0.289516519859878" STUDY_ID="STD-Van-den-Bosch-2005" TOTAL_1="23" TOTAL_2="25" WEIGHT="100.0">
<FOOTNOTE>BPDSI-IV-impulsivity</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.2837204594967473" CI_START="-1.5306057038206429" DF="0" EFFECT_SIZE="-0.9071630816586951" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.02" MODIFIED="2012-01-06 12:10:58 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.004345636793884082" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0" Z="2.8519175702003077">
<NAME>IPT-BPD+fluoxetine vs. CM+fluoxetine</NAME>
<CONT_DATA CI_END="-0.2837204594967473" CI_START="-1.5306057038206429" EFFECT_SIZE="-0.9071630816586951" ESTIMABLE="YES" MEAN_1="5.23" MEAN_2="6.26" MODIFIED="2010-10-13 09:44:14 +0100" MODIFIED_BY="[Empty name]" ORDER="145" SD_1="1.11" SD_2="1.12" SE="0.31808881544741824" STUDY_ID="STD-Bellino-2010" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0">
<FOOTNOTE>BPDSI-IV-impulsivity</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.453186151268529" CI_END="0.09028115152651572" CI_START="-0.6803431102823962" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.29503097937794026" ESTIMABLE="YES" I2="77.54416801742858" I2_Q="77.54416801742858" ID="CMP-001.06" MODIFIED="2013-01-16 15:41:49 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.03483623497153765" P_Q="0.034836234971537317" P_Z="0.13342499420703874" Q="4.453186151268528" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.5102428910817106" TOTALS="SUB" TOTAL_1="60" TOTAL_2="49" UNITS="" WEIGHT="200.0" Z="1.50073160828598">
<NAME>Suicidality</NAME>
<GROUP_LABEL_1>Active</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.2851301265474939" CI_START="-2.2443014209725956" DF="0" EFFECT_SIZE="-1.2647157737600447" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.01" MODIFIED="2010-09-13 10:45:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.01139147067615295" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="2.530454967672209">
<NAME>DBT vs. TAU</NAME>
<CONT_DATA CI_END="-0.28513012654749403" CI_START="-2.2443014209725956" EFFECT_SIZE="-1.2647157737600447" ESTIMABLE="YES" MEAN_1="26.2" MEAN_2="41.5" MODIFIED="2010-09-13 10:45:32 +0100" MODIFIED_BY="[Empty name]" ORDER="8" SD_1="8.0" SD_2="14.3" SE="0.49979777941808995" STUDY_ID="STD-Koons-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0">
<FOOTNOTE>Beck scale for suicidal ideation (BSS)</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.212238757773583E-33" CI_END="0.30155159162493245" CI_START="-0.5366371816300908" DF="0" EFFECT_SIZE="-0.11754279500257919" ESTIMABLE="YES" I2="100.0" ID="CMP-001.06.02" MODIFIED="2010-09-03 13:44:10 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.5825194949313766" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="39" WEIGHT="100.0" Z="0.5497082571329924">
<NAME>DBT vs. CTBE</NAME>
<CONT_DATA CI_END="0.30155159162493245" CI_START="-0.5366371816300909" EFFECT_SIZE="-0.1175427950025792" ESTIMABLE="YES" MEAN_1="29.8" MEAN_2="32.8" MODIFIED="2010-09-03 13:44:10 +0100" MODIFIED_BY="[Empty name]" ORDER="18" SD_1="24.5" SD_2="26.3" SE="0.21382759577894014" STUDY_ID="STD-Linehan-2006" TOTAL_1="50" TOTAL_2="39" WEIGHT="100.0">
<FOOTNOTE>SBQ</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="12.313492703685915" CI_END="0.8661243390853859" CI_START="0.3876489542121876" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5794412776668331" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="60" I2="75.63648209169783" I2_Q="71.07036024374891" ID="CMP-001.07" LOG_CI_END="-0.062419757056057346" LOG_CI_START="-0.4115613833196223" LOG_EFFECT_SIZE="-0.23699057018783984" METHOD="MH" MODIFIED="2013-01-31 12:24:16 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.006382925434431863" P_Q="0.015669303794512923" P_Z="0.007796192728224942" Q="10.369987408335296" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.7735328164397128" TOTALS="SUB" TOTAL_1="195" TOTAL_2="182" WEIGHT="400.0" Z="2.6607711444474678">
<NAME>Suicidality</NAME>
<GROUP_LABEL_1>Active</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5789422016333069" CI_START="0.01199505654425059" DF="0" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="-0.23736479165196578" LOG_CI_START="-1.920997700443284" LOG_EFFECT_SIZE="-1.0791812460476249" MODIFIED="2010-09-03 13:40:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.011984176415708685" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="2.5126099210817596">
<NAME>MBT-PH vs. TAU</NAME>
<DICH_DATA CI_END="0.578942201633307" CI_START="0.01199505654425059" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" LOG_CI_END="-0.2373647916519657" LOG_CI_START="-1.920997700443284" LOG_EFFECT_SIZE="-1.0791812460476249" MODIFIED="2010-09-03 13:27:52 +0100" MODIFIED_BY="[Empty name]" ORDER="76" O_E="0.0" SE="0.9889743047413297" STUDY_ID="STD-Bateman-1999" TOTAL_1="19" TOTAL_2="19" VAR="0.9780701754385965" WEIGHT="100.0">
<FOOTNOTE>number of participants with suicide attempt (last 6 months)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.46361861387820075" CI_START="0.026535273196110036" DF="0" EFFECT_SIZE="0.11091549295774648" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="16" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="-0.3338391358182207" LOG_CI_START="-1.5761764366966535" LOG_EFFECT_SIZE="-0.9550077862574371" MODIFIED="2010-09-03 13:42:57 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.0025840498276224087" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="63" WEIGHT="100.0" Z="3.01332152660377">
<NAME>MBT-outpatient vs. TAU</NAME>
<DICH_DATA CI_END="0.46361861387820075" CI_START="0.026535273196110036" EFFECT_SIZE="0.11091549295774648" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="16" LOG_CI_END="-0.3338391358182207" LOG_CI_START="-1.5761764366966535" LOG_EFFECT_SIZE="-0.9550077862574371" MODIFIED="2010-09-03 13:42:57 +0100" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="0.7297550802048114" STUDY_ID="STD-Bateman-2009" TOTAL_1="71" TOTAL_2="63" VAR="0.5325424770847307" WEIGHT="100.0">
<FOOTNOTE>participants with life-threatening suicide attempts (last 6 months)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5131407533793522" CI_START="0.2676278969960603" DF="0" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" I2="0.0" ID="CMP-001.07.03" LOG_CI_END="0.17987932826956501" LOG_CI_START="-0.5724686185575014" LOG_EFFECT_SIZE="-0.19629464514396822" MODIFIED="2010-09-03 14:06:32 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.30642795975508785" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="52" WEIGHT="100.0" Z="1.0227460218713975">
<NAME>TFP vs. CTBE</NAME>
<DICH_DATA CI_END="1.5131407533793522" CI_START="0.2676278969960603" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.17987932826956501" LOG_CI_START="-0.5724686185575014" LOG_EFFECT_SIZE="-0.19629464514396822" MODIFIED="2010-09-03 14:06:32 +0100" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="0.4419329081486185" STUDY_ID="STD-Doering-2010" TOTAL_1="52" TOTAL_2="52" VAR="0.1953046953046953" WEIGHT="100.0">
<FOOTNOTE>participants with suicidal act (last 12 months)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9419098809591258E-31" CI_END="1.2719486781804779" CI_START="0.47377001204001473" DF="0" EFFECT_SIZE="0.7762803234501348" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="21" I2="100.0" ID="CMP-001.07.04" LOG_CI_END="0.10446958833072968" LOG_CI_START="-0.3244324320423598" LOG_EFFECT_SIZE="-0.10998142185581504" MODIFIED="2013-01-31 12:24:16 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.3148152274922634" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="48" WEIGHT="100.0" Z="1.0051695518635924">
<NAME>CBT vs. TAU</NAME>
<DICH_DATA CI_END="1.2719486781804779" CI_START="0.47377001204001473" EFFECT_SIZE="0.7762803234501348" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="21" LOG_CI_END="0.10446958833072968" LOG_CI_START="-0.3244324320423598" LOG_EFFECT_SIZE="-0.10998142185581504" MODIFIED="2013-01-16 15:45:41 +0000" MODIFIED_BY="[Empty name]" ORDER="217" O_E="0.0" SE="0.2519391698663945" STUDY_ID="STD-Davidson-2006" TOTAL_1="53" TOTAL_2="48" VAR="0.06347334531296796" WEIGHT="100.0">
<FOOTNOTE>participants with suicidal act (last 12 months)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="3.1810117434371064" CI_END="-0.08023399059304745" CI_START="-0.5129387174928886" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.296586354042968" ESTIMABLE="YES" I2="0.0" I2_Q="28.51087155635794" ID="CMP-001.08" MODIFIED="2013-01-16 15:48:52 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.5280034519631214" P_Q="0.2468898602612194" P_Z="0.007213709695109881" Q="2.797628175837513" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="166" TOTAL_2="168" UNITS="" WEIGHT="300.0" Z="2.6868140609188074">
<NAME>Parasuicidality</NAME>
<GROUP_LABEL_1>Active</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.3833835675995936" CI_END="-0.1561258578942985" CI_START="-0.9194283613713019" DF="2" EFFECT_SIZE="-0.5377771096328002" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.01" MODIFIED="2010-09-13 13:08:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8255613391299497" P_Z="0.005749321029419713" STUDIES="3" TAU2="0.0" TOTAL_1="54" TOTAL_2="56" WEIGHT="100.0" Z="2.7617458656012177">
<NAME>DBT vs. TAU</NAME>
<CONT_DATA CI_END="0.5653713380681038" CI_START="-1.201419815330904" EFFECT_SIZE="-0.31802423863140006" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="1.0" MODIFIED="2010-09-03 12:20:11 +0100" MODIFIED_BY="[Empty name]" ORDER="9" SD_1="1.3" SD_2="2.2" SE="0.4507203110198021" STUDY_ID="STD-Koons-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="18.6647828466618">
<FOOTNOTE>mean number of self-harming acts (last 3 months)</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="0.07963327213546678" CI_START="-1.1241977190724612" EFFECT_SIZE="-0.5222822234684973" ESTIMABLE="YES" MEAN_1="6.82" MEAN_2="33.54" MODIFIED="2010-09-13 10:29:34 +0100" MODIFIED_BY="[Empty name]" ORDER="14" SD_1="12.35" SD_2="69.97" SE="0.30710538578861485" STUDY_ID="STD-Linehan-1991" TOTAL_1="22" TOTAL_2="22" WEIGHT="40.20335849035923">
<FOOTNOTE>mean number of parasuicial acts (last 12 months)</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-0.05755853258718091" CI_START="-1.2477244776437932" EFFECT_SIZE="-0.652641505115487" ESTIMABLE="YES" MEAN_1="3.31" MEAN_2="41.6" MODIFIED="2010-09-13 13:08:06 +0100" MODIFIED_BY="[Empty name]" ORDER="27" SD_1="13.15" SD_2="78.76" SE="0.3036193405706659" STUDY_ID="STD-Van-den-Bosch-2005" TOTAL_1="22" TOTAL_2="24" WEIGHT="41.13185866297896">
<FOOTNOTE>LPC self-mutilation (last 3 months)</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.062085646751194656" CI_START="-0.5242532199078274" DF="0" EFFECT_SIZE="-0.23108378657831635" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.02" MODIFIED="2010-09-03 12:05:39 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.12237173948073946" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="90" WEIGHT="100.0" Z="1.5448946841452622">
<NAME>DBT vs. general management</NAME>
<CONT_DATA CI_END="0.062085646751194656" CI_START="-0.5242532199078274" EFFECT_SIZE="-0.23108378657831635" ESTIMABLE="YES" MEAN_1="4.29" MEAN_2="12.87" MODIFIED="2010-09-03 12:05:39 +0100" MODIFIED_BY="[Empty name]" ORDER="22" SD_1="9.32" SD_2="51.45" SE="0.14957899004369166" STUDY_ID="STD-McMain-2009" TOTAL_1="90" TOTAL_2="90" WEIGHT="100.0">
<FOOTNOTE>mean number of suicidal and self-injurious episodes</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6065065698077748" CI_START="-0.5754157894362132" DF="0" EFFECT_SIZE="0.015545390185780793" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.03" MODIFIED="2013-01-16 15:48:52 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.9588813870050126" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0" Z="0.05155737117832642">
<NAME>IPT-BPD+fluoxetine vs. CM+fluoxetine</NAME>
<CONT_DATA CI_END="0.6065065698077748" CI_START="-0.5754157894362132" EFFECT_SIZE="0.015545390185780793" ESTIMABLE="YES" MEAN_1="2.02" MEAN_2="1.99" MODIFIED="2010-10-13 09:50:01 +0100" MODIFIED_BY="[Empty name]" ORDER="146" SD_1="1.92" SD_2="1.87" SE="0.3015163463632089" STUDY_ID="STD-Bellino-2010" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0">
<FOOTNOTE>BPDSI-IV-parasuicidal behaviour</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="14.824153133100936" CI_END="1.1380379739056292" CI_START="0.8401488741045544" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9778145644574142" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="135" I2="66.27126045510504" I2_Q="63.65287197651589" ID="CMP-001.09" LOG_CI_END="0.05615675378358569" LOG_CI_START="-0.07564375027939502" LOG_EFFECT_SIZE="-0.009743498247904664" METHOD="MH" MODIFIED="2013-01-31 12:24:27 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.01114074443337043" P_Q="0.01723425284905611" P_Z="0.7719807114274184" Q="13.756245051244402" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.07752750234354742" TOTALS="SUB" TOTAL_1="229" TOTAL_2="227" WEIGHT="600.0" Z="0.2897850169100545">
<NAME>Parasuicidality</NAME>
<GROUP_LABEL_1>Active</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5723057155247588" CI_START="0.7795973098738935" DF="0" EFFECT_SIZE="1.1071428571428572" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="21" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="0.19653699313900982" LOG_CI_START="-0.10812966815490281" LOG_EFFECT_SIZE="0.044203662492053486" MODIFIED="2010-09-13 10:41:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5695347038588243" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="31" WEIGHT="100.0" Z="0.5687369015122361">
<NAME>DBT vs. TAU</NAME>
<DICH_DATA CI_END="1.5723057155247588" CI_START="0.7795973098738935" EFFECT_SIZE="1.1071428571428572" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="21" LOG_CI_END="0.19653699313900982" LOG_CI_START="-0.10812966815490281" LOG_EFFECT_SIZE="0.044203662492053486" MODIFIED="2010-08-31 12:12:34 +0100" MODIFIED_BY="[Empty name]" ORDER="978" O_E="0.0" SE="0.1789627049683404" STUDY_ID="STD-Carter-2010" TOTAL_1="20" TOTAL_2="31" VAR="0.03202764976958525" WEIGHT="100.0">
<FOOTNOTE>number of participants with self-harm (prev. 6 months), per protocol</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8133511432061167" CI_START="0.23533040015841536" DF="0" EFFECT_SIZE="0.4375" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="16" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="-0.08972191857176588" LOG_CI_START="-0.6283219667115699" LOG_EFFECT_SIZE="-0.3590219426416679" MODIFIED="2010-09-03 13:32:33 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.00897619179630518" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="2.6129595779561576">
<NAME>MBT-PH vs. TAU</NAME>
<DICH_DATA CI_END="0.8133511432061167" CI_START="0.23533040015841536" EFFECT_SIZE="0.4375" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="16" LOG_CI_END="-0.08972191857176588" LOG_CI_START="-0.6283219667115699" LOG_EFFECT_SIZE="-0.3590219426416679" MODIFIED="2010-09-03 13:24:57 +0100" MODIFIED_BY="[Empty name]" ORDER="72" O_E="0.0" SE="0.31637633439055773" STUDY_ID="STD-Bateman-1999" TOTAL_1="19" TOTAL_2="19" VAR="0.10009398496240601" WEIGHT="100.0">
<FOOTNOTE>number of participants with self-mutilating behaviour (last 6 months)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9240262564522445" CI_START="0.33779281205830336" DF="0" EFFECT_SIZE="0.5586854460093896" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="27" I2="0.0" ID="CMP-001.09.03" LOG_CI_END="-0.03431568801115684" LOG_CI_START="-0.47134959608125715" LOG_EFFECT_SIZE="-0.252832642046207" MODIFIED="2011-08-16 12:47:52 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.023344155427643752" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="63" WEIGHT="100.0" Z="2.2677548051817893">
<NAME>MBT-outpatient vs. TAU</NAME>
<DICH_DATA CI_END="0.9240262564522445" CI_START="0.33779281205830336" EFFECT_SIZE="0.5586854460093896" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="27" LOG_CI_END="-0.03431568801115684" LOG_CI_START="-0.47134959608125715" LOG_EFFECT_SIZE="-0.252832642046207" MODIFIED="2011-08-16 12:47:52 +0100" MODIFIED_BY="[Empty name]" ORDER="83" O_E="0.0" SE="0.256715880953112" STUDY_ID="STD-Bateman-2009" TOTAL_1="71" TOTAL_2="63" VAR="0.06590304353353235" WEIGHT="100.0">
<FOOTNOTE>participants with severe self-harm incidents (last 6 months)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3957506752809328" CI_START="0.8445458999808979" DF="0" EFFECT_SIZE="1.0857142857142856" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="35" I2="0.0" ID="CMP-001.09.04" LOG_CI_END="0.14480784663940197" LOG_CI_START="-0.07337674210633302" LOG_EFFECT_SIZE="0.03571555226653449" MODIFIED="2010-09-03 14:08:00 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.5210878115143585" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="52" WEIGHT="100.0" Z="0.6416694830077349">
<NAME>TFP vs. CTBE</NAME>
<DICH_DATA CI_END="1.3957506752809328" CI_START="0.8445458999808979" EFFECT_SIZE="1.0857142857142856" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="35" LOG_CI_END="0.14480784663940197" LOG_CI_START="-0.07337674210633302" LOG_EFFECT_SIZE="0.03571555226653449" MODIFIED="2010-09-03 14:08:00 +0100" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="0.12816270746037753" STUDY_ID="STD-Doering-2010" TOTAL_1="52" TOTAL_2="52" VAR="0.016425679583574312" WEIGHT="100.0">
<FOOTNOTE>participants with self-harming behaviour (last 12 months)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.598296827120126" CI_START="0.8588951525590485" DF="0" EFFECT_SIZE="1.1716524216524216" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="27" I2="0.0" ID="CMP-001.09.05" LOG_CI_END="0.20365743731172506" LOG_CI_START="-0.06605984832731189" LOG_EFFECT_SIZE="0.06879879449220659" MODIFIED="2013-01-31 12:24:27 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.31736608689213874" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="47" WEIGHT="99.99999999999999" Z="0.9998851876698652">
<NAME>CBT vs. TAU</NAME>
<DICH_DATA CI_END="1.598296827120126" CI_START="0.8588951525590485" EFFECT_SIZE="1.1716524216524216" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="27" LOG_CI_END="0.20365743731172506" LOG_CI_START="-0.06605984832731189" LOG_EFFECT_SIZE="0.06879879449220659" MODIFIED="2013-01-16 15:53:00 +0000" MODIFIED_BY="[Empty name]" ORDER="219" O_E="0.0" SE="0.15843326870646682" STUDY_ID="STD-Davidson-2006" TOTAL_1="52" TOTAL_2="47" VAR="0.02510110063301552" WEIGHT="99.99999999999999">
<FOOTNOTE>participants with self-harming behaviour (last 12 months)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6662261811165466" CI_START="0.4741994008644479" DF="0" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" I2="0.0" ID="CMP-001.09.06" LOG_CI_END="0.2217339541797036" LOG_CI_START="-0.3240389990744662" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2013-01-16 15:49:40 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.7133244707312585" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.00000000000001" Z="0.3673949070486595">
<NAME>DDP vs. TAU</NAME>
<DICH_DATA CI_END="1.6662261811165466" CI_START="0.4741994008644479" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.2217339541797036" LOG_CI_START="-0.3240389990744662" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2013-01-16 15:49:40 +0000" MODIFIED_BY="[Empty name]" ORDER="218" O_E="0.0" SE="0.3205897343611891" STUDY_ID="STD-Gregory-2008" TOTAL_1="15" TOTAL_2="15" VAR="0.10277777777777779" WEIGHT="100.00000000000001">
<FOOTNOTE>participants with parasuicide (last 3 months, available case analysis)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="47.24179667048913" CI_END="-0.17498328666668392" CI_START="-0.5230704147436646" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.34902685070517425" ESTIMABLE="YES" I2="89.41615189855092" I2_Q="89.41615189855092" ID="CMP-001.10" MODIFIED="2012-06-13 13:46:11 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="5.0718114152914495E-9" P_Q="5.0718114152914495E-9" P_Z="8.476568920562862E-5" Q="47.24179667048913" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.4358250749679408" TOTALS="SUB" TOTAL_1="274" TOTAL_2="269" UNITS="" WEIGHT="600.0" Z="3.930510506371228">
<NAME>Interpersonal problems</NAME>
<GROUP_LABEL_1>Active</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6105341259189958" CI_START="-0.5372053926075071" DF="0" EFFECT_SIZE="0.0366643666557444" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.01" MODIFIED="2011-08-19 15:53:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9003481882788413" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="28" WEIGHT="100.0" Z="0.12522151063245965">
<NAME>DBT vs. TAU</NAME>
<CONT_DATA CI_END="0.6105341259189958" CI_START="-0.5372053926075071" EFFECT_SIZE="0.0366643666557444" ESTIMABLE="YES" MEAN_1="-48.75" MEAN_2="-49.73" MODIFIED="2011-08-19 15:53:02 +0100" MODIFIED_BY="[Empty name]" ORDER="979" SD_1="19.36" SD_2="30.23" SE="0.29279607369822247" STUDY_ID="STD-Carter-2010" TOTAL_1="20" TOTAL_2="28" WEIGHT="100.0">
<FOOTNOTE>WHOQOL-Bref-social relationships (scores multiplied by (-1))</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.26437924190400874" CI_START="-0.3199979943731135" DF="0" EFFECT_SIZE="-0.027809376234552357" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.02" MODIFIED="2010-09-03 12:07:56 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8520199425353288" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="90" WEIGHT="99.99999999999999" Z="0.18654174895477718">
<NAME>DBT vs. general management</NAME>
<CONT_DATA CI_END="0.26437924190400874" CI_START="-0.3199979943731135" EFFECT_SIZE="-0.027809376234552357" ESTIMABLE="YES" MEAN_1="100.24" MEAN_2="101.58" MODIFIED="2010-09-03 12:07:56 +0100" MODIFIED_BY="[Empty name]" ORDER="23" SD_1="50.62" SD_2="45.19" SE="0.1490785649345129" STUDY_ID="STD-McMain-2009" TOTAL_1="90" TOTAL_2="90" WEIGHT="99.99999999999999">
<FOOTNOTE>IIP-C total score</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.3908868754146495" CI_START="-3.041793840264458" DF="0" EFFECT_SIZE="-2.2163403578395537" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.03" MODIFIED="2010-09-03 13:54:36 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="1.421112305993751E-7" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="5.2624979739465">
<NAME>MBT-PH vs. TAU</NAME>
<CONT_DATA CI_END="-1.3908868754146495" CI_START="-3.041793840264458" EFFECT_SIZE="-2.2163403578395537" ESTIMABLE="YES" MEAN_1="1.86" MEAN_2="2.6" MODIFIED="2010-09-03 13:54:36 +0100" MODIFIED_BY="[Empty name]" ORDER="77" SD_1="0.36" SD_2="0.29" SE="0.4211574747985044" STUDY_ID="STD-Bateman-1999" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0">
<FOOTNOTE>IIP</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.5883955840279456" CI_START="-1.3048134199366714" DF="0" EFFECT_SIZE="-0.9466045019823085" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.04" MODIFIED="2011-08-16 12:52:22 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="2.2258916953337166E-7" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="63" WEIGHT="100.0" Z="5.179409664293093">
<NAME>MBT-outpatient vs. TAU</NAME>
<CONT_DATA CI_END="-0.5883955840279456" CI_START="-1.3048134199366714" EFFECT_SIZE="-0.9466045019823085" ESTIMABLE="YES" MEAN_1="1.28" MEAN_2="1.65" MODIFIED="2011-08-16 12:52:22 +0100" MODIFIED_BY="[Empty name]" ORDER="85" SD_1="0.13" SD_2="0.55" SE="0.18276301033073522" STUDY_ID="STD-Bateman-2009" TOTAL_1="71" TOTAL_2="63" WEIGHT="100.0">
<FOOTNOTE>IIP</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6272429086912928" CI_START="-0.16443713108133404" DF="0" EFFECT_SIZE="0.23140288880497942" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.05" MODIFIED="2012-01-06 12:11:53 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.25189065550764755" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="47" WEIGHT="99.99999999999999" Z="1.14576926331639">
<NAME>CBT vs. TAU</NAME>
<CONT_DATA CI_END="0.6272429086912928" CI_START="-0.16443713108133404" EFFECT_SIZE="0.23140288880497942" ESTIMABLE="YES" MEAN_1="60.4" MEAN_2="55.0" MODIFIED="2010-09-06 10:29:17 +0100" MODIFIED_BY="[Empty name]" ORDER="77" SD_1="23.9" SD_2="22.3" SE="0.20196290493531974" STUDY_ID="STD-Davidson-2006" TOTAL_1="52" TOTAL_2="47" WEIGHT="99.99999999999999">
<FOOTNOTE>IIP-SC</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.2045991005354858" CI_START="-1.440155379949954" DF="0" EFFECT_SIZE="-0.8223772402427199" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.06" MODIFIED="2012-01-06 12:11:53 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.009078722474992704" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0" Z="2.6090754414603">
<NAME>IPT-BPD+fluoxetine vs. CM+fluoxetine</NAME>
<CONT_DATA CI_END="-0.2045991005354859" CI_START="-1.440155379949954" EFFECT_SIZE="-0.82237724024272" ESTIMABLE="YES" MEAN_1="5.83" MEAN_2="6.97" MODIFIED="2010-10-13 09:50:55 +0100" MODIFIED_BY="[Empty name]" ORDER="147" SD_1="1.42" SD_2="1.3" SE="0.31519872027250967" STUDY_ID="STD-Bellino-2010" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0">
<FOOTNOTE>BPDSI-IV-interpersonal relationships</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.5973084024739609" CI_START="-0.584597627210884" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.006355387631538436" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.11" MODIFIED="2012-06-13 13:46:25 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.9831831331360531" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="22" TOTAL_2="22" UNITS="" WEIGHT="99.99999999999999" Z="0.02107837772674386">
<NAME>Avoidance of abandonment</NAME>
<GROUP_LABEL_1>Active</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5973084024739609" CI_START="-0.584597627210884" DF="0" EFFECT_SIZE="0.006355387631538436" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.01" MODIFIED="2010-10-13 09:52:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9831831331360531" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="99.99999999999999" Z="0.02107837772674386">
<NAME>IPT-BPD+fluoxetine vs. CM+fluoxetine</NAME>
<CONT_DATA CI_END="0.5973084024739609" CI_START="-0.584597627210884" EFFECT_SIZE="0.006355387631538436" ESTIMABLE="YES" MEAN_1="6.11" MEAN_2="6.1" MODIFIED="2010-10-13 09:52:20 +0100" MODIFIED_BY="[Empty name]" ORDER="148" SD_1="1.57" SD_2="1.52" SE="0.30151218058279866" STUDY_ID="STD-Bellino-2010" TOTAL_1="22" TOTAL_2="22" WEIGHT="99.99999999999999">
<FOOTNOTE>BPDSI-IV-abandonment</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.5578955756386619" CI_START="-0.6240960662873243" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.03310024532433124" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.12" MODIFIED="2012-06-13 13:46:37 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.9125895327131326" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="22" TOTAL_2="22" UNITS="" WEIGHT="100.0" Z="0.10977283834159618">
<NAME>Identity disturbance</NAME>
<GROUP_LABEL_1>Active</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5578955756386619" CI_START="-0.6240960662873243" DF="0" EFFECT_SIZE="-0.03310024532433124" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.01" MODIFIED="2010-10-19 15:00:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9125895327131326" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0" Z="0.10977283834159618">
<NAME>IPT-BPD+fluoxetine vs. CM+fluoxetine</NAME>
<CONT_DATA CI_END="0.5578955756386619" CI_START="-0.6240960662873243" EFFECT_SIZE="-0.03310024532433124" ESTIMABLE="YES" MEAN_1="2.46" MEAN_2="2.49" MODIFIED="2010-10-19 15:00:57 +0100" MODIFIED_BY="[Empty name]" ORDER="149" SD_1="0.9" SD_2="0.88" SE="0.30153402084155256" STUDY_ID="STD-Bellino-2010" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0">
<FOOTNOTE>BPDSI-IV-identity disturbance</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.618758531301519" CI_END="0.2411314508992144" CI_START="-0.47213566354469283" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.11550210632273922" ESTIMABLE="YES" I2="35.047481272968156" I2_Q="35.047481272968184" ID="CMP-001.13" MODIFIED="2012-06-13 13:46:48 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.20193883858304784" P_Q="0.20193883858304762" P_Z="0.5255790110893147" Q="4.618758531301521" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.07378085558916005" TOTALS="SUB" TOTAL_1="63" TOTAL_2="61" UNITS="" WEIGHT="400.0" Z="0.6347691178993446">
<NAME>Dissociation/psychoticism</NAME>
<GROUP_LABEL_1>Active</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.030822833539806527" CI_START="-1.8292845970532805" DF="0" EFFECT_SIZE="-0.899230881756737" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.01" MODIFIED="2010-09-06 10:57:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.058091212037269344" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="1.8950089796345235">
<NAME>DBT vs. TAU</NAME>
<CONT_DATA CI_END="0.030822833539806527" CI_START="-1.8292845970532805" EFFECT_SIZE="-0.899230881756737" ESTIMABLE="YES" MEAN_1="13.2" MEAN_2="30.6" MODIFIED="2010-09-06 10:57:04 +0100" MODIFIED_BY="[Empty name]" ORDER="11" SD_1="12.0" SD_2="23.3" SE="0.4745259212070674" STUDY_ID="STD-Koons-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0">
<FOOTNOTE>DES</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3835649644416588" CI_START="-1.0627845693983304" DF="0" EFFECT_SIZE="-0.33960980247833583" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.02" MODIFIED="2012-05-25 10:03:44 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.35735444226263546" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="14" WEIGHT="100.0" Z="0.9204178742148207">
<NAME>DBT-PTSD vs. WL</NAME>
<CONT_DATA CI_END="0.3835649644416588" CI_START="-1.0627845693983304" EFFECT_SIZE="-0.33960980247833583" ESTIMABLE="YES" MEAN_1="24.03" MEAN_2="30.13" MODIFIED="2010-10-19 13:36:35 +0100" MODIFIED_BY="[Empty name]" ORDER="156" SD_1="14.96" SD_2="19.99" SE="0.3689734977909313" STUDY_ID="STD-Steil-2010" TOTAL_1="16" TOTAL_2="14" WEIGHT="100.0">
<FOOTNOTE>DES (German version: FDS)</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9690401998643385" CI_START="-0.468744847774303" DF="0" EFFECT_SIZE="0.2501476760450178" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.03" MODIFIED="2012-05-25 10:03:44 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.49524270719306085" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.6819940667345846">
<NAME>DDP vs. TAU</NAME>
<CONT_DATA CI_END="0.9690401998643385" CI_START="-0.468744847774303" EFFECT_SIZE="0.2501476760450178" ESTIMABLE="YES" MEAN_1="27.7" MEAN_2="22.3" MODIFIED="2010-09-06 10:56:59 +0100" MODIFIED_BY="[Empty name]" ORDER="87" SD_1="21.4" SD_2="20.6" SE="0.36678863973514475" STUDY_ID="STD-Gregory-2008" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0">
<FOOTNOTE>DES</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6951894461870369" CI_START="-0.4875871771016825" DF="0" EFFECT_SIZE="0.10380113454267721" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.04" MODIFIED="2012-01-06 12:23:22 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.7308349612722742" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="99.99999999999999" Z="0.3440150595678149">
<NAME>IPT-BPD+fluoxetine vs. CM+fluoxetine</NAME>
<CONT_DATA CI_END="0.6951894461870369" CI_START="-0.4875871771016825" EFFECT_SIZE="0.10380113454267721" ESTIMABLE="YES" MEAN_1="4.32" MEAN_2="4.09" MODIFIED="2010-10-13 09:57:38 +0100" MODIFIED_BY="[Empty name]" ORDER="151" SD_1="2.11" SD_2="2.24" SE="0.3017342748689033" STUDY_ID="STD-Bellino-2010" TOTAL_1="22" TOTAL_2="22" WEIGHT="99.99999999999999">
<FOOTNOTE>BPDSI-IV-paranoid ideation</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="34.46417222076357" CI_END="-0.19332077191227146" CI_START="-0.47655358546977955" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.3349371786910255" ESTIMABLE="YES" I2="70.98436040783443" I2_Q="70.98436040783443" ID="CMP-001.14" MODIFIED="2012-06-13 13:46:59 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.5406421026575856E-4" P_Q="1.5406421026575856E-4" P_Z="3.5605197608083656E-6" Q="34.46417222076357" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.14849475031972464" TOTALS="SUB" TOTAL_1="414" TOTAL_2="386" UNITS="" WEIGHT="1100.0" Z="4.635513795682269">
<NAME>Depression</NAME>
<GROUP_LABEL_1>Active</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.16196558305690711" CI_START="-2.078622153265201" DF="0" EFFECT_SIZE="-1.1202938681610541" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.01" MODIFIED="2010-09-14 10:36:23 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.021951012481082166" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="2.2912144698495536">
<NAME>DBT vs. TAU</NAME>
<CONT_DATA CI_END="-0.16196558305690711" CI_START="-2.078622153265201" EFFECT_SIZE="-1.1202938681610541" ESTIMABLE="YES" MEAN_1="13.4" MEAN_2="29.3" MODIFIED="2010-09-14 10:36:23 +0100" MODIFIED_BY="[Empty name]" ORDER="100" SD_1="7.5" SD_2="17.7" SE="0.48895198721166216" STUDY_ID="STD-Koons-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0">
<FOOTNOTE>BDI</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.122455848027199" CI_START="-0.46297390219616374" DF="0" EFFECT_SIZE="-0.17025902708448237" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.02" MODIFIED="2010-09-14 10:36:23 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.25427692167302784" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="90" WEIGHT="100.00000000000001" Z="1.140022559499567">
<NAME>DBT vs. general management</NAME>
<CONT_DATA CI_END="0.122455848027199" CI_START="-0.46297390219616374" EFFECT_SIZE="-0.17025902708448237" ESTIMABLE="YES" MEAN_1="22.18" MEAN_2="24.83" MODIFIED="2010-09-14 10:36:23 +0100" MODIFIED_BY="[Empty name]" ORDER="101" SD_1="16.14" SD_2="14.83" SE="0.1493470683239993" STUDY_ID="STD-McMain-2009" TOTAL_1="90" TOTAL_2="90" WEIGHT="100.00000000000001">
<FOOTNOTE>BDI</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="6.624493967086611E-32" CI_END="0.03678009908317087" CI_START="-0.8086582944475624" DF="0" EFFECT_SIZE="-0.38593909768219575" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-001.14.03" MODIFIED="2010-09-14 10:36:23 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.07354546988285822" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="39" WEIGHT="100.0" Z="1.7894307556201423">
<NAME>DBT vs. CTBE</NAME>
<CONT_DATA CI_END="0.036780099083170814" CI_START="-0.8086582944475624" EFFECT_SIZE="-0.3859390976821958" ESTIMABLE="YES" MEAN_1="14.0" MEAN_2="17.0" MODIFIED="2010-09-14 10:36:23 +0100" MODIFIED_BY="[Empty name]" ORDER="102" SD_1="7.3" SD_2="8.2" SE="0.2156770226900707" STUDY_ID="STD-Linehan-2006" TOTAL_1="50" TOTAL_2="39" WEIGHT="100.0">
<FOOTNOTE>Ham-D-17</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.2858507557283455" CI_START="-1.841275642747195" DF="0" EFFECT_SIZE="-1.0635631992377703" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.04" MODIFIED="2012-01-06 12:23:44 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.007354408254052779" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="13" WEIGHT="100.0" Z="2.6803551662124923">
<NAME>DBT-PTSD vs. WL</NAME>
<CONT_DATA CI_END="-0.2858507557283455" CI_START="-1.841275642747195" EFFECT_SIZE="-1.0635631992377703" ESTIMABLE="YES" MEAN_1="29.13" MEAN_2="41.57" MODIFIED="2010-10-19 13:40:10 +0100" MODIFIED_BY="[Empty name]" ORDER="158" SD_1="10.63" SD_2="12.31" SE="0.39679935429626323" STUDY_ID="STD-Steil-2010" TOTAL_1="17" TOTAL_2="13" WEIGHT="100.0">
<FOOTNOTE>BDI-II</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.1929887177118663" CI_START="-2.77595432000017" DF="0" EFFECT_SIZE="-1.9844715188560182" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.05" MODIFIED="2012-01-06 12:23:44 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="8.915265447970991E-7" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="99.99999999999999" Z="4.914184742461518">
<NAME>MBT-PH vs. TAU</NAME>
<CONT_DATA CI_END="-1.1929887177118663" CI_START="-2.77595432000017" EFFECT_SIZE="-1.9844715188560182" ESTIMABLE="YES" MEAN_1="20.6" MEAN_2="35.2" MODIFIED="2010-09-14 10:36:23 +0100" MODIFIED_BY="[Empty name]" ORDER="103" SD_1="7.0" SD_2="7.4" SE="0.40382517606816615" STUDY_ID="STD-Bateman-1999" TOTAL_1="19" TOTAL_2="19" WEIGHT="99.99999999999999">
<FOOTNOTE>BDI</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.10250054024122107" CI_START="-0.7895775418762705" DF="0" EFFECT_SIZE="-0.4460390410587458" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.06" MODIFIED="2012-01-06 12:23:42 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.010935521962483655" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="63" WEIGHT="100.0" Z="2.544752492351006">
<NAME>MBT-outpatient vs. TAU</NAME>
<CONT_DATA CI_END="-0.10250054024122107" CI_START="-0.7895775418762705" EFFECT_SIZE="-0.4460390410587458" ESTIMABLE="YES" MEAN_1="14.8" MEAN_2="18.68" MODIFIED="2010-09-14 10:36:23 +0100" MODIFIED_BY="[Empty name]" ORDER="104" SD_1="8.55" SD_2="8.76" SE="0.17527796608882235" STUDY_ID="STD-Bateman-2009" TOTAL_1="71" TOTAL_2="63" WEIGHT="100.0">
<FOOTNOTE>BDI</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.9974746410092294E-33" CI_END="0.5085131808895913" CI_START="-0.2610123443295237" DF="0" EFFECT_SIZE="0.12375041828003377" ESTIMABLE="YES" I2="100.0" ID="CMP-001.14.07" MODIFIED="2012-01-06 12:23:41 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Z="0.5284466551628231" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="52" WEIGHT="100.0" Z="0.6303789931635357">
<NAME>TFP vs. CTBE</NAME>
<CONT_DATA CI_END="0.5085131808895913" CI_START="-0.26101234432952375" EFFECT_SIZE="0.12375041828003376" ESTIMABLE="YES" MEAN_1="21.67" MEAN_2="20.02" MODIFIED="2010-09-14 10:36:23 +0100" MODIFIED_BY="[Empty name]" ORDER="105" SD_1="13.25" SD_2="13.22" SE="0.1963111392069023" STUDY_ID="STD-Doering-2010" TOTAL_1="52" TOTAL_2="52" WEIGHT="100.0">
<FOOTNOTE>BDI</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2871852177326155" CI_START="-0.5023494057133253" DF="0" EFFECT_SIZE="-0.10758209399035491" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.08" MODIFIED="2012-01-06 12:23:39 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.593251658092104" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="47" WEIGHT="100.0" Z="0.534129912332935">
<NAME>CBT vs. TAU</NAME>
<CONT_DATA CI_END="0.2871852177326155" CI_START="-0.5023494057133253" EFFECT_SIZE="-0.10758209399035491" ESTIMABLE="YES" MEAN_1="29.6" MEAN_2="31.3" MODIFIED="2010-09-14 10:36:23 +0100" MODIFIED_BY="[Empty name]" ORDER="106" SD_1="14.8" SD_2="16.6" SE="0.20141559479502918" STUDY_ID="STD-Davidson-2006" TOTAL_1="52" TOTAL_2="47" WEIGHT="100.0">
<FOOTNOTE>BDI-II</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2138890263622265" CI_START="-1.2445596691859926" DF="0" EFFECT_SIZE="-0.515335321411883" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.09" MODIFIED="2012-01-06 12:23:37 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Z="0.16602607372236633" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.3850863222158094">
<NAME>DDP vs. TAU</NAME>
<CONT_DATA CI_END="0.2138890263622265" CI_START="-1.2445596691859926" EFFECT_SIZE="-0.515335321411883" ESTIMABLE="YES" MEAN_1="21.0" MEAN_2="25.9" MODIFIED="2010-09-14 10:36:23 +0100" MODIFIED_BY="[Empty name]" ORDER="107" SD_1="11.4" SD_2="6.42" SE="0.37206007535145447" STUDY_ID="STD-Gregory-2008" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0">
<FOOTNOTE>BDI</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.1648457713804835" CI_START="-1.6279739780152793" DF="0" EFFECT_SIZE="-0.8964098746978815" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.10" MODIFIED="2012-01-06 12:23:36 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Z="0.016323137001649897" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="2.4016091847957233">
<NAME>IPT vs. CM</NAME>
<CONT_DATA CI_END="-0.1648457713804835" CI_START="-1.6279739780152793" EFFECT_SIZE="-0.8964098746978815" ESTIMABLE="YES" MEAN_1="9.1" MEAN_2="12.0" MODIFIED="2010-09-14 10:36:23 +0100" MODIFIED_BY="[Empty name]" ORDER="108" SD_1="3.0" SD_2="3.3" SE="0.3732538501155543" STUDY_ID="STD-Bellino-2006" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0">
<FOOTNOTE>Ham-D</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.545662510389094" CI_START="-0.6364072573421937" DF="0" EFFECT_SIZE="-0.04537237347654991" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.11" MODIFIED="2012-01-06 12:23:35 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Z="0.8804002262026102" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0" Z="0.15046187684474088">
<NAME>IPT-BPD+fluoxetine vs. CM+fluoxetine</NAME>
<CONT_DATA CI_END="0.545662510389094" CI_START="-0.6364072573421937" EFFECT_SIZE="-0.04537237347654991" ESTIMABLE="YES" MEAN_1="10.75" MEAN_2="10.82" MODIFIED="2010-10-13 09:59:18 +0100" MODIFIED_BY="[Empty name]" ORDER="152" SD_1="1.5" SD_2="1.53" SE="0.3015539512601515" STUDY_ID="STD-Bellino-2010" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0">
<FOOTNOTE>Ham-D</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="13.376182639502847" CI_END="-0.010860498893878884" CI_START="-0.42618797018235743" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.21852423453811817" ESTIMABLE="YES" I2="55.144153143658016" I2_Q="55.144153143658016" ID="CMP-001.15" MODIFIED="2012-06-13 13:47:13 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.037436274091027455" P_Q="0.03743627409102768" P_Z="0.03916328358898719" Q="13.376182639502845" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.10380448180703294" TOTALS="SUB" TOTAL_1="187" TOTAL_2="180" UNITS="" WEIGHT="700.0" Z="2.062467132815333">
<NAME>Anxiety</NAME>
<GROUP_LABEL_1>Active</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.2509440545699624" CI_START="-2.1978195717565696" DF="0" EFFECT_SIZE="-1.224381813163266" ESTIMABLE="YES" I2="0.0" ID="CMP-001.15.01" MODIFIED="2010-09-14 10:36:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.013692678312271132" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="2.4652261903151116">
<NAME>DBT vs. TAU</NAME>
<CONT_DATA CI_END="-0.2509440545699624" CI_START="-2.1978195717565696" EFFECT_SIZE="-1.224381813163266" ESTIMABLE="YES" MEAN_1="19.1" MEAN_2="32.2" MODIFIED="2010-09-14 10:36:37 +0100" MODIFIED_BY="[Empty name]" ORDER="109" SD_1="7.5" SD_2="12.4" SE="0.49666104391287613" STUDY_ID="STD-Koons-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0">
<FOOTNOTE>HARS</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.19771527976053127" CI_START="-1.7242050480247477" DF="0" EFFECT_SIZE="-0.9609601638926395" ESTIMABLE="YES" I2="0.0" ID="CMP-001.15.02" MODIFIED="2012-01-06 12:24:15 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.013599024899734321" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="14" WEIGHT="100.0" Z="2.4676841613540117">
<NAME>DBT-PTSD vs. WL</NAME>
<CONT_DATA CI_END="-0.19771527976053127" CI_START="-1.7242050480247477" EFFECT_SIZE="-0.9609601638926395" ESTIMABLE="YES" MEAN_1="53.38" MEAN_2="66.14" MODIFIED="2010-10-19 13:41:17 +0100" MODIFIED_BY="[Empty name]" ORDER="159" SD_1="15.15" SD_2="9.73" SE="0.38941781081309984" STUDY_ID="STD-Steil-2010" TOTAL_1="16" TOTAL_2="14" WEIGHT="100.0">
<FOOTNOTE>STAI-state</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.1560076803729703" CI_START="-1.1369420686015363" DF="0" EFFECT_SIZE="-0.49046719411428297" ESTIMABLE="YES" I2="0.0" ID="CMP-001.15.03" MODIFIED="2012-01-06 12:24:15 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.13701893822891842" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="1.4869843732517163">
<NAME>MBT-PH vs. TAU</NAME>
<CONT_DATA CI_END="0.1560076803729703" CI_START="-1.1369420686015363" EFFECT_SIZE="-0.49046719411428297" ESTIMABLE="YES" MEAN_1="56.8" MEAN_2="61.0" MODIFIED="2010-09-14 10:36:37 +0100" MODIFIED_BY="[Empty name]" ORDER="110" SD_1="9.1" SD_2="7.6" SE="0.32984018052707326" STUDY_ID="STD-Bateman-1999" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0">
<FOOTNOTE>STAI-trait</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4195034228150159" CI_START="-0.3493191963702846" DF="0" EFFECT_SIZE="0.03509211322236565" ESTIMABLE="YES" I2="0.0" ID="CMP-001.15.04" MODIFIED="2012-01-06 12:24:13 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.8579996881096086" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="52" WEIGHT="100.0" Z="0.17892105757794158">
<NAME>TFP vs. CTBE</NAME>
<CONT_DATA CI_END="0.4195034228150159" CI_START="-0.3493191963702846" EFFECT_SIZE="0.03509211322236565" ESTIMABLE="YES" MEAN_1="55.92" MEAN_2="55.49" MODIFIED="2010-09-14 10:36:37 +0100" MODIFIED_BY="[Empty name]" ORDER="111" SD_1="11.39" SD_2="12.89" SE="0.19613182314819944" STUDY_ID="STD-Doering-2010" TOTAL_1="52" TOTAL_2="52" WEIGHT="100.0">
<FOOTNOTE>STAI-trait</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.36676449303416914" CI_START="-0.4222168939821934" DF="0" EFFECT_SIZE="-0.02772620047401213" ESTIMABLE="YES" I2="0.0" ID="CMP-001.15.05" MODIFIED="2012-01-06 12:24:11 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.8904354747468417" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="47" WEIGHT="100.0" Z="0.13775319735413266">
<NAME>CBT vs. TAU</NAME>
<CONT_DATA CI_END="0.36676449303416914" CI_START="-0.4222168939821934" EFFECT_SIZE="-0.02772620047401213" ESTIMABLE="YES" MEAN_1="59.7" MEAN_2="60.0" MODIFIED="2010-09-14 10:36:37 +0100" MODIFIED_BY="[Empty name]" ORDER="112" SD_1="10.3" SD_2="11.2" SE="0.2012744604594133" STUDY_ID="STD-Davidson-2006" TOTAL_1="52" TOTAL_2="47" WEIGHT="100.0">
<FOOTNOTE>STAI-trait</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8999223465784856" CI_START="-0.490122529018433" DF="0" EFFECT_SIZE="0.2048999087800263" ESTIMABLE="YES" I2="0.0" ID="CMP-001.15.06" MODIFIED="2012-01-06 12:24:09 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.5633870366093938" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.577817952059913">
<NAME>IPT vs. CM</NAME>
<CONT_DATA CI_END="0.8999223465784856" CI_START="-0.490122529018433" EFFECT_SIZE="0.2048999087800263" ESTIMABLE="YES" MEAN_1="11.0" MEAN_2="10.2" MODIFIED="2010-09-14 10:36:37 +0100" MODIFIED_BY="[Empty name]" ORDER="113" SD_1="4.4" SD_2="3.1" SE="0.35460980062935216" STUDY_ID="STD-Bellino-2006" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0">
<FOOTNOTE>HARS</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0818898664926041" CI_START="-1.12174565595129" DF="0" EFFECT_SIZE="-0.519927894729343" ESTIMABLE="YES" I2="0.0" ID="CMP-001.15.07" MODIFIED="2012-01-06 12:24:07 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.09040408963308061" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0" Z="1.6932699795336028">
<NAME>IPT-BPD+fluoxetine vs. CM+fluoxetine</NAME>
<CONT_DATA CI_END="0.0818898664926041" CI_START="-1.12174565595129" EFFECT_SIZE="-0.519927894729343" ESTIMABLE="YES" MEAN_1="9.03" MEAN_2="9.82" MODIFIED="2010-10-13 10:00:23 +0100" MODIFIED_BY="[Empty name]" ORDER="153" SD_1="1.67" SD_2="1.29" SE="0.3070555203917055" STUDY_ID="STD-Bellino-2010" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0">
<FOOTNOTE>HARS</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="13.437391749896424" CI_END="-0.03884629917143001" CI_START="-0.3661953590184553" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.20252082909494265" ESTIMABLE="YES" I2="62.790397920500155" I2_Q="62.790397920500155" ID="CMP-001.16" MODIFIED="2012-06-13 13:47:35 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.01960718779929982" P_Q="0.01960718779929982" P_Z="0.01530251477771814" Q="13.437391749896424" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.07503523113750664" TOTALS="SUB" TOTAL_1="301" TOTAL_2="284" UNITS="" WEIGHT="600.0" Z="2.4251392768977045">
<NAME>General psychopathology</NAME>
<GROUP_LABEL_1>DBT</GROUP_LABEL_1>
<GROUP_LABEL_2>TAU</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.280539897698399" CI_START="-0.3038135189496151" DF="0" EFFECT_SIZE="-0.011636810625608052" ESTIMABLE="YES" I2="0.0" ID="CMP-001.16.01" MODIFIED="2010-09-14 10:36:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9377791932289733" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="90" WEIGHT="100.0" Z="0.07806142334868237">
<NAME>DBT vs. general management</NAME>
<CONT_DATA CI_END="0.280539897698399" CI_START="-0.3038135189496151" EFFECT_SIZE="-0.01163681062560805" ESTIMABLE="YES" MEAN_1="1.35" MEAN_2="1.36" MODIFIED="2010-09-14 10:36:48 +0100" MODIFIED_BY="[Empty name]" ORDER="114" SD_1="0.89" SD_2="0.82" SE="0.14907248838685794" STUDY_ID="STD-McMain-2009" TOTAL_1="90" TOTAL_2="90" WEIGHT="100.0">
<FOOTNOTE>SCL-90-R-GSI</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.043274851439015105" CI_START="-1.4506624584768841" DF="0" EFFECT_SIZE="-0.7036938035189345" ESTIMABLE="YES" I2="0.0" ID="CMP-001.16.02" MODIFIED="2012-01-06 12:24:33 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.06483189668544638" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="13" WEIGHT="100.0" Z="1.8464155113962035">
<NAME>DBT-PTSD vs. WL</NAME>
<CONT_DATA CI_END="0.043274851439015105" CI_START="-1.4506624584768841" EFFECT_SIZE="-0.7036938035189345" ESTIMABLE="YES" MEAN_1="1.34" MEAN_2="1.87" MODIFIED="2010-10-19 13:38:04 +0100" MODIFIED_BY="[Empty name]" ORDER="157" SD_1="0.61" SD_2="0.87" SE="0.3811134596604545" STUDY_ID="STD-Steil-2010" TOTAL_1="17" TOTAL_2="13" WEIGHT="100.0">
<FOOTNOTE>SCL-90-R-GSI</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2571868722335084" CI_START="-1.0277007155063398" DF="0" EFFECT_SIZE="-0.38525692163641573" ESTIMABLE="YES" I2="0.0" ID="CMP-001.16.03" MODIFIED="2012-01-06 12:24:33 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.23985886115014843" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="1.1753396926035653">
<NAME>MBT-PH vs. TAU</NAME>
<CONT_DATA CI_END="0.2571868722335084" CI_START="-1.0277007155063398" EFFECT_SIZE="-0.38525692163641573" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="2.4" MODIFIED="2010-09-14 10:36:48 +0100" MODIFIED_BY="[Empty name]" ORDER="115" SD_1="0.82" SD_2="0.7" SE="0.32778346895016375" STUDY_ID="STD-Bateman-1999" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0">
<FOOTNOTE>SCL-90-R-GSI</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.3254032364131683" CI_START="-1.0233925591313633" DF="0" EFFECT_SIZE="-0.6743978977722658" ESTIMABLE="YES" I2="0.0" ID="CMP-001.16.04" MODIFIED="2012-01-06 12:24:31 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="1.52208739099172E-4" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="63" WEIGHT="100.0" Z="3.787437852876228">
<NAME>MBT-outpatient vs. TAU</NAME>
<CONT_DATA CI_END="-0.3254032364131683" CI_START="-1.0233925591313633" EFFECT_SIZE="-0.6743978977722658" ESTIMABLE="YES" MEAN_1="1.12" MEAN_2="1.55" MODIFIED="2010-09-14 10:36:48 +0100" MODIFIED_BY="[Empty name]" ORDER="116" SD_1="0.61" SD_2="0.66" SE="0.17806177262027403" STUDY_ID="STD-Bateman-2009" TOTAL_1="71" TOTAL_2="63" WEIGHT="100.0">
<FOOTNOTE>SCL-90-R-GSI</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4608570065173434" CI_START="-0.3081950302983183" DF="0" EFFECT_SIZE="0.07633098810951253" ESTIMABLE="YES" I2="0.0" ID="CMP-001.16.05" MODIFIED="2012-01-06 12:24:30 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.6972273484610938" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="52" WEIGHT="100.0" Z="0.3890659680675407">
<NAME>TFP vs. CTBE</NAME>
<CONT_DATA CI_END="0.4608570065173434" CI_START="-0.3081950302983183" EFFECT_SIZE="0.07633098810951253" ESTIMABLE="YES" MEAN_1="1.33" MEAN_2="1.27" MODIFIED="2010-09-14 10:36:48 +0100" MODIFIED_BY="[Empty name]" ORDER="117" SD_1="0.8" SD_2="0.76" SE="0.19619034912933248" STUDY_ID="STD-Doering-2010" TOTAL_1="52" TOTAL_2="52" WEIGHT="100.0">
<FOOTNOTE>BSI-GSI</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3621256994930012" CI_START="-0.42686998844943225" DF="0" EFFECT_SIZE="-0.03237214447821549" ESTIMABLE="YES" I2="0.0" ID="CMP-001.16.06" MODIFIED="2012-01-06 12:24:28 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.8722250021855702" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="47" WEIGHT="100.0" Z="0.1608329126489696">
<NAME>CBT vs. TAU</NAME>
<CONT_DATA CI_END="0.3621256994930012" CI_START="-0.42686998844943225" EFFECT_SIZE="-0.03237214447821549" ESTIMABLE="YES" MEAN_1="1.97" MEAN_2="2.0" MODIFIED="2010-09-14 10:36:48 +0100" MODIFIED_BY="[Empty name]" ORDER="119" SD_1="0.91" SD_2="0.93" SE="0.20127810872187724" STUDY_ID="STD-Davidson-2006" TOTAL_1="52" TOTAL_2="47" WEIGHT="100.0">
<FOOTNOTE>BSI-GSI</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.914367763820088" CI_END="0.48732080583930015" CI_START="0.11785046999940108" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.3025856379193506" ESTIMABLE="YES" I2="32.692927205094236" I2_Q="29.92789436848489" ID="CMP-001.17" MODIFIED="2012-07-06 17:20:20 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.17845161068908355" P_Q="0.21075609166518472" P_Z="0.001325924026715762" Q="7.135506996597569" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.030322159268836437" TOTALS="SUB" TOTAL_1="246" TOTAL_2="241" UNITS="" WEIGHT="600.0" Z="3.21030889374562">
<NAME>Mental health status/functioning</NAME>
<GROUP_LABEL_1>Active</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours experimental</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.4325624425998083" CI_END="1.24199147053825" CI_START="0.06695526991054535" DF="1" EFFECT_SIZE="0.6544733702243977" ESTIMABLE="YES" I2="30.195014872426487" ID="CMP-001.17.01" MODIFIED="2010-09-15 10:24:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.23134696095651142" P_Z="0.02901172466872796" STUDIES="2" TAU2="0.057508850005117414" TOTAL_1="33" TOTAL_2="41" WEIGHT="100.0" Z="2.183327175443831">
<NAME>DBT vs. TAU</NAME>
<CONT_DATA CI_END="0.9996384041144061" CI_START="-0.16127144726352316" EFFECT_SIZE="0.41918347842544146" ESTIMABLE="YES" MEAN_1="-8.15" MEAN_2="-13.07" MODIFIED="2010-09-15 10:24:35 +0100" MODIFIED_BY="[Empty name]" ORDER="121" SD_1="11.48" SD_2="11.59" SE="0.2961559142247097" STUDY_ID="STD-Carter-2010" TOTAL_1="20" TOTAL_2="28" WEIGHT="61.876869606741266">
<FOOTNOTE>BDQ-days out of role; mean scores multiplied by (-1)</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="1.8637188606298731" CI_START="0.2090162573443276" EFFECT_SIZE="1.0363675589871004" ESTIMABLE="YES" MEAN_1="51.42" MEAN_2="40.43" MODIFIED="2010-09-14 10:36:55 +0100" MODIFIED_BY="[Empty name]" ORDER="120" SD_1="9.71" SD_2="10.8" SE="0.4221257677022712" STUDY_ID="STD-Linehan-1994" TOTAL_1="13" TOTAL_2="13" WEIGHT="38.123130393258734">
<FOOTNOTE>GAS</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8915820997208854" CI_START="0.20025903634293396" DF="0" EFFECT_SIZE="0.5459205680319097" ESTIMABLE="YES" I2="0.0" ID="CMP-001.17.02" MODIFIED="2010-09-14 10:36:55 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.0019650172861979524" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="63" WEIGHT="100.0" Z="3.0954692775155483">
<NAME>MBT-outpatient vs. TAU</NAME>
<CONT_DATA CI_END="0.8915820997208854" CI_START="0.20025903634293396" EFFECT_SIZE="0.5459205680319097" ESTIMABLE="YES" MEAN_1="60.9" MEAN_2="53.2" MODIFIED="2010-09-14 10:36:55 +0100" MODIFIED_BY="[Empty name]" ORDER="122" SD_1="15.8" SD_2="11.7" SE="0.17636116500890311" STUDY_ID="STD-Bateman-2009" TOTAL_1="71" TOTAL_2="63" WEIGHT="100.0">
<FOOTNOTE>GAF</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.893443978802201E-32" CI_END="0.7270711400630374" CI_START="-0.04743533925655624" DF="0" EFFECT_SIZE="0.33981790040324056" ESTIMABLE="YES" I2="100.0" ID="CMP-001.17.03" MODIFIED="2010-09-14 10:36:55 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.08545343779592736" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="52" WEIGHT="100.0" Z="1.7198845042006128">
<NAME>TFP vs. CTBE</NAME>
<CONT_DATA CI_END="0.7270711400630374" CI_START="-0.04743533925655624" EFFECT_SIZE="0.33981790040324056" ESTIMABLE="YES" MEAN_1="58.62" MEAN_2="56.06" MODIFIED="2010-09-14 10:36:55 +0100" MODIFIED_BY="[Empty name]" ORDER="123" SD_1="8.04" SD_2="6.87" SE="0.1975818141120964" STUDY_ID="STD-Doering-2010" TOTAL_1="52" TOTAL_2="52" WEIGHT="100.0">
<FOOTNOTE>GAF</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.39447100589019085" CI_START="-0.39447100589019085" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.17.04" MODIFIED="2012-01-06 12:14:02 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="47" WEIGHT="99.99999999999999" Z="0.0">
<NAME>CBT vs. TAU</NAME>
<CONT_DATA CI_END="0.39447100589019085" CI_START="-0.39447100589019085" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-13.1" MEAN_2="-13.1" MODIFIED="2010-09-15 10:23:07 +0100" MODIFIED_BY="[Empty name]" ORDER="125" SD_1="4.4" SD_2="4.6" SE="0.2012644155717798" STUDY_ID="STD-Davidson-2006" TOTAL_1="52" TOTAL_2="47" WEIGHT="99.99999999999999">
<FOOTNOTE>SFQ; mean scores multiplied by (-1)</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8145813730538982" CI_START="-0.5727657560396429" DF="0" EFFECT_SIZE="0.12090780850712766" ESTIMABLE="YES" I2="0.0" ID="CMP-001.17.05" MODIFIED="2012-01-06 12:14:02 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.7326345116171598" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.34162315278436406">
<NAME>IPT vs. CM</NAME>
<CONT_DATA CI_END="0.8145813730538982" CI_START="-0.5727657560396429" EFFECT_SIZE="0.12090780850712766" ESTIMABLE="YES" MEAN_1="-2.9" MEAN_2="-3.0" MODIFIED="2010-09-15 10:24:08 +0100" MODIFIED_BY="[Empty name]" ORDER="126" SD_1="0.9" SD_2="0.7" SE="0.35392158734465484" STUDY_ID="STD-Bellino-2006" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0">
<FOOTNOTE>CGI-S; mean scores multiplied by (-1)</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5505237184289764" CI_START="-0.6315120686405098" DF="0" EFFECT_SIZE="-0.040494175105766715" ESTIMABLE="YES" I2="0.0" ID="CMP-001.17.06" MODIFIED="2012-01-06 12:14:02 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.8931741543846479" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0" Z="0.1342888695235343">
<NAME>IPT-BPD+fluoxetine vs. CM+fluoxetine</NAME>
<CONT_DATA CI_END="0.5505237184289764" CI_START="-0.6315120686405098" EFFECT_SIZE="-0.040494175105766715" ESTIMABLE="YES" MEAN_1="-4.37" MEAN_2="-4.35" MODIFIED="2010-10-13 10:02:07 +0100" MODIFIED_BY="[Empty name]" ORDER="154" SD_1="0.49" SD_2="0.48" SE="0.3015452825646883" STUDY_ID="STD-Bellino-2010" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0">
<FOOTNOTE>CGI-S; mean scores multiplied by (-1)</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="31.89352588290571" CI_END="0.8999569710715338" CI_START="0.6108939519063572" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7414703437114424" ESTIMABLE="YES" EVENTS_1="158" EVENTS_2="190" I2="56.103943943357734" I2_Q="39.19714065563181" ID="CMP-001.18" LOG_CI_END="-0.0457782546417048" LOG_CI_START="-0.2140341745351987" LOG_EFFECT_SIZE="-0.12990621458845175" METHOD="MH" MODIFIED="2012-07-04 16:14:51 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.004147998606782832" P_Q="0.0875420217218218" P_Z="0.002474200275117882" Q="16.44659495923236" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.15728348129862155" TOTALS="SUB" TOTAL_1="545" TOTAL_2="532" WEIGHT="1100.0" Z="3.0264789746769853">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="17.3584592717932" CI_END="2.9213922397731187" CI_START="0.5372190865414666" DF="4" EFFECT_SIZE="1.252768003454847" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="45" I2="76.95648019579802" ID="CMP-001.18.01" LOG_CI_END="0.4655898712949144" LOG_CI_START="-0.26984856593559126" LOG_EFFECT_SIZE="0.09787065267966154" MODIFIED="2011-11-02 15:43:33 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0016462666451049213" P_Z="0.6019098338405509" STUDIES="5" TAU2="0.6420972724410988" TOTAL_1="125" TOTAL_2="127" WEIGHT="99.99999999999999" Z="0.5216560481062887">
<NAME>DBT vs. TAU</NAME>
<DICH_DATA CI_END="11.057736668419652" CI_START="1.5535587440209737" EFFECT_SIZE="4.144736842105263" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="4" LOG_CI_END="1.0436662433334116" LOG_CI_START="0.19132767968420655" LOG_EFFECT_SIZE="0.6174969615088092" MODIFIED="2011-11-02 15:42:11 +0000" MODIFIED_BY="[Empty name]" ORDER="127" O_E="0.0" SE="0.5006678914314786" STUDY_ID="STD-Carter-2010" TOTAL_1="38" TOTAL_2="35" VAR="0.2506683375104428" WEIGHT="20.904048291155153">
<FOOTNOTE>non-completers (6 months treatment or waiting list, resp.); 3 more had been randomised but withdrew consent (N=2) or died (N=1), allocation of those unclear</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.3534207401180782" CI_START="0.2036567166499752" EFFECT_SIZE="0.6923076923076923" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.37169957646501317" LOG_CI_START="-0.691101262200037" LOG_EFFECT_SIZE="-0.1597008428675119" MODIFIED="2011-11-02 15:42:15 +0000" MODIFIED_BY="[Empty name]" ORDER="128" O_E="0.0" SE="0.6242944735808493" STUDY_ID="STD-Koons-2001" TOTAL_1="13" TOTAL_2="15" VAR="0.38974358974358975" WEIGHT="18.08652487709799">
<FOOTNOTE>lost after randomisation</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.4249689128561243" CI_START="0.5436128121508148" EFFECT_SIZE="1.1481481481481481" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.3847061754902076" LOG_CI_START="-0.26471031613963686" LOG_EFFECT_SIZE="0.05999792967528537" MODIFIED="2011-11-02 15:42:18 +0000" MODIFIED_BY="[Empty name]" ORDER="129" O_E="0.0" SE="0.38147046184684963" STUDY_ID="STD-Linehan-1991" TOTAL_1="30" TOTAL_2="31" VAR="0.14551971326164875" WEIGHT="23.694785361260536">
<FOOTNOTE>lost after randomisation or quit after attending less than four therapy session (N=2)</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="25.209362482671366" CI_START="0.3570102181753505" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4015618629807383" LOG_CI_START="-0.4473193535414135" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-11-02 15:42:21 +0000" MODIFIED_BY="[Empty name]" ORDER="130" O_E="0.0" SE="1.086041978694737" STUDY_ID="STD-Linehan-1994" TOTAL_1="13" TOTAL_2="13" VAR="1.1794871794871795" WEIGHT="10.245155201755317">
<FOOTNOTE>treatment non-completers</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.8779864437764664" CI_START="0.37421919233030965" EFFECT_SIZE="0.5732009925558312" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="26" LOG_CI_END="-0.05651218960474813" LOG_CI_START="-0.4268739428931822" LOG_EFFECT_SIZE="-0.24169306624896517" MODIFIED="2011-11-02 15:43:33 +0000" MODIFIED_BY="[Empty name]" ORDER="131" O_E="0.0" SE="0.2175523272018724" STUDY_ID="STD-Van-den-Bosch-2005" TOTAL_1="31" TOTAL_2="33" VAR="0.04732901507095055" WEIGHT="27.069486268730998">
<FOOTNOTE>not-continuing therapy throughout the whole year</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4912697309934004" CI_START="0.710594843636351" DF="0" EFFECT_SIZE="1.0294117647058822" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="34" I2="0.0" ID="CMP-001.18.02" LOG_CI_END="0.17355620286774776" LOG_CI_START="-0.1483779482517069" LOG_EFFECT_SIZE="0.012589127308020467" MODIFIED="2010-09-14 15:08:43 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8781715797006345" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="90" WEIGHT="100.0" Z="0.15328747220331">
<NAME>DBT vs. general management</NAME>
<DICH_DATA CI_END="1.4912697309934004" CI_START="0.710594843636351" EFFECT_SIZE="1.0294117647058822" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="34" LOG_CI_END="0.17355620286774776" LOG_CI_START="-0.1483779482517069" LOG_EFFECT_SIZE="0.012589127308020467" MODIFIED="2010-09-14 15:08:43 +0100" MODIFIED_BY="[Empty name]" ORDER="132" O_E="0.0" SE="0.18910571396731696" STUDY_ID="STD-McMain-2009" TOTAL_1="90" TOTAL_2="90" VAR="0.0357609710550887" WEIGHT="100.0">
<FOOTNOTE>disontinued intervention</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6718717884284038" CI_START="0.27618681625488245" DF="0" EFFECT_SIZE="0.4307692307692308" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="35" I2="0.0" ID="CMP-001.18.03" LOG_CI_END="-0.17271359434276537" LOG_CI_START="-0.5587970562585073" LOG_EFFECT_SIZE="-0.3657553253006363" MODIFIED="2010-09-14 15:12:13 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="2.0438401450706214E-4" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="49" WEIGHT="100.0" Z="3.713535209127536">
<NAME>DBT vs. CTBE</NAME>
<DICH_DATA CI_END="0.6718717884284038" CI_START="0.27618681625488245" EFFECT_SIZE="0.4307692307692308" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="35" LOG_CI_END="-0.17271359434276537" LOG_CI_START="-0.5587970562585073" LOG_EFFECT_SIZE="-0.3657553253006363" MODIFIED="2010-09-14 15:12:13 +0100" MODIFIED_BY="[Empty name]" ORDER="133" O_E="0.0" SE="0.2267873366732658" STUDY_ID="STD-Linehan-2006" TOTAL_1="52" TOTAL_2="49" VAR="0.05143249607535322" WEIGHT="100.0">
<FOOTNOTE>lost to follow-up or discontinued intervention (population: those randomised exclusive of training cases)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.573072225273833" CI_START="0.44101625393807997" DF="0" EFFECT_SIZE="1.9444444444444444" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-001.18.04" LOG_CI_END="0.9331364825282916" LOG_CI_START="-0.35554540403435236" LOG_EFFECT_SIZE="0.28879553924696955" MODIFIED="2012-01-06 12:24:57 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.3796932100315594" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="14" WEIGHT="100.0" Z="0.8784617239087251">
<NAME>DBT-PTSD vs. WL</NAME>
<DICH_DATA CI_END="8.573072225273833" CI_START="0.44101625393807997" EFFECT_SIZE="1.9444444444444444" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.9331364825282916" LOG_CI_START="-0.35554540403435236" LOG_EFFECT_SIZE="0.28879553924696955" MODIFIED="2010-10-19 13:46:33 +0100" MODIFIED_BY="[Empty name]" ORDER="160" O_E="0.0" SE="0.7569781192451159" STUDY_ID="STD-Steil-2010" TOTAL_1="18" TOTAL_2="14" VAR="0.573015873015873" WEIGHT="100.0">
<FOOTNOTE>received allocated intervention but discontinued participation</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.424666979658183" CI_START="0.22600570949121523" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-001.18.05" LOG_CI_END="0.6458805893074292" LOG_CI_START="-0.6458805893074291" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-01-06 12:24:57 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0" Z="0.0">
<NAME>MBT-PH vs. TAU</NAME>
<DICH_DATA CI_END="4.424666979658183" CI_START="0.22600570949121523" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6458805893074292" LOG_CI_START="-0.6458805893074291" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-09-14 15:16:26 +0100" MODIFIED_BY="[Empty name]" ORDER="134" O_E="0.0" SE="0.7587869106393281" STUDY_ID="STD-Bateman-1999" TOTAL_1="22" TOTAL_2="22" VAR="0.5757575757575758" WEIGHT="100.0">
<FOOTNOTE>dropped out of tratment (population: those randomised)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8669622577794127" CI_START="0.5946974819889955" DF="0" EFFECT_SIZE="1.0536971830985915" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" I2="0.0" ID="CMP-001.18.06" LOG_CI_END="0.27113553840766635" LOG_CI_START="-0.2257039003448452" LOG_EFFECT_SIZE="0.02271581903141058" MODIFIED="2012-01-06 12:24:55 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.8577636800136057" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="63" WEIGHT="100.0" Z="0.17922163060437687">
<NAME>MBT-out vs. TAU</NAME>
<DICH_DATA CI_END="1.8669622577794127" CI_START="0.5946974819889955" EFFECT_SIZE="1.0536971830985915" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" LOG_CI_END="0.27113553840766635" LOG_CI_START="-0.2257039003448452" LOG_EFFECT_SIZE="0.02271581903141058" MODIFIED="2010-09-14 15:18:51 +0100" MODIFIED_BY="[Empty name]" ORDER="135" O_E="0.0" SE="0.29184594571811173" STUDY_ID="STD-Bateman-2009" TOTAL_1="71" TOTAL_2="63" VAR="0.08517405603209903" WEIGHT="100.0">
<FOOTNOTE>non-completers (population: those randomised)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8461277646853669" CI_START="0.38591170964153215" DF="0" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="35" I2="0.0" ID="CMP-001.18.07" LOG_CI_END="-0.07256405385419173" LOG_CI_START="-0.41351204351839715" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2012-01-06 12:24:53 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.005202131938779685" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="52" WEIGHT="100.0" Z="2.7942433258936377">
<NAME>TFP vs. CTBE</NAME>
<DICH_DATA CI_END="0.8461277646853669" CI_START="0.38591170964153215" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="35" LOG_CI_END="-0.07256405385419173" LOG_CI_START="-0.41351204351839715" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2010-09-14 15:21:18 +0100" MODIFIED_BY="[Empty name]" ORDER="136" O_E="0.0" SE="0.20027453684852228" STUDY_ID="STD-Doering-2010" TOTAL_1="52" TOTAL_2="52" VAR="0.040109890109890106" WEIGHT="100.0">
<FOOTNOTE>lost after randomisation or quit treatment (population: those randomised)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.51739103704025" CI_START="0.09208915643163769" DF="0" EFFECT_SIZE="0.48148148148148145" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-001.18.08" LOG_CI_END="0.4009506815945607" LOG_CI_START="-1.0357915052988618" LOG_EFFECT_SIZE="-0.3174204118521506" MODIFIED="2012-01-06 12:24:51 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.3864724543436666" STUDIES="1" TAU2="0.0" TOTAL_1="54" TOTAL_2="52" WEIGHT="100.0" Z="0.866032306788853">
<NAME>CBT vs. TAU</NAME>
<DICH_DATA CI_END="2.51739103704025" CI_START="0.09208915643163769" EFFECT_SIZE="0.48148148148148145" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4009506815945607" LOG_CI_START="-1.0357915052988618" LOG_EFFECT_SIZE="-0.3174204118521506" MODIFIED="2010-09-14 15:29:54 +0100" MODIFIED_BY="[Empty name]" ORDER="138" O_E="0.0" SE="0.8439494725697222" STUDY_ID="STD-Davidson-2006" TOTAL_1="54" TOTAL_2="52" VAR="0.7122507122507122" WEIGHT="100.0">
<FOOTNOTE>lost to 12-months assessment (population: those randomised)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1477719307179903" CI_START="0.32333248913086166" DF="0" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="0.0" ID="CMP-001.18.09" LOG_CI_END="0.3319881622745195" LOG_CI_START="-0.4903506543697692" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2012-01-06 12:24:49 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Z="0.7058455457863808" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.3774414812075672">
<NAME>DDP vs. TAU</NAME>
<DICH_DATA CI_END="2.1477719307179903" CI_START="0.32333248913086166" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.3319881622745195" LOG_CI_START="-0.4903506543697692" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2010-09-14 15:32:43 +0100" MODIFIED_BY="[Empty name]" ORDER="139" O_E="0.0" SE="0.483045891539648" STUDY_ID="STD-Gregory-2008" TOTAL_1="15" TOTAL_2="15" VAR="0.2333333333333334" WEIGHT="100.0">
<FOOTNOTE>lost to follow-up or quit treatment (population: those randomised)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.072545463810684" CI_START="0.20285092780626948" DF="0" EFFECT_SIZE="0.7894736842105263" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-001.18.10" LOG_CI_END="0.48749831777037994" LOG_CI_START="-0.6928230015646754" LOG_EFFECT_SIZE="-0.10266234189714771" MODIFIED="2012-01-06 12:24:47 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Z="0.7331422239496824" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="20" WEIGHT="100.0" Z="0.34094867116405725">
<NAME>IPT vs. CM</NAME>
<DICH_DATA CI_END="3.072545463810684" CI_START="0.20285092780626948" EFFECT_SIZE="0.7894736842105263" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.48749831777037994" LOG_CI_START="-0.6928230015646754" LOG_EFFECT_SIZE="-0.10266234189714771" MODIFIED="2010-09-14 15:36:01 +0100" MODIFIED_BY="[Empty name]" ORDER="140" O_E="0.0" SE="0.6933265856621719" STUDY_ID="STD-Bellino-2006" TOTAL_1="19" TOTAL_2="20" VAR="0.4807017543859649" WEIGHT="100.0">
<FOOTNOTE>discontinued treatment due to noncompliance (population: those randomised)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5655219816465042" CI_START="0.07632852235687478" DF="0" EFFECT_SIZE="0.345679012345679" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" I2="0.0" ID="CMP-001.18.11" LOG_CI_END="0.19465916996683244" LOG_CI_START="-1.1173131450396936" LOG_EFFECT_SIZE="-0.46132698753643053" MODIFIED="2012-01-06 12:24:46 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Z="0.16809254287701686" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="28" WEIGHT="100.0" Z="1.378358781394354">
<NAME>IPT-BPD+fluoxetine vs. CM+fluoxetine</NAME>
<DICH_DATA CI_END="1.5655219816465042" CI_START="0.07632852235687478" EFFECT_SIZE="0.345679012345679" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.19465916996683244" LOG_CI_START="-1.1173131450396936" LOG_EFFECT_SIZE="-0.46132698753643053" MODIFIED="2010-10-13 10:04:59 +0100" MODIFIED_BY="[Empty name]" ORDER="155" O_E="0.0" SE="0.7706590322025324" STUDY_ID="STD-Bellino-2010" TOTAL_1="27" TOTAL_2="28" VAR="0.5939153439153438" WEIGHT="100.0">
<FOOTNOTE>discontinued treatment due to noncompliance (population: those randomised)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="22.548714354129366" CI_END="1.4235777550639732" CI_START="0.5777440061674168" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.906897742472368" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="86" I2="64.52125884270225" I2_Q="0.0" ID="CMP-001.19" LOG_CI_END="0.15338119306568934" LOG_CI_START="-0.23826455143417408" LOG_EFFECT_SIZE="-0.04244167918424239" METHOD="MH" MODIFIED="2012-07-04 16:15:05 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.003994646529036694" P_Q="0.3769213157612056" P_Z="0.6709876667828416" Q="0.7807192030859382" RANDOM="YES" SCALE="10.0" SORT_BY="EFFECT_SIZE" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.28203279614520443" TOTALS="SUB" TOTAL_1="212" TOTAL_2="219" WEIGHT="200.0" Z="0.4247928839402843">
<NAME>Leaving the study early: sensitivity analysis (non-rural areas only)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="17.358459271793198" CI_END="2.921392239773118" CI_START="0.5372190865414666" DF="4" EFFECT_SIZE="1.252768003454847" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="45" I2="76.95648019579802" ID="CMP-001.19.01" LOG_CI_END="0.4655898712949143" LOG_CI_START="-0.26984856593559126" LOG_EFFECT_SIZE="0.09787065267966154" MODIFIED="2012-02-01 15:12:57 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0016462666451048102" P_Z="0.6019098338405509" STUDIES="5" TAU2="0.6420972724410984" TOTAL_1="125" TOTAL_2="127" WEIGHT="100.0" Z="0.5216560481062887">
<NAME>DBT vs. TAU</NAME>
<DICH_DATA CI_END="0.8779864437764664" CI_START="0.37421919233030965" EFFECT_SIZE="0.5732009925558312" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="26" LOG_CI_END="-0.05651218960474813" LOG_CI_START="-0.4268739428931822" LOG_EFFECT_SIZE="-0.24169306624896517" MODIFIED="2011-11-04 14:33:18 +0000" MODIFIED_BY="[Empty name]" ORDER="215" O_E="0.0" SE="0.2175523272018724" STUDY_ID="STD-Van-den-Bosch-2005" TOTAL_1="31" TOTAL_2="33" VAR="0.04732901507095055" WEIGHT="27.069486268731005">
<FOOTNOTE>not-continuing therapy throughout the whole year</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.3534207401180782" CI_START="0.2036567166499752" EFFECT_SIZE="0.6923076923076923" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.37169957646501317" LOG_CI_START="-0.691101262200037" LOG_EFFECT_SIZE="-0.1597008428675119" MODIFIED="2011-11-04 14:33:18 +0000" MODIFIED_BY="[Empty name]" ORDER="212" O_E="0.0" SE="0.6242944735808493" STUDY_ID="STD-Koons-2001" TOTAL_1="13" TOTAL_2="15" VAR="0.38974358974358975" WEIGHT="18.08652487709799">
<FOOTNOTE>lost after randomisation</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.4249689128561243" CI_START="0.5436128121508148" EFFECT_SIZE="1.1481481481481481" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.3847061754902076" LOG_CI_START="-0.26471031613963686" LOG_EFFECT_SIZE="0.05999792967528537" MODIFIED="2011-11-04 14:33:18 +0000" MODIFIED_BY="[Empty name]" ORDER="216" O_E="0.0" SE="0.38147046184684963" STUDY_ID="STD-Linehan-1991" TOTAL_1="30" TOTAL_2="31" VAR="0.14551971326164875" WEIGHT="23.694785361260536">
<FOOTNOTE>lost after randomisation or quit after attending less than four therapy session (N=2)</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="25.209362482671366" CI_START="0.3570102181753505" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4015618629807383" LOG_CI_START="-0.4473193535414135" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-11-04 14:33:18 +0000" MODIFIED_BY="[Empty name]" ORDER="213" O_E="0.0" SE="1.086041978694737" STUDY_ID="STD-Linehan-1994" TOTAL_1="13" TOTAL_2="13" VAR="1.1794871794871795" WEIGHT="10.245155201755313">
<FOOTNOTE>treatment non-completers</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="11.057736668419652" CI_START="1.5535587440209737" EFFECT_SIZE="4.144736842105263" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="4" LOG_CI_END="1.0436662433334116" LOG_CI_START="0.19132767968420655" LOG_EFFECT_SIZE="0.6174969615088092" MODIFIED="2012-02-01 15:12:57 +0000" MODIFIED_BY="[Empty name]" ORDER="214" O_E="0.0" SE="0.5006678914314786" STUDY_ID="STD-Carter-2010" TOTAL_1="38" TOTAL_2="35" VAR="0.2506683375104428" WEIGHT="20.90404829115515">
<FOOTNOTE>non-completers (6 months treatment or waiting list, resp.); 3 more had been randomised but withdrew consent (N=2) or died (N=1), allocation of those unclear</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.581086908412937" CI_END="1.3594792913954628" CI_START="0.4684443001703264" DF="3" EFFECT_SIZE="0.798022759859516" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="41" I2="34.513357638104395" ID="CMP-001.19.02" LOG_CI_END="0.13337259647579774" LOG_CI_START="-0.32934204099127845" LOG_EFFECT_SIZE="-0.09798472225774038" MODIFIED="2012-01-15 22:45:32 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.20517061733610764" P_Z="0.40649003461289046" STUDIES="4" TAU2="0.1022184341979228" TOTAL_1="87" TOTAL_2="92" WEIGHT="99.99999999999999" Z="0.8300862393790004">
<NAME>DBT vs. TAU: non-rural areas only</NAME>
<DICH_DATA CI_END="0.8779864437764664" CI_START="0.37421919233030965" EFFECT_SIZE="0.5732009925558312" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="26" LOG_CI_END="-0.05651218960474813" LOG_CI_START="-0.4268739428931822" LOG_EFFECT_SIZE="-0.24169306624896517" MODIFIED="2011-11-02 15:31:42 +0000" MODIFIED_BY="[Empty name]" ORDER="207" O_E="0.0" SE="0.2175523272018724" STUDY_ID="STD-Van-den-Bosch-2005" TOTAL_1="31" TOTAL_2="33" VAR="0.04732901507095055" WEIGHT="49.3995133255625">
<FOOTNOTE>not-continuing therapy throughout the whole year</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.3534207401180782" CI_START="0.2036567166499752" EFFECT_SIZE="0.6923076923076923" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.37169957646501317" LOG_CI_START="-0.691101262200037" LOG_EFFECT_SIZE="-0.1597008428675119" MODIFIED="2011-11-02 15:31:42 +0000" MODIFIED_BY="[Empty name]" ORDER="211" O_E="0.0" SE="0.6242944735808493" STUDY_ID="STD-Koons-2001" TOTAL_1="13" TOTAL_2="15" VAR="0.38974358974358975" WEIGHT="15.016547728163406">
<FOOTNOTE>lost after randomisation</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.4249689128561243" CI_START="0.5436128121508148" EFFECT_SIZE="1.1481481481481481" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.3847061754902076" LOG_CI_START="-0.26471031613963686" LOG_EFFECT_SIZE="0.05999792967528537" MODIFIED="2011-11-02 15:31:42 +0000" MODIFIED_BY="[Empty name]" ORDER="208" O_E="0.0" SE="0.38147046184684963" STUDY_ID="STD-Linehan-1991" TOTAL_1="30" TOTAL_2="31" VAR="0.14551971326164875" WEIGHT="29.820079340696495">
<FOOTNOTE>lost after randomisation or quit after attending less than four therapy session (N=2)</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="25.209362482671366" CI_START="0.3570102181753505" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4015618629807383" LOG_CI_START="-0.4473193535414135" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-11-02 15:31:42 +0000" MODIFIED_BY="[Empty name]" ORDER="210" O_E="0.0" SE="1.086041978694737" STUDY_ID="STD-Linehan-1994" TOTAL_1="13" TOTAL_2="13" VAR="1.1794871794871795" WEIGHT="5.7638596055775855">
<FOOTNOTE>treatment non-completers</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2012-07-11 11:35:42 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Non-comprehensive psychotherapeutic interventions: active vs. control conditions</NAME>
<CONT_OUTCOME CHI2="14.318097354030932" CI_END="-0.33605158015072123" CI_START="-0.8188414833428354" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.5774465317467783" ESTIMABLE="YES" I2="72.06332726272538" I2_Q="72.06332726272537" ID="CMP-002.01" MODIFIED="2012-01-06 12:09:22 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.006346071728895009" P_Q="0.00634607172889512" P_Z="2.752473660064496E-6" Q="14.318097354030934" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.2248349855239632" TOTALS="SUB" TOTAL_1="148" TOTAL_2="137" UNITS="" WEIGHT="500.0" Z="4.688475868025306">
<NAME>BPD total severity</NAME>
<GROUP_LABEL_1>active</GROUP_LABEL_1>
<GROUP_LABEL_2>control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.4650152427375531" CI_START="-1.5531976910686518" DF="0" EFFECT_SIZE="-1.0091064669031025" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.01" MODIFIED="2010-09-03 12:40:21 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="2.7789992557644E-4" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="30" WEIGHT="100.0" Z="3.635074862179282">
<NAME>DBT-ST vs. standard group</NAME>
<CONT_DATA CI_END="-0.4650152427375531" CI_START="-1.5531976910686518" EFFECT_SIZE="-1.0091064669031025" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="4.44" MODIFIED="2010-09-03 12:40:21 +0100" MODIFIED_BY="[Empty name]" ORDER="54" SD_1="1.2" SD_2="0.52" SE="0.2776026643638717" STUDY_ID="STD-Soler-2009" TOTAL_1="29" TOTAL_2="30" WEIGHT="100.0">
<FOOTNOTE>CGI-BPD-global</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.11349396935251344" CI_START="-1.9179187459151685" DF="0" EFFECT_SIZE="-1.015706357633841" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.02" MODIFIED="2010-09-03 13:02:18 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.027347750925402495" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="10" WEIGHT="99.99999999999999" Z="2.2065180058355995">
<NAME>ERG vs. TAU</NAME>
<CONT_DATA CI_END="-0.11349396935251344" CI_START="-1.9179187459151685" EFFECT_SIZE="-1.015706357633841" ESTIMABLE="YES" MEAN_1="25.83" MEAN_2="34.7" MODIFIED="2010-09-03 13:02:18 +0100" MODIFIED_BY="[Empty name]" ORDER="66" SD_1="5.72" SD_2="10.81" SE="0.4603209015052642" STUDY_ID="STD-Gratz-2006" TOTAL_1="12" TOTAL_2="10" WEIGHT="99.99999999999999">
<FOOTNOTE>BEST</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.7767681935177131" CI_START="-2.543359832713529" DF="0" EFFECT_SIZE="-1.660064013115621" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.03" MODIFIED="2012-01-06 12:09:22 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="2.3000675069181082E-4" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="12" WEIGHT="100.0" Z="3.6835515413384075">
<NAME>SFT-G vs. TAU</NAME>
<CONT_DATA CI_END="-0.7767681935177131" CI_START="-2.543359832713529" EFFECT_SIZE="-1.660064013115621" ESTIMABLE="YES" MEAN_1="18.81" MEAN_2="32.75" MODIFIED="2012-01-06 12:09:16 +0000" MODIFIED_BY="[Empty name]" ORDER="98" SD_1="9.47" SD_2="5.9" SE="0.45066941360414403" STUDY_ID="STD-Farrell-2009" TOTAL_1="16" TOTAL_2="12" WEIGHT="100.0">
<FOOTNOTE>Borderline Syndrome Index</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.1869604854050225" CI_START="-0.5191562218084875" DF="0" EFFECT_SIZE="-0.16609786820173253" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.04" MODIFIED="2012-01-06 12:09:22 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.35649011962432864" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="59" WEIGHT="100.0" Z="0.9220737485987298">
<NAME>STEPPS vs. TAU</NAME>
<CONT_DATA CI_END="0.1869604854050225" CI_START="-0.5191562218084875" EFFECT_SIZE="-0.16609786820173253" ESTIMABLE="YES" MEAN_1="31.8" MEAN_2="34.1" MODIFIED="2011-08-16 16:22:03 +0100" MODIFIED_BY="[Empty name]" ORDER="91" SD_1="13.7" SD_2="13.83" SE="0.18013512308982932" STUDY_ID="STD-Blum-2008" TOTAL_1="65" TOTAL_2="59" WEIGHT="100.0">
<FOOTNOTE>BEST</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.003099930547677543" CI_START="-1.1062337422045392" DF="0" EFFECT_SIZE="-0.5515669058284308" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.05" MODIFIED="2012-01-06 12:09:20 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.05129421765612747" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="99.99999999999999" Z="1.9490101076727815">
<NAME>STEPPS+IT vs. TAU</NAME>
<CONT_DATA CI_END="0.003099930547677543" CI_START="-1.1062337422045392" EFFECT_SIZE="-0.5515669058284308" ESTIMABLE="YES" MEAN_1="79.7" MEAN_2="95.1" MODIFIED="2010-09-06 11:39:14 +0100" MODIFIED_BY="[Empty name]" ORDER="99" SD_1="25.8" SD_2="29.1" SE="0.28299848402891564" STUDY_ID="STD-Bos-2010" TOTAL_1="26" TOTAL_2="26" WEIGHT="99.99999999999999">
<FOOTNOTE>BPD-40</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.3048671857717663" CI_START="-1.3726784372649328" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.8387728115183495" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2012-06-13 13:25:39 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.0020760649682474396" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="29" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="3.0791293863752456">
<NAME>Inappropriate anger</NAME>
<GROUP_LABEL_1>Active</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.3048671857717663" CI_START="-1.3726784372649328" DF="0" EFFECT_SIZE="-0.8387728115183495" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.01" MODIFIED="2011-08-16 16:22:44 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0020760649682474396" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="30" WEIGHT="100.0" Z="3.0791293863752456">
<NAME>DBT-ST vs. standard group</NAME>
<CONT_DATA CI_END="-0.3048671857717663" CI_START="-1.3726784372649328" EFFECT_SIZE="-0.8387728115183495" ESTIMABLE="YES" MEAN_1="3.11" MEAN_2="3.88" MODIFIED="2011-08-16 16:22:44 +0100" MODIFIED_BY="[Empty name]" ORDER="55" SD_1="1.02" SD_2="0.78" SE="0.2724058349836847" STUDY_ID="STD-Soler-2009" TOTAL_1="29" TOTAL_2="30" WEIGHT="100.0">
<FOOTNOTE>CGI-BPD-anger</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="12.427388760266478" CI_END="-0.4376551221168157" CI_START="-0.9784626993085468" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.7080589107126812" ESTIMABLE="YES" I2="75.85977184851767" I2_Q="75.85977184851767" ID="CMP-002.03" MODIFIED="2012-06-13 13:25:26 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.006053734232551178" P_Q="0.006053734232551178" P_Z="2.8635446949921653E-7" Q="12.427388760266478" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.30563587756791283" TOTALS="SUB" TOTAL_1="122" TOTAL_2="111" UNITS="" WEIGHT="400.0" Z="5.132213461711594">
<NAME>Affective instability</NAME>
<GROUP_LABEL_1>Active</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.5180348432216887" CI_START="-1.6137456497231604" DF="0" EFFECT_SIZE="-1.0658902464724245" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.01" MODIFIED="2010-09-03 12:44:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.3715441654694945E-4" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="30" WEIGHT="100.0" Z="3.8132443016216024">
<NAME>DBT-ST vs. standard group</NAME>
<CONT_DATA CI_END="-0.5180348432216887" CI_START="-1.6137456497231604" EFFECT_SIZE="-1.0658902464724245" ESTIMABLE="YES" MEAN_1="3.61" MEAN_2="4.66" MODIFIED="2010-09-03 12:44:01 +0100" MODIFIED_BY="[Empty name]" ORDER="56" SD_1="1.19" SD_2="0.7" SE="0.2795231991874082" STUDY_ID="STD-Soler-2009" TOTAL_1="29" TOTAL_2="30" WEIGHT="100.0">
<FOOTNOTE>CGI-BPD-affective instability</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.9061806019531556E-31" CI_END="-0.6526045962635613" CI_START="-2.6461966288359005" DF="0" EFFECT_SIZE="-1.649400612549731" ESTIMABLE="YES" I2="100.0" ID="CMP-002.03.02" MODIFIED="2011-08-16 16:24:52 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0011821312659542071" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="10" WEIGHT="100.0" Z="3.2431568183030177">
<NAME>ERG vs. TAU</NAME>
<CONT_DATA CI_END="-0.6526045962635613" CI_START="-2.6461966288359005" EFFECT_SIZE="-1.649400612549731" ESTIMABLE="YES" MEAN_1="79.75" MEAN_2="115.8" MODIFIED="2011-08-16 16:24:52 +0100" MODIFIED_BY="[Empty name]" ORDER="67" SD_1="23.97" SD_2="16.74" SE="0.5085787413180902" STUDY_ID="STD-Gratz-2006" TOTAL_1="12" TOTAL_2="10" WEIGHT="100.0">
<FOOTNOTE>DERS-emotion dysregulation</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.5653962813736472" CI_START="-2.2621930299620443" DF="0" EFFECT_SIZE="-1.4137946556678458" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.03" MODIFIED="2012-01-06 12:09:59 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.0010902490572983648" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="12" WEIGHT="99.99999999999999" Z="3.266138515351859">
<NAME>SFT-G vs. TAU</NAME>
<CONT_DATA CI_END="-0.5653962813736472" CI_START="-2.2621930299620443" EFFECT_SIZE="-1.4137946556678458" ESTIMABLE="YES" MEAN_1="5.88" MEAN_2="9.83" MODIFIED="2012-01-06 12:09:56 +0000" MODIFIED_BY="[Empty name]" ORDER="99" SD_1="3.44" SD_2="1.12" SE="0.4328642673978995" STUDY_ID="STD-Farrell-2009" TOTAL_1="16" TOTAL_2="12" WEIGHT="99.99999999999999">
<FOOTNOTE>DIB-R-affect</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.409573102747987E-32" CI_END="0.0391386072192344" CI_START="-0.6702322793146522" DF="0" EFFECT_SIZE="-0.3155468360477089" ESTIMABLE="YES" I2="99.99999999999999" ID="CMP-002.03.04" MODIFIED="2012-01-06 12:09:59 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.08121366496065706" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="59" WEIGHT="100.0" Z="1.7436871059396966">
<NAME>STEPPS vs. TAU</NAME>
<CONT_DATA CI_END="0.039138607219234456" CI_START="-0.6702322793146521" EFFECT_SIZE="-0.31554683604770883" ESTIMABLE="YES" MEAN_1="3.9" MEAN_2="4.9" MODIFIED="2010-09-06 11:20:59 +0100" MODIFIED_BY="[Empty name]" ORDER="92" SD_1="3.22" SD_2="3.07" SE="0.18096528613008034" STUDY_ID="STD-Blum-2008" TOTAL_1="65" TOTAL_2="59" WEIGHT="100.0">
<FOOTNOTE>ZAN-BPD-affective subscale</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0859330055547129" CI_START="-0.9474808917144315" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.43077394307985933" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2012-06-13 13:25:10 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.10225793226165866" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="29" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="1.6340043735543845">
<NAME>Chronic feelings of emptiness</NAME>
<GROUP_LABEL_1>Active</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0859330055547129" CI_START="-0.9474808917144315" DF="0" EFFECT_SIZE="-0.43077394307985933" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.01" MODIFIED="2010-09-03 12:46:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.10225793226165866" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="30" WEIGHT="100.0" Z="1.6340043735543845">
<NAME>DBT-ST vs. standard group</NAME>
<CONT_DATA CI_END="0.0859330055547129" CI_START="-0.9474808917144315" EFFECT_SIZE="-0.43077394307985933" ESTIMABLE="YES" MEAN_1="4.33" MEAN_2="5.0" MODIFIED="2010-09-03 12:46:10 +0100" MODIFIED_BY="[Empty name]" ORDER="57" SD_1="1.57" SD_2="1.5" SE="0.26363083847983465" STUDY_ID="STD-Soler-2009" TOTAL_1="29" TOTAL_2="30" WEIGHT="100.0">
<FOOTNOTE>CGI-BPD-emptiness</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="13.113335796499149" CI_END="-0.32764017502495846" CI_START="-0.8133086223826362" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.5704743987037973" ESTIMABLE="YES" I2="69.49670120498344" I2_Q="69.49670120498345" ID="CMP-002.05" MODIFIED="2012-06-13 13:25:00 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.010735120844411083" P_Q="0.010735120844410861" P_Z="4.136290922306871E-6" Q="13.113335796499154" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.20227094559619996" TOTALS="SUB" TOTAL_1="152" TOTAL_2="131" UNITS="" WEIGHT="500.0" Z="4.604413902713914">
<NAME>Impulsivity</NAME>
<GROUP_LABEL_1>Active</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.09104003787344439" CI_START="-1.1373125019941652" DF="0" EFFECT_SIZE="-0.6141762699338048" ESTIMABLE="YES" I2="0.0" ID="CMP-002.05.01" MODIFIED="2010-09-03 12:47:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.021388724836588838" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="30" WEIGHT="100.0" Z="2.301051419222891">
<NAME>DBT-ST vs. standard group</NAME>
<CONT_DATA CI_END="-0.09104003787344439" CI_START="-1.1373125019941652" EFFECT_SIZE="-0.6141762699338048" ESTIMABLE="YES" MEAN_1="3.61" MEAN_2="4.11" MODIFIED="2010-09-03 12:47:41 +0100" MODIFIED_BY="[Empty name]" ORDER="58" SD_1="0.97" SD_2="0.6" SE="0.26691114540205446" STUDY_ID="STD-Soler-2009" TOTAL_1="29" TOTAL_2="30" WEIGHT="100.0">
<FOOTNOTE>CGI-BPD-impulsivity</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.357957088382461" CI_START="-2.237756349492466" DF="0" EFFECT_SIZE="-1.2978567189374637" ESTIMABLE="YES" I2="0.0" ID="CMP-002.05.02" MODIFIED="2010-09-03 13:05:33 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.006801530609485777" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="10" WEIGHT="100.0" Z="2.706408581848988">
<NAME>ERG vs. TAU</NAME>
<CONT_DATA CI_END="-0.357957088382461" CI_START="-2.237756349492466" EFFECT_SIZE="-1.2978567189374637" ESTIMABLE="YES" MEAN_1="10.92" MEAN_2="17.1" MODIFIED="2010-09-03 13:05:33 +0100" MODIFIED_BY="[Empty name]" ORDER="68" SD_1="3.85" SD_2="5.34" SE="0.479549439667673" STUDY_ID="STD-Gratz-2006" TOTAL_1="12" TOTAL_2="10" WEIGHT="100.0">
<FOOTNOTE>DERS-impulse dyscontrol</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.214518278395238E-31" CI_END="-0.9976671981978145" CI_START="-2.8472708641822586" DF="0" EFFECT_SIZE="-1.9224690311900365" ESTIMABLE="YES" I2="100.0" ID="CMP-002.05.03" MODIFIED="2012-01-06 12:10:48 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="4.614224621483873E-5" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="12" WEIGHT="100.0" Z="4.07435401629202">
<NAME>SFT-G vs. TAU</NAME>
<CONT_DATA CI_END="-0.9976671981978144" CI_START="-2.847270864182258" EFFECT_SIZE="-1.9224690311900363" ESTIMABLE="YES" MEAN_1="1.56" MEAN_2="5.58" MODIFIED="2012-01-06 12:10:44 +0000" MODIFIED_BY="[Empty name]" ORDER="100" SD_1="1.37" SD_2="2.68" SE="0.471846340181218" STUDY_ID="STD-Farrell-2009" TOTAL_1="16" TOTAL_2="12" WEIGHT="100.0">
<FOOTNOTE>DIB-R-impulses</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0671590348762311" CI_START="-0.6414392167860341" DF="0" EFFECT_SIZE="-0.2871400909549015" ESTIMABLE="YES" I2="0.0" ID="CMP-002.05.04" MODIFIED="2012-01-06 12:10:48 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.11218602808195632" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="59" WEIGHT="100.0" Z="1.5884437633566129">
<NAME>STEPPS vs. TAU</NAME>
<CONT_DATA CI_END="0.0671590348762311" CI_START="-0.6414392167860341" EFFECT_SIZE="-0.2871400909549015" ESTIMABLE="YES" MEAN_1="72.7" MEAN_2="76.8" MODIFIED="2010-09-06 11:29:15 +0100" MODIFIED_BY="[Empty name]" ORDER="93" SD_1="14.51" SD_2="13.83" SE="0.1807681817756851" STUDY_ID="STD-Blum-2008" TOTAL_1="65" TOTAL_2="59" WEIGHT="100.0">
<FOOTNOTE>BIS</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.10439167882014394" CI_START="-1.0433230909744489" DF="0" EFFECT_SIZE="-0.4694657060771525" ESTIMABLE="YES" I2="0.0" ID="CMP-002.05.05" MODIFIED="2012-01-06 12:10:47 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.10884139405748582" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="20" WEIGHT="100.00000000000001" Z="1.6034225577711492">
<NAME>PE vs. WL</NAME>
<CONT_DATA CI_END="0.10439167882014394" CI_START="-1.0433230909744489" EFFECT_SIZE="-0.4694657060771525" ESTIMABLE="YES" MEAN_1="-0.43" MEAN_2="0.05" MODIFIED="2010-09-06 11:52:30 +0100" MODIFIED_BY="[Empty name]" ORDER="104" SD_1="0.94" SD_2="1.1" SE="0.29278976013019126" STUDY_ID="STD-Zanarini-2008" TOTAL_1="30" TOTAL_2="20" WEIGHT="100.00000000000001">
<FOOTNOTE>ZAN-BPD-impulsivity baseline to endpoint change score</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="5.3721885335359885E-31" CI_END="1.2922446542137211" CI_START="0.6625879642626147" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9253246753246753" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="22" I2="100.00000000000001" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.11134474424442233" LOG_CI_START="-0.17875645722829037" LOG_EFFECT_SIZE="-0.033705856491934055" METHOD="MH" MODIFIED="2012-06-13 13:24:48 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="1.0" P_Z="0.6487906465195286" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="28" TOTAL_2="30" WEIGHT="100.0" Z="0.45544288997700155">
<NAME>Impulsivity</NAME>
<GROUP_LABEL_1>Active</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.3721885335359885E-31" CI_END="1.2922446542137211" CI_START="0.6625879642626147" DF="0" EFFECT_SIZE="0.9253246753246753" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="22" I2="100.00000000000001" ID="CMP-002.06.01" LOG_CI_END="0.11134474424442233" LOG_CI_START="-0.17875645722829037" LOG_EFFECT_SIZE="-0.033705856491934055" MODIFIED="2010-09-06 11:42:36 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.6487906465195286" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="30" WEIGHT="100.0" Z="0.45544288997700155">
<NAME>STEPPS+IT vs. TAU</NAME>
<DICH_DATA CI_END="1.2922446542137211" CI_START="0.6625879642626147" EFFECT_SIZE="0.9253246753246753" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="22" LOG_CI_END="0.11134474424442233" LOG_CI_START="-0.17875645722829037" LOG_EFFECT_SIZE="-0.033705856491934055" MODIFIED="2010-09-06 11:42:36 +0100" MODIFIED_BY="[Empty name]" ORDER="100" O_E="0.0" SE="0.17040688176917865" STUDY_ID="STD-Bos-2010" TOTAL_1="28" TOTAL_2="30" VAR="0.02903850535429483" WEIGHT="100.0">
<FOOTNOTE>participants scoring above BPDSI-IV-impulsivity-cut-off score</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.510097010610728" CI_END="0.10025605813779931" CI_START="-0.7546815989586424" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.3272127704104215" ESTIMABLE="YES" I2="60.16090231681159" I2_Q="60.1609023168116" ID="CMP-002.07" MODIFIED="2012-06-13 13:24:35 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.11311925979588244" P_Q="0.11311925979588233" P_Z="0.1335404879811778" Q="2.5100970106107283" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.17117902191256446" TOTALS="SUB" TOTAL_1="44" TOTAL_2="43" UNITS="" WEIGHT="200.0" Z="1.5002854066905482">
<NAME>Suicidality</NAME>
<GROUP_LABEL_1>Active</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4095041899759876" CI_START="-0.6120051769158242" DF="0" EFFECT_SIZE="-0.10125049346991835" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.01" MODIFIED="2010-09-03 12:49:03 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6976183487890388" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="30" WEIGHT="100.0" Z="0.3885374467426993">
<NAME>DBT-ST vs. standard group</NAME>
<CONT_DATA CI_END="0.4095041899759876" CI_START="-0.6120051769158242" EFFECT_SIZE="-0.10125049346991835" ESTIMABLE="YES" MEAN_1="2.44" MEAN_2="2.55" MODIFIED="2010-09-03 12:49:03 +0100" MODIFIED_BY="[Empty name]" ORDER="59" SD_1="1.24" SD_2="0.88" SE="0.260593912681393" STUDY_ID="STD-Soler-2009" TOTAL_1="29" TOTAL_2="30" WEIGHT="100.0">
<FOOTNOTE>CGI-BPD-suicidality</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.07456966879525295" CI_START="-1.6366667620379802" DF="0" EFFECT_SIZE="-0.8556182154166165" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.02" MODIFIED="2010-09-15 09:44:53 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.03178618220692568" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.0" Z="2.1470891841323256">
<NAME>MACT vs. TAU</NAME>
<CONT_DATA CI_END="-0.07456966879525295" CI_START="-1.6366667620379802" EFFECT_SIZE="-0.8556182154166165" ESTIMABLE="YES" MEAN_1="27.47" MEAN_2="42.69" MODIFIED="2010-09-15 09:44:53 +0100" MODIFIED_BY="[Empty name]" ORDER="89" SD_1="16.92" SD_2="17.67" SE="0.39850147899766264" STUDY_ID="STD-Weinberg-2006" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.0">
<FOOTNOTE>SBQ-suicide ideation</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.027011092362164" CI_END="-0.3364371870594016" CI_START="-1.5174784182995318" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.9269578026794667" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.08" MODIFIED="2012-06-13 13:24:13 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.8694552400361939" P_Q="0.8694552400361939" P_Z="0.002093663277874168" Q="0.027011092362164004" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="27" TOTAL_2="23" UNITS="" WEIGHT="200.0" Z="3.076613856287541">
<NAME>Parasuicidality</NAME>
<GROUP_LABEL_1>Active</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.08529898728010665" CI_START="-1.8821727070285739" DF="0" EFFECT_SIZE="-0.9837358471543403" ESTIMABLE="YES" I2="0.0" ID="CMP-002.08.01" MODIFIED="2010-09-06 11:04:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.031869308757208364" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="10" WEIGHT="100.0" Z="2.146046001489083">
<NAME>ERG vs. TAU</NAME>
<CONT_DATA CI_END="-0.08529898728010665" CI_START="-1.8821727070285739" EFFECT_SIZE="-0.9837358471543403" ESTIMABLE="YES" MEAN_1="2.05" MEAN_2="4.48" MODIFIED="2010-09-03 13:07:13 +0100" MODIFIED_BY="[Empty name]" ORDER="69" SD_1="0.93" SD_2="3.39" SE="0.4583945761049636" STUDY_ID="STD-Gratz-2006" TOTAL_1="12" TOTAL_2="10" WEIGHT="100.0">
<FOOTNOTE>DSHI-self-harm frequency (transformed)</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.10022530433748467" CI_START="-1.6673197563058446" DF="0" EFFECT_SIZE="-0.8837725303216646" ESTIMABLE="YES" I2="0.0" ID="CMP-002.08.02" MODIFIED="2010-09-06 11:07:04 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.027058875758093764" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.0" Z="2.2106674269449442">
<NAME>MACT vs. TAU</NAME>
<CONT_DATA CI_END="-0.10022530433748467" CI_START="-1.6673197563058446" EFFECT_SIZE="-0.8837725303216646" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="3.63" MODIFIED="2010-09-06 11:07:04 +0100" MODIFIED_BY="[Empty name]" ORDER="90" SD_1="0.91" SD_2="4.8" SE="0.3997763388331114" STUDY_ID="STD-Weinberg-2006" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.0">
<FOOTNOTE>PHI-deliberate self-harm frequency</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.217939905363568" CI_START="0.7840250387460589" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3186813186813187" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="0.34594977485076" LOG_CI_START="-0.10567006739769752" LOG_EFFECT_SIZE="0.12013985372653121" METHOD="MH" MODIFIED="2012-07-11 11:35:42 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.29705079214481767" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="28" TOTAL_2="30" WEIGHT="100.0" Z="1.042778746122356">
<NAME>Parasuicidality</NAME>
<GROUP_LABEL_1>Active</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.217939905363568" CI_START="0.7840250387460589" DF="0" EFFECT_SIZE="1.3186813186813187" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" I2="0.0" ID="CMP-002.09.01" LOG_CI_END="0.34594977485076" LOG_CI_START="-0.10567006739769752" LOG_EFFECT_SIZE="0.12013985372653121" MODIFIED="2010-09-06 11:43:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.29705079214481767" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="30" WEIGHT="100.0" Z="1.042778746122356">
<NAME>STEPPS+IT vs. TAU</NAME>
<DICH_DATA CI_END="2.217939905363568" CI_START="0.7840250387460589" EFFECT_SIZE="1.3186813186813187" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.34594977485076" LOG_CI_START="-0.10567006739769752" LOG_EFFECT_SIZE="0.12013985372653121" MODIFIED="2010-09-06 11:43:41 +0100" MODIFIED_BY="[Empty name]" ORDER="101" O_E="0.0" SE="0.26528373089101764" STUDY_ID="STD-Bos-2010" TOTAL_1="28" TOTAL_2="30" VAR="0.07037545787545788" WEIGHT="100.0">
<FOOTNOTE>participants scoring above BPDSI-IV-parasuicide-cut-off score</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="11.507735350230059" CI_END="-0.28105559690362203" CI_START="-0.7380345769444653" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.5095450869240437" ESTIMABLE="YES" I2="65.2407717221266" I2_Q="65.2407717221266" ID="CMP-002.10" MODIFIED="2012-06-13 13:23:39 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.021413149485384975" P_Q="0.021413149485384975" P_Z="1.2377190587131763E-5" Q="11.507735350230059" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.13914875817508812" TOTALS="SUB" TOTAL_1="167" TOTAL_2="147" UNITS="" WEIGHT="500.0" Z="4.370835694811159">
<NAME>Interpersonal problems</NAME>
<GROUP_LABEL_1>Active</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2276664388682253" CI_START="-0.7986989467278485" DF="0" EFFECT_SIZE="-0.28551625392981156" ESTIMABLE="YES" I2="0.0" ID="CMP-002.10.01" MODIFIED="2010-09-03 12:50:36 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2755136906971185" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="30" WEIGHT="100.0" Z="1.0904529372416982">
<NAME>DBT-ST vs. standard group</NAME>
<CONT_DATA CI_END="0.2276664388682253" CI_START="-0.7986989467278485" EFFECT_SIZE="-0.28551625392981156" ESTIMABLE="YES" MEAN_1="4.22" MEAN_2="4.44" MODIFIED="2010-09-03 12:50:36 +0100" MODIFIED_BY="[Empty name]" ORDER="60" SD_1="0.8" SD_2="0.72" SE="0.26183271572638905" STUDY_ID="STD-Soler-2009" TOTAL_1="29" TOTAL_2="30" WEIGHT="100.0">
<FOOTNOTE>CGI-BPD-unstable relations</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.0158692880364306" CI_START="-2.8727485422347105" DF="0" EFFECT_SIZE="-1.9443089151355706" ESTIMABLE="YES" I2="0.0" ID="CMP-002.10.02" MODIFIED="2012-01-06 12:11:39 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="4.051997118515387E-5" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="12" WEIGHT="100.0" Z="4.104494613605009">
<NAME>SFT-G vs. TAU</NAME>
<CONT_DATA CI_END="-1.0158692880364306" CI_START="-2.8727485422347105" EFFECT_SIZE="-1.9443089151355706" ESTIMABLE="YES" MEAN_1="4.88" MEAN_2="12.0" MODIFIED="2012-01-06 12:11:29 +0000" MODIFIED_BY="[Empty name]" ORDER="101" SD_1="4.02" SD_2="2.8" SE="0.4737023916880887" STUDY_ID="STD-Farrell-2009" TOTAL_1="16" TOTAL_2="12" WEIGHT="100.0">
<FOOTNOTE>DIB-R-interpersonal</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.06403491861107935" CI_START="-0.7768800645127705" DF="0" EFFECT_SIZE="-0.4204574915619249" ESTIMABLE="YES" I2="0.0" ID="CMP-002.10.03" MODIFIED="2012-01-06 12:11:39 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.020772650883248766" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="59" WEIGHT="100.0" Z="2.3120913293139718">
<NAME>STEPPS vs. TAU</NAME>
<CONT_DATA CI_END="-0.06403491861107935" CI_START="-0.7768800645127705" EFFECT_SIZE="-0.4204574915619249" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="3.2" MODIFIED="2010-09-06 11:32:07 +0100" MODIFIED_BY="[Empty name]" ORDER="94" SD_1="2.42" SD_2="2.3" SE="0.18185159307123056" STUDY_ID="STD-Blum-2008" TOTAL_1="65" TOTAL_2="59" WEIGHT="100.0">
<FOOTNOTE>ZAN-BPD-disturbed relations</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2675396390314941" CI_START="-0.8149719858869571" DF="0" EFFECT_SIZE="-0.2737161734277315" ESTIMABLE="YES" I2="0.0" ID="CMP-002.10.04" MODIFIED="2012-01-06 12:11:37 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.32160500881776977" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="26" WEIGHT="100.0" Z="0.9911650453543858">
<NAME>STEPPS+IT vs. TAU</NAME>
<CONT_DATA CI_END="0.2675396390314941" CI_START="-0.8149719858869571" EFFECT_SIZE="-0.2737161734277315" ESTIMABLE="YES" MEAN_1="-13.0" MEAN_2="-12.0" MODIFIED="2010-09-15 10:55:34 +0100" MODIFIED_BY="[Empty name]" ORDER="102" SD_1="3.5" SD_2="3.7" SE="0.27615599915538364" STUDY_ID="STD-Bos-2010" TOTAL_1="27" TOTAL_2="26" WEIGHT="100.0">
<FOOTNOTE>WHOQOL-Bref-social relationships (mean scores multiplied by -1)</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.16133517458051083" CI_START="-1.333363582741982" DF="0" EFFECT_SIZE="-0.7473493786612465" ESTIMABLE="YES" I2="0.0" ID="CMP-002.10.05" MODIFIED="2012-01-06 12:11:35 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.012434751938933236" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="20" WEIGHT="100.0" Z="2.499560344859195">
<NAME>PE vs. WL</NAME>
<CONT_DATA CI_END="-0.16133517458051083" CI_START="-1.333363582741982" EFFECT_SIZE="-0.7473493786612465" ESTIMABLE="YES" MEAN_1="-0.93" MEAN_2="-0.05" MODIFIED="2010-09-06 11:54:04 +0100" MODIFIED_BY="[Empty name]" ORDER="105" SD_1="0.94" SD_2="1.43" SE="0.29899233287098176" STUDY_ID="STD-Zanarini-2008" TOTAL_1="30" TOTAL_2="20" WEIGHT="100.0">
<FOOTNOTE>ZAN-BPD-stormy relationships baseline to endpoint change score</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.218937388094518" CI_END="-0.3120143795827904" CI_START="-0.8686559112078327" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.5903351453953115" ESTIMABLE="YES" I2="52.594698237432254" I2_Q="52.594698237432254" ID="CMP-002.11" MODIFIED="2012-06-13 13:23:26 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.12130245384944294" P_Q="0.12130245384944294" P_Z="3.221692132391679E-5" Q="4.218937388094518" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.08328413912930493" TOTALS="SUB" TOTAL_1="110" TOTAL_2="101" UNITS="" WEIGHT="300.0" Z="4.1572019263643964">
<NAME>Dissociation/psychoticism</NAME>
<GROUP_LABEL_1>Active</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.13144664948460894" CI_START="-1.1812875912104768" DF="0" EFFECT_SIZE="-0.6563671203475429" ESTIMABLE="YES" I2="0.0" ID="CMP-002.11.01" MODIFIED="2010-09-03 12:53:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.014255359193410838" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="30" WEIGHT="100.0" Z="2.450763473565061">
<NAME>DBT-ST vs. standard group</NAME>
<CONT_DATA CI_END="-0.13144664948460894" CI_START="-1.1812875912104768" EFFECT_SIZE="-0.6563671203475429" ESTIMABLE="YES" MEAN_1="8.74" MEAN_2="11.89" MODIFIED="2010-09-03 12:53:13 +0100" MODIFIED_BY="[Empty name]" ORDER="61" SD_1="5.06" SD_2="4.4" SE="0.26782148804949457" STUDY_ID="STD-Soler-2009" TOTAL_1="29" TOTAL_2="30" WEIGHT="100.0">
<FOOTNOTE>BPRS</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.5269816168962848" CI_START="-2.212155623110091" DF="0" EFFECT_SIZE="-1.369568620003188" ESTIMABLE="YES" I2="0.0" ID="CMP-002.11.02" MODIFIED="2012-01-06 12:12:14 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.0014435938846046588" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="12" WEIGHT="100.0" Z="3.185789906163436">
<NAME>SFT-G vs. TAU</NAME>
<CONT_DATA CI_END="-0.5269816168962848" CI_START="-2.212155623110091" EFFECT_SIZE="-1.369568620003188" ESTIMABLE="YES" MEAN_1="1.69" MEAN_2="4.25" MODIFIED="2012-01-06 12:12:12 +0000" MODIFIED_BY="[Empty name]" ORDER="150" SD_1="2.02" SD_2="1.49" SE="0.4298992276149572" STUDY_ID="STD-Farrell-2009" TOTAL_1="16" TOTAL_2="12" WEIGHT="100.0">
<FOOTNOTE>DIB-R-cognition</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.06403491861107935" CI_START="-0.7768800645127705" DF="0" EFFECT_SIZE="-0.4204574915619249" ESTIMABLE="YES" I2="0.0" ID="CMP-002.11.03" MODIFIED="2012-01-06 12:12:14 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.020772650883248766" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="59" WEIGHT="100.0" Z="2.3120913293139718">
<NAME>STEPPS vs. TAU</NAME>
<CONT_DATA CI_END="-0.06403491861107935" CI_START="-0.7768800645127705" EFFECT_SIZE="-0.4204574915619249" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="3.0" MODIFIED="2010-09-06 11:33:18 +0100" MODIFIED_BY="[Empty name]" ORDER="95" SD_1="2.42" SD_2="2.3" SE="0.18185159307123056" STUDY_ID="STD-Blum-2008" TOTAL_1="65" TOTAL_2="59" WEIGHT="100.0">
<FOOTNOTE>ZAN-BPD-cognitive subscale</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.135268985764053" CI_END="-0.24463531066901423" CI_START="-0.8088026623742188" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.5267189865216165" ESTIMABLE="YES" I2="71.97022279061513" I2_Q="71.97022279061513" ID="CMP-002.12" MODIFIED="2012-06-13 13:23:10 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.02822258284825019" P_Q="0.02822258284825019" P_Z="2.524806048260261E-4" Q="7.135268985764053" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.20720014159867398" TOTALS="SUB" TOTAL_1="106" TOTAL_2="99" UNITS="" WEIGHT="300.0" Z="3.659730540718147">
<NAME>Depression</NAME>
<GROUP_LABEL_1>Active</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.4270958911928686" CI_START="-1.510131648957384" DF="0" EFFECT_SIZE="-0.9686137700751263" ESTIMABLE="YES" I2="0.0" ID="CMP-002.12.01" MODIFIED="2010-09-14 15:41:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="4.5525381442354035E-4" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="30" WEIGHT="100.0" Z="3.5057902579234845">
<NAME>DBT-ST vs. standard group</NAME>
<CONT_DATA CI_END="-0.4270958911928686" CI_START="-1.510131648957384" EFFECT_SIZE="-0.9686137700751263" ESTIMABLE="YES" MEAN_1="11.11" MEAN_2="16.0" MODIFIED="2010-09-14 15:41:20 +0100" MODIFIED_BY="[Empty name]" ORDER="141" SD_1="3.99" SD_2="5.78" SE="0.27628970897102273" STUDY_ID="STD-Soler-2009" TOTAL_1="29" TOTAL_2="30" WEIGHT="100.0">
<FOOTNOTE>Ham-D-17</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.27642728708682063" CI_START="-2.1291281649046847" DF="0" EFFECT_SIZE="-1.2027777259957526" ESTIMABLE="YES" I2="0.0" ID="CMP-002.12.02" MODIFIED="2010-09-14 15:41:20 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.010933208752971478" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="10" WEIGHT="100.0" Z="2.5448263695273243">
<NAME>ERG vs. TAU</NAME>
<CONT_DATA CI_END="-0.27642728708682063" CI_START="-2.1291281649046847" EFFECT_SIZE="-1.2027777259957526" ESTIMABLE="YES" MEAN_1="9.0" MEAN_2="23.2" MODIFIED="2010-09-14 15:41:20 +0100" MODIFIED_BY="[Empty name]" ORDER="142" SD_1="6.52" SD_2="15.32" SE="0.4726364597593966" STUDY_ID="STD-Gratz-2006" TOTAL_1="12" TOTAL_2="10" WEIGHT="100.0">
<FOOTNOTE>DASS-depression</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.11415122018347557" CI_START="-0.5933150180142307" DF="0" EFFECT_SIZE="-0.23958189891537757" ESTIMABLE="YES" I2="0.0" ID="CMP-002.12.03" MODIFIED="2010-09-14 15:41:20 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.18435158489637563" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="59" WEIGHT="100.0" Z="1.3274750592144324">
<NAME>STEPPS vs. TAU</NAME>
<CONT_DATA CI_END="0.11415122018347557" CI_START="-0.5933150180142307" EFFECT_SIZE="-0.23958189891537757" ESTIMABLE="YES" MEAN_1="22.0" MEAN_2="25.8" MODIFIED="2010-09-14 15:41:20 +0100" MODIFIED_BY="[Empty name]" ORDER="143" SD_1="16.12" SD_2="15.36" SE="0.18047939752416617" STUDY_ID="STD-Blum-2008" TOTAL_1="65" TOTAL_2="59" WEIGHT="100.0">
<FOOTNOTE>BDI</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.17979228708018008" CI_END="-0.2770845797987623" CI_START="-1.1818217453454598" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.729453162572111" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.13" MODIFIED="2012-06-13 13:22:59 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.6715518121867868" P_Q="0.6715518121867868" P_Z="0.0015750933628552396" Q="0.17979228708018008" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="41" TOTAL_2="40" UNITS="" WEIGHT="200.0" Z="3.1604801515725627">
<NAME>Anxiety</NAME>
<GROUP_LABEL_1>Active</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.7140428183506452E-31" CI_END="-0.14597072602856298" CI_START="-1.1971516791741441" DF="0" EFFECT_SIZE="-0.6715612026013535" ESTIMABLE="YES" I2="100.0" ID="CMP-002.13.01" MODIFIED="2010-09-14 15:41:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.012269425429085415" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="30" WEIGHT="100.0" Z="2.5042991248544246">
<NAME>DBT-ST vs. standard group</NAME>
<CONT_DATA CI_END="-0.14597072602856298" CI_START="-1.1971516791741441" EFFECT_SIZE="-0.6715612026013535" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="16.56" MODIFIED="2010-09-14 15:41:28 +0100" MODIFIED_BY="[Empty name]" ORDER="144" SD_1="5.46" SD_2="5.0" SE="0.2681633339788798" STUDY_ID="STD-Soler-2009" TOTAL_1="29" TOTAL_2="30" WEIGHT="100.0">
<FOOTNOTE>HARS</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.006390105795464951" CI_START="-1.783396959160029" DF="0" EFFECT_SIZE="-0.894893532477747" ESTIMABLE="YES" I2="0.0" ID="CMP-002.13.02" MODIFIED="2010-09-14 15:41:28 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.0483749184700888" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="10" WEIGHT="100.0" Z="1.9740600215843669">
<NAME>ERG vs. TAU</NAME>
<CONT_DATA CI_END="-0.006390105795464951" CI_START="-1.783396959160029" EFFECT_SIZE="-0.894893532477747" ESTIMABLE="YES" MEAN_1="6.33" MEAN_2="14.0" MODIFIED="2010-09-14 15:41:28 +0100" MODIFIED_BY="[Empty name]" ORDER="145" SD_1="6.49" SD_2="9.98" SE="0.45332640481696784" STUDY_ID="STD-Gratz-2006" TOTAL_1="12" TOTAL_2="10" WEIGHT="100.0">
<FOOTNOTE>DASS-anxiety</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.2853590014678" CI_END="-0.20413328941323444" CI_START="-0.6977330441016807" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.45093316675745754" ESTIMABLE="YES" I2="8.685778368218205" I2_Q="8.68577836821823" ID="CMP-002.14" MODIFIED="2012-06-13 13:22:47 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.3496856667241798" P_Q="0.34968566672417967" P_Z="3.421627277918846E-4" Q="3.2853590014678007" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.006788438030767581" TOTALS="SUB" TOTAL_1="135" TOTAL_2="127" UNITS="" WEIGHT="400.0" Z="3.5810907841194632">
<NAME>General psychopathology</NAME>
<GROUP_LABEL_1>Active</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours active</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0987451057737257" CI_START="-0.933913060399403" DF="0" EFFECT_SIZE="-0.41758397731283864" ESTIMABLE="YES" I2="0.0" ID="CMP-002.14.01" MODIFIED="2010-09-14 15:41:36 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.11293643264266778" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="30" WEIGHT="100.0" Z="1.5851316202479708">
<NAME>DBT-ST vs. standard group</NAME>
<CONT_DATA CI_END="0.0987451057737257" CI_START="-0.933913060399403" EFFECT_SIZE="-0.41758397731283864" ESTIMABLE="YES" MEAN_1="2.09" MEAN_2="2.5" MODIFIED="2010-09-14 15:41:36 +0100" MODIFIED_BY="[Empty name]" ORDER="146" SD_1="1.07" SD_2="0.86" SE="0.2634380463923328" STUDY_ID="STD-Soler-2009" TOTAL_1="29" TOTAL_2="30" WEIGHT="100.0">
<FOOTNOTE>SCL-90-R-GSI</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.25398104183757764" CI_START="-1.8663572750680861" DF="0" EFFECT_SIZE="-1.0601691584528319" ESTIMABLE="YES" I2="0.0" ID="CMP-002.14.02" MODIFIED="2012-01-06 12:13:06 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.00995380647833668" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="12" WEIGHT="100.0" Z="2.5774299140151475">
<NAME>SFT-G vs. TAU</NAME>
<CONT_DATA CI_END="-0.25398104183757764" CI_START="-1.8663572750680861" EFFECT_SIZE="-1.0601691584528319" ESTIMABLE="YES" MEAN_1="1.26" MEAN_2="2.01" MODIFIED="2012-01-06 12:13:00 +0000" MODIFIED_BY="[Empty name]" ORDER="118" SD_1="0.6" SD_2="0.79" SE="0.41132802590984485" STUDY_ID="STD-Farrell-2009" TOTAL_1="16" TOTAL_2="12" WEIGHT="100.0">
<FOOTNOTE>SCL-90-R-GSI</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.06512856811741069" CI_START="-0.6435232190590963" DF="0" EFFECT_SIZE="-0.28919732547084276" ESTIMABLE="YES" I2="0.0" ID="CMP-002.14.03" MODIFIED="2012-01-06 12:13:06 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.10966439369843173" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="59" WEIGHT="100.0" Z="1.59970341599373">
<NAME>STEPPS vs. TAU</NAME>
<CONT_DATA CI_END="0.06512856811741069" CI_START="-0.6435232190590963" EFFECT_SIZE="-0.28919732547084276" ESTIMABLE="YES" MEAN_1="12.5" MEAN_2="14.9" MODIFIED="2010-09-14 15:41:36 +0100" MODIFIED_BY="[Empty name]" ORDER="147" SD_1="8.06" SD_2="8.45" SE="0.18078183904557985" STUDY_ID="STD-Blum-2008" TOTAL_1="65" TOTAL_2="59" WEIGHT="100.0">
<FOOTNOTE>SCL-90-R-GSI</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.03913080432764848" CI_START="-1.163710073915424" DF="0" EFFECT_SIZE="-0.6014204391215362" ESTIMABLE="YES" I2="0.0" ID="CMP-002.14.04" MODIFIED="2012-01-15 22:34:29 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.03605012581736275" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="26" WEIGHT="100.0" Z="2.0963616031737113">
<NAME>STEPPS+IT vs. TAU</NAME>
<CONT_DATA CI_END="-0.03913080432764848" CI_START="-1.163710073915424" EFFECT_SIZE="-0.6014204391215362" ESTIMABLE="YES" MEAN_1="205.8" MEAN_2="248.5" MODIFIED="2010-09-14 15:41:36 +0100" MODIFIED_BY="[Empty name]" ORDER="148" SD_1="60.6" SD_2="77.8" SE="0.2868877383610906" STUDY_ID="STD-Bos-2010" TOTAL_1="25" TOTAL_2="26" WEIGHT="100.0">
<FOOTNOTE>SCL-90-R-DV</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.772534635540725" CI_END="0.7199075035049001" CI_START="0.1690426210811758" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.44447506229303796" ESTIMABLE="YES" I2="46.98524484949265" I2_Q="46.98524484949265" ID="CMP-002.15" MODIFIED="2012-07-06 17:21:45 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.15163687317192798" P_Q="0.15163687317192798" P_Z="0.0015622576038953392" Q="3.772534635540725" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0642629437242913" TOTALS="SUB" TOTAL_1="110" TOTAL_2="101" UNITS="" WEIGHT="300.0" Z="3.1628631336512045">
<NAME>Mental health status/functioning</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours experimental</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8024944742839195" CI_START="-0.22401635030254402" DF="0" EFFECT_SIZE="0.2892390619906878" ESTIMABLE="YES" I2="0.0" ID="CMP-002.15.01" MODIFIED="2010-09-15 10:18:46 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2693699507585854" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="30" WEIGHT="100.0" Z="1.1045146935538155">
<NAME>DBT-ST vs. standard group</NAME>
<CONT_DATA CI_END="0.8024944742839195" CI_START="-0.22401635030254402" EFFECT_SIZE="0.2892390619906878" ESTIMABLE="YES" MEAN_1="-3.27" MEAN_2="-3.57" MODIFIED="2010-09-15 10:18:46 +0100" MODIFIED_BY="[Empty name]" ORDER="149" SD_1="0.9" SD_2="1.13" SE="0.2618698181914183" STUDY_ID="STD-Soler-2009" TOTAL_1="29" TOTAL_2="30" WEIGHT="100.0">
<FOOTNOTE>CGI-global improvement, patient-rated (mean scores multiplied by (-1) --&gt; positive effect favours experimental condition)</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.0266766134608547" CI_START="0.3822596589997499" DF="0" EFFECT_SIZE="1.2044681362303022" ESTIMABLE="YES" I2="0.0" ID="CMP-002.15.02" MODIFIED="2012-01-06 12:13:50 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.0040893372889312385" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="12" WEIGHT="100.0" Z="2.871186849701523">
<NAME>SFT-G vs. TAU</NAME>
<CONT_DATA CI_END="2.0266766134608547" CI_START="0.3822596589997499" EFFECT_SIZE="1.2044681362303022" ESTIMABLE="YES" MEAN_1="60.5" MEAN_2="50.08" MODIFIED="2012-01-06 12:13:48 +0000" MODIFIED_BY="[Empty name]" ORDER="124" SD_1="10.17" SD_2="5.07" SE="0.4195018294805557" STUDY_ID="STD-Farrell-2009" TOTAL_1="16" TOTAL_2="12" WEIGHT="100.0">
<FOOTNOTE>GAF</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7324589517886073" CI_START="0.021177193122887183" DF="0" EFFECT_SIZE="0.3768180724557472" ESTIMABLE="YES" I2="0.0" ID="CMP-002.15.03" MODIFIED="2012-01-15 22:34:48 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.037831740113029144" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="59" WEIGHT="100.0" Z="2.07667310946509">
<NAME>STEPPS vs. TAU</NAME>
<CONT_DATA CI_END="0.7324589517886073" CI_START="0.021177193122887183" EFFECT_SIZE="0.3768180724557472" ESTIMABLE="YES" MEAN_1="-4.4" MEAN_2="-4.7" MODIFIED="2010-09-15 10:18:26 +0100" MODIFIED_BY="[Empty name]" ORDER="150" SD_1="0.81" SD_2="0.77" SE="0.1814527624681422" STUDY_ID="STD-Blum-2008" TOTAL_1="65" TOTAL_2="59" WEIGHT="100.0">
<FOOTNOTE>CGI-S (mean scores multiplied by (-1) --&gt; positive effect favours experimental condition)</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="12.691219672006648" CI_END="1.3893466345090575" CI_START="0.645141859390048" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9467447761273778" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="40" I2="60.6026833573086" I2_Q="60.45999948232299" ID="CMP-002.16" LOG_CI_END="0.14281061339299175" LOG_CI_START="-0.1903447784247723" LOG_EFFECT_SIZE="-0.023767082515890263" METHOD="MH" MODIFIED="2012-07-04 16:16:37 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.0264507901778126" P_Q="0.026938118025433555" P_Z="0.7797498516915313" Q="12.64542219154668" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.4551085796837429" TOTALS="SUB" TOTAL_1="211" TOTAL_2="188" WEIGHT="600.0" Z="0.27964503587693557">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9968839384882632" CI_START="0.3362277617893513" DF="0" EFFECT_SIZE="0.5789473684210527" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" I2="0.0" ID="CMP-002.16.01" LOG_CI_END="-0.0013554011749749777" LOG_CI_START="-0.47336643041423276" LOG_EFFECT_SIZE="-0.23736091579460392" MODIFIED="2010-09-14 16:28:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.04869869022473423" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.9712202362926277">
<NAME>DBT-ST vs. standard group</NAME>
<DICH_DATA CI_END="0.9968839384882632" CI_START="0.3362277617893513" EFFECT_SIZE="0.5789473684210527" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" LOG_CI_END="-0.0013554011749749777" LOG_CI_START="-0.47336643041423276" LOG_EFFECT_SIZE="-0.23736091579460392" MODIFIED="2010-09-14 16:28:42 +0100" MODIFIED_BY="[Empty name]" ORDER="151" O_E="0.0" SE="0.2772616150674173" STUDY_ID="STD-Soler-2009" TOTAL_1="30" TOTAL_2="30" VAR="0.07687400318979268" WEIGHT="100.0">
<FOOTNOTE>quit therapy (population: those randomised)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="12.011998353083218" CI_START="0.05960509736310207" DF="0" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-002.16.02" LOG_CI_END="1.0796152639825778" LOG_CI_START="-1.2247165982798012" LOG_EFFECT_SIZE="-0.07255066714861173" MODIFIED="2010-09-14 15:51:21 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9017770114511134" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="11" WEIGHT="100.0" Z="0.12341685413838303">
<NAME>ERG vs. TAU</NAME>
<DICH_DATA CI_END="12.011998353083218" CI_START="0.05960509736310207" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0796152639825778" LOG_CI_START="-1.2247165982798012" LOG_EFFECT_SIZE="-0.07255066714861173" MODIFIED="2010-09-14 15:51:21 +0100" MODIFIED_BY="[Empty name]" ORDER="152" O_E="0.0" SE="1.3535759425196032" STUDY_ID="STD-Gratz-2006" TOTAL_1="13" TOTAL_2="11" VAR="1.8321678321678323" WEIGHT="100.0">
<FOOTNOTE>drop-outs (population: those randomised)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9081331444694032" CI_START="0.006470030169607817" DF="0" EFFECT_SIZE="0.11111111111111109" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" ID="CMP-002.16.03" LOG_CI_END="0.2806086753423485" LOG_CI_START="-2.1890936942209986" LOG_EFFECT_SIZE="-0.954242509439325" MODIFIED="2012-01-06 12:14:34 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.12987879127865717" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="1.5145800352848775">
<NAME>SFT-G vs. TAU</NAME>
<DICH_DATA CI_END="1.9081331444694032" CI_START="0.006470030169607817" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.2806086753423485" LOG_CI_START="-2.1890936942209986" LOG_EFFECT_SIZE="-0.9542425094393249" MODIFIED="2012-01-06 12:14:24 +0000" MODIFIED_BY="[Empty name]" ORDER="137" O_E="0.0" SE="1.4507153971054052" STUDY_ID="STD-Farrell-2009" TOTAL_1="16" TOTAL_2="16" VAR="2.1045751633986933" WEIGHT="100.0">
<FOOTNOTE>lost after randomisation (population: those randomised)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.845086034384407" CI_START="0.010402888164868843" DF="0" EFFECT_SIZE="0.20000000000000007" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-002.16.04" LOG_CI_END="0.5849060616512036" LOG_CI_START="-1.982846070323241" LOG_EFFECT_SIZE="-0.6989700043360186" MODIFIED="2012-01-06 12:14:34 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.28595065344202364" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.0670469456247629">
<NAME>MACT vs. TAU</NAME>
<DICH_DATA CI_END="3.845086034384406" CI_START="0.010402888164868843" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5849060616512035" LOG_CI_START="-1.982846070323241" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2010-09-14 16:17:06 +0100" MODIFIED_BY="[Empty name]" ORDER="153" O_E="0.0" SE="1.5083103128998356" STUDY_ID="STD-Weinberg-2006" TOTAL_1="15" TOTAL_2="15" VAR="2.275" WEIGHT="100.0">
<FOOTNOTE>non-completers/not available for post-treatment assessment</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.757596023652227" CI_START="1.0823550924508007" DF="0" EFFECT_SIZE="2.269230769230769" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="8" I2="0.0" ID="CMP-002.16.05" LOG_CI_END="0.6773875625126987" LOG_CI_START="0.034369764829953665" LOG_EFFECT_SIZE="0.3558786636713262" MODIFIED="2012-01-06 12:14:31 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.030045733278278093" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="59" WEIGHT="100.0" Z="2.1694869603164">
<NAME>STEPPS vs. TAU</NAME>
<DICH_DATA CI_END="4.757596023652227" CI_START="1.0823550924508007" EFFECT_SIZE="2.269230769230769" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="8" LOG_CI_END="0.6773875625126987" LOG_CI_START="0.034369764829953665" LOG_EFFECT_SIZE="0.3558786636713262" MODIFIED="2010-09-14 15:46:03 +0100" MODIFIED_BY="[Empty name]" ORDER="154" O_E="0.0" SE="0.3777118373482776" STUDY_ID="STD-Blum-2008" TOTAL_1="65" TOTAL_2="59" VAR="0.1426662320730117" WEIGHT="100.0">
<FOOTNOTE>lost to follow-up or quit intervention (population: those randomised)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.649625563242397" CI_START="0.5906824352080375" DF="0" EFFECT_SIZE="1.4682539682539681" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" I2="0.0" ID="CMP-002.16.06" LOG_CI_END="0.5622483098923036" LOG_CI_START="-0.2286459433214018" LOG_EFFECT_SIZE="0.16680118328545088" MODIFIED="2012-01-06 12:14:29 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.4083954131549701" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="37" WEIGHT="100.00000000000001" Z="0.8267206658531906">
<NAME>STEPPS+IT vs. TAU</NAME>
<DICH_DATA CI_END="3.649625563242397" CI_START="0.5906824352080375" EFFECT_SIZE="1.4682539682539681" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.5622483098923036" LOG_CI_START="-0.2286459433214018" LOG_EFFECT_SIZE="0.16680118328545088" MODIFIED="2010-09-14 15:48:19 +0100" MODIFIED_BY="[Empty name]" ORDER="155" O_E="0.0" SE="0.4645751993274241" STUDY_ID="STD-Bos-2010" TOTAL_1="42" TOTAL_2="37" VAR="0.21583011583011583" WEIGHT="100.00000000000001">
<FOOTNOTE>lost after randomisation or quit therapy, including those who attended less than 12 sessions (population: those randomised)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.16.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-01-06 12:14:27 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>PE vs. WL</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-09-14 15:54:05 +0100" MODIFIED_BY="[Empty name]" ORDER="156" O_E="0.0" SE="0.0" STUDY_ID="STD-Zanarini-2008" TOTAL_1="30" TOTAL_2="20" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>all participants attended all visits, no drop-outs</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2012-07-06 17:22:00 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Comprehensive psychotherapies: active vs. active conditions</NAME>
<CONT_OUTCOME CHI2="1.543948543637642" CI_END="0.055255343663798084" CI_START="-0.5963914822321548" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.27056806928417837" ESTIMABLE="YES" I2="35.23100208741829" I2_Q="35.23100208741829" ID="CMP-003.01" MODIFIED="2012-01-06 11:33:37 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.21403149487050255" P_Q="0.21403149487050255" P_Z="0.10361397228239287" Q="1.543948543637642" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.030828748246962256" TOTALS="SUB" TOTAL_1="74" TOTAL_2="73" UNITS="" WEIGHT="200.0" Z="1.6275800022026048">
<NAME>BPD total severity</NAME>
<GROUP_LABEL_1>treatment 1</GROUP_LABEL_1>
<GROUP_LABEL_2>treatment 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment 2</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.018506974118376318" CI_START="-0.8751095330128941" DF="0" EFFECT_SIZE="-0.4468082535656352" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.01" MODIFIED="2010-11-27 12:20:50 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0408889446588801" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="42" WEIGHT="99.99999999999999" Z="2.0446543753360946">
<NAME>SFT vs. TFP</NAME>
<CONT_DATA CI_END="-0.018506974118376318" CI_START="-0.8751095330128941" EFFECT_SIZE="-0.4468082535656352" ESTIMABLE="YES" MEAN_1="17.7631" MEAN_2="22.7148" MODIFIED="2010-11-27 12:20:19 +0000" MODIFIED_BY="[Empty name]" ORDER="204" SD_1="11.3231" SD_2="10.6149" SE="0.21852507639203816" STUDY_ID="STD-Giesen_x002d_Bloo-2006" TOTAL_1="44" TOTAL_2="42" WEIGHT="99.99999999999999">
<FOOTNOTE>BPDSI-IV-total score</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.47352273367990455" CI_START="-0.5304572115801798" DF="0" EFFECT_SIZE="-0.028467238950137634" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.02" MODIFIED="2011-04-22 12:20:22 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9114996469564363" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="31" WEIGHT="100.0" Z="0.11114716652454999">
<NAME>SFT vs. SFT+TTA</NAME>
<CONT_DATA CI_END="0.47352273367990455" CI_START="-0.5304572115801798" EFFECT_SIZE="-0.028467238950137634" ESTIMABLE="YES" MEAN_1="16.77" MEAN_2="17.07" MODIFIED="2011-04-22 12:20:22 +0100" MODIFIED_BY="[Empty name]" ORDER="322" SD_1="9.91" SD_2="10.86" SE="0.2561220392770862" STUDY_ID="STD-Nadort-2009" TOTAL_1="30" TOTAL_2="31" WEIGHT="100.0">
<FOOTNOTE>BPDSI-IV-total score</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.769042827511906E-32" CI_END="0.04965850242722403" CI_START="-1.6230670282443203" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.7867042629085481" ESTIMABLE="YES" I2="100.00000000000001" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2012-06-13 13:21:39 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="1.0" P_Z="0.06524256724806682" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="100.00000000000001" Z="1.8435923808323262">
<NAME>Inappropriate anger</NAME>
<GROUP_LABEL_1>Treatment 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours tretment 2</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="6.769042827511906E-32" CI_END="0.04965850242722403" CI_START="-1.6230670282443203" DF="0" EFFECT_SIZE="-0.7867042629085481" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-003.02.01" MODIFIED="2010-09-15 12:57:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.06524256724806682" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.00000000000001" Z="1.8435923808323262">
<NAME>DBT vs. CCT</NAME>
<CONT_DATA CI_END="0.04965850242722403" CI_START="-1.6230670282443203" EFFECT_SIZE="-0.7867042629085481" ESTIMABLE="YES" MEAN_1="4.67" MEAN_2="5.67" MODIFIED="2010-09-15 12:57:25 +0100" MODIFIED_BY="[Empty name]" ORDER="196" SD_1="1.3" SD_2="1.15" SE="0.4267235377450274" STUDY_ID="STD-Turner-2000" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.00000000000001">
<FOOTNOTE>TBR - anger</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.277094903290148" CI_END="-0.003555608785886566" CI_START="-1.0310096104149862" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.5172826096004364" ESTIMABLE="YES" I2="56.084395140707066" I2_Q="56.08439514070707" ID="CMP-003.03" MODIFIED="2012-06-13 13:21:26 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.1312977220831183" P_Q="0.1312977220831184" P_Z="0.048435290565516376" Q="2.2770949032901484" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.1919131011543207" TOTALS="SUB" TOTAL_1="32" TOTAL_2="30" UNITS="" WEIGHT="200.0" Z="1.973529292869969">
<NAME>Impulsivity</NAME>
<GROUP_LABEL_1>Treatment 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment 2</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.188134144656396" CI_START="-1.9157937418835091" DF="0" EFFECT_SIZE="-1.0519639432699526" ESTIMABLE="YES" I2="0.0" ID="CMP-003.03.01" MODIFIED="2010-09-15 13:03:44 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.01699453153372353" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="99.99999999999999" Z="2.3868260219235813">
<NAME>DBT vs. CCT</NAME>
<CONT_DATA CI_END="-0.18813414465639589" CI_START="-1.9157937418835091" EFFECT_SIZE="-1.0519639432699526" ESTIMABLE="YES" MEAN_1="4.58" MEAN_2="6.08" MODIFIED="2010-09-15 13:03:44 +0100" MODIFIED_BY="[Empty name]" ORDER="198" SD_1="1.62" SD_2="1.08" SE="0.44073758774515037" STUDY_ID="STD-Turner-2000" TOTAL_1="12" TOTAL_2="12" WEIGHT="99.99999999999999">
<FOOTNOTE>TBR - impulsiveness</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.247372902398718E-33" CI_END="0.41431472413542636" CI_START="-0.8637063676314125" DF="0" EFFECT_SIZE="-0.2246958217479931" ESTIMABLE="YES" I2="100.0" ID="CMP-003.03.02" MODIFIED="2010-09-17 09:57:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.4907076129839496" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0" Z="0.6891838028961791">
<NAME>CT vs. CCT</NAME>
<CONT_DATA CI_END="0.4143147241354263" CI_START="-0.8637063676314125" EFFECT_SIZE="-0.22469582174799313" ESTIMABLE="YES" MEAN_1="7.6" MEAN_2="8.61" MODIFIED="2010-09-15 13:34:29 +0100" MODIFIED_BY="[Empty name]" ORDER="208" SD_1="3.82" SD_2="4.97" SE="0.3260317796264896" STUDY_ID="STD-Cottraux-2009" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0">
<FOOTNOTE>IVE - impulsivity</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.4085207649017697" CI_END="0.2768390359461433" CI_START="-0.7405083511873074" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.23183465762058203" ESTIMABLE="YES" I2="70.66176007207575" I2_Q="70.66176007207574" ID="CMP-003.04" MODIFIED="2012-06-13 13:21:14 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0648606591070996" P_Q="0.0648606591070996" P_Z="0.37170773717979644" Q="3.408520764901768" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.35063926473724094" TOTALS="SUB" TOTAL_1="32" TOTAL_2="30" UNITS="" WEIGHT="200.0" Z="0.8932791002389647">
<NAME>Suicidality</NAME>
<GROUP_LABEL_1>Treatment 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment 2</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.022207908119773356" CI_START="-1.709878499103016" DF="0" EFFECT_SIZE="-0.8660432036113946" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.01" MODIFIED="2010-09-15 13:04:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.04426781978856493" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="2.011545970170759">
<NAME>DBT vs. CCT</NAME>
<CONT_DATA CI_END="-0.022207908119773467" CI_START="-1.709878499103016" EFFECT_SIZE="-0.8660432036113948" ESTIMABLE="YES" MEAN_1="3.83" MEAN_2="11.58" MODIFIED="2010-09-15 13:04:56 +0100" MODIFIED_BY="[Empty name]" ORDER="199" SD_1="8.03" SD_2="9.21" SE="0.4305361231878169" STUDY_ID="STD-Turner-2000" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0">
<FOOTNOTE>Beck Scale for Suicidal Ideation (BSS)</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7677004493466708" CI_START="-0.5073569974495491" DF="0" EFFECT_SIZE="0.1301717259485608" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.02" MODIFIED="2010-09-17 09:57:43 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6890174181253559" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.00000000000001" Z="0.40018886255777064">
<NAME>CT vs. CCT</NAME>
<CONT_DATA CI_END="0.7677004493466708" CI_START="-0.5073569974495491" EFFECT_SIZE="0.1301717259485608" ESTIMABLE="YES" MEAN_1="7.25" MEAN_2="6.56" MODIFIED="2010-09-15 13:35:40 +0100" MODIFIED_BY="[Empty name]" ORDER="209" SD_1="5.37" SD_2="4.98" SE="0.32527573385371117" STUDY_ID="STD-Cottraux-2009" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.00000000000001">
<FOOTNOTE>BHS</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="10.945680115147958" CI_END="0.4671884890087161" CI_START="-0.5856410916616375" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.05922630132646066" ESTIMABLE="YES" I2="90.86397565541789" I2_Q="90.8639756554179" ID="CMP-003.05" MODIFIED="2012-06-13 13:21:02 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="9.382305493964571E-4" P_Q="9.382305493967902E-4" P_Z="0.8254714821915663" Q="10.945680115147956" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="1.5806581187566051" TOTALS="SUB" TOTAL_1="32" TOTAL_2="30" UNITS="" WEIGHT="200.0" Z="0.22051321442444433">
<NAME>Parasuicidality</NAME>
<GROUP_LABEL_1>Treatment 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment 2</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.3829155594133159" CI_START="-2.167189395275041" DF="0" EFFECT_SIZE="-1.2750524773441785" ESTIMABLE="YES" I2="0.0" ID="CMP-003.05.01" MODIFIED="2010-09-15 13:06:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.005091242414031865" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="2.801203362135532">
<NAME>DBT vs. CCT</NAME>
<CONT_DATA CI_END="-0.3829155594133159" CI_START="-2.167189395275041" EFFECT_SIZE="-1.2750524773441785" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="4.25" MODIFIED="2010-09-15 13:06:28 +0100" MODIFIED_BY="[Empty name]" ORDER="200" SD_1="1.98" SD_2="2.18" SE="0.45518026094761166" STUDY_ID="STD-Turner-2000" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0">
<FOOTNOTE>TBR - frequency of parasuicide</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.2422227625997204" CI_START="-0.06181865632175776" DF="0" EFFECT_SIZE="0.5902020531389813" ESTIMABLE="YES" I2="0.0" ID="CMP-003.05.02" MODIFIED="2010-09-17 09:58:08 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.07604031379475495" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0" Z="1.7741380771643311">
<NAME>CT vs. CCT</NAME>
<CONT_DATA CI_END="1.2422227625997204" CI_START="-0.06181865632175776" EFFECT_SIZE="0.5902020531389813" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="1.06" MODIFIED="2010-09-15 13:45:48 +0100" MODIFIED_BY="[Empty name]" ORDER="211" SD_1="1.36" SD_2="1.06" SE="0.3326697401604291" STUDY_ID="STD-Cottraux-2009" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0">
<FOOTNOTE>Self-harming behaviours checklist (SHBCL)</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.23700857723985236" CI_START="-1.9778993636429898" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-1.107453970441421" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.06" MODIFIED="2012-06-13 13:20:47 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.012644380169067038" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="2.4936313220264616">
<NAME>Psychoticism</NAME>
<GROUP_LABEL_1>Treatment 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment 2</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.23700857723985236" CI_START="-1.9778993636429898" DF="0" EFFECT_SIZE="-1.107453970441421" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.01" MODIFIED="2010-09-15 13:08:09 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.012644380169067038" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="2.4936313220264616">
<NAME>DBT vs. CCT</NAME>
<CONT_DATA CI_END="-0.23700857723985236" CI_START="-1.9778993636429898" EFFECT_SIZE="-1.107453970441421" ESTIMABLE="YES" MEAN_1="18.17" MEAN_2="25.33" MODIFIED="2010-09-15 13:08:09 +0100" MODIFIED_BY="[Empty name]" ORDER="201" SD_1="7.9" SD_2="3.94" SE="0.444112953129512" STUDY_ID="STD-Turner-2000" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0">
<FOOTNOTE>Brief Psychiatric Rating Scale (BPRS)</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.260427542566312" CI_END="0.15897340929340742" CI_START="-0.7011121975648262" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.2710693941357094" ESTIMABLE="YES" I2="68.0533000917035" I2_Q="68.0533000917035" ID="CMP-003.07" MODIFIED="2012-06-13 13:20:35 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.043708492110833275" P_Q="0.043708492110833275" P_Z="0.21667186107851455" Q="6.260427542566312" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.31982842234661324" TOTALS="SUB" TOTAL_1="44" TOTAL_2="44" UNITS="" WEIGHT="300.0" Z="1.2354264403000395">
<NAME>Depression</NAME>
<GROUP_LABEL_1>Treatment 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment 2</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.36719829941494164" CI_START="-2.1465216500048268" DF="0" EFFECT_SIZE="-1.2568599747098843" ESTIMABLE="YES" I2="0.0" ID="CMP-003.07.01" MODIFIED="2010-09-15 13:09:08 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.005624277735780738" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="2.768918064526748">
<NAME>DBT vs. CCT</NAME>
<CONT_DATA CI_END="-0.36719829941494153" CI_START="-2.146521650004827" EFFECT_SIZE="-1.2568599747098843" ESTIMABLE="YES" MEAN_1="14.92" MEAN_2="24.08" MODIFIED="2010-09-15 13:09:08 +0100" MODIFIED_BY="[Empty name]" ORDER="202" SD_1="8.26" SD_2="5.55" SE="0.4539173588456117" STUDY_ID="STD-Turner-2000" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0">
<FOOTNOTE>BDI</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7340846913377681" CI_START="-0.5403041308987713" DF="0" EFFECT_SIZE="0.09689028021949841" ESTIMABLE="YES" I2="0.0" ID="CMP-003.07.02" MODIFIED="2010-09-17 09:58:26 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7656821724535237" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="99.99999999999999" Z="0.2980275036451362">
<NAME>CT vs. CCT</NAME>
<CONT_DATA CI_END="0.7340846913377681" CI_START="-0.5403041308987713" EFFECT_SIZE="0.09689028021949841" ESTIMABLE="YES" MEAN_1="13.6" MEAN_2="12.56" MODIFIED="2010-09-15 13:47:06 +0100" MODIFIED_BY="[Empty name]" ORDER="212" SD_1="11.29" SD_2="9.56" SE="0.3251051632297215" STUDY_ID="STD-Cottraux-2009" TOTAL_1="20" TOTAL_2="18" WEIGHT="99.99999999999999">
<FOOTNOTE>BDI</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7020515186650612" CI_START="-0.8405815646057334" DF="0" EFFECT_SIZE="-0.06926502297033606" ESTIMABLE="YES" I2="0.0" ID="CMP-003.07.03" MODIFIED="2010-09-15 14:02:12 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.8602886062748225" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="14" WEIGHT="100.0" Z="0.17600679238948672">
<NAME>CBT vs. IPT</NAME>
<CONT_DATA CI_END="0.7020515186650612" CI_START="-0.8405815646057334" EFFECT_SIZE="-0.06926502297033606" ESTIMABLE="YES" MEAN_1="13.7" MEAN_2="14.1" MODIFIED="2010-09-15 14:02:12 +0100" MODIFIED_BY="[Empty name]" ORDER="217" SD_1="5.7" SD_2="5.5" SE="0.3935360790909648" STUDY_ID="STD-Bellino-2007" TOTAL_1="12" TOTAL_2="14" WEIGHT="100.0">
<FOOTNOTE>Ham-D</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.13155153718552756" CI_END="-0.13993276221249334" CI_START="-0.9966558171035429" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.5682942896580181" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.08" MODIFIED="2012-06-13 13:20:23 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.9363408074818304" P_Q="0.9363408074818304" P_Z="0.009316266281383661" Q="0.13155153718552756" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="44" TOTAL_2="44" UNITS="" WEIGHT="300.0" Z="2.600224971163258">
<NAME>Anxiety</NAME>
<GROUP_LABEL_1>Treatment 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment 2</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.12976262846199904" CI_START="-1.5279973200707666" DF="0" EFFECT_SIZE="-0.6991173458043838" ESTIMABLE="YES" I2="0.0" ID="CMP-003.08.01" MODIFIED="2010-09-15 13:11:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.09830478528971151" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="1.6531281503773696">
<NAME>DBT vs. CCT</NAME>
<CONT_DATA CI_END="0.12976262846199904" CI_START="-1.5279973200707666" EFFECT_SIZE="-0.6991173458043838" ESTIMABLE="YES" MEAN_1="10.17" MEAN_2="14.83" MODIFIED="2010-09-15 13:11:04 +0100" MODIFIED_BY="[Empty name]" ORDER="203" SD_1="6.53" SD_2="6.34" SE="0.42290571704606933" STUDY_ID="STD-Turner-2000" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0">
<FOOTNOTE>Beck Anxiety Inventory (BAI)</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.13436131536182017" CI_START="-1.162383279732231" DF="0" EFFECT_SIZE="-0.5140109821852055" ESTIMABLE="YES" I2="0.0" ID="CMP-003.08.02" MODIFIED="2010-09-17 09:59:01 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.12023134419125704" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0" Z="1.55380329565668">
<NAME>CT vs. CCT</NAME>
<CONT_DATA CI_END="0.13436131536182017" CI_START="-1.162383279732231" EFFECT_SIZE="-0.5140109821852055" ESTIMABLE="YES" MEAN_1="12.5" MEAN_2="18.44" MODIFIED="2010-09-15 13:48:35 +0100" MODIFIED_BY="[Empty name]" ORDER="213" SD_1="7.8" SD_2="14.25" SE="0.33080827130564827" STUDY_ID="STD-Cottraux-2009" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0">
<FOOTNOTE>BAI</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2564097753719665" CI_START="-1.3171237819380681" DF="0" EFFECT_SIZE="-0.5303570032830508" ESTIMABLE="YES" I2="0.0" ID="CMP-003.08.03" MODIFIED="2010-09-15 14:03:25 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.18643284014320544" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="14" WEIGHT="100.0" Z="1.3212055383939436">
<NAME>CBT vs. IPT</NAME>
<CONT_DATA CI_END="0.2564097753719665" CI_START="-1.3171237819380681" EFFECT_SIZE="-0.5303570032830508" ESTIMABLE="YES" MEAN_1="12.5" MEAN_2="13.7" MODIFIED="2010-09-15 14:03:25 +0100" MODIFIED_BY="[Empty name]" ORDER="218" SD_1="1.1" SD_2="2.8" SE="0.4014189979310504" STUDY_ID="STD-Bellino-2007" TOTAL_1="12" TOTAL_2="14" WEIGHT="100.0">
<FOOTNOTE>HARS</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.47124564858143103" CI_END="0.3241960271718622" CI_START="-0.3231131882515494" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="5.414194601563729E-4" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.09" MODIFIED="2012-06-13 13:20:11 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.4924147056674082" P_Q="0.4924147056674082" P_Z="0.9973839897474979" Q="0.47124564858143103" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="74" TOTAL_2="73" UNITS="" WEIGHT="200.0" Z="0.0032786885066713976">
<NAME>General psychopathology</NAME>
<GROUP_LABEL_1>Treatment 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment 2</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.133637461722891E-33" CI_END="0.32817744001953003" CI_START="-0.5179429039827388" DF="0" EFFECT_SIZE="-0.09488273198160437" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-003.09.01" MODIFIED="2010-11-27 12:21:51 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.6602448452953088" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="42" WEIGHT="100.00000000000001" Z="0.43957514733439074">
<NAME>SFT vs. TFP</NAME>
<CONT_DATA CI_END="0.32817744001953003" CI_START="-0.5179429039827388" EFFECT_SIZE="-0.09488273198160437" ESTIMABLE="YES" MEAN_1="193.39" MEAN_2="200.55" MODIFIED="2010-11-27 12:21:43 +0000" MODIFIED_BY="[Empty name]" ORDER="163" SD_1="79.373" SD_2="69.651" SE="0.21585099284383744" STUDY_ID="STD-Giesen_x002d_Bloo-2006" TOTAL_1="44" TOTAL_2="42" WEIGHT="100.00000000000001">
<FOOTNOTE>SCL-90-R-Dutch version sum score</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6377823377248576" CI_START="-0.3673684337845623" DF="0" EFFECT_SIZE="0.13520695197014768" ESTIMABLE="YES" I2="0.0" ID="CMP-003.09.02" MODIFIED="2011-08-16 17:13:24 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5979952851369226" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="31" WEIGHT="100.0" Z="0.5272855850729313">
<NAME>SFT vs. SFT+TTA</NAME>
<CONT_DATA CI_END="0.6377823377248576" CI_START="-0.3673684337845623" EFFECT_SIZE="0.13520695197014768" ESTIMABLE="YES" MEAN_1="214.93" MEAN_2="207.62" MODIFIED="2011-08-16 17:13:24 +0100" MODIFIED_BY="[Empty name]" ORDER="323" SD_1="75.09" SD_2="12.34" SE="0.25642072493115203" STUDY_ID="STD-Nadort-2009" TOTAL_1="30" TOTAL_2="31" WEIGHT="100.0">
<FOOTNOTE>SCL-90-R-Dutch version sum score</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.04534009761558899" CI_END="0.7524012128891631" CI_START="-0.23439135706394804" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.2590049279126075" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.10" MODIFIED="2012-07-06 17:22:00 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.8313800387660022" P_Q="0.8313800387660022" P_Z="0.3035410725711387" Q="0.04534009761558902" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="32" TOTAL_2="32" UNITS="" WEIGHT="200.0" Z="1.0288693814369214">
<NAME>Mental health status/functioning</NAME>
<GROUP_LABEL_1>Treatment 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment 2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment 1</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9442763284444389" CI_START="-0.3374092608337293" DF="0" EFFECT_SIZE="0.3034335338053548" ESTIMABLE="YES" I2="0.0" ID="CMP-003.10.01" MODIFIED="2010-09-15 14:40:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.35339407556563607" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0" Z="0.9280260353011409">
<NAME>CBT vs. CCT</NAME>
<CONT_DATA CI_END="0.9442763284444389" CI_START="-0.3374092608337293" EFFECT_SIZE="0.3034335338053548" ESTIMABLE="YES" MEAN_1="-3.35" MEAN_2="-3.78" MODIFIED="2010-09-15 13:50:19 +0100" MODIFIED_BY="[Empty name]" ORDER="214" SD_1="1.42" SD_2="1.35" SE="0.32696661759806317" STUDY_ID="STD-Cottraux-2009" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0">
<FOOTNOTE>CGI-S (mean scores multiplied by -1)</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9675081174460415" CI_START="-0.5788419761049476" DF="0" EFFECT_SIZE="0.19433307067054698" ESTIMABLE="YES" I2="0.0" ID="CMP-003.10.02" MODIFIED="2010-09-17 09:59:11 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6222771595297963" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="14" WEIGHT="100.0" Z="0.4926255976674663">
<NAME>CT vs. IPT</NAME>
<CONT_DATA CI_END="0.9675081174460416" CI_START="-0.5788419761049475" EFFECT_SIZE="0.194333070670547" ESTIMABLE="YES" MEAN_1="-1.7" MEAN_2="-1.9" MODIFIED="2010-09-15 14:07:40 +0100" MODIFIED_BY="[Empty name]" ORDER="220" SD_1="1.1" SD_2="0.9" SE="0.39448431342320606" STUDY_ID="STD-Bellino-2007" TOTAL_1="12" TOTAL_2="14" WEIGHT="100.0">
<FOOTNOTE>CGI-S (mean scores multiplied by -1)</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="4.1333430983903465" CI_END="1.0237848581615838" CI_START="0.5131352525541873" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7248034918196085" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="51" I2="3.2260350814398766" I2_Q="3.139827337687704" ID="CMP-003.11" LOG_CI_END="0.010208702020732173" LOG_CI_START="-0.28976814815138985" LOG_EFFECT_SIZE="-0.13977972306532882" METHOD="MH" MODIFIED="2012-07-04 16:16:56 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.38826080305593713" P_Q="0.38874231090575395" P_Z="0.06776558577132069" Q="4.129664329574725" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.005864933310415961" TOTALS="SUB" TOTAL_1="136" TOTAL_2="135" WEIGHT="500.0" Z="1.8265624352001255">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Treatment 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment 2</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5502846411393316" CI_START="0.16126070875363285" DF="0" EFFECT_SIZE="0.49999999999999994" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="0.0" ID="CMP-003.11.01" LOG_CI_END="0.19041144444574076" LOG_CI_START="-0.7924714357737032" LOG_EFFECT_SIZE="-0.30102999566398125" MODIFIED="2010-09-15 13:23:50 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.22991956637728717" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="99.99999999999999" Z="1.2005661338529436">
<NAME>DBT vs. CCT</NAME>
<DICH_DATA CI_END="1.5502846411393318" CI_START="0.16126070875363288" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.19041144444574082" LOG_CI_START="-0.792471435773703" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2010-09-15 13:23:50 +0100" MODIFIED_BY="[Empty name]" ORDER="206" O_E="0.0" SE="0.5773502691896258" STUDY_ID="STD-Turner-2000" TOTAL_1="12" TOTAL_2="12" VAR="0.33333333333333337" WEIGHT="99.99999999999999">
<FOOTNOTE>quit treatment</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9176997041635819" CI_START="0.29602502220052435" DF="0" EFFECT_SIZE="0.5212121212121212" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="22" I2="0.0" ID="CMP-003.11.02" LOG_CI_END="-0.03729940829799584" LOG_CI_START="-0.5286715776426812" LOG_EFFECT_SIZE="-0.28298549297033854" MODIFIED="2011-04-22 12:22:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.023975569583130844" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="43" WEIGHT="100.00000000000001" Z="2.2575205067428596">
<NAME>SFT vs. TFP</NAME>
<DICH_DATA CI_END="0.9176997041635819" CI_START="0.29602502220052435" EFFECT_SIZE="0.5212121212121212" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="22" LOG_CI_END="-0.03729940829799584" LOG_CI_START="-0.5286715776426812" LOG_EFFECT_SIZE="-0.28298549297033854" MODIFIED="2011-04-22 12:21:56 +0100" MODIFIED_BY="[Empty name]" ORDER="324" O_E="0.0" SE="0.28863444460453463" STUDY_ID="STD-Giesen_x002d_Bloo-2006" TOTAL_1="45" TOTAL_2="43" VAR="0.08330984261216819" WEIGHT="100.00000000000001">
<FOOTNOTE>lost to therapy and assessments</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4118706801472243" CI_START="0.3465850695178702" DF="0" EFFECT_SIZE="0.9142857142857143" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" ID="CMP-003.11.03" LOG_CI_END="0.38235401806010905" LOG_CI_START="-0.4601901501208484" LOG_EFFECT_SIZE="-0.03891806603036967" MODIFIED="2011-04-22 21:49:00 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.8563158524856382" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="32" WEIGHT="100.0" Z="0.18106589695388803">
<NAME>SFT vs. SFT+TTA</NAME>
<DICH_DATA CI_END="2.4118706801472243" CI_START="0.3465850695178702" EFFECT_SIZE="0.9142857142857143" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.38235401806010905" LOG_CI_START="-0.4601901501208484" LOG_EFFECT_SIZE="-0.03891806603036967" MODIFIED="2011-04-22 21:48:53 +0100" MODIFIED_BY="[Empty name]" ORDER="481" O_E="0.0" SE="0.49491461505039047" STUDY_ID="STD-Nadort-2009" TOTAL_1="30" TOTAL_2="32" VAR="0.2449404761904762" WEIGHT="100.0">
<FOOTNOTE>lost to therapy and assessments</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.7972673874598612E-31" CI_END="1.6040909666460337" CI_START="0.5054447815246105" DF="0" EFFECT_SIZE="0.9004329004329005" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" I2="100.0" ID="CMP-003.11.04" LOG_CI_END="0.20522899312034149" LOG_CI_START="-0.29632628297910696" LOG_EFFECT_SIZE="-0.04554864492938274" MODIFIED="2011-04-22 21:48:26 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.7218499294961027" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="32" WEIGHT="100.0" Z="0.35598749673402674">
<NAME>CT vs. CCT</NAME>
<DICH_DATA CI_END="1.6040909666460337" CI_START="0.5054447815246105" EFFECT_SIZE="0.9004329004329005" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.20522899312034149" LOG_CI_START="-0.29632628297910696" LOG_EFFECT_SIZE="-0.04554864492938274" MODIFIED="2010-09-15 13:51:36 +0100" MODIFIED_BY="[Empty name]" ORDER="215" O_E="0.0" SE="0.29461605191947376" STUDY_ID="STD-Cottraux-2009" TOTAL_1="33" TOTAL_2="32" VAR="0.08679861804861805" WEIGHT="100.0">
<FOOTNOTE>quit treatment</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.418113106150045" CI_START="0.4247135232839784" DF="0" EFFECT_SIZE="1.9999999999999998" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-003.11.05" LOG_CI_END="0.9739639017662782" LOG_CI_START="-0.3719039104383159" LOG_EFFECT_SIZE="0.30102999566398114" MODIFIED="2011-04-22 12:22:11 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.3806118373804923" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.876769537717365">
<NAME>CBT vs. IPT</NAME>
<DICH_DATA CI_END="9.418113106150045" CI_START="0.4247135232839784" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9739639017662782" LOG_CI_START="-0.3719039104383159" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2010-09-15 14:04:24 +0100" MODIFIED_BY="[Empty name]" ORDER="219" O_E="0.0" SE="0.7905694150420949" STUDY_ID="STD-Bellino-2007" TOTAL_1="16" TOTAL_2="16" VAR="0.625" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2012-07-04 16:17:12 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Non-comprehensive psychotherapeutic interventions: active vs. active conditions</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.6554283098563592" CI_START="-1.3225343700467986" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.33355303009521964" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.01" MODIFIED="2012-01-06 11:59:54 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.5085894535721851" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="8" TOTAL_2="8" UNITS="" WEIGHT="100.0" Z="0.6610356530618094">
<NAME>BPD total severity</NAME>
<GROUP_LABEL_1>treatment 1</GROUP_LABEL_1>
<GROUP_LABEL_2>treatment 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment 2</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6554283098563592" CI_START="-1.3225343700467986" DF="0" EFFECT_SIZE="-0.33355303009521964" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.01" MODIFIED="2012-01-06 11:59:54 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5085894535721851" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0" Z="0.6610356530618094">
<NAME>MACT vs. MACT+TA</NAME>
<CONT_DATA CI_END="0.6554283098563592" CI_START="-1.3225343700467986" EFFECT_SIZE="-0.33355303009521964" ESTIMABLE="YES" MEAN_1="79.0" MEAN_2="82.75" MODIFIED="2012-01-06 11:33:37 +0000" MODIFIED_BY="[Empty name]" ORDER="326" SD_1="8.96" SD_2="12.07" SE="0.5045915882906714" STUDY_ID="STD-Morey-2010" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0">
<FOOTNOTE>PAI-BOR-total</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.3103113267013854" CI_START="-1.7298866059713558" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.7097876396349853" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.02" MODIFIED="2012-06-13 13:19:22 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.17264680330420293" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="8" TOTAL_2="8" UNITS="" WEIGHT="100.0" Z="1.3637482795934341">
<NAME>Affective instability</NAME>
<GROUP_LABEL_1>Treatment 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment 2</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3103113267013854" CI_START="-1.7298866059713558" DF="0" EFFECT_SIZE="-0.7097876396349853" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.01" MODIFIED="2012-01-06 11:34:13 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.17264680330420293" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0" Z="1.3637482795934341">
<NAME>MACT vs. MACT+TA</NAME>
<CONT_DATA CI_END="0.3103113267013854" CI_START="-1.7298866059713558" EFFECT_SIZE="-0.7097876396349853" ESTIMABLE="YES" MEAN_1="74.63" MEAN_2="79.88" MODIFIED="2012-01-06 11:34:13 +0000" MODIFIED_BY="[Empty name]" ORDER="329" SD_1="5.66" SD_2="8.11" SE="0.5204682200197458" STUDY_ID="STD-Morey-2010" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0">
<FOOTNOTE>PAI-BOR-A</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.9458966505230099" CI_START="-1.0142571928278517" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.03418027115242095" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.03" MODIFIED="2012-06-13 13:19:03 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.9455039017376716" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="8" TOTAL_2="8" UNITS="" WEIGHT="100.0" Z="0.06835392096166919">
<NAME>Suicidality</NAME>
<GROUP_LABEL_1>Treatment 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment 2</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9458966505230099" CI_START="-1.0142571928278517" DF="0" EFFECT_SIZE="-0.03418027115242095" ESTIMABLE="YES" I2="0.0" ID="CMP-004.03.01" MODIFIED="2012-01-06 12:00:28 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9455039017376716" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0" Z="0.06835392096166919">
<NAME>MACT vs. MACT+TA</NAME>
<CONT_DATA CI_END="0.9458966505230099" CI_START="-1.0142571928278517" EFFECT_SIZE="-0.03418027115242095" ESTIMABLE="YES" MEAN_1="80.25" MEAN_2="80.88" MODIFIED="2012-01-06 11:57:33 +0000" MODIFIED_BY="[Empty name]" ORDER="331" SD_1="15.78" SD_2="18.93" SE="0.5000484342600948" STUDY_ID="STD-Morey-2010" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0">
<FOOTNOTE>PAI-SI</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.0597303712990729" CI_START="-0.901253749522988" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.07923831088804244" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.04" MODIFIED="2012-06-13 13:18:53 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.8741461999262415" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="8" TOTAL_2="8" UNITS="" WEIGHT="100.0" Z="0.15839417962369465">
<NAME>Parasuicidality</NAME>
<GROUP_LABEL_1>Treatment 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment 2</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0597303712990729" CI_START="-0.901253749522988" DF="0" EFFECT_SIZE="0.07923831088804244" ESTIMABLE="YES" I2="0.0" ID="CMP-004.04.01" MODIFIED="2012-01-06 12:00:32 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8741461999262415" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0" Z="0.15839417962369465">
<NAME>MACT vs. MACT+TA</NAME>
<CONT_DATA CI_END="1.0597303712990729" CI_START="-0.901253749522988" EFFECT_SIZE="0.07923831088804244" ESTIMABLE="YES" MEAN_1="73.38" MEAN_2="71.63" MODIFIED="2012-01-06 11:57:50 +0000" MODIFIED_BY="[Empty name]" ORDER="332" SD_1="22.41" SD_2="19.23" SE="0.5002602436294884" STUDY_ID="STD-Morey-2010" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0">
<FOOTNOTE>PAI-BOR-S</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.9369894380095186" CI_START="-1.0232770316367465" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.04314379681361398" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.05" MODIFIED="2012-06-13 13:18:40 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.9312483848130304" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="8" TOTAL_2="8" UNITS="" WEIGHT="100.0" Z="0.08627427874768114">
<NAME>Interpersonal problems</NAME>
<GROUP_LABEL_1>Treatment 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment 2</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9369894380095186" CI_START="-1.0232770316367465" DF="0" EFFECT_SIZE="-0.04314379681361398" ESTIMABLE="YES" I2="0.0" ID="CMP-004.05.01" MODIFIED="2012-01-06 11:58:12 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9312483848130304" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0" Z="0.08627427874768114">
<NAME>MACT vs. MACT+TA</NAME>
<CONT_DATA CI_END="0.9369894380095186" CI_START="-1.0232770316367465" EFFECT_SIZE="-0.04314379681361398" ESTIMABLE="YES" MEAN_1="73.88" MEAN_2="74.38" MODIFIED="2012-01-06 11:58:12 +0000" MODIFIED_BY="[Empty name]" ORDER="333" SD_1="12.1" SD_2="9.68" SE="0.500077165985854" STUDY_ID="STD-Morey-2010" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0">
<FOOTNOTE>PAI-BOR-N</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.5485804548319801" CI_START="-1.4436692676127347" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.44754440639037724" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.06" MODIFIED="2012-06-13 13:18:28 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.3785434099171754" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="8" TOTAL_2="8" UNITS="" WEIGHT="100.0" Z="0.8805833005022177">
<NAME>Identity disturbance</NAME>
<GROUP_LABEL_1>Treatment 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment 2</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5485804548319801" CI_START="-1.4436692676127347" DF="0" EFFECT_SIZE="-0.44754440639037724" ESTIMABLE="YES" I2="0.0" ID="CMP-004.06.01" MODIFIED="2012-01-06 11:58:40 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3785434099171754" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0" Z="0.8805833005022177">
<NAME>MACT vs. MACT+TA</NAME>
<CONT_DATA CI_END="0.5485804548319801" CI_START="-1.4436692676127347" EFFECT_SIZE="-0.44754440639037724" ESTIMABLE="YES" MEAN_1="73.25" MEAN_2="78.13" MODIFIED="2012-01-06 11:58:40 +0000" MODIFIED_BY="[Empty name]" ORDER="334" SD_1="5.95" SD_2="13.31" SE="0.5082363089728501" STUDY_ID="STD-Morey-2010" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0">
<FOOTNOTE>PAI-BOR-I</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9220243686433105" CI_START="0.33298225061098136" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-004.07" LOG_CI_END="0.2837588896281722" LOG_CI_START="-0.477578915644285" LOG_EFFECT_SIZE="-0.09691001300805639" METHOD="MH" MODIFIED="2012-07-04 16:17:12 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.6178046421923429" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0" Z="0.49896414947928547">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Treatment 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment 2</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9220243686433105" CI_START="0.33298225061098136" DF="0" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-004.07.01" LOG_CI_END="0.2837588896281722" LOG_CI_START="-0.477578915644285" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2012-01-06 12:00:39 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6178046421923429" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0" Z="0.49896414947928547">
<NAME>MACT vs. MACT+TA</NAME>
<DICH_DATA CI_END="1.9220243686433105" CI_START="0.33298225061098136" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.2837588896281722" LOG_CI_START="-0.477578915644285" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2012-01-06 11:59:13 +0000" MODIFIED_BY="[Empty name]" ORDER="336" O_E="0.0" SE="0.4472135954999579" STUDY_ID="STD-Morey-2010" TOTAL_1="8" TOTAL_2="8" VAR="0.2" WEIGHT="100.0">
<FOOTNOTE>failing to complete all 6 sessions</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2012-07-11 11:36:16 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Funnel plot</NAME>
<IV_OUTCOME CHI2="38.78067762985414" CI_END="-0.11981530609128728" CI_START="-0.3638418646837633" CI_STUDY="95" CI_TOTAL="95" DF="17" EFFECT_SIZE="-0.24182858538752527" ESTIMABLE="YES" I2="56.163736584857766" I2_Q="60.32714884671022" ID="CMP-005.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2012-07-11 11:36:07 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0019172671886172887" P_Q="0.0013321185115288126" P_Z="1.0248974168027351E-4" Q="35.2886157486039" RANDOM="NO" SCALE="4.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="18" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="605" TOTAL_2="582" WEIGHT="100.00000000000003" Z="3.8846207603440157">
<NAME>Parasuicidality</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Std. Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.4900328329234708" CI_START="-0.2900328329234708" DF="0" EFFECT_SIZE="0.1" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="-0.30977482062498607" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6153070195315105" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="47" WEIGHT="9.786149912833618" Z="0.5025125628140703">
<NAME>CBT vs. TAU</NAME>
<IV_DATA CI_END="0.4900328329234708" CI_START="-0.2900328329234708" EFFECT_SIZE="0.1" ESTIMABLE="YES" ESTIMATE="0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="574" SE="0.199" STUDY_ID="STD-Davidson-2006" TOTAL_1="52" TOTAL_2="47" WEIGHT="9.786149912833618"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="3.492061881250233" CI_END="-0.006410798442733956" CI_START="-0.694271458840695" DF="3" EFFECT_SIZE="-0.35034112864171446" ESTIMABLE="YES" I2="14.09086946288776" ID="CMP-005.01.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3217932526146816" P_Z="0.045879813409474786" STUDIES="4" TAU2="0.0" TOTAL_1="74" TOTAL_2="87" WEIGHT="12.585580328630236" Z="1.996497354692767">
<NAME>DBT vs. TAU</NAME>
<IV_DATA CI_END="0.8919952217148113" CI_START="-0.4987952217148113" EFFECT_SIZE="0.1966" ESTIMABLE="YES" ESTIMATE="0.1966" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="576" SE="0.3548" STUDY_ID="STD-Carter-2010" TOTAL_1="20" TOTAL_2="31" WEIGHT="3.0785824897311356"/>
<IV_DATA CI_END="0.5649237390198345" CI_START="-1.2049237390198346" EFFECT_SIZE="-0.32" ESTIMABLE="YES" ESTIMATE="-0.32" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="578" SE="0.4515" STUDY_ID="STD-Koons-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.9010892580195906"/>
<IV_DATA CI_END="0.07994497566771053" CI_START="-1.1199449756677105" EFFECT_SIZE="-0.52" ESTIMABLE="YES" ESTIMATE="-0.52" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="575" SE="0.3061" STUDY_ID="STD-Linehan-1991" TOTAL_1="22" TOTAL_2="22" WEIGHT="4.136103120873334"/>
<IV_DATA CI_END="0.005019963633286162" CI_START="-1.3050199636332862" EFFECT_SIZE="-0.65" ESTIMABLE="YES" ESTIMATE="-0.65" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="577" SE="0.3342" STUDY_ID="STD-Van-den-Bosch-2005" TOTAL_1="22" TOTAL_2="24" WEIGHT="3.469805460006176"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="3.5170378823726005E-32" CI_END="0.060074669711927986" CI_START="-0.5200746697119281" DF="0" EFFECT_SIZE="-0.23000000000000004" ESTIMABLE="YES" I2="100.0" ID="CMP-005.01.03" LOG_CI_END="-1.2213086082507612" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.12017152351230215" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="90" WEIGHT="17.692719261236494" Z="1.5540540540540544">
<NAME>DBT vs. GM</NAME>
<IV_DATA CI_END="0.060074669711928014" CI_START="-0.5200746697119281" EFFECT_SIZE="-0.23" ESTIMABLE="YES" ESTIMATE="-0.23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="579" SE="0.148" STUDY_ID="STD-McMain-2009" TOTAL_1="90" TOTAL_2="90" WEIGHT="17.692719261236494"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.30002028188693364" CI_START="-0.5400202818869336" DF="0" EFFECT_SIZE="-0.12" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.04" LOG_CI_END="-0.5228493852341954" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.5755049036096187" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="39" WEIGHT="8.438663612772274" Z="0.5599626691553896">
<NAME>DBT vs. CTBE</NAME>
<IV_DATA CI_END="0.30002028188693364" CI_START="-0.5400202818869336" EFFECT_SIZE="-0.12" ESTIMABLE="YES" ESTIMATE="-0.12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="580" SE="0.2143" STUDY_ID="STD-Linehan-2006" TOTAL_1="50" TOTAL_2="39" WEIGHT="8.438663612772274"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.40998262877732217" CI_START="-0.6099826287773221" DF="0" EFFECT_SIZE="-0.1" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.05" LOG_CI_END="-0.3872345442216729" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.7007414694159788" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="30" WEIGHT="5.724050185160651" Z="0.38431975403535745">
<NAME>DBT-ST vs. SG</NAME>
<IV_DATA CI_END="0.40998262877732217" CI_START="-0.6099826287773221" EFFECT_SIZE="-0.1" ESTIMABLE="YES" ESTIMATE="-0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="581" SE="0.2602" STUDY_ID="STD-Soler-2009" TOTAL_1="29" TOTAL_2="30" WEIGHT="5.724050185160651"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="6.491211131110537E-34" CI_END="0.9825923823789675" CI_START="-1.1525923823789674" DF="0" EFFECT_SIZE="-0.08499999999999999" ESTIMABLE="YES" I2="100.0" ID="CMP-005.01.06" LOG_CI_END="-0.007626607088642056" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Z="0.875994239172338" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="9" WEIGHT="1.306180712852328" Z="0.15604920139526343">
<NAME>DDP vs. TAU</NAME>
<IV_DATA CI_END="0.9825923823789675" CI_START="-1.1525923823789674" EFFECT_SIZE="-0.085" ESTIMABLE="YES" ESTIMATE="-0.085" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="582" SE="0.5447" STUDY_ID="STD-Gregory-2008" TOTAL_1="10" TOTAL_2="9" WEIGHT="1.306180712852328"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="-0.08508044465901121" CI_START="-1.8749195553409888" DF="0" EFFECT_SIZE="-0.98" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.07" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.03184915288730731" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="10" WEIGHT="1.8588579487904184" Z="2.146298729741568">
<NAME>ERG vs. TAU</NAME>
<IV_DATA CI_END="-0.08508044465901121" CI_START="-1.8749195553409888" EFFECT_SIZE="-0.98" ESTIMABLE="YES" ESTIMATE="-0.98" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="583" SE="0.4566" STUDY_ID="STD-Gratz-2006" TOTAL_1="12" TOTAL_2="10" WEIGHT="1.8588579487904184"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.6150450657063604" CI_START="-0.5750450657063604" DF="0" EFFECT_SIZE="0.02" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.08" LOG_CI_END="-0.2110930613456501" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.6989700043360187" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.9474764266143817" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="4.204501219209237" Z="0.06587615283267458">
<NAME>IPT-BPD+fl vs. CM+fl</NAME>
<IV_DATA CI_END="0.6150450657063604" CI_START="-0.5750450657063604" EFFECT_SIZE="0.02" ESTIMABLE="YES" ESTIMATE="0.02" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="584" SE="0.3036" STUDY_ID="STD-Bellino-2010" TOTAL_1="22" TOTAL_2="22" WEIGHT="4.204501219209237"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="-0.09503442419170827" CI_START="-1.6649655758082917" DF="0" EFFECT_SIZE="-0.88" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.09" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Z="0.028002351381782944" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="13" WEIGHT="2.4160892685524127" Z="2.1972534332084894">
<NAME>MACT vs. TAU</NAME>
<IV_DATA CI_END="-0.09503442419170827" CI_START="-1.6649655758082917" EFFECT_SIZE="-0.88" ESTIMABLE="YES" ESTIMATE="-0.88" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="585" SE="0.4005" STUDY_ID="STD-Weinberg-2006" TOTAL_1="15" TOTAL_2="13" WEIGHT="2.4160892685524127"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="-0.36780765952198435" CI_START="-2.072192340478016" DF="0" EFFECT_SIZE="-1.22" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.10" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Z="0.005017816665080538" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="2.0499295994252353" Z="2.8058877644894205">
<NAME>MBT-PH vs. TAU</NAME>
<IV_DATA CI_END="-0.36780765952198435" CI_START="-2.072192340478016" EFFECT_SIZE="-1.22" ESTIMABLE="YES" ESTIMATE="-1.22" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="586" SE="0.4348" STUDY_ID="STD-Bateman-1999" TOTAL_1="19" TOTAL_2="19" WEIGHT="2.0499295994252353"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="-0.07112348761412274" CI_START="-0.8860765123858774" DF="0" EFFECT_SIZE="-0.4786" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.11" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Z="0.021331320656205546" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="63" WEIGHT="8.96621272849256" Z="2.302068302068302">
<NAME>MBT-out vs. TAU</NAME>
<IV_DATA CI_END="-0.07112348761412274" CI_START="-0.8860765123858774" EFFECT_SIZE="-0.4786" ESTIMABLE="YES" ESTIMATE="-0.4786" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="587" SE="0.2079" STUDY_ID="STD-Bateman-2009" TOTAL_1="71" TOTAL_2="63" WEIGHT="8.96621272849256"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="2.2140146806271404E-31" CI_END="-0.9950929956955481" CI_START="-2.844907004304451" DF="0" EFFECT_SIZE="-1.9199999999999997" ESTIMABLE="YES" I2="100.0" ID="CMP-005.01.12" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0" P_Z="4.728456744210323E-5" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="12" WEIGHT="1.740275725922391" Z="4.068658614113159">
<NAME>SFT-G vs. TAU</NAME>
<IV_DATA CI_END="-0.9950929956955483" CI_START="-2.8449070043044515" EFFECT_SIZE="-1.92" ESTIMABLE="YES" ESTIMATE="-1.92" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="588" SE="0.4719" STUDY_ID="STD-Farrell-2009" TOTAL_1="16" TOTAL_2="12" WEIGHT="1.740275725922391"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.06494947760020386" CI_START="-0.6449494776002038" DF="0" EFFECT_SIZE="-0.29" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.13" LOG_CI_END="-1.1874243376819649" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Z="0.1093049026746906" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="59" WEIGHT="11.816289333700155" Z="1.6013252346769737">
<NAME>STEPPS vs. TAU</NAME>
<IV_DATA CI_END="0.06494947760020386" CI_START="-0.6449494776002038" EFFECT_SIZE="-0.29" ESTIMABLE="YES" ESTIMATE="-0.29" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="589" SE="0.1811" STUDY_ID="STD-Blum-2008" TOTAL_1="65" TOTAL_2="59" WEIGHT="11.816289333700155"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.8799854618764199" CI_START="-0.2669854618764199" DF="0" EFFECT_SIZE="0.3065" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.14" LOG_CI_END="-0.05552450271233447" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-0.5135695211455662" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Z="0.294866684232852" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="30" WEIGHT="4.526571384398252" Z="1.0475051264524948">
<NAME>STEPPS+IT vs. TAU</NAME>
<IV_DATA CI_END="0.8799854618764199" CI_START="-0.2669854618764199" EFFECT_SIZE="0.3065" ESTIMABLE="YES" ESTIMATE="0.3065" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="590" SE="0.2926" STUDY_ID="STD-Bos-2010" TOTAL_1="28" TOTAL_2="30" WEIGHT="4.526571384398252"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.6173034571329009" CI_START="-0.31250345713290084" DF="0" EFFECT_SIZE="0.1524" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.15" LOG_CI_END="-0.2095012908126769" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-0.8170150329964183" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="1.0" P_Z="0.5205513296091586" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="52" WEIGHT="6.887928778023757" Z="0.642495784148398">
<NAME>TFP vs. CTBE</NAME>
<IV_DATA CI_END="0.6173034571329009" CI_START="-0.31250345713290084" EFFECT_SIZE="0.1524" ESTIMABLE="YES" ESTIMATE="0.1524" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="591" SE="0.2372" STUDY_ID="STD-Doering-2010" TOTAL_1="52" TOTAL_2="52" WEIGHT="6.887928778023757"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="39.05652784785097" CI_END="-0.11759479887943815" CI_START="-0.3616213574719141" CI_STUDY="95" CI_TOTAL="95" DF="17" EFFECT_SIZE="-0.23960807817567611" ESTIMABLE="YES" I2="56.473345336212724" I2_Q="85.68442283551424" ID="CMP-005.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2012-07-11 11:36:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0017551020121110428" P_Q="1.0750495422962025E-4" P_Z="1.1862445237523567E-4" Q="20.95619314212795" RANDOM="NO" SCALE="3.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="18" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="605" TOTAL_2="582" WEIGHT="99.99999999999997" Z="3.8489515759098434">
<NAME>By sample size - parasuicidality</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Std. Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.3276893189204506" CI_END="0.5262402705904357" CI_START="-0.8363627152180828" DF="1" EFFECT_SIZE="-0.1550612223138236" ESTIMABLE="YES" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="-0.27881592054904814" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5670230235972544" P_Z="0.6555400529837292" STUDIES="2" TAU2="0.0" TOTAL_1="20" TOTAL_2="19" WEIGHT="3.2072699708719172" Z="0.4460791797744686">
<NAME>0-20</NAME>
<IV_DATA CI_END="1.1525923823789674" CI_START="-0.9825923823789675" EFFECT_SIZE="0.085" ESTIMABLE="YES" ESTIMATE="0.085" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="592" SE="0.5447" STUDY_ID="STD-Gregory-2008" TOTAL_1="10" TOTAL_2="9" WEIGHT="1.3061807128523275"/>
<IV_DATA CI_END="0.5649237390198345" CI_START="-1.2049237390198346" EFFECT_SIZE="-0.32" ESTIMABLE="YES" ESTIMATE="-0.32" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="593" SE="0.4515" STUDY_ID="STD-Koons-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.9010892580195897"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="14.679320836742107" CI_END="-0.43634196431000816" CI_START="-0.9837074164624977" DF="6" EFFECT_SIZE="-0.7100246903862529" ESTIMABLE="YES" I2="59.126174386882425" ID="CMP-005.02.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.022903031451580014" P_Z="3.68007307307911E-7" STUDIES="7" TAU2="0.0" TOTAL_1="128" TOTAL_2="122" WEIGHT="19.875562342779194" Z="5.084803272909409">
<NAME>21-50</NAME>
<IV_DATA CI_END="-0.36780765952198435" CI_START="-2.072192340478016" EFFECT_SIZE="-1.22" ESTIMABLE="YES" ESTIMATE="-1.22" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="599" SE="0.4348" STUDY_ID="STD-Bateman-1999" TOTAL_1="19" TOTAL_2="19" WEIGHT="2.0499295994252344"/>
<IV_DATA CI_END="0.6150450657063604" CI_START="-0.5750450657063604" EFFECT_SIZE="0.02" ESTIMABLE="YES" ESTIMATE="0.02" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="600" SE="0.3036" STUDY_ID="STD-Bellino-2010" TOTAL_1="22" TOTAL_2="22" WEIGHT="4.204501219209235"/>
<IV_DATA CI_END="-0.9950929956955483" CI_START="-2.8449070043044515" EFFECT_SIZE="-1.92" ESTIMABLE="YES" ESTIMATE="-1.92" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="596" SE="0.4719" STUDY_ID="STD-Farrell-2009" TOTAL_1="16" TOTAL_2="12" WEIGHT="1.7402757259223904"/>
<IV_DATA CI_END="-0.08508044465901121" CI_START="-1.8749195553409888" EFFECT_SIZE="-0.98" ESTIMABLE="YES" ESTIMATE="-0.98" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="597" SE="0.4566" STUDY_ID="STD-Gratz-2006" TOTAL_1="12" TOTAL_2="10" WEIGHT="1.8588579487904175"/>
<IV_DATA CI_END="0.07994497566771053" CI_START="-1.1199449756677105" EFFECT_SIZE="-0.52" ESTIMABLE="YES" ESTIMATE="-0.52" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="594" SE="0.3061" STUDY_ID="STD-Linehan-1991" TOTAL_1="22" TOTAL_2="22" WEIGHT="4.136103120873332"/>
<IV_DATA CI_END="0.005019963633286162" CI_START="-1.3050199636332862" EFFECT_SIZE="-0.65" ESTIMABLE="YES" ESTIMATE="-0.65" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="598" SE="0.3342" STUDY_ID="STD-Van-den-Bosch-2005" TOTAL_1="22" TOTAL_2="24" WEIGHT="3.4698054600061745"/>
<IV_DATA CI_END="-0.09503442419170827" CI_START="-1.6649655758082917" EFFECT_SIZE="-0.88" ESTIMABLE="YES" ESTIMATE="-0.88" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="595" SE="0.4005" STUDY_ID="STD-Weinberg-2006" TOTAL_1="15" TOTAL_2="13" WEIGHT="2.4160892685524114"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="2.1325923837907186" CI_END="0.2601571957145908" CI_START="-0.13342406369220694" DF="5" EFFECT_SIZE="0.06336656601119194" ESTIMABLE="YES" I2="0.0" ID="CMP-005.02.03" LOG_CI_END="-0.5847641574061473" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.198139827714587" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.830510922187645" P_Z="0.5279697599121231" STUDIES="6" TAU2="0.0" TOTAL_1="231" TOTAL_2="229" WEIGHT="38.44194636291967" Z="0.6311082361650224">
<NAME>51-100</NAME>
<IV_DATA CI_END="0.8799854618764199" CI_START="-0.2669854618764199" EFFECT_SIZE="0.3065" ESTIMABLE="YES" ESTIMATE="0.3065" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="604" SE="0.2926" STUDY_ID="STD-Bos-2010" TOTAL_1="28" TOTAL_2="30" WEIGHT="4.52657138439825"/>
<IV_DATA CI_END="0.8919952217148113" CI_START="-0.4987952217148113" EFFECT_SIZE="0.1966" ESTIMABLE="YES" ESTIMATE="0.1966" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="601" SE="0.3548" STUDY_ID="STD-Carter-2010" TOTAL_1="20" TOTAL_2="31" WEIGHT="3.0785824897311342"/>
<IV_DATA CI_END="0.4900328329234708" CI_START="-0.2900328329234708" EFFECT_SIZE="0.1" ESTIMABLE="YES" ESTIMATE="0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="605" SE="0.199" STUDY_ID="STD-Davidson-2006" TOTAL_1="52" TOTAL_2="47" WEIGHT="9.786149912833613"/>
<IV_DATA CI_END="0.6173034571329009" CI_START="-0.31250345713290084" EFFECT_SIZE="0.1524" ESTIMABLE="YES" ESTIMATE="0.1524" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="602" SE="0.2372" STUDY_ID="STD-Doering-2010" TOTAL_1="52" TOTAL_2="52" WEIGHT="6.8879287780237535"/>
<IV_DATA CI_END="0.30002028188693364" CI_START="-0.5400202818869336" EFFECT_SIZE="-0.12" ESTIMABLE="YES" ESTIMATE="-0.12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="603" SE="0.2143" STUDY_ID="STD-Linehan-2006" TOTAL_1="50" TOTAL_2="39" WEIGHT="8.43866361277227"/>
<IV_DATA CI_END="0.40998262877732217" CI_START="-0.6099826287773221" EFFECT_SIZE="-0.1" ESTIMABLE="YES" ESTIMATE="-0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="606" SE="0.2602" STUDY_ID="STD-Soler-2009" TOTAL_1="29" TOTAL_2="30" WEIGHT="5.72405018516065"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.9607321662697514" CI_END="-0.10965474348931534" CI_START="-0.5030657734183392" DF="2" EFFECT_SIZE="-0.3063602584538273" ESTIMABLE="YES" I2="0.0" ID="CMP-005.02.04" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6185569530338364" P_Z="0.0022689957192428304" STUDIES="3" TAU2="0.0" TOTAL_1="226" TOTAL_2="212" WEIGHT="38.475221323429196" Z="3.0525584042329137">
<NAME>101-</NAME>
<IV_DATA CI_END="-0.07112348761412274" CI_START="-0.8860765123858774" EFFECT_SIZE="-0.4786" ESTIMABLE="YES" ESTIMATE="-0.4786" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="609" SE="0.2079" STUDY_ID="STD-Bateman-2009" TOTAL_1="71" TOTAL_2="63" WEIGHT="8.966212728492556"/>
<IV_DATA CI_END="0.06494947760020386" CI_START="-0.6449494776002038" EFFECT_SIZE="-0.29" ESTIMABLE="YES" ESTIMATE="-0.29" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="607" SE="0.1811" STUDY_ID="STD-Blum-2008" TOTAL_1="65" TOTAL_2="59" WEIGHT="11.81628933370015"/>
<IV_DATA CI_END="0.060074669711928014" CI_START="-0.5200746697119281" EFFECT_SIZE="-0.23" ESTIMABLE="YES" ESTIMATE="-0.23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-04 21:22:28 +0100" MODIFIED_BY="[Empty name]" ORDER="608" SE="0.148" STUDY_ID="STD-McMain-2009" TOTAL_1="90" TOTAL_2="90" WEIGHT="17.692719261236487"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2017-04-06 11:47:13 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2012-06-26 15:06:47 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAo8AAAO7CAYAAAA1DG50AACAAElEQVR42uydD2RX7f//PyRJkpjc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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2017-04-06 11:47:13 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAxEAAAEACAMAAAD7rAtDAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2017-04-06 11:47:13 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAV0AAAVQCAIAAABnOx4tAABDGklEQVR42u3dv24kxfrG8ZGQEIGD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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2012-07-11 14:13:25 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-005.01" SETTINGS="SHOW_CI_LINES:YES;SHOW_STUDY_NAMES:NO;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_EFFECT_ESTIMATE:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison of all controlled comparisons for the outcome of parasuicidality</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAHcCAMAAAA9cSS9AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2017-06-30 15:58:43 +0100" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2017-06-30 15:58:43 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2017-04-06 11:52:13 +0100" MODIFIED_BY="[Empty name]">Comments on the Gregory et al 2008 study</TITLE>
<DATE_SUBMITTED>
<DATE DAY="14" MONTH="2" YEAR="2017"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2017-04-06 17:21:40 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>On 14 February 2017, Dr Robert Gregory submitted the following comments, having identified himself as an author of an included study within the present review.</B>
</P>
<P>
<I>I have a number of concerns regarding the 2012 review of &#8220;Psychological Therapies for People with Borderline Personality Disorder&#8221;, specifically in regards to your review of Dynamic Deconstructive Psychotherapy (DDP). I realize that several years have passed since the Cochrane review. However, since the time of its publication, both clinical and academic colleagues have repeatedly brought the review to my attention, citing it as evidence that DDP is ineffective. So I felt I needed to respond.</I>
</P>
<P>
<I>I have a great respect for Cochrane reviews and the time and effort needed by the Cochrane authors to make a fair and accurate assessment. And in such a large review (over 200 pages), it is possible for oversights to occur. Nevertheless, since busy clinicians are making decisions that affect vulnerable patients based on the review, it&#8217;s important to get it right. I have listed my concerns below:</I>
</P>
<P>
<I>
<B>1. </B>My largest concern is how the data from my 2008 study were analyzed and reported. The 2008 study by Gregory and colleagues was a small randomized controlled trial (n = 30) comparing DDP to TAU for participants suffering from co-occurring borderline personality disorder (BPD) and alcohol dependence. In their Discussion section, Summary of Main Results, the authors conclude that &#8220;There were no statistically significant results, but DDP was indicated to be superior to the control group in terms of BPD severity and parasuicidality, with small to moderate effects&#8221; (p 74). The authors draw the same conclusion on pages 2 and 31.</I>
</P>
<P>
<I>This would be a reasonable conclusion based on the Cochrane authors&#8217; method of analysis, which calculated standardized mean differences &#8220;on the basis of post-treatment results&#8221; (p 15). The difficulty of that method of analysis for the 2008 study was that there were substantial differences in baseline scores between the two groups, which were not accounted for in the analysis. Participants assigned to DDP through randomization had substantially greater baseline psychopathology than control participants (see </I>
<LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>
<I>, Table 4, p 37). In fact, on the continuous outcome variables, participants receiving DDP had baseline scores averaging more than half a standard deviation higher than the control group! By not taking into account baseline differences in either the analysis, summary of results, or discussion, the Cochrane authors markedly understate positive treatment effects and leave clinicians with the wrong impression that DDP was shown to be an ineffective treatment in this RCT, a potential Type II error.</I>
</P>
<P>
<I>
<B>2.</B> There was also a simple error in the same section of the report summarizing results in the wrong direction. The Cochrane authors state: &#8220;For depression, a non-statistically significant effect favouring the control group was found&#8221; (p 74). This conclusion contradicts the authors&#8217; own analysis of treatment effects for depression as outlined on p 164 and p 184 of the report, and is clearly a misstatement and an honest mistake in a very lengthy report. Nevertheless, it&#8217;s important to get it corrected. </I>
</P>
<P>
<I>
<B>3.</B> The Cochrane authors mention concern regarding attentional bias in the 2008 RCT (see p 14, p 26, and p 120). A strength of the RCT (</I>
<LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>
<I>) is that the control participants were assigned to the best alternative treatment available in the community. In regards to total treatment contact hours, there were no statistically significant differences between the groups; three of the time points indicated contact hours favoring the control group (3, 6, and 12 months) and one time point (9 months) favored the DDP group (see Table 2, p 33). </I>
</P>
<P>
<I>Admittedly, I am focusing on concerns and am omitting all the aspects that the authors did extremely well in this complex and large review. For that I am very appreciative. Nevertheless, Cochrane has an enormous responsibility given its well-deserved reputation among clinicians for accurate and unbiased reporting of treatment reviews. The patient population with BPD is high risk, with substantial morbidity and mortality. Clinicians need to get the most accurate information possible and I hope you will consider amending your report to take these concerns into account. </I>
</P>
<P>
<I>Sincerely,</I>
</P>
<P>
<I>Robert J. Gregory, MD </I>
</P>
<P>
<B>Do you have any affiliation with or involvement in any organisation with a financial interest in the subject matter of your comment?:</B> <I>I do not have any affiliation with or involvement in any organisation with a financial interest in the subject matter of my comment.&#8203;</I>
<BR/>_____________________________________________________________________________________________________________________<BR/>
</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2017-06-30 15:58:37 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>On 20 February the Feedback Editor of the Cochrane Developmental, Psychosocial and Learning Problems Group (CDPLPG) sent the above comments to Professor Julian Higgins, Statistical Editor of the CDPLPG, for advice / comment, which was duly supplied on 27 February. This was then circulated to other members of CDPLPG's editorial team, approved and sent on to the author team.</B>
</P>
<P>
<B>On 27 March 2017, Dr Jutta Stoffers-Winterling submitted the following comments on behalf of the author team as a whole:</B>
</P>
<P>
<I>First, we would like to thank Dr Gregory for his most respectful and appreciative feedback. We understand his concerns, and take them seriously.</I>
</P>
<P>
<I>Though an update of this review is currently being finalised by our working group, we would like to address Dr Gregory&#8217;s comments and concerns. In the following, we will try to reply to each of the points raised by Dr Gregory.</I>
</P>
<P>
<B>Ad 1:</B> <I>We agree that obviously greater pathology scores were observed in the experimental group (DDP) at baseline for most measures (cf. </I>
<LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>
<I>, Table 4, p 37). We have sought statistical advice and were reassured that this is a situation that often occurs in samples of smaller size. However, as this is a randomised trial (using a minimization procedure), the trialists have gone to some lengths to try and ensure balance. That means, if baseline imbalance occurs, it is due to chance. The statistical methods used in our review to compare the groups allow for such chance differences, and we were advised not to change them (</I>
<LINK REF="REF-Higgins-2017-_x005b_pers-comm_x005d_" TYPE="REFERENCE">Higgins 2017 [pers comm]</LINK>).</P>
<P>
<I>We understand your concerns regarding the possibility of Type II errors, and have, therefore, inserted the following amendment (see 'Discussion &gt; Quality of the evidence'):</I>
</P>
<P>"Most studies had comparatively small samples (12 out of 28 trials included 39 participants or less). As a consequence, the experimental groups may seem to be imbalanced at baseline, which was, for example, the case in the RCT of <LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>. Dr Gregory, the main investigator of this trial, has raised concerns about the appropriateness of using endpoint data alone for effect size calculation, and referred to "substantially greater baseline psychopathology" in the active group, which may have led to an underestimation of positive treatment effects and a Type II error (<LINK REF="REF-Gregory-2017" TYPE="REFERENCE">Gregory 2017</LINK>). However, group allocation was randomised (as in any here-included study), so any imbalances at baseline are regarded to be due to chance alone, and the the statistical methods used in this review allow for such chance differences." See <LINK TAG="QUALITY_OF_EVIDENCE" TYPE="SECTION">Quality of the evidence</LINK>.</P>
<P>Nevertheless, we are aware that the power of studies that include smaller samples (such as 
<LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>
<I>) </I>may be too small to detect a real effect as statistically significant if it exists. Therefore, we have not only reported statistical significance throughout the text but also referred to their magnitude ("small, moderate, large").</P>
<P>
<B>Ad 2:</B> <I>We apologise for this mistake! Actually, this finding was reported correctly elsewhere in the text but erroneously in the 'Discussion &gt; Summary of main results' section. We have corrected this, so that it now reads:</I>
</P>
<P>&#8220;Dynamic Deconstructive Psychotherapy (DDP) was also investigated in a single trial only (<LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>). There were no statistically significant results, but DDP was indicated to be superior to the control group in terms of BPD severity, parasuicidality and depression with small to moderate effects.&#8221; See <LINK TAG="SUMMARY_OF_RESULTS" TYPE="SECTION">Summary of main results</LINK>.</P>
<P>
<B>Ad 3:</B> <I>Thank you for bringing this to our attention. We agree that there is actually a low risk of bias due to a higher amount of attention spent to the participants of the treatment of investigation (DDP).</I>
</P>
<P>
<I>We have now changed the judgement of attention bias from 'high risk' to 'low risk'. The 'Risk of bias' table now reads:</I>
</P>
<TABLE COLS="2" ROWS="1">
<TR>
<TD VALIGN="TOP">
<P>
<B>Low risk </B>
</P>
</TD>
<TD>
<P>Though participants of the control group did not receive an alternate, obligatory control treatment, but were free to join alternative treatments, they did not receive less professional attention. Indeed, "[...] DDP participants received fewer overall treatment contact hours than did participants receiving community care." (<LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>, p 39). Also, cf. <LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK>, Table 2, p 33.</P>
</TD>
</TR>
</TABLE>
<P>
<I>Figures 2 (&#8220;Risk of bias graph&#8221;) and 3 (&#8220;Risk of bias summary) were updated accordingly.</I>
</P>
<P>
<I>We also changed the text in the 'Results &gt; Risk of Bias in included studies &gt; Other potential sources of bias &gt; Attention bias' section:</I>
</P>
<P>"Only 10 studies (<LINK REF="STD-Koons-2001" TYPE="STUDY">Koons 2001</LINK>; <LINK REF="STD-Giesen_x002d_Bloo-2006" TYPE="STUDY">Giesen-Bloo 2006</LINK>; <LINK REF="STD-Linehan-2006" TYPE="STUDY">Linehan 2006</LINK>; <LINK REF="STD-Bellino-2007" TYPE="STUDY">Bellino 2007</LINK>; <LINK REF="STD-Bateman-2009" TYPE="STUDY">Bateman 2009</LINK>; <LINK REF="STD-Cottraux-2009" TYPE="STUDY">Cottraux 2009</LINK>; <LINK REF="STD-Nadort-2009" TYPE="STUDY">Nadort 2009</LINK>; <LINK REF="STD-Soler-2009" TYPE="STUDY">Soler 2009</LINK>; <LINK REF="STD-Doering-2010" TYPE="STUDY">Doering 2010</LINK>; <LINK REF="STD-Morey-2010" TYPE="STUDY">Morey 2010</LINK>) were rated as providing similar amounts of attention as obligatory components of the study protocol to all trial groups. The participants allocated to the control group of <LINK REF="STD-Gregory-2008" TYPE="STUDY">Gregory 2008</LINK> did not get an obligatory control treatment, but were referred to alternative treatments in the community and had not less but markedly more professional contact hours during most of the study period. The risk of attention bias was therefore also judged low for this trial. All remaining trials provided more attention (that is, in terms of frequency of appointments, involvement in additional group treatments etc.) to one group, usually the experimental group (EG)." See <LINK TAG="OTHER_BIAS_SOURCES" TYPE="SECTION">Other potential sources of bias</LINK>.</P>
<P>
<I>We hope we have addressed your concerns adequately. An update of this review is currently under way, and publication is intended for the end of this year/early 2018. Of course, any changes incorporated now will also be included in the updated version.</I>
</P>
<P>
<I>We are aware that without the most valuable, time-consuming and hard work of the primary study authors, no meta-analysis or systematic review would exist. What is more, the study sample in Dr Gregory&#8217;s study included persons with BPD plus substance-related disorder (alcohol abuse or dependence), who are usually considered as most difficult to treat (or to be kept in treatment at all), and we can understand how much work and effort this study must have meant.</I>
</P>
<P>
<I>Sincerely,</I>
</P>
<P>
<I>Jutta Stoffers-Winterling, University Medical Center, Mainz, Germany</I>
</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2017-06-30 15:58:43 +0100" MODIFIED_BY="[Empty name]">
<P>Robert J Gregory, MD, SUNY Upstate Medical University, New York, USA<BR/>
<B>Email address: </B>gregoryr@upstate.edu</P>
<P>Jutta Stoffers-Winterling, University Medical Center, Mainz, Germany<BR/>
<B>Email address:</B> jutta.winterling@gmail.com</P>
<P>
<I>(on behalf of the review author team </I>&#8212;<I> Jutta Stoffers-Winterling, Birgit A Völlm, Gerta Rücker, Antje Timmer, Nick Huband, Klaus Lieb)</I>
</P>
<P>
<B>From the editorial board of the CDPLPG:</B>
<BR/>
<BR/>Professor Julian Higgins, University of Bristol, UK (Statistical Editor, CDPLPG)<BR/>
<B>Email address:</B> julian.higgins@bristol.ac.uk<BR/>
<BR/>Jane Dennis, PhD, University of Bristol, UK (Feedback Editor, CDPLPG)<BR/>
<B>Email address:</B> jane.dennis@bristol.ac.uk</P>
<P>Professor Geraldine Macdonald, Coordinating Editor, University of Bristol, UK (Coordinating Editor, CDPLPG)<BR/>
<B>Email address: </B>geraldine.macdonald@bristol.ac.uk<BR/>
<BR/>Joanne Wilson, PhD, Managing Editor, Queens University Belfast, UK (Managing Editor, CDPLPG)<BR/>
<B>Email address: </B>CDPLPG@qub.ac.uk<BR/>
</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2013-01-31 17:08:01 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-01-31 17:08:01 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-02-25 18:41:01 +0000" MODIFIED_BY="[Empty name]">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2013-01-31 17:08:01 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Cochrane Central Register of Controlled Trials (CENTRAL)</B>
<BR/>
<BR/>#1 MeSH descriptor Personality Disorders explode all trees<BR/>#2 (moral near/2 insanity)<BR/>#3 (DSM and (axis and II))<BR/>#4 (ICD and (F60 or F61 or F62))<BR/>#5 ((Odd* or eccentric* or dramatic* or emotional* or anxious* or fearful*) near/5 cluster*)<BR/>#6 ("Cluster A" or "Cluster B" or "Cluster C")<BR/>#7 ((aggressiv* or anxious* or borderline* or dependent* or emotional* or passiv* or unstable) near/5 personalit*)<BR/>#8 anankastic* or asocial* or avoidant*or antisocial* or anti-social* or compulsiv* or dissocial* or histrionic* or narciss* or<BR/>obsessiv* or paranoi* or psychopath* or sadist* or schizoid* or schizotyp* or sociopath*<BR/>#9 personalit* near/5 disorder*<BR/>#10 character disorder*<BR/>#11 anal* next (personalit* or character* or retentiv*)<BR/>#12 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11<BR/>
<BR/>
<B>MEDLINE</B>
<BR/>
<BR/>1 randomized controlled trial.pt.<BR/>2 controlled clinical trial.pt.<BR/>3 randomi#ed.ab.<BR/>4 placebo.ab.<BR/>5 drug therapy.fs.<BR/>6 randomly.ab.<BR/>7 trial.ab.<BR/>8 groups.ab.<BR/>9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8<BR/>10 exp animals/ not humans.sh.<BR/>11 exp Personality Disorders/<BR/>12 (moral adj2 insanity).tw.<BR/>13 (DSM and (axis and II)).tw.<BR/>14 (ICD and (F60 or F61 or F62)).tw.<BR/>15 ((odd$ or eccentric$ or dramatic$ or emotional$ or anxious$ or fearful$) adj5 cluster$).tw.<BR/>16 ("Cluster A" or "Cluster B" or "Cluster C").tw.<BR/>17 ((aggressiv$ or anxious$ or borderline$ or dependent$ or emotional$ or passiv$ or unstable) adj5 personalit$).tw.<BR/>18 (personalit$ adj5 disorder$).tw.<BR/>19 character disorder$.tw.<BR/>20 (anal$ adj (personalit$ or character$ or retentiv$)).tw.<BR/>21 9 not 10<BR/>22 (anankastic$ or asocial$ or avoidant$ or antisocial$ or anti-social$ or compulsiv$ or dissocial$ or histrionic$ or<BR/>narciss$ or obsessiv$ or paranoi$ or psychopath or psychopaths or psychopathic or sadist$ or schizoid$ or schizotyp$ or<BR/>sociopath$).tw.<BR/>23 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 22<BR/>24 21 and 23<BR/>
<BR/>
<B>EMBASE</B>
<BR/>
<BR/>1 (moral adj2 insanity).tw.<BR/>2 (DSM and (axis and II)).tw.<BR/>3 (ICD and (F60 or F61 or F62)).tw.<BR/>4 ((odd$ or eccentric$ or dramatic$ or emotional$ or anxious$ or fearful$) adj5 cluster$).tw.<BR/>5 ("Cluster A" or "Cluster B" or "Cluster C").tw.<BR/>6 ((aggressiv$ or anxious$ or borderline$ or dependent$ or emotional$ or passiv$ or unstable) adj5 personalit$).tw.<BR/>7 (anankastic$ or asocial$ or avoidant$ or antisocial$ or anti-social$ or compulsiv$ or dissocial$ or histrionic$ or<BR/>narciss$ or obsessiv$ or paranoi$ or psychopath$ or sadist$ or schizoid$ or schizotyp$ or sociopath$).tw.<BR/>8 (personalit$ adj5 disorder$).tw.<BR/>9 character disorder$.tw.<BR/>10 (anal$ adj (personalit$ or character$ or retentiv$)).tw.<BR/>11 exp personality disorder/<BR/>12 or/1-11<BR/>13 random$.tw.<BR/>14 factorial$.tw.<BR/>15 crossover$.tw.<BR/>16 cross over$.tw.<BR/>17 cross-over$.tw.<BR/>18 placebo$.tw. (1<BR/>19 (doubl$ adj blind$).tw.<BR/>20 (singl$ adj blind$).tw.<BR/>21 assign$.tw.<BR/>22 allocat$.tw.<BR/>23 volunteer$.tw.<BR/>24 Crossover Procedure/<BR/>25 double-blind procedure.tw.<BR/>26 Randomized Controlled Trial/<BR/>27 Single Blind Procedure/<BR/>28 or/13-27<BR/>29 12 and 28<BR/>
<BR/>
<B>ASSIA</B>
<BR/>
<BR/>((DE=("personality disorders" or "antisocial personality disorder" or "avoidant personality disorders" or "borderline<BR/>personality disorder" or "dependent personality" or "depressive personality disorders" or "gender identity disorder" or<BR/>"histrionic personality disorder" or "identity crisis" or "kleptomania" or "multi impulsive personality disorder" or<BR/>"multiple personality disorder" or "narcissistic personality disorder" or "passive aggressive personality disorder" or<BR/>"sadistic personality disorder" or "schizotypal personality disorders" or "selfdefeating personality disorder")) or((moral<BR/>within 2 insanity) or(DSM and (axis and II)) or(icd and (F60 or F61 or F62)) or((odd* or eccentric* or dramatic* or<BR/>emotional* or anxious* or fearful*) within 5 cluster*) or("Cluster A" or "Cluster B" or "Cluster C") or((aggressiv* or<BR/>anxious* or borderline* or dependent* or emotional* or passiv* or unstable) within 5 personalit*) or(anankastic* or<BR/>asocial* or avoidant* or antisocial* or anti-social* or compulsiv* or dissocial* or histrionic* or narciss* or obsessiv* or<BR/>paranoi* or psychopath* or sadist* or schizoid* or schizotyp* or sociopath*) or(personalit* within 5 disorder*) or(character<BR/>disorder*) or(anal* within 1 (personalit* or character* or retentiv*)))) and((DE=("randomized controlled trials" or "clinical<BR/>randomized controlled trials" or "cluster randomized controlled trials" or "double blind randomized controlled trials" or<BR/>"randomized consent design" or "single blind randomized controlled trials" or "urn randomization" or "random testing"<BR/>or "randomization" or "unequal randomization")) or(TI=randomi* or AB=randomi*) or((TI=(single or double) near<BR/>blind*)or (AB=(single or double) near blind*)))<BR/>
<B>
<BR/>BIOSIS</B>
<BR/>
<BR/># 15 #14 AND #12<BR/># 14 #13 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1<BR/># 13 TS=(anankastic* or asocial* or avoidant* or antisocial* or anti-social* or compulsiv* or dissocial* or histrionic* or narciss* or obsessiv* or paranoi* or psychopath or psychopaths or psychopathic or sadist* or schizoid* or schizotyp* or sociopath*)<BR/># 12 #11 OR #10<BR/># 11 TS=(singl* or doubl* or tripl*or trebl*) OR TS=(mask* or blind*)<BR/># 10 TS=(random* or crossover )<BR/># 9 TS=((anal or anally) SAME (personalit* or character* or retentiv*))<BR/># 8 TS=("Cluster B" or "Cluster C")<BR/># 7 TS=("character disorder*")<BR/># 6 TS=(personalit* SAME disorder*)<BR/># 5 TS=((agressiv* or anxious* or borderline* or dependent* or emotional* or passiv* or unstable) SAME (personalit*))<BR/># 4 TS=((odd* or eccentric* or dramatic* or emotional* or anxious* or fearful*) SAME cluster*)<BR/># 3 TS=(ICD AND (F60 or F61 or F62))<BR/># 2 TS=(DSM SAME (axis SAME II))<BR/># 1 TS=(moral SAME insanity)<BR/>
<BR/>
<B>CINAHL</B>
</P>
<P>
<BR/>S30 S13 and S29<BR/>S29 S14 or S15 or S16 or S17 or S18 or S19 or S20 or S21 or S22 or S23 or<BR/>S24 or S25 or S26 or S27 or S28<BR/>S28 allocat* random*<BR/>S27 (MH "Quantitative Studies")<BR/>S26 (MH "Placebos")<BR/>S25 placebo*<BR/>S24 random* allocat*<BR/>S23 (MH "Random Assignment")<BR/>S22 (Randomi?ed control* trial*)<BR/>S21 (singl* mask* )<BR/>S20 (doubl* mask* )<BR/>S19 (tripl* mask* )<BR/>S18 (trebl* mask* )<BR/>S17 (trebl* blind* )<BR/>S16 (tripl* blind* )<BR/>S15 (doubl* blind* )<BR/>S14 (singl* blind* )<BR/>S13 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12<BR/>S12 (anal* N1 personalit* or anal* N1 character* or anal N1 retentiv*) and<BR/>(S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11)<BR/>S11 anal* N1 personalit* or anal* N1 character* or anal N1 retentiv*<BR/>S10 character N1 disorder*<BR/>S9 personalit* N5 disorder*<BR/>S8 anankastic* or asocial* or avoidant* or antisocial* or anti-social* or<BR/>compulsiv* or dissocial* or histrionic* or narciss* or obsessiv* or<BR/>paranoi* or psychopath* or sadist* or schizoid* or schizotyp* or<BR/>sociopath*<BR/>S7 aggressiv* N5 personalit* or anxious* N5 personalit* or borderline* N5<BR/>personalit* or dependent* N5 personalit* or emotional* N5 personalit* or<BR/>passiv* N5 personalit* or unstable N5 personalit*<BR/>S6 ("Cluster A" or "Cluster B" or "Cluster C")<BR/>S5 odd* N5 cluster* or eccentric* N5 cluster* or dramatic* N5 cluster* or<BR/>emotional* N5 cluster* or anxious* N5 cluster* or fearful* N5 cluster*<BR/>S4 (ICD and (F60 or F61 or F62))<BR/>S3 (DSM and (axis and II))<BR/>S2 moral N2 insanity<BR/>S1 (MH "Personality Disorders+")<BR/>
<BR/>
<B>Dissertation Abstracts</B>
</P>
<P>Searched using the Proquest keyword " personality disorders"<BR/>
<BR/>
<B>ICTRP</B>
</P>
<P>condition = borderline personality disorder AND recruitment status = all</P>
<P>
<B>metaRegister of Controlled Trials</B>
<BR/>
<BR/>Searched using the search strings :<BR/>antisocial personality<BR/>borderline personality<BR/>compulsive personality<BR/>dependent personality<BR/>histrionic personality<BR/>hysteria<BR/>paranoid personality<BR/>passive-aggressive personality<BR/>schizoid personality<BR/>schizotypal personality<BR/>personality disorder<BR/>
<BR/>
<B>National Criminal Justice Reference Service Abstracts (NCJRS)</B>
<BR/>
<BR/>Searched using the search strings:<BR/>random* AND compulsive personality<BR/>random* AND antisocial personality<BR/>random* AND borderline personality<BR/>random* AND dependent personality<BR/>random* AND histrionic personality<BR/>random* AND hysteria<BR/>random* AND paranoid personality<BR/>random* AND passive aggressive personality<BR/>random AND schizoid personality<BR/>random* AND schizotypal personality<BR/>random* AND personality disorder*<BR/>
<BR/>
<B>PsycINFO</B>
<BR/>
<BR/>1 (moral adj2 insanity).tw.<BR/>2 (DSM and (axis and II)).tw.<BR/>3 (ICD and (F60 or F61 or F62)).tw.<BR/>4 ((odd$ or eccentric$ or dramatic$ or emotional$ or anxious$ or fearful$) adj5 cluster$).tw.<BR/>5 ("Cluster A" or "Cluster B" or "Cluster C").tw.<BR/>6 ((aggressiv$ or anxious$ or borderline$ or dependent$ or emotional$ or passiv$ or unstable) adj5 personalit$).tw.<BR/>7 (anankastic$ or asocial$ or avoidant$ or antisocial$ or anti-social$ or compulsiv$ or dissocial$ or histrionic$ or<BR/>narciss$ or obsessiv$ or paranoi$ or psychopath$ or sadist$ or schizoid$ or schizotyp$ or sociopath$).tw.<BR/>8 (personalit$ adj5 disorder$).tw.<BR/>9 character disorder$.tw.<BR/>10 (anal$ adj (personalit$ or character$ or retentiv$)).tw.<BR/>11 exp personality disorders/<BR/>12 or/1-11<BR/>13 randomi$.tw.<BR/>14 singl$.tw.<BR/>15 doubl$.tw.<BR/>16 trebl$.tw.<BR/>17 tripl$.tw.<BR/>18 blind$.tw.<BR/>19 mask$.tw.<BR/>20 (or/14-17) adj3 (or/18-19)<BR/>21 clin$.tw.<BR/>22 trial$.tw.<BR/>23 (clin$ adj3 trial$).tw.<BR/>24 placebo$.tw.<BR/>25 exp PLACEBO/<BR/>26 crossover.tw.<BR/>27 exp Treatment Effectiveness Evaluation/<BR/>28 exp Mental Health Program Evaluation/<BR/>29 random$.tw.<BR/>30 assign$.tw.<BR/>31 allocate$.tw. (<BR/>32 (random$ adj3 (assign$ or allocate$)).tw.<BR/>33 32 or 28 or 27 or 26 or 25 or 24 or 23 or 20 or 13<BR/>34 12 and 33<BR/>
<BR/>
<B>Science Citation Index</B>
<BR/>
<BR/># 15 #14 AND #12<BR/># 14 #13 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1<BR/># 13 TS=(anankastic* or asocial* or avoidant* or antisocial* or anti-social* or compulsiv* or dissocial* or histrionic* or<BR/>narciss* or obsessiv* or paranoi* or psychopath or psychopaths or psychopathic or sadist* or schizoid* or schizotyp* or<BR/>sociopath*)<BR/># 12 #11 OR #10<BR/># 11 TS=(singl* or doubl* or tripl*or trebl*) OR TS=(mask* or blind*)<BR/># 10 TS=(random* or crossover )<BR/># 9 TS=((anal or anally) SAME (personalit* or character* or retentiv*))<BR/># 8 TS=("Cluster B" or "Cluster C")<BR/># 7 TS=("character disorder*")<BR/># 6 TS=(personalit* SAME disorder*)<BR/># 5 TS=((agressiv* or anxious* or borderline* or dependent* or emotional* or passiv* or unstable) SAME (personalit*))<BR/># 4 TS=((odd* or eccentric* or dramatic* or emotional* or anxious* or fearful*) SAME cluster*)<BR/># 3 TS=(ICD AND (F60 or F61 or F62))<BR/># 2 TS=(DSM SAME (axis SAME II))<BR/># 1 TS=(moral SAME insanity)<BR/>
<BR/>
<B>Social Science Citation Index</B>
<BR/>
<BR/># 15 #14 AND #12<BR/># 14 #13 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1<BR/># 13 TS=(anankastic* or asocial* or avoidant* or antisocial* or anti-social* or compulsiv* or dissocial* or histrionic* or<BR/>narciss* or obsessiv* or paranoi* or psychopath or psychopaths or psychopathic or sadist* or schizoid* or schizotyp* or<BR/>sociopath*)<BR/># 12 #11 OR #10<BR/># 11 TS=(singl* or doubl* or tripl*or trebl*) OR TS=(mask* or blind*)<BR/># 10 TS=(random* or crossover )<BR/># 9 TS=((anal or anally) SAME (personalit* or character* or retentiv*))<BR/># 8 TS=("Cluster B" or "Cluster C")<BR/># 7 TS=("character disorder*")<BR/># 6 TS=(personalit* SAME disorder*)<BR/># 5 TS=((agressiv* or anxious* or borderline* or dependent* or emotional* or passiv* or unstable) SAME (personalit*))<BR/># 4 TS=((odd* or eccentric* or dramatic* or emotional* or anxious* or fearful*) SAME cluster*)<BR/># 3 TS=(ICD AND (F60 or F61 or F62))<BR/># 2 TS=(DSM SAME (axis SAME II))<BR/># 1 TS=(moral SAME insanity)<BR/>
<BR/>
<B>Sociological Abstracts (CSA)<BR/>
</B>
<BR/>((DE="personality disorders") or(moral within 2 insanity) or(DSM and (axis and II)) or(icd and (F60 or F61 or F62)) or((odd*<BR/>or eccentric* or dramatic* or emotional* or anxious* or fearful*) within 5 cluster*) or("Cluster A" or "Cluster B" or "Cluster<BR/>C") or((aggressiv* or anxious* or borderline* or dependent* or emotional* or passiv* or unstable) within 5 personalit*)<BR/>or(anankastic* or asocial* or avoidant* or antisocial* or anti-social* or compulsiv* or dissocial* or histrionic* or narciss*<BR/>or obsessiv* or paranoi* or psychopath* or sadist* or schizoid* or schizotyp* or sociopath*) or(personalit* within 5<BR/>disorder*) or(character disorder*) or(anal* within 1 (personalit* or character* or retentiv*))) and((TI=randomi* or<BR/>DE=(randomi?ed controlled trial*) or AB=randomi*) or(TI=(double* blind*) or AB=(double* blind*) or DE=(double blind<BR/>studies)) or(single near blind*))<BR/>
<B>
<BR/>ZETOC (Conference search)</B>
<BR/>
<BR/>23 conference: hysteria trial*<BR/>22 conference: histrionic personality trial*<BR/>21 conference: dependent personality trial*<BR/>20 conference: borderline personality trial*<BR/>19 conference: antisocial personality trial*<BR/>18 conference: compulsive personality trial*<BR/>17 conference: compulsive personality random*<BR/>16 conference: schizotypal trial*<BR/>15 conference: schizotypal random*<BR/>14 conference: schizoid trial*<BR/>13 conference: schizoid random*<BR/>12 conference: passive aggressive trial*<BR/>11 conference: passive aggressive random*<BR/>10 conference: personality disorder* trial*<BR/>9 conference: paranoid personality trial*<BR/>8 conference: paranoid personality random*<BR/>7 conference: paranoid personality<BR/>6 conference: hysteria random*<BR/>5 conference: histrionic personality random*<BR/>4 conference: dependent personality random*<BR/>3 conference: borderline personality random*<BR/>2 conference: antisocial personality random*<BR/>1 conference: personality disorder* random*<BR/>
<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2012-06-13 13:13:18 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2012-05-12 12:16:20 +0100" MODIFIED_BY="[Empty name]">Trial register searches</TITLE>
<APPENDIX_BODY MODIFIED="2012-06-13 13:13:18 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the WHO International Clinical Trails Registry Platform on 9 August 2011 (http://apps.who.int/trialsearch/), a meta-register that includes the following trial registration databases:</P>
<UL>
<LI>Australian New Zealand Clinical Trials Registry, last data file imported on 9 August 2011</LI>
<LI>ClinicalTrials.gov, last data file imported on 9 August 2011</LI>
<LI>ISRCTN, last data file imported on 9 August 2011</LI>
<LI>Brazilian Clinical Trials Registry (ReBec), last data file imported on 26 July 2011</LI>
<LI>Chinese Clinical Trial Registry, last data file imported on 26 July 2011</LI>
<LI>Clinical Trials Registry - India, last data file imported on 26 July 2011</LI>
<LI>Clinical Research Information Service - Republic of Korea, last data file imported on 26 July 2011</LI>
<LI>Cuban Public Registry of Clinical Trials, last data file imported on 26 July 2011</LI>
<LI>German Clinical Trials Register, last data file imported on 26 July 2011</LI>
<LI>Iranian Registry of Clinical Trials, last data file imported on 2 August 2011</LI>
<LI>Japan Primary Registries Network, last data file imported on 26 July 2011</LI>
<LI>Pan African Clinical Trial Registry, last data file imported on 26 July 2011</LI>
<LI>Sri Lanka Clinical Trials Registry, last data file imported on 26 July 2011</LI>
<LI>The Netherlands National Trial Register, last data file imported on 26 July 2011</LI>
</UL>
<P>The following phrase was searched:</P>
<P>condition = borderline personality disorder AND recruitment status = all</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2012-05-25 15:42:26 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2012-05-25 15:41:44 +0100" MODIFIED_BY="[Empty name]">Additional methods for future updates</TITLE>
<APPENDIX_BODY MODIFIED="2012-05-25 15:42:26 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="3">
<TR>
<TH>
<P>Issue</P>
</TH>
<TH>
<P>Method</P>
</TH>
</TR>
<TR>
<TD>
<P>Unit of analysis issues/cross-over trials</P>
</TD>
<TD>
<P>Data from randomised cross-over studies up to the point of first cross-over were eligible for inclusion. We excluded data from subsequent phases. Due to the characteristically unstable course of BPD, it did not seem appropriate to us that participants served as their own controls (within-subject comparisons). However, we would have used first phase data up to the point of first cross-over for those studies and applied the inverse variance methods as recommended by <LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>.</P>
</TD>
</TR>
<TR>
<TD>
<P>Search methods for identification of studies</P>
</TD>
<TD>
<P>Contact psychotherapeutic associations directly in order to identify any published and upcoming research.</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2009-08-17 21:57:59 +0100" MODIFIED_BY="[Empty name]">
<EXTENSION ID="AFF_2FE6F4A782E26AA2000C5DBB80392281_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="2FE6F4A782E26AA2000C5DBB80392281">
<ADDRESS>
<DEPARTMENT>Department of Psychiatry and Psychotherapy</DEPARTMENT>
<ORGANISATION>University Medical Center Mainz</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Mainz</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;91 records (including primary and secondary papers; cf. &lt;a link_type=&quot;SECTION&quot; href=&quot;INCLUDED_STUDIES&quot; protected=&quot;true&quot;&gt;Included studies&lt;/a&gt;) for 28 RCTs included in quantitative synthesis&lt;/p&gt;" WIDTH="300">
<FLOWCHARTBOX TEXT="&lt;p&gt;109 records&lt;/p&gt;" WIDTH="300">
<FLOWCHARTBOX TEXT="&lt;p&gt;141 records (of which 32 records for 28 ongoing studies, cf. &lt;a link_type=&quot;SECTION&quot; href=&quot;CHARACTERISTICS_OF_ONGOING_STUDIES&quot; protected=&quot;true&quot;&gt;Characteristics of ongoing studies&lt;/a&gt;)&lt;/p&gt;" WIDTH="300">
<FLOWCHARTBOX TEXT="&lt;p&gt;503 full text articles screened for eligibility&lt;/p&gt;" WIDTH="300">
<FLOWCHARTBOX TEXT="&lt;p&gt;2458 records screened by abstract&lt;/p&gt;" WIDTH="300">
<FLOWCHARTBOX TEXT="&lt;p&gt;28,535 records screened by title &lt;/p&gt;" WIDTH="300">
<FLOWCHARTBOX TEXT="&lt;p&gt;38,701 records&lt;/p&gt;" WIDTH="300">
<FLOWCHARTBOX TEXT="&lt;p&gt;38,602 of records identified through database searching&lt;/p&gt;" WIDTH="200"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;99 additional records identified through clinical trial register searching&lt;/p&gt;" WIDTH="200"/>
<OUT TEXT="&lt;p&gt;10,166 records identified as duplicates and removed&lt;/p&gt;" WIDTH="200"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;26,077 records excluded &lt;/p&gt;" WIDTH="200"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1955 records excluded&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="200"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;362 full-text articles excluded, reasons:&lt;/p&gt;&lt;p&gt;review articles/tutorials: N = 164&lt;/p&gt;&lt;p&gt;intervention not psychotherapy: N = 143&lt;/p&gt;&lt;p&gt;allocation not randomised/non-RCT study design: N = 30&lt;/p&gt;&lt;p&gt;sample characteristics: N = 25&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="200"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;18 records of studies with no outcomes of interest/unable to use available data&lt;/p&gt;" WIDTH="200"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>